bio-datasets/bigbio-ner-merged · Datasets at Hugging Face

answer stringlengths 1 16.1k	id stringlengths 7 56	instruction stringlengths 106 72.6k	ner_tags list	text stringlengths 5 72.4k	tokens list	types list
over 40 years is a Value, Medical examination is a Procedure, prior to participation in research is a Temporal, without is a Negation, history is a Observation, inner ear disease is a Condition	NCT02529475_inc_task1	Sentence: Major subjects of over 40 years (mean age of Meniere's disease 40 to 50 years) Informed consent signed Medical examination performed prior to participation in research Patients without history of inner ear disease Recipient of a French social security scheme Instructions: please typing these entity words according to sentence: over 40 years, Medical examination, prior to participation in research, without, history, inner ear disease Options: Temporal, Condition, Value, Observation, Procedure, Negation	[ "O", "O", "O", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Negation", "B-Observation", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Major subjects of over 40 years (mean age of Meniere's disease 40 to 50 years) Informed consent signed Medical examination performed prior to participation in research Patients without history of inner ear disease Recipient of a French social security scheme	[ "Major", "subjects", "of", "over", "40", "years", "(", "mean", "age", "of", "Meniere", "'s", "disease", "40", "to", "50", "years", ")", "\n", "Informed", "consent", "signed", "\n", "Medical", "examination", "performed", "prior", "to", "participation", "in", "research", "\n", "Patients", "without", "history", "of", "inner", "ear", "disease", "\n", "Recipient", "of", "a", "French", "social", "security", "scheme", "\n" ]	[ "Temporal", "Procedure", "Condition", "Value", "Observation", "Negation", "Person" ]
over 40 years, Medical examination, prior to participation in research, without, history, inner ear disease	NCT02529475_inc_task2	Sentence: Major subjects of over 40 years (mean age of Meniere's disease 40 to 50 years) Informed consent signed Medical examination performed prior to participation in research Patients without history of inner ear disease Recipient of a French social security scheme Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Negation", "B-Observation", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Major subjects of over 40 years (mean age of Meniere's disease 40 to 50 years) Informed consent signed Medical examination performed prior to participation in research Patients without history of inner ear disease Recipient of a French social security scheme	[ "Major", "subjects", "of", "over", "40", "years", "(", "mean", "age", "of", "Meniere", "'s", "disease", "40", "to", "50", "years", ")", "\n", "Informed", "consent", "signed", "\n", "Medical", "examination", "performed", "prior", "to", "participation", "in", "research", "\n", "Patients", "without", "history", "of", "inner", "ear", "disease", "\n", "Recipient", "of", "a", "French", "social", "security", "scheme", "\n" ]	[ "Temporal", "Procedure", "Condition", "Value", "Observation", "Negation", "Person" ]
Virtual reality intervention is a Intervention_Educational, older is a Participant_Age, women is a Participant_Sex, breast cancer is a Participant_Condition, virtual reality distraction intervention is a Intervention_Educational, symptom distress is a Outcome_Physical, 16 is a Participant_Sample-size, 50 and older is a Participant_Age, a head - mounted display ( Sony PC Glasstron PLM - S700 ) was used to display encompassing images and block competing stimuli during chemotherapy infusions . is a Intervention_Psychological, Symptom Distress Scale ( SDS ) is a Outcome_Physical, Revised Piper Fatigue Scale ( PFS ) , is a Outcome_Physical, State Anxiety Inventory ( SAI is a Outcome_Mental, VR distraction intervention during one chemotherapy treatment is a Intervention_Educational, no distraction intervention ( control condition ) is a Intervention_Control, decrease is a Outcome_Other, improved symptoms is a Outcome_Physical, cybersickness is a Outcome_Physical	13500_task0	Sentence: Virtual reality intervention for older women with breast cancer . This study examined the effects of a virtual reality distraction intervention on chemotherapy-related symptom distress levels in 16 women aged 50 and older . A cross-over design was used to answer the following research questions : ( 1 ) Is virtual reality an effective distraction intervention for reducing chemotherapy-related symptom distress levels in older women with breast cancer ? ( 2 ) Does virtual reality have a lasting effect ? Chemotherapy treatments are intensive and difficult to endure . One way to cope with chemotherapy-related symptom distress is through the use of distraction . For this study , a head-mounted display ( Sony PC Glasstron PLM - S700 ) was used to display encompassing images and block competing stimuli during chemotherapy infusions . The Symptom Distress Scale ( SDS ) , Revised Piper Fatigue Scale ( PFS ) , and the State Anxiety Inventory ( SAI ) were used to measure symptom distress . For two matched chemotherapy treatments , one pre-test and two post-test measures were employed . Participants were randomly assigned to receive the VR distraction intervention during one chemotherapy treatment and received no distraction intervention ( control condition ) during an alternate chemotherapy treatment . Analysis using paired t-tests demonstrated a significant decrease in the SAI ( p = 0.10 ) scores immediately following chemotherapy treatments when participants used VR . No significant changes were found in SDS or PFS values . There was a consistent trend toward improved symptoms on all measures 48 h following completion of chemotherapy . Evaluation of the intervention indicated that women thought the head mounted device was easy to use , they experienced no cybersickness , and 100 % would use VR again . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Psychological, Participant_Condition, Participant_Sex, Intervention_Control, Intervention_Educational, Outcome_Physical, Participant_Age, Participant_Sample-size, Outcome_Other, Outcome_Mental	[ "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Participant_Age", "B-Participant_Sex", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Virtual reality intervention for older women with breast cancer . This study examined the effects of a virtual reality distraction intervention on chemotherapy-related symptom distress levels in 16 women aged 50 and older . A cross-over design was used to answer the following research questions : ( 1 ) Is virtual reality an effective distraction intervention for reducing chemotherapy-related symptom distress levels in older women with breast cancer ? ( 2 ) Does virtual reality have a lasting effect ? Chemotherapy treatments are intensive and difficult to endure . One way to cope with chemotherapy-related symptom distress is through the use of distraction . For this study , a head-mounted display ( Sony PC Glasstron PLM - S700 ) was used to display encompassing images and block competing stimuli during chemotherapy infusions . The Symptom Distress Scale ( SDS ) , Revised Piper Fatigue Scale ( PFS ) , and the State Anxiety Inventory ( SAI ) were used to measure symptom distress . For two matched chemotherapy treatments , one pre-test and two post-test measures were employed . Participants were randomly assigned to receive the VR distraction intervention during one chemotherapy treatment and received no distraction intervention ( control condition ) during an alternate chemotherapy treatment . Analysis using paired t-tests demonstrated a significant decrease in the SAI ( p = 0.10 ) scores immediately following chemotherapy treatments when participants used VR . No significant changes were found in SDS or PFS values . There was a consistent trend toward improved symptoms on all measures 48 h following completion of chemotherapy . Evaluation of the intervention indicated that women thought the head mounted device was easy to use , they experienced no cybersickness , and 100 % would use VR again .	[ "Virtual", "reality", "intervention", "for", "older", "women", "with", "breast", "cancer", ".", "This", "study", "examined", "the", "effects", "of", "a", "virtual", "reality", "distraction", "intervention", "on", "chemotherapy", "-", "related", "symptom", "distress", "levels", "in", "16", "women", "aged", "50", "and", "older", ".", "A", "cross", "-", "over", "design", "was", "used", "to", "answer", "the", "following", "research", "questions", ":", "(", "1", ")", "Is", "virtual", "reality", "an", "effective", "distraction", "intervention", "for", "reducing", "chemotherapy", "-", "related", "symptom", "distress", "levels", "in", "older", "women", "with", "breast", "cancer", "?", "(", "2", ")", "Does", "virtual", "reality", "have", "a", "lasting", "effect", "?", "Chemotherapy", "treatments", "are", "intensive", "and", "difficult", "to", "endure", ".", "One", "way", "to", "cope", "with", "chemotherapy", "-", "related", "symptom", "distress", "is", "through", "the", "use", "of", "distraction", ".", "For", "this", "study", ",", "a", "head", "-", "mounted", "display", "(", "Sony", "PC", "Glasstron", "PLM", "-", "S700", ")", "was", "used", "to", "display", "encompassing", "images", "and", "block", "competing", "stimuli", "during", "chemotherapy", "infusions", ".", "The", "Symptom", "Distress", "Scale", "(", "SDS", ")", ",", "Revised", "Piper", "Fatigue", "Scale", "(", "PFS", ")", ",", "and", "the", "State", "Anxiety", "Inventory", "(", "SAI", ")", "were", "used", "to", "measure", "symptom", "distress", ".", "For", "two", "matched", "chemotherapy", "treatments", ",", "one", "pre", "-", "test", "and", "two", "post", "-", "test", "measures", "were", "employed", ".", "Participants", "were", "randomly", "assigned", "to", "receive", "the", "VR", "distraction", "intervention", "during", "one", "chemotherapy", "treatment", "and", "received", "no", "distraction", "intervention", "(", "control", "condition", ")", "during", "an", "alternate", "chemotherapy", "treatment", ".", "Analysis", "using", "paired", "t", "-", "tests", "demonstrated", "a", "significant", "decrease", "in", "the", "SAI", "(", "p", "=", "0.10", ")", "scores", "immediately", "following", "chemotherapy", "treatments", "when", "participants", "used", "VR", ".", "No", "significant", "changes", "were", "found", "in", "SDS", "or", "PFS", "values", ".", "There", "was", "a", "consistent", "trend", "toward", "improved", "symptoms", "on", "all", "measures", "48", "h", "following", "completion", "of", "chemotherapy", ".", "Evaluation", "of", "the", "intervention", "indicated", "that", "women", "thought", "the", "head", "mounted", "device", "was", "easy", "to", "use", ",", "they", "experienced", "no", "cybersickness", ",", "and", "100", "%", "would", "use", "VR", "again", "." ]	[ "Intervention_Psychological", "Intervention_Educational", "Intervention_Control", "Outcome_Physical", "Outcome_Mental", "Participant_Condition", "Participant_Age", "Outcome_Other", "Participant_Sex", "Participant_Sample-size" ]
Virtual reality intervention is a Intervention_Educational, older is a Participant_Age, women is a Participant_Sex, breast cancer is a Participant_Condition, virtual reality distraction intervention is a Intervention_Educational, symptom distress is a Outcome_Physical, 16 is a Participant_Sample-size, 50 and older is a Participant_Age, a head - mounted display ( Sony PC Glasstron PLM - S700 ) was used to display encompassing images and block competing stimuli during chemotherapy infusions . is a Intervention_Psychological, Symptom Distress Scale ( SDS ) is a Outcome_Physical, Revised Piper Fatigue Scale ( PFS ) , is a Outcome_Physical, State Anxiety Inventory ( SAI is a Outcome_Mental, VR distraction intervention during one chemotherapy treatment is a Intervention_Educational, no distraction intervention ( control condition ) is a Intervention_Control, decrease is a Outcome_Other, improved symptoms is a Outcome_Physical, cybersickness is a Outcome_Physical	13500_task1	Sentence: Virtual reality intervention for older women with breast cancer . This study examined the effects of a virtual reality distraction intervention on chemotherapy-related symptom distress levels in 16 women aged 50 and older . A cross-over design was used to answer the following research questions : ( 1 ) Is virtual reality an effective distraction intervention for reducing chemotherapy-related symptom distress levels in older women with breast cancer ? ( 2 ) Does virtual reality have a lasting effect ? Chemotherapy treatments are intensive and difficult to endure . One way to cope with chemotherapy-related symptom distress is through the use of distraction . For this study , a head-mounted display ( Sony PC Glasstron PLM - S700 ) was used to display encompassing images and block competing stimuli during chemotherapy infusions . The Symptom Distress Scale ( SDS ) , Revised Piper Fatigue Scale ( PFS ) , and the State Anxiety Inventory ( SAI ) were used to measure symptom distress . For two matched chemotherapy treatments , one pre-test and two post-test measures were employed . Participants were randomly assigned to receive the VR distraction intervention during one chemotherapy treatment and received no distraction intervention ( control condition ) during an alternate chemotherapy treatment . Analysis using paired t-tests demonstrated a significant decrease in the SAI ( p = 0.10 ) scores immediately following chemotherapy treatments when participants used VR . No significant changes were found in SDS or PFS values . There was a consistent trend toward improved symptoms on all measures 48 h following completion of chemotherapy . Evaluation of the intervention indicated that women thought the head mounted device was easy to use , they experienced no cybersickness , and 100 % would use VR again . Instructions: please typing these entity words according to sentence: Virtual reality intervention, older, women, breast cancer, virtual reality distraction intervention, symptom distress, 16, 50 and older, a head - mounted display ( Sony PC Glasstron PLM - S700 ) was used to display encompassing images and block competing stimuli during chemotherapy infusions ., Symptom Distress Scale ( SDS ), Revised Piper Fatigue Scale ( PFS ) ,, State Anxiety Inventory ( SAI, VR distraction intervention during one chemotherapy treatment, no distraction intervention ( control condition ), decrease, improved symptoms, cybersickness Options: Intervention_Psychological, Participant_Condition, Participant_Sex, Intervention_Control, Intervention_Educational, Outcome_Physical, Participant_Age, Participant_Sample-size, Outcome_Other, Outcome_Mental	[ "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Participant_Age", "B-Participant_Sex", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Virtual reality intervention for older women with breast cancer . This study examined the effects of a virtual reality distraction intervention on chemotherapy-related symptom distress levels in 16 women aged 50 and older . A cross-over design was used to answer the following research questions : ( 1 ) Is virtual reality an effective distraction intervention for reducing chemotherapy-related symptom distress levels in older women with breast cancer ? ( 2 ) Does virtual reality have a lasting effect ? Chemotherapy treatments are intensive and difficult to endure . One way to cope with chemotherapy-related symptom distress is through the use of distraction . For this study , a head-mounted display ( Sony PC Glasstron PLM - S700 ) was used to display encompassing images and block competing stimuli during chemotherapy infusions . The Symptom Distress Scale ( SDS ) , Revised Piper Fatigue Scale ( PFS ) , and the State Anxiety Inventory ( SAI ) were used to measure symptom distress . For two matched chemotherapy treatments , one pre-test and two post-test measures were employed . Participants were randomly assigned to receive the VR distraction intervention during one chemotherapy treatment and received no distraction intervention ( control condition ) during an alternate chemotherapy treatment . Analysis using paired t-tests demonstrated a significant decrease in the SAI ( p = 0.10 ) scores immediately following chemotherapy treatments when participants used VR . No significant changes were found in SDS or PFS values . There was a consistent trend toward improved symptoms on all measures 48 h following completion of chemotherapy . Evaluation of the intervention indicated that women thought the head mounted device was easy to use , they experienced no cybersickness , and 100 % would use VR again .	[ "Virtual", "reality", "intervention", "for", "older", "women", "with", "breast", "cancer", ".", "This", "study", "examined", "the", "effects", "of", "a", "virtual", "reality", "distraction", "intervention", "on", "chemotherapy", "-", "related", "symptom", "distress", "levels", "in", "16", "women", "aged", "50", "and", "older", ".", "A", "cross", "-", "over", "design", "was", "used", "to", "answer", "the", "following", "research", "questions", ":", "(", "1", ")", "Is", "virtual", "reality", "an", "effective", "distraction", "intervention", "for", "reducing", "chemotherapy", "-", "related", "symptom", "distress", "levels", "in", "older", "women", "with", "breast", "cancer", "?", "(", "2", ")", "Does", "virtual", "reality", "have", "a", "lasting", "effect", "?", "Chemotherapy", "treatments", "are", "intensive", "and", "difficult", "to", "endure", ".", "One", "way", "to", "cope", "with", "chemotherapy", "-", "related", "symptom", "distress", "is", "through", "the", "use", "of", "distraction", ".", "For", "this", "study", ",", "a", "head", "-", "mounted", "display", "(", "Sony", "PC", "Glasstron", "PLM", "-", "S700", ")", "was", "used", "to", "display", "encompassing", "images", "and", "block", "competing", "stimuli", "during", "chemotherapy", "infusions", ".", "The", "Symptom", "Distress", "Scale", "(", "SDS", ")", ",", "Revised", "Piper", "Fatigue", "Scale", "(", "PFS", ")", ",", "and", "the", "State", "Anxiety", "Inventory", "(", "SAI", ")", "were", "used", "to", "measure", "symptom", "distress", ".", "For", "two", "matched", "chemotherapy", "treatments", ",", "one", "pre", "-", "test", "and", "two", "post", "-", "test", "measures", "were", "employed", ".", "Participants", "were", "randomly", "assigned", "to", "receive", "the", "VR", "distraction", "intervention", "during", "one", "chemotherapy", "treatment", "and", "received", "no", "distraction", "intervention", "(", "control", "condition", ")", "during", "an", "alternate", "chemotherapy", "treatment", ".", "Analysis", "using", "paired", "t", "-", "tests", "demonstrated", "a", "significant", "decrease", "in", "the", "SAI", "(", "p", "=", "0.10", ")", "scores", "immediately", "following", "chemotherapy", "treatments", "when", "participants", "used", "VR", ".", "No", "significant", "changes", "were", "found", "in", "SDS", "or", "PFS", "values", ".", "There", "was", "a", "consistent", "trend", "toward", "improved", "symptoms", "on", "all", "measures", "48", "h", "following", "completion", "of", "chemotherapy", ".", "Evaluation", "of", "the", "intervention", "indicated", "that", "women", "thought", "the", "head", "mounted", "device", "was", "easy", "to", "use", ",", "they", "experienced", "no", "cybersickness", ",", "and", "100", "%", "would", "use", "VR", "again", "." ]	[ "Intervention_Psychological", "Intervention_Educational", "Intervention_Control", "Outcome_Physical", "Outcome_Mental", "Participant_Condition", "Participant_Age", "Outcome_Other", "Participant_Sex", "Participant_Sample-size" ]
Virtual reality intervention, older, women, breast cancer, virtual reality distraction intervention, symptom distress, 16, 50 and older, a head - mounted display ( Sony PC Glasstron PLM - S700 ) was used to display encompassing images and block competing stimuli during chemotherapy infusions ., Symptom Distress Scale ( SDS ), Revised Piper Fatigue Scale ( PFS ) ,, State Anxiety Inventory ( SAI, VR distraction intervention during one chemotherapy treatment, no distraction intervention ( control condition ), decrease, improved symptoms, cybersickness	13500_task2	Sentence: Virtual reality intervention for older women with breast cancer . This study examined the effects of a virtual reality distraction intervention on chemotherapy-related symptom distress levels in 16 women aged 50 and older . A cross-over design was used to answer the following research questions : ( 1 ) Is virtual reality an effective distraction intervention for reducing chemotherapy-related symptom distress levels in older women with breast cancer ? ( 2 ) Does virtual reality have a lasting effect ? Chemotherapy treatments are intensive and difficult to endure . One way to cope with chemotherapy-related symptom distress is through the use of distraction . For this study , a head-mounted display ( Sony PC Glasstron PLM - S700 ) was used to display encompassing images and block competing stimuli during chemotherapy infusions . The Symptom Distress Scale ( SDS ) , Revised Piper Fatigue Scale ( PFS ) , and the State Anxiety Inventory ( SAI ) were used to measure symptom distress . For two matched chemotherapy treatments , one pre-test and two post-test measures were employed . Participants were randomly assigned to receive the VR distraction intervention during one chemotherapy treatment and received no distraction intervention ( control condition ) during an alternate chemotherapy treatment . Analysis using paired t-tests demonstrated a significant decrease in the SAI ( p = 0.10 ) scores immediately following chemotherapy treatments when participants used VR . No significant changes were found in SDS or PFS values . There was a consistent trend toward improved symptoms on all measures 48 h following completion of chemotherapy . Evaluation of the intervention indicated that women thought the head mounted device was easy to use , they experienced no cybersickness , and 100 % would use VR again . Instructions: please extract entity words from the input sentence	[ "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Participant_Age", "B-Participant_Sex", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Virtual reality intervention for older women with breast cancer . This study examined the effects of a virtual reality distraction intervention on chemotherapy-related symptom distress levels in 16 women aged 50 and older . A cross-over design was used to answer the following research questions : ( 1 ) Is virtual reality an effective distraction intervention for reducing chemotherapy-related symptom distress levels in older women with breast cancer ? ( 2 ) Does virtual reality have a lasting effect ? Chemotherapy treatments are intensive and difficult to endure . One way to cope with chemotherapy-related symptom distress is through the use of distraction . For this study , a head-mounted display ( Sony PC Glasstron PLM - S700 ) was used to display encompassing images and block competing stimuli during chemotherapy infusions . The Symptom Distress Scale ( SDS ) , Revised Piper Fatigue Scale ( PFS ) , and the State Anxiety Inventory ( SAI ) were used to measure symptom distress . For two matched chemotherapy treatments , one pre-test and two post-test measures were employed . Participants were randomly assigned to receive the VR distraction intervention during one chemotherapy treatment and received no distraction intervention ( control condition ) during an alternate chemotherapy treatment . Analysis using paired t-tests demonstrated a significant decrease in the SAI ( p = 0.10 ) scores immediately following chemotherapy treatments when participants used VR . No significant changes were found in SDS or PFS values . There was a consistent trend toward improved symptoms on all measures 48 h following completion of chemotherapy . Evaluation of the intervention indicated that women thought the head mounted device was easy to use , they experienced no cybersickness , and 100 % would use VR again .	[ "Virtual", "reality", "intervention", "for", "older", "women", "with", "breast", "cancer", ".", "This", "study", "examined", "the", "effects", "of", "a", "virtual", "reality", "distraction", "intervention", "on", "chemotherapy", "-", "related", "symptom", "distress", "levels", "in", "16", "women", "aged", "50", "and", "older", ".", "A", "cross", "-", "over", "design", "was", "used", "to", "answer", "the", "following", "research", "questions", ":", "(", "1", ")", "Is", "virtual", "reality", "an", "effective", "distraction", "intervention", "for", "reducing", "chemotherapy", "-", "related", "symptom", "distress", "levels", "in", "older", "women", "with", "breast", "cancer", "?", "(", "2", ")", "Does", "virtual", "reality", "have", "a", "lasting", "effect", "?", "Chemotherapy", "treatments", "are", "intensive", "and", "difficult", "to", "endure", ".", "One", "way", "to", "cope", "with", "chemotherapy", "-", "related", "symptom", "distress", "is", "through", "the", "use", "of", "distraction", ".", "For", "this", "study", ",", "a", "head", "-", "mounted", "display", "(", "Sony", "PC", "Glasstron", "PLM", "-", "S700", ")", "was", "used", "to", "display", "encompassing", "images", "and", "block", "competing", "stimuli", "during", "chemotherapy", "infusions", ".", "The", "Symptom", "Distress", "Scale", "(", "SDS", ")", ",", "Revised", "Piper", "Fatigue", "Scale", "(", "PFS", ")", ",", "and", "the", "State", "Anxiety", "Inventory", "(", "SAI", ")", "were", "used", "to", "measure", "symptom", "distress", ".", "For", "two", "matched", "chemotherapy", "treatments", ",", "one", "pre", "-", "test", "and", "two", "post", "-", "test", "measures", "were", "employed", ".", "Participants", "were", "randomly", "assigned", "to", "receive", "the", "VR", "distraction", "intervention", "during", "one", "chemotherapy", "treatment", "and", "received", "no", "distraction", "intervention", "(", "control", "condition", ")", "during", "an", "alternate", "chemotherapy", "treatment", ".", "Analysis", "using", "paired", "t", "-", "tests", "demonstrated", "a", "significant", "decrease", "in", "the", "SAI", "(", "p", "=", "0.10", ")", "scores", "immediately", "following", "chemotherapy", "treatments", "when", "participants", "used", "VR", ".", "No", "significant", "changes", "were", "found", "in", "SDS", "or", "PFS", "values", ".", "There", "was", "a", "consistent", "trend", "toward", "improved", "symptoms", "on", "all", "measures", "48", "h", "following", "completion", "of", "chemotherapy", ".", "Evaluation", "of", "the", "intervention", "indicated", "that", "women", "thought", "the", "head", "mounted", "device", "was", "easy", "to", "use", ",", "they", "experienced", "no", "cybersickness", ",", "and", "100", "%", "would", "use", "VR", "again", "." ]	[ "Intervention_Psychological", "Intervention_Educational", "Intervention_Control", "Outcome_Physical", "Outcome_Mental", "Participant_Condition", "Participant_Age", "Outcome_Other", "Participant_Sex", "Participant_Sample-size" ]
Polydioxanone sternal sutures is a Intervention_Surgical, Sternal dehiscence is a Outcome_Physical, wound instability is a Outcome_Physical, complications is a Outcome_Adverse-effects, stainless steel is a Intervention_Surgical, efficacy is a Outcome_Other, polydioxanone ( PDS ) suture is a Intervention_Surgical, sternal closure is a Outcome_Physical, aseptic sternal complications is a Outcome_Adverse-effects, bone dehiscence is a Outcome_Physical, superficial wound instability is a Outcome_Physical, diabetes is a Outcome_Physical, osteoporosis is a Outcome_Physical	28527_task0	Sentence: Polydioxanone sternal sutures for prevention of sternal dehiscence . BACKGROUND Sternal dehiscence and wound instability are troublesome complications following median sternotomy . Classic sternal approximation with stainless steel wires may not be the ideal approach in patients predisposed to these complications . We tested the efficacy of polydioxanone ( PDS ) suture in sternal closure and in prevention of complications in comparison to steel wires in high-risk individuals . METHODS Three hundred sixty-six patients undergoing elective cardiac surgery with full median sternotomy and having body surface area ( BSA ) less than 1.5 m ( 2 ) were randomly assigned to receive PDS ( n = 181 ) or stainless steel ( SS , n = 185 ) sternal approximation . The study was focused on aseptic sternal complications , namely bone dehiscence and superficial wound instability . RESULTS Both bone dehiscence and superficial wound instability were less frequent in the PDS Group ( 4 and 3 cases in the SS Group , respectively , vs. no cases in the PDS Group ) . Cox proportional hazards regression model in the whole study population identified female sex , chronic renal insufficiency , diabetes , advanced age , lower sternal thickness , osteoporosis , corticosteroid therapy , and prolonged CPB or ventilation times as predisposing factors to any of the two studied sternal complications . DISCUSSION Data suggest that PDS suture can protect against development of aseptic sternal complications following median sternotomy in high-risk patients with little body mass . The adoption of PDS in other subsets of patients , i.e. , obese individuals , is to be questioned . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Outcome_Other, Outcome_Physical, Outcome_Adverse-effects, Intervention_Surgical	[ "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Polydioxanone sternal sutures for prevention of sternal dehiscence . BACKGROUND Sternal dehiscence and wound instability are troublesome complications following median sternotomy . Classic sternal approximation with stainless steel wires may not be the ideal approach in patients predisposed to these complications . We tested the efficacy of polydioxanone ( PDS ) suture in sternal closure and in prevention of complications in comparison to steel wires in high-risk individuals . METHODS Three hundred sixty-six patients undergoing elective cardiac surgery with full median sternotomy and having body surface area ( BSA ) less than 1.5 m ( 2 ) were randomly assigned to receive PDS ( n = 181 ) or stainless steel ( SS , n = 185 ) sternal approximation . The study was focused on aseptic sternal complications , namely bone dehiscence and superficial wound instability . RESULTS Both bone dehiscence and superficial wound instability were less frequent in the PDS Group ( 4 and 3 cases in the SS Group , respectively , vs. no cases in the PDS Group ) . Cox proportional hazards regression model in the whole study population identified female sex , chronic renal insufficiency , diabetes , advanced age , lower sternal thickness , osteoporosis , corticosteroid therapy , and prolonged CPB or ventilation times as predisposing factors to any of the two studied sternal complications . DISCUSSION Data suggest that PDS suture can protect against development of aseptic sternal complications following median sternotomy in high-risk patients with little body mass . The adoption of PDS in other subsets of patients , i.e. , obese individuals , is to be questioned .	[ "Polydioxanone", "sternal", "sutures", "for", "prevention", "of", "sternal", "dehiscence", ".", "BACKGROUND", "Sternal", "dehiscence", "and", "wound", "instability", "are", "troublesome", "complications", "following", "median", "sternotomy", ".", "Classic", "sternal", "approximation", "with", "stainless", "steel", "wires", "may", "not", "be", "the", "ideal", "approach", "in", "patients", "predisposed", "to", "these", "complications", ".", "We", "tested", "the", "efficacy", "of", "polydioxanone", "(", "PDS", ")", "suture", "in", "sternal", "closure", "and", "in", "prevention", "of", "complications", "in", "comparison", "to", "steel", "wires", "in", "high", "-", "risk", "individuals", ".", "METHODS", "Three", "hundred", "sixty", "-", "six", "patients", "undergoing", "elective", "cardiac", "surgery", "with", "full", "median", "sternotomy", "and", "having", "body", "surface", "area", "(", "BSA", ")", "less", "than", "1.5", "m", "(", "2", ")", "were", "randomly", "assigned", "to", "receive", "PDS", "(", "n", "=", "181", ")", "or", "stainless", "steel", "(", "SS", ",", "n", "=", "185", ")", "sternal", "approximation", ".", "The", "study", "was", "focused", "on", "aseptic", "sternal", "complications", ",", "namely", "bone", "dehiscence", "and", "superficial", "wound", "instability", ".", "RESULTS", "Both", "bone", "dehiscence", "and", "superficial", "wound", "instability", "were", "less", "frequent", "in", "the", "PDS", "Group", "(", "4", "and", "3", "cases", "in", "the", "SS", "Group", ",", "respectively", ",", "vs", ".", "no", "cases", "in", "the", "PDS", "Group", ")", ".", "Cox", "proportional", "hazards", "regression", "model", "in", "the", "whole", "study", "population", "identified", "female", "sex", ",", "chronic", "renal", "insufficiency", ",", "diabetes", ",", "advanced", "age", ",", "lower", "sternal", "thickness", ",", "osteoporosis", ",", "corticosteroid", "therapy", ",", "and", "prolonged", "CPB", "or", "ventilation", "times", "as", "predisposing", "factors", "to", "any", "of", "the", "two", "studied", "sternal", "complications", ".", "DISCUSSION", "Data", "suggest", "that", "PDS", "suture", "can", "protect", "against", "development", "of", "aseptic", "sternal", "complications", "following", "median", "sternotomy", "in", "high", "-", "risk", "patients", "with", "little", "body", "mass", ".", "The", "adoption", "of", "PDS", "in", "other", "subsets", "of", "patients", ",", "i.e", ".", ",", "obese", "individuals", ",", "is", "to", "be", "questioned", "." ]	[ "Intervention_Surgical", "Outcome_Physical", "Outcome_Adverse-effects", "Outcome_Other" ]
Polydioxanone sternal sutures is a Intervention_Surgical, Sternal dehiscence is a Outcome_Physical, wound instability is a Outcome_Physical, complications is a Outcome_Adverse-effects, stainless steel is a Intervention_Surgical, efficacy is a Outcome_Other, polydioxanone ( PDS ) suture is a Intervention_Surgical, sternal closure is a Outcome_Physical, aseptic sternal complications is a Outcome_Adverse-effects, bone dehiscence is a Outcome_Physical, superficial wound instability is a Outcome_Physical, diabetes is a Outcome_Physical, osteoporosis is a Outcome_Physical	28527_task1	Sentence: Polydioxanone sternal sutures for prevention of sternal dehiscence . BACKGROUND Sternal dehiscence and wound instability are troublesome complications following median sternotomy . Classic sternal approximation with stainless steel wires may not be the ideal approach in patients predisposed to these complications . We tested the efficacy of polydioxanone ( PDS ) suture in sternal closure and in prevention of complications in comparison to steel wires in high-risk individuals . METHODS Three hundred sixty-six patients undergoing elective cardiac surgery with full median sternotomy and having body surface area ( BSA ) less than 1.5 m ( 2 ) were randomly assigned to receive PDS ( n = 181 ) or stainless steel ( SS , n = 185 ) sternal approximation . The study was focused on aseptic sternal complications , namely bone dehiscence and superficial wound instability . RESULTS Both bone dehiscence and superficial wound instability were less frequent in the PDS Group ( 4 and 3 cases in the SS Group , respectively , vs. no cases in the PDS Group ) . Cox proportional hazards regression model in the whole study population identified female sex , chronic renal insufficiency , diabetes , advanced age , lower sternal thickness , osteoporosis , corticosteroid therapy , and prolonged CPB or ventilation times as predisposing factors to any of the two studied sternal complications . DISCUSSION Data suggest that PDS suture can protect against development of aseptic sternal complications following median sternotomy in high-risk patients with little body mass . The adoption of PDS in other subsets of patients , i.e. , obese individuals , is to be questioned . Instructions: please typing these entity words according to sentence: Polydioxanone sternal sutures, Sternal dehiscence, wound instability, complications, stainless steel, efficacy, polydioxanone ( PDS ) suture, sternal closure, aseptic sternal complications, bone dehiscence, superficial wound instability, diabetes, osteoporosis Options: Outcome_Other, Outcome_Physical, Outcome_Adverse-effects, Intervention_Surgical	[ "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Polydioxanone sternal sutures for prevention of sternal dehiscence . BACKGROUND Sternal dehiscence and wound instability are troublesome complications following median sternotomy . Classic sternal approximation with stainless steel wires may not be the ideal approach in patients predisposed to these complications . We tested the efficacy of polydioxanone ( PDS ) suture in sternal closure and in prevention of complications in comparison to steel wires in high-risk individuals . METHODS Three hundred sixty-six patients undergoing elective cardiac surgery with full median sternotomy and having body surface area ( BSA ) less than 1.5 m ( 2 ) were randomly assigned to receive PDS ( n = 181 ) or stainless steel ( SS , n = 185 ) sternal approximation . The study was focused on aseptic sternal complications , namely bone dehiscence and superficial wound instability . RESULTS Both bone dehiscence and superficial wound instability were less frequent in the PDS Group ( 4 and 3 cases in the SS Group , respectively , vs. no cases in the PDS Group ) . Cox proportional hazards regression model in the whole study population identified female sex , chronic renal insufficiency , diabetes , advanced age , lower sternal thickness , osteoporosis , corticosteroid therapy , and prolonged CPB or ventilation times as predisposing factors to any of the two studied sternal complications . DISCUSSION Data suggest that PDS suture can protect against development of aseptic sternal complications following median sternotomy in high-risk patients with little body mass . The adoption of PDS in other subsets of patients , i.e. , obese individuals , is to be questioned .	[ "Polydioxanone", "sternal", "sutures", "for", "prevention", "of", "sternal", "dehiscence", ".", "BACKGROUND", "Sternal", "dehiscence", "and", "wound", "instability", "are", "troublesome", "complications", "following", "median", "sternotomy", ".", "Classic", "sternal", "approximation", "with", "stainless", "steel", "wires", "may", "not", "be", "the", "ideal", "approach", "in", "patients", "predisposed", "to", "these", "complications", ".", "We", "tested", "the", "efficacy", "of", "polydioxanone", "(", "PDS", ")", "suture", "in", "sternal", "closure", "and", "in", "prevention", "of", "complications", "in", "comparison", "to", "steel", "wires", "in", "high", "-", "risk", "individuals", ".", "METHODS", "Three", "hundred", "sixty", "-", "six", "patients", "undergoing", "elective", "cardiac", "surgery", "with", "full", "median", "sternotomy", "and", "having", "body", "surface", "area", "(", "BSA", ")", "less", "than", "1.5", "m", "(", "2", ")", "were", "randomly", "assigned", "to", "receive", "PDS", "(", "n", "=", "181", ")", "or", "stainless", "steel", "(", "SS", ",", "n", "=", "185", ")", "sternal", "approximation", ".", "The", "study", "was", "focused", "on", "aseptic", "sternal", "complications", ",", "namely", "bone", "dehiscence", "and", "superficial", "wound", "instability", ".", "RESULTS", "Both", "bone", "dehiscence", "and", "superficial", "wound", "instability", "were", "less", "frequent", "in", "the", "PDS", "Group", "(", "4", "and", "3", "cases", "in", "the", "SS", "Group", ",", "respectively", ",", "vs", ".", "no", "cases", "in", "the", "PDS", "Group", ")", ".", "Cox", "proportional", "hazards", "regression", "model", "in", "the", "whole", "study", "population", "identified", "female", "sex", ",", "chronic", "renal", "insufficiency", ",", "diabetes", ",", "advanced", "age", ",", "lower", "sternal", "thickness", ",", "osteoporosis", ",", "corticosteroid", "therapy", ",", "and", "prolonged", "CPB", "or", "ventilation", "times", "as", "predisposing", "factors", "to", "any", "of", "the", "two", "studied", "sternal", "complications", ".", "DISCUSSION", "Data", "suggest", "that", "PDS", "suture", "can", "protect", "against", "development", "of", "aseptic", "sternal", "complications", "following", "median", "sternotomy", "in", "high", "-", "risk", "patients", "with", "little", "body", "mass", ".", "The", "adoption", "of", "PDS", "in", "other", "subsets", "of", "patients", ",", "i.e", ".", ",", "obese", "individuals", ",", "is", "to", "be", "questioned", "." ]	[ "Intervention_Surgical", "Outcome_Physical", "Outcome_Adverse-effects", "Outcome_Other" ]
Polydioxanone sternal sutures, Sternal dehiscence, wound instability, complications, stainless steel, efficacy, polydioxanone ( PDS ) suture, sternal closure, aseptic sternal complications, bone dehiscence, superficial wound instability, diabetes, osteoporosis	28527_task2	Sentence: Polydioxanone sternal sutures for prevention of sternal dehiscence . BACKGROUND Sternal dehiscence and wound instability are troublesome complications following median sternotomy . Classic sternal approximation with stainless steel wires may not be the ideal approach in patients predisposed to these complications . We tested the efficacy of polydioxanone ( PDS ) suture in sternal closure and in prevention of complications in comparison to steel wires in high-risk individuals . METHODS Three hundred sixty-six patients undergoing elective cardiac surgery with full median sternotomy and having body surface area ( BSA ) less than 1.5 m ( 2 ) were randomly assigned to receive PDS ( n = 181 ) or stainless steel ( SS , n = 185 ) sternal approximation . The study was focused on aseptic sternal complications , namely bone dehiscence and superficial wound instability . RESULTS Both bone dehiscence and superficial wound instability were less frequent in the PDS Group ( 4 and 3 cases in the SS Group , respectively , vs. no cases in the PDS Group ) . Cox proportional hazards regression model in the whole study population identified female sex , chronic renal insufficiency , diabetes , advanced age , lower sternal thickness , osteoporosis , corticosteroid therapy , and prolonged CPB or ventilation times as predisposing factors to any of the two studied sternal complications . DISCUSSION Data suggest that PDS suture can protect against development of aseptic sternal complications following median sternotomy in high-risk patients with little body mass . The adoption of PDS in other subsets of patients , i.e. , obese individuals , is to be questioned . Instructions: please extract entity words from the input sentence	[ "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Polydioxanone sternal sutures for prevention of sternal dehiscence . BACKGROUND Sternal dehiscence and wound instability are troublesome complications following median sternotomy . Classic sternal approximation with stainless steel wires may not be the ideal approach in patients predisposed to these complications . We tested the efficacy of polydioxanone ( PDS ) suture in sternal closure and in prevention of complications in comparison to steel wires in high-risk individuals . METHODS Three hundred sixty-six patients undergoing elective cardiac surgery with full median sternotomy and having body surface area ( BSA ) less than 1.5 m ( 2 ) were randomly assigned to receive PDS ( n = 181 ) or stainless steel ( SS , n = 185 ) sternal approximation . The study was focused on aseptic sternal complications , namely bone dehiscence and superficial wound instability . RESULTS Both bone dehiscence and superficial wound instability were less frequent in the PDS Group ( 4 and 3 cases in the SS Group , respectively , vs. no cases in the PDS Group ) . Cox proportional hazards regression model in the whole study population identified female sex , chronic renal insufficiency , diabetes , advanced age , lower sternal thickness , osteoporosis , corticosteroid therapy , and prolonged CPB or ventilation times as predisposing factors to any of the two studied sternal complications . DISCUSSION Data suggest that PDS suture can protect against development of aseptic sternal complications following median sternotomy in high-risk patients with little body mass . The adoption of PDS in other subsets of patients , i.e. , obese individuals , is to be questioned .	[ "Polydioxanone", "sternal", "sutures", "for", "prevention", "of", "sternal", "dehiscence", ".", "BACKGROUND", "Sternal", "dehiscence", "and", "wound", "instability", "are", "troublesome", "complications", "following", "median", "sternotomy", ".", "Classic", "sternal", "approximation", "with", "stainless", "steel", "wires", "may", "not", "be", "the", "ideal", "approach", "in", "patients", "predisposed", "to", "these", "complications", ".", "We", "tested", "the", "efficacy", "of", "polydioxanone", "(", "PDS", ")", "suture", "in", "sternal", "closure", "and", "in", "prevention", "of", "complications", "in", "comparison", "to", "steel", "wires", "in", "high", "-", "risk", "individuals", ".", "METHODS", "Three", "hundred", "sixty", "-", "six", "patients", "undergoing", "elective", "cardiac", "surgery", "with", "full", "median", "sternotomy", "and", "having", "body", "surface", "area", "(", "BSA", ")", "less", "than", "1.5", "m", "(", "2", ")", "were", "randomly", "assigned", "to", "receive", "PDS", "(", "n", "=", "181", ")", "or", "stainless", "steel", "(", "SS", ",", "n", "=", "185", ")", "sternal", "approximation", ".", "The", "study", "was", "focused", "on", "aseptic", "sternal", "complications", ",", "namely", "bone", "dehiscence", "and", "superficial", "wound", "instability", ".", "RESULTS", "Both", "bone", "dehiscence", "and", "superficial", "wound", "instability", "were", "less", "frequent", "in", "the", "PDS", "Group", "(", "4", "and", "3", "cases", "in", "the", "SS", "Group", ",", "respectively", ",", "vs", ".", "no", "cases", "in", "the", "PDS", "Group", ")", ".", "Cox", "proportional", "hazards", "regression", "model", "in", "the", "whole", "study", "population", "identified", "female", "sex", ",", "chronic", "renal", "insufficiency", ",", "diabetes", ",", "advanced", "age", ",", "lower", "sternal", "thickness", ",", "osteoporosis", ",", "corticosteroid", "therapy", ",", "and", "prolonged", "CPB", "or", "ventilation", "times", "as", "predisposing", "factors", "to", "any", "of", "the", "two", "studied", "sternal", "complications", ".", "DISCUSSION", "Data", "suggest", "that", "PDS", "suture", "can", "protect", "against", "development", "of", "aseptic", "sternal", "complications", "following", "median", "sternotomy", "in", "high", "-", "risk", "patients", "with", "little", "body", "mass", ".", "The", "adoption", "of", "PDS", "in", "other", "subsets", "of", "patients", ",", "i.e", ".", ",", "obese", "individuals", ",", "is", "to", "be", "questioned", "." ]	[ "Intervention_Surgical", "Outcome_Physical", "Outcome_Adverse-effects", "Outcome_Other" ]
use is an umlsterm, porcine is an umlsterm, skin is an umlsterm, human is an umlsterm, integument is an umlsterm, literature is an umlsterm, epidermis is an umlsterm, dermis is an umlsterm, human is an umlsterm, skin is an umlsterm, utilization is an umlsterm, porcine is an umlsterm, skin is an umlsterm, research is an umlsterm, use is an umlsterm, porcine is an umlsterm, skin is an umlsterm, research is an umlsterm, breeds is an umlsterm	DerHautarzt.60470178.eng.abstr_task0	Sentence: The use of porcine skin as a biomedical model for the human integument is discussed with reference to the literature . The epidermis and dermis can be used as a model as there are clear structural , functional and biochemical similarities with human skin layers . The actual utilization of porcine skin in dermatological research is reviewed . Practical difficulties are emphasized : in particular , the conditions required for use of porcine skin in experimental research , the most suitable breeds , and restrictions on biological interpretation of the results . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The use of porcine skin as a biomedical model for the human integument is discussed with reference to the literature . The epidermis and dermis can be used as a model as there are clear structural , functional and biochemical similarities with human skin layers . The actual utilization of porcine skin in dermatological research is reviewed . Practical difficulties are emphasized : in particular , the conditions required for use of porcine skin in experimental research , the most suitable breeds , and restrictions on biological interpretation of the results .	[ "The", "use", "of", "porcine", "skin", "as", "a", "biomedical", "model", "for", "the", "human", "integument", "is", "discussed", "with", "reference", "to", "the", "literature", ".", "The", "epidermis", "and", "dermis", "can", "be", "used", "as", "a", "model", "as", "there", "are", "clear", "structural", ",", "functional", "and", "biochemical", "similarities", "with", "human", "skin", "layers", ".", "The", "actual", "utilization", "of", "porcine", "skin", "in", "dermatological", "research", "is", "reviewed", ".", "Practical", "difficulties", "are", "emphasized", ":", "in", "particular", ",", "the", "conditions", "required", "for", "use", "of", "porcine", "skin", "in", "experimental", "research", ",", "the", "most", "suitable", "breeds", ",", "and", "restrictions", "on", "biological", "interpretation", "of", "the", "results", "." ]	[ "umlsterm" ]
use is an umlsterm, porcine is an umlsterm, skin is an umlsterm, human is an umlsterm, integument is an umlsterm, literature is an umlsterm, epidermis is an umlsterm, dermis is an umlsterm, human is an umlsterm, skin is an umlsterm, utilization is an umlsterm, porcine is an umlsterm, skin is an umlsterm, research is an umlsterm, use is an umlsterm, porcine is an umlsterm, skin is an umlsterm, research is an umlsterm, breeds is an umlsterm	DerHautarzt.60470178.eng.abstr_task1	Sentence: The use of porcine skin as a biomedical model for the human integument is discussed with reference to the literature . The epidermis and dermis can be used as a model as there are clear structural , functional and biochemical similarities with human skin layers . The actual utilization of porcine skin in dermatological research is reviewed . Practical difficulties are emphasized : in particular , the conditions required for use of porcine skin in experimental research , the most suitable breeds , and restrictions on biological interpretation of the results . Instructions: please typing these entity words according to sentence: use, porcine, skin, human, integument, literature, epidermis, dermis, human, skin, utilization, porcine, skin, research, use, porcine, skin, research, breeds Options: umlsterm	[ "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The use of porcine skin as a biomedical model for the human integument is discussed with reference to the literature . The epidermis and dermis can be used as a model as there are clear structural , functional and biochemical similarities with human skin layers . The actual utilization of porcine skin in dermatological research is reviewed . Practical difficulties are emphasized : in particular , the conditions required for use of porcine skin in experimental research , the most suitable breeds , and restrictions on biological interpretation of the results .	[ "The", "use", "of", "porcine", "skin", "as", "a", "biomedical", "model", "for", "the", "human", "integument", "is", "discussed", "with", "reference", "to", "the", "literature", ".", "The", "epidermis", "and", "dermis", "can", "be", "used", "as", "a", "model", "as", "there", "are", "clear", "structural", ",", "functional", "and", "biochemical", "similarities", "with", "human", "skin", "layers", ".", "The", "actual", "utilization", "of", "porcine", "skin", "in", "dermatological", "research", "is", "reviewed", ".", "Practical", "difficulties", "are", "emphasized", ":", "in", "particular", ",", "the", "conditions", "required", "for", "use", "of", "porcine", "skin", "in", "experimental", "research", ",", "the", "most", "suitable", "breeds", ",", "and", "restrictions", "on", "biological", "interpretation", "of", "the", "results", "." ]	[ "umlsterm" ]
use, porcine, skin, human, integument, literature, epidermis, dermis, human, skin, utilization, porcine, skin, research, use, porcine, skin, research, breeds	DerHautarzt.60470178.eng.abstr_task2	Sentence: The use of porcine skin as a biomedical model for the human integument is discussed with reference to the literature . The epidermis and dermis can be used as a model as there are clear structural , functional and biochemical similarities with human skin layers . The actual utilization of porcine skin in dermatological research is reviewed . Practical difficulties are emphasized : in particular , the conditions required for use of porcine skin in experimental research , the most suitable breeds , and restrictions on biological interpretation of the results . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The use of porcine skin as a biomedical model for the human integument is discussed with reference to the literature . The epidermis and dermis can be used as a model as there are clear structural , functional and biochemical similarities with human skin layers . The actual utilization of porcine skin in dermatological research is reviewed . Practical difficulties are emphasized : in particular , the conditions required for use of porcine skin in experimental research , the most suitable breeds , and restrictions on biological interpretation of the results .	[ "The", "use", "of", "porcine", "skin", "as", "a", "biomedical", "model", "for", "the", "human", "integument", "is", "discussed", "with", "reference", "to", "the", "literature", ".", "The", "epidermis", "and", "dermis", "can", "be", "used", "as", "a", "model", "as", "there", "are", "clear", "structural", ",", "functional", "and", "biochemical", "similarities", "with", "human", "skin", "layers", ".", "The", "actual", "utilization", "of", "porcine", "skin", "in", "dermatological", "research", "is", "reviewed", ".", "Practical", "difficulties", "are", "emphasized", ":", "in", "particular", ",", "the", "conditions", "required", "for", "use", "of", "porcine", "skin", "in", "experimental", "research", ",", "the", "most", "suitable", "breeds", ",", "and", "restrictions", "on", "biological", "interpretation", "of", "the", "results", "." ]	[ "umlsterm" ]
Stress incontinence is an umlsterm, form is an umlsterm, females is an umlsterm, method is an umlsterm, surgery is an umlsterm, bladder is an umlsterm, neck is an umlsterm, techniques is an umlsterm, bladder is an umlsterm, neck is an umlsterm, suspension is an umlsterm, women is an umlsterm, surgery is an umlsterm, postoperative is an umlsterm, patients is an umlsterm, surgical is an umlsterm, techniques is an umlsterm, patients is an umlsterm, patients is an umlsterm, patients is an umlsterm, technique is an umlsterm, obese is an umlsterm, patients is an umlsterm, regression is an umlsterm, time is an umlsterm, surgery is an umlsterm, method is an umlsterm, technique is an umlsterm, procedure is an umlsterm, method is an umlsterm, choice is an umlsterm, stress incontinence is an umlsterm	DerUrologeA.70360400.eng.abstr_task0	Sentence: Stress incontinence is the most frequent form of incontinence found in females . The usual method of surgery for this is to lift the bladder neck towards cranial and ventral . Two competitive techniques - bladder neck suspension in accordance with Stamey and colposuspension in accordance with Burch - were retrospectively investigated . A total of 95 women underwent surgery and it was possible to evaluate the postoperative course in 46 and 30 ( total 76 ) patients respectively . Initially , both surgical techniques demonstrated a very good success rate ( 91.3 % and 96.7 % resp. ) . However , the continence rate of the Stamey patients deteriorated after 6 weeks down to 78.3 % and after more than 2 years only 28.6 % of these patients were still completely continent ( mean follow-up 40.4 mths ) , whereas deterioration in the Burch patients was only 87 % ( mean follow-up 44.25 mths ) . The disappointing results with the Stamey technique did not correlate with the degree of initial continence . It was noted here that obese patients showed a greater tendency towards regression . The three cases of recurring incontinence after Burch colposuspension were already relapses at the time of surgery . With respect to long-term follow-up , our results with the Stamey method were distinctly poorer than with the Burch technique . Therefore , in our opinion , the Burch colposuspension procedure and fascioplasty should be the method of choice for the management of stress incontinence . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Stress incontinence is the most frequent form of incontinence found in females . The usual method of surgery for this is to lift the bladder neck towards cranial and ventral . Two competitive techniques - bladder neck suspension in accordance with Stamey and colposuspension in accordance with Burch - were retrospectively investigated . A total of 95 women underwent surgery and it was possible to evaluate the postoperative course in 46 and 30 ( total 76 ) patients respectively . Initially , both surgical techniques demonstrated a very good success rate ( 91.3 % and 96.7 % resp. ) . However , the continence rate of the Stamey patients deteriorated after 6 weeks down to 78.3 % and after more than 2 years only 28.6 % of these patients were still completely continent ( mean follow-up 40.4 mths ) , whereas deterioration in the Burch patients was only 87 % ( mean follow-up 44.25 mths ) . The disappointing results with the Stamey technique did not correlate with the degree of initial continence . It was noted here that obese patients showed a greater tendency towards regression . The three cases of recurring incontinence after Burch colposuspension were already relapses at the time of surgery . With respect to long-term follow-up , our results with the Stamey method were distinctly poorer than with the Burch technique . Therefore , in our opinion , the Burch colposuspension procedure and fascioplasty should be the method of choice for the management of stress incontinence .	[ "Stress", "incontinence", "is", "the", "most", "frequent", "form", "of", "incontinence", "found", "in", "females", ".", "The", "usual", "method", "of", "surgery", "for", "this", "is", "to", "lift", "the", "bladder", "neck", "towards", "cranial", "and", "ventral", ".", "Two", "competitive", "techniques", "-", "bladder", "neck", "suspension", "in", "accordance", "with", "Stamey", "and", "colposuspension", "in", "accordance", "with", "Burch", "-", "were", "retrospectively", "investigated", ".", "A", "total", "of", "95", "women", "underwent", "surgery", "and", "it", "was", "possible", "to", "evaluate", "the", "postoperative", "course", "in", "46", "and", "30", "(", "total", "76", ")", "patients", "respectively", ".", "Initially", ",", "both", "surgical", "techniques", "demonstrated", "a", "very", "good", "success", "rate", "(", "91.3", "%", "and", "96.7", "%", "resp", ".", ")", ".", "However", ",", "the", "continence", "rate", "of", "the", "Stamey", "patients", "deteriorated", "after", "6", "weeks", "down", "to", "78.3", "%", "and", "after", "more", "than", "2", "years", "only", "28.6", "%", "of", "these", "patients", "were", "still", "completely", "continent", "(", "mean", "follow", "-", "up", "40.4", "mths", ")", ",", "whereas", "deterioration", "in", "the", "Burch", "patients", "was", "only", "87", "%", "(", "mean", "follow", "-", "up", "44.25", "mths", ")", ".", "The", "disappointing", "results", "with", "the", "Stamey", "technique", "did", "not", "correlate", "with", "the", "degree", "of", "initial", "continence", ".", "It", "was", "noted", "here", "that", "obese", "patients", "showed", "a", "greater", "tendency", "towards", "regression", ".", "The", "three", "cases", "of", "recurring", "incontinence", "after", "Burch", "colposuspension", "were", "already", "relapses", "at", "the", "time", "of", "surgery", ".", "With", "respect", "to", "long", "-", "term", "follow", "-", "up", ",", "our", "results", "with", "the", "Stamey", "method", "were", "distinctly", "poorer", "than", "with", "the", "Burch", "technique", ".", "Therefore", ",", "in", "our", "opinion", ",", "the", "Burch", "colposuspension", "procedure", "and", "fascioplasty", "should", "be", "the", "method", "of", "choice", "for", "the", "management", "of", "stress", "incontinence", "." ]	[ "umlsterm" ]
Stress incontinence is an umlsterm, form is an umlsterm, females is an umlsterm, method is an umlsterm, surgery is an umlsterm, bladder is an umlsterm, neck is an umlsterm, techniques is an umlsterm, bladder is an umlsterm, neck is an umlsterm, suspension is an umlsterm, women is an umlsterm, surgery is an umlsterm, postoperative is an umlsterm, patients is an umlsterm, surgical is an umlsterm, techniques is an umlsterm, patients is an umlsterm, patients is an umlsterm, patients is an umlsterm, technique is an umlsterm, obese is an umlsterm, patients is an umlsterm, regression is an umlsterm, time is an umlsterm, surgery is an umlsterm, method is an umlsterm, technique is an umlsterm, procedure is an umlsterm, method is an umlsterm, choice is an umlsterm, stress incontinence is an umlsterm	DerUrologeA.70360400.eng.abstr_task1	Sentence: Stress incontinence is the most frequent form of incontinence found in females . The usual method of surgery for this is to lift the bladder neck towards cranial and ventral . Two competitive techniques - bladder neck suspension in accordance with Stamey and colposuspension in accordance with Burch - were retrospectively investigated . A total of 95 women underwent surgery and it was possible to evaluate the postoperative course in 46 and 30 ( total 76 ) patients respectively . Initially , both surgical techniques demonstrated a very good success rate ( 91.3 % and 96.7 % resp. ) . However , the continence rate of the Stamey patients deteriorated after 6 weeks down to 78.3 % and after more than 2 years only 28.6 % of these patients were still completely continent ( mean follow-up 40.4 mths ) , whereas deterioration in the Burch patients was only 87 % ( mean follow-up 44.25 mths ) . The disappointing results with the Stamey technique did not correlate with the degree of initial continence . It was noted here that obese patients showed a greater tendency towards regression . The three cases of recurring incontinence after Burch colposuspension were already relapses at the time of surgery . With respect to long-term follow-up , our results with the Stamey method were distinctly poorer than with the Burch technique . Therefore , in our opinion , the Burch colposuspension procedure and fascioplasty should be the method of choice for the management of stress incontinence . Instructions: please typing these entity words according to sentence: Stress incontinence, form, females, method, surgery, bladder, neck, techniques, bladder, neck, suspension, women, surgery, postoperative, patients, surgical, techniques, patients, patients, patients, technique, obese, patients, regression, time, surgery, method, technique, procedure, method, choice, stress incontinence Options: umlsterm	[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Stress incontinence is the most frequent form of incontinence found in females . The usual method of surgery for this is to lift the bladder neck towards cranial and ventral . Two competitive techniques - bladder neck suspension in accordance with Stamey and colposuspension in accordance with Burch - were retrospectively investigated . A total of 95 women underwent surgery and it was possible to evaluate the postoperative course in 46 and 30 ( total 76 ) patients respectively . Initially , both surgical techniques demonstrated a very good success rate ( 91.3 % and 96.7 % resp. ) . However , the continence rate of the Stamey patients deteriorated after 6 weeks down to 78.3 % and after more than 2 years only 28.6 % of these patients were still completely continent ( mean follow-up 40.4 mths ) , whereas deterioration in the Burch patients was only 87 % ( mean follow-up 44.25 mths ) . The disappointing results with the Stamey technique did not correlate with the degree of initial continence . It was noted here that obese patients showed a greater tendency towards regression . The three cases of recurring incontinence after Burch colposuspension were already relapses at the time of surgery . With respect to long-term follow-up , our results with the Stamey method were distinctly poorer than with the Burch technique . Therefore , in our opinion , the Burch colposuspension procedure and fascioplasty should be the method of choice for the management of stress incontinence .	[ "Stress", "incontinence", "is", "the", "most", "frequent", "form", "of", "incontinence", "found", "in", "females", ".", "The", "usual", "method", "of", "surgery", "for", "this", "is", "to", "lift", "the", "bladder", "neck", "towards", "cranial", "and", "ventral", ".", "Two", "competitive", "techniques", "-", "bladder", "neck", "suspension", "in", "accordance", "with", "Stamey", "and", "colposuspension", "in", "accordance", "with", "Burch", "-", "were", "retrospectively", "investigated", ".", "A", "total", "of", "95", "women", "underwent", "surgery", "and", "it", "was", "possible", "to", "evaluate", "the", "postoperative", "course", "in", "46", "and", "30", "(", "total", "76", ")", "patients", "respectively", ".", "Initially", ",", "both", "surgical", "techniques", "demonstrated", "a", "very", "good", "success", "rate", "(", "91.3", "%", "and", "96.7", "%", "resp", ".", ")", ".", "However", ",", "the", "continence", "rate", "of", "the", "Stamey", "patients", "deteriorated", "after", "6", "weeks", "down", "to", "78.3", "%", "and", "after", "more", "than", "2", "years", "only", "28.6", "%", "of", "these", "patients", "were", "still", "completely", "continent", "(", "mean", "follow", "-", "up", "40.4", "mths", ")", ",", "whereas", "deterioration", "in", "the", "Burch", "patients", "was", "only", "87", "%", "(", "mean", "follow", "-", "up", "44.25", "mths", ")", ".", "The", "disappointing", "results", "with", "the", "Stamey", "technique", "did", "not", "correlate", "with", "the", "degree", "of", "initial", "continence", ".", "It", "was", "noted", "here", "that", "obese", "patients", "showed", "a", "greater", "tendency", "towards", "regression", ".", "The", "three", "cases", "of", "recurring", "incontinence", "after", "Burch", "colposuspension", "were", "already", "relapses", "at", "the", "time", "of", "surgery", ".", "With", "respect", "to", "long", "-", "term", "follow", "-", "up", ",", "our", "results", "with", "the", "Stamey", "method", "were", "distinctly", "poorer", "than", "with", "the", "Burch", "technique", ".", "Therefore", ",", "in", "our", "opinion", ",", "the", "Burch", "colposuspension", "procedure", "and", "fascioplasty", "should", "be", "the", "method", "of", "choice", "for", "the", "management", "of", "stress", "incontinence", "." ]	[ "umlsterm" ]
Stress incontinence, form, females, method, surgery, bladder, neck, techniques, bladder, neck, suspension, women, surgery, postoperative, patients, surgical, techniques, patients, patients, patients, technique, obese, patients, regression, time, surgery, method, technique, procedure, method, choice, stress incontinence	DerUrologeA.70360400.eng.abstr_task2	Sentence: Stress incontinence is the most frequent form of incontinence found in females . The usual method of surgery for this is to lift the bladder neck towards cranial and ventral . Two competitive techniques - bladder neck suspension in accordance with Stamey and colposuspension in accordance with Burch - were retrospectively investigated . A total of 95 women underwent surgery and it was possible to evaluate the postoperative course in 46 and 30 ( total 76 ) patients respectively . Initially , both surgical techniques demonstrated a very good success rate ( 91.3 % and 96.7 % resp. ) . However , the continence rate of the Stamey patients deteriorated after 6 weeks down to 78.3 % and after more than 2 years only 28.6 % of these patients were still completely continent ( mean follow-up 40.4 mths ) , whereas deterioration in the Burch patients was only 87 % ( mean follow-up 44.25 mths ) . The disappointing results with the Stamey technique did not correlate with the degree of initial continence . It was noted here that obese patients showed a greater tendency towards regression . The three cases of recurring incontinence after Burch colposuspension were already relapses at the time of surgery . With respect to long-term follow-up , our results with the Stamey method were distinctly poorer than with the Burch technique . Therefore , in our opinion , the Burch colposuspension procedure and fascioplasty should be the method of choice for the management of stress incontinence . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Stress incontinence is the most frequent form of incontinence found in females . The usual method of surgery for this is to lift the bladder neck towards cranial and ventral . Two competitive techniques - bladder neck suspension in accordance with Stamey and colposuspension in accordance with Burch - were retrospectively investigated . A total of 95 women underwent surgery and it was possible to evaluate the postoperative course in 46 and 30 ( total 76 ) patients respectively . Initially , both surgical techniques demonstrated a very good success rate ( 91.3 % and 96.7 % resp. ) . However , the continence rate of the Stamey patients deteriorated after 6 weeks down to 78.3 % and after more than 2 years only 28.6 % of these patients were still completely continent ( mean follow-up 40.4 mths ) , whereas deterioration in the Burch patients was only 87 % ( mean follow-up 44.25 mths ) . The disappointing results with the Stamey technique did not correlate with the degree of initial continence . It was noted here that obese patients showed a greater tendency towards regression . The three cases of recurring incontinence after Burch colposuspension were already relapses at the time of surgery . With respect to long-term follow-up , our results with the Stamey method were distinctly poorer than with the Burch technique . Therefore , in our opinion , the Burch colposuspension procedure and fascioplasty should be the method of choice for the management of stress incontinence .	[ "Stress", "incontinence", "is", "the", "most", "frequent", "form", "of", "incontinence", "found", "in", "females", ".", "The", "usual", "method", "of", "surgery", "for", "this", "is", "to", "lift", "the", "bladder", "neck", "towards", "cranial", "and", "ventral", ".", "Two", "competitive", "techniques", "-", "bladder", "neck", "suspension", "in", "accordance", "with", "Stamey", "and", "colposuspension", "in", "accordance", "with", "Burch", "-", "were", "retrospectively", "investigated", ".", "A", "total", "of", "95", "women", "underwent", "surgery", "and", "it", "was", "possible", "to", "evaluate", "the", "postoperative", "course", "in", "46", "and", "30", "(", "total", "76", ")", "patients", "respectively", ".", "Initially", ",", "both", "surgical", "techniques", "demonstrated", "a", "very", "good", "success", "rate", "(", "91.3", "%", "and", "96.7", "%", "resp", ".", ")", ".", "However", ",", "the", "continence", "rate", "of", "the", "Stamey", "patients", "deteriorated", "after", "6", "weeks", "down", "to", "78.3", "%", "and", "after", "more", "than", "2", "years", "only", "28.6", "%", "of", "these", "patients", "were", "still", "completely", "continent", "(", "mean", "follow", "-", "up", "40.4", "mths", ")", ",", "whereas", "deterioration", "in", "the", "Burch", "patients", "was", "only", "87", "%", "(", "mean", "follow", "-", "up", "44.25", "mths", ")", ".", "The", "disappointing", "results", "with", "the", "Stamey", "technique", "did", "not", "correlate", "with", "the", "degree", "of", "initial", "continence", ".", "It", "was", "noted", "here", "that", "obese", "patients", "showed", "a", "greater", "tendency", "towards", "regression", ".", "The", "three", "cases", "of", "recurring", "incontinence", "after", "Burch", "colposuspension", "were", "already", "relapses", "at", "the", "time", "of", "surgery", ".", "With", "respect", "to", "long", "-", "term", "follow", "-", "up", ",", "our", "results", "with", "the", "Stamey", "method", "were", "distinctly", "poorer", "than", "with", "the", "Burch", "technique", ".", "Therefore", ",", "in", "our", "opinion", ",", "the", "Burch", "colposuspension", "procedure", "and", "fascioplasty", "should", "be", "the", "method", "of", "choice", "for", "the", "management", "of", "stress", "incontinence", "." ]	[ "umlsterm" ]
lenalidomide is a compound, beta - catenin is a protein	DS.d1259_task0	Sentence: We also found an inhibitory effect of lenalidomide on the associations between cadherin 5, beta-catenin and CD31, adherens junction proteins whose interaction is critical for endothelial cell cord formation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	We also found an inhibitory effect of lenalidomide on the associations between cadherin 5, beta-catenin and CD31, adherens junction proteins whose interaction is critical for endothelial cell cord formation.	[ "We", "also", "found", "an", "inhibitory", "effect", "of", "lenalidomide", "on", "the", "associations", "between", "cadherin", "5", ",", "beta", "-", "catenin", "and", "CD31", ",", "adherens", "junction", "proteins", "whose", "interaction", "is", "critical", "for", "endothelial", "cell", "cord", "formation", "." ]	[ "compound", "protein" ]
lenalidomide is a compound, beta - catenin is a protein	DS.d1259_task1	Sentence: We also found an inhibitory effect of lenalidomide on the associations between cadherin 5, beta-catenin and CD31, adherens junction proteins whose interaction is critical for endothelial cell cord formation. Instructions: please typing these entity words according to sentence: lenalidomide, beta - catenin Options: compound, protein	[ "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	We also found an inhibitory effect of lenalidomide on the associations between cadherin 5, beta-catenin and CD31, adherens junction proteins whose interaction is critical for endothelial cell cord formation.	[ "We", "also", "found", "an", "inhibitory", "effect", "of", "lenalidomide", "on", "the", "associations", "between", "cadherin", "5", ",", "beta", "-", "catenin", "and", "CD31", ",", "adherens", "junction", "proteins", "whose", "interaction", "is", "critical", "for", "endothelial", "cell", "cord", "formation", "." ]	[ "compound", "protein" ]
lenalidomide, beta - catenin	DS.d1259_task2	Sentence: We also found an inhibitory effect of lenalidomide on the associations between cadherin 5, beta-catenin and CD31, adherens junction proteins whose interaction is critical for endothelial cell cord formation. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	We also found an inhibitory effect of lenalidomide on the associations between cadherin 5, beta-catenin and CD31, adherens junction proteins whose interaction is critical for endothelial cell cord formation.	[ "We", "also", "found", "an", "inhibitory", "effect", "of", "lenalidomide", "on", "the", "associations", "between", "cadherin", "5", ",", "beta", "-", "catenin", "and", "CD31", ",", "adherens", "junction", "proteins", "whose", "interaction", "is", "critical", "for", "endothelial", "cell", "cord", "formation", "." ]	[ "compound", "protein" ]
PEG is a CHEMICAL, interferon - alpha2a is a GENE-Y, IFNAR2 is a GENE-Y, Type - I Interferons is a GENE-N, IFNAR1 is a GENE-Y, IFNAR2 is a GENE-Y, Human recombinant Interferon - alpha(2a ) is a GENE-Y, IFNalpha(2a ) is a GENE-Y, IFNalpha(2a ) is a GENE-Y, PEG is a CHEMICAL, IFNalpha(2a ) is a GENE-Y, IFNalpha(2a ) is a GENE-Y, lysine is a CHEMICAL, IFNalpha(2a ) is a GENE-Y, IFNAR2 is a GENE-Y, IFNalpha(2a ) is a GENE-Y, IFNalpha(2a ) is a GENE-Y, PEG is a CHEMICAL, IFNalpha(2a ) is a GENE-Y	22002_task0	Sentence: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Type-I Interferons exert antiviral and antiproliferative activities through the binding to a common cell surface receptor comprising two subunits, IFNAR1 and IFNAR2. Human recombinant Interferon-alpha(2a) (IFNalpha(2a)) is a potent drug (Roferon-A) used to treat various cancers and viral diseases including Hepatitis B/C infections. To significantly improve the pharmacological properties of the drug, a pegylated form of IFNalpha(2a) was developed (PEGASYS). This 40 kDa PEG-conjugated IFNalpha(2a) ((40)PEG-IFNalpha(2a)) is obtained by the covalent binding of one 40 kDa branched PEG-polymer to a lysine side-chain of IFNalpha(2a). Here, we report the detailed structural, kinetic, and thermodynamic analysis of the binding to the extracellular domain of the receptor IFNAR2 of (40)PEG-IFNalpha(2a) and its isolated positional isomers modified at K31, K134, K131, K121, K164, and K70, respectively, in comparison with unmodified IFNalpha(2a). Our binding studies, using the surface plasmon resonance technique, show that the pegylation does not abolish the binding to the receptor, but significantly reduces the affinity mainly due to a change of the association rate. The results are supported by modeling and simulation of the binding, using Self-Avoiding-Walk calculations for the polymer conformations. A correlation between the structural parameters and the kinetic and thermodynamic parameters of the binding of the positional isomers could be established. For the Isomer-K31 and -K164, the PEG-polymer attachment point is located in proximity to the binding interface, and the isomers display affinity in the range 150-520 nM in an enthalpy-driven binding process. In contrast for the Isomer-K134, -K131, -K121, and -K70, the PEG-polymer is attached remotely from the binding interface, and the isomers exhibit a higher affinity (32-76 nM) in an entropy-driven binding process. This study constitutes an essential collection of knowledge on which the interaction of (40)PEG-IFNalpha(2a) and its positional isomers with its cellular receptors can be better understood. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, GENE-Y, CHEMICAL	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Type-I Interferons exert antiviral and antiproliferative activities through the binding to a common cell surface receptor comprising two subunits, IFNAR1 and IFNAR2. Human recombinant Interferon-alpha(2a) (IFNalpha(2a)) is a potent drug (Roferon-A) used to treat various cancers and viral diseases including Hepatitis B/C infections. To significantly improve the pharmacological properties of the drug, a pegylated form of IFNalpha(2a) was developed (PEGASYS). This 40 kDa PEG-conjugated IFNalpha(2a) ((40)PEG-IFNalpha(2a)) is obtained by the covalent binding of one 40 kDa branched PEG-polymer to a lysine side-chain of IFNalpha(2a). Here, we report the detailed structural, kinetic, and thermodynamic analysis of the binding to the extracellular domain of the receptor IFNAR2 of (40)PEG-IFNalpha(2a) and its isolated positional isomers modified at K31, K134, K131, K121, K164, and K70, respectively, in comparison with unmodified IFNalpha(2a). Our binding studies, using the surface plasmon resonance technique, show that the pegylation does not abolish the binding to the receptor, but significantly reduces the affinity mainly due to a change of the association rate. The results are supported by modeling and simulation of the binding, using Self-Avoiding-Walk calculations for the polymer conformations. A correlation between the structural parameters and the kinetic and thermodynamic parameters of the binding of the positional isomers could be established. For the Isomer-K31 and -K164, the PEG-polymer attachment point is located in proximity to the binding interface, and the isomers display affinity in the range 150-520 nM in an enthalpy-driven binding process. In contrast for the Isomer-K134, -K131, -K121, and -K70, the PEG-polymer is attached remotely from the binding interface, and the isomers exhibit a higher affinity (32-76 nM) in an entropy-driven binding process. This study constitutes an essential collection of knowledge on which the interaction of (40)PEG-IFNalpha(2a) and its positional isomers with its cellular receptors can be better understood.	[ "Structural", ",", "kinetic", ",", "and", "thermodynamic", "analysis", "of", "the", "binding", "of", "the", "40", "kDa", "PEG", "-", "interferon", "-", "alpha2a", "and", "its", "individual", "positional", "isomers", "to", "the", "extracellular", "domain", "of", "the", "receptor", "IFNAR2", ".", "\n", "Type", "-", "I", "Interferons", "exert", "antiviral", "and", "antiproliferative", "activities", "through", "the", "binding", "to", "a", "common", "cell", "surface", "receptor", "comprising", "two", "subunits", ",", "IFNAR1", "and", "IFNAR2", ".", "Human", "recombinant", "Interferon", "-", "alpha(2a", ")", "(", "IFNalpha(2a", ")", ")", "is", "a", "potent", "drug", "(", "Roferon", "-", "A", ")", "used", "to", "treat", "various", "cancers", "and", "viral", "diseases", "including", "Hepatitis", "B", "/", "C", "infections", ".", "To", "significantly", "improve", "the", "pharmacological", "properties", "of", "the", "drug", ",", "a", "pegylated", "form", "of", "IFNalpha(2a", ")", "was", "developed", "(", "PEGASYS", ")", ".", "This", "40", "kDa", "PEG", "-", "conjugated", "IFNalpha(2a", ")", "(", "(", "40)PEG", "-", "IFNalpha(2a", ")", ")", "is", "obtained", "by", "the", "covalent", "binding", "of", "one", "40", "kDa", "branched", "PEG", "-", "polymer", "to", "a", "lysine", "side", "-", "chain", "of", "IFNalpha(2a", ")", ".", "Here", ",", "we", "report", "the", "detailed", "structural", ",", "kinetic", ",", "and", "thermodynamic", "analysis", "of", "the", "binding", "to", "the", "extracellular", "domain", "of", "the", "receptor", "IFNAR2", "of", "(", "40)PEG", "-", "IFNalpha(2a", ")", "and", "its", "isolated", "positional", "isomers", "modified", "at", "K31", ",", "K134", ",", "K131", ",", "K121", ",", "K164", ",", "and", "K70", ",", "respectively", ",", "in", "comparison", "with", "unmodified", "IFNalpha(2a", ")", ".", "Our", "binding", "studies", ",", "using", "the", "surface", "plasmon", "resonance", "technique", ",", "show", "that", "the", "pegylation", "does", "not", "abolish", "the", "binding", "to", "the", "receptor", ",", "but", "significantly", "reduces", "the", "affinity", "mainly", "due", "to", "a", "change", "of", "the", "association", "rate", ".", "The", "results", "are", "supported", "by", "modeling", "and", "simulation", "of", "the", "binding", ",", "using", "Self", "-", "Avoiding", "-", "Walk", "calculations", "for", "the", "polymer", "conformations", ".", "A", "correlation", "between", "the", "structural", "parameters", "and", "the", "kinetic", "and", "thermodynamic", "parameters", "of", "the", "binding", "of", "the", "positional", "isomers", "could", "be", "established", ".", "For", "the", "Isomer", "-", "K31", "and", "-K164", ",", "the", "PEG", "-", "polymer", "attachment", "point", "is", "located", "in", "proximity", "to", "the", "binding", "interface", ",", "and", "the", "isomers", "display", "affinity", "in", "the", "range", "150", "-", "520", "nM", "in", "an", "enthalpy", "-", "driven", "binding", "process", ".", "In", "contrast", "for", "the", "Isomer", "-", "K134", ",", "-K131", ",", "-K121", ",", "and", "-K70", ",", "the", "PEG", "-", "polymer", "is", "attached", "remotely", "from", "the", "binding", "interface", ",", "and", "the", "isomers", "exhibit", "a", "higher", "affinity", "(", "32", "-", "76", "nM", ")", "in", "an", "entropy", "-", "driven", "binding", "process", ".", "This", "study", "constitutes", "an", "essential", "collection", "of", "knowledge", "on", "which", "the", "interaction", "of", "(", "40)PEG", "-", "IFNalpha(2a", ")", "and", "its", "positional", "isomers", "with", "its", "cellular", "receptors", "can", "be", "better", "understood", "." ]	[ "GENE-Y", "GENE-N", "CHEMICAL" ]
PEG is a CHEMICAL, interferon - alpha2a is a GENE-Y, IFNAR2 is a GENE-Y, Type - I Interferons is a GENE-N, IFNAR1 is a GENE-Y, IFNAR2 is a GENE-Y, Human recombinant Interferon - alpha(2a ) is a GENE-Y, IFNalpha(2a ) is a GENE-Y, IFNalpha(2a ) is a GENE-Y, PEG is a CHEMICAL, IFNalpha(2a ) is a GENE-Y, IFNalpha(2a ) is a GENE-Y, lysine is a CHEMICAL, IFNalpha(2a ) is a GENE-Y, IFNAR2 is a GENE-Y, IFNalpha(2a ) is a GENE-Y, IFNalpha(2a ) is a GENE-Y, PEG is a CHEMICAL, IFNalpha(2a ) is a GENE-Y	22002_task1	Sentence: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Type-I Interferons exert antiviral and antiproliferative activities through the binding to a common cell surface receptor comprising two subunits, IFNAR1 and IFNAR2. Human recombinant Interferon-alpha(2a) (IFNalpha(2a)) is a potent drug (Roferon-A) used to treat various cancers and viral diseases including Hepatitis B/C infections. To significantly improve the pharmacological properties of the drug, a pegylated form of IFNalpha(2a) was developed (PEGASYS). This 40 kDa PEG-conjugated IFNalpha(2a) ((40)PEG-IFNalpha(2a)) is obtained by the covalent binding of one 40 kDa branched PEG-polymer to a lysine side-chain of IFNalpha(2a). Here, we report the detailed structural, kinetic, and thermodynamic analysis of the binding to the extracellular domain of the receptor IFNAR2 of (40)PEG-IFNalpha(2a) and its isolated positional isomers modified at K31, K134, K131, K121, K164, and K70, respectively, in comparison with unmodified IFNalpha(2a). Our binding studies, using the surface plasmon resonance technique, show that the pegylation does not abolish the binding to the receptor, but significantly reduces the affinity mainly due to a change of the association rate. The results are supported by modeling and simulation of the binding, using Self-Avoiding-Walk calculations for the polymer conformations. A correlation between the structural parameters and the kinetic and thermodynamic parameters of the binding of the positional isomers could be established. For the Isomer-K31 and -K164, the PEG-polymer attachment point is located in proximity to the binding interface, and the isomers display affinity in the range 150-520 nM in an enthalpy-driven binding process. In contrast for the Isomer-K134, -K131, -K121, and -K70, the PEG-polymer is attached remotely from the binding interface, and the isomers exhibit a higher affinity (32-76 nM) in an entropy-driven binding process. This study constitutes an essential collection of knowledge on which the interaction of (40)PEG-IFNalpha(2a) and its positional isomers with its cellular receptors can be better understood. Instructions: please typing these entity words according to sentence: PEG, interferon - alpha2a, IFNAR2, Type - I Interferons, IFNAR1, IFNAR2, Human recombinant Interferon - alpha(2a ), IFNalpha(2a ), IFNalpha(2a ), PEG, IFNalpha(2a ), IFNalpha(2a ), lysine, IFNalpha(2a ), IFNAR2, IFNalpha(2a ), IFNalpha(2a ), PEG, IFNalpha(2a ) Options: GENE-N, GENE-Y, CHEMICAL	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Type-I Interferons exert antiviral and antiproliferative activities through the binding to a common cell surface receptor comprising two subunits, IFNAR1 and IFNAR2. Human recombinant Interferon-alpha(2a) (IFNalpha(2a)) is a potent drug (Roferon-A) used to treat various cancers and viral diseases including Hepatitis B/C infections. To significantly improve the pharmacological properties of the drug, a pegylated form of IFNalpha(2a) was developed (PEGASYS). This 40 kDa PEG-conjugated IFNalpha(2a) ((40)PEG-IFNalpha(2a)) is obtained by the covalent binding of one 40 kDa branched PEG-polymer to a lysine side-chain of IFNalpha(2a). Here, we report the detailed structural, kinetic, and thermodynamic analysis of the binding to the extracellular domain of the receptor IFNAR2 of (40)PEG-IFNalpha(2a) and its isolated positional isomers modified at K31, K134, K131, K121, K164, and K70, respectively, in comparison with unmodified IFNalpha(2a). Our binding studies, using the surface plasmon resonance technique, show that the pegylation does not abolish the binding to the receptor, but significantly reduces the affinity mainly due to a change of the association rate. The results are supported by modeling and simulation of the binding, using Self-Avoiding-Walk calculations for the polymer conformations. A correlation between the structural parameters and the kinetic and thermodynamic parameters of the binding of the positional isomers could be established. For the Isomer-K31 and -K164, the PEG-polymer attachment point is located in proximity to the binding interface, and the isomers display affinity in the range 150-520 nM in an enthalpy-driven binding process. In contrast for the Isomer-K134, -K131, -K121, and -K70, the PEG-polymer is attached remotely from the binding interface, and the isomers exhibit a higher affinity (32-76 nM) in an entropy-driven binding process. This study constitutes an essential collection of knowledge on which the interaction of (40)PEG-IFNalpha(2a) and its positional isomers with its cellular receptors can be better understood.	[ "Structural", ",", "kinetic", ",", "and", "thermodynamic", "analysis", "of", "the", "binding", "of", "the", "40", "kDa", "PEG", "-", "interferon", "-", "alpha2a", "and", "its", "individual", "positional", "isomers", "to", "the", "extracellular", "domain", "of", "the", "receptor", "IFNAR2", ".", "\n", "Type", "-", "I", "Interferons", "exert", "antiviral", "and", "antiproliferative", "activities", "through", "the", "binding", "to", "a", "common", "cell", "surface", "receptor", "comprising", "two", "subunits", ",", "IFNAR1", "and", "IFNAR2", ".", "Human", "recombinant", "Interferon", "-", "alpha(2a", ")", "(", "IFNalpha(2a", ")", ")", "is", "a", "potent", "drug", "(", "Roferon", "-", "A", ")", "used", "to", "treat", "various", "cancers", "and", "viral", "diseases", "including", "Hepatitis", "B", "/", "C", "infections", ".", "To", "significantly", "improve", "the", "pharmacological", "properties", "of", "the", "drug", ",", "a", "pegylated", "form", "of", "IFNalpha(2a", ")", "was", "developed", "(", "PEGASYS", ")", ".", "This", "40", "kDa", "PEG", "-", "conjugated", "IFNalpha(2a", ")", "(", "(", "40)PEG", "-", "IFNalpha(2a", ")", ")", "is", "obtained", "by", "the", "covalent", "binding", "of", "one", "40", "kDa", "branched", "PEG", "-", "polymer", "to", "a", "lysine", "side", "-", "chain", "of", "IFNalpha(2a", ")", ".", "Here", ",", "we", "report", "the", "detailed", "structural", ",", "kinetic", ",", "and", "thermodynamic", "analysis", "of", "the", "binding", "to", "the", "extracellular", "domain", "of", "the", "receptor", "IFNAR2", "of", "(", "40)PEG", "-", "IFNalpha(2a", ")", "and", "its", "isolated", "positional", "isomers", "modified", "at", "K31", ",", "K134", ",", "K131", ",", "K121", ",", "K164", ",", "and", "K70", ",", "respectively", ",", "in", "comparison", "with", "unmodified", "IFNalpha(2a", ")", ".", "Our", "binding", "studies", ",", "using", "the", "surface", "plasmon", "resonance", "technique", ",", "show", "that", "the", "pegylation", "does", "not", "abolish", "the", "binding", "to", "the", "receptor", ",", "but", "significantly", "reduces", "the", "affinity", "mainly", "due", "to", "a", "change", "of", "the", "association", "rate", ".", "The", "results", "are", "supported", "by", "modeling", "and", "simulation", "of", "the", "binding", ",", "using", "Self", "-", "Avoiding", "-", "Walk", "calculations", "for", "the", "polymer", "conformations", ".", "A", "correlation", "between", "the", "structural", "parameters", "and", "the", "kinetic", "and", "thermodynamic", "parameters", "of", "the", "binding", "of", "the", "positional", "isomers", "could", "be", "established", ".", "For", "the", "Isomer", "-", "K31", "and", "-K164", ",", "the", "PEG", "-", "polymer", "attachment", "point", "is", "located", "in", "proximity", "to", "the", "binding", "interface", ",", "and", "the", "isomers", "display", "affinity", "in", "the", "range", "150", "-", "520", "nM", "in", "an", "enthalpy", "-", "driven", "binding", "process", ".", "In", "contrast", "for", "the", "Isomer", "-", "K134", ",", "-K131", ",", "-K121", ",", "and", "-K70", ",", "the", "PEG", "-", "polymer", "is", "attached", "remotely", "from", "the", "binding", "interface", ",", "and", "the", "isomers", "exhibit", "a", "higher", "affinity", "(", "32", "-", "76", "nM", ")", "in", "an", "entropy", "-", "driven", "binding", "process", ".", "This", "study", "constitutes", "an", "essential", "collection", "of", "knowledge", "on", "which", "the", "interaction", "of", "(", "40)PEG", "-", "IFNalpha(2a", ")", "and", "its", "positional", "isomers", "with", "its", "cellular", "receptors", "can", "be", "better", "understood", "." ]	[ "GENE-Y", "GENE-N", "CHEMICAL" ]
PEG, interferon - alpha2a, IFNAR2, Type - I Interferons, IFNAR1, IFNAR2, Human recombinant Interferon - alpha(2a ), IFNalpha(2a ), IFNalpha(2a ), PEG, IFNalpha(2a ), IFNalpha(2a ), lysine, IFNalpha(2a ), IFNAR2, IFNalpha(2a ), IFNalpha(2a ), PEG, IFNalpha(2a )	22002_task2	Sentence: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Type-I Interferons exert antiviral and antiproliferative activities through the binding to a common cell surface receptor comprising two subunits, IFNAR1 and IFNAR2. Human recombinant Interferon-alpha(2a) (IFNalpha(2a)) is a potent drug (Roferon-A) used to treat various cancers and viral diseases including Hepatitis B/C infections. To significantly improve the pharmacological properties of the drug, a pegylated form of IFNalpha(2a) was developed (PEGASYS). This 40 kDa PEG-conjugated IFNalpha(2a) ((40)PEG-IFNalpha(2a)) is obtained by the covalent binding of one 40 kDa branched PEG-polymer to a lysine side-chain of IFNalpha(2a). Here, we report the detailed structural, kinetic, and thermodynamic analysis of the binding to the extracellular domain of the receptor IFNAR2 of (40)PEG-IFNalpha(2a) and its isolated positional isomers modified at K31, K134, K131, K121, K164, and K70, respectively, in comparison with unmodified IFNalpha(2a). Our binding studies, using the surface plasmon resonance technique, show that the pegylation does not abolish the binding to the receptor, but significantly reduces the affinity mainly due to a change of the association rate. The results are supported by modeling and simulation of the binding, using Self-Avoiding-Walk calculations for the polymer conformations. A correlation between the structural parameters and the kinetic and thermodynamic parameters of the binding of the positional isomers could be established. For the Isomer-K31 and -K164, the PEG-polymer attachment point is located in proximity to the binding interface, and the isomers display affinity in the range 150-520 nM in an enthalpy-driven binding process. In contrast for the Isomer-K134, -K131, -K121, and -K70, the PEG-polymer is attached remotely from the binding interface, and the isomers exhibit a higher affinity (32-76 nM) in an entropy-driven binding process. This study constitutes an essential collection of knowledge on which the interaction of (40)PEG-IFNalpha(2a) and its positional isomers with its cellular receptors can be better understood. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Type-I Interferons exert antiviral and antiproliferative activities through the binding to a common cell surface receptor comprising two subunits, IFNAR1 and IFNAR2. Human recombinant Interferon-alpha(2a) (IFNalpha(2a)) is a potent drug (Roferon-A) used to treat various cancers and viral diseases including Hepatitis B/C infections. To significantly improve the pharmacological properties of the drug, a pegylated form of IFNalpha(2a) was developed (PEGASYS). This 40 kDa PEG-conjugated IFNalpha(2a) ((40)PEG-IFNalpha(2a)) is obtained by the covalent binding of one 40 kDa branched PEG-polymer to a lysine side-chain of IFNalpha(2a). Here, we report the detailed structural, kinetic, and thermodynamic analysis of the binding to the extracellular domain of the receptor IFNAR2 of (40)PEG-IFNalpha(2a) and its isolated positional isomers modified at K31, K134, K131, K121, K164, and K70, respectively, in comparison with unmodified IFNalpha(2a). Our binding studies, using the surface plasmon resonance technique, show that the pegylation does not abolish the binding to the receptor, but significantly reduces the affinity mainly due to a change of the association rate. The results are supported by modeling and simulation of the binding, using Self-Avoiding-Walk calculations for the polymer conformations. A correlation between the structural parameters and the kinetic and thermodynamic parameters of the binding of the positional isomers could be established. For the Isomer-K31 and -K164, the PEG-polymer attachment point is located in proximity to the binding interface, and the isomers display affinity in the range 150-520 nM in an enthalpy-driven binding process. In contrast for the Isomer-K134, -K131, -K121, and -K70, the PEG-polymer is attached remotely from the binding interface, and the isomers exhibit a higher affinity (32-76 nM) in an entropy-driven binding process. This study constitutes an essential collection of knowledge on which the interaction of (40)PEG-IFNalpha(2a) and its positional isomers with its cellular receptors can be better understood.	[ "Structural", ",", "kinetic", ",", "and", "thermodynamic", "analysis", "of", "the", "binding", "of", "the", "40", "kDa", "PEG", "-", "interferon", "-", "alpha2a", "and", "its", "individual", "positional", "isomers", "to", "the", "extracellular", "domain", "of", "the", "receptor", "IFNAR2", ".", "\n", "Type", "-", "I", "Interferons", "exert", "antiviral", "and", "antiproliferative", "activities", "through", "the", "binding", "to", "a", "common", "cell", "surface", "receptor", "comprising", "two", "subunits", ",", "IFNAR1", "and", "IFNAR2", ".", "Human", "recombinant", "Interferon", "-", "alpha(2a", ")", "(", "IFNalpha(2a", ")", ")", "is", "a", "potent", "drug", "(", "Roferon", "-", "A", ")", "used", "to", "treat", "various", "cancers", "and", "viral", "diseases", "including", "Hepatitis", "B", "/", "C", "infections", ".", "To", "significantly", "improve", "the", "pharmacological", "properties", "of", "the", "drug", ",", "a", "pegylated", "form", "of", "IFNalpha(2a", ")", "was", "developed", "(", "PEGASYS", ")", ".", "This", "40", "kDa", "PEG", "-", "conjugated", "IFNalpha(2a", ")", "(", "(", "40)PEG", "-", "IFNalpha(2a", ")", ")", "is", "obtained", "by", "the", "covalent", "binding", "of", "one", "40", "kDa", "branched", "PEG", "-", "polymer", "to", "a", "lysine", "side", "-", "chain", "of", "IFNalpha(2a", ")", ".", "Here", ",", "we", "report", "the", "detailed", "structural", ",", "kinetic", ",", "and", "thermodynamic", "analysis", "of", "the", "binding", "to", "the", "extracellular", "domain", "of", "the", "receptor", "IFNAR2", "of", "(", "40)PEG", "-", "IFNalpha(2a", ")", "and", "its", "isolated", "positional", "isomers", "modified", "at", "K31", ",", "K134", ",", "K131", ",", "K121", ",", "K164", ",", "and", "K70", ",", "respectively", ",", "in", "comparison", "with", "unmodified", "IFNalpha(2a", ")", ".", "Our", "binding", "studies", ",", "using", "the", "surface", "plasmon", "resonance", "technique", ",", "show", "that", "the", "pegylation", "does", "not", "abolish", "the", "binding", "to", "the", "receptor", ",", "but", "significantly", "reduces", "the", "affinity", "mainly", "due", "to", "a", "change", "of", "the", "association", "rate", ".", "The", "results", "are", "supported", "by", "modeling", "and", "simulation", "of", "the", "binding", ",", "using", "Self", "-", "Avoiding", "-", "Walk", "calculations", "for", "the", "polymer", "conformations", ".", "A", "correlation", "between", "the", "structural", "parameters", "and", "the", "kinetic", "and", "thermodynamic", "parameters", "of", "the", "binding", "of", "the", "positional", "isomers", "could", "be", "established", ".", "For", "the", "Isomer", "-", "K31", "and", "-K164", ",", "the", "PEG", "-", "polymer", "attachment", "point", "is", "located", "in", "proximity", "to", "the", "binding", "interface", ",", "and", "the", "isomers", "display", "affinity", "in", "the", "range", "150", "-", "520", "nM", "in", "an", "enthalpy", "-", "driven", "binding", "process", ".", "In", "contrast", "for", "the", "Isomer", "-", "K134", ",", "-K131", ",", "-K121", ",", "and", "-K70", ",", "the", "PEG", "-", "polymer", "is", "attached", "remotely", "from", "the", "binding", "interface", ",", "and", "the", "isomers", "exhibit", "a", "higher", "affinity", "(", "32", "-", "76", "nM", ")", "in", "an", "entropy", "-", "driven", "binding", "process", ".", "This", "study", "constitutes", "an", "essential", "collection", "of", "knowledge", "on", "which", "the", "interaction", "of", "(", "40)PEG", "-", "IFNalpha(2a", ")", "and", "its", "positional", "isomers", "with", "its", "cellular", "receptors", "can", "be", "better", "understood", "." ]	[ "GENE-Y", "GENE-N", "CHEMICAL" ]
peripheral nerves is a Habitat, peripheral nervous system is a Habitat, PNS is a Habitat, nerve is a Habitat, Schwann cells is a Habitat, glial cells of the PNS is a Habitat, Schwann cells is a Habitat, nerve injury is a Habitat, Schwann cell is a Habitat, nerve is a Habitat, human is a Habitat, Mycobacterium leprae is a Microorganism, Schwann cells of the adult PNS is a Habitat, M. leprae is a Microorganism, myelinated Schwann cells is a Habitat, injury is a Habitat, M. leprae is a Microorganism, myelin - free cells is a Habitat, M. leprae is a Microorganism, M. leprae is a Microorganism, cell is a Habitat, infected cells is a Habitat, adult Schwann cells is a Habitat, M. leprae is a Microorganism, PNS is a Habitat	27_task0	Sentence: Usage of signaling in neurodegeneration and regeneration of peripheral nerves by leprosy bacteria. Multiple signaling pathways play key regulatory roles during the development of peripheral nervous system (PNS) and also in neuroregeneration process following nerve degeneration. Schwann cells, the glial cells of the PNS, by interacting with neuronal (axonal) ligands, mainly neuregulins via receptor tyrosine kinase (RTK) complex, ErbB2/ErbB3, initiate intracellular signaling pathways to drive proliferation and differentiation of Schwann cells, both during development and the process of regeneration and re-myelination after nerve injury. One of the major signaling kinases, extracellular signal-regulated kinase-1/2 (ERK1/2), that is also a downstream signaling pathway of neuregulin-ErbB2/ErbB3 activation, has been identified as a key regulator of Schwann cell proliferation, differentiation, demyelination and nerve regeneration. Recent studies have provided evidence that the bacterium that causes human leprosy, Mycobacterium leprae that has a unique capacity to invade Schwann cells of the adult PNS, utilizes the neuregulin-ErbB2/ErbB3 associated signaling network to the bacterial advantage. M. leprae directly bind to ErbB2 on myelinated Schwann cells and activate the RTK by a novel route that bypasses the classical neuregulin/growth factor-induced ErbB2-ErbB3 heterodimerization, and subsequently induce downstream the canonical Erk1/2 signaling, leading to myelin breakdown and subsequent axonal damage. This initial injury provides a survival advantage for M. leprae as it induces de-differentiation and generates myelin-free cells, which are highly susceptible to M. leprae invasion and promote bacterial survival. Once invaded M. leprae activate Erk1/2 via a non-canonical pathway and subsequently increase the cell proliferation and maintain the infected cells in de-differentiated state, thereby preventing remyelination. Therefore, by subverting major RTKs and signaling pathways in adult Schwann cells M. leprae appear to propagate the bacterial niche and maintain survival within the PNS. These studies may also provide new insights into our understanding of signaling mechanisms involve in both neurodegeneration and neuroregeneration. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Habitat, Microorganism	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Usage of signaling in neurodegeneration and regeneration of peripheral nerves by leprosy bacteria. Multiple signaling pathways play key regulatory roles during the development of peripheral nervous system (PNS) and also in neuroregeneration process following nerve degeneration. Schwann cells, the glial cells of the PNS, by interacting with neuronal (axonal) ligands, mainly neuregulins via receptor tyrosine kinase (RTK) complex, ErbB2/ErbB3, initiate intracellular signaling pathways to drive proliferation and differentiation of Schwann cells, both during development and the process of regeneration and re-myelination after nerve injury. One of the major signaling kinases, extracellular signal-regulated kinase-1/2 (ERK1/2), that is also a downstream signaling pathway of neuregulin-ErbB2/ErbB3 activation, has been identified as a key regulator of Schwann cell proliferation, differentiation, demyelination and nerve regeneration. Recent studies have provided evidence that the bacterium that causes human leprosy, Mycobacterium leprae that has a unique capacity to invade Schwann cells of the adult PNS, utilizes the neuregulin-ErbB2/ErbB3 associated signaling network to the bacterial advantage. M. leprae directly bind to ErbB2 on myelinated Schwann cells and activate the RTK by a novel route that bypasses the classical neuregulin/growth factor-induced ErbB2-ErbB3 heterodimerization, and subsequently induce downstream the canonical Erk1/2 signaling, leading to myelin breakdown and subsequent axonal damage. This initial injury provides a survival advantage for M. leprae as it induces de-differentiation and generates myelin-free cells, which are highly susceptible to M. leprae invasion and promote bacterial survival. Once invaded M. leprae activate Erk1/2 via a non-canonical pathway and subsequently increase the cell proliferation and maintain the infected cells in de-differentiated state, thereby preventing remyelination. Therefore, by subverting major RTKs and signaling pathways in adult Schwann cells M. leprae appear to propagate the bacterial niche and maintain survival within the PNS. These studies may also provide new insights into our understanding of signaling mechanisms involve in both neurodegeneration and neuroregeneration.	[ "Usage", "of", "signaling", "in", "neurodegeneration", "and", "regeneration", "of", "peripheral", "nerves", "by", "leprosy", "bacteria", ".", "Multiple", "signaling", "pathways", "play", "key", "regulatory", "roles", "during", "the", "development", "of", "peripheral", "nervous", "system", "(", "PNS", ")", "and", "also", "in", "neuroregeneration", "process", "following", "nerve", "degeneration", ".", "Schwann", "cells", ",", "the", "glial", "cells", "of", "the", "PNS", ",", "by", "interacting", "with", "neuronal", "(", "axonal", ")", "ligands", ",", "mainly", "neuregulins", "via", "receptor", "tyrosine", "kinase", "(", "RTK", ")", "complex", ",", "ErbB2", "/", "ErbB3", ",", "initiate", "intracellular", "signaling", "pathways", "to", "drive", "proliferation", "and", "differentiation", "of", "Schwann", "cells", ",", "both", "during", "development", "and", "the", "process", "of", "regeneration", "and", "re", "-", "myelination", "after", "nerve", "injury", ".", "One", "of", "the", "major", "signaling", "kinases", ",", "extracellular", "signal", "-", "regulated", "kinase-1/2", "(", "ERK1/2", ")", ",", "that", "is", "also", "a", "downstream", "signaling", "pathway", "of", "neuregulin", "-", "ErbB2", "/", "ErbB3", "activation", ",", "has", "been", "identified", "as", "a", "key", "regulator", "of", "Schwann", "cell", "proliferation", ",", "differentiation", ",", "demyelination", "and", "nerve", "regeneration", ".", "Recent", "studies", "have", "provided", "evidence", "that", "the", "bacterium", "that", "causes", "human", "leprosy", ",", "Mycobacterium", "leprae", "that", "has", "a", "unique", "capacity", "to", "invade", "Schwann", "cells", "of", "the", "adult", "PNS", ",", "utilizes", "the", "neuregulin", "-", "ErbB2", "/", "ErbB3", "associated", "signaling", "network", "to", "the", "bacterial", "advantage", ".", "M.", "leprae", "directly", "bind", "to", "ErbB2", "on", "myelinated", "Schwann", "cells", "and", "activate", "the", "RTK", "by", "a", "novel", "route", "that", "bypasses", "the", "classical", "neuregulin", "/", "growth", "factor", "-", "induced", "ErbB2-ErbB3", "heterodimerization", ",", "and", "subsequently", "induce", "downstream", "the", "canonical", "Erk1/2", "signaling", ",", "leading", "to", "myelin", "breakdown", "and", "subsequent", "axonal", "damage", ".", "This", "initial", "injury", "provides", "a", "survival", "advantage", "for", "M.", "leprae", "as", "it", "induces", "de", "-", "differentiation", "and", "generates", "myelin", "-", "free", "cells", ",", "which", "are", "highly", "susceptible", "to", "M.", "leprae", "invasion", "and", "promote", "bacterial", "survival", ".", "Once", "invaded", "M.", "leprae", "activate", "Erk1/2", "via", "a", "non", "-", "canonical", "pathway", "and", "subsequently", "increase", "the", "cell", "proliferation", "and", "maintain", "the", "infected", "cells", "in", "de", "-", "differentiated", "state", ",", "thereby", "preventing", "remyelination", ".", "Therefore", ",", "by", "subverting", "major", "RTKs", "and", "signaling", "pathways", "in", "adult", "Schwann", "cells", "M.", "leprae", "appear", "to", "propagate", "the", "bacterial", "niche", "and", "maintain", "survival", "within", "the", "PNS", ".", "These", "studies", "may", "also", "provide", "new", "insights", "into", "our", "understanding", "of", "signaling", "mechanisms", "involve", "in", "both", "neurodegeneration", "and", "neuroregeneration", ".", " " ]	[ "Habitat", "Microorganism" ]
peripheral nerves is a Habitat, peripheral nervous system is a Habitat, PNS is a Habitat, nerve is a Habitat, Schwann cells is a Habitat, glial cells of the PNS is a Habitat, Schwann cells is a Habitat, nerve injury is a Habitat, Schwann cell is a Habitat, nerve is a Habitat, human is a Habitat, Mycobacterium leprae is a Microorganism, Schwann cells of the adult PNS is a Habitat, M. leprae is a Microorganism, myelinated Schwann cells is a Habitat, injury is a Habitat, M. leprae is a Microorganism, myelin - free cells is a Habitat, M. leprae is a Microorganism, M. leprae is a Microorganism, cell is a Habitat, infected cells is a Habitat, adult Schwann cells is a Habitat, M. leprae is a Microorganism, PNS is a Habitat	27_task1	Sentence: Usage of signaling in neurodegeneration and regeneration of peripheral nerves by leprosy bacteria. Multiple signaling pathways play key regulatory roles during the development of peripheral nervous system (PNS) and also in neuroregeneration process following nerve degeneration. Schwann cells, the glial cells of the PNS, by interacting with neuronal (axonal) ligands, mainly neuregulins via receptor tyrosine kinase (RTK) complex, ErbB2/ErbB3, initiate intracellular signaling pathways to drive proliferation and differentiation of Schwann cells, both during development and the process of regeneration and re-myelination after nerve injury. One of the major signaling kinases, extracellular signal-regulated kinase-1/2 (ERK1/2), that is also a downstream signaling pathway of neuregulin-ErbB2/ErbB3 activation, has been identified as a key regulator of Schwann cell proliferation, differentiation, demyelination and nerve regeneration. Recent studies have provided evidence that the bacterium that causes human leprosy, Mycobacterium leprae that has a unique capacity to invade Schwann cells of the adult PNS, utilizes the neuregulin-ErbB2/ErbB3 associated signaling network to the bacterial advantage. M. leprae directly bind to ErbB2 on myelinated Schwann cells and activate the RTK by a novel route that bypasses the classical neuregulin/growth factor-induced ErbB2-ErbB3 heterodimerization, and subsequently induce downstream the canonical Erk1/2 signaling, leading to myelin breakdown and subsequent axonal damage. This initial injury provides a survival advantage for M. leprae as it induces de-differentiation and generates myelin-free cells, which are highly susceptible to M. leprae invasion and promote bacterial survival. Once invaded M. leprae activate Erk1/2 via a non-canonical pathway and subsequently increase the cell proliferation and maintain the infected cells in de-differentiated state, thereby preventing remyelination. Therefore, by subverting major RTKs and signaling pathways in adult Schwann cells M. leprae appear to propagate the bacterial niche and maintain survival within the PNS. These studies may also provide new insights into our understanding of signaling mechanisms involve in both neurodegeneration and neuroregeneration. Instructions: please typing these entity words according to sentence: peripheral nerves, peripheral nervous system, PNS, nerve, Schwann cells, glial cells of the PNS, Schwann cells, nerve injury, Schwann cell, nerve, human, Mycobacterium leprae, Schwann cells of the adult PNS, M. leprae, myelinated Schwann cells, injury, M. leprae, myelin - free cells, M. leprae, M. leprae, cell, infected cells, adult Schwann cells, M. leprae, PNS Options: Habitat, Microorganism	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Usage of signaling in neurodegeneration and regeneration of peripheral nerves by leprosy bacteria. Multiple signaling pathways play key regulatory roles during the development of peripheral nervous system (PNS) and also in neuroregeneration process following nerve degeneration. Schwann cells, the glial cells of the PNS, by interacting with neuronal (axonal) ligands, mainly neuregulins via receptor tyrosine kinase (RTK) complex, ErbB2/ErbB3, initiate intracellular signaling pathways to drive proliferation and differentiation of Schwann cells, both during development and the process of regeneration and re-myelination after nerve injury. One of the major signaling kinases, extracellular signal-regulated kinase-1/2 (ERK1/2), that is also a downstream signaling pathway of neuregulin-ErbB2/ErbB3 activation, has been identified as a key regulator of Schwann cell proliferation, differentiation, demyelination and nerve regeneration. Recent studies have provided evidence that the bacterium that causes human leprosy, Mycobacterium leprae that has a unique capacity to invade Schwann cells of the adult PNS, utilizes the neuregulin-ErbB2/ErbB3 associated signaling network to the bacterial advantage. M. leprae directly bind to ErbB2 on myelinated Schwann cells and activate the RTK by a novel route that bypasses the classical neuregulin/growth factor-induced ErbB2-ErbB3 heterodimerization, and subsequently induce downstream the canonical Erk1/2 signaling, leading to myelin breakdown and subsequent axonal damage. This initial injury provides a survival advantage for M. leprae as it induces de-differentiation and generates myelin-free cells, which are highly susceptible to M. leprae invasion and promote bacterial survival. Once invaded M. leprae activate Erk1/2 via a non-canonical pathway and subsequently increase the cell proliferation and maintain the infected cells in de-differentiated state, thereby preventing remyelination. Therefore, by subverting major RTKs and signaling pathways in adult Schwann cells M. leprae appear to propagate the bacterial niche and maintain survival within the PNS. These studies may also provide new insights into our understanding of signaling mechanisms involve in both neurodegeneration and neuroregeneration.	[ "Usage", "of", "signaling", "in", "neurodegeneration", "and", "regeneration", "of", "peripheral", "nerves", "by", "leprosy", "bacteria", ".", "Multiple", "signaling", "pathways", "play", "key", "regulatory", "roles", "during", "the", "development", "of", "peripheral", "nervous", "system", "(", "PNS", ")", "and", "also", "in", "neuroregeneration", "process", "following", "nerve", "degeneration", ".", "Schwann", "cells", ",", "the", "glial", "cells", "of", "the", "PNS", ",", "by", "interacting", "with", "neuronal", "(", "axonal", ")", "ligands", ",", "mainly", "neuregulins", "via", "receptor", "tyrosine", "kinase", "(", "RTK", ")", "complex", ",", "ErbB2", "/", "ErbB3", ",", "initiate", "intracellular", "signaling", "pathways", "to", "drive", "proliferation", "and", "differentiation", "of", "Schwann", "cells", ",", "both", "during", "development", "and", "the", "process", "of", "regeneration", "and", "re", "-", "myelination", "after", "nerve", "injury", ".", "One", "of", "the", "major", "signaling", "kinases", ",", "extracellular", "signal", "-", "regulated", "kinase-1/2", "(", "ERK1/2", ")", ",", "that", "is", "also", "a", "downstream", "signaling", "pathway", "of", "neuregulin", "-", "ErbB2", "/", "ErbB3", "activation", ",", "has", "been", "identified", "as", "a", "key", "regulator", "of", "Schwann", "cell", "proliferation", ",", "differentiation", ",", "demyelination", "and", "nerve", "regeneration", ".", "Recent", "studies", "have", "provided", "evidence", "that", "the", "bacterium", "that", "causes", "human", "leprosy", ",", "Mycobacterium", "leprae", "that", "has", "a", "unique", "capacity", "to", "invade", "Schwann", "cells", "of", "the", "adult", "PNS", ",", "utilizes", "the", "neuregulin", "-", "ErbB2", "/", "ErbB3", "associated", "signaling", "network", "to", "the", "bacterial", "advantage", ".", "M.", "leprae", "directly", "bind", "to", "ErbB2", "on", "myelinated", "Schwann", "cells", "and", "activate", "the", "RTK", "by", "a", "novel", "route", "that", "bypasses", "the", "classical", "neuregulin", "/", "growth", "factor", "-", "induced", "ErbB2-ErbB3", "heterodimerization", ",", "and", "subsequently", "induce", "downstream", "the", "canonical", "Erk1/2", "signaling", ",", "leading", "to", "myelin", "breakdown", "and", "subsequent", "axonal", "damage", ".", "This", "initial", "injury", "provides", "a", "survival", "advantage", "for", "M.", "leprae", "as", "it", "induces", "de", "-", "differentiation", "and", "generates", "myelin", "-", "free", "cells", ",", "which", "are", "highly", "susceptible", "to", "M.", "leprae", "invasion", "and", "promote", "bacterial", "survival", ".", "Once", "invaded", "M.", "leprae", "activate", "Erk1/2", "via", "a", "non", "-", "canonical", "pathway", "and", "subsequently", "increase", "the", "cell", "proliferation", "and", "maintain", "the", "infected", "cells", "in", "de", "-", "differentiated", "state", ",", "thereby", "preventing", "remyelination", ".", "Therefore", ",", "by", "subverting", "major", "RTKs", "and", "signaling", "pathways", "in", "adult", "Schwann", "cells", "M.", "leprae", "appear", "to", "propagate", "the", "bacterial", "niche", "and", "maintain", "survival", "within", "the", "PNS", ".", "These", "studies", "may", "also", "provide", "new", "insights", "into", "our", "understanding", "of", "signaling", "mechanisms", "involve", "in", "both", "neurodegeneration", "and", "neuroregeneration", ".", " " ]	[ "Habitat", "Microorganism" ]
peripheral nerves, peripheral nervous system, PNS, nerve, Schwann cells, glial cells of the PNS, Schwann cells, nerve injury, Schwann cell, nerve, human, Mycobacterium leprae, Schwann cells of the adult PNS, M. leprae, myelinated Schwann cells, injury, M. leprae, myelin - free cells, M. leprae, M. leprae, cell, infected cells, adult Schwann cells, M. leprae, PNS	27_task2	Sentence: Usage of signaling in neurodegeneration and regeneration of peripheral nerves by leprosy bacteria. Multiple signaling pathways play key regulatory roles during the development of peripheral nervous system (PNS) and also in neuroregeneration process following nerve degeneration. Schwann cells, the glial cells of the PNS, by interacting with neuronal (axonal) ligands, mainly neuregulins via receptor tyrosine kinase (RTK) complex, ErbB2/ErbB3, initiate intracellular signaling pathways to drive proliferation and differentiation of Schwann cells, both during development and the process of regeneration and re-myelination after nerve injury. One of the major signaling kinases, extracellular signal-regulated kinase-1/2 (ERK1/2), that is also a downstream signaling pathway of neuregulin-ErbB2/ErbB3 activation, has been identified as a key regulator of Schwann cell proliferation, differentiation, demyelination and nerve regeneration. Recent studies have provided evidence that the bacterium that causes human leprosy, Mycobacterium leprae that has a unique capacity to invade Schwann cells of the adult PNS, utilizes the neuregulin-ErbB2/ErbB3 associated signaling network to the bacterial advantage. M. leprae directly bind to ErbB2 on myelinated Schwann cells and activate the RTK by a novel route that bypasses the classical neuregulin/growth factor-induced ErbB2-ErbB3 heterodimerization, and subsequently induce downstream the canonical Erk1/2 signaling, leading to myelin breakdown and subsequent axonal damage. This initial injury provides a survival advantage for M. leprae as it induces de-differentiation and generates myelin-free cells, which are highly susceptible to M. leprae invasion and promote bacterial survival. Once invaded M. leprae activate Erk1/2 via a non-canonical pathway and subsequently increase the cell proliferation and maintain the infected cells in de-differentiated state, thereby preventing remyelination. Therefore, by subverting major RTKs and signaling pathways in adult Schwann cells M. leprae appear to propagate the bacterial niche and maintain survival within the PNS. These studies may also provide new insights into our understanding of signaling mechanisms involve in both neurodegeneration and neuroregeneration. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Usage of signaling in neurodegeneration and regeneration of peripheral nerves by leprosy bacteria. Multiple signaling pathways play key regulatory roles during the development of peripheral nervous system (PNS) and also in neuroregeneration process following nerve degeneration. Schwann cells, the glial cells of the PNS, by interacting with neuronal (axonal) ligands, mainly neuregulins via receptor tyrosine kinase (RTK) complex, ErbB2/ErbB3, initiate intracellular signaling pathways to drive proliferation and differentiation of Schwann cells, both during development and the process of regeneration and re-myelination after nerve injury. One of the major signaling kinases, extracellular signal-regulated kinase-1/2 (ERK1/2), that is also a downstream signaling pathway of neuregulin-ErbB2/ErbB3 activation, has been identified as a key regulator of Schwann cell proliferation, differentiation, demyelination and nerve regeneration. Recent studies have provided evidence that the bacterium that causes human leprosy, Mycobacterium leprae that has a unique capacity to invade Schwann cells of the adult PNS, utilizes the neuregulin-ErbB2/ErbB3 associated signaling network to the bacterial advantage. M. leprae directly bind to ErbB2 on myelinated Schwann cells and activate the RTK by a novel route that bypasses the classical neuregulin/growth factor-induced ErbB2-ErbB3 heterodimerization, and subsequently induce downstream the canonical Erk1/2 signaling, leading to myelin breakdown and subsequent axonal damage. This initial injury provides a survival advantage for M. leprae as it induces de-differentiation and generates myelin-free cells, which are highly susceptible to M. leprae invasion and promote bacterial survival. Once invaded M. leprae activate Erk1/2 via a non-canonical pathway and subsequently increase the cell proliferation and maintain the infected cells in de-differentiated state, thereby preventing remyelination. Therefore, by subverting major RTKs and signaling pathways in adult Schwann cells M. leprae appear to propagate the bacterial niche and maintain survival within the PNS. These studies may also provide new insights into our understanding of signaling mechanisms involve in both neurodegeneration and neuroregeneration.	[ "Usage", "of", "signaling", "in", "neurodegeneration", "and", "regeneration", "of", "peripheral", "nerves", "by", "leprosy", "bacteria", ".", "Multiple", "signaling", "pathways", "play", "key", "regulatory", "roles", "during", "the", "development", "of", "peripheral", "nervous", "system", "(", "PNS", ")", "and", "also", "in", "neuroregeneration", "process", "following", "nerve", "degeneration", ".", "Schwann", "cells", ",", "the", "glial", "cells", "of", "the", "PNS", ",", "by", "interacting", "with", "neuronal", "(", "axonal", ")", "ligands", ",", "mainly", "neuregulins", "via", "receptor", "tyrosine", "kinase", "(", "RTK", ")", "complex", ",", "ErbB2", "/", "ErbB3", ",", "initiate", "intracellular", "signaling", "pathways", "to", "drive", "proliferation", "and", "differentiation", "of", "Schwann", "cells", ",", "both", "during", "development", "and", "the", "process", "of", "regeneration", "and", "re", "-", "myelination", "after", "nerve", "injury", ".", "One", "of", "the", "major", "signaling", "kinases", ",", "extracellular", "signal", "-", "regulated", "kinase-1/2", "(", "ERK1/2", ")", ",", "that", "is", "also", "a", "downstream", "signaling", "pathway", "of", "neuregulin", "-", "ErbB2", "/", "ErbB3", "activation", ",", "has", "been", "identified", "as", "a", "key", "regulator", "of", "Schwann", "cell", "proliferation", ",", "differentiation", ",", "demyelination", "and", "nerve", "regeneration", ".", "Recent", "studies", "have", "provided", "evidence", "that", "the", "bacterium", "that", "causes", "human", "leprosy", ",", "Mycobacterium", "leprae", "that", "has", "a", "unique", "capacity", "to", "invade", "Schwann", "cells", "of", "the", "adult", "PNS", ",", "utilizes", "the", "neuregulin", "-", "ErbB2", "/", "ErbB3", "associated", "signaling", "network", "to", "the", "bacterial", "advantage", ".", "M.", "leprae", "directly", "bind", "to", "ErbB2", "on", "myelinated", "Schwann", "cells", "and", "activate", "the", "RTK", "by", "a", "novel", "route", "that", "bypasses", "the", "classical", "neuregulin", "/", "growth", "factor", "-", "induced", "ErbB2-ErbB3", "heterodimerization", ",", "and", "subsequently", "induce", "downstream", "the", "canonical", "Erk1/2", "signaling", ",", "leading", "to", "myelin", "breakdown", "and", "subsequent", "axonal", "damage", ".", "This", "initial", "injury", "provides", "a", "survival", "advantage", "for", "M.", "leprae", "as", "it", "induces", "de", "-", "differentiation", "and", "generates", "myelin", "-", "free", "cells", ",", "which", "are", "highly", "susceptible", "to", "M.", "leprae", "invasion", "and", "promote", "bacterial", "survival", ".", "Once", "invaded", "M.", "leprae", "activate", "Erk1/2", "via", "a", "non", "-", "canonical", "pathway", "and", "subsequently", "increase", "the", "cell", "proliferation", "and", "maintain", "the", "infected", "cells", "in", "de", "-", "differentiated", "state", ",", "thereby", "preventing", "remyelination", ".", "Therefore", ",", "by", "subverting", "major", "RTKs", "and", "signaling", "pathways", "in", "adult", "Schwann", "cells", "M.", "leprae", "appear", "to", "propagate", "the", "bacterial", "niche", "and", "maintain", "survival", "within", "the", "PNS", ".", "These", "studies", "may", "also", "provide", "new", "insights", "into", "our", "understanding", "of", "signaling", "mechanisms", "involve", "in", "both", "neurodegeneration", "and", "neuroregeneration", ".", " " ]	[ "Habitat", "Microorganism" ]
IkappaBalpha is a Protein, IkappaBalpha is a Protein, IL-2 is a Protein, IFN - gamma is a Protein	231_task0	Sentence: Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells. Activation of the transcription factor nuclear factor-kappaB (NFkappaB) is impaired in T cells from patients with renal cell carcinomas (RCCs). In circulating T cells from a subset of patients with RCCs, the suppression of NFkappaB binding activity is downstream from the stimulus-induced degradation of the cytoplasmic factor IkappaBalpha. Tumor-derived soluble products from cultured RCC explants inhibit NFkappaB activity in T cells from healthy volunteers, despite a normal level of stimulus-induced IkappaBalpha degradation in these cells. The inhibitory agent has several features characteristic of a ganglioside, including sensitivity to neuraminidase but not protease treatment; hydrophobicity; and molecular weight less than 3 kDa. Indeed, we detected gangliosides in supernatants from RCC explants and not from adjacent normal kidney tissue. Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), suppressed NFkappaB binding activity in T cells and reduced expression of the cytokines IL-2 and IFN-gamma. Taken together, our findings suggest that tumor-derived gangliosides may blunt antitumor immune responses in patients with RCCs. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells. Activation of the transcription factor nuclear factor-kappaB (NFkappaB) is impaired in T cells from patients with renal cell carcinomas (RCCs). In circulating T cells from a subset of patients with RCCs, the suppression of NFkappaB binding activity is downstream from the stimulus-induced degradation of the cytoplasmic factor IkappaBalpha. Tumor-derived soluble products from cultured RCC explants inhibit NFkappaB activity in T cells from healthy volunteers, despite a normal level of stimulus-induced IkappaBalpha degradation in these cells. The inhibitory agent has several features characteristic of a ganglioside, including sensitivity to neuraminidase but not protease treatment; hydrophobicity; and molecular weight less than 3 kDa. Indeed, we detected gangliosides in supernatants from RCC explants and not from adjacent normal kidney tissue. Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), suppressed NFkappaB binding activity in T cells and reduced expression of the cytokines IL-2 and IFN-gamma. Taken together, our findings suggest that tumor-derived gangliosides may blunt antitumor immune responses in patients with RCCs.	[ "Renal", "cell", "carcinoma", "-", "derived", "gangliosides", "suppress", "nuclear", "factor", "-", "kappaB", "activation", "in", "T", "cells", ".", "\n", "Activation", "of", "the", "transcription", "factor", "nuclear", "factor", "-", "kappaB", "(", "NFkappaB", ")", "is", "impaired", "in", "T", "cells", "from", "patients", "with", "renal", "cell", "carcinomas", "(", "RCCs", ")", ".", "In", "circulating", "T", "cells", "from", "a", "subset", "of", "patients", "with", "RCCs", ",", "the", "suppression", "of", "NFkappaB", "binding", "activity", "is", "downstream", "from", "the", "stimulus", "-", "induced", "degradation", "of", "the", "cytoplasmic", "factor", "IkappaBalpha", ".", "Tumor", "-", "derived", "soluble", "products", "from", "cultured", "RCC", "explants", "inhibit", "NFkappaB", "activity", "in", "T", "cells", "from", "healthy", "volunteers", ",", "despite", "a", "normal", "level", "of", "stimulus", "-", "induced", "IkappaBalpha", "degradation", "in", "these", "cells", ".", "The", "inhibitory", "agent", "has", "several", "features", "characteristic", "of", "a", "ganglioside", ",", "including", "sensitivity", "to", "neuraminidase", "but", "not", "protease", "treatment", ";", "hydrophobicity", ";", "and", "molecular", "weight", "less", "than", "3", "kDa", ".", "Indeed", ",", "we", "detected", "gangliosides", "in", "supernatants", "from", "RCC", "explants", "and", "not", "from", "adjacent", "normal", "kidney", "tissue", ".", "Gangliosides", "prepared", "from", "RCC", "supernatants", ",", "as", "well", "as", "the", "purified", "bovine", "gangliosides", "G(m1", ")", "and", "G(d1a", ")", ",", "suppressed", "NFkappaB", "binding", "activity", "in", "T", "cells", "and", "reduced", "expression", "of", "the", "cytokines", "IL-2", "and", "IFN", "-", "gamma", ".", "Taken", "together", ",", "our", "findings", "suggest", "that", "tumor", "-", "derived", "gangliosides", "may", "blunt", "antitumor", "immune", "responses", "in", "patients", "with", "RCCs", "." ]	[ "Protein" ]
IkappaBalpha is a Protein, IkappaBalpha is a Protein, IL-2 is a Protein, IFN - gamma is a Protein	231_task1	Sentence: Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells. Activation of the transcription factor nuclear factor-kappaB (NFkappaB) is impaired in T cells from patients with renal cell carcinomas (RCCs). In circulating T cells from a subset of patients with RCCs, the suppression of NFkappaB binding activity is downstream from the stimulus-induced degradation of the cytoplasmic factor IkappaBalpha. Tumor-derived soluble products from cultured RCC explants inhibit NFkappaB activity in T cells from healthy volunteers, despite a normal level of stimulus-induced IkappaBalpha degradation in these cells. The inhibitory agent has several features characteristic of a ganglioside, including sensitivity to neuraminidase but not protease treatment; hydrophobicity; and molecular weight less than 3 kDa. Indeed, we detected gangliosides in supernatants from RCC explants and not from adjacent normal kidney tissue. Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), suppressed NFkappaB binding activity in T cells and reduced expression of the cytokines IL-2 and IFN-gamma. Taken together, our findings suggest that tumor-derived gangliosides may blunt antitumor immune responses in patients with RCCs. Instructions: please typing these entity words according to sentence: IkappaBalpha, IkappaBalpha, IL-2, IFN - gamma Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells. Activation of the transcription factor nuclear factor-kappaB (NFkappaB) is impaired in T cells from patients with renal cell carcinomas (RCCs). In circulating T cells from a subset of patients with RCCs, the suppression of NFkappaB binding activity is downstream from the stimulus-induced degradation of the cytoplasmic factor IkappaBalpha. Tumor-derived soluble products from cultured RCC explants inhibit NFkappaB activity in T cells from healthy volunteers, despite a normal level of stimulus-induced IkappaBalpha degradation in these cells. The inhibitory agent has several features characteristic of a ganglioside, including sensitivity to neuraminidase but not protease treatment; hydrophobicity; and molecular weight less than 3 kDa. Indeed, we detected gangliosides in supernatants from RCC explants and not from adjacent normal kidney tissue. Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), suppressed NFkappaB binding activity in T cells and reduced expression of the cytokines IL-2 and IFN-gamma. Taken together, our findings suggest that tumor-derived gangliosides may blunt antitumor immune responses in patients with RCCs.	[ "Renal", "cell", "carcinoma", "-", "derived", "gangliosides", "suppress", "nuclear", "factor", "-", "kappaB", "activation", "in", "T", "cells", ".", "\n", "Activation", "of", "the", "transcription", "factor", "nuclear", "factor", "-", "kappaB", "(", "NFkappaB", ")", "is", "impaired", "in", "T", "cells", "from", "patients", "with", "renal", "cell", "carcinomas", "(", "RCCs", ")", ".", "In", "circulating", "T", "cells", "from", "a", "subset", "of", "patients", "with", "RCCs", ",", "the", "suppression", "of", "NFkappaB", "binding", "activity", "is", "downstream", "from", "the", "stimulus", "-", "induced", "degradation", "of", "the", "cytoplasmic", "factor", "IkappaBalpha", ".", "Tumor", "-", "derived", "soluble", "products", "from", "cultured", "RCC", "explants", "inhibit", "NFkappaB", "activity", "in", "T", "cells", "from", "healthy", "volunteers", ",", "despite", "a", "normal", "level", "of", "stimulus", "-", "induced", "IkappaBalpha", "degradation", "in", "these", "cells", ".", "The", "inhibitory", "agent", "has", "several", "features", "characteristic", "of", "a", "ganglioside", ",", "including", "sensitivity", "to", "neuraminidase", "but", "not", "protease", "treatment", ";", "hydrophobicity", ";", "and", "molecular", "weight", "less", "than", "3", "kDa", ".", "Indeed", ",", "we", "detected", "gangliosides", "in", "supernatants", "from", "RCC", "explants", "and", "not", "from", "adjacent", "normal", "kidney", "tissue", ".", "Gangliosides", "prepared", "from", "RCC", "supernatants", ",", "as", "well", "as", "the", "purified", "bovine", "gangliosides", "G(m1", ")", "and", "G(d1a", ")", ",", "suppressed", "NFkappaB", "binding", "activity", "in", "T", "cells", "and", "reduced", "expression", "of", "the", "cytokines", "IL-2", "and", "IFN", "-", "gamma", ".", "Taken", "together", ",", "our", "findings", "suggest", "that", "tumor", "-", "derived", "gangliosides", "may", "blunt", "antitumor", "immune", "responses", "in", "patients", "with", "RCCs", "." ]	[ "Protein" ]
IkappaBalpha, IkappaBalpha, IL-2, IFN - gamma	231_task2	Sentence: Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells. Activation of the transcription factor nuclear factor-kappaB (NFkappaB) is impaired in T cells from patients with renal cell carcinomas (RCCs). In circulating T cells from a subset of patients with RCCs, the suppression of NFkappaB binding activity is downstream from the stimulus-induced degradation of the cytoplasmic factor IkappaBalpha. Tumor-derived soluble products from cultured RCC explants inhibit NFkappaB activity in T cells from healthy volunteers, despite a normal level of stimulus-induced IkappaBalpha degradation in these cells. The inhibitory agent has several features characteristic of a ganglioside, including sensitivity to neuraminidase but not protease treatment; hydrophobicity; and molecular weight less than 3 kDa. Indeed, we detected gangliosides in supernatants from RCC explants and not from adjacent normal kidney tissue. Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), suppressed NFkappaB binding activity in T cells and reduced expression of the cytokines IL-2 and IFN-gamma. Taken together, our findings suggest that tumor-derived gangliosides may blunt antitumor immune responses in patients with RCCs. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells. Activation of the transcription factor nuclear factor-kappaB (NFkappaB) is impaired in T cells from patients with renal cell carcinomas (RCCs). In circulating T cells from a subset of patients with RCCs, the suppression of NFkappaB binding activity is downstream from the stimulus-induced degradation of the cytoplasmic factor IkappaBalpha. Tumor-derived soluble products from cultured RCC explants inhibit NFkappaB activity in T cells from healthy volunteers, despite a normal level of stimulus-induced IkappaBalpha degradation in these cells. The inhibitory agent has several features characteristic of a ganglioside, including sensitivity to neuraminidase but not protease treatment; hydrophobicity; and molecular weight less than 3 kDa. Indeed, we detected gangliosides in supernatants from RCC explants and not from adjacent normal kidney tissue. Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), suppressed NFkappaB binding activity in T cells and reduced expression of the cytokines IL-2 and IFN-gamma. Taken together, our findings suggest that tumor-derived gangliosides may blunt antitumor immune responses in patients with RCCs.	[ "Renal", "cell", "carcinoma", "-", "derived", "gangliosides", "suppress", "nuclear", "factor", "-", "kappaB", "activation", "in", "T", "cells", ".", "\n", "Activation", "of", "the", "transcription", "factor", "nuclear", "factor", "-", "kappaB", "(", "NFkappaB", ")", "is", "impaired", "in", "T", "cells", "from", "patients", "with", "renal", "cell", "carcinomas", "(", "RCCs", ")", ".", "In", "circulating", "T", "cells", "from", "a", "subset", "of", "patients", "with", "RCCs", ",", "the", "suppression", "of", "NFkappaB", "binding", "activity", "is", "downstream", "from", "the", "stimulus", "-", "induced", "degradation", "of", "the", "cytoplasmic", "factor", "IkappaBalpha", ".", "Tumor", "-", "derived", "soluble", "products", "from", "cultured", "RCC", "explants", "inhibit", "NFkappaB", "activity", "in", "T", "cells", "from", "healthy", "volunteers", ",", "despite", "a", "normal", "level", "of", "stimulus", "-", "induced", "IkappaBalpha", "degradation", "in", "these", "cells", ".", "The", "inhibitory", "agent", "has", "several", "features", "characteristic", "of", "a", "ganglioside", ",", "including", "sensitivity", "to", "neuraminidase", "but", "not", "protease", "treatment", ";", "hydrophobicity", ";", "and", "molecular", "weight", "less", "than", "3", "kDa", ".", "Indeed", ",", "we", "detected", "gangliosides", "in", "supernatants", "from", "RCC", "explants", "and", "not", "from", "adjacent", "normal", "kidney", "tissue", ".", "Gangliosides", "prepared", "from", "RCC", "supernatants", ",", "as", "well", "as", "the", "purified", "bovine", "gangliosides", "G(m1", ")", "and", "G(d1a", ")", ",", "suppressed", "NFkappaB", "binding", "activity", "in", "T", "cells", "and", "reduced", "expression", "of", "the", "cytokines", "IL-2", "and", "IFN", "-", "gamma", ".", "Taken", "together", ",", "our", "findings", "suggest", "that", "tumor", "-", "derived", "gangliosides", "may", "blunt", "antitumor", "immune", "responses", "in", "patients", "with", "RCCs", "." ]	[ "Protein" ]
Abstract is an umlsterm, transmissions is an umlsterm, hepatitis B is an umlsterm, hepatitis C is an umlsterm, HIV is an umlsterm, health care is an umlsterm, transmission is an umlsterm, patients is an umlsterm, patients is an umlsterm, HIV is an umlsterm, patients is an umlsterm, transmissions is an umlsterm, transmissions is an umlsterm, EEG is an umlsterm, transmissions is an umlsterm, infection control is an umlsterm, health care workers is an umlsterm, infection control is an umlsterm, measures is an umlsterm, risk is an umlsterm, transmission is an umlsterm, patients is an umlsterm, invasive procedures is an umlsterm, personnel is an umlsterm, disease is an umlsterm, devices is an umlsterm, risk of is an umlsterm, infection is an umlsterm, patients is an umlsterm, personnel is an umlsterm	DerChirurg.00710389.eng.abstr_task0	Sentence: Abstract . This report analyzes 46 cases of personnel-to-patient transmissions of hepatitis B ( HB ) , hepatitis C ( HC ) and HIV in health care settings . Similar circumstances were found for transmission of HB ( 40 cases , 404 infected patients ) , HC ( 4 cases , 224 infected patients ) and HIV ( 2 cases , 7 infected patients ) . Cases with the highest number of transmissions ( one anesthesiologist with 217 HC transmissions , and one EEG technologist with 75 HB transmissions ) were attributed to poor infection control practices . As long as infected health care workers ( HCW ) adhere to general infection control measures , a risk for transmission to patients exists only from infected surgeons who perform'xposure-prone invasive procedures ' . Whether changes in duties of infected HCW are necessary should be decided on an individual basis . Often , the infected personnel were assumed to have acquired the disease occupationally . Medical practices and devices bearing a risk of infection should constantly be reviewed with regard to risk for patients and personnel . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	Abstract . This report analyzes 46 cases of personnel-to-patient transmissions of hepatitis B ( HB ) , hepatitis C ( HC ) and HIV in health care settings . Similar circumstances were found for transmission of HB ( 40 cases , 404 infected patients ) , HC ( 4 cases , 224 infected patients ) and HIV ( 2 cases , 7 infected patients ) . Cases with the highest number of transmissions ( one anesthesiologist with 217 HC transmissions , and one EEG technologist with 75 HB transmissions ) were attributed to poor infection control practices . As long as infected health care workers ( HCW ) adhere to general infection control measures , a risk for transmission to patients exists only from infected surgeons who perform'xposure-prone invasive procedures ' . Whether changes in duties of infected HCW are necessary should be decided on an individual basis . Often , the infected personnel were assumed to have acquired the disease occupationally . Medical practices and devices bearing a risk of infection should constantly be reviewed with regard to risk for patients and personnel .	[ "Abstract", ".", "This", "report", "analyzes", "46", "cases", "of", "personnel", "-", "to", "-", "patient", "transmissions", "of", "hepatitis", "B", "(", "HB", ")", ",", "hepatitis", "C", "(", "HC", ")", "and", "HIV", "in", "health", "care", "settings", ".", "Similar", "circumstances", "were", "found", "for", "transmission", "of", "HB", "(", "40", "cases", ",", "404", "infected", "patients", ")", ",", "HC", "(", "4", "cases", ",", "224", "infected", "patients", ")", "and", "HIV", "(", "2", "cases", ",", "7", "infected", "patients", ")", ".", "Cases", "with", "the", "highest", "number", "of", "transmissions", "(", "one", "anesthesiologist", "with", "217", "HC", "transmissions", ",", "and", "one", "EEG", "technologist", "with", "75", "HB", "transmissions", ")", "were", "attributed", "to", "poor", "infection", "control", "practices", ".", "As", "long", "as", "infected", "health", "care", "workers", "(", "HCW", ")", "adhere", "to", "general", "infection", "control", "measures", ",", "a", "risk", "for", "transmission", "to", "patients", "exists", "only", "from", "infected", "surgeons", "who", "perform'xposure", "-", "prone", "invasive", "procedures", "'", ".", "Whether", "changes", "in", "duties", "of", "infected", "HCW", "are", "necessary", "should", "be", "decided", "on", "an", "individual", "basis", ".", "Often", ",", "the", "infected", "personnel", "were", "assumed", "to", "have", "acquired", "the", "disease", "occupationally", ".", "Medical", "practices", "and", "devices", "bearing", "a", "risk", "of", "infection", "should", "constantly", "be", "reviewed", "with", "regard", "to", "risk", "for", "patients", "and", "personnel", "." ]	[ "umlsterm" ]
Abstract is an umlsterm, transmissions is an umlsterm, hepatitis B is an umlsterm, hepatitis C is an umlsterm, HIV is an umlsterm, health care is an umlsterm, transmission is an umlsterm, patients is an umlsterm, patients is an umlsterm, HIV is an umlsterm, patients is an umlsterm, transmissions is an umlsterm, transmissions is an umlsterm, EEG is an umlsterm, transmissions is an umlsterm, infection control is an umlsterm, health care workers is an umlsterm, infection control is an umlsterm, measures is an umlsterm, risk is an umlsterm, transmission is an umlsterm, patients is an umlsterm, invasive procedures is an umlsterm, personnel is an umlsterm, disease is an umlsterm, devices is an umlsterm, risk of is an umlsterm, infection is an umlsterm, patients is an umlsterm, personnel is an umlsterm	DerChirurg.00710389.eng.abstr_task1	Sentence: Abstract . This report analyzes 46 cases of personnel-to-patient transmissions of hepatitis B ( HB ) , hepatitis C ( HC ) and HIV in health care settings . Similar circumstances were found for transmission of HB ( 40 cases , 404 infected patients ) , HC ( 4 cases , 224 infected patients ) and HIV ( 2 cases , 7 infected patients ) . Cases with the highest number of transmissions ( one anesthesiologist with 217 HC transmissions , and one EEG technologist with 75 HB transmissions ) were attributed to poor infection control practices . As long as infected health care workers ( HCW ) adhere to general infection control measures , a risk for transmission to patients exists only from infected surgeons who perform'xposure-prone invasive procedures ' . Whether changes in duties of infected HCW are necessary should be decided on an individual basis . Often , the infected personnel were assumed to have acquired the disease occupationally . Medical practices and devices bearing a risk of infection should constantly be reviewed with regard to risk for patients and personnel . Instructions: please typing these entity words according to sentence: Abstract, transmissions, hepatitis B, hepatitis C, HIV, health care, transmission, patients, patients, HIV, patients, transmissions, transmissions, EEG, transmissions, infection control, health care workers, infection control, measures, risk, transmission, patients, invasive procedures, personnel, disease, devices, risk of, infection, patients, personnel Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	Abstract . This report analyzes 46 cases of personnel-to-patient transmissions of hepatitis B ( HB ) , hepatitis C ( HC ) and HIV in health care settings . Similar circumstances were found for transmission of HB ( 40 cases , 404 infected patients ) , HC ( 4 cases , 224 infected patients ) and HIV ( 2 cases , 7 infected patients ) . Cases with the highest number of transmissions ( one anesthesiologist with 217 HC transmissions , and one EEG technologist with 75 HB transmissions ) were attributed to poor infection control practices . As long as infected health care workers ( HCW ) adhere to general infection control measures , a risk for transmission to patients exists only from infected surgeons who perform'xposure-prone invasive procedures ' . Whether changes in duties of infected HCW are necessary should be decided on an individual basis . Often , the infected personnel were assumed to have acquired the disease occupationally . Medical practices and devices bearing a risk of infection should constantly be reviewed with regard to risk for patients and personnel .	[ "Abstract", ".", "This", "report", "analyzes", "46", "cases", "of", "personnel", "-", "to", "-", "patient", "transmissions", "of", "hepatitis", "B", "(", "HB", ")", ",", "hepatitis", "C", "(", "HC", ")", "and", "HIV", "in", "health", "care", "settings", ".", "Similar", "circumstances", "were", "found", "for", "transmission", "of", "HB", "(", "40", "cases", ",", "404", "infected", "patients", ")", ",", "HC", "(", "4", "cases", ",", "224", "infected", "patients", ")", "and", "HIV", "(", "2", "cases", ",", "7", "infected", "patients", ")", ".", "Cases", "with", "the", "highest", "number", "of", "transmissions", "(", "one", "anesthesiologist", "with", "217", "HC", "transmissions", ",", "and", "one", "EEG", "technologist", "with", "75", "HB", "transmissions", ")", "were", "attributed", "to", "poor", "infection", "control", "practices", ".", "As", "long", "as", "infected", "health", "care", "workers", "(", "HCW", ")", "adhere", "to", "general", "infection", "control", "measures", ",", "a", "risk", "for", "transmission", "to", "patients", "exists", "only", "from", "infected", "surgeons", "who", "perform'xposure", "-", "prone", "invasive", "procedures", "'", ".", "Whether", "changes", "in", "duties", "of", "infected", "HCW", "are", "necessary", "should", "be", "decided", "on", "an", "individual", "basis", ".", "Often", ",", "the", "infected", "personnel", "were", "assumed", "to", "have", "acquired", "the", "disease", "occupationally", ".", "Medical", "practices", "and", "devices", "bearing", "a", "risk", "of", "infection", "should", "constantly", "be", "reviewed", "with", "regard", "to", "risk", "for", "patients", "and", "personnel", "." ]	[ "umlsterm" ]
Abstract, transmissions, hepatitis B, hepatitis C, HIV, health care, transmission, patients, patients, HIV, patients, transmissions, transmissions, EEG, transmissions, infection control, health care workers, infection control, measures, risk, transmission, patients, invasive procedures, personnel, disease, devices, risk of, infection, patients, personnel	DerChirurg.00710389.eng.abstr_task2	Sentence: Abstract . This report analyzes 46 cases of personnel-to-patient transmissions of hepatitis B ( HB ) , hepatitis C ( HC ) and HIV in health care settings . Similar circumstances were found for transmission of HB ( 40 cases , 404 infected patients ) , HC ( 4 cases , 224 infected patients ) and HIV ( 2 cases , 7 infected patients ) . Cases with the highest number of transmissions ( one anesthesiologist with 217 HC transmissions , and one EEG technologist with 75 HB transmissions ) were attributed to poor infection control practices . As long as infected health care workers ( HCW ) adhere to general infection control measures , a risk for transmission to patients exists only from infected surgeons who perform'xposure-prone invasive procedures ' . Whether changes in duties of infected HCW are necessary should be decided on an individual basis . Often , the infected personnel were assumed to have acquired the disease occupationally . Medical practices and devices bearing a risk of infection should constantly be reviewed with regard to risk for patients and personnel . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	Abstract . This report analyzes 46 cases of personnel-to-patient transmissions of hepatitis B ( HB ) , hepatitis C ( HC ) and HIV in health care settings . Similar circumstances were found for transmission of HB ( 40 cases , 404 infected patients ) , HC ( 4 cases , 224 infected patients ) and HIV ( 2 cases , 7 infected patients ) . Cases with the highest number of transmissions ( one anesthesiologist with 217 HC transmissions , and one EEG technologist with 75 HB transmissions ) were attributed to poor infection control practices . As long as infected health care workers ( HCW ) adhere to general infection control measures , a risk for transmission to patients exists only from infected surgeons who perform'xposure-prone invasive procedures ' . Whether changes in duties of infected HCW are necessary should be decided on an individual basis . Often , the infected personnel were assumed to have acquired the disease occupationally . Medical practices and devices bearing a risk of infection should constantly be reviewed with regard to risk for patients and personnel .	[ "Abstract", ".", "This", "report", "analyzes", "46", "cases", "of", "personnel", "-", "to", "-", "patient", "transmissions", "of", "hepatitis", "B", "(", "HB", ")", ",", "hepatitis", "C", "(", "HC", ")", "and", "HIV", "in", "health", "care", "settings", ".", "Similar", "circumstances", "were", "found", "for", "transmission", "of", "HB", "(", "40", "cases", ",", "404", "infected", "patients", ")", ",", "HC", "(", "4", "cases", ",", "224", "infected", "patients", ")", "and", "HIV", "(", "2", "cases", ",", "7", "infected", "patients", ")", ".", "Cases", "with", "the", "highest", "number", "of", "transmissions", "(", "one", "anesthesiologist", "with", "217", "HC", "transmissions", ",", "and", "one", "EEG", "technologist", "with", "75", "HB", "transmissions", ")", "were", "attributed", "to", "poor", "infection", "control", "practices", ".", "As", "long", "as", "infected", "health", "care", "workers", "(", "HCW", ")", "adhere", "to", "general", "infection", "control", "measures", ",", "a", "risk", "for", "transmission", "to", "patients", "exists", "only", "from", "infected", "surgeons", "who", "perform'xposure", "-", "prone", "invasive", "procedures", "'", ".", "Whether", "changes", "in", "duties", "of", "infected", "HCW", "are", "necessary", "should", "be", "decided", "on", "an", "individual", "basis", ".", "Often", ",", "the", "infected", "personnel", "were", "assumed", "to", "have", "acquired", "the", "disease", "occupationally", ".", "Medical", "practices", "and", "devices", "bearing", "a", "risk", "of", "infection", "should", "constantly", "be", "reviewed", "with", "regard", "to", "risk", "for", "patients", "and", "personnel", "." ]	[ "umlsterm" ]
Andreu is a NOMBRE_SUJETO_ASISTENCIA, Bernabe Loza is a NOMBRE_SUJETO_ASISTENCIA, 7845123 is a ID_SUJETO_ASISTENCIA, 23 56479608 12 is a ID_ASEGURAMIENTO, Girona is a TERRITORIO, 17006 is a TERRITORIO, 13/01/1978 is a FECHAS, España is a PAIS, 40 años is a EDAD_SUJETO_ASISTENCIA, 10/05/2018 is a FECHAS, 1330431 is a ID_CONTACTO_ASISTENCIAL, Paula Ortiz Ballujera is a NOMBRE_PERSONAL_SANITARIO, 17 17 85423 is a ID_TITULACION_PERSONAL_SANITARIO, varón is a SEXO_SUJETO_ASISTENCIA, 40 años is a EDAD_SUJETO_ASISTENCIA, Paula Ortiz Ballujera is a NOMBRE_PERSONAL_SANITARIO, Hospital Universitari de Girona Doctor Josep Trueta is a HOSPITAL, 17007 is a TERRITORIO, Girona is a TERRITORIO, España is a PAIS, ballujera@hotmail.com is a CORREO_ELECTRONICO	98_task0	Sentence: Nombre: Andreu. Apellidos: Bernabe Loza. NHC: 7845123. NASS: 23 56479608 12. Domicilio: Carrer de Joan Maragall, 26 2B. Localidad/ Provincia: Girona. CP: 17006. Datos asistenciales. Fecha de nacimiento: 13/01/1978. País: España. Edad: 40 años Sexo: H. Fecha de Ingreso: 10/05/2018 . Servicio: Medicina intensiva. Episodio: 1330431. Médico: Paula Ortiz Ballujera NºCol: 17 17 85423. Historia Actual: Se trata de un varón de 40 años que sufrió un accidente de coche. La TACHT al ingreso mostraba un seudoaneurisma de la aorta torácica a la salida de la arteria subclavia izquierda con un hematoma periaórtico extendido al mediastino posterior. El paciente ingresó en la UCI en respiración espontánea con tensión arterial sistólica (TAS) inferior a 120 mmHg. Se llevó a cabo un tratamiento conservador de las lesiones asociadas. A las 10 horas del ingreso en la UCI se le colocó una endoprótesis en la aorta torácica descendente por vía femoral izquierda, con oclusión parcial de la arteria subclavia izquierda. Fue dado de alta a planta a las 48 horas. Siguió controles con TACHT a los 7 días, al mes y a los 45 días. A los dos meses del accidente presentó una pericarditis aguda y ausencia de pulso radial izquierdo sin repercusión clínica. La TACHT mostraba una correcta localización de la endoprótesis. Remitido por: Dra. Paula Ortiz Ballujera. Servicio de Medicina Intensiva (UCI). Hospital Universitari de Girona Doctor Josep Trueta. Avda. de França, s/n. 17007 Girona. España. Correo electrónico: ballujera@hotmail.com Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, HOSPITAL, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_CONTACTO_ASISTENCIAL, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ID_CONTACTO_ASISTENCIAL", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "B-TERRITORIO", "O", "B-PAIS", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Nombre: Andreu. Apellidos: Bernabe Loza. NHC: 7845123. NASS: 23 56479608 12. Domicilio: Carrer de Joan Maragall, 26 2B. Localidad/ Provincia: Girona. CP: 17006. Datos asistenciales. Fecha de nacimiento: 13/01/1978. País: España. Edad: 40 años Sexo: H. Fecha de Ingreso: 10/05/2018 . Servicio: Medicina intensiva. Episodio: 1330431. Médico: Paula Ortiz Ballujera NºCol: 17 17 85423. Historia Actual: Se trata de un varón de 40 años que sufrió un accidente de coche. La TACHT al ingreso mostraba un seudoaneurisma de la aorta torácica a la salida de la arteria subclavia izquierda con un hematoma periaórtico extendido al mediastino posterior. El paciente ingresó en la UCI en respiración espontánea con tensión arterial sistólica (TAS) inferior a 120 mmHg. Se llevó a cabo un tratamiento conservador de las lesiones asociadas. A las 10 horas del ingreso en la UCI se le colocó una endoprótesis en la aorta torácica descendente por vía femoral izquierda, con oclusión parcial de la arteria subclavia izquierda. Fue dado de alta a planta a las 48 horas. Siguió controles con TACHT a los 7 días, al mes y a los 45 días. A los dos meses del accidente presentó una pericarditis aguda y ausencia de pulso radial izquierdo sin repercusión clínica. La TACHT mostraba una correcta localización de la endoprótesis. Remitido por: Dra. Paula Ortiz Ballujera. Servicio de Medicina Intensiva (UCI). Hospital Universitari de Girona Doctor Josep Trueta. Avda. de França, s/n. 17007 Girona. España. Correo electrónico: ballujera@hotmail.com	[ "Nombre", ":", " ", "Andreu", ".", "\n", "Apellidos", ":", "Bernabe", "Loza", ".", "\n", "NHC", ":", "7845123", ".", "\n", "NASS", ":", "23", "56479608", "12", ".", "\n", "Domicilio", ":", "Carrer", "de", "Joan", "Maragall", ",", "26", "2B.", "\n", "Localidad/", "Provincia", ":", "Girona", ".", "\n", "CP", ":", "17006", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "13/01/1978", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "40", "años", " ", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "10/05/2018", ".", "\n", "Servicio", ":", "Medicina", "intensiva", ".", "\n", "Episodio", ":", "1330431", ".", "\n", "Médico", ":", "Paula", "Ortiz", "Ballujera", "NºCol", ":", "17", "17", "85423", ".", "\n", "Historia", "Actual", ":", "Se", "trata", "de", "un", "varón", "de", "40", "años", "que", "sufrió", "un", "accidente", "de", "coche", ".", "La", "TACHT", "al", "ingreso", "mostraba", "un", "seudoaneurisma", "de", "la", "aorta", "torácica", "a", "la", "salida", "de", "la", "arteria", "subclavia", "izquierda", "con", "un", "hematoma", "periaórtico", "extendido", "al", "mediastino", "posterior", ".", "El", "paciente", "ingresó", "en", "la", "UCI", "en", "respiración", "espontánea", "con", "tensión", "arterial", "sistólica", "(", "TAS", ")", "inferior", "a", "120", "mmHg", ".", "Se", "llevó", "a", "cabo", "un", "tratamiento", "conservador", "de", "las", "lesiones", "asociadas", ".", "\n", "A", "las", "10", "horas", "del", "ingreso", "en", "la", "UCI", "se", "le", "colocó", "una", "endoprótesis", "en", "la", "aorta", "torácica", "descendente", "por", "vía", "femoral", "izquierda", ",", "con", "oclusión", "parcial", "de", "la", "arteria", "subclavia", "izquierda", ".", "Fue", "dado", "de", "alta", "a", "planta", "a", "las", "48", "horas", ".", "Siguió", "controles", "con", "TACHT", "a", "los", "7", "días", ",", "al", "mes", "y", "a", "los", "45", "días", ".", "\n", "A", "los", "dos", "meses", "del", "accidente", "presentó", "una", "pericarditis", "aguda", "y", "ausencia", "de", "pulso", "radial", "izquierdo", "sin", "repercusión", "clínica", ".", "La", "TACHT", "mostraba", "una", "correcta", "localización", "de", "la", "endoprótesis", ".", "\n", "Remitido", "por", ":", "Dra", ".", "Paula", "Ortiz", "Ballujera", ".", "Servicio", "de", "Medicina", "Intensiva", "(", "UCI", ")", ".", "Hospital", "Universitari", "de", "Girona", "Doctor", "Josep", "Trueta", ".", "Avda", ".", "de", "França", ",", "s", "/", "n.", "17007", "Girona", ".", "España", ".", "Correo", "electrónico", ":", "ballujera@hotmail.com", "\n" ]	[ "HOSPITAL", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_CONTACTO_ASISTENCIAL", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]
Andreu is a NOMBRE_SUJETO_ASISTENCIA, Bernabe Loza is a NOMBRE_SUJETO_ASISTENCIA, 7845123 is a ID_SUJETO_ASISTENCIA, 23 56479608 12 is a ID_ASEGURAMIENTO, Girona is a TERRITORIO, 17006 is a TERRITORIO, 13/01/1978 is a FECHAS, España is a PAIS, 40 años is a EDAD_SUJETO_ASISTENCIA, 10/05/2018 is a FECHAS, 1330431 is a ID_CONTACTO_ASISTENCIAL, Paula Ortiz Ballujera is a NOMBRE_PERSONAL_SANITARIO, 17 17 85423 is a ID_TITULACION_PERSONAL_SANITARIO, varón is a SEXO_SUJETO_ASISTENCIA, 40 años is a EDAD_SUJETO_ASISTENCIA, Paula Ortiz Ballujera is a NOMBRE_PERSONAL_SANITARIO, Hospital Universitari de Girona Doctor Josep Trueta is a HOSPITAL, 17007 is a TERRITORIO, Girona is a TERRITORIO, España is a PAIS, ballujera@hotmail.com is a CORREO_ELECTRONICO	98_task1	Sentence: Nombre: Andreu. Apellidos: Bernabe Loza. NHC: 7845123. NASS: 23 56479608 12. Domicilio: Carrer de Joan Maragall, 26 2B. Localidad/ Provincia: Girona. CP: 17006. Datos asistenciales. Fecha de nacimiento: 13/01/1978. País: España. Edad: 40 años Sexo: H. Fecha de Ingreso: 10/05/2018 . Servicio: Medicina intensiva. Episodio: 1330431. Médico: Paula Ortiz Ballujera NºCol: 17 17 85423. Historia Actual: Se trata de un varón de 40 años que sufrió un accidente de coche. La TACHT al ingreso mostraba un seudoaneurisma de la aorta torácica a la salida de la arteria subclavia izquierda con un hematoma periaórtico extendido al mediastino posterior. El paciente ingresó en la UCI en respiración espontánea con tensión arterial sistólica (TAS) inferior a 120 mmHg. Se llevó a cabo un tratamiento conservador de las lesiones asociadas. A las 10 horas del ingreso en la UCI se le colocó una endoprótesis en la aorta torácica descendente por vía femoral izquierda, con oclusión parcial de la arteria subclavia izquierda. Fue dado de alta a planta a las 48 horas. Siguió controles con TACHT a los 7 días, al mes y a los 45 días. A los dos meses del accidente presentó una pericarditis aguda y ausencia de pulso radial izquierdo sin repercusión clínica. La TACHT mostraba una correcta localización de la endoprótesis. Remitido por: Dra. Paula Ortiz Ballujera. Servicio de Medicina Intensiva (UCI). Hospital Universitari de Girona Doctor Josep Trueta. Avda. de França, s/n. 17007 Girona. España. Correo electrónico: ballujera@hotmail.com Instructions: please typing these entity words according to sentence: Andreu, Bernabe Loza, 7845123, 23 56479608 12, Girona, 17006, 13/01/1978, España, 40 años, 10/05/2018, 1330431, Paula Ortiz Ballujera, 17 17 85423, varón, 40 años, Paula Ortiz Ballujera, Hospital Universitari de Girona Doctor Josep Trueta, 17007, Girona, España, ballujera@hotmail.com Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, HOSPITAL, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_CONTACTO_ASISTENCIAL, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ID_CONTACTO_ASISTENCIAL", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "B-TERRITORIO", "O", "B-PAIS", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Nombre: Andreu. Apellidos: Bernabe Loza. NHC: 7845123. NASS: 23 56479608 12. Domicilio: Carrer de Joan Maragall, 26 2B. Localidad/ Provincia: Girona. CP: 17006. Datos asistenciales. Fecha de nacimiento: 13/01/1978. País: España. Edad: 40 años Sexo: H. Fecha de Ingreso: 10/05/2018 . Servicio: Medicina intensiva. Episodio: 1330431. Médico: Paula Ortiz Ballujera NºCol: 17 17 85423. Historia Actual: Se trata de un varón de 40 años que sufrió un accidente de coche. La TACHT al ingreso mostraba un seudoaneurisma de la aorta torácica a la salida de la arteria subclavia izquierda con un hematoma periaórtico extendido al mediastino posterior. El paciente ingresó en la UCI en respiración espontánea con tensión arterial sistólica (TAS) inferior a 120 mmHg. Se llevó a cabo un tratamiento conservador de las lesiones asociadas. A las 10 horas del ingreso en la UCI se le colocó una endoprótesis en la aorta torácica descendente por vía femoral izquierda, con oclusión parcial de la arteria subclavia izquierda. Fue dado de alta a planta a las 48 horas. Siguió controles con TACHT a los 7 días, al mes y a los 45 días. A los dos meses del accidente presentó una pericarditis aguda y ausencia de pulso radial izquierdo sin repercusión clínica. La TACHT mostraba una correcta localización de la endoprótesis. Remitido por: Dra. Paula Ortiz Ballujera. Servicio de Medicina Intensiva (UCI). Hospital Universitari de Girona Doctor Josep Trueta. Avda. de França, s/n. 17007 Girona. España. Correo electrónico: ballujera@hotmail.com	[ "Nombre", ":", " ", "Andreu", ".", "\n", "Apellidos", ":", "Bernabe", "Loza", ".", "\n", "NHC", ":", "7845123", ".", "\n", "NASS", ":", "23", "56479608", "12", ".", "\n", "Domicilio", ":", "Carrer", "de", "Joan", "Maragall", ",", "26", "2B.", "\n", "Localidad/", "Provincia", ":", "Girona", ".", "\n", "CP", ":", "17006", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "13/01/1978", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "40", "años", " ", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "10/05/2018", ".", "\n", "Servicio", ":", "Medicina", "intensiva", ".", "\n", "Episodio", ":", "1330431", ".", "\n", "Médico", ":", "Paula", "Ortiz", "Ballujera", "NºCol", ":", "17", "17", "85423", ".", "\n", "Historia", "Actual", ":", "Se", "trata", "de", "un", "varón", "de", "40", "años", "que", "sufrió", "un", "accidente", "de", "coche", ".", "La", "TACHT", "al", "ingreso", "mostraba", "un", "seudoaneurisma", "de", "la", "aorta", "torácica", "a", "la", "salida", "de", "la", "arteria", "subclavia", "izquierda", "con", "un", "hematoma", "periaórtico", "extendido", "al", "mediastino", "posterior", ".", "El", "paciente", "ingresó", "en", "la", "UCI", "en", "respiración", "espontánea", "con", "tensión", "arterial", "sistólica", "(", "TAS", ")", "inferior", "a", "120", "mmHg", ".", "Se", "llevó", "a", "cabo", "un", "tratamiento", "conservador", "de", "las", "lesiones", "asociadas", ".", "\n", "A", "las", "10", "horas", "del", "ingreso", "en", "la", "UCI", "se", "le", "colocó", "una", "endoprótesis", "en", "la", "aorta", "torácica", "descendente", "por", "vía", "femoral", "izquierda", ",", "con", "oclusión", "parcial", "de", "la", "arteria", "subclavia", "izquierda", ".", "Fue", "dado", "de", "alta", "a", "planta", "a", "las", "48", "horas", ".", "Siguió", "controles", "con", "TACHT", "a", "los", "7", "días", ",", "al", "mes", "y", "a", "los", "45", "días", ".", "\n", "A", "los", "dos", "meses", "del", "accidente", "presentó", "una", "pericarditis", "aguda", "y", "ausencia", "de", "pulso", "radial", "izquierdo", "sin", "repercusión", "clínica", ".", "La", "TACHT", "mostraba", "una", "correcta", "localización", "de", "la", "endoprótesis", ".", "\n", "Remitido", "por", ":", "Dra", ".", "Paula", "Ortiz", "Ballujera", ".", "Servicio", "de", "Medicina", "Intensiva", "(", "UCI", ")", ".", "Hospital", "Universitari", "de", "Girona", "Doctor", "Josep", "Trueta", ".", "Avda", ".", "de", "França", ",", "s", "/", "n.", "17007", "Girona", ".", "España", ".", "Correo", "electrónico", ":", "ballujera@hotmail.com", "\n" ]	[ "HOSPITAL", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_CONTACTO_ASISTENCIAL", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]
Andreu, Bernabe Loza, 7845123, 23 56479608 12, Girona, 17006, 13/01/1978, España, 40 años, 10/05/2018, 1330431, Paula Ortiz Ballujera, 17 17 85423, varón, 40 años, Paula Ortiz Ballujera, Hospital Universitari de Girona Doctor Josep Trueta, 17007, Girona, España, ballujera@hotmail.com	98_task2	Sentence: Nombre: Andreu. Apellidos: Bernabe Loza. NHC: 7845123. NASS: 23 56479608 12. Domicilio: Carrer de Joan Maragall, 26 2B. Localidad/ Provincia: Girona. CP: 17006. Datos asistenciales. Fecha de nacimiento: 13/01/1978. País: España. Edad: 40 años Sexo: H. Fecha de Ingreso: 10/05/2018 . Servicio: Medicina intensiva. Episodio: 1330431. Médico: Paula Ortiz Ballujera NºCol: 17 17 85423. Historia Actual: Se trata de un varón de 40 años que sufrió un accidente de coche. La TACHT al ingreso mostraba un seudoaneurisma de la aorta torácica a la salida de la arteria subclavia izquierda con un hematoma periaórtico extendido al mediastino posterior. El paciente ingresó en la UCI en respiración espontánea con tensión arterial sistólica (TAS) inferior a 120 mmHg. Se llevó a cabo un tratamiento conservador de las lesiones asociadas. A las 10 horas del ingreso en la UCI se le colocó una endoprótesis en la aorta torácica descendente por vía femoral izquierda, con oclusión parcial de la arteria subclavia izquierda. Fue dado de alta a planta a las 48 horas. Siguió controles con TACHT a los 7 días, al mes y a los 45 días. A los dos meses del accidente presentó una pericarditis aguda y ausencia de pulso radial izquierdo sin repercusión clínica. La TACHT mostraba una correcta localización de la endoprótesis. Remitido por: Dra. Paula Ortiz Ballujera. Servicio de Medicina Intensiva (UCI). Hospital Universitari de Girona Doctor Josep Trueta. Avda. de França, s/n. 17007 Girona. España. Correo electrónico: ballujera@hotmail.com Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ID_CONTACTO_ASISTENCIAL", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "B-TERRITORIO", "O", "B-PAIS", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Nombre: Andreu. Apellidos: Bernabe Loza. NHC: 7845123. NASS: 23 56479608 12. Domicilio: Carrer de Joan Maragall, 26 2B. Localidad/ Provincia: Girona. CP: 17006. Datos asistenciales. Fecha de nacimiento: 13/01/1978. País: España. Edad: 40 años Sexo: H. Fecha de Ingreso: 10/05/2018 . Servicio: Medicina intensiva. Episodio: 1330431. Médico: Paula Ortiz Ballujera NºCol: 17 17 85423. Historia Actual: Se trata de un varón de 40 años que sufrió un accidente de coche. La TACHT al ingreso mostraba un seudoaneurisma de la aorta torácica a la salida de la arteria subclavia izquierda con un hematoma periaórtico extendido al mediastino posterior. El paciente ingresó en la UCI en respiración espontánea con tensión arterial sistólica (TAS) inferior a 120 mmHg. Se llevó a cabo un tratamiento conservador de las lesiones asociadas. A las 10 horas del ingreso en la UCI se le colocó una endoprótesis en la aorta torácica descendente por vía femoral izquierda, con oclusión parcial de la arteria subclavia izquierda. Fue dado de alta a planta a las 48 horas. Siguió controles con TACHT a los 7 días, al mes y a los 45 días. A los dos meses del accidente presentó una pericarditis aguda y ausencia de pulso radial izquierdo sin repercusión clínica. La TACHT mostraba una correcta localización de la endoprótesis. Remitido por: Dra. Paula Ortiz Ballujera. Servicio de Medicina Intensiva (UCI). Hospital Universitari de Girona Doctor Josep Trueta. Avda. de França, s/n. 17007 Girona. España. Correo electrónico: ballujera@hotmail.com	[ "Nombre", ":", " ", "Andreu", ".", "\n", "Apellidos", ":", "Bernabe", "Loza", ".", "\n", "NHC", ":", "7845123", ".", "\n", "NASS", ":", "23", "56479608", "12", ".", "\n", "Domicilio", ":", "Carrer", "de", "Joan", "Maragall", ",", "26", "2B.", "\n", "Localidad/", "Provincia", ":", "Girona", ".", "\n", "CP", ":", "17006", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "13/01/1978", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "40", "años", " ", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "10/05/2018", ".", "\n", "Servicio", ":", "Medicina", "intensiva", ".", "\n", "Episodio", ":", "1330431", ".", "\n", "Médico", ":", "Paula", "Ortiz", "Ballujera", "NºCol", ":", "17", "17", "85423", ".", "\n", "Historia", "Actual", ":", "Se", "trata", "de", "un", "varón", "de", "40", "años", "que", "sufrió", "un", "accidente", "de", "coche", ".", "La", "TACHT", "al", "ingreso", "mostraba", "un", "seudoaneurisma", "de", "la", "aorta", "torácica", "a", "la", "salida", "de", "la", "arteria", "subclavia", "izquierda", "con", "un", "hematoma", "periaórtico", "extendido", "al", "mediastino", "posterior", ".", "El", "paciente", "ingresó", "en", "la", "UCI", "en", "respiración", "espontánea", "con", "tensión", "arterial", "sistólica", "(", "TAS", ")", "inferior", "a", "120", "mmHg", ".", "Se", "llevó", "a", "cabo", "un", "tratamiento", "conservador", "de", "las", "lesiones", "asociadas", ".", "\n", "A", "las", "10", "horas", "del", "ingreso", "en", "la", "UCI", "se", "le", "colocó", "una", "endoprótesis", "en", "la", "aorta", "torácica", "descendente", "por", "vía", "femoral", "izquierda", ",", "con", "oclusión", "parcial", "de", "la", "arteria", "subclavia", "izquierda", ".", "Fue", "dado", "de", "alta", "a", "planta", "a", "las", "48", "horas", ".", "Siguió", "controles", "con", "TACHT", "a", "los", "7", "días", ",", "al", "mes", "y", "a", "los", "45", "días", ".", "\n", "A", "los", "dos", "meses", "del", "accidente", "presentó", "una", "pericarditis", "aguda", "y", "ausencia", "de", "pulso", "radial", "izquierdo", "sin", "repercusión", "clínica", ".", "La", "TACHT", "mostraba", "una", "correcta", "localización", "de", "la", "endoprótesis", ".", "\n", "Remitido", "por", ":", "Dra", ".", "Paula", "Ortiz", "Ballujera", ".", "Servicio", "de", "Medicina", "Intensiva", "(", "UCI", ")", ".", "Hospital", "Universitari", "de", "Girona", "Doctor", "Josep", "Trueta", ".", "Avda", ".", "de", "França", ",", "s", "/", "n.", "17007", "Girona", ".", "España", ".", "Correo", "electrónico", ":", "ballujera@hotmail.com", "\n" ]	[ "HOSPITAL", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_CONTACTO_ASISTENCIAL", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]
pimecrolimus is a Intervention_Pharmacological, cetuximab - associated acnelike eruption is a Participant_Condition, cetuximab - related facial rash . is a Participant_Condition, 24 is a Participant_Sample-size, metastatic colorectal cancer with cetuximab facial rash is a Participant_Condition, lesion counts is a Outcome_Physical, rash severity is a Outcome_Physical, Pimecrolimus is a Intervention_Pharmacological	41389_task0	Sentence: A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption . BACKGROUND Clinical trials addressing the acneiform rash associated with epidermal growth factor receptor inhibitors are lacking . OBJECTIVE We evaluated the ability of topical pimecrolimus to reduce the severity of cetuximab-related facial rash . METHODS In all , 24 patients with metastatic colorectal cancer with cetuximab facial rash received twice daily pimecrolimus application for 5 weeks to half of the face . At baseline , week 2 , and week 5 , a dermatologist performed facial lesion counts , patients reported perceived severity of rash-related symptoms , and standardized facial photographs were obtained for blinded evaluation of global rash severity . RESULTS Treatment sides had greater decrease in lesion counts than observation sides of face at weeks 2 ( P < .001 ) and 5 ( P = .02 ) . However , there were no significant differences in patients ' assessment of symptoms and in review of facial photographs for rash severity between treatment and observation sides . LIMITATIONS This study was not placebo controlled . CONCLUSIONS Pimecrolimus application did not translate into clinically meaningful benefit for patients with cetuximab-related facial rash . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Physical, Participant_Condition, Participant_Sample-size	[ "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption . BACKGROUND Clinical trials addressing the acneiform rash associated with epidermal growth factor receptor inhibitors are lacking . OBJECTIVE We evaluated the ability of topical pimecrolimus to reduce the severity of cetuximab-related facial rash . METHODS In all , 24 patients with metastatic colorectal cancer with cetuximab facial rash received twice daily pimecrolimus application for 5 weeks to half of the face . At baseline , week 2 , and week 5 , a dermatologist performed facial lesion counts , patients reported perceived severity of rash-related symptoms , and standardized facial photographs were obtained for blinded evaluation of global rash severity . RESULTS Treatment sides had greater decrease in lesion counts than observation sides of face at weeks 2 ( P < .001 ) and 5 ( P = .02 ) . However , there were no significant differences in patients ' assessment of symptoms and in review of facial photographs for rash severity between treatment and observation sides . LIMITATIONS This study was not placebo controlled . CONCLUSIONS Pimecrolimus application did not translate into clinically meaningful benefit for patients with cetuximab-related facial rash .	[ "A", "prospective", "randomized", "trial", "of", "topical", "pimecrolimus", "for", "cetuximab", "-", "associated", "acnelike", "eruption", ".", "BACKGROUND", "Clinical", "trials", "addressing", "the", "acneiform", "rash", "associated", "with", "epidermal", "growth", "factor", "receptor", "inhibitors", "are", "lacking", ".", "OBJECTIVE", "We", "evaluated", "the", "ability", "of", "topical", "pimecrolimus", "to", "reduce", "the", "severity", "of", "cetuximab", "-", "related", "facial", "rash", ".", "METHODS", "In", "all", ",", "24", "patients", "with", "metastatic", "colorectal", "cancer", "with", "cetuximab", "facial", "rash", "received", "twice", "daily", "pimecrolimus", "application", "for", "5", "weeks", "to", "half", "of", "the", "face", ".", "At", "baseline", ",", "week", "2", ",", "and", "week", "5", ",", "a", "dermatologist", "performed", "facial", "lesion", "counts", ",", "patients", "reported", "perceived", "severity", "of", "rash", "-", "related", "symptoms", ",", "and", "standardized", "facial", "photographs", "were", "obtained", "for", "blinded", "evaluation", "of", "global", "rash", "severity", ".", "RESULTS", "Treatment", "sides", "had", "greater", "decrease", "in", "lesion", "counts", "than", "observation", "sides", "of", "face", "at", "weeks", "2", "(", "P", "<", ".001", ")", "and", "5", "(", "P", "=", ".02", ")", ".", "However", ",", "there", "were", "no", "significant", "differences", "in", "patients", "'", "assessment", "of", "symptoms", "and", "in", "review", "of", "facial", "photographs", "for", "rash", "severity", "between", "treatment", "and", "observation", "sides", ".", "LIMITATIONS", "This", "study", "was", "not", "placebo", "controlled", ".", "CONCLUSIONS", "Pimecrolimus", "application", "did", "not", "translate", "into", "clinically", "meaningful", "benefit", "for", "patients", "with", "cetuximab", "-", "related", "facial", "rash", "." ]	[ "Participant_Condition", "Outcome_Physical", "Intervention_Pharmacological", "Participant_Sample-size" ]
pimecrolimus is a Intervention_Pharmacological, cetuximab - associated acnelike eruption is a Participant_Condition, cetuximab - related facial rash . is a Participant_Condition, 24 is a Participant_Sample-size, metastatic colorectal cancer with cetuximab facial rash is a Participant_Condition, lesion counts is a Outcome_Physical, rash severity is a Outcome_Physical, Pimecrolimus is a Intervention_Pharmacological	41389_task1	Sentence: A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption . BACKGROUND Clinical trials addressing the acneiform rash associated with epidermal growth factor receptor inhibitors are lacking . OBJECTIVE We evaluated the ability of topical pimecrolimus to reduce the severity of cetuximab-related facial rash . METHODS In all , 24 patients with metastatic colorectal cancer with cetuximab facial rash received twice daily pimecrolimus application for 5 weeks to half of the face . At baseline , week 2 , and week 5 , a dermatologist performed facial lesion counts , patients reported perceived severity of rash-related symptoms , and standardized facial photographs were obtained for blinded evaluation of global rash severity . RESULTS Treatment sides had greater decrease in lesion counts than observation sides of face at weeks 2 ( P < .001 ) and 5 ( P = .02 ) . However , there were no significant differences in patients ' assessment of symptoms and in review of facial photographs for rash severity between treatment and observation sides . LIMITATIONS This study was not placebo controlled . CONCLUSIONS Pimecrolimus application did not translate into clinically meaningful benefit for patients with cetuximab-related facial rash . Instructions: please typing these entity words according to sentence: pimecrolimus, cetuximab - associated acnelike eruption, cetuximab - related facial rash ., 24, metastatic colorectal cancer with cetuximab facial rash, lesion counts, rash severity, Pimecrolimus Options: Intervention_Pharmacological, Outcome_Physical, Participant_Condition, Participant_Sample-size	[ "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption . BACKGROUND Clinical trials addressing the acneiform rash associated with epidermal growth factor receptor inhibitors are lacking . OBJECTIVE We evaluated the ability of topical pimecrolimus to reduce the severity of cetuximab-related facial rash . METHODS In all , 24 patients with metastatic colorectal cancer with cetuximab facial rash received twice daily pimecrolimus application for 5 weeks to half of the face . At baseline , week 2 , and week 5 , a dermatologist performed facial lesion counts , patients reported perceived severity of rash-related symptoms , and standardized facial photographs were obtained for blinded evaluation of global rash severity . RESULTS Treatment sides had greater decrease in lesion counts than observation sides of face at weeks 2 ( P < .001 ) and 5 ( P = .02 ) . However , there were no significant differences in patients ' assessment of symptoms and in review of facial photographs for rash severity between treatment and observation sides . LIMITATIONS This study was not placebo controlled . CONCLUSIONS Pimecrolimus application did not translate into clinically meaningful benefit for patients with cetuximab-related facial rash .	[ "A", "prospective", "randomized", "trial", "of", "topical", "pimecrolimus", "for", "cetuximab", "-", "associated", "acnelike", "eruption", ".", "BACKGROUND", "Clinical", "trials", "addressing", "the", "acneiform", "rash", "associated", "with", "epidermal", "growth", "factor", "receptor", "inhibitors", "are", "lacking", ".", "OBJECTIVE", "We", "evaluated", "the", "ability", "of", "topical", "pimecrolimus", "to", "reduce", "the", "severity", "of", "cetuximab", "-", "related", "facial", "rash", ".", "METHODS", "In", "all", ",", "24", "patients", "with", "metastatic", "colorectal", "cancer", "with", "cetuximab", "facial", "rash", "received", "twice", "daily", "pimecrolimus", "application", "for", "5", "weeks", "to", "half", "of", "the", "face", ".", "At", "baseline", ",", "week", "2", ",", "and", "week", "5", ",", "a", "dermatologist", "performed", "facial", "lesion", "counts", ",", "patients", "reported", "perceived", "severity", "of", "rash", "-", "related", "symptoms", ",", "and", "standardized", "facial", "photographs", "were", "obtained", "for", "blinded", "evaluation", "of", "global", "rash", "severity", ".", "RESULTS", "Treatment", "sides", "had", "greater", "decrease", "in", "lesion", "counts", "than", "observation", "sides", "of", "face", "at", "weeks", "2", "(", "P", "<", ".001", ")", "and", "5", "(", "P", "=", ".02", ")", ".", "However", ",", "there", "were", "no", "significant", "differences", "in", "patients", "'", "assessment", "of", "symptoms", "and", "in", "review", "of", "facial", "photographs", "for", "rash", "severity", "between", "treatment", "and", "observation", "sides", ".", "LIMITATIONS", "This", "study", "was", "not", "placebo", "controlled", ".", "CONCLUSIONS", "Pimecrolimus", "application", "did", "not", "translate", "into", "clinically", "meaningful", "benefit", "for", "patients", "with", "cetuximab", "-", "related", "facial", "rash", "." ]	[ "Participant_Condition", "Outcome_Physical", "Intervention_Pharmacological", "Participant_Sample-size" ]
pimecrolimus, cetuximab - associated acnelike eruption, cetuximab - related facial rash ., 24, metastatic colorectal cancer with cetuximab facial rash, lesion counts, rash severity, Pimecrolimus	41389_task2	Sentence: A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption . BACKGROUND Clinical trials addressing the acneiform rash associated with epidermal growth factor receptor inhibitors are lacking . OBJECTIVE We evaluated the ability of topical pimecrolimus to reduce the severity of cetuximab-related facial rash . METHODS In all , 24 patients with metastatic colorectal cancer with cetuximab facial rash received twice daily pimecrolimus application for 5 weeks to half of the face . At baseline , week 2 , and week 5 , a dermatologist performed facial lesion counts , patients reported perceived severity of rash-related symptoms , and standardized facial photographs were obtained for blinded evaluation of global rash severity . RESULTS Treatment sides had greater decrease in lesion counts than observation sides of face at weeks 2 ( P < .001 ) and 5 ( P = .02 ) . However , there were no significant differences in patients ' assessment of symptoms and in review of facial photographs for rash severity between treatment and observation sides . LIMITATIONS This study was not placebo controlled . CONCLUSIONS Pimecrolimus application did not translate into clinically meaningful benefit for patients with cetuximab-related facial rash . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption . BACKGROUND Clinical trials addressing the acneiform rash associated with epidermal growth factor receptor inhibitors are lacking . OBJECTIVE We evaluated the ability of topical pimecrolimus to reduce the severity of cetuximab-related facial rash . METHODS In all , 24 patients with metastatic colorectal cancer with cetuximab facial rash received twice daily pimecrolimus application for 5 weeks to half of the face . At baseline , week 2 , and week 5 , a dermatologist performed facial lesion counts , patients reported perceived severity of rash-related symptoms , and standardized facial photographs were obtained for blinded evaluation of global rash severity . RESULTS Treatment sides had greater decrease in lesion counts than observation sides of face at weeks 2 ( P < .001 ) and 5 ( P = .02 ) . However , there were no significant differences in patients ' assessment of symptoms and in review of facial photographs for rash severity between treatment and observation sides . LIMITATIONS This study was not placebo controlled . CONCLUSIONS Pimecrolimus application did not translate into clinically meaningful benefit for patients with cetuximab-related facial rash .	[ "A", "prospective", "randomized", "trial", "of", "topical", "pimecrolimus", "for", "cetuximab", "-", "associated", "acnelike", "eruption", ".", "BACKGROUND", "Clinical", "trials", "addressing", "the", "acneiform", "rash", "associated", "with", "epidermal", "growth", "factor", "receptor", "inhibitors", "are", "lacking", ".", "OBJECTIVE", "We", "evaluated", "the", "ability", "of", "topical", "pimecrolimus", "to", "reduce", "the", "severity", "of", "cetuximab", "-", "related", "facial", "rash", ".", "METHODS", "In", "all", ",", "24", "patients", "with", "metastatic", "colorectal", "cancer", "with", "cetuximab", "facial", "rash", "received", "twice", "daily", "pimecrolimus", "application", "for", "5", "weeks", "to", "half", "of", "the", "face", ".", "At", "baseline", ",", "week", "2", ",", "and", "week", "5", ",", "a", "dermatologist", "performed", "facial", "lesion", "counts", ",", "patients", "reported", "perceived", "severity", "of", "rash", "-", "related", "symptoms", ",", "and", "standardized", "facial", "photographs", "were", "obtained", "for", "blinded", "evaluation", "of", "global", "rash", "severity", ".", "RESULTS", "Treatment", "sides", "had", "greater", "decrease", "in", "lesion", "counts", "than", "observation", "sides", "of", "face", "at", "weeks", "2", "(", "P", "<", ".001", ")", "and", "5", "(", "P", "=", ".02", ")", ".", "However", ",", "there", "were", "no", "significant", "differences", "in", "patients", "'", "assessment", "of", "symptoms", "and", "in", "review", "of", "facial", "photographs", "for", "rash", "severity", "between", "treatment", "and", "observation", "sides", ".", "LIMITATIONS", "This", "study", "was", "not", "placebo", "controlled", ".", "CONCLUSIONS", "Pimecrolimus", "application", "did", "not", "translate", "into", "clinically", "meaningful", "benefit", "for", "patients", "with", "cetuximab", "-", "related", "facial", "rash", "." ]	[ "Participant_Condition", "Outcome_Physical", "Intervention_Pharmacological", "Participant_Sample-size" ]
systemischen Sklerodermie is an umlsterm, Rolle is an umlsterm, Zellen is an umlsterm, Plazenta is an umlsterm, Schwangerschaft is an umlsterm, Ueberleben is an umlsterm, weiblichen is an umlsterm, T - Zellen is an umlsterm, Zellen is an umlsterm, Hautgewebe is an umlsterm, Y - Chromosomen - spezifischen is an umlsterm, Patienten is an umlsterm	DerHautarzt.00510059.ger.abstr_task0	Sentence: Ein persistierender zellulaerer Mikrochimerismus koennte in der Pathogenese der systemischen Sklerodermie ( SSc ) eine Rolle spielen . Der Mikrochimerismus entsteht durch den Transport fetaler Zellen durch die Plazenta waehrend der Schwangerschaft in die maternale Zirkulation und deren Ueberleben aufgrund einer weitgehenden HLA-Klasse-II-Kompatibilitaet . Bei weiblichen SSc-Patienten wurde die Anwesenheit von fetalen CD3-positiven T-Zellen in der maternalen Zirkulation und von fetalen Zellen im befallenen Hautgewebe in Form von Y-Chromosomen-spezifischen DNA-Sequenzen nachgewiesen . Der persistierende Mikrochimerismus koennte bei bestimmten Patienten ueber eine fetoantimaternale Graft-versus-Host-aehnliche Reaktion eine SSc ausloesen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Ein persistierender zellulaerer Mikrochimerismus koennte in der Pathogenese der systemischen Sklerodermie ( SSc ) eine Rolle spielen . Der Mikrochimerismus entsteht durch den Transport fetaler Zellen durch die Plazenta waehrend der Schwangerschaft in die maternale Zirkulation und deren Ueberleben aufgrund einer weitgehenden HLA-Klasse-II-Kompatibilitaet . Bei weiblichen SSc-Patienten wurde die Anwesenheit von fetalen CD3-positiven T-Zellen in der maternalen Zirkulation und von fetalen Zellen im befallenen Hautgewebe in Form von Y-Chromosomen-spezifischen DNA-Sequenzen nachgewiesen . Der persistierende Mikrochimerismus koennte bei bestimmten Patienten ueber eine fetoantimaternale Graft-versus-Host-aehnliche Reaktion eine SSc ausloesen .	[ "Ein", "persistierender", "zellulaerer", "Mikrochimerismus", "koennte", "in", "der", "Pathogenese", "der", "systemischen", "Sklerodermie", "(", "SSc", ")", "eine", "Rolle", "spielen", ".", "Der", "Mikrochimerismus", "entsteht", "durch", "den", "Transport", "fetaler", "Zellen", "durch", "die", "Plazenta", "waehrend", "der", "Schwangerschaft", "in", "die", "maternale", "Zirkulation", "und", "deren", "Ueberleben", "aufgrund", "einer", "weitgehenden", "HLA", "-", "Klasse", "-", "II", "-", "Kompatibilitaet", ".", "Bei", "weiblichen", "SSc", "-", "Patienten", "wurde", "die", "Anwesenheit", "von", "fetalen", "CD3-positiven", "T", "-", "Zellen", "in", "der", "maternalen", "Zirkulation", "und", "von", "fetalen", "Zellen", "im", "befallenen", "Hautgewebe", "in", "Form", "von", "Y", "-", "Chromosomen", "-", "spezifischen", "DNA", "-", "Sequenzen", "nachgewiesen", ".", "Der", "persistierende", "Mikrochimerismus", "koennte", "bei", "bestimmten", "Patienten", "ueber", "eine", "fetoantimaternale", "Graft", "-", "versus", "-", "Host", "-", "aehnliche", "Reaktion", "eine", "SSc", "ausloesen", "." ]	[ "umlsterm" ]
systemischen Sklerodermie is an umlsterm, Rolle is an umlsterm, Zellen is an umlsterm, Plazenta is an umlsterm, Schwangerschaft is an umlsterm, Ueberleben is an umlsterm, weiblichen is an umlsterm, T - Zellen is an umlsterm, Zellen is an umlsterm, Hautgewebe is an umlsterm, Y - Chromosomen - spezifischen is an umlsterm, Patienten is an umlsterm	DerHautarzt.00510059.ger.abstr_task1	Sentence: Ein persistierender zellulaerer Mikrochimerismus koennte in der Pathogenese der systemischen Sklerodermie ( SSc ) eine Rolle spielen . Der Mikrochimerismus entsteht durch den Transport fetaler Zellen durch die Plazenta waehrend der Schwangerschaft in die maternale Zirkulation und deren Ueberleben aufgrund einer weitgehenden HLA-Klasse-II-Kompatibilitaet . Bei weiblichen SSc-Patienten wurde die Anwesenheit von fetalen CD3-positiven T-Zellen in der maternalen Zirkulation und von fetalen Zellen im befallenen Hautgewebe in Form von Y-Chromosomen-spezifischen DNA-Sequenzen nachgewiesen . Der persistierende Mikrochimerismus koennte bei bestimmten Patienten ueber eine fetoantimaternale Graft-versus-Host-aehnliche Reaktion eine SSc ausloesen . Instructions: please typing these entity words according to sentence: systemischen Sklerodermie, Rolle, Zellen, Plazenta, Schwangerschaft, Ueberleben, weiblichen, T - Zellen, Zellen, Hautgewebe, Y - Chromosomen - spezifischen, Patienten Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Ein persistierender zellulaerer Mikrochimerismus koennte in der Pathogenese der systemischen Sklerodermie ( SSc ) eine Rolle spielen . Der Mikrochimerismus entsteht durch den Transport fetaler Zellen durch die Plazenta waehrend der Schwangerschaft in die maternale Zirkulation und deren Ueberleben aufgrund einer weitgehenden HLA-Klasse-II-Kompatibilitaet . Bei weiblichen SSc-Patienten wurde die Anwesenheit von fetalen CD3-positiven T-Zellen in der maternalen Zirkulation und von fetalen Zellen im befallenen Hautgewebe in Form von Y-Chromosomen-spezifischen DNA-Sequenzen nachgewiesen . Der persistierende Mikrochimerismus koennte bei bestimmten Patienten ueber eine fetoantimaternale Graft-versus-Host-aehnliche Reaktion eine SSc ausloesen .	[ "Ein", "persistierender", "zellulaerer", "Mikrochimerismus", "koennte", "in", "der", "Pathogenese", "der", "systemischen", "Sklerodermie", "(", "SSc", ")", "eine", "Rolle", "spielen", ".", "Der", "Mikrochimerismus", "entsteht", "durch", "den", "Transport", "fetaler", "Zellen", "durch", "die", "Plazenta", "waehrend", "der", "Schwangerschaft", "in", "die", "maternale", "Zirkulation", "und", "deren", "Ueberleben", "aufgrund", "einer", "weitgehenden", "HLA", "-", "Klasse", "-", "II", "-", "Kompatibilitaet", ".", "Bei", "weiblichen", "SSc", "-", "Patienten", "wurde", "die", "Anwesenheit", "von", "fetalen", "CD3-positiven", "T", "-", "Zellen", "in", "der", "maternalen", "Zirkulation", "und", "von", "fetalen", "Zellen", "im", "befallenen", "Hautgewebe", "in", "Form", "von", "Y", "-", "Chromosomen", "-", "spezifischen", "DNA", "-", "Sequenzen", "nachgewiesen", ".", "Der", "persistierende", "Mikrochimerismus", "koennte", "bei", "bestimmten", "Patienten", "ueber", "eine", "fetoantimaternale", "Graft", "-", "versus", "-", "Host", "-", "aehnliche", "Reaktion", "eine", "SSc", "ausloesen", "." ]	[ "umlsterm" ]
systemischen Sklerodermie, Rolle, Zellen, Plazenta, Schwangerschaft, Ueberleben, weiblichen, T - Zellen, Zellen, Hautgewebe, Y - Chromosomen - spezifischen, Patienten	DerHautarzt.00510059.ger.abstr_task2	Sentence: Ein persistierender zellulaerer Mikrochimerismus koennte in der Pathogenese der systemischen Sklerodermie ( SSc ) eine Rolle spielen . Der Mikrochimerismus entsteht durch den Transport fetaler Zellen durch die Plazenta waehrend der Schwangerschaft in die maternale Zirkulation und deren Ueberleben aufgrund einer weitgehenden HLA-Klasse-II-Kompatibilitaet . Bei weiblichen SSc-Patienten wurde die Anwesenheit von fetalen CD3-positiven T-Zellen in der maternalen Zirkulation und von fetalen Zellen im befallenen Hautgewebe in Form von Y-Chromosomen-spezifischen DNA-Sequenzen nachgewiesen . Der persistierende Mikrochimerismus koennte bei bestimmten Patienten ueber eine fetoantimaternale Graft-versus-Host-aehnliche Reaktion eine SSc ausloesen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Ein persistierender zellulaerer Mikrochimerismus koennte in der Pathogenese der systemischen Sklerodermie ( SSc ) eine Rolle spielen . Der Mikrochimerismus entsteht durch den Transport fetaler Zellen durch die Plazenta waehrend der Schwangerschaft in die maternale Zirkulation und deren Ueberleben aufgrund einer weitgehenden HLA-Klasse-II-Kompatibilitaet . Bei weiblichen SSc-Patienten wurde die Anwesenheit von fetalen CD3-positiven T-Zellen in der maternalen Zirkulation und von fetalen Zellen im befallenen Hautgewebe in Form von Y-Chromosomen-spezifischen DNA-Sequenzen nachgewiesen . Der persistierende Mikrochimerismus koennte bei bestimmten Patienten ueber eine fetoantimaternale Graft-versus-Host-aehnliche Reaktion eine SSc ausloesen .	[ "Ein", "persistierender", "zellulaerer", "Mikrochimerismus", "koennte", "in", "der", "Pathogenese", "der", "systemischen", "Sklerodermie", "(", "SSc", ")", "eine", "Rolle", "spielen", ".", "Der", "Mikrochimerismus", "entsteht", "durch", "den", "Transport", "fetaler", "Zellen", "durch", "die", "Plazenta", "waehrend", "der", "Schwangerschaft", "in", "die", "maternale", "Zirkulation", "und", "deren", "Ueberleben", "aufgrund", "einer", "weitgehenden", "HLA", "-", "Klasse", "-", "II", "-", "Kompatibilitaet", ".", "Bei", "weiblichen", "SSc", "-", "Patienten", "wurde", "die", "Anwesenheit", "von", "fetalen", "CD3-positiven", "T", "-", "Zellen", "in", "der", "maternalen", "Zirkulation", "und", "von", "fetalen", "Zellen", "im", "befallenen", "Hautgewebe", "in", "Form", "von", "Y", "-", "Chromosomen", "-", "spezifischen", "DNA", "-", "Sequenzen", "nachgewiesen", ".", "Der", "persistierende", "Mikrochimerismus", "koennte", "bei", "bestimmten", "Patienten", "ueber", "eine", "fetoantimaternale", "Graft", "-", "versus", "-", "Host", "-", "aehnliche", "Reaktion", "eine", "SSc", "ausloesen", "." ]	[ "umlsterm" ]
transforming growth factor ( TGF)-beta1 is a Protein	10064064_task0	Sentence: AML and Ets proteins regulate the I alpha1 germ-line promoter. The immunoglobulin heavy chain (IgH) class switch recombination of B lymphocytes preferentially targets unrearranged IgH genes that have already been rendered transcriptionally active. Transcription of the germ-line IgH genes is controlled by intervening (I) regions upstream of their switch regions. The I alpha1 promoter activates transcription of the human germ-line C alpha1 gene for IgA1 and mediates the transforming growth factor (TGF)-beta1 responsiveness of this locus. Here we show that the I alpha1 promoter contains several binding sites for the AML/PEBP2/CBF family of transcription factors and that AML and Ets proteins are major regulators of the basal and TGF-beta-inducible promoter activity. Our data constitute a starting point for studies to elucidate the molecular mechanism by which TGF-beta regulates IgA production. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	AML and Ets proteins regulate the I alpha1 germ-line promoter. The immunoglobulin heavy chain (IgH) class switch recombination of B lymphocytes preferentially targets unrearranged IgH genes that have already been rendered transcriptionally active. Transcription of the germ-line IgH genes is controlled by intervening (I) regions upstream of their switch regions. The I alpha1 promoter activates transcription of the human germ-line C alpha1 gene for IgA1 and mediates the transforming growth factor (TGF)-beta1 responsiveness of this locus. Here we show that the I alpha1 promoter contains several binding sites for the AML/PEBP2/CBF family of transcription factors and that AML and Ets proteins are major regulators of the basal and TGF-beta-inducible promoter activity. Our data constitute a starting point for studies to elucidate the molecular mechanism by which TGF-beta regulates IgA production.	[ "AML", "and", "Ets", "proteins", "regulate", "the", "I", "alpha1", "germ", "-", "line", "promoter", ".", "\n", "The", "immunoglobulin", "heavy", "chain", "(", "IgH", ")", "class", "switch", "recombination", "of", "B", "lymphocytes", "preferentially", "targets", "unrearranged", "IgH", "genes", "that", "have", "already", "been", "rendered", "transcriptionally", "active", ".", "Transcription", "of", "the", "germ", "-", "line", "IgH", "genes", "is", "controlled", "by", "intervening", "(", "I", ")", "regions", "upstream", "of", "their", "switch", "regions", ".", "The", "I", "alpha1", "promoter", "activates", "transcription", "of", "the", "human", "germ", "-", "line", "C", "alpha1", "gene", "for", "IgA1", "and", "mediates", "the", "transforming", "growth", "factor", "(", "TGF)-beta1", "responsiveness", "of", "this", "locus", ".", "Here", "we", "show", "that", "the", "I", "alpha1", "promoter", "contains", "several", "binding", "sites", "for", "the", "AML", "/", "PEBP2", "/", "CBF", "family", "of", "transcription", "factors", "and", "that", "AML", "and", "Ets", "proteins", "are", "major", "regulators", "of", "the", "basal", "and", "TGF", "-", "beta", "-", "inducible", "promoter", "activity", ".", "Our", "data", "constitute", "a", "starting", "point", "for", "studies", "to", "elucidate", "the", "molecular", "mechanism", "by", "which", "TGF", "-", "beta", "regulates", "IgA", "production", "." ]	[ "Protein" ]
transforming growth factor ( TGF)-beta1 is a Protein	10064064_task1	Sentence: AML and Ets proteins regulate the I alpha1 germ-line promoter. The immunoglobulin heavy chain (IgH) class switch recombination of B lymphocytes preferentially targets unrearranged IgH genes that have already been rendered transcriptionally active. Transcription of the germ-line IgH genes is controlled by intervening (I) regions upstream of their switch regions. The I alpha1 promoter activates transcription of the human germ-line C alpha1 gene for IgA1 and mediates the transforming growth factor (TGF)-beta1 responsiveness of this locus. Here we show that the I alpha1 promoter contains several binding sites for the AML/PEBP2/CBF family of transcription factors and that AML and Ets proteins are major regulators of the basal and TGF-beta-inducible promoter activity. Our data constitute a starting point for studies to elucidate the molecular mechanism by which TGF-beta regulates IgA production. Instructions: please typing these entity words according to sentence: transforming growth factor ( TGF)-beta1 Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	AML and Ets proteins regulate the I alpha1 germ-line promoter. The immunoglobulin heavy chain (IgH) class switch recombination of B lymphocytes preferentially targets unrearranged IgH genes that have already been rendered transcriptionally active. Transcription of the germ-line IgH genes is controlled by intervening (I) regions upstream of their switch regions. The I alpha1 promoter activates transcription of the human germ-line C alpha1 gene for IgA1 and mediates the transforming growth factor (TGF)-beta1 responsiveness of this locus. Here we show that the I alpha1 promoter contains several binding sites for the AML/PEBP2/CBF family of transcription factors and that AML and Ets proteins are major regulators of the basal and TGF-beta-inducible promoter activity. Our data constitute a starting point for studies to elucidate the molecular mechanism by which TGF-beta regulates IgA production.	[ "AML", "and", "Ets", "proteins", "regulate", "the", "I", "alpha1", "germ", "-", "line", "promoter", ".", "\n", "The", "immunoglobulin", "heavy", "chain", "(", "IgH", ")", "class", "switch", "recombination", "of", "B", "lymphocytes", "preferentially", "targets", "unrearranged", "IgH", "genes", "that", "have", "already", "been", "rendered", "transcriptionally", "active", ".", "Transcription", "of", "the", "germ", "-", "line", "IgH", "genes", "is", "controlled", "by", "intervening", "(", "I", ")", "regions", "upstream", "of", "their", "switch", "regions", ".", "The", "I", "alpha1", "promoter", "activates", "transcription", "of", "the", "human", "germ", "-", "line", "C", "alpha1", "gene", "for", "IgA1", "and", "mediates", "the", "transforming", "growth", "factor", "(", "TGF)-beta1", "responsiveness", "of", "this", "locus", ".", "Here", "we", "show", "that", "the", "I", "alpha1", "promoter", "contains", "several", "binding", "sites", "for", "the", "AML", "/", "PEBP2", "/", "CBF", "family", "of", "transcription", "factors", "and", "that", "AML", "and", "Ets", "proteins", "are", "major", "regulators", "of", "the", "basal", "and", "TGF", "-", "beta", "-", "inducible", "promoter", "activity", ".", "Our", "data", "constitute", "a", "starting", "point", "for", "studies", "to", "elucidate", "the", "molecular", "mechanism", "by", "which", "TGF", "-", "beta", "regulates", "IgA", "production", "." ]	[ "Protein" ]
transforming growth factor ( TGF)-beta1	10064064_task2	Sentence: AML and Ets proteins regulate the I alpha1 germ-line promoter. The immunoglobulin heavy chain (IgH) class switch recombination of B lymphocytes preferentially targets unrearranged IgH genes that have already been rendered transcriptionally active. Transcription of the germ-line IgH genes is controlled by intervening (I) regions upstream of their switch regions. The I alpha1 promoter activates transcription of the human germ-line C alpha1 gene for IgA1 and mediates the transforming growth factor (TGF)-beta1 responsiveness of this locus. Here we show that the I alpha1 promoter contains several binding sites for the AML/PEBP2/CBF family of transcription factors and that AML and Ets proteins are major regulators of the basal and TGF-beta-inducible promoter activity. Our data constitute a starting point for studies to elucidate the molecular mechanism by which TGF-beta regulates IgA production. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	AML and Ets proteins regulate the I alpha1 germ-line promoter. The immunoglobulin heavy chain (IgH) class switch recombination of B lymphocytes preferentially targets unrearranged IgH genes that have already been rendered transcriptionally active. Transcription of the germ-line IgH genes is controlled by intervening (I) regions upstream of their switch regions. The I alpha1 promoter activates transcription of the human germ-line C alpha1 gene for IgA1 and mediates the transforming growth factor (TGF)-beta1 responsiveness of this locus. Here we show that the I alpha1 promoter contains several binding sites for the AML/PEBP2/CBF family of transcription factors and that AML and Ets proteins are major regulators of the basal and TGF-beta-inducible promoter activity. Our data constitute a starting point for studies to elucidate the molecular mechanism by which TGF-beta regulates IgA production.	[ "AML", "and", "Ets", "proteins", "regulate", "the", "I", "alpha1", "germ", "-", "line", "promoter", ".", "\n", "The", "immunoglobulin", "heavy", "chain", "(", "IgH", ")", "class", "switch", "recombination", "of", "B", "lymphocytes", "preferentially", "targets", "unrearranged", "IgH", "genes", "that", "have", "already", "been", "rendered", "transcriptionally", "active", ".", "Transcription", "of", "the", "germ", "-", "line", "IgH", "genes", "is", "controlled", "by", "intervening", "(", "I", ")", "regions", "upstream", "of", "their", "switch", "regions", ".", "The", "I", "alpha1", "promoter", "activates", "transcription", "of", "the", "human", "germ", "-", "line", "C", "alpha1", "gene", "for", "IgA1", "and", "mediates", "the", "transforming", "growth", "factor", "(", "TGF)-beta1", "responsiveness", "of", "this", "locus", ".", "Here", "we", "show", "that", "the", "I", "alpha1", "promoter", "contains", "several", "binding", "sites", "for", "the", "AML", "/", "PEBP2", "/", "CBF", "family", "of", "transcription", "factors", "and", "that", "AML", "and", "Ets", "proteins", "are", "major", "regulators", "of", "the", "basal", "and", "TGF", "-", "beta", "-", "inducible", "promoter", "activity", ".", "Our", "data", "constitute", "a", "starting", "point", "for", "studies", "to", "elucidate", "the", "molecular", "mechanism", "by", "which", "TGF", "-", "beta", "regulates", "IgA", "production", "." ]	[ "Protein" ]
device is an umlsterm, electrode is an umlsterm, blood is an umlsterm, oxygen is an umlsterm, CO2 is an umlsterm, temperature is an umlsterm, Paratrend is an umlsterm, Wycombe is an umlsterm, probe is an umlsterm, blood gas is an umlsterm, fiberoptic is an umlsterm, measurement is an umlsterm, haemoglobin is an umlsterm	DerAnaesthesist.70460329.eng.abstr_task0	Sentence: Introduction : Recently , a compact multisensor device 0.5 mm in diameter has become available with a miniaturised Clark electrode for measuring blood oxygen tension and two optical fibres for measuring CO2 tension , pH , and temperature ( Paratrend 7 , Biomedical Sensors , High Wycombe , UK ) . We used this new probe for continuous blood gas monitoring in the jugular bulb as an alternative to the commonly used fiberoptic spectrophotometric oximetric measurement of haemoglobin saturation . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]	Introduction : Recently , a compact multisensor device 0.5 mm in diameter has become available with a miniaturised Clark electrode for measuring blood oxygen tension and two optical fibres for measuring CO2 tension , pH , and temperature ( Paratrend 7 , Biomedical Sensors , High Wycombe , UK ) . We used this new probe for continuous blood gas monitoring in the jugular bulb as an alternative to the commonly used fiberoptic spectrophotometric oximetric measurement of haemoglobin saturation .	[ "Introduction", ":", "Recently", ",", "a", "compact", "multisensor", "device", "0.5", "mm", "in", "diameter", "has", "become", "available", "with", "a", "miniaturised", "Clark", "electrode", "for", "measuring", "blood", "oxygen", "tension", "and", "two", "optical", "fibres", "for", "measuring", "CO2", "tension", ",", "pH", ",", "and", "temperature", "(", "Paratrend", "7", ",", "Biomedical", "Sensors", ",", "High", "Wycombe", ",", "UK", ")", ".", "We", "used", "this", "new", "probe", "for", "continuous", "blood", "gas", "monitoring", "in", "the", "jugular", "bulb", "as", "an", "alternative", "to", "the", "commonly", "used", "fiberoptic", "spectrophotometric", "oximetric", "measurement", "of", "haemoglobin", "saturation", "." ]	[ "umlsterm" ]
device is an umlsterm, electrode is an umlsterm, blood is an umlsterm, oxygen is an umlsterm, CO2 is an umlsterm, temperature is an umlsterm, Paratrend is an umlsterm, Wycombe is an umlsterm, probe is an umlsterm, blood gas is an umlsterm, fiberoptic is an umlsterm, measurement is an umlsterm, haemoglobin is an umlsterm	DerAnaesthesist.70460329.eng.abstr_task1	Sentence: Introduction : Recently , a compact multisensor device 0.5 mm in diameter has become available with a miniaturised Clark electrode for measuring blood oxygen tension and two optical fibres for measuring CO2 tension , pH , and temperature ( Paratrend 7 , Biomedical Sensors , High Wycombe , UK ) . We used this new probe for continuous blood gas monitoring in the jugular bulb as an alternative to the commonly used fiberoptic spectrophotometric oximetric measurement of haemoglobin saturation . Instructions: please typing these entity words according to sentence: device, electrode, blood, oxygen, CO2, temperature, Paratrend, Wycombe, probe, blood gas, fiberoptic, measurement, haemoglobin Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]	Introduction : Recently , a compact multisensor device 0.5 mm in diameter has become available with a miniaturised Clark electrode for measuring blood oxygen tension and two optical fibres for measuring CO2 tension , pH , and temperature ( Paratrend 7 , Biomedical Sensors , High Wycombe , UK ) . We used this new probe for continuous blood gas monitoring in the jugular bulb as an alternative to the commonly used fiberoptic spectrophotometric oximetric measurement of haemoglobin saturation .	[ "Introduction", ":", "Recently", ",", "a", "compact", "multisensor", "device", "0.5", "mm", "in", "diameter", "has", "become", "available", "with", "a", "miniaturised", "Clark", "electrode", "for", "measuring", "blood", "oxygen", "tension", "and", "two", "optical", "fibres", "for", "measuring", "CO2", "tension", ",", "pH", ",", "and", "temperature", "(", "Paratrend", "7", ",", "Biomedical", "Sensors", ",", "High", "Wycombe", ",", "UK", ")", ".", "We", "used", "this", "new", "probe", "for", "continuous", "blood", "gas", "monitoring", "in", "the", "jugular", "bulb", "as", "an", "alternative", "to", "the", "commonly", "used", "fiberoptic", "spectrophotometric", "oximetric", "measurement", "of", "haemoglobin", "saturation", "." ]	[ "umlsterm" ]
device, electrode, blood, oxygen, CO2, temperature, Paratrend, Wycombe, probe, blood gas, fiberoptic, measurement, haemoglobin	DerAnaesthesist.70460329.eng.abstr_task2	Sentence: Introduction : Recently , a compact multisensor device 0.5 mm in diameter has become available with a miniaturised Clark electrode for measuring blood oxygen tension and two optical fibres for measuring CO2 tension , pH , and temperature ( Paratrend 7 , Biomedical Sensors , High Wycombe , UK ) . We used this new probe for continuous blood gas monitoring in the jugular bulb as an alternative to the commonly used fiberoptic spectrophotometric oximetric measurement of haemoglobin saturation . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]	Introduction : Recently , a compact multisensor device 0.5 mm in diameter has become available with a miniaturised Clark electrode for measuring blood oxygen tension and two optical fibres for measuring CO2 tension , pH , and temperature ( Paratrend 7 , Biomedical Sensors , High Wycombe , UK ) . We used this new probe for continuous blood gas monitoring in the jugular bulb as an alternative to the commonly used fiberoptic spectrophotometric oximetric measurement of haemoglobin saturation .	[ "Introduction", ":", "Recently", ",", "a", "compact", "multisensor", "device", "0.5", "mm", "in", "diameter", "has", "become", "available", "with", "a", "miniaturised", "Clark", "electrode", "for", "measuring", "blood", "oxygen", "tension", "and", "two", "optical", "fibres", "for", "measuring", "CO2", "tension", ",", "pH", ",", "and", "temperature", "(", "Paratrend", "7", ",", "Biomedical", "Sensors", ",", "High", "Wycombe", ",", "UK", ")", ".", "We", "used", "this", "new", "probe", "for", "continuous", "blood", "gas", "monitoring", "in", "the", "jugular", "bulb", "as", "an", "alternative", "to", "the", "commonly", "used", "fiberoptic", "spectrophotometric", "oximetric", "measurement", "of", "haemoglobin", "saturation", "." ]	[ "umlsterm" ]
therapy is an umlsterm, squamous cell carcinomas is an umlsterm, surgery is an umlsterm, radiotherapy is an umlsterm, chemotherapy is an umlsterm, therapeutic is an umlsterm, treatment failures is an umlsterm, mutations is an umlsterm, tumor is an umlsterm, gene is an umlsterm, therapeutic is an umlsterm, gene is an umlsterm, today 's is an umlsterm, therapy is an umlsterm, patients is an umlsterm, squamous cell carcinomas is an umlsterm, oral cavity is an umlsterm, biopsy is an umlsterm, patients is an umlsterm, biopsy is an umlsterm, analysis is an umlsterm, radiation is an umlsterm, treatment is an umlsterm, patients is an umlsterm, patients is an umlsterm, tumors is an umlsterm, tumors is an umlsterm, residual tumors is an umlsterm, radiation is an umlsterm, treatment is an umlsterm, p53 protein is an umlsterm, immunohistochemistry is an umlsterm, tumors is an umlsterm, radiation therapy is an umlsterm, tissue is an umlsterm, origin is an umlsterm, tumor is an umlsterm	MundKieferGesichtschirurgie.80020011.eng.abstr_task0	Sentence: Multimodal therapy of oral squamous cell carcinomas today is based on surgery , radiotherapy and chemotherapy . Despite the combination of all three therapeutic options , there is still a large number of treatment failures and therefore major questions remain . Recent investigations suggest that mutations of the p53 tumor supressor gene may account for some of the therapeutic failures . Inactivation of the gene may be an important determinant of the efficiacy of today's multimodal therapy protocols . In 90 patients with squamous cell carcinomas of the oral cavity biopsy specimens were taken before and after preoperative radiochemotherapy . From all patients , biopsy and resection material was available for immunohistochemical analysis of p53. After radiation treatment , 51 patients ( 57% ) showed a complete response ; 39 patients ( 43% ) only showed a partial response or did not respond at all . Among the responders , 82% of the pretherapeutic tumors were p53 positive , whereas among the nonresponders only 56% of the pretherapeutic tumors were p53 positive . The majority of the residual tumors were also p53 negative according to immunohistology after radiation treatment . In our study , detection of p53 protein by immunohistochemistry seemed to be connected with a more radiosensitive reaction of the tumors . Nevertheless , successful strategies for radiation therapy may need to take into account the tissue of origin and the status of p53 in the tumor . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Multimodal therapy of oral squamous cell carcinomas today is based on surgery , radiotherapy and chemotherapy . Despite the combination of all three therapeutic options , there is still a large number of treatment failures and therefore major questions remain . Recent investigations suggest that mutations of the p53 tumor supressor gene may account for some of the therapeutic failures . Inactivation of the gene may be an important determinant of the efficiacy of today's multimodal therapy protocols . In 90 patients with squamous cell carcinomas of the oral cavity biopsy specimens were taken before and after preoperative radiochemotherapy . From all patients , biopsy and resection material was available for immunohistochemical analysis of p53. After radiation treatment , 51 patients ( 57% ) showed a complete response ; 39 patients ( 43% ) only showed a partial response or did not respond at all . Among the responders , 82% of the pretherapeutic tumors were p53 positive , whereas among the nonresponders only 56% of the pretherapeutic tumors were p53 positive . The majority of the residual tumors were also p53 negative according to immunohistology after radiation treatment . In our study , detection of p53 protein by immunohistochemistry seemed to be connected with a more radiosensitive reaction of the tumors . Nevertheless , successful strategies for radiation therapy may need to take into account the tissue of origin and the status of p53 in the tumor .	[ "Multimodal", "therapy", "of", "oral", "squamous", "cell", "carcinomas", "today", "is", "based", "on", "surgery", ",", "radiotherapy", "and", "chemotherapy", ".", "Despite", "the", "combination", "of", "all", "three", "therapeutic", "options", ",", "there", "is", "still", "a", "large", "number", "of", "treatment", "failures", "and", "therefore", "major", "questions", "remain", ".", "Recent", "investigations", "suggest", "that", "mutations", "of", "the", "p53", "tumor", "supressor", "gene", "may", "account", "for", "some", "of", "the", "therapeutic", "failures", ".", "Inactivation", "of", "the", "gene", "may", "be", "an", "important", "determinant", "of", "the", "efficiacy", "of", "today", "'s", "multimodal", "therapy", "protocols", ".", "In", "90", "patients", "with", "squamous", "cell", "carcinomas", "of", "the", "oral", "cavity", "biopsy", "specimens", "were", "taken", "before", "and", "after", "preoperative", "radiochemotherapy", ".", "From", "all", "patients", ",", "biopsy", "and", "resection", "material", "was", "available", "for", "immunohistochemical", "analysis", "of", "p53", ".", "After", "radiation", "treatment", ",", "51", "patients", "(", "57", "%", ")", "showed", "a", "complete", "response", ";", "39", "patients", "(", "43", "%", ")", "only", "showed", "a", "partial", "response", "or", "did", "not", "respond", "at", "all", ".", "Among", "the", "responders", ",", "82", "%", "of", "the", "pretherapeutic", "tumors", "were", "p53", "positive", ",", "whereas", "among", "the", "nonresponders", "only", "56", "%", "of", "the", "pretherapeutic", "tumors", "were", "p53", "positive", ".", "The", "majority", "of", "the", "residual", "tumors", "were", "also", "p53", "negative", "according", "to", "immunohistology", "after", "radiation", "treatment", ".", "In", "our", "study", ",", "detection", "of", "p53", "protein", "by", "immunohistochemistry", "seemed", "to", "be", "connected", "with", "a", "more", "radiosensitive", "reaction", "of", "the", "tumors", ".", "Nevertheless", ",", "successful", "strategies", "for", "radiation", "therapy", "may", "need", "to", "take", "into", "account", "the", "tissue", "of", "origin", "and", "the", "status", "of", "p53", "in", "the", "tumor", "." ]	[ "umlsterm" ]
therapy is an umlsterm, squamous cell carcinomas is an umlsterm, surgery is an umlsterm, radiotherapy is an umlsterm, chemotherapy is an umlsterm, therapeutic is an umlsterm, treatment failures is an umlsterm, mutations is an umlsterm, tumor is an umlsterm, gene is an umlsterm, therapeutic is an umlsterm, gene is an umlsterm, today 's is an umlsterm, therapy is an umlsterm, patients is an umlsterm, squamous cell carcinomas is an umlsterm, oral cavity is an umlsterm, biopsy is an umlsterm, patients is an umlsterm, biopsy is an umlsterm, analysis is an umlsterm, radiation is an umlsterm, treatment is an umlsterm, patients is an umlsterm, patients is an umlsterm, tumors is an umlsterm, tumors is an umlsterm, residual tumors is an umlsterm, radiation is an umlsterm, treatment is an umlsterm, p53 protein is an umlsterm, immunohistochemistry is an umlsterm, tumors is an umlsterm, radiation therapy is an umlsterm, tissue is an umlsterm, origin is an umlsterm, tumor is an umlsterm	MundKieferGesichtschirurgie.80020011.eng.abstr_task1	Sentence: Multimodal therapy of oral squamous cell carcinomas today is based on surgery , radiotherapy and chemotherapy . Despite the combination of all three therapeutic options , there is still a large number of treatment failures and therefore major questions remain . Recent investigations suggest that mutations of the p53 tumor supressor gene may account for some of the therapeutic failures . Inactivation of the gene may be an important determinant of the efficiacy of today's multimodal therapy protocols . In 90 patients with squamous cell carcinomas of the oral cavity biopsy specimens were taken before and after preoperative radiochemotherapy . From all patients , biopsy and resection material was available for immunohistochemical analysis of p53. After radiation treatment , 51 patients ( 57% ) showed a complete response ; 39 patients ( 43% ) only showed a partial response or did not respond at all . Among the responders , 82% of the pretherapeutic tumors were p53 positive , whereas among the nonresponders only 56% of the pretherapeutic tumors were p53 positive . The majority of the residual tumors were also p53 negative according to immunohistology after radiation treatment . In our study , detection of p53 protein by immunohistochemistry seemed to be connected with a more radiosensitive reaction of the tumors . Nevertheless , successful strategies for radiation therapy may need to take into account the tissue of origin and the status of p53 in the tumor . Instructions: please typing these entity words according to sentence: therapy, squamous cell carcinomas, surgery, radiotherapy, chemotherapy, therapeutic, treatment failures, mutations, tumor, gene, therapeutic, gene, today 's, therapy, patients, squamous cell carcinomas, oral cavity, biopsy, patients, biopsy, analysis, radiation, treatment, patients, patients, tumors, tumors, residual tumors, radiation, treatment, p53 protein, immunohistochemistry, tumors, radiation therapy, tissue, origin, tumor Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Multimodal therapy of oral squamous cell carcinomas today is based on surgery , radiotherapy and chemotherapy . Despite the combination of all three therapeutic options , there is still a large number of treatment failures and therefore major questions remain . Recent investigations suggest that mutations of the p53 tumor supressor gene may account for some of the therapeutic failures . Inactivation of the gene may be an important determinant of the efficiacy of today's multimodal therapy protocols . In 90 patients with squamous cell carcinomas of the oral cavity biopsy specimens were taken before and after preoperative radiochemotherapy . From all patients , biopsy and resection material was available for immunohistochemical analysis of p53. After radiation treatment , 51 patients ( 57% ) showed a complete response ; 39 patients ( 43% ) only showed a partial response or did not respond at all . Among the responders , 82% of the pretherapeutic tumors were p53 positive , whereas among the nonresponders only 56% of the pretherapeutic tumors were p53 positive . The majority of the residual tumors were also p53 negative according to immunohistology after radiation treatment . In our study , detection of p53 protein by immunohistochemistry seemed to be connected with a more radiosensitive reaction of the tumors . Nevertheless , successful strategies for radiation therapy may need to take into account the tissue of origin and the status of p53 in the tumor .	[ "Multimodal", "therapy", "of", "oral", "squamous", "cell", "carcinomas", "today", "is", "based", "on", "surgery", ",", "radiotherapy", "and", "chemotherapy", ".", "Despite", "the", "combination", "of", "all", "three", "therapeutic", "options", ",", "there", "is", "still", "a", "large", "number", "of", "treatment", "failures", "and", "therefore", "major", "questions", "remain", ".", "Recent", "investigations", "suggest", "that", "mutations", "of", "the", "p53", "tumor", "supressor", "gene", "may", "account", "for", "some", "of", "the", "therapeutic", "failures", ".", "Inactivation", "of", "the", "gene", "may", "be", "an", "important", "determinant", "of", "the", "efficiacy", "of", "today", "'s", "multimodal", "therapy", "protocols", ".", "In", "90", "patients", "with", "squamous", "cell", "carcinomas", "of", "the", "oral", "cavity", "biopsy", "specimens", "were", "taken", "before", "and", "after", "preoperative", "radiochemotherapy", ".", "From", "all", "patients", ",", "biopsy", "and", "resection", "material", "was", "available", "for", "immunohistochemical", "analysis", "of", "p53", ".", "After", "radiation", "treatment", ",", "51", "patients", "(", "57", "%", ")", "showed", "a", "complete", "response", ";", "39", "patients", "(", "43", "%", ")", "only", "showed", "a", "partial", "response", "or", "did", "not", "respond", "at", "all", ".", "Among", "the", "responders", ",", "82", "%", "of", "the", "pretherapeutic", "tumors", "were", "p53", "positive", ",", "whereas", "among", "the", "nonresponders", "only", "56", "%", "of", "the", "pretherapeutic", "tumors", "were", "p53", "positive", ".", "The", "majority", "of", "the", "residual", "tumors", "were", "also", "p53", "negative", "according", "to", "immunohistology", "after", "radiation", "treatment", ".", "In", "our", "study", ",", "detection", "of", "p53", "protein", "by", "immunohistochemistry", "seemed", "to", "be", "connected", "with", "a", "more", "radiosensitive", "reaction", "of", "the", "tumors", ".", "Nevertheless", ",", "successful", "strategies", "for", "radiation", "therapy", "may", "need", "to", "take", "into", "account", "the", "tissue", "of", "origin", "and", "the", "status", "of", "p53", "in", "the", "tumor", "." ]	[ "umlsterm" ]
therapy, squamous cell carcinomas, surgery, radiotherapy, chemotherapy, therapeutic, treatment failures, mutations, tumor, gene, therapeutic, gene, today 's, therapy, patients, squamous cell carcinomas, oral cavity, biopsy, patients, biopsy, analysis, radiation, treatment, patients, patients, tumors, tumors, residual tumors, radiation, treatment, p53 protein, immunohistochemistry, tumors, radiation therapy, tissue, origin, tumor	MundKieferGesichtschirurgie.80020011.eng.abstr_task2	Sentence: Multimodal therapy of oral squamous cell carcinomas today is based on surgery , radiotherapy and chemotherapy . Despite the combination of all three therapeutic options , there is still a large number of treatment failures and therefore major questions remain . Recent investigations suggest that mutations of the p53 tumor supressor gene may account for some of the therapeutic failures . Inactivation of the gene may be an important determinant of the efficiacy of today's multimodal therapy protocols . In 90 patients with squamous cell carcinomas of the oral cavity biopsy specimens were taken before and after preoperative radiochemotherapy . From all patients , biopsy and resection material was available for immunohistochemical analysis of p53. After radiation treatment , 51 patients ( 57% ) showed a complete response ; 39 patients ( 43% ) only showed a partial response or did not respond at all . Among the responders , 82% of the pretherapeutic tumors were p53 positive , whereas among the nonresponders only 56% of the pretherapeutic tumors were p53 positive . The majority of the residual tumors were also p53 negative according to immunohistology after radiation treatment . In our study , detection of p53 protein by immunohistochemistry seemed to be connected with a more radiosensitive reaction of the tumors . Nevertheless , successful strategies for radiation therapy may need to take into account the tissue of origin and the status of p53 in the tumor . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Multimodal therapy of oral squamous cell carcinomas today is based on surgery , radiotherapy and chemotherapy . Despite the combination of all three therapeutic options , there is still a large number of treatment failures and therefore major questions remain . Recent investigations suggest that mutations of the p53 tumor supressor gene may account for some of the therapeutic failures . Inactivation of the gene may be an important determinant of the efficiacy of today's multimodal therapy protocols . In 90 patients with squamous cell carcinomas of the oral cavity biopsy specimens were taken before and after preoperative radiochemotherapy . From all patients , biopsy and resection material was available for immunohistochemical analysis of p53. After radiation treatment , 51 patients ( 57% ) showed a complete response ; 39 patients ( 43% ) only showed a partial response or did not respond at all . Among the responders , 82% of the pretherapeutic tumors were p53 positive , whereas among the nonresponders only 56% of the pretherapeutic tumors were p53 positive . The majority of the residual tumors were also p53 negative according to immunohistology after radiation treatment . In our study , detection of p53 protein by immunohistochemistry seemed to be connected with a more radiosensitive reaction of the tumors . Nevertheless , successful strategies for radiation therapy may need to take into account the tissue of origin and the status of p53 in the tumor .	[ "Multimodal", "therapy", "of", "oral", "squamous", "cell", "carcinomas", "today", "is", "based", "on", "surgery", ",", "radiotherapy", "and", "chemotherapy", ".", "Despite", "the", "combination", "of", "all", "three", "therapeutic", "options", ",", "there", "is", "still", "a", "large", "number", "of", "treatment", "failures", "and", "therefore", "major", "questions", "remain", ".", "Recent", "investigations", "suggest", "that", "mutations", "of", "the", "p53", "tumor", "supressor", "gene", "may", "account", "for", "some", "of", "the", "therapeutic", "failures", ".", "Inactivation", "of", "the", "gene", "may", "be", "an", "important", "determinant", "of", "the", "efficiacy", "of", "today", "'s", "multimodal", "therapy", "protocols", ".", "In", "90", "patients", "with", "squamous", "cell", "carcinomas", "of", "the", "oral", "cavity", "biopsy", "specimens", "were", "taken", "before", "and", "after", "preoperative", "radiochemotherapy", ".", "From", "all", "patients", ",", "biopsy", "and", "resection", "material", "was", "available", "for", "immunohistochemical", "analysis", "of", "p53", ".", "After", "radiation", "treatment", ",", "51", "patients", "(", "57", "%", ")", "showed", "a", "complete", "response", ";", "39", "patients", "(", "43", "%", ")", "only", "showed", "a", "partial", "response", "or", "did", "not", "respond", "at", "all", ".", "Among", "the", "responders", ",", "82", "%", "of", "the", "pretherapeutic", "tumors", "were", "p53", "positive", ",", "whereas", "among", "the", "nonresponders", "only", "56", "%", "of", "the", "pretherapeutic", "tumors", "were", "p53", "positive", ".", "The", "majority", "of", "the", "residual", "tumors", "were", "also", "p53", "negative", "according", "to", "immunohistology", "after", "radiation", "treatment", ".", "In", "our", "study", ",", "detection", "of", "p53", "protein", "by", "immunohistochemistry", "seemed", "to", "be", "connected", "with", "a", "more", "radiosensitive", "reaction", "of", "the", "tumors", ".", "Nevertheless", ",", "successful", "strategies", "for", "radiation", "therapy", "may", "need", "to", "take", "into", "account", "the", "tissue", "of", "origin", "and", "the", "status", "of", "p53", "in", "the", "tumor", "." ]	[ "umlsterm" ]
use is an umlsterm, grafts is an umlsterm, treatment is an umlsterm, urethral strictures is an umlsterm, patients is an umlsterm, urologic surgery is an umlsterm, urethral strictures is an umlsterm, patients is an umlsterm, donor is an umlsterm, sutures is an umlsterm, patients is an umlsterm, Lyodura is an umlsterm, patients is an umlsterm, wound is an umlsterm, patients is an umlsterm, Donor is an umlsterm, pain is an umlsterm, patients is an umlsterm, visual analogue scale is an umlsterm, postoperative is an umlsterm, patients is an umlsterm, pain is an umlsterm, rigidity is an umlsterm, patients is an umlsterm, regeneration is an umlsterm, donor is an umlsterm, mucosa is an umlsterm, period is an umlsterm, scar is an umlsterm, complication is an umlsterm, mouth is an umlsterm, stenosis is an umlsterm, parotid duct is an umlsterm, hypesthesia is an umlsterm	MundKieferGesichtschirurgie.90030034.eng.abstr_task0	Sentence: The use of free buccal mucosal grafts in the treatment of urethral strictures has become very popular . In 1996 and 1997 we harvested free buccal mucosal grafts up to 7 cm long and 4 cm wide from 12 patients who underwent urologic surgery for urethral strictures . In 2 patients the donor site was closed primarily by sutures . Four patients received Lyodura and another 4 patients received Syspurderm as temporary wound coverage . In 2 patients Ethisorp patches were used . Donor site pain was judged by the patients on a visual analogue scale during the first postoperative week . The 2 patients who received the Ethisorp patches complained of more intense pain , probably caused by the rigidity of the material . In all patients regeneration of the donor site mucosa was good . During the follow-up period of 4-18 months scar formation at the lower vestibulum was noticed as the only complication . Permanent limitation of mouth opening , stenosis of the parotid duct or hypesthesia did not occur . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]	The use of free buccal mucosal grafts in the treatment of urethral strictures has become very popular . In 1996 and 1997 we harvested free buccal mucosal grafts up to 7 cm long and 4 cm wide from 12 patients who underwent urologic surgery for urethral strictures . In 2 patients the donor site was closed primarily by sutures . Four patients received Lyodura and another 4 patients received Syspurderm as temporary wound coverage . In 2 patients Ethisorp patches were used . Donor site pain was judged by the patients on a visual analogue scale during the first postoperative week . The 2 patients who received the Ethisorp patches complained of more intense pain , probably caused by the rigidity of the material . In all patients regeneration of the donor site mucosa was good . During the follow-up period of 4-18 months scar formation at the lower vestibulum was noticed as the only complication . Permanent limitation of mouth opening , stenosis of the parotid duct or hypesthesia did not occur .	[ "The", "use", "of", "free", "buccal", "mucosal", "grafts", "in", "the", "treatment", "of", "urethral", "strictures", "has", "become", "very", "popular", ".", "In", "1996", "and", "1997", "we", "harvested", "free", "buccal", "mucosal", "grafts", "up", "to", "7", "cm", "long", "and", "4", "cm", "wide", "from", "12", "patients", "who", "underwent", "urologic", "surgery", "for", "urethral", "strictures", ".", "In", "2", "patients", "the", "donor", "site", "was", "closed", "primarily", "by", "sutures", ".", "Four", "patients", "received", "Lyodura", "and", "another", "4", "patients", "received", "Syspurderm", "as", "temporary", "wound", "coverage", ".", "In", "2", "patients", "Ethisorp", "patches", "were", "used", ".", "Donor", "site", "pain", "was", "judged", "by", "the", "patients", "on", "a", "visual", "analogue", "scale", "during", "the", "first", "postoperative", "week", ".", "The", "2", "patients", "who", "received", "the", "Ethisorp", "patches", "complained", "of", "more", "intense", "pain", ",", "probably", "caused", "by", "the", "rigidity", "of", "the", "material", ".", "In", "all", "patients", "regeneration", "of", "the", "donor", "site", "mucosa", "was", "good", ".", "During", "the", "follow", "-", "up", "period", "of", "4", "-", "18", "months", "scar", "formation", "at", "the", "lower", "vestibulum", "was", "noticed", "as", "the", "only", "complication", ".", "Permanent", "limitation", "of", "mouth", "opening", ",", "stenosis", "of", "the", "parotid", "duct", "or", "hypesthesia", "did", "not", "occur", "." ]	[ "umlsterm" ]
use is an umlsterm, grafts is an umlsterm, treatment is an umlsterm, urethral strictures is an umlsterm, patients is an umlsterm, urologic surgery is an umlsterm, urethral strictures is an umlsterm, patients is an umlsterm, donor is an umlsterm, sutures is an umlsterm, patients is an umlsterm, Lyodura is an umlsterm, patients is an umlsterm, wound is an umlsterm, patients is an umlsterm, Donor is an umlsterm, pain is an umlsterm, patients is an umlsterm, visual analogue scale is an umlsterm, postoperative is an umlsterm, patients is an umlsterm, pain is an umlsterm, rigidity is an umlsterm, patients is an umlsterm, regeneration is an umlsterm, donor is an umlsterm, mucosa is an umlsterm, period is an umlsterm, scar is an umlsterm, complication is an umlsterm, mouth is an umlsterm, stenosis is an umlsterm, parotid duct is an umlsterm, hypesthesia is an umlsterm	MundKieferGesichtschirurgie.90030034.eng.abstr_task1	Sentence: The use of free buccal mucosal grafts in the treatment of urethral strictures has become very popular . In 1996 and 1997 we harvested free buccal mucosal grafts up to 7 cm long and 4 cm wide from 12 patients who underwent urologic surgery for urethral strictures . In 2 patients the donor site was closed primarily by sutures . Four patients received Lyodura and another 4 patients received Syspurderm as temporary wound coverage . In 2 patients Ethisorp patches were used . Donor site pain was judged by the patients on a visual analogue scale during the first postoperative week . The 2 patients who received the Ethisorp patches complained of more intense pain , probably caused by the rigidity of the material . In all patients regeneration of the donor site mucosa was good . During the follow-up period of 4-18 months scar formation at the lower vestibulum was noticed as the only complication . Permanent limitation of mouth opening , stenosis of the parotid duct or hypesthesia did not occur . Instructions: please typing these entity words according to sentence: use, grafts, treatment, urethral strictures, patients, urologic surgery, urethral strictures, patients, donor, sutures, patients, Lyodura, patients, wound, patients, Donor, pain, patients, visual analogue scale, postoperative, patients, pain, rigidity, patients, regeneration, donor, mucosa, period, scar, complication, mouth, stenosis, parotid duct, hypesthesia Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]	The use of free buccal mucosal grafts in the treatment of urethral strictures has become very popular . In 1996 and 1997 we harvested free buccal mucosal grafts up to 7 cm long and 4 cm wide from 12 patients who underwent urologic surgery for urethral strictures . In 2 patients the donor site was closed primarily by sutures . Four patients received Lyodura and another 4 patients received Syspurderm as temporary wound coverage . In 2 patients Ethisorp patches were used . Donor site pain was judged by the patients on a visual analogue scale during the first postoperative week . The 2 patients who received the Ethisorp patches complained of more intense pain , probably caused by the rigidity of the material . In all patients regeneration of the donor site mucosa was good . During the follow-up period of 4-18 months scar formation at the lower vestibulum was noticed as the only complication . Permanent limitation of mouth opening , stenosis of the parotid duct or hypesthesia did not occur .	[ "The", "use", "of", "free", "buccal", "mucosal", "grafts", "in", "the", "treatment", "of", "urethral", "strictures", "has", "become", "very", "popular", ".", "In", "1996", "and", "1997", "we", "harvested", "free", "buccal", "mucosal", "grafts", "up", "to", "7", "cm", "long", "and", "4", "cm", "wide", "from", "12", "patients", "who", "underwent", "urologic", "surgery", "for", "urethral", "strictures", ".", "In", "2", "patients", "the", "donor", "site", "was", "closed", "primarily", "by", "sutures", ".", "Four", "patients", "received", "Lyodura", "and", "another", "4", "patients", "received", "Syspurderm", "as", "temporary", "wound", "coverage", ".", "In", "2", "patients", "Ethisorp", "patches", "were", "used", ".", "Donor", "site", "pain", "was", "judged", "by", "the", "patients", "on", "a", "visual", "analogue", "scale", "during", "the", "first", "postoperative", "week", ".", "The", "2", "patients", "who", "received", "the", "Ethisorp", "patches", "complained", "of", "more", "intense", "pain", ",", "probably", "caused", "by", "the", "rigidity", "of", "the", "material", ".", "In", "all", "patients", "regeneration", "of", "the", "donor", "site", "mucosa", "was", "good", ".", "During", "the", "follow", "-", "up", "period", "of", "4", "-", "18", "months", "scar", "formation", "at", "the", "lower", "vestibulum", "was", "noticed", "as", "the", "only", "complication", ".", "Permanent", "limitation", "of", "mouth", "opening", ",", "stenosis", "of", "the", "parotid", "duct", "or", "hypesthesia", "did", "not", "occur", "." ]	[ "umlsterm" ]
use, grafts, treatment, urethral strictures, patients, urologic surgery, urethral strictures, patients, donor, sutures, patients, Lyodura, patients, wound, patients, Donor, pain, patients, visual analogue scale, postoperative, patients, pain, rigidity, patients, regeneration, donor, mucosa, period, scar, complication, mouth, stenosis, parotid duct, hypesthesia	MundKieferGesichtschirurgie.90030034.eng.abstr_task2	Sentence: The use of free buccal mucosal grafts in the treatment of urethral strictures has become very popular . In 1996 and 1997 we harvested free buccal mucosal grafts up to 7 cm long and 4 cm wide from 12 patients who underwent urologic surgery for urethral strictures . In 2 patients the donor site was closed primarily by sutures . Four patients received Lyodura and another 4 patients received Syspurderm as temporary wound coverage . In 2 patients Ethisorp patches were used . Donor site pain was judged by the patients on a visual analogue scale during the first postoperative week . The 2 patients who received the Ethisorp patches complained of more intense pain , probably caused by the rigidity of the material . In all patients regeneration of the donor site mucosa was good . During the follow-up period of 4-18 months scar formation at the lower vestibulum was noticed as the only complication . Permanent limitation of mouth opening , stenosis of the parotid duct or hypesthesia did not occur . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]	The use of free buccal mucosal grafts in the treatment of urethral strictures has become very popular . In 1996 and 1997 we harvested free buccal mucosal grafts up to 7 cm long and 4 cm wide from 12 patients who underwent urologic surgery for urethral strictures . In 2 patients the donor site was closed primarily by sutures . Four patients received Lyodura and another 4 patients received Syspurderm as temporary wound coverage . In 2 patients Ethisorp patches were used . Donor site pain was judged by the patients on a visual analogue scale during the first postoperative week . The 2 patients who received the Ethisorp patches complained of more intense pain , probably caused by the rigidity of the material . In all patients regeneration of the donor site mucosa was good . During the follow-up period of 4-18 months scar formation at the lower vestibulum was noticed as the only complication . Permanent limitation of mouth opening , stenosis of the parotid duct or hypesthesia did not occur .	[ "The", "use", "of", "free", "buccal", "mucosal", "grafts", "in", "the", "treatment", "of", "urethral", "strictures", "has", "become", "very", "popular", ".", "In", "1996", "and", "1997", "we", "harvested", "free", "buccal", "mucosal", "grafts", "up", "to", "7", "cm", "long", "and", "4", "cm", "wide", "from", "12", "patients", "who", "underwent", "urologic", "surgery", "for", "urethral", "strictures", ".", "In", "2", "patients", "the", "donor", "site", "was", "closed", "primarily", "by", "sutures", ".", "Four", "patients", "received", "Lyodura", "and", "another", "4", "patients", "received", "Syspurderm", "as", "temporary", "wound", "coverage", ".", "In", "2", "patients", "Ethisorp", "patches", "were", "used", ".", "Donor", "site", "pain", "was", "judged", "by", "the", "patients", "on", "a", "visual", "analogue", "scale", "during", "the", "first", "postoperative", "week", ".", "The", "2", "patients", "who", "received", "the", "Ethisorp", "patches", "complained", "of", "more", "intense", "pain", ",", "probably", "caused", "by", "the", "rigidity", "of", "the", "material", ".", "In", "all", "patients", "regeneration", "of", "the", "donor", "site", "mucosa", "was", "good", ".", "During", "the", "follow", "-", "up", "period", "of", "4", "-", "18", "months", "scar", "formation", "at", "the", "lower", "vestibulum", "was", "noticed", "as", "the", "only", "complication", ".", "Permanent", "limitation", "of", "mouth", "opening", ",", "stenosis", "of", "the", "parotid", "duct", "or", "hypesthesia", "did", "not", "occur", "." ]	[ "umlsterm" ]
pyruvate kinase erythroid - specific promoter is a Entity, L is a Protein, R - PK is a Protein, L - PK is a Protein, promoters is a Entity, cis- is a Entity, trans - acting elements is a Entity, L is a Protein, promoter is a Entity, R - PK is a Protein, cap site is a Entity, reporter gene is a Entity, minimal promoter is a Entity, DNA binding sites is a Entity, GATA-1 is a Protein, GATA binding site is a Entity, AGATAA is a Entity, TFIID binding site is a Entity, TFIID is a Entity, GATA binding site is a Entity, TFIID binding site is a Entity, binding sites is a Entity, R - PK is a Protein, minimal promoter is a Entity, elements is a Entity, hGATA-1 is a Protein, R - PK is a Protein, promoter is a Entity	29_task0	Sentence: Transcriptional regulation of the pyruvate kinase erythroid-specific promoter. Mammal pyruvate kinases are encoded by two genes. The L gene produces the erythroid (R-PK) or the hepatic (L-PK) isozymes by the alternative use of two promoters. We report the characterization of the cis- and trans-acting elements involved in the tissue-specific activity of the L gene erythroid promoter. A R-PK DNA fragment extending from -870 to +54 relative to the cap site confers erythroid specificity to a reporter gene. Within this region, we define a minimal promoter (-62 to +54) that displays erythroid-specific activity and contains two DNA binding sites. One, located at -50, binds members of the CCACC/Sp1 family and the other, located at -20, binds the erythroid factor GATA-1. Although the -20 GATA binding site (AGATAA) is also a potential TFIID binding site, it does not bind TFIID. Furthermore, the substitution of this GATA binding site by a canonical TFIID binding site suppresses the promoter activity. Mutations and deletions of both sites indicate that only the association of CCACC/Sp1 and GATA binding sites can drive efficient and tissue-specific expression of this R-PK minimal promoter. Finally, by co-transfection experiments, we study the elements involved in the hGATA-1 transactivation of the R-PK promoter in HeLa cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O" ]	Transcriptional regulation of the pyruvate kinase erythroid-specific promoter. Mammal pyruvate kinases are encoded by two genes. The L gene produces the erythroid (R-PK) or the hepatic (L-PK) isozymes by the alternative use of two promoters. We report the characterization of the cis- and trans-acting elements involved in the tissue-specific activity of the L gene erythroid promoter. A R-PK DNA fragment extending from -870 to +54 relative to the cap site confers erythroid specificity to a reporter gene. Within this region, we define a minimal promoter (-62 to +54) that displays erythroid-specific activity and contains two DNA binding sites. One, located at -50, binds members of the CCACC/Sp1 family and the other, located at -20, binds the erythroid factor GATA-1. Although the -20 GATA binding site (AGATAA) is also a potential TFIID binding site, it does not bind TFIID. Furthermore, the substitution of this GATA binding site by a canonical TFIID binding site suppresses the promoter activity. Mutations and deletions of both sites indicate that only the association of CCACC/Sp1 and GATA binding sites can drive efficient and tissue-specific expression of this R-PK minimal promoter. Finally, by co-transfection experiments, we study the elements involved in the hGATA-1 transactivation of the R-PK promoter in HeLa cells.	[ "Transcriptional", "regulation", "of", "the", "pyruvate", "kinase", "erythroid", "-", "specific", "promoter", ".", "\n", "Mammal", "pyruvate", "kinases", "are", "encoded", "by", "two", "genes", ".", "The", "L", "gene", "produces", "the", "erythroid", "(", "R", "-", "PK", ")", "or", "the", "hepatic", "(", "L", "-", "PK", ")", "isozymes", "by", "the", "alternative", "use", "of", "two", "promoters", ".", "We", "report", "the", "characterization", "of", "the", "cis-", "and", "trans", "-", "acting", "elements", "involved", "in", "the", "tissue", "-", "specific", "activity", "of", "the", "L", "gene", "erythroid", "promoter", ".", "A", "R", "-", "PK", "DNA", "fragment", "extending", "from", "-870", "to", "+54", "relative", "to", "the", "cap", "site", "confers", "erythroid", "specificity", "to", "a", "reporter", "gene", ".", "Within", "this", "region", ",", "we", "define", "a", "minimal", "promoter", "(", "-62", "to", "+54", ")", "that", "displays", "erythroid", "-", "specific", "activity", "and", "contains", "two", "DNA", "binding", "sites", ".", "One", ",", "located", "at", "-50", ",", "binds", "members", "of", "the", "CCACC", "/", "Sp1", "family", "and", "the", "other", ",", "located", "at", "-20", ",", "binds", "the", "erythroid", "factor", "GATA-1", ".", "Although", "the", "-20", "GATA", "binding", "site", "(", "AGATAA", ")", "is", "also", "a", "potential", "TFIID", "binding", "site", ",", "it", "does", "not", "bind", "TFIID", ".", "Furthermore", ",", "the", "substitution", "of", "this", "GATA", "binding", "site", "by", "a", "canonical", "TFIID", "binding", "site", "suppresses", "the", "promoter", "activity", ".", "Mutations", "and", "deletions", "of", "both", "sites", "indicate", "that", "only", "the", "association", "of", "CCACC", "/", "Sp1", "and", "GATA", "binding", "sites", "can", "drive", "efficient", "and", "tissue", "-", "specific", "expression", "of", "this", "R", "-", "PK", "minimal", "promoter", ".", "Finally", ",", "by", "co", "-", "transfection", "experiments", ",", "we", "study", "the", "elements", "involved", "in", "the", "hGATA-1", "transactivation", "of", "the", "R", "-", "PK", "promoter", "in", "HeLa", "cells", ".", "\n" ]	[ "Entity", "Protein" ]
pyruvate kinase erythroid - specific promoter is a Entity, L is a Protein, R - PK is a Protein, L - PK is a Protein, promoters is a Entity, cis- is a Entity, trans - acting elements is a Entity, L is a Protein, promoter is a Entity, R - PK is a Protein, cap site is a Entity, reporter gene is a Entity, minimal promoter is a Entity, DNA binding sites is a Entity, GATA-1 is a Protein, GATA binding site is a Entity, AGATAA is a Entity, TFIID binding site is a Entity, TFIID is a Entity, GATA binding site is a Entity, TFIID binding site is a Entity, binding sites is a Entity, R - PK is a Protein, minimal promoter is a Entity, elements is a Entity, hGATA-1 is a Protein, R - PK is a Protein, promoter is a Entity	29_task1	Sentence: Transcriptional regulation of the pyruvate kinase erythroid-specific promoter. Mammal pyruvate kinases are encoded by two genes. The L gene produces the erythroid (R-PK) or the hepatic (L-PK) isozymes by the alternative use of two promoters. We report the characterization of the cis- and trans-acting elements involved in the tissue-specific activity of the L gene erythroid promoter. A R-PK DNA fragment extending from -870 to +54 relative to the cap site confers erythroid specificity to a reporter gene. Within this region, we define a minimal promoter (-62 to +54) that displays erythroid-specific activity and contains two DNA binding sites. One, located at -50, binds members of the CCACC/Sp1 family and the other, located at -20, binds the erythroid factor GATA-1. Although the -20 GATA binding site (AGATAA) is also a potential TFIID binding site, it does not bind TFIID. Furthermore, the substitution of this GATA binding site by a canonical TFIID binding site suppresses the promoter activity. Mutations and deletions of both sites indicate that only the association of CCACC/Sp1 and GATA binding sites can drive efficient and tissue-specific expression of this R-PK minimal promoter. Finally, by co-transfection experiments, we study the elements involved in the hGATA-1 transactivation of the R-PK promoter in HeLa cells. Instructions: please typing these entity words according to sentence: pyruvate kinase erythroid - specific promoter, L, R - PK, L - PK, promoters, cis-, trans - acting elements, L, promoter, R - PK, cap site, reporter gene, minimal promoter, DNA binding sites, GATA-1, GATA binding site, AGATAA, TFIID binding site, TFIID, GATA binding site, TFIID binding site, binding sites, R - PK, minimal promoter, elements, hGATA-1, R - PK, promoter Options: Entity, Protein	[ "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O" ]	Transcriptional regulation of the pyruvate kinase erythroid-specific promoter. Mammal pyruvate kinases are encoded by two genes. The L gene produces the erythroid (R-PK) or the hepatic (L-PK) isozymes by the alternative use of two promoters. We report the characterization of the cis- and trans-acting elements involved in the tissue-specific activity of the L gene erythroid promoter. A R-PK DNA fragment extending from -870 to +54 relative to the cap site confers erythroid specificity to a reporter gene. Within this region, we define a minimal promoter (-62 to +54) that displays erythroid-specific activity and contains two DNA binding sites. One, located at -50, binds members of the CCACC/Sp1 family and the other, located at -20, binds the erythroid factor GATA-1. Although the -20 GATA binding site (AGATAA) is also a potential TFIID binding site, it does not bind TFIID. Furthermore, the substitution of this GATA binding site by a canonical TFIID binding site suppresses the promoter activity. Mutations and deletions of both sites indicate that only the association of CCACC/Sp1 and GATA binding sites can drive efficient and tissue-specific expression of this R-PK minimal promoter. Finally, by co-transfection experiments, we study the elements involved in the hGATA-1 transactivation of the R-PK promoter in HeLa cells.	[ "Transcriptional", "regulation", "of", "the", "pyruvate", "kinase", "erythroid", "-", "specific", "promoter", ".", "\n", "Mammal", "pyruvate", "kinases", "are", "encoded", "by", "two", "genes", ".", "The", "L", "gene", "produces", "the", "erythroid", "(", "R", "-", "PK", ")", "or", "the", "hepatic", "(", "L", "-", "PK", ")", "isozymes", "by", "the", "alternative", "use", "of", "two", "promoters", ".", "We", "report", "the", "characterization", "of", "the", "cis-", "and", "trans", "-", "acting", "elements", "involved", "in", "the", "tissue", "-", "specific", "activity", "of", "the", "L", "gene", "erythroid", "promoter", ".", "A", "R", "-", "PK", "DNA", "fragment", "extending", "from", "-870", "to", "+54", "relative", "to", "the", "cap", "site", "confers", "erythroid", "specificity", "to", "a", "reporter", "gene", ".", "Within", "this", "region", ",", "we", "define", "a", "minimal", "promoter", "(", "-62", "to", "+54", ")", "that", "displays", "erythroid", "-", "specific", "activity", "and", "contains", "two", "DNA", "binding", "sites", ".", "One", ",", "located", "at", "-50", ",", "binds", "members", "of", "the", "CCACC", "/", "Sp1", "family", "and", "the", "other", ",", "located", "at", "-20", ",", "binds", "the", "erythroid", "factor", "GATA-1", ".", "Although", "the", "-20", "GATA", "binding", "site", "(", "AGATAA", ")", "is", "also", "a", "potential", "TFIID", "binding", "site", ",", "it", "does", "not", "bind", "TFIID", ".", "Furthermore", ",", "the", "substitution", "of", "this", "GATA", "binding", "site", "by", "a", "canonical", "TFIID", "binding", "site", "suppresses", "the", "promoter", "activity", ".", "Mutations", "and", "deletions", "of", "both", "sites", "indicate", "that", "only", "the", "association", "of", "CCACC", "/", "Sp1", "and", "GATA", "binding", "sites", "can", "drive", "efficient", "and", "tissue", "-", "specific", "expression", "of", "this", "R", "-", "PK", "minimal", "promoter", ".", "Finally", ",", "by", "co", "-", "transfection", "experiments", ",", "we", "study", "the", "elements", "involved", "in", "the", "hGATA-1", "transactivation", "of", "the", "R", "-", "PK", "promoter", "in", "HeLa", "cells", ".", "\n" ]	[ "Entity", "Protein" ]
pyruvate kinase erythroid - specific promoter, L, R - PK, L - PK, promoters, cis-, trans - acting elements, L, promoter, R - PK, cap site, reporter gene, minimal promoter, DNA binding sites, GATA-1, GATA binding site, AGATAA, TFIID binding site, TFIID, GATA binding site, TFIID binding site, binding sites, R - PK, minimal promoter, elements, hGATA-1, R - PK, promoter	29_task2	Sentence: Transcriptional regulation of the pyruvate kinase erythroid-specific promoter. Mammal pyruvate kinases are encoded by two genes. The L gene produces the erythroid (R-PK) or the hepatic (L-PK) isozymes by the alternative use of two promoters. We report the characterization of the cis- and trans-acting elements involved in the tissue-specific activity of the L gene erythroid promoter. A R-PK DNA fragment extending from -870 to +54 relative to the cap site confers erythroid specificity to a reporter gene. Within this region, we define a minimal promoter (-62 to +54) that displays erythroid-specific activity and contains two DNA binding sites. One, located at -50, binds members of the CCACC/Sp1 family and the other, located at -20, binds the erythroid factor GATA-1. Although the -20 GATA binding site (AGATAA) is also a potential TFIID binding site, it does not bind TFIID. Furthermore, the substitution of this GATA binding site by a canonical TFIID binding site suppresses the promoter activity. Mutations and deletions of both sites indicate that only the association of CCACC/Sp1 and GATA binding sites can drive efficient and tissue-specific expression of this R-PK minimal promoter. Finally, by co-transfection experiments, we study the elements involved in the hGATA-1 transactivation of the R-PK promoter in HeLa cells. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O" ]	Transcriptional regulation of the pyruvate kinase erythroid-specific promoter. Mammal pyruvate kinases are encoded by two genes. The L gene produces the erythroid (R-PK) or the hepatic (L-PK) isozymes by the alternative use of two promoters. We report the characterization of the cis- and trans-acting elements involved in the tissue-specific activity of the L gene erythroid promoter. A R-PK DNA fragment extending from -870 to +54 relative to the cap site confers erythroid specificity to a reporter gene. Within this region, we define a minimal promoter (-62 to +54) that displays erythroid-specific activity and contains two DNA binding sites. One, located at -50, binds members of the CCACC/Sp1 family and the other, located at -20, binds the erythroid factor GATA-1. Although the -20 GATA binding site (AGATAA) is also a potential TFIID binding site, it does not bind TFIID. Furthermore, the substitution of this GATA binding site by a canonical TFIID binding site suppresses the promoter activity. Mutations and deletions of both sites indicate that only the association of CCACC/Sp1 and GATA binding sites can drive efficient and tissue-specific expression of this R-PK minimal promoter. Finally, by co-transfection experiments, we study the elements involved in the hGATA-1 transactivation of the R-PK promoter in HeLa cells.	[ "Transcriptional", "regulation", "of", "the", "pyruvate", "kinase", "erythroid", "-", "specific", "promoter", ".", "\n", "Mammal", "pyruvate", "kinases", "are", "encoded", "by", "two", "genes", ".", "The", "L", "gene", "produces", "the", "erythroid", "(", "R", "-", "PK", ")", "or", "the", "hepatic", "(", "L", "-", "PK", ")", "isozymes", "by", "the", "alternative", "use", "of", "two", "promoters", ".", "We", "report", "the", "characterization", "of", "the", "cis-", "and", "trans", "-", "acting", "elements", "involved", "in", "the", "tissue", "-", "specific", "activity", "of", "the", "L", "gene", "erythroid", "promoter", ".", "A", "R", "-", "PK", "DNA", "fragment", "extending", "from", "-870", "to", "+54", "relative", "to", "the", "cap", "site", "confers", "erythroid", "specificity", "to", "a", "reporter", "gene", ".", "Within", "this", "region", ",", "we", "define", "a", "minimal", "promoter", "(", "-62", "to", "+54", ")", "that", "displays", "erythroid", "-", "specific", "activity", "and", "contains", "two", "DNA", "binding", "sites", ".", "One", ",", "located", "at", "-50", ",", "binds", "members", "of", "the", "CCACC", "/", "Sp1", "family", "and", "the", "other", ",", "located", "at", "-20", ",", "binds", "the", "erythroid", "factor", "GATA-1", ".", "Although", "the", "-20", "GATA", "binding", "site", "(", "AGATAA", ")", "is", "also", "a", "potential", "TFIID", "binding", "site", ",", "it", "does", "not", "bind", "TFIID", ".", "Furthermore", ",", "the", "substitution", "of", "this", "GATA", "binding", "site", "by", "a", "canonical", "TFIID", "binding", "site", "suppresses", "the", "promoter", "activity", ".", "Mutations", "and", "deletions", "of", "both", "sites", "indicate", "that", "only", "the", "association", "of", "CCACC", "/", "Sp1", "and", "GATA", "binding", "sites", "can", "drive", "efficient", "and", "tissue", "-", "specific", "expression", "of", "this", "R", "-", "PK", "minimal", "promoter", ".", "Finally", ",", "by", "co", "-", "transfection", "experiments", ",", "we", "study", "the", "elements", "involved", "in", "the", "hGATA-1", "transactivation", "of", "the", "R", "-", "PK", "promoter", "in", "HeLa", "cells", ".", "\n" ]	[ "Entity", "Protein" ]
adjuvant interferon effectiveness is a Outcome_Other, kidney carcinoma with high risk of relapse " ] is a Participant_Condition	49596_task0	Sentence: [ Presentation of a randomized multicenter study protocol . " Evaluation of adjuvant interferon effectiveness after radical nephrectomy in kidney carcinoma with high risk of relapse " ] . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Outcome_Other, Participant_Condition	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O" ]	[ Presentation of a randomized multicenter study protocol . " Evaluation of adjuvant interferon effectiveness after radical nephrectomy in kidney carcinoma with high risk of relapse " ] .	[ "[", "Presentation", "of", "a", "randomized", "multicenter", "study", "protocol", ".", "\"", "Evaluation", "of", "adjuvant", "interferon", "effectiveness", "after", "radical", "nephrectomy", "in", "kidney", "carcinoma", "with", "high", "risk", "of", "relapse", "\"", "]", "." ]	[ "Participant_Condition", "Outcome_Other", "Intervention_Pharmacological" ]
adjuvant interferon effectiveness is a Outcome_Other, kidney carcinoma with high risk of relapse " ] is a Participant_Condition	49596_task1	Sentence: [ Presentation of a randomized multicenter study protocol . " Evaluation of adjuvant interferon effectiveness after radical nephrectomy in kidney carcinoma with high risk of relapse " ] . Instructions: please typing these entity words according to sentence: adjuvant interferon effectiveness, kidney carcinoma with high risk of relapse " ] Options: Outcome_Other, Participant_Condition	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O" ]	[ Presentation of a randomized multicenter study protocol . " Evaluation of adjuvant interferon effectiveness after radical nephrectomy in kidney carcinoma with high risk of relapse " ] .	[ "[", "Presentation", "of", "a", "randomized", "multicenter", "study", "protocol", ".", "\"", "Evaluation", "of", "adjuvant", "interferon", "effectiveness", "after", "radical", "nephrectomy", "in", "kidney", "carcinoma", "with", "high", "risk", "of", "relapse", "\"", "]", "." ]	[ "Participant_Condition", "Outcome_Other", "Intervention_Pharmacological" ]
adjuvant interferon effectiveness, kidney carcinoma with high risk of relapse " ]	49596_task2	Sentence: [ Presentation of a randomized multicenter study protocol . " Evaluation of adjuvant interferon effectiveness after radical nephrectomy in kidney carcinoma with high risk of relapse " ] . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O" ]	[ Presentation of a randomized multicenter study protocol . " Evaluation of adjuvant interferon effectiveness after radical nephrectomy in kidney carcinoma with high risk of relapse " ] .	[ "[", "Presentation", "of", "a", "randomized", "multicenter", "study", "protocol", ".", "\"", "Evaluation", "of", "adjuvant", "interferon", "effectiveness", "after", "radical", "nephrectomy", "in", "kidney", "carcinoma", "with", "high", "risk", "of", "relapse", "\"", "]", "." ]	[ "Participant_Condition", "Outcome_Other", "Intervention_Pharmacological" ]
Arbeit is an umlsterm, Analyse is an umlsterm, Knochenbildung is an umlsterm, Periostlappen is an umlsterm, Ratte is an umlsterm, Periostlappen is an umlsterm, Periostseite is an umlsterm, Periostlappen is an umlsterm, Oberschenkelmuskulatur is an umlsterm, Tiere is an umlsterm, Tiere is an umlsterm, Periostlappens is an umlsterm, Knochenbildung is an umlsterm, Knochenbildung is an umlsterm, Knochen is an umlsterm, radiologisch is an umlsterm, radiologische is an umlsterm, Knochenformation is an umlsterm, Ratten is an umlsterm, Periostlappen is an umlsterm, Knochenbildung is an umlsterm, Periostlappen is an umlsterm, Periostlappen is an umlsterm, Knochenbildung is an umlsterm, Periost is an umlsterm, Knochenbildung is an umlsterm, Knochendefekte is an umlsterm, Periostlappens is an umlsterm, Knochensegment is an umlsterm, Periostlappen is an umlsterm	MundKieferGesichtschirurgie.0004s454.ger.abstr_task0	Sentence: Ziel dieser Arbeit war die Analyse von orthotoper und heterotoper Knochenbildung mit Hilfe einer strukturellen Polylaktatmatrix ( OPLA/HY ) , dem osteoinduktiven rh-BMP-2 und einem vaskularisierten Periostlappen . An der Ratte wurde ein an den saphenischen Gefaessen gestielter Periostlappen von der medialen Tibiaoberflaeche praepariert , mit der Periostseite als Innenauskleidung zu einer Kammer geformt und in die Leiste transportiert . In diese Kammer wurde die OPLA/HY-Matrix mit und ohne BMP eingepackt bzw. dieser vaskularisierte Periostlappen " leer " durch die Oberschenkelmuskulatur nach dorsal zu einem Femurdefekt transferiert und um die OPLA/HY-Matrix mit und ohne BMP gewickelt . Die Tiere wurden in 10 Gruppen ( 82 Tiere ) unterteilt . Der Effekt des vaskularisierten Periostlappens mit oder ohne OPLA/HY-Matrix und mit oder ohne rh-BMP-2 wurde in der Leiste ( heterotope Knochenbildung ) anhand von 6 Gruppen und im Femurdefekt ( orthotope Knochenbildung ) anhand von 4 Gruppen untersucht . Die Praesenz und Dichte von neuem Knochen in der Leiste und im Femurdefekt wurden radiologisch und histologisch nach 4 und 8 Wochen evaluiert . Eine radiologische und histologische Knochenformation in der Leiste ( heterotop ) konnte nur bei Ratten mit vaskularisiertem Periostlappen , OPLA/HY-Matrix und rh-BMP-2 demonstriert werden , waehrend bei den Femurdefekten auch eine zunehmende Knochenbildung ( orthotop ) mit der OPLA/HY-Matrix und rh-BMP-2 mit und ohne Periostlappen feststellbar war . Der Periostlappen bewirkte jedoch eine staerkere Knochenbildung am Rand mit definierter Begrenzung des Defekts . 4 Faktoren - autonome Vaskularitaet , Osteoprogenitorzellen enthaltendes Periost , eine strukturelle Matrix und BMP - sind fuer eine optimale Knochenbildung sowohl heterotop in der Leiste als auch orthotop im Femurdefekt notwendig . Aufgrund dieser Ergebnisse koennten potenziell in Zukunft Knochendefekte oder Pseudarthrosen mit Hilfe eines vaskularisierten Periostlappens , einer Matrix und BMP erfolgreich rekonstruiert werden . Alternativ koennte ein vaskularisiertes Knochensegment fern von einem Defekt in einem vaskularisierten Periostlappen praefabriziert und sekundaer mikrochirurgisch in den Defekt transferiert werden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Ziel dieser Arbeit war die Analyse von orthotoper und heterotoper Knochenbildung mit Hilfe einer strukturellen Polylaktatmatrix ( OPLA/HY ) , dem osteoinduktiven rh-BMP-2 und einem vaskularisierten Periostlappen . An der Ratte wurde ein an den saphenischen Gefaessen gestielter Periostlappen von der medialen Tibiaoberflaeche praepariert , mit der Periostseite als Innenauskleidung zu einer Kammer geformt und in die Leiste transportiert . In diese Kammer wurde die OPLA/HY-Matrix mit und ohne BMP eingepackt bzw. dieser vaskularisierte Periostlappen " leer " durch die Oberschenkelmuskulatur nach dorsal zu einem Femurdefekt transferiert und um die OPLA/HY-Matrix mit und ohne BMP gewickelt . Die Tiere wurden in 10 Gruppen ( 82 Tiere ) unterteilt . Der Effekt des vaskularisierten Periostlappens mit oder ohne OPLA/HY-Matrix und mit oder ohne rh-BMP-2 wurde in der Leiste ( heterotope Knochenbildung ) anhand von 6 Gruppen und im Femurdefekt ( orthotope Knochenbildung ) anhand von 4 Gruppen untersucht . Die Praesenz und Dichte von neuem Knochen in der Leiste und im Femurdefekt wurden radiologisch und histologisch nach 4 und 8 Wochen evaluiert . Eine radiologische und histologische Knochenformation in der Leiste ( heterotop ) konnte nur bei Ratten mit vaskularisiertem Periostlappen , OPLA/HY-Matrix und rh-BMP-2 demonstriert werden , waehrend bei den Femurdefekten auch eine zunehmende Knochenbildung ( orthotop ) mit der OPLA/HY-Matrix und rh-BMP-2 mit und ohne Periostlappen feststellbar war . Der Periostlappen bewirkte jedoch eine staerkere Knochenbildung am Rand mit definierter Begrenzung des Defekts . 4 Faktoren - autonome Vaskularitaet , Osteoprogenitorzellen enthaltendes Periost , eine strukturelle Matrix und BMP - sind fuer eine optimale Knochenbildung sowohl heterotop in der Leiste als auch orthotop im Femurdefekt notwendig . Aufgrund dieser Ergebnisse koennten potenziell in Zukunft Knochendefekte oder Pseudarthrosen mit Hilfe eines vaskularisierten Periostlappens , einer Matrix und BMP erfolgreich rekonstruiert werden . Alternativ koennte ein vaskularisiertes Knochensegment fern von einem Defekt in einem vaskularisierten Periostlappen praefabriziert und sekundaer mikrochirurgisch in den Defekt transferiert werden .	[ "Ziel", "dieser", "Arbeit", "war", "die", "Analyse", "von", "orthotoper", "und", "heterotoper", "Knochenbildung", "mit", "Hilfe", "einer", "strukturellen", "Polylaktatmatrix", "(", "OPLA", "/", "HY", ")", ",", "dem", "osteoinduktiven", "rh", "-", "BMP-2", "und", "einem", "vaskularisierten", "Periostlappen", ".", "An", "der", "Ratte", "wurde", "ein", "an", "den", "saphenischen", "Gefaessen", "gestielter", "Periostlappen", "von", "der", "medialen", "Tibiaoberflaeche", "praepariert", ",", "mit", "der", "Periostseite", "als", "Innenauskleidung", "zu", "einer", "Kammer", "geformt", "und", "in", "die", "Leiste", "transportiert", ".", "In", "diese", "Kammer", "wurde", "die", "OPLA", "/", "HY", "-", "Matrix", "mit", "und", "ohne", "BMP", "eingepackt", "bzw", ".", "dieser", "vaskularisierte", "Periostlappen", "\"", "leer", "\"", "durch", "die", "Oberschenkelmuskulatur", "nach", "dorsal", "zu", "einem", "Femurdefekt", "transferiert", "und", "um", "die", "OPLA", "/", "HY", "-", "Matrix", "mit", "und", "ohne", "BMP", "gewickelt", ".", "Die", "Tiere", "wurden", "in", "10", "Gruppen", "(", "82", "Tiere", ")", "unterteilt", ".", "Der", "Effekt", "des", "vaskularisierten", "Periostlappens", "mit", "oder", "ohne", "OPLA", "/", "HY", "-", "Matrix", "und", "mit", "oder", "ohne", "rh", "-", "BMP-2", "wurde", "in", "der", "Leiste", "(", "heterotope", "Knochenbildung", ")", "anhand", "von", "6", "Gruppen", "und", "im", "Femurdefekt", "(", "orthotope", "Knochenbildung", ")", "anhand", "von", "4", "Gruppen", "untersucht", ".", "Die", "Praesenz", "und", "Dichte", "von", "neuem", "Knochen", "in", "der", "Leiste", "und", "im", "Femurdefekt", "wurden", "radiologisch", "und", "histologisch", "nach", "4", "und", "8", "Wochen", "evaluiert", ".", "Eine", "radiologische", "und", "histologische", "Knochenformation", "in", "der", "Leiste", "(", "heterotop", ")", "konnte", "nur", "bei", "Ratten", "mit", "vaskularisiertem", "Periostlappen", ",", "OPLA", "/", "HY", "-", "Matrix", "und", "rh", "-", "BMP-2", "demonstriert", "werden", ",", "waehrend", "bei", "den", "Femurdefekten", "auch", "eine", "zunehmende", "Knochenbildung", "(", "orthotop", ")", "mit", "der", "OPLA", "/", "HY", "-", "Matrix", "und", "rh", "-", "BMP-2", "mit", "und", "ohne", "Periostlappen", "feststellbar", "war", ".", "Der", "Periostlappen", "bewirkte", "jedoch", "eine", "staerkere", "Knochenbildung", "am", "Rand", "mit", "definierter", "Begrenzung", "des", "Defekts", ".", "4", "Faktoren", "-", "autonome", "Vaskularitaet", ",", "Osteoprogenitorzellen", "enthaltendes", "Periost", ",", "eine", "strukturelle", "Matrix", "und", "BMP", "-", "sind", "fuer", "eine", "optimale", "Knochenbildung", "sowohl", "heterotop", "in", "der", "Leiste", "als", "auch", "orthotop", "im", "Femurdefekt", "notwendig", ".", "Aufgrund", "dieser", "Ergebnisse", "koennten", "potenziell", "in", "Zukunft", "Knochendefekte", "oder", "Pseudarthrosen", "mit", "Hilfe", "eines", "vaskularisierten", "Periostlappens", ",", "einer", "Matrix", "und", "BMP", "erfolgreich", "rekonstruiert", "werden", ".", "Alternativ", "koennte", "ein", "vaskularisiertes", "Knochensegment", "fern", "von", "einem", "Defekt", "in", "einem", "vaskularisierten", "Periostlappen", "praefabriziert", "und", "sekundaer", "mikrochirurgisch", "in", "den", "Defekt", "transferiert", "werden", "." ]	[ "umlsterm" ]
Arbeit is an umlsterm, Analyse is an umlsterm, Knochenbildung is an umlsterm, Periostlappen is an umlsterm, Ratte is an umlsterm, Periostlappen is an umlsterm, Periostseite is an umlsterm, Periostlappen is an umlsterm, Oberschenkelmuskulatur is an umlsterm, Tiere is an umlsterm, Tiere is an umlsterm, Periostlappens is an umlsterm, Knochenbildung is an umlsterm, Knochenbildung is an umlsterm, Knochen is an umlsterm, radiologisch is an umlsterm, radiologische is an umlsterm, Knochenformation is an umlsterm, Ratten is an umlsterm, Periostlappen is an umlsterm, Knochenbildung is an umlsterm, Periostlappen is an umlsterm, Periostlappen is an umlsterm, Knochenbildung is an umlsterm, Periost is an umlsterm, Knochenbildung is an umlsterm, Knochendefekte is an umlsterm, Periostlappens is an umlsterm, Knochensegment is an umlsterm, Periostlappen is an umlsterm	MundKieferGesichtschirurgie.0004s454.ger.abstr_task1	Sentence: Ziel dieser Arbeit war die Analyse von orthotoper und heterotoper Knochenbildung mit Hilfe einer strukturellen Polylaktatmatrix ( OPLA/HY ) , dem osteoinduktiven rh-BMP-2 und einem vaskularisierten Periostlappen . An der Ratte wurde ein an den saphenischen Gefaessen gestielter Periostlappen von der medialen Tibiaoberflaeche praepariert , mit der Periostseite als Innenauskleidung zu einer Kammer geformt und in die Leiste transportiert . In diese Kammer wurde die OPLA/HY-Matrix mit und ohne BMP eingepackt bzw. dieser vaskularisierte Periostlappen " leer " durch die Oberschenkelmuskulatur nach dorsal zu einem Femurdefekt transferiert und um die OPLA/HY-Matrix mit und ohne BMP gewickelt . Die Tiere wurden in 10 Gruppen ( 82 Tiere ) unterteilt . Der Effekt des vaskularisierten Periostlappens mit oder ohne OPLA/HY-Matrix und mit oder ohne rh-BMP-2 wurde in der Leiste ( heterotope Knochenbildung ) anhand von 6 Gruppen und im Femurdefekt ( orthotope Knochenbildung ) anhand von 4 Gruppen untersucht . Die Praesenz und Dichte von neuem Knochen in der Leiste und im Femurdefekt wurden radiologisch und histologisch nach 4 und 8 Wochen evaluiert . Eine radiologische und histologische Knochenformation in der Leiste ( heterotop ) konnte nur bei Ratten mit vaskularisiertem Periostlappen , OPLA/HY-Matrix und rh-BMP-2 demonstriert werden , waehrend bei den Femurdefekten auch eine zunehmende Knochenbildung ( orthotop ) mit der OPLA/HY-Matrix und rh-BMP-2 mit und ohne Periostlappen feststellbar war . Der Periostlappen bewirkte jedoch eine staerkere Knochenbildung am Rand mit definierter Begrenzung des Defekts . 4 Faktoren - autonome Vaskularitaet , Osteoprogenitorzellen enthaltendes Periost , eine strukturelle Matrix und BMP - sind fuer eine optimale Knochenbildung sowohl heterotop in der Leiste als auch orthotop im Femurdefekt notwendig . Aufgrund dieser Ergebnisse koennten potenziell in Zukunft Knochendefekte oder Pseudarthrosen mit Hilfe eines vaskularisierten Periostlappens , einer Matrix und BMP erfolgreich rekonstruiert werden . Alternativ koennte ein vaskularisiertes Knochensegment fern von einem Defekt in einem vaskularisierten Periostlappen praefabriziert und sekundaer mikrochirurgisch in den Defekt transferiert werden . Instructions: please typing these entity words according to sentence: Arbeit, Analyse, Knochenbildung, Periostlappen, Ratte, Periostlappen, Periostseite, Periostlappen, Oberschenkelmuskulatur, Tiere, Tiere, Periostlappens, Knochenbildung, Knochenbildung, Knochen, radiologisch, radiologische, Knochenformation, Ratten, Periostlappen, Knochenbildung, Periostlappen, Periostlappen, Knochenbildung, Periost, Knochenbildung, Knochendefekte, Periostlappens, Knochensegment, Periostlappen Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Ziel dieser Arbeit war die Analyse von orthotoper und heterotoper Knochenbildung mit Hilfe einer strukturellen Polylaktatmatrix ( OPLA/HY ) , dem osteoinduktiven rh-BMP-2 und einem vaskularisierten Periostlappen . An der Ratte wurde ein an den saphenischen Gefaessen gestielter Periostlappen von der medialen Tibiaoberflaeche praepariert , mit der Periostseite als Innenauskleidung zu einer Kammer geformt und in die Leiste transportiert . In diese Kammer wurde die OPLA/HY-Matrix mit und ohne BMP eingepackt bzw. dieser vaskularisierte Periostlappen " leer " durch die Oberschenkelmuskulatur nach dorsal zu einem Femurdefekt transferiert und um die OPLA/HY-Matrix mit und ohne BMP gewickelt . Die Tiere wurden in 10 Gruppen ( 82 Tiere ) unterteilt . Der Effekt des vaskularisierten Periostlappens mit oder ohne OPLA/HY-Matrix und mit oder ohne rh-BMP-2 wurde in der Leiste ( heterotope Knochenbildung ) anhand von 6 Gruppen und im Femurdefekt ( orthotope Knochenbildung ) anhand von 4 Gruppen untersucht . Die Praesenz und Dichte von neuem Knochen in der Leiste und im Femurdefekt wurden radiologisch und histologisch nach 4 und 8 Wochen evaluiert . Eine radiologische und histologische Knochenformation in der Leiste ( heterotop ) konnte nur bei Ratten mit vaskularisiertem Periostlappen , OPLA/HY-Matrix und rh-BMP-2 demonstriert werden , waehrend bei den Femurdefekten auch eine zunehmende Knochenbildung ( orthotop ) mit der OPLA/HY-Matrix und rh-BMP-2 mit und ohne Periostlappen feststellbar war . Der Periostlappen bewirkte jedoch eine staerkere Knochenbildung am Rand mit definierter Begrenzung des Defekts . 4 Faktoren - autonome Vaskularitaet , Osteoprogenitorzellen enthaltendes Periost , eine strukturelle Matrix und BMP - sind fuer eine optimale Knochenbildung sowohl heterotop in der Leiste als auch orthotop im Femurdefekt notwendig . Aufgrund dieser Ergebnisse koennten potenziell in Zukunft Knochendefekte oder Pseudarthrosen mit Hilfe eines vaskularisierten Periostlappens , einer Matrix und BMP erfolgreich rekonstruiert werden . Alternativ koennte ein vaskularisiertes Knochensegment fern von einem Defekt in einem vaskularisierten Periostlappen praefabriziert und sekundaer mikrochirurgisch in den Defekt transferiert werden .	[ "Ziel", "dieser", "Arbeit", "war", "die", "Analyse", "von", "orthotoper", "und", "heterotoper", "Knochenbildung", "mit", "Hilfe", "einer", "strukturellen", "Polylaktatmatrix", "(", "OPLA", "/", "HY", ")", ",", "dem", "osteoinduktiven", "rh", "-", "BMP-2", "und", "einem", "vaskularisierten", "Periostlappen", ".", "An", "der", "Ratte", "wurde", "ein", "an", "den", "saphenischen", "Gefaessen", "gestielter", "Periostlappen", "von", "der", "medialen", "Tibiaoberflaeche", "praepariert", ",", "mit", "der", "Periostseite", "als", "Innenauskleidung", "zu", "einer", "Kammer", "geformt", "und", "in", "die", "Leiste", "transportiert", ".", "In", "diese", "Kammer", "wurde", "die", "OPLA", "/", "HY", "-", "Matrix", "mit", "und", "ohne", "BMP", "eingepackt", "bzw", ".", "dieser", "vaskularisierte", "Periostlappen", "\"", "leer", "\"", "durch", "die", "Oberschenkelmuskulatur", "nach", "dorsal", "zu", "einem", "Femurdefekt", "transferiert", "und", "um", "die", "OPLA", "/", "HY", "-", "Matrix", "mit", "und", "ohne", "BMP", "gewickelt", ".", "Die", "Tiere", "wurden", "in", "10", "Gruppen", "(", "82", "Tiere", ")", "unterteilt", ".", "Der", "Effekt", "des", "vaskularisierten", "Periostlappens", "mit", "oder", "ohne", "OPLA", "/", "HY", "-", "Matrix", "und", "mit", "oder", "ohne", "rh", "-", "BMP-2", "wurde", "in", "der", "Leiste", "(", "heterotope", "Knochenbildung", ")", "anhand", "von", "6", "Gruppen", "und", "im", "Femurdefekt", "(", "orthotope", "Knochenbildung", ")", "anhand", "von", "4", "Gruppen", "untersucht", ".", "Die", "Praesenz", "und", "Dichte", "von", "neuem", "Knochen", "in", "der", "Leiste", "und", "im", "Femurdefekt", "wurden", "radiologisch", "und", "histologisch", "nach", "4", "und", "8", "Wochen", "evaluiert", ".", "Eine", "radiologische", "und", "histologische", "Knochenformation", "in", "der", "Leiste", "(", "heterotop", ")", "konnte", "nur", "bei", "Ratten", "mit", "vaskularisiertem", "Periostlappen", ",", "OPLA", "/", "HY", "-", "Matrix", "und", "rh", "-", "BMP-2", "demonstriert", "werden", ",", "waehrend", "bei", "den", "Femurdefekten", "auch", "eine", "zunehmende", "Knochenbildung", "(", "orthotop", ")", "mit", "der", "OPLA", "/", "HY", "-", "Matrix", "und", "rh", "-", "BMP-2", "mit", "und", "ohne", "Periostlappen", "feststellbar", "war", ".", "Der", "Periostlappen", "bewirkte", "jedoch", "eine", "staerkere", "Knochenbildung", "am", "Rand", "mit", "definierter", "Begrenzung", "des", "Defekts", ".", "4", "Faktoren", "-", "autonome", "Vaskularitaet", ",", "Osteoprogenitorzellen", "enthaltendes", "Periost", ",", "eine", "strukturelle", "Matrix", "und", "BMP", "-", "sind", "fuer", "eine", "optimale", "Knochenbildung", "sowohl", "heterotop", "in", "der", "Leiste", "als", "auch", "orthotop", "im", "Femurdefekt", "notwendig", ".", "Aufgrund", "dieser", "Ergebnisse", "koennten", "potenziell", "in", "Zukunft", "Knochendefekte", "oder", "Pseudarthrosen", "mit", "Hilfe", "eines", "vaskularisierten", "Periostlappens", ",", "einer", "Matrix", "und", "BMP", "erfolgreich", "rekonstruiert", "werden", ".", "Alternativ", "koennte", "ein", "vaskularisiertes", "Knochensegment", "fern", "von", "einem", "Defekt", "in", "einem", "vaskularisierten", "Periostlappen", "praefabriziert", "und", "sekundaer", "mikrochirurgisch", "in", "den", "Defekt", "transferiert", "werden", "." ]	[ "umlsterm" ]
Arbeit, Analyse, Knochenbildung, Periostlappen, Ratte, Periostlappen, Periostseite, Periostlappen, Oberschenkelmuskulatur, Tiere, Tiere, Periostlappens, Knochenbildung, Knochenbildung, Knochen, radiologisch, radiologische, Knochenformation, Ratten, Periostlappen, Knochenbildung, Periostlappen, Periostlappen, Knochenbildung, Periost, Knochenbildung, Knochendefekte, Periostlappens, Knochensegment, Periostlappen	MundKieferGesichtschirurgie.0004s454.ger.abstr_task2	Sentence: Ziel dieser Arbeit war die Analyse von orthotoper und heterotoper Knochenbildung mit Hilfe einer strukturellen Polylaktatmatrix ( OPLA/HY ) , dem osteoinduktiven rh-BMP-2 und einem vaskularisierten Periostlappen . An der Ratte wurde ein an den saphenischen Gefaessen gestielter Periostlappen von der medialen Tibiaoberflaeche praepariert , mit der Periostseite als Innenauskleidung zu einer Kammer geformt und in die Leiste transportiert . In diese Kammer wurde die OPLA/HY-Matrix mit und ohne BMP eingepackt bzw. dieser vaskularisierte Periostlappen " leer " durch die Oberschenkelmuskulatur nach dorsal zu einem Femurdefekt transferiert und um die OPLA/HY-Matrix mit und ohne BMP gewickelt . Die Tiere wurden in 10 Gruppen ( 82 Tiere ) unterteilt . Der Effekt des vaskularisierten Periostlappens mit oder ohne OPLA/HY-Matrix und mit oder ohne rh-BMP-2 wurde in der Leiste ( heterotope Knochenbildung ) anhand von 6 Gruppen und im Femurdefekt ( orthotope Knochenbildung ) anhand von 4 Gruppen untersucht . Die Praesenz und Dichte von neuem Knochen in der Leiste und im Femurdefekt wurden radiologisch und histologisch nach 4 und 8 Wochen evaluiert . Eine radiologische und histologische Knochenformation in der Leiste ( heterotop ) konnte nur bei Ratten mit vaskularisiertem Periostlappen , OPLA/HY-Matrix und rh-BMP-2 demonstriert werden , waehrend bei den Femurdefekten auch eine zunehmende Knochenbildung ( orthotop ) mit der OPLA/HY-Matrix und rh-BMP-2 mit und ohne Periostlappen feststellbar war . Der Periostlappen bewirkte jedoch eine staerkere Knochenbildung am Rand mit definierter Begrenzung des Defekts . 4 Faktoren - autonome Vaskularitaet , Osteoprogenitorzellen enthaltendes Periost , eine strukturelle Matrix und BMP - sind fuer eine optimale Knochenbildung sowohl heterotop in der Leiste als auch orthotop im Femurdefekt notwendig . Aufgrund dieser Ergebnisse koennten potenziell in Zukunft Knochendefekte oder Pseudarthrosen mit Hilfe eines vaskularisierten Periostlappens , einer Matrix und BMP erfolgreich rekonstruiert werden . Alternativ koennte ein vaskularisiertes Knochensegment fern von einem Defekt in einem vaskularisierten Periostlappen praefabriziert und sekundaer mikrochirurgisch in den Defekt transferiert werden . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Ziel dieser Arbeit war die Analyse von orthotoper und heterotoper Knochenbildung mit Hilfe einer strukturellen Polylaktatmatrix ( OPLA/HY ) , dem osteoinduktiven rh-BMP-2 und einem vaskularisierten Periostlappen . An der Ratte wurde ein an den saphenischen Gefaessen gestielter Periostlappen von der medialen Tibiaoberflaeche praepariert , mit der Periostseite als Innenauskleidung zu einer Kammer geformt und in die Leiste transportiert . In diese Kammer wurde die OPLA/HY-Matrix mit und ohne BMP eingepackt bzw. dieser vaskularisierte Periostlappen " leer " durch die Oberschenkelmuskulatur nach dorsal zu einem Femurdefekt transferiert und um die OPLA/HY-Matrix mit und ohne BMP gewickelt . Die Tiere wurden in 10 Gruppen ( 82 Tiere ) unterteilt . Der Effekt des vaskularisierten Periostlappens mit oder ohne OPLA/HY-Matrix und mit oder ohne rh-BMP-2 wurde in der Leiste ( heterotope Knochenbildung ) anhand von 6 Gruppen und im Femurdefekt ( orthotope Knochenbildung ) anhand von 4 Gruppen untersucht . Die Praesenz und Dichte von neuem Knochen in der Leiste und im Femurdefekt wurden radiologisch und histologisch nach 4 und 8 Wochen evaluiert . Eine radiologische und histologische Knochenformation in der Leiste ( heterotop ) konnte nur bei Ratten mit vaskularisiertem Periostlappen , OPLA/HY-Matrix und rh-BMP-2 demonstriert werden , waehrend bei den Femurdefekten auch eine zunehmende Knochenbildung ( orthotop ) mit der OPLA/HY-Matrix und rh-BMP-2 mit und ohne Periostlappen feststellbar war . Der Periostlappen bewirkte jedoch eine staerkere Knochenbildung am Rand mit definierter Begrenzung des Defekts . 4 Faktoren - autonome Vaskularitaet , Osteoprogenitorzellen enthaltendes Periost , eine strukturelle Matrix und BMP - sind fuer eine optimale Knochenbildung sowohl heterotop in der Leiste als auch orthotop im Femurdefekt notwendig . Aufgrund dieser Ergebnisse koennten potenziell in Zukunft Knochendefekte oder Pseudarthrosen mit Hilfe eines vaskularisierten Periostlappens , einer Matrix und BMP erfolgreich rekonstruiert werden . Alternativ koennte ein vaskularisiertes Knochensegment fern von einem Defekt in einem vaskularisierten Periostlappen praefabriziert und sekundaer mikrochirurgisch in den Defekt transferiert werden .	[ "Ziel", "dieser", "Arbeit", "war", "die", "Analyse", "von", "orthotoper", "und", "heterotoper", "Knochenbildung", "mit", "Hilfe", "einer", "strukturellen", "Polylaktatmatrix", "(", "OPLA", "/", "HY", ")", ",", "dem", "osteoinduktiven", "rh", "-", "BMP-2", "und", "einem", "vaskularisierten", "Periostlappen", ".", "An", "der", "Ratte", "wurde", "ein", "an", "den", "saphenischen", "Gefaessen", "gestielter", "Periostlappen", "von", "der", "medialen", "Tibiaoberflaeche", "praepariert", ",", "mit", "der", "Periostseite", "als", "Innenauskleidung", "zu", "einer", "Kammer", "geformt", "und", "in", "die", "Leiste", "transportiert", ".", "In", "diese", "Kammer", "wurde", "die", "OPLA", "/", "HY", "-", "Matrix", "mit", "und", "ohne", "BMP", "eingepackt", "bzw", ".", "dieser", "vaskularisierte", "Periostlappen", "\"", "leer", "\"", "durch", "die", "Oberschenkelmuskulatur", "nach", "dorsal", "zu", "einem", "Femurdefekt", "transferiert", "und", "um", "die", "OPLA", "/", "HY", "-", "Matrix", "mit", "und", "ohne", "BMP", "gewickelt", ".", "Die", "Tiere", "wurden", "in", "10", "Gruppen", "(", "82", "Tiere", ")", "unterteilt", ".", "Der", "Effekt", "des", "vaskularisierten", "Periostlappens", "mit", "oder", "ohne", "OPLA", "/", "HY", "-", "Matrix", "und", "mit", "oder", "ohne", "rh", "-", "BMP-2", "wurde", "in", "der", "Leiste", "(", "heterotope", "Knochenbildung", ")", "anhand", "von", "6", "Gruppen", "und", "im", "Femurdefekt", "(", "orthotope", "Knochenbildung", ")", "anhand", "von", "4", "Gruppen", "untersucht", ".", "Die", "Praesenz", "und", "Dichte", "von", "neuem", "Knochen", "in", "der", "Leiste", "und", "im", "Femurdefekt", "wurden", "radiologisch", "und", "histologisch", "nach", "4", "und", "8", "Wochen", "evaluiert", ".", "Eine", "radiologische", "und", "histologische", "Knochenformation", "in", "der", "Leiste", "(", "heterotop", ")", "konnte", "nur", "bei", "Ratten", "mit", "vaskularisiertem", "Periostlappen", ",", "OPLA", "/", "HY", "-", "Matrix", "und", "rh", "-", "BMP-2", "demonstriert", "werden", ",", "waehrend", "bei", "den", "Femurdefekten", "auch", "eine", "zunehmende", "Knochenbildung", "(", "orthotop", ")", "mit", "der", "OPLA", "/", "HY", "-", "Matrix", "und", "rh", "-", "BMP-2", "mit", "und", "ohne", "Periostlappen", "feststellbar", "war", ".", "Der", "Periostlappen", "bewirkte", "jedoch", "eine", "staerkere", "Knochenbildung", "am", "Rand", "mit", "definierter", "Begrenzung", "des", "Defekts", ".", "4", "Faktoren", "-", "autonome", "Vaskularitaet", ",", "Osteoprogenitorzellen", "enthaltendes", "Periost", ",", "eine", "strukturelle", "Matrix", "und", "BMP", "-", "sind", "fuer", "eine", "optimale", "Knochenbildung", "sowohl", "heterotop", "in", "der", "Leiste", "als", "auch", "orthotop", "im", "Femurdefekt", "notwendig", ".", "Aufgrund", "dieser", "Ergebnisse", "koennten", "potenziell", "in", "Zukunft", "Knochendefekte", "oder", "Pseudarthrosen", "mit", "Hilfe", "eines", "vaskularisierten", "Periostlappens", ",", "einer", "Matrix", "und", "BMP", "erfolgreich", "rekonstruiert", "werden", ".", "Alternativ", "koennte", "ein", "vaskularisiertes", "Knochensegment", "fern", "von", "einem", "Defekt", "in", "einem", "vaskularisierten", "Periostlappen", "praefabriziert", "und", "sekundaer", "mikrochirurgisch", "in", "den", "Defekt", "transferiert", "werden", "." ]	[ "umlsterm" ]
Kniegelenkverletzungen is an umlsterm, Arthroskopie is an umlsterm, Kniegelenk is an umlsterm, Diagnose is an umlsterm, Arthroskopie is an umlsterm, Kniegelenkuntersuchung is an umlsterm, Verletzungen is an umlsterm, Wachstumsalter is an umlsterm, Arthroskopie is an umlsterm, Diagnostik is an umlsterm, Kindern is an umlsterm, Wachstumsfugen is an umlsterm, Kinder is an umlsterm, Krankengut is an umlsterm, Patientenguts is an umlsterm, Befunderhebung is an umlsterm, Arthroskopie is an umlsterm, Diagnose is an umlsterm, Verletzungen is an umlsterm, Arthroskopie is an umlsterm, Kreuzbandrupturen is an umlsterm, Seitenbandverletzungen is an umlsterm, Patellaluxationen is an umlsterm, Arthroskopie is an umlsterm, Haemarthros is an umlsterm, Verletzung is an umlsterm, Techniken is an umlsterm, Arthroskopie is an umlsterm, wachsenden is an umlsterm, Kniegelenk is an umlsterm, Arthroskopie is an umlsterm, Kniegelenkverletzungen is an umlsterm	Arthroskopie.80110011.ger.abstr_task0	Sentence: Von frischen Kniegelenkverletzungen des Erwachsenen ist bekannt , dass bei der klinischen Erstuntersuchung haeufig nicht alle Befunde erfasst werden . Erst durch die Arthroskopie wird der Nachweis zusaetzlicher uebersehener Befunde , gefuehrt . Auch fuer das verletzte kindliche Kniegelenk ist die geringe Treffsicherheit der klinischen Diagnose bekannt . Trotzdem wurde der Einsatz der Arthroskopie zunaechst nur zoegernd akzeptiert . Dabei wurde schon in den 80er Jahren von verschiedenen Autoren auf die Problematik der klinischen Kniegelenkuntersuchung bei akuten Verletzungen im Wachstumsalter sowie auf die Bedeutung der Arthroskopie zur Optimierung der Diagnostik hingewiesen . An 2 verschiedenen Gruppen von Kindern und Jugendlichen mit noch offenen bzw. noch nicht geschlossenen Wachstumsfugen der Jahre von 1985-1988 und 1987-1996 wurde eine vergleichende Untersuchung durchgefuehrt . Es handelte sich dabei um Kinder und Jugendliche aus dem klinikeigenen Krankengut im Alter zwischen 6 und 15 Jahren . Anhand dieses Patientenguts wurde die Diskrepanz zwischen dem klinischen Erstbefund und der Befunderhebung durch Arthroskopie aufgezeigt . Die Differenz zwischen dem klinischen Erstbefund und der arthroskopisch erhobenen Diagnose lag in der ersten Gruppe bei ca. 45% und in der 2. , spaeter untersuchten Gruppe bei ca. 36% . Sowohl isolierte als auch kombinierte Verletzungen waren erst durch die Arthroskopie erfasst worden . Im Vordergrund standen dabei ligamentaere vordere Kreuzbandrupturen , mediale Seitenbandverletzungen und Meniskuslaesionen . Patellaluxationen mit Retinaculumrupturen sowie mit osteochondralen Fragmenten , die der klinischen Erstuntersuchung entgangen waren , wurden ebenfalls in beiden Gruppen erst durch die Arthroskopie nachgewiesen . Der Haemarthros erwies sich als wichtigster Hinweis auf den Schweregrad der Verletzung . Trotz der neuen , bildgebenden Techniken , wie dem MRI , kommt dem Einsatz der Arthroskopie auch am wachsenden Kniegelenk aufgrund der gleichzeitigen diagnostischen und therapeutischen Moeglichkeiten eine besondere Bedeutung zu . Diese zunehmend etablierte Feststellung soll der Anlass dafuer sein , die Arthroskopie generell in das Management akuter Kniegelenkverletzungen im Wachtumsalter einzubeziehen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Von frischen Kniegelenkverletzungen des Erwachsenen ist bekannt , dass bei der klinischen Erstuntersuchung haeufig nicht alle Befunde erfasst werden . Erst durch die Arthroskopie wird der Nachweis zusaetzlicher uebersehener Befunde , gefuehrt . Auch fuer das verletzte kindliche Kniegelenk ist die geringe Treffsicherheit der klinischen Diagnose bekannt . Trotzdem wurde der Einsatz der Arthroskopie zunaechst nur zoegernd akzeptiert . Dabei wurde schon in den 80er Jahren von verschiedenen Autoren auf die Problematik der klinischen Kniegelenkuntersuchung bei akuten Verletzungen im Wachstumsalter sowie auf die Bedeutung der Arthroskopie zur Optimierung der Diagnostik hingewiesen . An 2 verschiedenen Gruppen von Kindern und Jugendlichen mit noch offenen bzw. noch nicht geschlossenen Wachstumsfugen der Jahre von 1985-1988 und 1987-1996 wurde eine vergleichende Untersuchung durchgefuehrt . Es handelte sich dabei um Kinder und Jugendliche aus dem klinikeigenen Krankengut im Alter zwischen 6 und 15 Jahren . Anhand dieses Patientenguts wurde die Diskrepanz zwischen dem klinischen Erstbefund und der Befunderhebung durch Arthroskopie aufgezeigt . Die Differenz zwischen dem klinischen Erstbefund und der arthroskopisch erhobenen Diagnose lag in der ersten Gruppe bei ca. 45% und in der 2. , spaeter untersuchten Gruppe bei ca. 36% . Sowohl isolierte als auch kombinierte Verletzungen waren erst durch die Arthroskopie erfasst worden . Im Vordergrund standen dabei ligamentaere vordere Kreuzbandrupturen , mediale Seitenbandverletzungen und Meniskuslaesionen . Patellaluxationen mit Retinaculumrupturen sowie mit osteochondralen Fragmenten , die der klinischen Erstuntersuchung entgangen waren , wurden ebenfalls in beiden Gruppen erst durch die Arthroskopie nachgewiesen . Der Haemarthros erwies sich als wichtigster Hinweis auf den Schweregrad der Verletzung . Trotz der neuen , bildgebenden Techniken , wie dem MRI , kommt dem Einsatz der Arthroskopie auch am wachsenden Kniegelenk aufgrund der gleichzeitigen diagnostischen und therapeutischen Moeglichkeiten eine besondere Bedeutung zu . Diese zunehmend etablierte Feststellung soll der Anlass dafuer sein , die Arthroskopie generell in das Management akuter Kniegelenkverletzungen im Wachtumsalter einzubeziehen .	[ "Von", "frischen", "Kniegelenkverletzungen", "des", "Erwachsenen", "ist", "bekannt", ",", "dass", "bei", "der", "klinischen", "Erstuntersuchung", "haeufig", "nicht", "alle", "Befunde", "erfasst", "werden", ".", "Erst", "durch", "die", "Arthroskopie", "wird", "der", "Nachweis", "zusaetzlicher", "uebersehener", "Befunde", ",", "gefuehrt", ".", "Auch", "fuer", "das", "verletzte", "kindliche", "Kniegelenk", "ist", "die", "geringe", "Treffsicherheit", "der", "klinischen", "Diagnose", "bekannt", ".", "Trotzdem", "wurde", "der", "Einsatz", "der", "Arthroskopie", "zunaechst", "nur", "zoegernd", "akzeptiert", ".", "Dabei", "wurde", "schon", "in", "den", "80er", "Jahren", "von", "verschiedenen", "Autoren", "auf", "die", "Problematik", "der", "klinischen", "Kniegelenkuntersuchung", "bei", "akuten", "Verletzungen", "im", "Wachstumsalter", "sowie", "auf", "die", "Bedeutung", "der", "Arthroskopie", "zur", "Optimierung", "der", "Diagnostik", "hingewiesen", ".", "An", "2", "verschiedenen", "Gruppen", "von", "Kindern", "und", "Jugendlichen", "mit", "noch", "offenen", "bzw", ".", "noch", "nicht", "geschlossenen", "Wachstumsfugen", "der", "Jahre", "von", "1985", "-", "1988", "und", "1987", "-", "1996", "wurde", "eine", "vergleichende", "Untersuchung", "durchgefuehrt", ".", "Es", "handelte", "sich", "dabei", "um", "Kinder", "und", "Jugendliche", "aus", "dem", "klinikeigenen", "Krankengut", "im", "Alter", "zwischen", "6", "und", "15", "Jahren", ".", "Anhand", "dieses", "Patientenguts", "wurde", "die", "Diskrepanz", "zwischen", "dem", "klinischen", "Erstbefund", "und", "der", "Befunderhebung", "durch", "Arthroskopie", "aufgezeigt", ".", "Die", "Differenz", "zwischen", "dem", "klinischen", "Erstbefund", "und", "der", "arthroskopisch", "erhobenen", "Diagnose", "lag", "in", "der", "ersten", "Gruppe", "bei", "ca", ".", "45", "%", "und", "in", "der", "2", ".", ",", "spaeter", "untersuchten", "Gruppe", "bei", "ca", ".", "36", "%", ".", "Sowohl", "isolierte", "als", "auch", "kombinierte", "Verletzungen", "waren", "erst", "durch", "die", "Arthroskopie", "erfasst", "worden", ".", "Im", "Vordergrund", "standen", "dabei", "ligamentaere", "vordere", "Kreuzbandrupturen", ",", "mediale", "Seitenbandverletzungen", "und", "Meniskuslaesionen", ".", "Patellaluxationen", "mit", "Retinaculumrupturen", "sowie", "mit", "osteochondralen", "Fragmenten", ",", "die", "der", "klinischen", "Erstuntersuchung", "entgangen", "waren", ",", "wurden", "ebenfalls", "in", "beiden", "Gruppen", "erst", "durch", "die", "Arthroskopie", "nachgewiesen", ".", "Der", "Haemarthros", "erwies", "sich", "als", "wichtigster", "Hinweis", "auf", "den", "Schweregrad", "der", "Verletzung", ".", "Trotz", "der", "neuen", ",", "bildgebenden", "Techniken", ",", "wie", "dem", "MRI", ",", "kommt", "dem", "Einsatz", "der", "Arthroskopie", "auch", "am", "wachsenden", "Kniegelenk", "aufgrund", "der", "gleichzeitigen", "diagnostischen", "und", "therapeutischen", "Moeglichkeiten", "eine", "besondere", "Bedeutung", "zu", ".", "Diese", "zunehmend", "etablierte", "Feststellung", "soll", "der", "Anlass", "dafuer", "sein", ",", "die", "Arthroskopie", "generell", "in", "das", "Management", "akuter", "Kniegelenkverletzungen", "im", "Wachtumsalter", "einzubeziehen", "." ]	[ "umlsterm" ]
Kniegelenkverletzungen is an umlsterm, Arthroskopie is an umlsterm, Kniegelenk is an umlsterm, Diagnose is an umlsterm, Arthroskopie is an umlsterm, Kniegelenkuntersuchung is an umlsterm, Verletzungen is an umlsterm, Wachstumsalter is an umlsterm, Arthroskopie is an umlsterm, Diagnostik is an umlsterm, Kindern is an umlsterm, Wachstumsfugen is an umlsterm, Kinder is an umlsterm, Krankengut is an umlsterm, Patientenguts is an umlsterm, Befunderhebung is an umlsterm, Arthroskopie is an umlsterm, Diagnose is an umlsterm, Verletzungen is an umlsterm, Arthroskopie is an umlsterm, Kreuzbandrupturen is an umlsterm, Seitenbandverletzungen is an umlsterm, Patellaluxationen is an umlsterm, Arthroskopie is an umlsterm, Haemarthros is an umlsterm, Verletzung is an umlsterm, Techniken is an umlsterm, Arthroskopie is an umlsterm, wachsenden is an umlsterm, Kniegelenk is an umlsterm, Arthroskopie is an umlsterm, Kniegelenkverletzungen is an umlsterm	Arthroskopie.80110011.ger.abstr_task1	Sentence: Von frischen Kniegelenkverletzungen des Erwachsenen ist bekannt , dass bei der klinischen Erstuntersuchung haeufig nicht alle Befunde erfasst werden . Erst durch die Arthroskopie wird der Nachweis zusaetzlicher uebersehener Befunde , gefuehrt . Auch fuer das verletzte kindliche Kniegelenk ist die geringe Treffsicherheit der klinischen Diagnose bekannt . Trotzdem wurde der Einsatz der Arthroskopie zunaechst nur zoegernd akzeptiert . Dabei wurde schon in den 80er Jahren von verschiedenen Autoren auf die Problematik der klinischen Kniegelenkuntersuchung bei akuten Verletzungen im Wachstumsalter sowie auf die Bedeutung der Arthroskopie zur Optimierung der Diagnostik hingewiesen . An 2 verschiedenen Gruppen von Kindern und Jugendlichen mit noch offenen bzw. noch nicht geschlossenen Wachstumsfugen der Jahre von 1985-1988 und 1987-1996 wurde eine vergleichende Untersuchung durchgefuehrt . Es handelte sich dabei um Kinder und Jugendliche aus dem klinikeigenen Krankengut im Alter zwischen 6 und 15 Jahren . Anhand dieses Patientenguts wurde die Diskrepanz zwischen dem klinischen Erstbefund und der Befunderhebung durch Arthroskopie aufgezeigt . Die Differenz zwischen dem klinischen Erstbefund und der arthroskopisch erhobenen Diagnose lag in der ersten Gruppe bei ca. 45% und in der 2. , spaeter untersuchten Gruppe bei ca. 36% . Sowohl isolierte als auch kombinierte Verletzungen waren erst durch die Arthroskopie erfasst worden . Im Vordergrund standen dabei ligamentaere vordere Kreuzbandrupturen , mediale Seitenbandverletzungen und Meniskuslaesionen . Patellaluxationen mit Retinaculumrupturen sowie mit osteochondralen Fragmenten , die der klinischen Erstuntersuchung entgangen waren , wurden ebenfalls in beiden Gruppen erst durch die Arthroskopie nachgewiesen . Der Haemarthros erwies sich als wichtigster Hinweis auf den Schweregrad der Verletzung . Trotz der neuen , bildgebenden Techniken , wie dem MRI , kommt dem Einsatz der Arthroskopie auch am wachsenden Kniegelenk aufgrund der gleichzeitigen diagnostischen und therapeutischen Moeglichkeiten eine besondere Bedeutung zu . Diese zunehmend etablierte Feststellung soll der Anlass dafuer sein , die Arthroskopie generell in das Management akuter Kniegelenkverletzungen im Wachtumsalter einzubeziehen . Instructions: please typing these entity words according to sentence: Kniegelenkverletzungen, Arthroskopie, Kniegelenk, Diagnose, Arthroskopie, Kniegelenkuntersuchung, Verletzungen, Wachstumsalter, Arthroskopie, Diagnostik, Kindern, Wachstumsfugen, Kinder, Krankengut, Patientenguts, Befunderhebung, Arthroskopie, Diagnose, Verletzungen, Arthroskopie, Kreuzbandrupturen, Seitenbandverletzungen, Patellaluxationen, Arthroskopie, Haemarthros, Verletzung, Techniken, Arthroskopie, wachsenden, Kniegelenk, Arthroskopie, Kniegelenkverletzungen Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Von frischen Kniegelenkverletzungen des Erwachsenen ist bekannt , dass bei der klinischen Erstuntersuchung haeufig nicht alle Befunde erfasst werden . Erst durch die Arthroskopie wird der Nachweis zusaetzlicher uebersehener Befunde , gefuehrt . Auch fuer das verletzte kindliche Kniegelenk ist die geringe Treffsicherheit der klinischen Diagnose bekannt . Trotzdem wurde der Einsatz der Arthroskopie zunaechst nur zoegernd akzeptiert . Dabei wurde schon in den 80er Jahren von verschiedenen Autoren auf die Problematik der klinischen Kniegelenkuntersuchung bei akuten Verletzungen im Wachstumsalter sowie auf die Bedeutung der Arthroskopie zur Optimierung der Diagnostik hingewiesen . An 2 verschiedenen Gruppen von Kindern und Jugendlichen mit noch offenen bzw. noch nicht geschlossenen Wachstumsfugen der Jahre von 1985-1988 und 1987-1996 wurde eine vergleichende Untersuchung durchgefuehrt . Es handelte sich dabei um Kinder und Jugendliche aus dem klinikeigenen Krankengut im Alter zwischen 6 und 15 Jahren . Anhand dieses Patientenguts wurde die Diskrepanz zwischen dem klinischen Erstbefund und der Befunderhebung durch Arthroskopie aufgezeigt . Die Differenz zwischen dem klinischen Erstbefund und der arthroskopisch erhobenen Diagnose lag in der ersten Gruppe bei ca. 45% und in der 2. , spaeter untersuchten Gruppe bei ca. 36% . Sowohl isolierte als auch kombinierte Verletzungen waren erst durch die Arthroskopie erfasst worden . Im Vordergrund standen dabei ligamentaere vordere Kreuzbandrupturen , mediale Seitenbandverletzungen und Meniskuslaesionen . Patellaluxationen mit Retinaculumrupturen sowie mit osteochondralen Fragmenten , die der klinischen Erstuntersuchung entgangen waren , wurden ebenfalls in beiden Gruppen erst durch die Arthroskopie nachgewiesen . Der Haemarthros erwies sich als wichtigster Hinweis auf den Schweregrad der Verletzung . Trotz der neuen , bildgebenden Techniken , wie dem MRI , kommt dem Einsatz der Arthroskopie auch am wachsenden Kniegelenk aufgrund der gleichzeitigen diagnostischen und therapeutischen Moeglichkeiten eine besondere Bedeutung zu . Diese zunehmend etablierte Feststellung soll der Anlass dafuer sein , die Arthroskopie generell in das Management akuter Kniegelenkverletzungen im Wachtumsalter einzubeziehen .	[ "Von", "frischen", "Kniegelenkverletzungen", "des", "Erwachsenen", "ist", "bekannt", ",", "dass", "bei", "der", "klinischen", "Erstuntersuchung", "haeufig", "nicht", "alle", "Befunde", "erfasst", "werden", ".", "Erst", "durch", "die", "Arthroskopie", "wird", "der", "Nachweis", "zusaetzlicher", "uebersehener", "Befunde", ",", "gefuehrt", ".", "Auch", "fuer", "das", "verletzte", "kindliche", "Kniegelenk", "ist", "die", "geringe", "Treffsicherheit", "der", "klinischen", "Diagnose", "bekannt", ".", "Trotzdem", "wurde", "der", "Einsatz", "der", "Arthroskopie", "zunaechst", "nur", "zoegernd", "akzeptiert", ".", "Dabei", "wurde", "schon", "in", "den", "80er", "Jahren", "von", "verschiedenen", "Autoren", "auf", "die", "Problematik", "der", "klinischen", "Kniegelenkuntersuchung", "bei", "akuten", "Verletzungen", "im", "Wachstumsalter", "sowie", "auf", "die", "Bedeutung", "der", "Arthroskopie", "zur", "Optimierung", "der", "Diagnostik", "hingewiesen", ".", "An", "2", "verschiedenen", "Gruppen", "von", "Kindern", "und", "Jugendlichen", "mit", "noch", "offenen", "bzw", ".", "noch", "nicht", "geschlossenen", "Wachstumsfugen", "der", "Jahre", "von", "1985", "-", "1988", "und", "1987", "-", "1996", "wurde", "eine", "vergleichende", "Untersuchung", "durchgefuehrt", ".", "Es", "handelte", "sich", "dabei", "um", "Kinder", "und", "Jugendliche", "aus", "dem", "klinikeigenen", "Krankengut", "im", "Alter", "zwischen", "6", "und", "15", "Jahren", ".", "Anhand", "dieses", "Patientenguts", "wurde", "die", "Diskrepanz", "zwischen", "dem", "klinischen", "Erstbefund", "und", "der", "Befunderhebung", "durch", "Arthroskopie", "aufgezeigt", ".", "Die", "Differenz", "zwischen", "dem", "klinischen", "Erstbefund", "und", "der", "arthroskopisch", "erhobenen", "Diagnose", "lag", "in", "der", "ersten", "Gruppe", "bei", "ca", ".", "45", "%", "und", "in", "der", "2", ".", ",", "spaeter", "untersuchten", "Gruppe", "bei", "ca", ".", "36", "%", ".", "Sowohl", "isolierte", "als", "auch", "kombinierte", "Verletzungen", "waren", "erst", "durch", "die", "Arthroskopie", "erfasst", "worden", ".", "Im", "Vordergrund", "standen", "dabei", "ligamentaere", "vordere", "Kreuzbandrupturen", ",", "mediale", "Seitenbandverletzungen", "und", "Meniskuslaesionen", ".", "Patellaluxationen", "mit", "Retinaculumrupturen", "sowie", "mit", "osteochondralen", "Fragmenten", ",", "die", "der", "klinischen", "Erstuntersuchung", "entgangen", "waren", ",", "wurden", "ebenfalls", "in", "beiden", "Gruppen", "erst", "durch", "die", "Arthroskopie", "nachgewiesen", ".", "Der", "Haemarthros", "erwies", "sich", "als", "wichtigster", "Hinweis", "auf", "den", "Schweregrad", "der", "Verletzung", ".", "Trotz", "der", "neuen", ",", "bildgebenden", "Techniken", ",", "wie", "dem", "MRI", ",", "kommt", "dem", "Einsatz", "der", "Arthroskopie", "auch", "am", "wachsenden", "Kniegelenk", "aufgrund", "der", "gleichzeitigen", "diagnostischen", "und", "therapeutischen", "Moeglichkeiten", "eine", "besondere", "Bedeutung", "zu", ".", "Diese", "zunehmend", "etablierte", "Feststellung", "soll", "der", "Anlass", "dafuer", "sein", ",", "die", "Arthroskopie", "generell", "in", "das", "Management", "akuter", "Kniegelenkverletzungen", "im", "Wachtumsalter", "einzubeziehen", "." ]	[ "umlsterm" ]
Kniegelenkverletzungen, Arthroskopie, Kniegelenk, Diagnose, Arthroskopie, Kniegelenkuntersuchung, Verletzungen, Wachstumsalter, Arthroskopie, Diagnostik, Kindern, Wachstumsfugen, Kinder, Krankengut, Patientenguts, Befunderhebung, Arthroskopie, Diagnose, Verletzungen, Arthroskopie, Kreuzbandrupturen, Seitenbandverletzungen, Patellaluxationen, Arthroskopie, Haemarthros, Verletzung, Techniken, Arthroskopie, wachsenden, Kniegelenk, Arthroskopie, Kniegelenkverletzungen	Arthroskopie.80110011.ger.abstr_task2	Sentence: Von frischen Kniegelenkverletzungen des Erwachsenen ist bekannt , dass bei der klinischen Erstuntersuchung haeufig nicht alle Befunde erfasst werden . Erst durch die Arthroskopie wird der Nachweis zusaetzlicher uebersehener Befunde , gefuehrt . Auch fuer das verletzte kindliche Kniegelenk ist die geringe Treffsicherheit der klinischen Diagnose bekannt . Trotzdem wurde der Einsatz der Arthroskopie zunaechst nur zoegernd akzeptiert . Dabei wurde schon in den 80er Jahren von verschiedenen Autoren auf die Problematik der klinischen Kniegelenkuntersuchung bei akuten Verletzungen im Wachstumsalter sowie auf die Bedeutung der Arthroskopie zur Optimierung der Diagnostik hingewiesen . An 2 verschiedenen Gruppen von Kindern und Jugendlichen mit noch offenen bzw. noch nicht geschlossenen Wachstumsfugen der Jahre von 1985-1988 und 1987-1996 wurde eine vergleichende Untersuchung durchgefuehrt . Es handelte sich dabei um Kinder und Jugendliche aus dem klinikeigenen Krankengut im Alter zwischen 6 und 15 Jahren . Anhand dieses Patientenguts wurde die Diskrepanz zwischen dem klinischen Erstbefund und der Befunderhebung durch Arthroskopie aufgezeigt . Die Differenz zwischen dem klinischen Erstbefund und der arthroskopisch erhobenen Diagnose lag in der ersten Gruppe bei ca. 45% und in der 2. , spaeter untersuchten Gruppe bei ca. 36% . Sowohl isolierte als auch kombinierte Verletzungen waren erst durch die Arthroskopie erfasst worden . Im Vordergrund standen dabei ligamentaere vordere Kreuzbandrupturen , mediale Seitenbandverletzungen und Meniskuslaesionen . Patellaluxationen mit Retinaculumrupturen sowie mit osteochondralen Fragmenten , die der klinischen Erstuntersuchung entgangen waren , wurden ebenfalls in beiden Gruppen erst durch die Arthroskopie nachgewiesen . Der Haemarthros erwies sich als wichtigster Hinweis auf den Schweregrad der Verletzung . Trotz der neuen , bildgebenden Techniken , wie dem MRI , kommt dem Einsatz der Arthroskopie auch am wachsenden Kniegelenk aufgrund der gleichzeitigen diagnostischen und therapeutischen Moeglichkeiten eine besondere Bedeutung zu . Diese zunehmend etablierte Feststellung soll der Anlass dafuer sein , die Arthroskopie generell in das Management akuter Kniegelenkverletzungen im Wachtumsalter einzubeziehen . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Von frischen Kniegelenkverletzungen des Erwachsenen ist bekannt , dass bei der klinischen Erstuntersuchung haeufig nicht alle Befunde erfasst werden . Erst durch die Arthroskopie wird der Nachweis zusaetzlicher uebersehener Befunde , gefuehrt . Auch fuer das verletzte kindliche Kniegelenk ist die geringe Treffsicherheit der klinischen Diagnose bekannt . Trotzdem wurde der Einsatz der Arthroskopie zunaechst nur zoegernd akzeptiert . Dabei wurde schon in den 80er Jahren von verschiedenen Autoren auf die Problematik der klinischen Kniegelenkuntersuchung bei akuten Verletzungen im Wachstumsalter sowie auf die Bedeutung der Arthroskopie zur Optimierung der Diagnostik hingewiesen . An 2 verschiedenen Gruppen von Kindern und Jugendlichen mit noch offenen bzw. noch nicht geschlossenen Wachstumsfugen der Jahre von 1985-1988 und 1987-1996 wurde eine vergleichende Untersuchung durchgefuehrt . Es handelte sich dabei um Kinder und Jugendliche aus dem klinikeigenen Krankengut im Alter zwischen 6 und 15 Jahren . Anhand dieses Patientenguts wurde die Diskrepanz zwischen dem klinischen Erstbefund und der Befunderhebung durch Arthroskopie aufgezeigt . Die Differenz zwischen dem klinischen Erstbefund und der arthroskopisch erhobenen Diagnose lag in der ersten Gruppe bei ca. 45% und in der 2. , spaeter untersuchten Gruppe bei ca. 36% . Sowohl isolierte als auch kombinierte Verletzungen waren erst durch die Arthroskopie erfasst worden . Im Vordergrund standen dabei ligamentaere vordere Kreuzbandrupturen , mediale Seitenbandverletzungen und Meniskuslaesionen . Patellaluxationen mit Retinaculumrupturen sowie mit osteochondralen Fragmenten , die der klinischen Erstuntersuchung entgangen waren , wurden ebenfalls in beiden Gruppen erst durch die Arthroskopie nachgewiesen . Der Haemarthros erwies sich als wichtigster Hinweis auf den Schweregrad der Verletzung . Trotz der neuen , bildgebenden Techniken , wie dem MRI , kommt dem Einsatz der Arthroskopie auch am wachsenden Kniegelenk aufgrund der gleichzeitigen diagnostischen und therapeutischen Moeglichkeiten eine besondere Bedeutung zu . Diese zunehmend etablierte Feststellung soll der Anlass dafuer sein , die Arthroskopie generell in das Management akuter Kniegelenkverletzungen im Wachtumsalter einzubeziehen .	[ "Von", "frischen", "Kniegelenkverletzungen", "des", "Erwachsenen", "ist", "bekannt", ",", "dass", "bei", "der", "klinischen", "Erstuntersuchung", "haeufig", "nicht", "alle", "Befunde", "erfasst", "werden", ".", "Erst", "durch", "die", "Arthroskopie", "wird", "der", "Nachweis", "zusaetzlicher", "uebersehener", "Befunde", ",", "gefuehrt", ".", "Auch", "fuer", "das", "verletzte", "kindliche", "Kniegelenk", "ist", "die", "geringe", "Treffsicherheit", "der", "klinischen", "Diagnose", "bekannt", ".", "Trotzdem", "wurde", "der", "Einsatz", "der", "Arthroskopie", "zunaechst", "nur", "zoegernd", "akzeptiert", ".", "Dabei", "wurde", "schon", "in", "den", "80er", "Jahren", "von", "verschiedenen", "Autoren", "auf", "die", "Problematik", "der", "klinischen", "Kniegelenkuntersuchung", "bei", "akuten", "Verletzungen", "im", "Wachstumsalter", "sowie", "auf", "die", "Bedeutung", "der", "Arthroskopie", "zur", "Optimierung", "der", "Diagnostik", "hingewiesen", ".", "An", "2", "verschiedenen", "Gruppen", "von", "Kindern", "und", "Jugendlichen", "mit", "noch", "offenen", "bzw", ".", "noch", "nicht", "geschlossenen", "Wachstumsfugen", "der", "Jahre", "von", "1985", "-", "1988", "und", "1987", "-", "1996", "wurde", "eine", "vergleichende", "Untersuchung", "durchgefuehrt", ".", "Es", "handelte", "sich", "dabei", "um", "Kinder", "und", "Jugendliche", "aus", "dem", "klinikeigenen", "Krankengut", "im", "Alter", "zwischen", "6", "und", "15", "Jahren", ".", "Anhand", "dieses", "Patientenguts", "wurde", "die", "Diskrepanz", "zwischen", "dem", "klinischen", "Erstbefund", "und", "der", "Befunderhebung", "durch", "Arthroskopie", "aufgezeigt", ".", "Die", "Differenz", "zwischen", "dem", "klinischen", "Erstbefund", "und", "der", "arthroskopisch", "erhobenen", "Diagnose", "lag", "in", "der", "ersten", "Gruppe", "bei", "ca", ".", "45", "%", "und", "in", "der", "2", ".", ",", "spaeter", "untersuchten", "Gruppe", "bei", "ca", ".", "36", "%", ".", "Sowohl", "isolierte", "als", "auch", "kombinierte", "Verletzungen", "waren", "erst", "durch", "die", "Arthroskopie", "erfasst", "worden", ".", "Im", "Vordergrund", "standen", "dabei", "ligamentaere", "vordere", "Kreuzbandrupturen", ",", "mediale", "Seitenbandverletzungen", "und", "Meniskuslaesionen", ".", "Patellaluxationen", "mit", "Retinaculumrupturen", "sowie", "mit", "osteochondralen", "Fragmenten", ",", "die", "der", "klinischen", "Erstuntersuchung", "entgangen", "waren", ",", "wurden", "ebenfalls", "in", "beiden", "Gruppen", "erst", "durch", "die", "Arthroskopie", "nachgewiesen", ".", "Der", "Haemarthros", "erwies", "sich", "als", "wichtigster", "Hinweis", "auf", "den", "Schweregrad", "der", "Verletzung", ".", "Trotz", "der", "neuen", ",", "bildgebenden", "Techniken", ",", "wie", "dem", "MRI", ",", "kommt", "dem", "Einsatz", "der", "Arthroskopie", "auch", "am", "wachsenden", "Kniegelenk", "aufgrund", "der", "gleichzeitigen", "diagnostischen", "und", "therapeutischen", "Moeglichkeiten", "eine", "besondere", "Bedeutung", "zu", ".", "Diese", "zunehmend", "etablierte", "Feststellung", "soll", "der", "Anlass", "dafuer", "sein", ",", "die", "Arthroskopie", "generell", "in", "das", "Management", "akuter", "Kniegelenkverletzungen", "im", "Wachtumsalter", "einzubeziehen", "." ]	[ "umlsterm" ]
Heimdiagnostik is an umlsterm, schlafbezogener is an umlsterm, Atmungsstoerungen is an umlsterm, Zeit is an umlsterm, Geraete is an umlsterm, Geraet is an umlsterm, Geraets is an umlsterm, Arzt is an umlsterm, Patient is an umlsterm, Belastbarkeit is an umlsterm, Geraets is an umlsterm, Software is an umlsterm, Handauswertung is an umlsterm, Patienten is an umlsterm, Geschlechts is an umlsterm, obstruktiven Schlafapnoe is an umlsterm, Patienten is an umlsterm, Aerzten is an umlsterm, Patienten is an umlsterm, selbst is an umlsterm, Patienten is an umlsterm, Handauswertung is an umlsterm, Geraets is an umlsterm, Patienten is an umlsterm, Handauswertung is an umlsterm, Geraet is an umlsterm, Patienten is an umlsterm, selbst is an umlsterm, Polysomnographie is an umlsterm	HNO.90470249.ger.abstr_task0	Sentence: In der ambulanten Heimdiagnostik schlafbezogener Atmungsstoerungen kommen seit einiger Zeit 7kanalige Geraete zum Einsatz . Ein solches Geraet ist das POLY-MESAM ( Fa. MAP ) . Der vorliegende 1. Teil der Studie hat die Handhabung des Geraets fuer Arzt und Patient , die technische Belastbarkeit des Geraets und die Zuverlaessigkeit der automatischen Auswertung durch die zugehoerige Software vs. Handauswertung prospektiv untersucht . 104 Patienten beiderlei Geschlechts und mit unterschiedlichem Schweregrad einer obstruktiven Schlafapnoe wurden untersucht . Die ersten 51 Patienten wurden am Abend in der Klinik von 2 Aerzten an das POLY-MESAM-Geraet angeschlossen und ueber seine Funktionen unterrichtet . Die 2. Serie von 53 Patienten bekam am Nachmittag lediglich eine Einweisung in das POLY-MESAM-Geraet und hat den Anschluss zu Hause selbst vollzogen . Das Befinden der Patienten wurde mittels einer visuellen Analogskala festgehalten . Die automatische Auswertung wurde mit einer Handauswertung verglichen . Die Studie hat insgesamt knapp 6% unbrauchbare Ergebnisse erbracht . Die Akzeptanz des Geraets durch die Patienten ist mit bis zu 94,3% ausgesprochen hoch . Bezueglich des Apnoe-Hypopnoe-Indexes ( AHI ) ist die Korrelation zwischen automatischer ( AHI=11,1) und Handauswertung ( AHI=11,3) sehr gut . Das Geraet laesst sich aufgrund seiner soliden Bauart und Bedienungsfreundlichkeit sehr gut als ambulante Screeningmethode fuer obstruktive Schlafatmungsstoerungen durch den Patienten selbst einsetzen . Validierungsuntersuchungen mittels simultaner Polysomnographie sind Gegenstand des 2. Teils der Studie . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In der ambulanten Heimdiagnostik schlafbezogener Atmungsstoerungen kommen seit einiger Zeit 7kanalige Geraete zum Einsatz . Ein solches Geraet ist das POLY-MESAM ( Fa. MAP ) . Der vorliegende 1. Teil der Studie hat die Handhabung des Geraets fuer Arzt und Patient , die technische Belastbarkeit des Geraets und die Zuverlaessigkeit der automatischen Auswertung durch die zugehoerige Software vs. Handauswertung prospektiv untersucht . 104 Patienten beiderlei Geschlechts und mit unterschiedlichem Schweregrad einer obstruktiven Schlafapnoe wurden untersucht . Die ersten 51 Patienten wurden am Abend in der Klinik von 2 Aerzten an das POLY-MESAM-Geraet angeschlossen und ueber seine Funktionen unterrichtet . Die 2. Serie von 53 Patienten bekam am Nachmittag lediglich eine Einweisung in das POLY-MESAM-Geraet und hat den Anschluss zu Hause selbst vollzogen . Das Befinden der Patienten wurde mittels einer visuellen Analogskala festgehalten . Die automatische Auswertung wurde mit einer Handauswertung verglichen . Die Studie hat insgesamt knapp 6% unbrauchbare Ergebnisse erbracht . Die Akzeptanz des Geraets durch die Patienten ist mit bis zu 94,3% ausgesprochen hoch . Bezueglich des Apnoe-Hypopnoe-Indexes ( AHI ) ist die Korrelation zwischen automatischer ( AHI=11,1) und Handauswertung ( AHI=11,3) sehr gut . Das Geraet laesst sich aufgrund seiner soliden Bauart und Bedienungsfreundlichkeit sehr gut als ambulante Screeningmethode fuer obstruktive Schlafatmungsstoerungen durch den Patienten selbst einsetzen . Validierungsuntersuchungen mittels simultaner Polysomnographie sind Gegenstand des 2. Teils der Studie .	[ "In", "der", "ambulanten", "Heimdiagnostik", "schlafbezogener", "Atmungsstoerungen", "kommen", "seit", "einiger", "Zeit", "7kanalige", "Geraete", "zum", "Einsatz", ".", "Ein", "solches", "Geraet", "ist", "das", "POLY", "-", "MESAM", "(", "Fa", ".", "MAP", ")", ".", "Der", "vorliegende", "1", ".", "Teil", "der", "Studie", "hat", "die", "Handhabung", "des", "Geraets", "fuer", "Arzt", "und", "Patient", ",", "die", "technische", "Belastbarkeit", "des", "Geraets", "und", "die", "Zuverlaessigkeit", "der", "automatischen", "Auswertung", "durch", "die", "zugehoerige", "Software", "vs", ".", "Handauswertung", "prospektiv", "untersucht", ".", "104", "Patienten", "beiderlei", "Geschlechts", "und", "mit", "unterschiedlichem", "Schweregrad", "einer", "obstruktiven", "Schlafapnoe", "wurden", "untersucht", ".", "Die", "ersten", "51", "Patienten", "wurden", "am", "Abend", "in", "der", "Klinik", "von", "2", "Aerzten", "an", "das", "POLY", "-", "MESAM", "-", "Geraet", "angeschlossen", "und", "ueber", "seine", "Funktionen", "unterrichtet", ".", "Die", "2", ".", "Serie", "von", "53", "Patienten", "bekam", "am", "Nachmittag", "lediglich", "eine", "Einweisung", "in", "das", "POLY", "-", "MESAM", "-", "Geraet", "und", "hat", "den", "Anschluss", "zu", "Hause", "selbst", "vollzogen", ".", "Das", "Befinden", "der", "Patienten", "wurde", "mittels", "einer", "visuellen", "Analogskala", "festgehalten", ".", "Die", "automatische", "Auswertung", "wurde", "mit", "einer", "Handauswertung", "verglichen", ".", "Die", "Studie", "hat", "insgesamt", "knapp", "6", "%", "unbrauchbare", "Ergebnisse", "erbracht", ".", "Die", "Akzeptanz", "des", "Geraets", "durch", "die", "Patienten", "ist", "mit", "bis", "zu", "94,3", "%", "ausgesprochen", "hoch", ".", "Bezueglich", "des", "Apnoe", "-", "Hypopnoe", "-", "Indexes", "(", "AHI", ")", "ist", "die", "Korrelation", "zwischen", "automatischer", "(", "AHI=11,1", ")", "und", "Handauswertung", "(", "AHI=11,3", ")", "sehr", "gut", ".", "Das", "Geraet", "laesst", "sich", "aufgrund", "seiner", "soliden", "Bauart", "und", "Bedienungsfreundlichkeit", "sehr", "gut", "als", "ambulante", "Screeningmethode", "fuer", "obstruktive", "Schlafatmungsstoerungen", "durch", "den", "Patienten", "selbst", "einsetzen", ".", "Validierungsuntersuchungen", "mittels", "simultaner", "Polysomnographie", "sind", "Gegenstand", "des", "2", ".", "Teils", "der", "Studie", "." ]	[ "umlsterm" ]
Heimdiagnostik is an umlsterm, schlafbezogener is an umlsterm, Atmungsstoerungen is an umlsterm, Zeit is an umlsterm, Geraete is an umlsterm, Geraet is an umlsterm, Geraets is an umlsterm, Arzt is an umlsterm, Patient is an umlsterm, Belastbarkeit is an umlsterm, Geraets is an umlsterm, Software is an umlsterm, Handauswertung is an umlsterm, Patienten is an umlsterm, Geschlechts is an umlsterm, obstruktiven Schlafapnoe is an umlsterm, Patienten is an umlsterm, Aerzten is an umlsterm, Patienten is an umlsterm, selbst is an umlsterm, Patienten is an umlsterm, Handauswertung is an umlsterm, Geraets is an umlsterm, Patienten is an umlsterm, Handauswertung is an umlsterm, Geraet is an umlsterm, Patienten is an umlsterm, selbst is an umlsterm, Polysomnographie is an umlsterm	HNO.90470249.ger.abstr_task1	Sentence: In der ambulanten Heimdiagnostik schlafbezogener Atmungsstoerungen kommen seit einiger Zeit 7kanalige Geraete zum Einsatz . Ein solches Geraet ist das POLY-MESAM ( Fa. MAP ) . Der vorliegende 1. Teil der Studie hat die Handhabung des Geraets fuer Arzt und Patient , die technische Belastbarkeit des Geraets und die Zuverlaessigkeit der automatischen Auswertung durch die zugehoerige Software vs. Handauswertung prospektiv untersucht . 104 Patienten beiderlei Geschlechts und mit unterschiedlichem Schweregrad einer obstruktiven Schlafapnoe wurden untersucht . Die ersten 51 Patienten wurden am Abend in der Klinik von 2 Aerzten an das POLY-MESAM-Geraet angeschlossen und ueber seine Funktionen unterrichtet . Die 2. Serie von 53 Patienten bekam am Nachmittag lediglich eine Einweisung in das POLY-MESAM-Geraet und hat den Anschluss zu Hause selbst vollzogen . Das Befinden der Patienten wurde mittels einer visuellen Analogskala festgehalten . Die automatische Auswertung wurde mit einer Handauswertung verglichen . Die Studie hat insgesamt knapp 6% unbrauchbare Ergebnisse erbracht . Die Akzeptanz des Geraets durch die Patienten ist mit bis zu 94,3% ausgesprochen hoch . Bezueglich des Apnoe-Hypopnoe-Indexes ( AHI ) ist die Korrelation zwischen automatischer ( AHI=11,1) und Handauswertung ( AHI=11,3) sehr gut . Das Geraet laesst sich aufgrund seiner soliden Bauart und Bedienungsfreundlichkeit sehr gut als ambulante Screeningmethode fuer obstruktive Schlafatmungsstoerungen durch den Patienten selbst einsetzen . Validierungsuntersuchungen mittels simultaner Polysomnographie sind Gegenstand des 2. Teils der Studie . Instructions: please typing these entity words according to sentence: Heimdiagnostik, schlafbezogener, Atmungsstoerungen, Zeit, Geraete, Geraet, Geraets, Arzt, Patient, Belastbarkeit, Geraets, Software, Handauswertung, Patienten, Geschlechts, obstruktiven Schlafapnoe, Patienten, Aerzten, Patienten, selbst, Patienten, Handauswertung, Geraets, Patienten, Handauswertung, Geraet, Patienten, selbst, Polysomnographie Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In der ambulanten Heimdiagnostik schlafbezogener Atmungsstoerungen kommen seit einiger Zeit 7kanalige Geraete zum Einsatz . Ein solches Geraet ist das POLY-MESAM ( Fa. MAP ) . Der vorliegende 1. Teil der Studie hat die Handhabung des Geraets fuer Arzt und Patient , die technische Belastbarkeit des Geraets und die Zuverlaessigkeit der automatischen Auswertung durch die zugehoerige Software vs. Handauswertung prospektiv untersucht . 104 Patienten beiderlei Geschlechts und mit unterschiedlichem Schweregrad einer obstruktiven Schlafapnoe wurden untersucht . Die ersten 51 Patienten wurden am Abend in der Klinik von 2 Aerzten an das POLY-MESAM-Geraet angeschlossen und ueber seine Funktionen unterrichtet . Die 2. Serie von 53 Patienten bekam am Nachmittag lediglich eine Einweisung in das POLY-MESAM-Geraet und hat den Anschluss zu Hause selbst vollzogen . Das Befinden der Patienten wurde mittels einer visuellen Analogskala festgehalten . Die automatische Auswertung wurde mit einer Handauswertung verglichen . Die Studie hat insgesamt knapp 6% unbrauchbare Ergebnisse erbracht . Die Akzeptanz des Geraets durch die Patienten ist mit bis zu 94,3% ausgesprochen hoch . Bezueglich des Apnoe-Hypopnoe-Indexes ( AHI ) ist die Korrelation zwischen automatischer ( AHI=11,1) und Handauswertung ( AHI=11,3) sehr gut . Das Geraet laesst sich aufgrund seiner soliden Bauart und Bedienungsfreundlichkeit sehr gut als ambulante Screeningmethode fuer obstruktive Schlafatmungsstoerungen durch den Patienten selbst einsetzen . Validierungsuntersuchungen mittels simultaner Polysomnographie sind Gegenstand des 2. Teils der Studie .	[ "In", "der", "ambulanten", "Heimdiagnostik", "schlafbezogener", "Atmungsstoerungen", "kommen", "seit", "einiger", "Zeit", "7kanalige", "Geraete", "zum", "Einsatz", ".", "Ein", "solches", "Geraet", "ist", "das", "POLY", "-", "MESAM", "(", "Fa", ".", "MAP", ")", ".", "Der", "vorliegende", "1", ".", "Teil", "der", "Studie", "hat", "die", "Handhabung", "des", "Geraets", "fuer", "Arzt", "und", "Patient", ",", "die", "technische", "Belastbarkeit", "des", "Geraets", "und", "die", "Zuverlaessigkeit", "der", "automatischen", "Auswertung", "durch", "die", "zugehoerige", "Software", "vs", ".", "Handauswertung", "prospektiv", "untersucht", ".", "104", "Patienten", "beiderlei", "Geschlechts", "und", "mit", "unterschiedlichem", "Schweregrad", "einer", "obstruktiven", "Schlafapnoe", "wurden", "untersucht", ".", "Die", "ersten", "51", "Patienten", "wurden", "am", "Abend", "in", "der", "Klinik", "von", "2", "Aerzten", "an", "das", "POLY", "-", "MESAM", "-", "Geraet", "angeschlossen", "und", "ueber", "seine", "Funktionen", "unterrichtet", ".", "Die", "2", ".", "Serie", "von", "53", "Patienten", "bekam", "am", "Nachmittag", "lediglich", "eine", "Einweisung", "in", "das", "POLY", "-", "MESAM", "-", "Geraet", "und", "hat", "den", "Anschluss", "zu", "Hause", "selbst", "vollzogen", ".", "Das", "Befinden", "der", "Patienten", "wurde", "mittels", "einer", "visuellen", "Analogskala", "festgehalten", ".", "Die", "automatische", "Auswertung", "wurde", "mit", "einer", "Handauswertung", "verglichen", ".", "Die", "Studie", "hat", "insgesamt", "knapp", "6", "%", "unbrauchbare", "Ergebnisse", "erbracht", ".", "Die", "Akzeptanz", "des", "Geraets", "durch", "die", "Patienten", "ist", "mit", "bis", "zu", "94,3", "%", "ausgesprochen", "hoch", ".", "Bezueglich", "des", "Apnoe", "-", "Hypopnoe", "-", "Indexes", "(", "AHI", ")", "ist", "die", "Korrelation", "zwischen", "automatischer", "(", "AHI=11,1", ")", "und", "Handauswertung", "(", "AHI=11,3", ")", "sehr", "gut", ".", "Das", "Geraet", "laesst", "sich", "aufgrund", "seiner", "soliden", "Bauart", "und", "Bedienungsfreundlichkeit", "sehr", "gut", "als", "ambulante", "Screeningmethode", "fuer", "obstruktive", "Schlafatmungsstoerungen", "durch", "den", "Patienten", "selbst", "einsetzen", ".", "Validierungsuntersuchungen", "mittels", "simultaner", "Polysomnographie", "sind", "Gegenstand", "des", "2", ".", "Teils", "der", "Studie", "." ]	[ "umlsterm" ]
Heimdiagnostik, schlafbezogener, Atmungsstoerungen, Zeit, Geraete, Geraet, Geraets, Arzt, Patient, Belastbarkeit, Geraets, Software, Handauswertung, Patienten, Geschlechts, obstruktiven Schlafapnoe, Patienten, Aerzten, Patienten, selbst, Patienten, Handauswertung, Geraets, Patienten, Handauswertung, Geraet, Patienten, selbst, Polysomnographie	HNO.90470249.ger.abstr_task2	Sentence: In der ambulanten Heimdiagnostik schlafbezogener Atmungsstoerungen kommen seit einiger Zeit 7kanalige Geraete zum Einsatz . Ein solches Geraet ist das POLY-MESAM ( Fa. MAP ) . Der vorliegende 1. Teil der Studie hat die Handhabung des Geraets fuer Arzt und Patient , die technische Belastbarkeit des Geraets und die Zuverlaessigkeit der automatischen Auswertung durch die zugehoerige Software vs. Handauswertung prospektiv untersucht . 104 Patienten beiderlei Geschlechts und mit unterschiedlichem Schweregrad einer obstruktiven Schlafapnoe wurden untersucht . Die ersten 51 Patienten wurden am Abend in der Klinik von 2 Aerzten an das POLY-MESAM-Geraet angeschlossen und ueber seine Funktionen unterrichtet . Die 2. Serie von 53 Patienten bekam am Nachmittag lediglich eine Einweisung in das POLY-MESAM-Geraet und hat den Anschluss zu Hause selbst vollzogen . Das Befinden der Patienten wurde mittels einer visuellen Analogskala festgehalten . Die automatische Auswertung wurde mit einer Handauswertung verglichen . Die Studie hat insgesamt knapp 6% unbrauchbare Ergebnisse erbracht . Die Akzeptanz des Geraets durch die Patienten ist mit bis zu 94,3% ausgesprochen hoch . Bezueglich des Apnoe-Hypopnoe-Indexes ( AHI ) ist die Korrelation zwischen automatischer ( AHI=11,1) und Handauswertung ( AHI=11,3) sehr gut . Das Geraet laesst sich aufgrund seiner soliden Bauart und Bedienungsfreundlichkeit sehr gut als ambulante Screeningmethode fuer obstruktive Schlafatmungsstoerungen durch den Patienten selbst einsetzen . Validierungsuntersuchungen mittels simultaner Polysomnographie sind Gegenstand des 2. Teils der Studie . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In der ambulanten Heimdiagnostik schlafbezogener Atmungsstoerungen kommen seit einiger Zeit 7kanalige Geraete zum Einsatz . Ein solches Geraet ist das POLY-MESAM ( Fa. MAP ) . Der vorliegende 1. Teil der Studie hat die Handhabung des Geraets fuer Arzt und Patient , die technische Belastbarkeit des Geraets und die Zuverlaessigkeit der automatischen Auswertung durch die zugehoerige Software vs. Handauswertung prospektiv untersucht . 104 Patienten beiderlei Geschlechts und mit unterschiedlichem Schweregrad einer obstruktiven Schlafapnoe wurden untersucht . Die ersten 51 Patienten wurden am Abend in der Klinik von 2 Aerzten an das POLY-MESAM-Geraet angeschlossen und ueber seine Funktionen unterrichtet . Die 2. Serie von 53 Patienten bekam am Nachmittag lediglich eine Einweisung in das POLY-MESAM-Geraet und hat den Anschluss zu Hause selbst vollzogen . Das Befinden der Patienten wurde mittels einer visuellen Analogskala festgehalten . Die automatische Auswertung wurde mit einer Handauswertung verglichen . Die Studie hat insgesamt knapp 6% unbrauchbare Ergebnisse erbracht . Die Akzeptanz des Geraets durch die Patienten ist mit bis zu 94,3% ausgesprochen hoch . Bezueglich des Apnoe-Hypopnoe-Indexes ( AHI ) ist die Korrelation zwischen automatischer ( AHI=11,1) und Handauswertung ( AHI=11,3) sehr gut . Das Geraet laesst sich aufgrund seiner soliden Bauart und Bedienungsfreundlichkeit sehr gut als ambulante Screeningmethode fuer obstruktive Schlafatmungsstoerungen durch den Patienten selbst einsetzen . Validierungsuntersuchungen mittels simultaner Polysomnographie sind Gegenstand des 2. Teils der Studie .	[ "In", "der", "ambulanten", "Heimdiagnostik", "schlafbezogener", "Atmungsstoerungen", "kommen", "seit", "einiger", "Zeit", "7kanalige", "Geraete", "zum", "Einsatz", ".", "Ein", "solches", "Geraet", "ist", "das", "POLY", "-", "MESAM", "(", "Fa", ".", "MAP", ")", ".", "Der", "vorliegende", "1", ".", "Teil", "der", "Studie", "hat", "die", "Handhabung", "des", "Geraets", "fuer", "Arzt", "und", "Patient", ",", "die", "technische", "Belastbarkeit", "des", "Geraets", "und", "die", "Zuverlaessigkeit", "der", "automatischen", "Auswertung", "durch", "die", "zugehoerige", "Software", "vs", ".", "Handauswertung", "prospektiv", "untersucht", ".", "104", "Patienten", "beiderlei", "Geschlechts", "und", "mit", "unterschiedlichem", "Schweregrad", "einer", "obstruktiven", "Schlafapnoe", "wurden", "untersucht", ".", "Die", "ersten", "51", "Patienten", "wurden", "am", "Abend", "in", "der", "Klinik", "von", "2", "Aerzten", "an", "das", "POLY", "-", "MESAM", "-", "Geraet", "angeschlossen", "und", "ueber", "seine", "Funktionen", "unterrichtet", ".", "Die", "2", ".", "Serie", "von", "53", "Patienten", "bekam", "am", "Nachmittag", "lediglich", "eine", "Einweisung", "in", "das", "POLY", "-", "MESAM", "-", "Geraet", "und", "hat", "den", "Anschluss", "zu", "Hause", "selbst", "vollzogen", ".", "Das", "Befinden", "der", "Patienten", "wurde", "mittels", "einer", "visuellen", "Analogskala", "festgehalten", ".", "Die", "automatische", "Auswertung", "wurde", "mit", "einer", "Handauswertung", "verglichen", ".", "Die", "Studie", "hat", "insgesamt", "knapp", "6", "%", "unbrauchbare", "Ergebnisse", "erbracht", ".", "Die", "Akzeptanz", "des", "Geraets", "durch", "die", "Patienten", "ist", "mit", "bis", "zu", "94,3", "%", "ausgesprochen", "hoch", ".", "Bezueglich", "des", "Apnoe", "-", "Hypopnoe", "-", "Indexes", "(", "AHI", ")", "ist", "die", "Korrelation", "zwischen", "automatischer", "(", "AHI=11,1", ")", "und", "Handauswertung", "(", "AHI=11,3", ")", "sehr", "gut", ".", "Das", "Geraet", "laesst", "sich", "aufgrund", "seiner", "soliden", "Bauart", "und", "Bedienungsfreundlichkeit", "sehr", "gut", "als", "ambulante", "Screeningmethode", "fuer", "obstruktive", "Schlafatmungsstoerungen", "durch", "den", "Patienten", "selbst", "einsetzen", ".", "Validierungsuntersuchungen", "mittels", "simultaner", "Polysomnographie", "sind", "Gegenstand", "des", "2", ".", "Teils", "der", "Studie", "." ]	[ "umlsterm" ]
Antonio is a NOMBRE_SUJETO_ASISTENCIA, Pagudo Henao is a NOMBRE_SUJETO_ASISTENCIA, 987345 is a ID_SUJETO_ASISTENCIA, Cundinamarca , Cra . 15a # 26 is a CALLE, Bogotá is a TERRITORIO, 15/06/1979 is a FECHAS, Colombia is a PAIS, 38 años is a EDAD_SUJETO_ASISTENCIA, 03/05/2018 is a FECHAS, Ricardo Galán Suárez is a NOMBRE_PERSONAL_SANITARIO, Varón is a SEXO_SUJETO_ASISTENCIA, 38 años is a EDAD_SUJETO_ASISTENCIA, fuerza policial is a PROFESION, Ricardo Galán Suárez is a NOMBRE_PERSONAL_SANITARIO, Hospital Militar Çentral is a HOSPITAL, Carrera 3 # 49 - 00 is a CALLE, Bogotá D.C. is a TERRITORIO, Colombia is a PAIS, ricgalan@gmail.com is a CORREO_ELECTRONICO	258_task0	Sentence: Nombre: Antonio. Apellidos: Pagudo Henao. NHC: 987345. Domicilio: Cundinamarca, Cra. 15a #26. Localidad/ Provincia: Bogotá. Datos asistenciales. Fecha de nacimiento: 15/06/1979. País: Colombia. Edad: 38 años Sexo: H. Fecha de Ingreso: 03/05/2018. Médico:Ricardo Galán Suárez . Historia del paciente: Varón de 38 años que trabaja como miembro de la fuerza policial y que sufre un accidente de tránsito en calidad de motociclista con traumatismo contundente en mano izquierda en hiperextensión. Inicialmente es visto por el Servicio de Urgencias donde le toman radiografía de la mano sin encontrar fracturas, por lo que es tratado con vendaje, analgesia y reposo. Dos meses después el paciente consulta en otra institución médica por dolor persistente y limitación funcional; se le toman nuevas radiografías en las que se observa fractura de polo distal del escafoides, y se le practica tratamiento ortopédico cerrado con férula durante 4 semanas tras las que se le indica rehabilitación con terapia física que siguió durante 6 meses. Tratamiento realizado en otra institución médica. Un año después regresa a la consulta médica nuevamente por persistencia de dolor y limitación funcional, por lo que es remitido a nuestro Servicio de Cirugía de Mano, donde solicitamos tomografía axial computarizada (TAC) y resonancia nuclear magnética (RNM) con contraste de la mano y muñeca izquierdas, encontrando necrosis del polo distal del escafoides. Con este diagnóstico, decidimos realizar tratamiento quirúrgico mediante artrodesis escafo-trapecio-trapezoide con placa. Remitido por: Dr. Ricardo Galán Suárez. Servicio de Cirugía Plástica Hospital Militar Çentral Carrera 3 # 49-00 Bogotá D.C. Colombia Correo electrónico: ricgalan@gmail.com. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, PROFESION, FECHAS, HOSPITAL, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "B-PROFESION", "I-PROFESION", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "I-TERRITORIO", "B-PAIS", "O", "O", "O", "B-CORREO_ELECTRONICO", "O", "O" ]	Nombre: Antonio. Apellidos: Pagudo Henao. NHC: 987345. Domicilio: Cundinamarca, Cra. 15a #26. Localidad/ Provincia: Bogotá. Datos asistenciales. Fecha de nacimiento: 15/06/1979. País: Colombia. Edad: 38 años Sexo: H. Fecha de Ingreso: 03/05/2018. Médico:Ricardo Galán Suárez . Historia del paciente: Varón de 38 años que trabaja como miembro de la fuerza policial y que sufre un accidente de tránsito en calidad de motociclista con traumatismo contundente en mano izquierda en hiperextensión. Inicialmente es visto por el Servicio de Urgencias donde le toman radiografía de la mano sin encontrar fracturas, por lo que es tratado con vendaje, analgesia y reposo. Dos meses después el paciente consulta en otra institución médica por dolor persistente y limitación funcional; se le toman nuevas radiografías en las que se observa fractura de polo distal del escafoides, y se le practica tratamiento ortopédico cerrado con férula durante 4 semanas tras las que se le indica rehabilitación con terapia física que siguió durante 6 meses. Tratamiento realizado en otra institución médica. Un año después regresa a la consulta médica nuevamente por persistencia de dolor y limitación funcional, por lo que es remitido a nuestro Servicio de Cirugía de Mano, donde solicitamos tomografía axial computarizada (TAC) y resonancia nuclear magnética (RNM) con contraste de la mano y muñeca izquierdas, encontrando necrosis del polo distal del escafoides. Con este diagnóstico, decidimos realizar tratamiento quirúrgico mediante artrodesis escafo-trapecio-trapezoide con placa. Remitido por: Dr. Ricardo Galán Suárez. Servicio de Cirugía Plástica Hospital Militar Çentral Carrera 3 # 49-00 Bogotá D.C. Colombia Correo electrónico: ricgalan@gmail.com.	[ "Nombre", ":", " ", "Antonio", ".", "\n", "Apellidos", ":", "Pagudo", "Henao", ".", "\n", "NHC", ":", "987345", ".", "\n", "Domicilio", ":", "Cundinamarca", ",", "Cra", ".", "15a", "#", "26", ".", "\n", "Localidad/", "Provincia", ":", "Bogotá", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "15/06/1979", ".", "\n", "País", ":", "Colombia", ".", "\n", "Edad", ":", "38", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "03/05/2018", ".", "\n", "Médico", ":", "Ricardo", "Galán", "Suárez", ".", "\n", "Historia", "del", "paciente", ":", "Varón", "de", "38", "años", "que", "trabaja", "como", "miembro", "de", "la", "fuerza", "policial", "y", "que", "sufre", "un", "accidente", "de", "tránsito", "en", "calidad", "de", "motociclista", "con", "traumatismo", "contundente", "en", "mano", "izquierda", "en", "hiperextensión", ".", "Inicialmente", "es", "visto", "por", "el", "Servicio", "de", "Urgencias", "donde", "le", "toman", "radiografía", "de", "la", "mano", "sin", "encontrar", "fracturas", ",", "por", "lo", "que", "es", "tratado", "con", "vendaje", ",", "analgesia", "y", "reposo", ".", "\n", "Dos", "meses", "después", "el", "paciente", "consulta", "en", "otra", "institución", "médica", "por", "dolor", "persistente", "y", "limitación", "funcional", ";", "se", "le", "toman", "nuevas", "radiografías", "en", "las", "que", "se", "observa", "fractura", "de", "polo", "distal", "del", "escafoides", ",", "y", "se", "le", "practica", "tratamiento", "ortopédico", "cerrado", "con", "férula", "durante", "4", "semanas", "tras", "las", "que", "se", "le", "indica", "rehabilitación", "con", "terapia", "física", "que", "siguió", "durante", "6", "meses", ".", "Tratamiento", "realizado", "en", "otra", "institución", "médica", ".", "\n", "Un", "año", "después", "regresa", "a", "la", "consulta", "médica", "nuevamente", "por", "persistencia", "de", "dolor", "y", "limitación", "funcional", ",", "por", "lo", "que", "es", "remitido", "a", "nuestro", "Servicio", "de", "Cirugía", "de", "Mano", ",", "donde", "solicitamos", "tomografía", "axial", "computarizada", "(", "TAC", ")", "y", "resonancia", "nuclear", "magnética", "(", "RNM", ")", "con", "contraste", "de", "la", "mano", "y", "muñeca", "izquierdas", ",", "encontrando", "necrosis", "del", "polo", "distal", "del", "escafoides", ".", "Con", "este", "diagnóstico", ",", "decidimos", "realizar", "tratamiento", "quirúrgico", "mediante", "artrodesis", "escafo", "-", "trapecio", "-", "trapezoide", "con", "placa", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Ricardo", "Galán", "Suárez", ".", "Servicio", "de", "Cirugía", "Plástica", "Hospital", "Militar", "Çentral", "Carrera", "3", "#", "49", "-", "00", "Bogotá", "D.C.", "Colombia", "Correo", "electrónico", ":", "ricgalan@gmail.com", ".", "\n" ]	[ "CALLE", "HOSPITAL", "NOMBRE_PERSONAL_SANITARIO", "CORREO_ELECTRONICO", "PROFESION", "NOMBRE_SUJETO_ASISTENCIA", "TERRITORIO", "FECHAS", "PAIS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "SEXO_SUJETO_ASISTENCIA" ]
Antonio is a NOMBRE_SUJETO_ASISTENCIA, Pagudo Henao is a NOMBRE_SUJETO_ASISTENCIA, 987345 is a ID_SUJETO_ASISTENCIA, Cundinamarca , Cra . 15a # 26 is a CALLE, Bogotá is a TERRITORIO, 15/06/1979 is a FECHAS, Colombia is a PAIS, 38 años is a EDAD_SUJETO_ASISTENCIA, 03/05/2018 is a FECHAS, Ricardo Galán Suárez is a NOMBRE_PERSONAL_SANITARIO, Varón is a SEXO_SUJETO_ASISTENCIA, 38 años is a EDAD_SUJETO_ASISTENCIA, fuerza policial is a PROFESION, Ricardo Galán Suárez is a NOMBRE_PERSONAL_SANITARIO, Hospital Militar Çentral is a HOSPITAL, Carrera 3 # 49 - 00 is a CALLE, Bogotá D.C. is a TERRITORIO, Colombia is a PAIS, ricgalan@gmail.com is a CORREO_ELECTRONICO	258_task1	Sentence: Nombre: Antonio. Apellidos: Pagudo Henao. NHC: 987345. Domicilio: Cundinamarca, Cra. 15a #26. Localidad/ Provincia: Bogotá. Datos asistenciales. Fecha de nacimiento: 15/06/1979. País: Colombia. Edad: 38 años Sexo: H. Fecha de Ingreso: 03/05/2018. Médico:Ricardo Galán Suárez . Historia del paciente: Varón de 38 años que trabaja como miembro de la fuerza policial y que sufre un accidente de tránsito en calidad de motociclista con traumatismo contundente en mano izquierda en hiperextensión. Inicialmente es visto por el Servicio de Urgencias donde le toman radiografía de la mano sin encontrar fracturas, por lo que es tratado con vendaje, analgesia y reposo. Dos meses después el paciente consulta en otra institución médica por dolor persistente y limitación funcional; se le toman nuevas radiografías en las que se observa fractura de polo distal del escafoides, y se le practica tratamiento ortopédico cerrado con férula durante 4 semanas tras las que se le indica rehabilitación con terapia física que siguió durante 6 meses. Tratamiento realizado en otra institución médica. Un año después regresa a la consulta médica nuevamente por persistencia de dolor y limitación funcional, por lo que es remitido a nuestro Servicio de Cirugía de Mano, donde solicitamos tomografía axial computarizada (TAC) y resonancia nuclear magnética (RNM) con contraste de la mano y muñeca izquierdas, encontrando necrosis del polo distal del escafoides. Con este diagnóstico, decidimos realizar tratamiento quirúrgico mediante artrodesis escafo-trapecio-trapezoide con placa. Remitido por: Dr. Ricardo Galán Suárez. Servicio de Cirugía Plástica Hospital Militar Çentral Carrera 3 # 49-00 Bogotá D.C. Colombia Correo electrónico: ricgalan@gmail.com. Instructions: please typing these entity words according to sentence: Antonio, Pagudo Henao, 987345, Cundinamarca , Cra . 15a # 26, Bogotá, 15/06/1979, Colombia, 38 años, 03/05/2018, Ricardo Galán Suárez, Varón, 38 años, fuerza policial, Ricardo Galán Suárez, Hospital Militar Çentral, Carrera 3 # 49 - 00, Bogotá D.C., Colombia, ricgalan@gmail.com Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, PROFESION, FECHAS, HOSPITAL, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "B-PROFESION", "I-PROFESION", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "I-TERRITORIO", "B-PAIS", "O", "O", "O", "B-CORREO_ELECTRONICO", "O", "O" ]	Nombre: Antonio. Apellidos: Pagudo Henao. NHC: 987345. Domicilio: Cundinamarca, Cra. 15a #26. Localidad/ Provincia: Bogotá. Datos asistenciales. Fecha de nacimiento: 15/06/1979. País: Colombia. Edad: 38 años Sexo: H. Fecha de Ingreso: 03/05/2018. Médico:Ricardo Galán Suárez . Historia del paciente: Varón de 38 años que trabaja como miembro de la fuerza policial y que sufre un accidente de tránsito en calidad de motociclista con traumatismo contundente en mano izquierda en hiperextensión. Inicialmente es visto por el Servicio de Urgencias donde le toman radiografía de la mano sin encontrar fracturas, por lo que es tratado con vendaje, analgesia y reposo. Dos meses después el paciente consulta en otra institución médica por dolor persistente y limitación funcional; se le toman nuevas radiografías en las que se observa fractura de polo distal del escafoides, y se le practica tratamiento ortopédico cerrado con férula durante 4 semanas tras las que se le indica rehabilitación con terapia física que siguió durante 6 meses. Tratamiento realizado en otra institución médica. Un año después regresa a la consulta médica nuevamente por persistencia de dolor y limitación funcional, por lo que es remitido a nuestro Servicio de Cirugía de Mano, donde solicitamos tomografía axial computarizada (TAC) y resonancia nuclear magnética (RNM) con contraste de la mano y muñeca izquierdas, encontrando necrosis del polo distal del escafoides. Con este diagnóstico, decidimos realizar tratamiento quirúrgico mediante artrodesis escafo-trapecio-trapezoide con placa. Remitido por: Dr. Ricardo Galán Suárez. Servicio de Cirugía Plástica Hospital Militar Çentral Carrera 3 # 49-00 Bogotá D.C. Colombia Correo electrónico: ricgalan@gmail.com.	[ "Nombre", ":", " ", "Antonio", ".", "\n", "Apellidos", ":", "Pagudo", "Henao", ".", "\n", "NHC", ":", "987345", ".", "\n", "Domicilio", ":", "Cundinamarca", ",", "Cra", ".", "15a", "#", "26", ".", "\n", "Localidad/", "Provincia", ":", "Bogotá", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "15/06/1979", ".", "\n", "País", ":", "Colombia", ".", "\n", "Edad", ":", "38", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "03/05/2018", ".", "\n", "Médico", ":", "Ricardo", "Galán", "Suárez", ".", "\n", "Historia", "del", "paciente", ":", "Varón", "de", "38", "años", "que", "trabaja", "como", "miembro", "de", "la", "fuerza", "policial", "y", "que", "sufre", "un", "accidente", "de", "tránsito", "en", "calidad", "de", "motociclista", "con", "traumatismo", "contundente", "en", "mano", "izquierda", "en", "hiperextensión", ".", "Inicialmente", "es", "visto", "por", "el", "Servicio", "de", "Urgencias", "donde", "le", "toman", "radiografía", "de", "la", "mano", "sin", "encontrar", "fracturas", ",", "por", "lo", "que", "es", "tratado", "con", "vendaje", ",", "analgesia", "y", "reposo", ".", "\n", "Dos", "meses", "después", "el", "paciente", "consulta", "en", "otra", "institución", "médica", "por", "dolor", "persistente", "y", "limitación", "funcional", ";", "se", "le", "toman", "nuevas", "radiografías", "en", "las", "que", "se", "observa", "fractura", "de", "polo", "distal", "del", "escafoides", ",", "y", "se", "le", "practica", "tratamiento", "ortopédico", "cerrado", "con", "férula", "durante", "4", "semanas", "tras", "las", "que", "se", "le", "indica", "rehabilitación", "con", "terapia", "física", "que", "siguió", "durante", "6", "meses", ".", "Tratamiento", "realizado", "en", "otra", "institución", "médica", ".", "\n", "Un", "año", "después", "regresa", "a", "la", "consulta", "médica", "nuevamente", "por", "persistencia", "de", "dolor", "y", "limitación", "funcional", ",", "por", "lo", "que", "es", "remitido", "a", "nuestro", "Servicio", "de", "Cirugía", "de", "Mano", ",", "donde", "solicitamos", "tomografía", "axial", "computarizada", "(", "TAC", ")", "y", "resonancia", "nuclear", "magnética", "(", "RNM", ")", "con", "contraste", "de", "la", "mano", "y", "muñeca", "izquierdas", ",", "encontrando", "necrosis", "del", "polo", "distal", "del", "escafoides", ".", "Con", "este", "diagnóstico", ",", "decidimos", "realizar", "tratamiento", "quirúrgico", "mediante", "artrodesis", "escafo", "-", "trapecio", "-", "trapezoide", "con", "placa", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Ricardo", "Galán", "Suárez", ".", "Servicio", "de", "Cirugía", "Plástica", "Hospital", "Militar", "Çentral", "Carrera", "3", "#", "49", "-", "00", "Bogotá", "D.C.", "Colombia", "Correo", "electrónico", ":", "ricgalan@gmail.com", ".", "\n" ]	[ "CALLE", "HOSPITAL", "NOMBRE_PERSONAL_SANITARIO", "CORREO_ELECTRONICO", "PROFESION", "NOMBRE_SUJETO_ASISTENCIA", "TERRITORIO", "FECHAS", "PAIS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "SEXO_SUJETO_ASISTENCIA" ]
Antonio, Pagudo Henao, 987345, Cundinamarca , Cra . 15a # 26, Bogotá, 15/06/1979, Colombia, 38 años, 03/05/2018, Ricardo Galán Suárez, Varón, 38 años, fuerza policial, Ricardo Galán Suárez, Hospital Militar Çentral, Carrera 3 # 49 - 00, Bogotá D.C., Colombia, ricgalan@gmail.com	258_task2	Sentence: Nombre: Antonio. Apellidos: Pagudo Henao. NHC: 987345. Domicilio: Cundinamarca, Cra. 15a #26. Localidad/ Provincia: Bogotá. Datos asistenciales. Fecha de nacimiento: 15/06/1979. País: Colombia. Edad: 38 años Sexo: H. Fecha de Ingreso: 03/05/2018. Médico:Ricardo Galán Suárez . Historia del paciente: Varón de 38 años que trabaja como miembro de la fuerza policial y que sufre un accidente de tránsito en calidad de motociclista con traumatismo contundente en mano izquierda en hiperextensión. Inicialmente es visto por el Servicio de Urgencias donde le toman radiografía de la mano sin encontrar fracturas, por lo que es tratado con vendaje, analgesia y reposo. Dos meses después el paciente consulta en otra institución médica por dolor persistente y limitación funcional; se le toman nuevas radiografías en las que se observa fractura de polo distal del escafoides, y se le practica tratamiento ortopédico cerrado con férula durante 4 semanas tras las que se le indica rehabilitación con terapia física que siguió durante 6 meses. Tratamiento realizado en otra institución médica. Un año después regresa a la consulta médica nuevamente por persistencia de dolor y limitación funcional, por lo que es remitido a nuestro Servicio de Cirugía de Mano, donde solicitamos tomografía axial computarizada (TAC) y resonancia nuclear magnética (RNM) con contraste de la mano y muñeca izquierdas, encontrando necrosis del polo distal del escafoides. Con este diagnóstico, decidimos realizar tratamiento quirúrgico mediante artrodesis escafo-trapecio-trapezoide con placa. Remitido por: Dr. Ricardo Galán Suárez. Servicio de Cirugía Plástica Hospital Militar Çentral Carrera 3 # 49-00 Bogotá D.C. Colombia Correo electrónico: ricgalan@gmail.com. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "B-PROFESION", "I-PROFESION", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "I-TERRITORIO", "B-PAIS", "O", "O", "O", "B-CORREO_ELECTRONICO", "O", "O" ]	Nombre: Antonio. Apellidos: Pagudo Henao. NHC: 987345. Domicilio: Cundinamarca, Cra. 15a #26. Localidad/ Provincia: Bogotá. Datos asistenciales. Fecha de nacimiento: 15/06/1979. País: Colombia. Edad: 38 años Sexo: H. Fecha de Ingreso: 03/05/2018. Médico:Ricardo Galán Suárez . Historia del paciente: Varón de 38 años que trabaja como miembro de la fuerza policial y que sufre un accidente de tránsito en calidad de motociclista con traumatismo contundente en mano izquierda en hiperextensión. Inicialmente es visto por el Servicio de Urgencias donde le toman radiografía de la mano sin encontrar fracturas, por lo que es tratado con vendaje, analgesia y reposo. Dos meses después el paciente consulta en otra institución médica por dolor persistente y limitación funcional; se le toman nuevas radiografías en las que se observa fractura de polo distal del escafoides, y se le practica tratamiento ortopédico cerrado con férula durante 4 semanas tras las que se le indica rehabilitación con terapia física que siguió durante 6 meses. Tratamiento realizado en otra institución médica. Un año después regresa a la consulta médica nuevamente por persistencia de dolor y limitación funcional, por lo que es remitido a nuestro Servicio de Cirugía de Mano, donde solicitamos tomografía axial computarizada (TAC) y resonancia nuclear magnética (RNM) con contraste de la mano y muñeca izquierdas, encontrando necrosis del polo distal del escafoides. Con este diagnóstico, decidimos realizar tratamiento quirúrgico mediante artrodesis escafo-trapecio-trapezoide con placa. Remitido por: Dr. Ricardo Galán Suárez. Servicio de Cirugía Plástica Hospital Militar Çentral Carrera 3 # 49-00 Bogotá D.C. Colombia Correo electrónico: ricgalan@gmail.com.	[ "Nombre", ":", " ", "Antonio", ".", "\n", "Apellidos", ":", "Pagudo", "Henao", ".", "\n", "NHC", ":", "987345", ".", "\n", "Domicilio", ":", "Cundinamarca", ",", "Cra", ".", "15a", "#", "26", ".", "\n", "Localidad/", "Provincia", ":", "Bogotá", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "15/06/1979", ".", "\n", "País", ":", "Colombia", ".", "\n", "Edad", ":", "38", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "03/05/2018", ".", "\n", "Médico", ":", "Ricardo", "Galán", "Suárez", ".", "\n", "Historia", "del", "paciente", ":", "Varón", "de", "38", "años", "que", "trabaja", "como", "miembro", "de", "la", "fuerza", "policial", "y", "que", "sufre", "un", "accidente", "de", "tránsito", "en", "calidad", "de", "motociclista", "con", "traumatismo", "contundente", "en", "mano", "izquierda", "en", "hiperextensión", ".", "Inicialmente", "es", "visto", "por", "el", "Servicio", "de", "Urgencias", "donde", "le", "toman", "radiografía", "de", "la", "mano", "sin", "encontrar", "fracturas", ",", "por", "lo", "que", "es", "tratado", "con", "vendaje", ",", "analgesia", "y", "reposo", ".", "\n", "Dos", "meses", "después", "el", "paciente", "consulta", "en", "otra", "institución", "médica", "por", "dolor", "persistente", "y", "limitación", "funcional", ";", "se", "le", "toman", "nuevas", "radiografías", "en", "las", "que", "se", "observa", "fractura", "de", "polo", "distal", "del", "escafoides", ",", "y", "se", "le", "practica", "tratamiento", "ortopédico", "cerrado", "con", "férula", "durante", "4", "semanas", "tras", "las", "que", "se", "le", "indica", "rehabilitación", "con", "terapia", "física", "que", "siguió", "durante", "6", "meses", ".", "Tratamiento", "realizado", "en", "otra", "institución", "médica", ".", "\n", "Un", "año", "después", "regresa", "a", "la", "consulta", "médica", "nuevamente", "por", "persistencia", "de", "dolor", "y", "limitación", "funcional", ",", "por", "lo", "que", "es", "remitido", "a", "nuestro", "Servicio", "de", "Cirugía", "de", "Mano", ",", "donde", "solicitamos", "tomografía", "axial", "computarizada", "(", "TAC", ")", "y", "resonancia", "nuclear", "magnética", "(", "RNM", ")", "con", "contraste", "de", "la", "mano", "y", "muñeca", "izquierdas", ",", "encontrando", "necrosis", "del", "polo", "distal", "del", "escafoides", ".", "Con", "este", "diagnóstico", ",", "decidimos", "realizar", "tratamiento", "quirúrgico", "mediante", "artrodesis", "escafo", "-", "trapecio", "-", "trapezoide", "con", "placa", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Ricardo", "Galán", "Suárez", ".", "Servicio", "de", "Cirugía", "Plástica", "Hospital", "Militar", "Çentral", "Carrera", "3", "#", "49", "-", "00", "Bogotá", "D.C.", "Colombia", "Correo", "electrónico", ":", "ricgalan@gmail.com", ".", "\n" ]	[ "CALLE", "HOSPITAL", "NOMBRE_PERSONAL_SANITARIO", "CORREO_ELECTRONICO", "PROFESION", "NOMBRE_SUJETO_ASISTENCIA", "TERRITORIO", "FECHAS", "PAIS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "SEXO_SUJETO_ASISTENCIA" ]
Effects is a Outcome_Other, telmisartan is a Intervention_Pharmacological, enalapril is a Intervention_Pharmacological, mild to moderate chronic kidney disease is a Participant_Condition, chronic kidney disease ( CKD ) . is a Participant_Condition, urinary liver - type fatty acid - binding protein ( L - FABP ) is a Outcome_Physical, endothelin ( ET ) -1 levels is a Outcome_Physical, mild CKD is a Participant_Condition, Thirty CKD patients is a Participant_Condition, mild to moderate renal insufficiency is a Participant_Condition, 20 men and 10 women is a Participant_Sex, 37 years ; estimated glomerular filtration rate ( eGFR ) > 60 mL min ( -1 ) and blood pressure > 130/85 mmHg ) were included in the study . is a Participant_Age, telmisartan at 80 mg day ( -1 ) is a Intervention_Pharmacological, enalapril at 10 mg day ( -1 ) is a Intervention_Pharmacological, serum creatinine , eGFR is a Outcome_Physical, urinary protein is a Outcome_Physical, ET-1 is a Outcome_Physical, blood pressure reduction rate is a Outcome_Physical, Urinary protein is a Outcome_Physical, ET-1 levels is a Outcome_Physical, reduction rates is a Outcome_Physical, urinary markers is a Outcome_Physical	46354_task0	Sentence: Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease . BACKGROUND Blocking the renin-angiotensin system ( RAS ) with angiotensin receptor blockers or angiotensin-converting enzyme inhibitors protects against renal injury in patients with chronic kidney disease ( CKD ) . The aim of this study was to compare the chronic effects of telmisartan and enalapril on proteinuria , urinary liver-type fatty acid-binding protein ( L-FABP ) and endothelin ( ET ) -1 levels in patients with mild CKD . MATERIALS AND METHODS Thirty CKD patients with mild to moderate renal insufficiency ( 20 men and 10 women ; mean age , 37 years ; estimated glomerular filtration rate ( eGFR ) > 60 mL min ( -1 ) and blood pressure > 130/85 mmHg ) were included in the study . Patients were randomly assigned to receive telmisartan at 80 mg day ( -1 ) ( n = 15 ) or enalapril at 10 mg day ( -1 ) ( n = 15 ) . We measured blood pressure , serum creatinine , eGFR , urinary protein , L-FABP and ET-1 before the start of treatment and 6 and 12 months after the start of treatment . RESULTS The blood pressure reduction rate was similar between the two groups . Urinary protein , L-FABP and ET-1 levels were significantly reduced in both groups 6 and 12 months ( P < 0.001 ) after treatment , but the reduction rates were more pronounced in patients receiving telmisartan than in those receiving enalapril ( P < 0.001 ) . Estimated glomerular filtration rate was increased similarly in both groups at 12 months . CONCLUSIONS The study results suggest that telmisartan results in a greater reduction of urinary markers than does enalapril and that this effect occurs by a mechanism independent of blood pressure reduction . It would be needed to investigate whether the differences may be distinct or not the same when other dosages are used . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Sex, Participant_Condition, Outcome_Physical, Participant_Age, Outcome_Other	[ "B-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Sex", "I-Participant_Sex", "I-Participant_Sex", "I-Participant_Sex", "I-Participant_Sex", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease . BACKGROUND Blocking the renin-angiotensin system ( RAS ) with angiotensin receptor blockers or angiotensin-converting enzyme inhibitors protects against renal injury in patients with chronic kidney disease ( CKD ) . The aim of this study was to compare the chronic effects of telmisartan and enalapril on proteinuria , urinary liver-type fatty acid-binding protein ( L-FABP ) and endothelin ( ET ) -1 levels in patients with mild CKD . MATERIALS AND METHODS Thirty CKD patients with mild to moderate renal insufficiency ( 20 men and 10 women ; mean age , 37 years ; estimated glomerular filtration rate ( eGFR ) > 60 mL min ( -1 ) and blood pressure > 130/85 mmHg ) were included in the study . Patients were randomly assigned to receive telmisartan at 80 mg day ( -1 ) ( n = 15 ) or enalapril at 10 mg day ( -1 ) ( n = 15 ) . We measured blood pressure , serum creatinine , eGFR , urinary protein , L-FABP and ET-1 before the start of treatment and 6 and 12 months after the start of treatment . RESULTS The blood pressure reduction rate was similar between the two groups . Urinary protein , L-FABP and ET-1 levels were significantly reduced in both groups 6 and 12 months ( P < 0.001 ) after treatment , but the reduction rates were more pronounced in patients receiving telmisartan than in those receiving enalapril ( P < 0.001 ) . Estimated glomerular filtration rate was increased similarly in both groups at 12 months . CONCLUSIONS The study results suggest that telmisartan results in a greater reduction of urinary markers than does enalapril and that this effect occurs by a mechanism independent of blood pressure reduction . It would be needed to investigate whether the differences may be distinct or not the same when other dosages are used .	[ "Effects", "of", "telmisartan", "and", "enalapril", "on", "renoprotection", "in", "patients", "with", "mild", "to", "moderate", "chronic", "kidney", "disease", ".", "BACKGROUND", "Blocking", "the", "renin", "-", "angiotensin", "system", "(", "RAS", ")", "with", "angiotensin", "receptor", "blockers", "or", "angiotensin", "-", "converting", "enzyme", "inhibitors", "protects", "against", "renal", "injury", "in", "patients", "with", "chronic", "kidney", "disease", "(", "CKD", ")", ".", "The", "aim", "of", "this", "study", "was", "to", "compare", "the", "chronic", "effects", "of", "telmisartan", "and", "enalapril", "on", "proteinuria", ",", "urinary", "liver", "-", "type", "fatty", "acid", "-", "binding", "protein", "(", "L", "-", "FABP", ")", "and", "endothelin", "(", "ET", ")", "-1", "levels", "in", "patients", "with", "mild", "CKD", ".", "MATERIALS", "AND", "METHODS", "Thirty", "CKD", "patients", "with", "mild", "to", "moderate", "renal", "insufficiency", "(", "20", "men", "and", "10", "women", ";", "mean", "age", ",", "37", "years", ";", "estimated", "glomerular", "filtration", "rate", "(", "eGFR", ")", ">", "60", "mL", "min", "(", "-1", ")", "and", "blood", "pressure", ">", "130/85", "mmHg", ")", "were", "included", "in", "the", "study", ".", "Patients", "were", "randomly", "assigned", "to", "receive", "telmisartan", "at", "80", "mg", "day", "(", "-1", ")", "(", "n", "=", "15", ")", "or", "enalapril", "at", "10", "mg", "day", "(", "-1", ")", "(", "n", "=", "15", ")", ".", "We", "measured", "blood", "pressure", ",", "serum", "creatinine", ",", "eGFR", ",", "urinary", "protein", ",", "L", "-", "FABP", "and", "ET-1", "before", "the", "start", "of", "treatment", "and", "6", "and", "12", "months", "after", "the", "start", "of", "treatment", ".", "RESULTS", "The", "blood", "pressure", "reduction", "rate", "was", "similar", "between", "the", "two", "groups", ".", "Urinary", "protein", ",", "L", "-", "FABP", "and", "ET-1", "levels", "were", "significantly", "reduced", "in", "both", "groups", "6", "and", "12", "months", "(", "P", "<", "0.001", ")", "after", "treatment", ",", "but", "the", "reduction", "rates", "were", "more", "pronounced", "in", "patients", "receiving", "telmisartan", "than", "in", "those", "receiving", "enalapril", "(", "P", "<", "0.001", ")", ".", "Estimated", "glomerular", "filtration", "rate", "was", "increased", "similarly", "in", "both", "groups", "at", "12", "months", ".", "CONCLUSIONS", "The", "study", "results", "suggest", "that", "telmisartan", "results", "in", "a", "greater", "reduction", "of", "urinary", "markers", "than", "does", "enalapril", "and", "that", "this", "effect", "occurs", "by", "a", "mechanism", "independent", "of", "blood", "pressure", "reduction", ".", "It", "would", "be", "needed", "to", "investigate", "whether", "the", "differences", "may", "be", "distinct", "or", "not", "the", "same", "when", "other", "dosages", "are", "used", "." ]	[ "Participant_Age", "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Participant_Sex", "Outcome_Other" ]
Effects is a Outcome_Other, telmisartan is a Intervention_Pharmacological, enalapril is a Intervention_Pharmacological, mild to moderate chronic kidney disease is a Participant_Condition, chronic kidney disease ( CKD ) . is a Participant_Condition, urinary liver - type fatty acid - binding protein ( L - FABP ) is a Outcome_Physical, endothelin ( ET ) -1 levels is a Outcome_Physical, mild CKD is a Participant_Condition, Thirty CKD patients is a Participant_Condition, mild to moderate renal insufficiency is a Participant_Condition, 20 men and 10 women is a Participant_Sex, 37 years ; estimated glomerular filtration rate ( eGFR ) > 60 mL min ( -1 ) and blood pressure > 130/85 mmHg ) were included in the study . is a Participant_Age, telmisartan at 80 mg day ( -1 ) is a Intervention_Pharmacological, enalapril at 10 mg day ( -1 ) is a Intervention_Pharmacological, serum creatinine , eGFR is a Outcome_Physical, urinary protein is a Outcome_Physical, ET-1 is a Outcome_Physical, blood pressure reduction rate is a Outcome_Physical, Urinary protein is a Outcome_Physical, ET-1 levels is a Outcome_Physical, reduction rates is a Outcome_Physical, urinary markers is a Outcome_Physical	46354_task1	Sentence: Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease . BACKGROUND Blocking the renin-angiotensin system ( RAS ) with angiotensin receptor blockers or angiotensin-converting enzyme inhibitors protects against renal injury in patients with chronic kidney disease ( CKD ) . The aim of this study was to compare the chronic effects of telmisartan and enalapril on proteinuria , urinary liver-type fatty acid-binding protein ( L-FABP ) and endothelin ( ET ) -1 levels in patients with mild CKD . MATERIALS AND METHODS Thirty CKD patients with mild to moderate renal insufficiency ( 20 men and 10 women ; mean age , 37 years ; estimated glomerular filtration rate ( eGFR ) > 60 mL min ( -1 ) and blood pressure > 130/85 mmHg ) were included in the study . Patients were randomly assigned to receive telmisartan at 80 mg day ( -1 ) ( n = 15 ) or enalapril at 10 mg day ( -1 ) ( n = 15 ) . We measured blood pressure , serum creatinine , eGFR , urinary protein , L-FABP and ET-1 before the start of treatment and 6 and 12 months after the start of treatment . RESULTS The blood pressure reduction rate was similar between the two groups . Urinary protein , L-FABP and ET-1 levels were significantly reduced in both groups 6 and 12 months ( P < 0.001 ) after treatment , but the reduction rates were more pronounced in patients receiving telmisartan than in those receiving enalapril ( P < 0.001 ) . Estimated glomerular filtration rate was increased similarly in both groups at 12 months . CONCLUSIONS The study results suggest that telmisartan results in a greater reduction of urinary markers than does enalapril and that this effect occurs by a mechanism independent of blood pressure reduction . It would be needed to investigate whether the differences may be distinct or not the same when other dosages are used . Instructions: please typing these entity words according to sentence: Effects, telmisartan, enalapril, mild to moderate chronic kidney disease, chronic kidney disease ( CKD ) ., urinary liver - type fatty acid - binding protein ( L - FABP ), endothelin ( ET ) -1 levels, mild CKD, Thirty CKD patients, mild to moderate renal insufficiency, 20 men and 10 women, 37 years ; estimated glomerular filtration rate ( eGFR ) > 60 mL min ( -1 ) and blood pressure > 130/85 mmHg ) were included in the study ., telmisartan at 80 mg day ( -1 ), enalapril at 10 mg day ( -1 ), serum creatinine , eGFR, urinary protein, ET-1, blood pressure reduction rate, Urinary protein, ET-1 levels, reduction rates, urinary markers Options: Intervention_Pharmacological, Participant_Sex, Participant_Condition, Outcome_Physical, Participant_Age, Outcome_Other	[ "B-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Sex", "I-Participant_Sex", "I-Participant_Sex", "I-Participant_Sex", "I-Participant_Sex", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease . BACKGROUND Blocking the renin-angiotensin system ( RAS ) with angiotensin receptor blockers or angiotensin-converting enzyme inhibitors protects against renal injury in patients with chronic kidney disease ( CKD ) . The aim of this study was to compare the chronic effects of telmisartan and enalapril on proteinuria , urinary liver-type fatty acid-binding protein ( L-FABP ) and endothelin ( ET ) -1 levels in patients with mild CKD . MATERIALS AND METHODS Thirty CKD patients with mild to moderate renal insufficiency ( 20 men and 10 women ; mean age , 37 years ; estimated glomerular filtration rate ( eGFR ) > 60 mL min ( -1 ) and blood pressure > 130/85 mmHg ) were included in the study . Patients were randomly assigned to receive telmisartan at 80 mg day ( -1 ) ( n = 15 ) or enalapril at 10 mg day ( -1 ) ( n = 15 ) . We measured blood pressure , serum creatinine , eGFR , urinary protein , L-FABP and ET-1 before the start of treatment and 6 and 12 months after the start of treatment . RESULTS The blood pressure reduction rate was similar between the two groups . Urinary protein , L-FABP and ET-1 levels were significantly reduced in both groups 6 and 12 months ( P < 0.001 ) after treatment , but the reduction rates were more pronounced in patients receiving telmisartan than in those receiving enalapril ( P < 0.001 ) . Estimated glomerular filtration rate was increased similarly in both groups at 12 months . CONCLUSIONS The study results suggest that telmisartan results in a greater reduction of urinary markers than does enalapril and that this effect occurs by a mechanism independent of blood pressure reduction . It would be needed to investigate whether the differences may be distinct or not the same when other dosages are used .	[ "Effects", "of", "telmisartan", "and", "enalapril", "on", "renoprotection", "in", "patients", "with", "mild", "to", "moderate", "chronic", "kidney", "disease", ".", "BACKGROUND", "Blocking", "the", "renin", "-", "angiotensin", "system", "(", "RAS", ")", "with", "angiotensin", "receptor", "blockers", "or", "angiotensin", "-", "converting", "enzyme", "inhibitors", "protects", "against", "renal", "injury", "in", "patients", "with", "chronic", "kidney", "disease", "(", "CKD", ")", ".", "The", "aim", "of", "this", "study", "was", "to", "compare", "the", "chronic", "effects", "of", "telmisartan", "and", "enalapril", "on", "proteinuria", ",", "urinary", "liver", "-", "type", "fatty", "acid", "-", "binding", "protein", "(", "L", "-", "FABP", ")", "and", "endothelin", "(", "ET", ")", "-1", "levels", "in", "patients", "with", "mild", "CKD", ".", "MATERIALS", "AND", "METHODS", "Thirty", "CKD", "patients", "with", "mild", "to", "moderate", "renal", "insufficiency", "(", "20", "men", "and", "10", "women", ";", "mean", "age", ",", "37", "years", ";", "estimated", "glomerular", "filtration", "rate", "(", "eGFR", ")", ">", "60", "mL", "min", "(", "-1", ")", "and", "blood", "pressure", ">", "130/85", "mmHg", ")", "were", "included", "in", "the", "study", ".", "Patients", "were", "randomly", "assigned", "to", "receive", "telmisartan", "at", "80", "mg", "day", "(", "-1", ")", "(", "n", "=", "15", ")", "or", "enalapril", "at", "10", "mg", "day", "(", "-1", ")", "(", "n", "=", "15", ")", ".", "We", "measured", "blood", "pressure", ",", "serum", "creatinine", ",", "eGFR", ",", "urinary", "protein", ",", "L", "-", "FABP", "and", "ET-1", "before", "the", "start", "of", "treatment", "and", "6", "and", "12", "months", "after", "the", "start", "of", "treatment", ".", "RESULTS", "The", "blood", "pressure", "reduction", "rate", "was", "similar", "between", "the", "two", "groups", ".", "Urinary", "protein", ",", "L", "-", "FABP", "and", "ET-1", "levels", "were", "significantly", "reduced", "in", "both", "groups", "6", "and", "12", "months", "(", "P", "<", "0.001", ")", "after", "treatment", ",", "but", "the", "reduction", "rates", "were", "more", "pronounced", "in", "patients", "receiving", "telmisartan", "than", "in", "those", "receiving", "enalapril", "(", "P", "<", "0.001", ")", ".", "Estimated", "glomerular", "filtration", "rate", "was", "increased", "similarly", "in", "both", "groups", "at", "12", "months", ".", "CONCLUSIONS", "The", "study", "results", "suggest", "that", "telmisartan", "results", "in", "a", "greater", "reduction", "of", "urinary", "markers", "than", "does", "enalapril", "and", "that", "this", "effect", "occurs", "by", "a", "mechanism", "independent", "of", "blood", "pressure", "reduction", ".", "It", "would", "be", "needed", "to", "investigate", "whether", "the", "differences", "may", "be", "distinct", "or", "not", "the", "same", "when", "other", "dosages", "are", "used", "." ]	[ "Participant_Age", "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Participant_Sex", "Outcome_Other" ]
Effects, telmisartan, enalapril, mild to moderate chronic kidney disease, chronic kidney disease ( CKD ) ., urinary liver - type fatty acid - binding protein ( L - FABP ), endothelin ( ET ) -1 levels, mild CKD, Thirty CKD patients, mild to moderate renal insufficiency, 20 men and 10 women, 37 years ; estimated glomerular filtration rate ( eGFR ) > 60 mL min ( -1 ) and blood pressure > 130/85 mmHg ) were included in the study ., telmisartan at 80 mg day ( -1 ), enalapril at 10 mg day ( -1 ), serum creatinine , eGFR, urinary protein, ET-1, blood pressure reduction rate, Urinary protein, ET-1 levels, reduction rates, urinary markers	46354_task2	Sentence: Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease . BACKGROUND Blocking the renin-angiotensin system ( RAS ) with angiotensin receptor blockers or angiotensin-converting enzyme inhibitors protects against renal injury in patients with chronic kidney disease ( CKD ) . The aim of this study was to compare the chronic effects of telmisartan and enalapril on proteinuria , urinary liver-type fatty acid-binding protein ( L-FABP ) and endothelin ( ET ) -1 levels in patients with mild CKD . MATERIALS AND METHODS Thirty CKD patients with mild to moderate renal insufficiency ( 20 men and 10 women ; mean age , 37 years ; estimated glomerular filtration rate ( eGFR ) > 60 mL min ( -1 ) and blood pressure > 130/85 mmHg ) were included in the study . Patients were randomly assigned to receive telmisartan at 80 mg day ( -1 ) ( n = 15 ) or enalapril at 10 mg day ( -1 ) ( n = 15 ) . We measured blood pressure , serum creatinine , eGFR , urinary protein , L-FABP and ET-1 before the start of treatment and 6 and 12 months after the start of treatment . RESULTS The blood pressure reduction rate was similar between the two groups . Urinary protein , L-FABP and ET-1 levels were significantly reduced in both groups 6 and 12 months ( P < 0.001 ) after treatment , but the reduction rates were more pronounced in patients receiving telmisartan than in those receiving enalapril ( P < 0.001 ) . Estimated glomerular filtration rate was increased similarly in both groups at 12 months . CONCLUSIONS The study results suggest that telmisartan results in a greater reduction of urinary markers than does enalapril and that this effect occurs by a mechanism independent of blood pressure reduction . It would be needed to investigate whether the differences may be distinct or not the same when other dosages are used . Instructions: please extract entity words from the input sentence	[ "B-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Sex", "I-Participant_Sex", "I-Participant_Sex", "I-Participant_Sex", "I-Participant_Sex", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease . BACKGROUND Blocking the renin-angiotensin system ( RAS ) with angiotensin receptor blockers or angiotensin-converting enzyme inhibitors protects against renal injury in patients with chronic kidney disease ( CKD ) . The aim of this study was to compare the chronic effects of telmisartan and enalapril on proteinuria , urinary liver-type fatty acid-binding protein ( L-FABP ) and endothelin ( ET ) -1 levels in patients with mild CKD . MATERIALS AND METHODS Thirty CKD patients with mild to moderate renal insufficiency ( 20 men and 10 women ; mean age , 37 years ; estimated glomerular filtration rate ( eGFR ) > 60 mL min ( -1 ) and blood pressure > 130/85 mmHg ) were included in the study . Patients were randomly assigned to receive telmisartan at 80 mg day ( -1 ) ( n = 15 ) or enalapril at 10 mg day ( -1 ) ( n = 15 ) . We measured blood pressure , serum creatinine , eGFR , urinary protein , L-FABP and ET-1 before the start of treatment and 6 and 12 months after the start of treatment . RESULTS The blood pressure reduction rate was similar between the two groups . Urinary protein , L-FABP and ET-1 levels were significantly reduced in both groups 6 and 12 months ( P < 0.001 ) after treatment , but the reduction rates were more pronounced in patients receiving telmisartan than in those receiving enalapril ( P < 0.001 ) . Estimated glomerular filtration rate was increased similarly in both groups at 12 months . CONCLUSIONS The study results suggest that telmisartan results in a greater reduction of urinary markers than does enalapril and that this effect occurs by a mechanism independent of blood pressure reduction . It would be needed to investigate whether the differences may be distinct or not the same when other dosages are used .	[ "Effects", "of", "telmisartan", "and", "enalapril", "on", "renoprotection", "in", "patients", "with", "mild", "to", "moderate", "chronic", "kidney", "disease", ".", "BACKGROUND", "Blocking", "the", "renin", "-", "angiotensin", "system", "(", "RAS", ")", "with", "angiotensin", "receptor", "blockers", "or", "angiotensin", "-", "converting", "enzyme", "inhibitors", "protects", "against", "renal", "injury", "in", "patients", "with", "chronic", "kidney", "disease", "(", "CKD", ")", ".", "The", "aim", "of", "this", "study", "was", "to", "compare", "the", "chronic", "effects", "of", "telmisartan", "and", "enalapril", "on", "proteinuria", ",", "urinary", "liver", "-", "type", "fatty", "acid", "-", "binding", "protein", "(", "L", "-", "FABP", ")", "and", "endothelin", "(", "ET", ")", "-1", "levels", "in", "patients", "with", "mild", "CKD", ".", "MATERIALS", "AND", "METHODS", "Thirty", "CKD", "patients", "with", "mild", "to", "moderate", "renal", "insufficiency", "(", "20", "men", "and", "10", "women", ";", "mean", "age", ",", "37", "years", ";", "estimated", "glomerular", "filtration", "rate", "(", "eGFR", ")", ">", "60", "mL", "min", "(", "-1", ")", "and", "blood", "pressure", ">", "130/85", "mmHg", ")", "were", "included", "in", "the", "study", ".", "Patients", "were", "randomly", "assigned", "to", "receive", "telmisartan", "at", "80", "mg", "day", "(", "-1", ")", "(", "n", "=", "15", ")", "or", "enalapril", "at", "10", "mg", "day", "(", "-1", ")", "(", "n", "=", "15", ")", ".", "We", "measured", "blood", "pressure", ",", "serum", "creatinine", ",", "eGFR", ",", "urinary", "protein", ",", "L", "-", "FABP", "and", "ET-1", "before", "the", "start", "of", "treatment", "and", "6", "and", "12", "months", "after", "the", "start", "of", "treatment", ".", "RESULTS", "The", "blood", "pressure", "reduction", "rate", "was", "similar", "between", "the", "two", "groups", ".", "Urinary", "protein", ",", "L", "-", "FABP", "and", "ET-1", "levels", "were", "significantly", "reduced", "in", "both", "groups", "6", "and", "12", "months", "(", "P", "<", "0.001", ")", "after", "treatment", ",", "but", "the", "reduction", "rates", "were", "more", "pronounced", "in", "patients", "receiving", "telmisartan", "than", "in", "those", "receiving", "enalapril", "(", "P", "<", "0.001", ")", ".", "Estimated", "glomerular", "filtration", "rate", "was", "increased", "similarly", "in", "both", "groups", "at", "12", "months", ".", "CONCLUSIONS", "The", "study", "results", "suggest", "that", "telmisartan", "results", "in", "a", "greater", "reduction", "of", "urinary", "markers", "than", "does", "enalapril", "and", "that", "this", "effect", "occurs", "by", "a", "mechanism", "independent", "of", "blood", "pressure", "reduction", ".", "It", "would", "be", "needed", "to", "investigate", "whether", "the", "differences", "may", "be", "distinct", "or", "not", "the", "same", "when", "other", "dosages", "are", "used", "." ]	[ "Participant_Age", "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Participant_Sex", "Outcome_Other" ]
Behandlung is an umlsterm, Histologie is an umlsterm, Rumpfhautbasalioms is an umlsterm, Tumor is an umlsterm, photodynamischen Therapie is an umlsterm, Gewebe is an umlsterm, Licht is an umlsterm, Tumors is an umlsterm, Diagnostik is an umlsterm, Therapieformen is an umlsterm, Tumor is an umlsterm, Effizienz is an umlsterm, gezieltem is an umlsterm	DerHautarzt.60470438.ger.abstr_task0	Sentence: Es wird die Behandlung eines grossflaechigen Basalioms ( ca. 10x6 cm ) an der rechten Mamma einer 48jaehrigen Patientin dargestellt . Aufgrund der Histologie eines oberflaechlichen Rumpfhautbasalioms entschlossen wir uns , den Tumor mit der photodynamischen Therapie ( PDT ) zu behandeln . Hierzu wurden -Aminolaevulinsaeure ( -ALA , 20% ) topisch aufgetragen und das Gewebe mit rotem Licht ( 570-750 nm ; 180 J/cm2) bestrahlt . Die PDT wurde zweimal wiederholt . Hierdurch konnte klinisch eine nahezu vollstaendige Remission des Tumors erzielt werden . In der photodynamischen Diagnostik ( PDD ) zeigten sich aber noch deutlich einige persistierende , z.T. die Mamille infiltrierende Basaliominseln . Diese wurden durch Exzision entfernt und anschliessend wurde der Defekt mittels einer Mamillenplastik verschlossen . Durch die Kombination der beiden Therapieformen konnte der grossflaechige Tumor mit einem ausgezeichneten kosmetischen Ergebnis behandelt werden . Die Falldarstellung soll zum einen die Grenzen der topischen PDT , zum anderen die Effizienz der PDD bei gezieltem Einsatz darstellen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Es wird die Behandlung eines grossflaechigen Basalioms ( ca. 10x6 cm ) an der rechten Mamma einer 48jaehrigen Patientin dargestellt . Aufgrund der Histologie eines oberflaechlichen Rumpfhautbasalioms entschlossen wir uns , den Tumor mit der photodynamischen Therapie ( PDT ) zu behandeln . Hierzu wurden -Aminolaevulinsaeure ( -ALA , 20% ) topisch aufgetragen und das Gewebe mit rotem Licht ( 570-750 nm ; 180 J/cm2) bestrahlt . Die PDT wurde zweimal wiederholt . Hierdurch konnte klinisch eine nahezu vollstaendige Remission des Tumors erzielt werden . In der photodynamischen Diagnostik ( PDD ) zeigten sich aber noch deutlich einige persistierende , z.T. die Mamille infiltrierende Basaliominseln . Diese wurden durch Exzision entfernt und anschliessend wurde der Defekt mittels einer Mamillenplastik verschlossen . Durch die Kombination der beiden Therapieformen konnte der grossflaechige Tumor mit einem ausgezeichneten kosmetischen Ergebnis behandelt werden . Die Falldarstellung soll zum einen die Grenzen der topischen PDT , zum anderen die Effizienz der PDD bei gezieltem Einsatz darstellen .	[ "Es", "wird", "die", "Behandlung", "eines", "grossflaechigen", "Basalioms", "(", "ca", ".", "10x6", "cm", ")", "an", "der", "rechten", "Mamma", "einer", "48jaehrigen", "Patientin", "dargestellt", ".", "Aufgrund", "der", "Histologie", "eines", "oberflaechlichen", "Rumpfhautbasalioms", "entschlossen", "wir", "uns", ",", "den", "Tumor", "mit", "der", "photodynamischen", "Therapie", "(", "PDT", ")", "zu", "behandeln", ".", "Hierzu", "wurden", "-Aminolaevulinsaeure", "(", "-ALA", ",", "20", "%", ")", "topisch", "aufgetragen", "und", "das", "Gewebe", "mit", "rotem", "Licht", "(", "570", "-", "750", "nm", ";", "180", "J", "/", "cm2", ")", "bestrahlt", ".", "Die", "PDT", "wurde", "zweimal", "wiederholt", ".", "Hierdurch", "konnte", "klinisch", "eine", "nahezu", "vollstaendige", "Remission", "des", "Tumors", "erzielt", "werden", ".", "In", "der", "photodynamischen", "Diagnostik", "(", "PDD", ")", "zeigten", "sich", "aber", "noch", "deutlich", "einige", "persistierende", ",", "z.", "T.", "die", "Mamille", "infiltrierende", "Basaliominseln", ".", "Diese", "wurden", "durch", "Exzision", "entfernt", "und", "anschliessend", "wurde", "der", "Defekt", "mittels", "einer", "Mamillenplastik", "verschlossen", ".", "Durch", "die", "Kombination", "der", "beiden", "Therapieformen", "konnte", "der", "grossflaechige", "Tumor", "mit", "einem", "ausgezeichneten", "kosmetischen", "Ergebnis", "behandelt", "werden", ".", "Die", "Falldarstellung", "soll", "zum", "einen", "die", "Grenzen", "der", "topischen", "PDT", ",", "zum", "anderen", "die", "Effizienz", "der", "PDD", "bei", "gezieltem", "Einsatz", "darstellen", "." ]	[ "umlsterm" ]
Behandlung is an umlsterm, Histologie is an umlsterm, Rumpfhautbasalioms is an umlsterm, Tumor is an umlsterm, photodynamischen Therapie is an umlsterm, Gewebe is an umlsterm, Licht is an umlsterm, Tumors is an umlsterm, Diagnostik is an umlsterm, Therapieformen is an umlsterm, Tumor is an umlsterm, Effizienz is an umlsterm, gezieltem is an umlsterm	DerHautarzt.60470438.ger.abstr_task1	Sentence: Es wird die Behandlung eines grossflaechigen Basalioms ( ca. 10x6 cm ) an der rechten Mamma einer 48jaehrigen Patientin dargestellt . Aufgrund der Histologie eines oberflaechlichen Rumpfhautbasalioms entschlossen wir uns , den Tumor mit der photodynamischen Therapie ( PDT ) zu behandeln . Hierzu wurden -Aminolaevulinsaeure ( -ALA , 20% ) topisch aufgetragen und das Gewebe mit rotem Licht ( 570-750 nm ; 180 J/cm2) bestrahlt . Die PDT wurde zweimal wiederholt . Hierdurch konnte klinisch eine nahezu vollstaendige Remission des Tumors erzielt werden . In der photodynamischen Diagnostik ( PDD ) zeigten sich aber noch deutlich einige persistierende , z.T. die Mamille infiltrierende Basaliominseln . Diese wurden durch Exzision entfernt und anschliessend wurde der Defekt mittels einer Mamillenplastik verschlossen . Durch die Kombination der beiden Therapieformen konnte der grossflaechige Tumor mit einem ausgezeichneten kosmetischen Ergebnis behandelt werden . Die Falldarstellung soll zum einen die Grenzen der topischen PDT , zum anderen die Effizienz der PDD bei gezieltem Einsatz darstellen . Instructions: please typing these entity words according to sentence: Behandlung, Histologie, Rumpfhautbasalioms, Tumor, photodynamischen Therapie, Gewebe, Licht, Tumors, Diagnostik, Therapieformen, Tumor, Effizienz, gezieltem Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Es wird die Behandlung eines grossflaechigen Basalioms ( ca. 10x6 cm ) an der rechten Mamma einer 48jaehrigen Patientin dargestellt . Aufgrund der Histologie eines oberflaechlichen Rumpfhautbasalioms entschlossen wir uns , den Tumor mit der photodynamischen Therapie ( PDT ) zu behandeln . Hierzu wurden -Aminolaevulinsaeure ( -ALA , 20% ) topisch aufgetragen und das Gewebe mit rotem Licht ( 570-750 nm ; 180 J/cm2) bestrahlt . Die PDT wurde zweimal wiederholt . Hierdurch konnte klinisch eine nahezu vollstaendige Remission des Tumors erzielt werden . In der photodynamischen Diagnostik ( PDD ) zeigten sich aber noch deutlich einige persistierende , z.T. die Mamille infiltrierende Basaliominseln . Diese wurden durch Exzision entfernt und anschliessend wurde der Defekt mittels einer Mamillenplastik verschlossen . Durch die Kombination der beiden Therapieformen konnte der grossflaechige Tumor mit einem ausgezeichneten kosmetischen Ergebnis behandelt werden . Die Falldarstellung soll zum einen die Grenzen der topischen PDT , zum anderen die Effizienz der PDD bei gezieltem Einsatz darstellen .	[ "Es", "wird", "die", "Behandlung", "eines", "grossflaechigen", "Basalioms", "(", "ca", ".", "10x6", "cm", ")", "an", "der", "rechten", "Mamma", "einer", "48jaehrigen", "Patientin", "dargestellt", ".", "Aufgrund", "der", "Histologie", "eines", "oberflaechlichen", "Rumpfhautbasalioms", "entschlossen", "wir", "uns", ",", "den", "Tumor", "mit", "der", "photodynamischen", "Therapie", "(", "PDT", ")", "zu", "behandeln", ".", "Hierzu", "wurden", "-Aminolaevulinsaeure", "(", "-ALA", ",", "20", "%", ")", "topisch", "aufgetragen", "und", "das", "Gewebe", "mit", "rotem", "Licht", "(", "570", "-", "750", "nm", ";", "180", "J", "/", "cm2", ")", "bestrahlt", ".", "Die", "PDT", "wurde", "zweimal", "wiederholt", ".", "Hierdurch", "konnte", "klinisch", "eine", "nahezu", "vollstaendige", "Remission", "des", "Tumors", "erzielt", "werden", ".", "In", "der", "photodynamischen", "Diagnostik", "(", "PDD", ")", "zeigten", "sich", "aber", "noch", "deutlich", "einige", "persistierende", ",", "z.", "T.", "die", "Mamille", "infiltrierende", "Basaliominseln", ".", "Diese", "wurden", "durch", "Exzision", "entfernt", "und", "anschliessend", "wurde", "der", "Defekt", "mittels", "einer", "Mamillenplastik", "verschlossen", ".", "Durch", "die", "Kombination", "der", "beiden", "Therapieformen", "konnte", "der", "grossflaechige", "Tumor", "mit", "einem", "ausgezeichneten", "kosmetischen", "Ergebnis", "behandelt", "werden", ".", "Die", "Falldarstellung", "soll", "zum", "einen", "die", "Grenzen", "der", "topischen", "PDT", ",", "zum", "anderen", "die", "Effizienz", "der", "PDD", "bei", "gezieltem", "Einsatz", "darstellen", "." ]	[ "umlsterm" ]
Behandlung, Histologie, Rumpfhautbasalioms, Tumor, photodynamischen Therapie, Gewebe, Licht, Tumors, Diagnostik, Therapieformen, Tumor, Effizienz, gezieltem	DerHautarzt.60470438.ger.abstr_task2	Sentence: Es wird die Behandlung eines grossflaechigen Basalioms ( ca. 10x6 cm ) an der rechten Mamma einer 48jaehrigen Patientin dargestellt . Aufgrund der Histologie eines oberflaechlichen Rumpfhautbasalioms entschlossen wir uns , den Tumor mit der photodynamischen Therapie ( PDT ) zu behandeln . Hierzu wurden -Aminolaevulinsaeure ( -ALA , 20% ) topisch aufgetragen und das Gewebe mit rotem Licht ( 570-750 nm ; 180 J/cm2) bestrahlt . Die PDT wurde zweimal wiederholt . Hierdurch konnte klinisch eine nahezu vollstaendige Remission des Tumors erzielt werden . In der photodynamischen Diagnostik ( PDD ) zeigten sich aber noch deutlich einige persistierende , z.T. die Mamille infiltrierende Basaliominseln . Diese wurden durch Exzision entfernt und anschliessend wurde der Defekt mittels einer Mamillenplastik verschlossen . Durch die Kombination der beiden Therapieformen konnte der grossflaechige Tumor mit einem ausgezeichneten kosmetischen Ergebnis behandelt werden . Die Falldarstellung soll zum einen die Grenzen der topischen PDT , zum anderen die Effizienz der PDD bei gezieltem Einsatz darstellen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Es wird die Behandlung eines grossflaechigen Basalioms ( ca. 10x6 cm ) an der rechten Mamma einer 48jaehrigen Patientin dargestellt . Aufgrund der Histologie eines oberflaechlichen Rumpfhautbasalioms entschlossen wir uns , den Tumor mit der photodynamischen Therapie ( PDT ) zu behandeln . Hierzu wurden -Aminolaevulinsaeure ( -ALA , 20% ) topisch aufgetragen und das Gewebe mit rotem Licht ( 570-750 nm ; 180 J/cm2) bestrahlt . Die PDT wurde zweimal wiederholt . Hierdurch konnte klinisch eine nahezu vollstaendige Remission des Tumors erzielt werden . In der photodynamischen Diagnostik ( PDD ) zeigten sich aber noch deutlich einige persistierende , z.T. die Mamille infiltrierende Basaliominseln . Diese wurden durch Exzision entfernt und anschliessend wurde der Defekt mittels einer Mamillenplastik verschlossen . Durch die Kombination der beiden Therapieformen konnte der grossflaechige Tumor mit einem ausgezeichneten kosmetischen Ergebnis behandelt werden . Die Falldarstellung soll zum einen die Grenzen der topischen PDT , zum anderen die Effizienz der PDD bei gezieltem Einsatz darstellen .	[ "Es", "wird", "die", "Behandlung", "eines", "grossflaechigen", "Basalioms", "(", "ca", ".", "10x6", "cm", ")", "an", "der", "rechten", "Mamma", "einer", "48jaehrigen", "Patientin", "dargestellt", ".", "Aufgrund", "der", "Histologie", "eines", "oberflaechlichen", "Rumpfhautbasalioms", "entschlossen", "wir", "uns", ",", "den", "Tumor", "mit", "der", "photodynamischen", "Therapie", "(", "PDT", ")", "zu", "behandeln", ".", "Hierzu", "wurden", "-Aminolaevulinsaeure", "(", "-ALA", ",", "20", "%", ")", "topisch", "aufgetragen", "und", "das", "Gewebe", "mit", "rotem", "Licht", "(", "570", "-", "750", "nm", ";", "180", "J", "/", "cm2", ")", "bestrahlt", ".", "Die", "PDT", "wurde", "zweimal", "wiederholt", ".", "Hierdurch", "konnte", "klinisch", "eine", "nahezu", "vollstaendige", "Remission", "des", "Tumors", "erzielt", "werden", ".", "In", "der", "photodynamischen", "Diagnostik", "(", "PDD", ")", "zeigten", "sich", "aber", "noch", "deutlich", "einige", "persistierende", ",", "z.", "T.", "die", "Mamille", "infiltrierende", "Basaliominseln", ".", "Diese", "wurden", "durch", "Exzision", "entfernt", "und", "anschliessend", "wurde", "der", "Defekt", "mittels", "einer", "Mamillenplastik", "verschlossen", ".", "Durch", "die", "Kombination", "der", "beiden", "Therapieformen", "konnte", "der", "grossflaechige", "Tumor", "mit", "einem", "ausgezeichneten", "kosmetischen", "Ergebnis", "behandelt", "werden", ".", "Die", "Falldarstellung", "soll", "zum", "einen", "die", "Grenzen", "der", "topischen", "PDT", ",", "zum", "anderen", "die", "Effizienz", "der", "PDD", "bei", "gezieltem", "Einsatz", "darstellen", "." ]	[ "umlsterm" ]
Sp1 is a protein	1.0alpha7.train.354_task0	Sentence: The results of this study suggest that the third positive response element at bp 125 also binds Sp1. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O" ]	The results of this study suggest that the third positive response element at bp 125 also binds Sp1.	[ "The", "results", "of", "this", "study", "suggest", "that", "the", "third", "positive", "response", "element", "at", " ", "bp", " ", "125", "also", "binds", " ", "Sp1", "." ]	[ "protein" ]
Sp1 is a protein	1.0alpha7.train.354_task1	Sentence: The results of this study suggest that the third positive response element at bp 125 also binds Sp1. Instructions: please typing these entity words according to sentence: Sp1 Options: protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O" ]	The results of this study suggest that the third positive response element at bp 125 also binds Sp1.	[ "The", "results", "of", "this", "study", "suggest", "that", "the", "third", "positive", "response", "element", "at", " ", "bp", " ", "125", "also", "binds", " ", "Sp1", "." ]	[ "protein" ]
Sp1	1.0alpha7.train.354_task2	Sentence: The results of this study suggest that the third positive response element at bp 125 also binds Sp1. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O" ]	The results of this study suggest that the third positive response element at bp 125 also binds Sp1.	[ "The", "results", "of", "this", "study", "suggest", "that", "the", "third", "positive", "response", "element", "at", " ", "bp", " ", "125", "also", "binds", " ", "Sp1", "." ]	[ "protein" ]
Sentinel lymph node detection is a Outcome_Physical, adjuvant therapy is a Intervention_Pharmacological, sensibility in detect positive nodes is a Outcome_Physical, stage and prognosis is a Outcome_Physical, utilizing either patent blue alone , or in association with radiotracer based on technetium 99 m colloid solution in a randomized fashion is a Intervention_Physical, mean number of sentinel nodes per patient is a Outcome_Other, transoperative lympho - scintigraphy is a Outcome_Physical, extra sentinel nodes is a Outcome_Physical, association of hematoxylin and eosin and immunohistochemical examination is a Outcome_Physical, feasible is a Outcome_Other, simple is a Outcome_Other, produce upstage is a Outcome_Other, Blue staining and radio guided techniques is a Intervention_Physical, safe is a Outcome_Other, accuracy is a Outcome_Other, lymph drainage is a Outcome_Physical, Upstaging rate is a Outcome_Other, chemotherapy is a Intervention_Pharmacological	29074_task0	Sentence: [ Sentinel lymph node detection in colorectal cancer : importance , techniques and results ] . BACKGROUND AND AIM Considering that lymph node status is a key factor in colorectal cancer staging , and the main determinant for adjuvant therapy of colorectal cancer being this therapy , responsible for a significant increase in colorectal cancer patients survival , the staging methods should be the most accurate possible in order to offer this individuals the opportunity to be adequate treated in order to achieve the best survival possible . Sentinel lymph node study is progressively being popularized as a method that increases sensibility in detect positive nodes to reveal a more accurate stage and prognosis in colorectal cancer patients . PATIENTS AND METHODS Thirty one colorectal cancer patients were prospectively studied and sentinel lymph node was identified in 100 % of the cases utilizing either patent blue alone , or in association with radiotracer based on technetium 99m colloid solution in a randomized fashion . RESULTS The mean number of sentinel nodes per patient was 1.96 ranging from 1 to 3 nodes . With the addition of transoperative lympho-scintigraphy five extra sentinel nodes , not identified by the blue dye alone , were identified and considered for histopathology study . In four cases ( 12.9 % ) the sentinel lymph node was the only site of metastasis , all of them being detected by association of hematoxylin and eosin and immunohistochemical examination . CONCLUSION Sentinel lymph node detection and analysis is feasible , technique is relatively simple and is able to produce upstage in colorectal cancer . Blue staining and radio guided techniques are both safe and their superposition has shown good results in terms of increase accuracy in our experience . There was no aberrant lymph drainage that would alter resection margins in patients studied . Upstaging rate , identifying potential candidates for adjuvant therapy was 12.9 % ( 4/31 ) . To this individuals chemotherapy could be a chance to increase their global survival . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Outcome_Other, Intervention_Pharmacological, Outcome_Physical	[ "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	[ Sentinel lymph node detection in colorectal cancer : importance , techniques and results ] . BACKGROUND AND AIM Considering that lymph node status is a key factor in colorectal cancer staging , and the main determinant for adjuvant therapy of colorectal cancer being this therapy , responsible for a significant increase in colorectal cancer patients survival , the staging methods should be the most accurate possible in order to offer this individuals the opportunity to be adequate treated in order to achieve the best survival possible . Sentinel lymph node study is progressively being popularized as a method that increases sensibility in detect positive nodes to reveal a more accurate stage and prognosis in colorectal cancer patients . PATIENTS AND METHODS Thirty one colorectal cancer patients were prospectively studied and sentinel lymph node was identified in 100 % of the cases utilizing either patent blue alone , or in association with radiotracer based on technetium 99m colloid solution in a randomized fashion . RESULTS The mean number of sentinel nodes per patient was 1.96 ranging from 1 to 3 nodes . With the addition of transoperative lympho-scintigraphy five extra sentinel nodes , not identified by the blue dye alone , were identified and considered for histopathology study . In four cases ( 12.9 % ) the sentinel lymph node was the only site of metastasis , all of them being detected by association of hematoxylin and eosin and immunohistochemical examination . CONCLUSION Sentinel lymph node detection and analysis is feasible , technique is relatively simple and is able to produce upstage in colorectal cancer . Blue staining and radio guided techniques are both safe and their superposition has shown good results in terms of increase accuracy in our experience . There was no aberrant lymph drainage that would alter resection margins in patients studied . Upstaging rate , identifying potential candidates for adjuvant therapy was 12.9 % ( 4/31 ) . To this individuals chemotherapy could be a chance to increase their global survival .	[ "[", "Sentinel", "lymph", "node", "detection", "in", "colorectal", "cancer", ":", "importance", ",", "techniques", "and", "results", "]", ".", "BACKGROUND", "AND", "AIM", "Considering", "that", "lymph", "node", "status", "is", "a", "key", "factor", "in", "colorectal", "cancer", "staging", ",", "and", "the", "main", "determinant", "for", "adjuvant", "therapy", "of", "colorectal", "cancer", "being", "this", "therapy", ",", "responsible", "for", "a", "significant", "increase", "in", "colorectal", "cancer", "patients", "survival", ",", "the", "staging", "methods", "should", "be", "the", "most", "accurate", "possible", "in", "order", "to", "offer", "this", "individuals", "the", "opportunity", "to", "be", "adequate", "treated", "in", "order", "to", "achieve", "the", "best", "survival", "possible", ".", "Sentinel", "lymph", "node", "study", "is", "progressively", "being", "popularized", "as", "a", "method", "that", "increases", "sensibility", "in", "detect", "positive", "nodes", "to", "reveal", "a", "more", "accurate", "stage", "and", "prognosis", "in", "colorectal", "cancer", "patients", ".", "PATIENTS", "AND", "METHODS", "Thirty", "one", "colorectal", "cancer", "patients", "were", "prospectively", "studied", "and", "sentinel", "lymph", "node", "was", "identified", "in", "100", "%", "of", "the", "cases", "utilizing", "either", "patent", "blue", "alone", ",", "or", "in", "association", "with", "radiotracer", "based", "on", "technetium", "99", "m", "colloid", "solution", "in", "a", "randomized", "fashion", ".", "RESULTS", "The", "mean", "number", "of", "sentinel", "nodes", "per", "patient", "was", "1.96", "ranging", "from", "1", "to", "3", "nodes", ".", "With", "the", "addition", "of", "transoperative", "lympho", "-", "scintigraphy", "five", "extra", "sentinel", "nodes", ",", "not", "identified", "by", "the", "blue", "dye", "alone", ",", "were", "identified", "and", "considered", "for", "histopathology", "study", ".", "In", "four", "cases", "(", "12.9", "%", ")", "the", "sentinel", "lymph", "node", "was", "the", "only", "site", "of", "metastasis", ",", "all", "of", "them", "being", "detected", "by", "association", "of", "hematoxylin", "and", "eosin", "and", "immunohistochemical", "examination", ".", "CONCLUSION", "Sentinel", "lymph", "node", "detection", "and", "analysis", "is", "feasible", ",", "technique", "is", "relatively", "simple", "and", "is", "able", "to", "produce", "upstage", "in", "colorectal", "cancer", ".", "Blue", "staining", "and", "radio", "guided", "techniques", "are", "both", "safe", "and", "their", "superposition", "has", "shown", "good", "results", "in", "terms", "of", "increase", "accuracy", "in", "our", "experience", ".", "There", "was", "no", "aberrant", "lymph", "drainage", "that", "would", "alter", "resection", "margins", "in", "patients", "studied", ".", "Upstaging", "rate", ",", "identifying", "potential", "candidates", "for", "adjuvant", "therapy", "was", "12.9", "%", "(", "4/31", ")", ".", "To", "this", "individuals", "chemotherapy", "could", "be", "a", "chance", "to", "increase", "their", "global", "survival", "." ]	[ "Intervention_Physical", "Outcome_Physical", "Outcome_Other", "Intervention_Pharmacological" ]
Sentinel lymph node detection is a Outcome_Physical, adjuvant therapy is a Intervention_Pharmacological, sensibility in detect positive nodes is a Outcome_Physical, stage and prognosis is a Outcome_Physical, utilizing either patent blue alone , or in association with radiotracer based on technetium 99 m colloid solution in a randomized fashion is a Intervention_Physical, mean number of sentinel nodes per patient is a Outcome_Other, transoperative lympho - scintigraphy is a Outcome_Physical, extra sentinel nodes is a Outcome_Physical, association of hematoxylin and eosin and immunohistochemical examination is a Outcome_Physical, feasible is a Outcome_Other, simple is a Outcome_Other, produce upstage is a Outcome_Other, Blue staining and radio guided techniques is a Intervention_Physical, safe is a Outcome_Other, accuracy is a Outcome_Other, lymph drainage is a Outcome_Physical, Upstaging rate is a Outcome_Other, chemotherapy is a Intervention_Pharmacological	29074_task1	Sentence: [ Sentinel lymph node detection in colorectal cancer : importance , techniques and results ] . BACKGROUND AND AIM Considering that lymph node status is a key factor in colorectal cancer staging , and the main determinant for adjuvant therapy of colorectal cancer being this therapy , responsible for a significant increase in colorectal cancer patients survival , the staging methods should be the most accurate possible in order to offer this individuals the opportunity to be adequate treated in order to achieve the best survival possible . Sentinel lymph node study is progressively being popularized as a method that increases sensibility in detect positive nodes to reveal a more accurate stage and prognosis in colorectal cancer patients . PATIENTS AND METHODS Thirty one colorectal cancer patients were prospectively studied and sentinel lymph node was identified in 100 % of the cases utilizing either patent blue alone , or in association with radiotracer based on technetium 99m colloid solution in a randomized fashion . RESULTS The mean number of sentinel nodes per patient was 1.96 ranging from 1 to 3 nodes . With the addition of transoperative lympho-scintigraphy five extra sentinel nodes , not identified by the blue dye alone , were identified and considered for histopathology study . In four cases ( 12.9 % ) the sentinel lymph node was the only site of metastasis , all of them being detected by association of hematoxylin and eosin and immunohistochemical examination . CONCLUSION Sentinel lymph node detection and analysis is feasible , technique is relatively simple and is able to produce upstage in colorectal cancer . Blue staining and radio guided techniques are both safe and their superposition has shown good results in terms of increase accuracy in our experience . There was no aberrant lymph drainage that would alter resection margins in patients studied . Upstaging rate , identifying potential candidates for adjuvant therapy was 12.9 % ( 4/31 ) . To this individuals chemotherapy could be a chance to increase their global survival . Instructions: please typing these entity words according to sentence: Sentinel lymph node detection, adjuvant therapy, sensibility in detect positive nodes, stage and prognosis, utilizing either patent blue alone , or in association with radiotracer based on technetium 99 m colloid solution in a randomized fashion, mean number of sentinel nodes per patient, transoperative lympho - scintigraphy, extra sentinel nodes, association of hematoxylin and eosin and immunohistochemical examination, feasible, simple, produce upstage, Blue staining and radio guided techniques, safe, accuracy, lymph drainage, Upstaging rate, chemotherapy Options: Intervention_Physical, Outcome_Other, Intervention_Pharmacological, Outcome_Physical	[ "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	[ Sentinel lymph node detection in colorectal cancer : importance , techniques and results ] . BACKGROUND AND AIM Considering that lymph node status is a key factor in colorectal cancer staging , and the main determinant for adjuvant therapy of colorectal cancer being this therapy , responsible for a significant increase in colorectal cancer patients survival , the staging methods should be the most accurate possible in order to offer this individuals the opportunity to be adequate treated in order to achieve the best survival possible . Sentinel lymph node study is progressively being popularized as a method that increases sensibility in detect positive nodes to reveal a more accurate stage and prognosis in colorectal cancer patients . PATIENTS AND METHODS Thirty one colorectal cancer patients were prospectively studied and sentinel lymph node was identified in 100 % of the cases utilizing either patent blue alone , or in association with radiotracer based on technetium 99m colloid solution in a randomized fashion . RESULTS The mean number of sentinel nodes per patient was 1.96 ranging from 1 to 3 nodes . With the addition of transoperative lympho-scintigraphy five extra sentinel nodes , not identified by the blue dye alone , were identified and considered for histopathology study . In four cases ( 12.9 % ) the sentinel lymph node was the only site of metastasis , all of them being detected by association of hematoxylin and eosin and immunohistochemical examination . CONCLUSION Sentinel lymph node detection and analysis is feasible , technique is relatively simple and is able to produce upstage in colorectal cancer . Blue staining and radio guided techniques are both safe and their superposition has shown good results in terms of increase accuracy in our experience . There was no aberrant lymph drainage that would alter resection margins in patients studied . Upstaging rate , identifying potential candidates for adjuvant therapy was 12.9 % ( 4/31 ) . To this individuals chemotherapy could be a chance to increase their global survival .	[ "[", "Sentinel", "lymph", "node", "detection", "in", "colorectal", "cancer", ":", "importance", ",", "techniques", "and", "results", "]", ".", "BACKGROUND", "AND", "AIM", "Considering", "that", "lymph", "node", "status", "is", "a", "key", "factor", "in", "colorectal", "cancer", "staging", ",", "and", "the", "main", "determinant", "for", "adjuvant", "therapy", "of", "colorectal", "cancer", "being", "this", "therapy", ",", "responsible", "for", "a", "significant", "increase", "in", "colorectal", "cancer", "patients", "survival", ",", "the", "staging", "methods", "should", "be", "the", "most", "accurate", "possible", "in", "order", "to", "offer", "this", "individuals", "the", "opportunity", "to", "be", "adequate", "treated", "in", "order", "to", "achieve", "the", "best", "survival", "possible", ".", "Sentinel", "lymph", "node", "study", "is", "progressively", "being", "popularized", "as", "a", "method", "that", "increases", "sensibility", "in", "detect", "positive", "nodes", "to", "reveal", "a", "more", "accurate", "stage", "and", "prognosis", "in", "colorectal", "cancer", "patients", ".", "PATIENTS", "AND", "METHODS", "Thirty", "one", "colorectal", "cancer", "patients", "were", "prospectively", "studied", "and", "sentinel", "lymph", "node", "was", "identified", "in", "100", "%", "of", "the", "cases", "utilizing", "either", "patent", "blue", "alone", ",", "or", "in", "association", "with", "radiotracer", "based", "on", "technetium", "99", "m", "colloid", "solution", "in", "a", "randomized", "fashion", ".", "RESULTS", "The", "mean", "number", "of", "sentinel", "nodes", "per", "patient", "was", "1.96", "ranging", "from", "1", "to", "3", "nodes", ".", "With", "the", "addition", "of", "transoperative", "lympho", "-", "scintigraphy", "five", "extra", "sentinel", "nodes", ",", "not", "identified", "by", "the", "blue", "dye", "alone", ",", "were", "identified", "and", "considered", "for", "histopathology", "study", ".", "In", "four", "cases", "(", "12.9", "%", ")", "the", "sentinel", "lymph", "node", "was", "the", "only", "site", "of", "metastasis", ",", "all", "of", "them", "being", "detected", "by", "association", "of", "hematoxylin", "and", "eosin", "and", "immunohistochemical", "examination", ".", "CONCLUSION", "Sentinel", "lymph", "node", "detection", "and", "analysis", "is", "feasible", ",", "technique", "is", "relatively", "simple", "and", "is", "able", "to", "produce", "upstage", "in", "colorectal", "cancer", ".", "Blue", "staining", "and", "radio", "guided", "techniques", "are", "both", "safe", "and", "their", "superposition", "has", "shown", "good", "results", "in", "terms", "of", "increase", "accuracy", "in", "our", "experience", ".", "There", "was", "no", "aberrant", "lymph", "drainage", "that", "would", "alter", "resection", "margins", "in", "patients", "studied", ".", "Upstaging", "rate", ",", "identifying", "potential", "candidates", "for", "adjuvant", "therapy", "was", "12.9", "%", "(", "4/31", ")", ".", "To", "this", "individuals", "chemotherapy", "could", "be", "a", "chance", "to", "increase", "their", "global", "survival", "." ]	[ "Intervention_Physical", "Outcome_Physical", "Outcome_Other", "Intervention_Pharmacological" ]
Sentinel lymph node detection, adjuvant therapy, sensibility in detect positive nodes, stage and prognosis, utilizing either patent blue alone , or in association with radiotracer based on technetium 99 m colloid solution in a randomized fashion, mean number of sentinel nodes per patient, transoperative lympho - scintigraphy, extra sentinel nodes, association of hematoxylin and eosin and immunohistochemical examination, feasible, simple, produce upstage, Blue staining and radio guided techniques, safe, accuracy, lymph drainage, Upstaging rate, chemotherapy	29074_task2	Sentence: [ Sentinel lymph node detection in colorectal cancer : importance , techniques and results ] . BACKGROUND AND AIM Considering that lymph node status is a key factor in colorectal cancer staging , and the main determinant for adjuvant therapy of colorectal cancer being this therapy , responsible for a significant increase in colorectal cancer patients survival , the staging methods should be the most accurate possible in order to offer this individuals the opportunity to be adequate treated in order to achieve the best survival possible . Sentinel lymph node study is progressively being popularized as a method that increases sensibility in detect positive nodes to reveal a more accurate stage and prognosis in colorectal cancer patients . PATIENTS AND METHODS Thirty one colorectal cancer patients were prospectively studied and sentinel lymph node was identified in 100 % of the cases utilizing either patent blue alone , or in association with radiotracer based on technetium 99m colloid solution in a randomized fashion . RESULTS The mean number of sentinel nodes per patient was 1.96 ranging from 1 to 3 nodes . With the addition of transoperative lympho-scintigraphy five extra sentinel nodes , not identified by the blue dye alone , were identified and considered for histopathology study . In four cases ( 12.9 % ) the sentinel lymph node was the only site of metastasis , all of them being detected by association of hematoxylin and eosin and immunohistochemical examination . CONCLUSION Sentinel lymph node detection and analysis is feasible , technique is relatively simple and is able to produce upstage in colorectal cancer . Blue staining and radio guided techniques are both safe and their superposition has shown good results in terms of increase accuracy in our experience . There was no aberrant lymph drainage that would alter resection margins in patients studied . Upstaging rate , identifying potential candidates for adjuvant therapy was 12.9 % ( 4/31 ) . To this individuals chemotherapy could be a chance to increase their global survival . Instructions: please extract entity words from the input sentence	[ "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	[ Sentinel lymph node detection in colorectal cancer : importance , techniques and results ] . BACKGROUND AND AIM Considering that lymph node status is a key factor in colorectal cancer staging , and the main determinant for adjuvant therapy of colorectal cancer being this therapy , responsible for a significant increase in colorectal cancer patients survival , the staging methods should be the most accurate possible in order to offer this individuals the opportunity to be adequate treated in order to achieve the best survival possible . Sentinel lymph node study is progressively being popularized as a method that increases sensibility in detect positive nodes to reveal a more accurate stage and prognosis in colorectal cancer patients . PATIENTS AND METHODS Thirty one colorectal cancer patients were prospectively studied and sentinel lymph node was identified in 100 % of the cases utilizing either patent blue alone , or in association with radiotracer based on technetium 99m colloid solution in a randomized fashion . RESULTS The mean number of sentinel nodes per patient was 1.96 ranging from 1 to 3 nodes . With the addition of transoperative lympho-scintigraphy five extra sentinel nodes , not identified by the blue dye alone , were identified and considered for histopathology study . In four cases ( 12.9 % ) the sentinel lymph node was the only site of metastasis , all of them being detected by association of hematoxylin and eosin and immunohistochemical examination . CONCLUSION Sentinel lymph node detection and analysis is feasible , technique is relatively simple and is able to produce upstage in colorectal cancer . Blue staining and radio guided techniques are both safe and their superposition has shown good results in terms of increase accuracy in our experience . There was no aberrant lymph drainage that would alter resection margins in patients studied . Upstaging rate , identifying potential candidates for adjuvant therapy was 12.9 % ( 4/31 ) . To this individuals chemotherapy could be a chance to increase their global survival .	[ "[", "Sentinel", "lymph", "node", "detection", "in", "colorectal", "cancer", ":", "importance", ",", "techniques", "and", "results", "]", ".", "BACKGROUND", "AND", "AIM", "Considering", "that", "lymph", "node", "status", "is", "a", "key", "factor", "in", "colorectal", "cancer", "staging", ",", "and", "the", "main", "determinant", "for", "adjuvant", "therapy", "of", "colorectal", "cancer", "being", "this", "therapy", ",", "responsible", "for", "a", "significant", "increase", "in", "colorectal", "cancer", "patients", "survival", ",", "the", "staging", "methods", "should", "be", "the", "most", "accurate", "possible", "in", "order", "to", "offer", "this", "individuals", "the", "opportunity", "to", "be", "adequate", "treated", "in", "order", "to", "achieve", "the", "best", "survival", "possible", ".", "Sentinel", "lymph", "node", "study", "is", "progressively", "being", "popularized", "as", "a", "method", "that", "increases", "sensibility", "in", "detect", "positive", "nodes", "to", "reveal", "a", "more", "accurate", "stage", "and", "prognosis", "in", "colorectal", "cancer", "patients", ".", "PATIENTS", "AND", "METHODS", "Thirty", "one", "colorectal", "cancer", "patients", "were", "prospectively", "studied", "and", "sentinel", "lymph", "node", "was", "identified", "in", "100", "%", "of", "the", "cases", "utilizing", "either", "patent", "blue", "alone", ",", "or", "in", "association", "with", "radiotracer", "based", "on", "technetium", "99", "m", "colloid", "solution", "in", "a", "randomized", "fashion", ".", "RESULTS", "The", "mean", "number", "of", "sentinel", "nodes", "per", "patient", "was", "1.96", "ranging", "from", "1", "to", "3", "nodes", ".", "With", "the", "addition", "of", "transoperative", "lympho", "-", "scintigraphy", "five", "extra", "sentinel", "nodes", ",", "not", "identified", "by", "the", "blue", "dye", "alone", ",", "were", "identified", "and", "considered", "for", "histopathology", "study", ".", "In", "four", "cases", "(", "12.9", "%", ")", "the", "sentinel", "lymph", "node", "was", "the", "only", "site", "of", "metastasis", ",", "all", "of", "them", "being", "detected", "by", "association", "of", "hematoxylin", "and", "eosin", "and", "immunohistochemical", "examination", ".", "CONCLUSION", "Sentinel", "lymph", "node", "detection", "and", "analysis", "is", "feasible", ",", "technique", "is", "relatively", "simple", "and", "is", "able", "to", "produce", "upstage", "in", "colorectal", "cancer", ".", "Blue", "staining", "and", "radio", "guided", "techniques", "are", "both", "safe", "and", "their", "superposition", "has", "shown", "good", "results", "in", "terms", "of", "increase", "accuracy", "in", "our", "experience", ".", "There", "was", "no", "aberrant", "lymph", "drainage", "that", "would", "alter", "resection", "margins", "in", "patients", "studied", ".", "Upstaging", "rate", ",", "identifying", "potential", "candidates", "for", "adjuvant", "therapy", "was", "12.9", "%", "(", "4/31", ")", ".", "To", "this", "individuals", "chemotherapy", "could", "be", "a", "chance", "to", "increase", "their", "global", "survival", "." ]	[ "Intervention_Physical", "Outcome_Physical", "Outcome_Other", "Intervention_Pharmacological" ]
ATP is a CHEMICAL, GLUT4 is a GENE-Y, Glucose is a CHEMICAL, PI3Kγ is a GENE-Y, Akt is a GENE-N, AS160 is a GENE-Y	23274898_task0	Sentence: Electrical Stimuli Release ATP to Increase GLUT4 Translocation and Glucose Uptake via PI3Kγ-Akt-AS160 in Skeletal Muscle Cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, GENE-Y, CHEMICAL	[ "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "B-GENE-N", "O", "B-GENE-Y", "O", "O", "O", "O", "O" ]	Electrical Stimuli Release ATP to Increase GLUT4 Translocation and Glucose Uptake via PI3Kγ-Akt-AS160 in Skeletal Muscle Cells.	[ "Electrical", "Stimuli", "Release", "ATP", "to", "Increase", "GLUT4", "Translocation", "and", "Glucose", "Uptake", "via", "PI3Kγ", "-", "Akt", "-", "AS160", "in", "Skeletal", "Muscle", "Cells", "." ]	[ "GENE-Y", "GENE-N", "CHEMICAL" ]
ATP is a CHEMICAL, GLUT4 is a GENE-Y, Glucose is a CHEMICAL, PI3Kγ is a GENE-Y, Akt is a GENE-N, AS160 is a GENE-Y	23274898_task1	Sentence: Electrical Stimuli Release ATP to Increase GLUT4 Translocation and Glucose Uptake via PI3Kγ-Akt-AS160 in Skeletal Muscle Cells. Instructions: please typing these entity words according to sentence: ATP, GLUT4, Glucose, PI3Kγ, Akt, AS160 Options: GENE-N, GENE-Y, CHEMICAL	[ "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "B-GENE-N", "O", "B-GENE-Y", "O", "O", "O", "O", "O" ]	Electrical Stimuli Release ATP to Increase GLUT4 Translocation and Glucose Uptake via PI3Kγ-Akt-AS160 in Skeletal Muscle Cells.	[ "Electrical", "Stimuli", "Release", "ATP", "to", "Increase", "GLUT4", "Translocation", "and", "Glucose", "Uptake", "via", "PI3Kγ", "-", "Akt", "-", "AS160", "in", "Skeletal", "Muscle", "Cells", "." ]	[ "GENE-Y", "GENE-N", "CHEMICAL" ]
ATP, GLUT4, Glucose, PI3Kγ, Akt, AS160	23274898_task2	Sentence: Electrical Stimuli Release ATP to Increase GLUT4 Translocation and Glucose Uptake via PI3Kγ-Akt-AS160 in Skeletal Muscle Cells. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "B-GENE-N", "O", "B-GENE-Y", "O", "O", "O", "O", "O" ]	Electrical Stimuli Release ATP to Increase GLUT4 Translocation and Glucose Uptake via PI3Kγ-Akt-AS160 in Skeletal Muscle Cells.	[ "Electrical", "Stimuli", "Release", "ATP", "to", "Increase", "GLUT4", "Translocation", "and", "Glucose", "Uptake", "via", "PI3Kγ", "-", "Akt", "-", "AS160", "in", "Skeletal", "Muscle", "Cells", "." ]	[ "GENE-Y", "GENE-N", "CHEMICAL" ]
Risperidone is a Intervention_Pharmacological, children is a Participant_Age, autism is a Participant_Condition, placebo - controlled is a Intervention_Control, . is a Outcome_Physical, risperidone is a Intervention_Pharmacological, hyperactivity is a Outcome_Mental, 40 is a Participant_Sample-size, ages ranged from 2 to 9 years is a Participant_Age, total is a Outcome_Physical, Childhood Autism Rating Scale is a Outcome_Mental, Childhood Autism Rating Scale score is a Outcome_Mental, Children ' s Global Assessment Scale score is a Outcome_Mental, social responsiveness is a Outcome_Mental, nonverbal communication is a Outcome_Mental, symptoms of is a Outcome_Physical, aggression is a Outcome_Mental, appetite is a Outcome_Physical, weight gain is a Outcome_Physical, mild sedation is a Outcome_Physical, transient dyskinesias is a Outcome_Physical, global functioning is a Outcome_Mental, reducing is a Outcome_Physical	27871_task0	Sentence: Risperidone in children with autism : randomized , placebo-controlled , double-blind study . Some open-label studies suggest that risperidone can be useful in the treatment of certain target symptoms in children with autism . We aimed to study whether the use of risperidone in comparison with placebo improved functioning in children with autism with regard to behavior ( aggressiveness , hyperactivity , irritability ) , social and emotional responsiveness , and communication skills . We conducted a randomized , double-blind , placebo-controlled trial with 40 consecutive children with autism , whose ages ranged from 2 to 9 years , who were receiving either risperidone or placebo given orally at a dose of 1 mg/day for 6 months . Autism symptoms were monitored periodically . The outcome variables were total scores on the Childhood Autism Rating Scale ( CARS ) and the Children 's Global Assessment Scale ( CGAS ) after 6 months . Of the 40 children enrolled , 39 completed the trial over a period of 18 months ; 19 received risperidone , and 20 received placebo . In the risperidone group , 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children 's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children 's Global Assessment Scale score in the placebo group ( P < .001 and P = .035 , respectively ) . Risperidone also improved social responsiveness and nonverbal communication and reduced the symptoms of hyperactivity and aggression . Risperidone was associated with increased appetite and a mild weight gain , mild sedation in 20 % , and transient dyskinesias in three children . Risperidone improved global functioning and social responsiveness while reducing hyperactivity and aggression in children with autism and was well tolerated . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Participant_Age, Participant_Sample-size, Outcome_Mental	[ "B-Intervention_Pharmacological", "O", "B-Participant_Age", "O", "B-Participant_Condition", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Risperidone in children with autism : randomized , placebo-controlled , double-blind study . Some open-label studies suggest that risperidone can be useful in the treatment of certain target symptoms in children with autism . We aimed to study whether the use of risperidone in comparison with placebo improved functioning in children with autism with regard to behavior ( aggressiveness , hyperactivity , irritability ) , social and emotional responsiveness , and communication skills . We conducted a randomized , double-blind , placebo-controlled trial with 40 consecutive children with autism , whose ages ranged from 2 to 9 years , who were receiving either risperidone or placebo given orally at a dose of 1 mg/day for 6 months . Autism symptoms were monitored periodically . The outcome variables were total scores on the Childhood Autism Rating Scale ( CARS ) and the Children 's Global Assessment Scale ( CGAS ) after 6 months . Of the 40 children enrolled , 39 completed the trial over a period of 18 months ; 19 received risperidone , and 20 received placebo . In the risperidone group , 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children 's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children 's Global Assessment Scale score in the placebo group ( P < .001 and P = .035 , respectively ) . Risperidone also improved social responsiveness and nonverbal communication and reduced the symptoms of hyperactivity and aggression . Risperidone was associated with increased appetite and a mild weight gain , mild sedation in 20 % , and transient dyskinesias in three children . Risperidone improved global functioning and social responsiveness while reducing hyperactivity and aggression in children with autism and was well tolerated .	[ "Risperidone", "in", "children", "with", "autism", ":", "randomized", ",", "placebo", "-", "controlled", ",", "double", "-", "blind", "study", ".", "Some", "open", "-", "label", "studies", "suggest", "that", "risperidone", "can", "be", "useful", "in", "the", "treatment", "of", "certain", "target", "symptoms", "in", "children", "with", "autism", ".", "We", "aimed", "to", "study", "whether", "the", "use", "of", "risperidone", "in", "comparison", "with", "placebo", "improved", "functioning", "in", "children", "with", "autism", "with", "regard", "to", "behavior", "(", "aggressiveness", ",", "hyperactivity", ",", "irritability", ")", ",", "social", "and", "emotional", "responsiveness", ",", "and", "communication", "skills", ".", "We", "conducted", "a", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", "trial", "with", "40", "consecutive", "children", "with", "autism", ",", "whose", "ages", "ranged", "from", "2", "to", "9", "years", ",", "who", "were", "receiving", "either", "risperidone", "or", "placebo", "given", "orally", "at", "a", "dose", "of", "1", "mg", "/", "day", "for", "6", "months", ".", "Autism", "symptoms", "were", "monitored", "periodically", ".", "The", "outcome", "variables", "were", "total", "scores", "on", "the", "Childhood", "Autism", "Rating", "Scale", "(", "CARS", ")", "and", "the", "Children", "'", "s", "Global", "Assessment", "Scale", "(", "CGAS", ")", "after", "6", "months", ".", "Of", "the", "40", "children", "enrolled", ",", "39", "completed", "the", "trial", "over", "a", "period", "of", "18", "months", ";", "19", "received", "risperidone", ",", "and", "20", "received", "placebo", ".", "In", "the", "risperidone", "group", ",", "12", "of", "19", "children", "showed", "improvement", "in", "the", "total", "Childhood", "Autism", "Rating", "Scale", "score", "and", "17", "of", "19", "children", "in", "the", "Children", "'", "s", "Global", "Assessment", "Scale", "score", "compared", "with", "0", "of", "20", "children", "for", "the", "Childhood", "Autism", "Rating", "Scale", "score", "and", "2", "of", "20", "children", "for", "the", "Children", "'", "s", "Global", "Assessment", "Scale", "score", "in", "the", "placebo", "group", "(", "P", "<", ".001", "and", "P", "=", ".035", ",", "respectively", ")", ".", "Risperidone", "also", "improved", "social", "responsiveness", "and", "nonverbal", "communication", "and", "reduced", "the", "symptoms", "of", "hyperactivity", "and", "aggression", ".", "Risperidone", "was", "associated", "with", "increased", "appetite", "and", "a", "mild", "weight", "gain", ",", "mild", "sedation", "in", "20", "%", ",", "and", "transient", "dyskinesias", "in", "three", "children", ".", "Risperidone", "improved", "global", "functioning", "and", "social", "responsiveness", "while", "reducing", "hyperactivity", "and", "aggression", "in", "children", "with", "autism", "and", "was", "well", "tolerated", "." ]	[ "Outcome_Mental", "Participant_Age", "Outcome_Physical", "Intervention_Control", "Intervention_Pharmacological", "Participant_Condition", "Outcome_Other", "Participant_Sample-size" ]
Risperidone is a Intervention_Pharmacological, children is a Participant_Age, autism is a Participant_Condition, placebo - controlled is a Intervention_Control, . is a Outcome_Physical, risperidone is a Intervention_Pharmacological, hyperactivity is a Outcome_Mental, 40 is a Participant_Sample-size, ages ranged from 2 to 9 years is a Participant_Age, total is a Outcome_Physical, Childhood Autism Rating Scale is a Outcome_Mental, Childhood Autism Rating Scale score is a Outcome_Mental, Children ' s Global Assessment Scale score is a Outcome_Mental, social responsiveness is a Outcome_Mental, nonverbal communication is a Outcome_Mental, symptoms of is a Outcome_Physical, aggression is a Outcome_Mental, appetite is a Outcome_Physical, weight gain is a Outcome_Physical, mild sedation is a Outcome_Physical, transient dyskinesias is a Outcome_Physical, global functioning is a Outcome_Mental, reducing is a Outcome_Physical	27871_task1	Sentence: Risperidone in children with autism : randomized , placebo-controlled , double-blind study . Some open-label studies suggest that risperidone can be useful in the treatment of certain target symptoms in children with autism . We aimed to study whether the use of risperidone in comparison with placebo improved functioning in children with autism with regard to behavior ( aggressiveness , hyperactivity , irritability ) , social and emotional responsiveness , and communication skills . We conducted a randomized , double-blind , placebo-controlled trial with 40 consecutive children with autism , whose ages ranged from 2 to 9 years , who were receiving either risperidone or placebo given orally at a dose of 1 mg/day for 6 months . Autism symptoms were monitored periodically . The outcome variables were total scores on the Childhood Autism Rating Scale ( CARS ) and the Children 's Global Assessment Scale ( CGAS ) after 6 months . Of the 40 children enrolled , 39 completed the trial over a period of 18 months ; 19 received risperidone , and 20 received placebo . In the risperidone group , 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children 's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children 's Global Assessment Scale score in the placebo group ( P < .001 and P = .035 , respectively ) . Risperidone also improved social responsiveness and nonverbal communication and reduced the symptoms of hyperactivity and aggression . Risperidone was associated with increased appetite and a mild weight gain , mild sedation in 20 % , and transient dyskinesias in three children . Risperidone improved global functioning and social responsiveness while reducing hyperactivity and aggression in children with autism and was well tolerated . Instructions: please typing these entity words according to sentence: Risperidone, children, autism, placebo - controlled, ., risperidone, hyperactivity, 40, ages ranged from 2 to 9 years, total, Childhood Autism Rating Scale, Childhood Autism Rating Scale score, Children ' s Global Assessment Scale score, social responsiveness, nonverbal communication, symptoms of, aggression, appetite, weight gain, mild sedation, transient dyskinesias, global functioning, reducing Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Participant_Age, Participant_Sample-size, Outcome_Mental	[ "B-Intervention_Pharmacological", "O", "B-Participant_Age", "O", "B-Participant_Condition", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Risperidone in children with autism : randomized , placebo-controlled , double-blind study . Some open-label studies suggest that risperidone can be useful in the treatment of certain target symptoms in children with autism . We aimed to study whether the use of risperidone in comparison with placebo improved functioning in children with autism with regard to behavior ( aggressiveness , hyperactivity , irritability ) , social and emotional responsiveness , and communication skills . We conducted a randomized , double-blind , placebo-controlled trial with 40 consecutive children with autism , whose ages ranged from 2 to 9 years , who were receiving either risperidone or placebo given orally at a dose of 1 mg/day for 6 months . Autism symptoms were monitored periodically . The outcome variables were total scores on the Childhood Autism Rating Scale ( CARS ) and the Children 's Global Assessment Scale ( CGAS ) after 6 months . Of the 40 children enrolled , 39 completed the trial over a period of 18 months ; 19 received risperidone , and 20 received placebo . In the risperidone group , 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children 's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children 's Global Assessment Scale score in the placebo group ( P < .001 and P = .035 , respectively ) . Risperidone also improved social responsiveness and nonverbal communication and reduced the symptoms of hyperactivity and aggression . Risperidone was associated with increased appetite and a mild weight gain , mild sedation in 20 % , and transient dyskinesias in three children . Risperidone improved global functioning and social responsiveness while reducing hyperactivity and aggression in children with autism and was well tolerated .	[ "Risperidone", "in", "children", "with", "autism", ":", "randomized", ",", "placebo", "-", "controlled", ",", "double", "-", "blind", "study", ".", "Some", "open", "-", "label", "studies", "suggest", "that", "risperidone", "can", "be", "useful", "in", "the", "treatment", "of", "certain", "target", "symptoms", "in", "children", "with", "autism", ".", "We", "aimed", "to", "study", "whether", "the", "use", "of", "risperidone", "in", "comparison", "with", "placebo", "improved", "functioning", "in", "children", "with", "autism", "with", "regard", "to", "behavior", "(", "aggressiveness", ",", "hyperactivity", ",", "irritability", ")", ",", "social", "and", "emotional", "responsiveness", ",", "and", "communication", "skills", ".", "We", "conducted", "a", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", "trial", "with", "40", "consecutive", "children", "with", "autism", ",", "whose", "ages", "ranged", "from", "2", "to", "9", "years", ",", "who", "were", "receiving", "either", "risperidone", "or", "placebo", "given", "orally", "at", "a", "dose", "of", "1", "mg", "/", "day", "for", "6", "months", ".", "Autism", "symptoms", "were", "monitored", "periodically", ".", "The", "outcome", "variables", "were", "total", "scores", "on", "the", "Childhood", "Autism", "Rating", "Scale", "(", "CARS", ")", "and", "the", "Children", "'", "s", "Global", "Assessment", "Scale", "(", "CGAS", ")", "after", "6", "months", ".", "Of", "the", "40", "children", "enrolled", ",", "39", "completed", "the", "trial", "over", "a", "period", "of", "18", "months", ";", "19", "received", "risperidone", ",", "and", "20", "received", "placebo", ".", "In", "the", "risperidone", "group", ",", "12", "of", "19", "children", "showed", "improvement", "in", "the", "total", "Childhood", "Autism", "Rating", "Scale", "score", "and", "17", "of", "19", "children", "in", "the", "Children", "'", "s", "Global", "Assessment", "Scale", "score", "compared", "with", "0", "of", "20", "children", "for", "the", "Childhood", "Autism", "Rating", "Scale", "score", "and", "2", "of", "20", "children", "for", "the", "Children", "'", "s", "Global", "Assessment", "Scale", "score", "in", "the", "placebo", "group", "(", "P", "<", ".001", "and", "P", "=", ".035", ",", "respectively", ")", ".", "Risperidone", "also", "improved", "social", "responsiveness", "and", "nonverbal", "communication", "and", "reduced", "the", "symptoms", "of", "hyperactivity", "and", "aggression", ".", "Risperidone", "was", "associated", "with", "increased", "appetite", "and", "a", "mild", "weight", "gain", ",", "mild", "sedation", "in", "20", "%", ",", "and", "transient", "dyskinesias", "in", "three", "children", ".", "Risperidone", "improved", "global", "functioning", "and", "social", "responsiveness", "while", "reducing", "hyperactivity", "and", "aggression", "in", "children", "with", "autism", "and", "was", "well", "tolerated", "." ]	[ "Outcome_Mental", "Participant_Age", "Outcome_Physical", "Intervention_Control", "Intervention_Pharmacological", "Participant_Condition", "Outcome_Other", "Participant_Sample-size" ]
Risperidone, children, autism, placebo - controlled, ., risperidone, hyperactivity, 40, ages ranged from 2 to 9 years, total, Childhood Autism Rating Scale, Childhood Autism Rating Scale score, Children ' s Global Assessment Scale score, social responsiveness, nonverbal communication, symptoms of, aggression, appetite, weight gain, mild sedation, transient dyskinesias, global functioning, reducing	27871_task2	Sentence: Risperidone in children with autism : randomized , placebo-controlled , double-blind study . Some open-label studies suggest that risperidone can be useful in the treatment of certain target symptoms in children with autism . We aimed to study whether the use of risperidone in comparison with placebo improved functioning in children with autism with regard to behavior ( aggressiveness , hyperactivity , irritability ) , social and emotional responsiveness , and communication skills . We conducted a randomized , double-blind , placebo-controlled trial with 40 consecutive children with autism , whose ages ranged from 2 to 9 years , who were receiving either risperidone or placebo given orally at a dose of 1 mg/day for 6 months . Autism symptoms were monitored periodically . The outcome variables were total scores on the Childhood Autism Rating Scale ( CARS ) and the Children 's Global Assessment Scale ( CGAS ) after 6 months . Of the 40 children enrolled , 39 completed the trial over a period of 18 months ; 19 received risperidone , and 20 received placebo . In the risperidone group , 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children 's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children 's Global Assessment Scale score in the placebo group ( P < .001 and P = .035 , respectively ) . Risperidone also improved social responsiveness and nonverbal communication and reduced the symptoms of hyperactivity and aggression . Risperidone was associated with increased appetite and a mild weight gain , mild sedation in 20 % , and transient dyskinesias in three children . Risperidone improved global functioning and social responsiveness while reducing hyperactivity and aggression in children with autism and was well tolerated . Instructions: please extract entity words from the input sentence	[ "B-Intervention_Pharmacological", "O", "B-Participant_Age", "O", "B-Participant_Condition", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Risperidone in children with autism : randomized , placebo-controlled , double-blind study . Some open-label studies suggest that risperidone can be useful in the treatment of certain target symptoms in children with autism . We aimed to study whether the use of risperidone in comparison with placebo improved functioning in children with autism with regard to behavior ( aggressiveness , hyperactivity , irritability ) , social and emotional responsiveness , and communication skills . We conducted a randomized , double-blind , placebo-controlled trial with 40 consecutive children with autism , whose ages ranged from 2 to 9 years , who were receiving either risperidone or placebo given orally at a dose of 1 mg/day for 6 months . Autism symptoms were monitored periodically . The outcome variables were total scores on the Childhood Autism Rating Scale ( CARS ) and the Children 's Global Assessment Scale ( CGAS ) after 6 months . Of the 40 children enrolled , 39 completed the trial over a period of 18 months ; 19 received risperidone , and 20 received placebo . In the risperidone group , 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children 's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children 's Global Assessment Scale score in the placebo group ( P < .001 and P = .035 , respectively ) . Risperidone also improved social responsiveness and nonverbal communication and reduced the symptoms of hyperactivity and aggression . Risperidone was associated with increased appetite and a mild weight gain , mild sedation in 20 % , and transient dyskinesias in three children . Risperidone improved global functioning and social responsiveness while reducing hyperactivity and aggression in children with autism and was well tolerated .	[ "Risperidone", "in", "children", "with", "autism", ":", "randomized", ",", "placebo", "-", "controlled", ",", "double", "-", "blind", "study", ".", "Some", "open", "-", "label", "studies", "suggest", "that", "risperidone", "can", "be", "useful", "in", "the", "treatment", "of", "certain", "target", "symptoms", "in", "children", "with", "autism", ".", "We", "aimed", "to", "study", "whether", "the", "use", "of", "risperidone", "in", "comparison", "with", "placebo", "improved", "functioning", "in", "children", "with", "autism", "with", "regard", "to", "behavior", "(", "aggressiveness", ",", "hyperactivity", ",", "irritability", ")", ",", "social", "and", "emotional", "responsiveness", ",", "and", "communication", "skills", ".", "We", "conducted", "a", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", "trial", "with", "40", "consecutive", "children", "with", "autism", ",", "whose", "ages", "ranged", "from", "2", "to", "9", "years", ",", "who", "were", "receiving", "either", "risperidone", "or", "placebo", "given", "orally", "at", "a", "dose", "of", "1", "mg", "/", "day", "for", "6", "months", ".", "Autism", "symptoms", "were", "monitored", "periodically", ".", "The", "outcome", "variables", "were", "total", "scores", "on", "the", "Childhood", "Autism", "Rating", "Scale", "(", "CARS", ")", "and", "the", "Children", "'", "s", "Global", "Assessment", "Scale", "(", "CGAS", ")", "after", "6", "months", ".", "Of", "the", "40", "children", "enrolled", ",", "39", "completed", "the", "trial", "over", "a", "period", "of", "18", "months", ";", "19", "received", "risperidone", ",", "and", "20", "received", "placebo", ".", "In", "the", "risperidone", "group", ",", "12", "of", "19", "children", "showed", "improvement", "in", "the", "total", "Childhood", "Autism", "Rating", "Scale", "score", "and", "17", "of", "19", "children", "in", "the", "Children", "'", "s", "Global", "Assessment", "Scale", "score", "compared", "with", "0", "of", "20", "children", "for", "the", "Childhood", "Autism", "Rating", "Scale", "score", "and", "2", "of", "20", "children", "for", "the", "Children", "'", "s", "Global", "Assessment", "Scale", "score", "in", "the", "placebo", "group", "(", "P", "<", ".001", "and", "P", "=", ".035", ",", "respectively", ")", ".", "Risperidone", "also", "improved", "social", "responsiveness", "and", "nonverbal", "communication", "and", "reduced", "the", "symptoms", "of", "hyperactivity", "and", "aggression", ".", "Risperidone", "was", "associated", "with", "increased", "appetite", "and", "a", "mild", "weight", "gain", ",", "mild", "sedation", "in", "20", "%", ",", "and", "transient", "dyskinesias", "in", "three", "children", ".", "Risperidone", "improved", "global", "functioning", "and", "social", "responsiveness", "while", "reducing", "hyperactivity", "and", "aggression", "in", "children", "with", "autism", "and", "was", "well", "tolerated", "." ]	[ "Outcome_Mental", "Participant_Age", "Outcome_Physical", "Intervention_Control", "Intervention_Pharmacological", "Participant_Condition", "Outcome_Other", "Participant_Sample-size" ]
proteasomal is a Cellular_component, mitochondrial is a Cellular_component, mitochondrial is a Cellular_component, mitochondria is a Cellular_component, mitochondria is a Cellular_component, mitochondrial membrane is a Cellular_component, mitochondrial is a Cellular_component, cell is a Cell, proteasomal is a Cellular_component, mitochondrial is a Cellular_component, mitochondrial is a Cellular_component, cellular is a Cell, mitochondria is a Cellular_component, mitochondrial is a Cellular_component, mitochondrial is a Cellular_component, mitochondrial is a Cellular_component	PMC-3124045-caption-01_task0	Sentence: Parkin regulates the proteasomal degradation of PARIS and PGC-1alpha-dependent mitochondrial biogenesis. (A) Normal physiological conditions that maintain mitochondrial homeostasis: PINK1 recruits parkin to the mitochondria, where these two proteins interact to eliminate abnormal mitochondria through mitophagy. Alterations in mitochondrial membrane potential (DeltaPsim; a key indicator of mitochondrial physiology and cell viability) initiate the PINK1-parkin cascade of events that lead to mitophagy. Furthermore, parkin ubiquitylates and thereby promotes proteasomal degradation of PARIS. Because PARIS represses the expression of PGC-1alpha, degradation of PARIS by parkin allows PGC-1alpha-dependent gene expression and enables mitochondrial biogenesis. Parkin seems to be an integral regulator of mitochondrial homeostasis, controlling both degradation and biogenesis. (B) Loss of parkin function as a result of familial mutations (in the case of AR-PD) or aging, environmental or cellular stress (in the case of sporadic PD) leads to the accumulation of abnormal mitochondria, owing to faulty mitophagy. In addition, PARIS accumulates and represses PGC-1alpha, preventing mitochondrial biogenesis. Loss of parkin function does not tip the balance between mitochondrial biogenesis and degradation to either side, but leads to a general breakdown of mitochondrial homeostasis that can ultimately lead to PD. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Cellular_component, Cell	[ "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Parkin regulates the proteasomal degradation of PARIS and PGC-1alpha-dependent mitochondrial biogenesis. (A) Normal physiological conditions that maintain mitochondrial homeostasis: PINK1 recruits parkin to the mitochondria, where these two proteins interact to eliminate abnormal mitochondria through mitophagy. Alterations in mitochondrial membrane potential (DeltaPsim; a key indicator of mitochondrial physiology and cell viability) initiate the PINK1-parkin cascade of events that lead to mitophagy. Furthermore, parkin ubiquitylates and thereby promotes proteasomal degradation of PARIS. Because PARIS represses the expression of PGC-1alpha, degradation of PARIS by parkin allows PGC-1alpha-dependent gene expression and enables mitochondrial biogenesis. Parkin seems to be an integral regulator of mitochondrial homeostasis, controlling both degradation and biogenesis. (B) Loss of parkin function as a result of familial mutations (in the case of AR-PD) or aging, environmental or cellular stress (in the case of sporadic PD) leads to the accumulation of abnormal mitochondria, owing to faulty mitophagy. In addition, PARIS accumulates and represses PGC-1alpha, preventing mitochondrial biogenesis. Loss of parkin function does not tip the balance between mitochondrial biogenesis and degradation to either side, but leads to a general breakdown of mitochondrial homeostasis that can ultimately lead to PD.	[ "Parkin", "regulates", "the", "proteasomal", "degradation", "of", "PARIS", "and", "PGC-1alpha", "-", "dependent", "mitochondrial", "biogenesis", ".", "(", "A", ")", "Normal", "physiological", "conditions", "that", "maintain", "mitochondrial", "homeostasis", ":", "PINK1", "recruits", "parkin", "to", "the", "mitochondria", ",", "where", "these", "two", "proteins", "interact", "to", "eliminate", "abnormal", "mitochondria", "through", "mitophagy", ".", "Alterations", "in", "mitochondrial", "membrane", "potential", "(", "DeltaPsim", ";", "a", "key", "indicator", "of", "mitochondrial", "physiology", "and", "cell", "viability", ")", "initiate", "the", "PINK1-parkin", "cascade", "of", "events", "that", "lead", "to", "mitophagy", ".", "Furthermore", ",", "parkin", "ubiquitylates", "and", "thereby", "promotes", "proteasomal", "degradation", "of", "PARIS", ".", "Because", "PARIS", "represses", "the", "expression", "of", "PGC-1alpha", ",", "degradation", "of", "PARIS", "by", "parkin", "allows", "PGC-1alpha", "-", "dependent", "gene", "expression", "and", "enables", "mitochondrial", "biogenesis", ".", "Parkin", "seems", "to", "be", "an", "integral", "regulator", "of", "mitochondrial", "homeostasis", ",", "controlling", "both", "degradation", "and", "biogenesis", ".", "(", "B", ")", "Loss", "of", "parkin", "function", "as", "a", "result", "of", "familial", "mutations", "(", "in", "the", "case", "of", "AR", "-", "PD", ")", "or", "aging", ",", "environmental", "or", "cellular", "stress", "(", "in", "the", "case", "of", "sporadic", "PD", ")", "leads", "to", "the", "accumulation", "of", "abnormal", "mitochondria", ",", "owing", "to", "faulty", "mitophagy", ".", "In", "addition", ",", "PARIS", "accumulates", "and", "represses", "PGC-1alpha", ",", "preventing", "mitochondrial", "biogenesis", ".", "Loss", "of", "parkin", "function", "does", "not", "tip", "the", "balance", "between", "mitochondrial", "biogenesis", "and", "degradation", "to", "either", "side", ",", "but", "leads", "to", "a", "general", "breakdown", "of", "mitochondrial", "homeostasis", "that", "can", "ultimately", "lead", "to", "PD", ".", "\n" ]	[ "Cellular_component", "Cell" ]
proteasomal is a Cellular_component, mitochondrial is a Cellular_component, mitochondrial is a Cellular_component, mitochondria is a Cellular_component, mitochondria is a Cellular_component, mitochondrial membrane is a Cellular_component, mitochondrial is a Cellular_component, cell is a Cell, proteasomal is a Cellular_component, mitochondrial is a Cellular_component, mitochondrial is a Cellular_component, cellular is a Cell, mitochondria is a Cellular_component, mitochondrial is a Cellular_component, mitochondrial is a Cellular_component, mitochondrial is a Cellular_component	PMC-3124045-caption-01_task1	Sentence: Parkin regulates the proteasomal degradation of PARIS and PGC-1alpha-dependent mitochondrial biogenesis. (A) Normal physiological conditions that maintain mitochondrial homeostasis: PINK1 recruits parkin to the mitochondria, where these two proteins interact to eliminate abnormal mitochondria through mitophagy. Alterations in mitochondrial membrane potential (DeltaPsim; a key indicator of mitochondrial physiology and cell viability) initiate the PINK1-parkin cascade of events that lead to mitophagy. Furthermore, parkin ubiquitylates and thereby promotes proteasomal degradation of PARIS. Because PARIS represses the expression of PGC-1alpha, degradation of PARIS by parkin allows PGC-1alpha-dependent gene expression and enables mitochondrial biogenesis. Parkin seems to be an integral regulator of mitochondrial homeostasis, controlling both degradation and biogenesis. (B) Loss of parkin function as a result of familial mutations (in the case of AR-PD) or aging, environmental or cellular stress (in the case of sporadic PD) leads to the accumulation of abnormal mitochondria, owing to faulty mitophagy. In addition, PARIS accumulates and represses PGC-1alpha, preventing mitochondrial biogenesis. Loss of parkin function does not tip the balance between mitochondrial biogenesis and degradation to either side, but leads to a general breakdown of mitochondrial homeostasis that can ultimately lead to PD. Instructions: please typing these entity words according to sentence: proteasomal, mitochondrial, mitochondrial, mitochondria, mitochondria, mitochondrial membrane, mitochondrial, cell, proteasomal, mitochondrial, mitochondrial, cellular, mitochondria, mitochondrial, mitochondrial, mitochondrial Options: Cellular_component, Cell	[ "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Parkin regulates the proteasomal degradation of PARIS and PGC-1alpha-dependent mitochondrial biogenesis. (A) Normal physiological conditions that maintain mitochondrial homeostasis: PINK1 recruits parkin to the mitochondria, where these two proteins interact to eliminate abnormal mitochondria through mitophagy. Alterations in mitochondrial membrane potential (DeltaPsim; a key indicator of mitochondrial physiology and cell viability) initiate the PINK1-parkin cascade of events that lead to mitophagy. Furthermore, parkin ubiquitylates and thereby promotes proteasomal degradation of PARIS. Because PARIS represses the expression of PGC-1alpha, degradation of PARIS by parkin allows PGC-1alpha-dependent gene expression and enables mitochondrial biogenesis. Parkin seems to be an integral regulator of mitochondrial homeostasis, controlling both degradation and biogenesis. (B) Loss of parkin function as a result of familial mutations (in the case of AR-PD) or aging, environmental or cellular stress (in the case of sporadic PD) leads to the accumulation of abnormal mitochondria, owing to faulty mitophagy. In addition, PARIS accumulates and represses PGC-1alpha, preventing mitochondrial biogenesis. Loss of parkin function does not tip the balance between mitochondrial biogenesis and degradation to either side, but leads to a general breakdown of mitochondrial homeostasis that can ultimately lead to PD.	[ "Parkin", "regulates", "the", "proteasomal", "degradation", "of", "PARIS", "and", "PGC-1alpha", "-", "dependent", "mitochondrial", "biogenesis", ".", "(", "A", ")", "Normal", "physiological", "conditions", "that", "maintain", "mitochondrial", "homeostasis", ":", "PINK1", "recruits", "parkin", "to", "the", "mitochondria", ",", "where", "these", "two", "proteins", "interact", "to", "eliminate", "abnormal", "mitochondria", "through", "mitophagy", ".", "Alterations", "in", "mitochondrial", "membrane", "potential", "(", "DeltaPsim", ";", "a", "key", "indicator", "of", "mitochondrial", "physiology", "and", "cell", "viability", ")", "initiate", "the", "PINK1-parkin", "cascade", "of", "events", "that", "lead", "to", "mitophagy", ".", "Furthermore", ",", "parkin", "ubiquitylates", "and", "thereby", "promotes", "proteasomal", "degradation", "of", "PARIS", ".", "Because", "PARIS", "represses", "the", "expression", "of", "PGC-1alpha", ",", "degradation", "of", "PARIS", "by", "parkin", "allows", "PGC-1alpha", "-", "dependent", "gene", "expression", "and", "enables", "mitochondrial", "biogenesis", ".", "Parkin", "seems", "to", "be", "an", "integral", "regulator", "of", "mitochondrial", "homeostasis", ",", "controlling", "both", "degradation", "and", "biogenesis", ".", "(", "B", ")", "Loss", "of", "parkin", "function", "as", "a", "result", "of", "familial", "mutations", "(", "in", "the", "case", "of", "AR", "-", "PD", ")", "or", "aging", ",", "environmental", "or", "cellular", "stress", "(", "in", "the", "case", "of", "sporadic", "PD", ")", "leads", "to", "the", "accumulation", "of", "abnormal", "mitochondria", ",", "owing", "to", "faulty", "mitophagy", ".", "In", "addition", ",", "PARIS", "accumulates", "and", "represses", "PGC-1alpha", ",", "preventing", "mitochondrial", "biogenesis", ".", "Loss", "of", "parkin", "function", "does", "not", "tip", "the", "balance", "between", "mitochondrial", "biogenesis", "and", "degradation", "to", "either", "side", ",", "but", "leads", "to", "a", "general", "breakdown", "of", "mitochondrial", "homeostasis", "that", "can", "ultimately", "lead", "to", "PD", ".", "\n" ]	[ "Cellular_component", "Cell" ]
proteasomal, mitochondrial, mitochondrial, mitochondria, mitochondria, mitochondrial membrane, mitochondrial, cell, proteasomal, mitochondrial, mitochondrial, cellular, mitochondria, mitochondrial, mitochondrial, mitochondrial	PMC-3124045-caption-01_task2	Sentence: Parkin regulates the proteasomal degradation of PARIS and PGC-1alpha-dependent mitochondrial biogenesis. (A) Normal physiological conditions that maintain mitochondrial homeostasis: PINK1 recruits parkin to the mitochondria, where these two proteins interact to eliminate abnormal mitochondria through mitophagy. Alterations in mitochondrial membrane potential (DeltaPsim; a key indicator of mitochondrial physiology and cell viability) initiate the PINK1-parkin cascade of events that lead to mitophagy. Furthermore, parkin ubiquitylates and thereby promotes proteasomal degradation of PARIS. Because PARIS represses the expression of PGC-1alpha, degradation of PARIS by parkin allows PGC-1alpha-dependent gene expression and enables mitochondrial biogenesis. Parkin seems to be an integral regulator of mitochondrial homeostasis, controlling both degradation and biogenesis. (B) Loss of parkin function as a result of familial mutations (in the case of AR-PD) or aging, environmental or cellular stress (in the case of sporadic PD) leads to the accumulation of abnormal mitochondria, owing to faulty mitophagy. In addition, PARIS accumulates and represses PGC-1alpha, preventing mitochondrial biogenesis. Loss of parkin function does not tip the balance between mitochondrial biogenesis and degradation to either side, but leads to a general breakdown of mitochondrial homeostasis that can ultimately lead to PD. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Parkin regulates the proteasomal degradation of PARIS and PGC-1alpha-dependent mitochondrial biogenesis. (A) Normal physiological conditions that maintain mitochondrial homeostasis: PINK1 recruits parkin to the mitochondria, where these two proteins interact to eliminate abnormal mitochondria through mitophagy. Alterations in mitochondrial membrane potential (DeltaPsim; a key indicator of mitochondrial physiology and cell viability) initiate the PINK1-parkin cascade of events that lead to mitophagy. Furthermore, parkin ubiquitylates and thereby promotes proteasomal degradation of PARIS. Because PARIS represses the expression of PGC-1alpha, degradation of PARIS by parkin allows PGC-1alpha-dependent gene expression and enables mitochondrial biogenesis. Parkin seems to be an integral regulator of mitochondrial homeostasis, controlling both degradation and biogenesis. (B) Loss of parkin function as a result of familial mutations (in the case of AR-PD) or aging, environmental or cellular stress (in the case of sporadic PD) leads to the accumulation of abnormal mitochondria, owing to faulty mitophagy. In addition, PARIS accumulates and represses PGC-1alpha, preventing mitochondrial biogenesis. Loss of parkin function does not tip the balance between mitochondrial biogenesis and degradation to either side, but leads to a general breakdown of mitochondrial homeostasis that can ultimately lead to PD.	[ "Parkin", "regulates", "the", "proteasomal", "degradation", "of", "PARIS", "and", "PGC-1alpha", "-", "dependent", "mitochondrial", "biogenesis", ".", "(", "A", ")", "Normal", "physiological", "conditions", "that", "maintain", "mitochondrial", "homeostasis", ":", "PINK1", "recruits", "parkin", "to", "the", "mitochondria", ",", "where", "these", "two", "proteins", "interact", "to", "eliminate", "abnormal", "mitochondria", "through", "mitophagy", ".", "Alterations", "in", "mitochondrial", "membrane", "potential", "(", "DeltaPsim", ";", "a", "key", "indicator", "of", "mitochondrial", "physiology", "and", "cell", "viability", ")", "initiate", "the", "PINK1-parkin", "cascade", "of", "events", "that", "lead", "to", "mitophagy", ".", "Furthermore", ",", "parkin", "ubiquitylates", "and", "thereby", "promotes", "proteasomal", "degradation", "of", "PARIS", ".", "Because", "PARIS", "represses", "the", "expression", "of", "PGC-1alpha", ",", "degradation", "of", "PARIS", "by", "parkin", "allows", "PGC-1alpha", "-", "dependent", "gene", "expression", "and", "enables", "mitochondrial", "biogenesis", ".", "Parkin", "seems", "to", "be", "an", "integral", "regulator", "of", "mitochondrial", "homeostasis", ",", "controlling", "both", "degradation", "and", "biogenesis", ".", "(", "B", ")", "Loss", "of", "parkin", "function", "as", "a", "result", "of", "familial", "mutations", "(", "in", "the", "case", "of", "AR", "-", "PD", ")", "or", "aging", ",", "environmental", "or", "cellular", "stress", "(", "in", "the", "case", "of", "sporadic", "PD", ")", "leads", "to", "the", "accumulation", "of", "abnormal", "mitochondria", ",", "owing", "to", "faulty", "mitophagy", ".", "In", "addition", ",", "PARIS", "accumulates", "and", "represses", "PGC-1alpha", ",", "preventing", "mitochondrial", "biogenesis", ".", "Loss", "of", "parkin", "function", "does", "not", "tip", "the", "balance", "between", "mitochondrial", "biogenesis", "and", "degradation", "to", "either", "side", ",", "but", "leads", "to", "a", "general", "breakdown", "of", "mitochondrial", "homeostasis", "that", "can", "ultimately", "lead", "to", "PD", ".", "\n" ]	[ "Cellular_component", "Cell" ]
Gelenkblockierung is an umlsterm, Behandlung is an umlsterm, Patienten is an umlsterm, Kopfgelenke is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Gelenkspiels is an umlsterm, Gelenk is an umlsterm, selbst is an umlsterm	ManuelleMedizin.70350056.ger.abstr_task0	Sentence: Seit langem wird immer wieder nach einem Substrat der Gelenkblockierung gesucht . Es sind diesbezueglich verschiedene Theorien entwickelt worden , von denen aber keine allein saemtliche klinische Erscheinungen der Blockierungen oder der deblockierenden Behandlung erklaeren kann . Es wurden 50 Patienten mit Blockierungen der HWS von den Kopfgelenke bis zum zervikothorakalen Uebergang und 8 Patienten mit Iliosakralgelenkblockierungen in Narkose untersucht . Bei 8 Patienten waren unter Muskelrelaxierung die HWS - Blockierungen nicht mehr nachweisbar . Nach Narkoseausleitung waren sie bei 6 dieser Patienten wieder vorhanden . Die ISG - Blockierungen zeigten keinen veraenderten Befund bei Untersuchung in Narkose . Es konnte damit gezeigt werden , dass es mehrere Mechanismen fuer die Blockierung geben muss . Bei den in Narkose nicht nachzuweisenden und hinterher wieder aufgetretenen Blockierungen ist eine muskulaere Aethiogenese anzunehmen . In der Mehrzahl der Faelle ist allerdings die Stoerung des Gelenkspiels im Gelenk selbst zu suchen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O" ]	Seit langem wird immer wieder nach einem Substrat der Gelenkblockierung gesucht . Es sind diesbezueglich verschiedene Theorien entwickelt worden , von denen aber keine allein saemtliche klinische Erscheinungen der Blockierungen oder der deblockierenden Behandlung erklaeren kann . Es wurden 50 Patienten mit Blockierungen der HWS von den Kopfgelenke bis zum zervikothorakalen Uebergang und 8 Patienten mit Iliosakralgelenkblockierungen in Narkose untersucht . Bei 8 Patienten waren unter Muskelrelaxierung die HWS - Blockierungen nicht mehr nachweisbar . Nach Narkoseausleitung waren sie bei 6 dieser Patienten wieder vorhanden . Die ISG - Blockierungen zeigten keinen veraenderten Befund bei Untersuchung in Narkose . Es konnte damit gezeigt werden , dass es mehrere Mechanismen fuer die Blockierung geben muss . Bei den in Narkose nicht nachzuweisenden und hinterher wieder aufgetretenen Blockierungen ist eine muskulaere Aethiogenese anzunehmen . In der Mehrzahl der Faelle ist allerdings die Stoerung des Gelenkspiels im Gelenk selbst zu suchen .	[ "Seit", "langem", "wird", "immer", "wieder", "nach", "einem", "Substrat", "der", "Gelenkblockierung", "gesucht", ".", "Es", "sind", "diesbezueglich", "verschiedene", "Theorien", "entwickelt", "worden", ",", "von", "denen", "aber", "keine", "allein", "saemtliche", "klinische", "Erscheinungen", "der", "Blockierungen", "oder", "der", "deblockierenden", "Behandlung", "erklaeren", "kann", ".", "Es", "wurden", "50", "Patienten", "mit", "Blockierungen", "der", "HWS", "von", "den", "Kopfgelenke", "bis", "zum", "zervikothorakalen", "Uebergang", "und", "8", "Patienten", "mit", "Iliosakralgelenkblockierungen", "in", "Narkose", "untersucht", ".", "Bei", "8", "Patienten", "waren", "unter", "Muskelrelaxierung", "die", "HWS", "-", "Blockierungen", "nicht", "mehr", "nachweisbar", ".", "Nach", "Narkoseausleitung", "waren", "sie", "bei", "6", "dieser", "Patienten", "wieder", "vorhanden", ".", "Die", "ISG", "-", "Blockierungen", "zeigten", "keinen", "veraenderten", "Befund", "bei", "Untersuchung", "in", "Narkose", ".", "Es", "konnte", "damit", "gezeigt", "werden", ",", "dass", "es", "mehrere", "Mechanismen", "fuer", "die", "Blockierung", "geben", "muss", ".", "Bei", "den", "in", "Narkose", "nicht", "nachzuweisenden", "und", "hinterher", "wieder", "aufgetretenen", "Blockierungen", "ist", "eine", "muskulaere", "Aethiogenese", "anzunehmen", ".", "In", "der", "Mehrzahl", "der", "Faelle", "ist", "allerdings", "die", "Stoerung", "des", "Gelenkspiels", "im", "Gelenk", "selbst", "zu", "suchen", "." ]	[ "umlsterm" ]
Gelenkblockierung is an umlsterm, Behandlung is an umlsterm, Patienten is an umlsterm, Kopfgelenke is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Gelenkspiels is an umlsterm, Gelenk is an umlsterm, selbst is an umlsterm	ManuelleMedizin.70350056.ger.abstr_task1	Sentence: Seit langem wird immer wieder nach einem Substrat der Gelenkblockierung gesucht . Es sind diesbezueglich verschiedene Theorien entwickelt worden , von denen aber keine allein saemtliche klinische Erscheinungen der Blockierungen oder der deblockierenden Behandlung erklaeren kann . Es wurden 50 Patienten mit Blockierungen der HWS von den Kopfgelenke bis zum zervikothorakalen Uebergang und 8 Patienten mit Iliosakralgelenkblockierungen in Narkose untersucht . Bei 8 Patienten waren unter Muskelrelaxierung die HWS - Blockierungen nicht mehr nachweisbar . Nach Narkoseausleitung waren sie bei 6 dieser Patienten wieder vorhanden . Die ISG - Blockierungen zeigten keinen veraenderten Befund bei Untersuchung in Narkose . Es konnte damit gezeigt werden , dass es mehrere Mechanismen fuer die Blockierung geben muss . Bei den in Narkose nicht nachzuweisenden und hinterher wieder aufgetretenen Blockierungen ist eine muskulaere Aethiogenese anzunehmen . In der Mehrzahl der Faelle ist allerdings die Stoerung des Gelenkspiels im Gelenk selbst zu suchen . Instructions: please typing these entity words according to sentence: Gelenkblockierung, Behandlung, Patienten, Kopfgelenke, Patienten, Patienten, Patienten, Gelenkspiels, Gelenk, selbst Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O" ]	Seit langem wird immer wieder nach einem Substrat der Gelenkblockierung gesucht . Es sind diesbezueglich verschiedene Theorien entwickelt worden , von denen aber keine allein saemtliche klinische Erscheinungen der Blockierungen oder der deblockierenden Behandlung erklaeren kann . Es wurden 50 Patienten mit Blockierungen der HWS von den Kopfgelenke bis zum zervikothorakalen Uebergang und 8 Patienten mit Iliosakralgelenkblockierungen in Narkose untersucht . Bei 8 Patienten waren unter Muskelrelaxierung die HWS - Blockierungen nicht mehr nachweisbar . Nach Narkoseausleitung waren sie bei 6 dieser Patienten wieder vorhanden . Die ISG - Blockierungen zeigten keinen veraenderten Befund bei Untersuchung in Narkose . Es konnte damit gezeigt werden , dass es mehrere Mechanismen fuer die Blockierung geben muss . Bei den in Narkose nicht nachzuweisenden und hinterher wieder aufgetretenen Blockierungen ist eine muskulaere Aethiogenese anzunehmen . In der Mehrzahl der Faelle ist allerdings die Stoerung des Gelenkspiels im Gelenk selbst zu suchen .	[ "Seit", "langem", "wird", "immer", "wieder", "nach", "einem", "Substrat", "der", "Gelenkblockierung", "gesucht", ".", "Es", "sind", "diesbezueglich", "verschiedene", "Theorien", "entwickelt", "worden", ",", "von", "denen", "aber", "keine", "allein", "saemtliche", "klinische", "Erscheinungen", "der", "Blockierungen", "oder", "der", "deblockierenden", "Behandlung", "erklaeren", "kann", ".", "Es", "wurden", "50", "Patienten", "mit", "Blockierungen", "der", "HWS", "von", "den", "Kopfgelenke", "bis", "zum", "zervikothorakalen", "Uebergang", "und", "8", "Patienten", "mit", "Iliosakralgelenkblockierungen", "in", "Narkose", "untersucht", ".", "Bei", "8", "Patienten", "waren", "unter", "Muskelrelaxierung", "die", "HWS", "-", "Blockierungen", "nicht", "mehr", "nachweisbar", ".", "Nach", "Narkoseausleitung", "waren", "sie", "bei", "6", "dieser", "Patienten", "wieder", "vorhanden", ".", "Die", "ISG", "-", "Blockierungen", "zeigten", "keinen", "veraenderten", "Befund", "bei", "Untersuchung", "in", "Narkose", ".", "Es", "konnte", "damit", "gezeigt", "werden", ",", "dass", "es", "mehrere", "Mechanismen", "fuer", "die", "Blockierung", "geben", "muss", ".", "Bei", "den", "in", "Narkose", "nicht", "nachzuweisenden", "und", "hinterher", "wieder", "aufgetretenen", "Blockierungen", "ist", "eine", "muskulaere", "Aethiogenese", "anzunehmen", ".", "In", "der", "Mehrzahl", "der", "Faelle", "ist", "allerdings", "die", "Stoerung", "des", "Gelenkspiels", "im", "Gelenk", "selbst", "zu", "suchen", "." ]	[ "umlsterm" ]
Gelenkblockierung, Behandlung, Patienten, Kopfgelenke, Patienten, Patienten, Patienten, Gelenkspiels, Gelenk, selbst	ManuelleMedizin.70350056.ger.abstr_task2	Sentence: Seit langem wird immer wieder nach einem Substrat der Gelenkblockierung gesucht . Es sind diesbezueglich verschiedene Theorien entwickelt worden , von denen aber keine allein saemtliche klinische Erscheinungen der Blockierungen oder der deblockierenden Behandlung erklaeren kann . Es wurden 50 Patienten mit Blockierungen der HWS von den Kopfgelenke bis zum zervikothorakalen Uebergang und 8 Patienten mit Iliosakralgelenkblockierungen in Narkose untersucht . Bei 8 Patienten waren unter Muskelrelaxierung die HWS - Blockierungen nicht mehr nachweisbar . Nach Narkoseausleitung waren sie bei 6 dieser Patienten wieder vorhanden . Die ISG - Blockierungen zeigten keinen veraenderten Befund bei Untersuchung in Narkose . Es konnte damit gezeigt werden , dass es mehrere Mechanismen fuer die Blockierung geben muss . Bei den in Narkose nicht nachzuweisenden und hinterher wieder aufgetretenen Blockierungen ist eine muskulaere Aethiogenese anzunehmen . In der Mehrzahl der Faelle ist allerdings die Stoerung des Gelenkspiels im Gelenk selbst zu suchen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O" ]	Seit langem wird immer wieder nach einem Substrat der Gelenkblockierung gesucht . Es sind diesbezueglich verschiedene Theorien entwickelt worden , von denen aber keine allein saemtliche klinische Erscheinungen der Blockierungen oder der deblockierenden Behandlung erklaeren kann . Es wurden 50 Patienten mit Blockierungen der HWS von den Kopfgelenke bis zum zervikothorakalen Uebergang und 8 Patienten mit Iliosakralgelenkblockierungen in Narkose untersucht . Bei 8 Patienten waren unter Muskelrelaxierung die HWS - Blockierungen nicht mehr nachweisbar . Nach Narkoseausleitung waren sie bei 6 dieser Patienten wieder vorhanden . Die ISG - Blockierungen zeigten keinen veraenderten Befund bei Untersuchung in Narkose . Es konnte damit gezeigt werden , dass es mehrere Mechanismen fuer die Blockierung geben muss . Bei den in Narkose nicht nachzuweisenden und hinterher wieder aufgetretenen Blockierungen ist eine muskulaere Aethiogenese anzunehmen . In der Mehrzahl der Faelle ist allerdings die Stoerung des Gelenkspiels im Gelenk selbst zu suchen .	[ "Seit", "langem", "wird", "immer", "wieder", "nach", "einem", "Substrat", "der", "Gelenkblockierung", "gesucht", ".", "Es", "sind", "diesbezueglich", "verschiedene", "Theorien", "entwickelt", "worden", ",", "von", "denen", "aber", "keine", "allein", "saemtliche", "klinische", "Erscheinungen", "der", "Blockierungen", "oder", "der", "deblockierenden", "Behandlung", "erklaeren", "kann", ".", "Es", "wurden", "50", "Patienten", "mit", "Blockierungen", "der", "HWS", "von", "den", "Kopfgelenke", "bis", "zum", "zervikothorakalen", "Uebergang", "und", "8", "Patienten", "mit", "Iliosakralgelenkblockierungen", "in", "Narkose", "untersucht", ".", "Bei", "8", "Patienten", "waren", "unter", "Muskelrelaxierung", "die", "HWS", "-", "Blockierungen", "nicht", "mehr", "nachweisbar", ".", "Nach", "Narkoseausleitung", "waren", "sie", "bei", "6", "dieser", "Patienten", "wieder", "vorhanden", ".", "Die", "ISG", "-", "Blockierungen", "zeigten", "keinen", "veraenderten", "Befund", "bei", "Untersuchung", "in", "Narkose", ".", "Es", "konnte", "damit", "gezeigt", "werden", ",", "dass", "es", "mehrere", "Mechanismen", "fuer", "die", "Blockierung", "geben", "muss", ".", "Bei", "den", "in", "Narkose", "nicht", "nachzuweisenden", "und", "hinterher", "wieder", "aufgetretenen", "Blockierungen", "ist", "eine", "muskulaere", "Aethiogenese", "anzunehmen", ".", "In", "der", "Mehrzahl", "der", "Faelle", "ist", "allerdings", "die", "Stoerung", "des", "Gelenkspiels", "im", "Gelenk", "selbst", "zu", "suchen", "." ]	[ "umlsterm" ]
Patienten is an umlsterm, Kaliumchloridloesung is an umlsterm, Paraesthesien is an umlsterm, Schmerzen is an umlsterm, Beinen is an umlsterm, Innervationsausfall is an umlsterm, Hypertension is an umlsterm, Tachykardie is an umlsterm, Therapie is an umlsterm, Dexamethason is an umlsterm, neurologischen Defizite is an umlsterm, Patient is an umlsterm, Komplikationen is an umlsterm, Leitungen is an umlsterm, Verwendung is an umlsterm, Spritzenpumpen is an umlsterm, Medikamentenreservoir is an umlsterm, Spritzenwechsels is an umlsterm	DerAnaesthesist.90480896.ger.abstr_task0	Sentence: Bei einem 65jaehrigen Patienten wurden am ersten postoperativen Tag innerhalb von 3 h versehentlich 36 ml einer 7,45%-igen Kaliumchloridloesung in einen lumbalen Epiduralkatheter infundiert . Nach voruebergehenden Paraesthesien stellten sich als Folge der versehentlichen Infusion brennende Schmerzen in den Beinen ein , verbunden mit einem motorischen und sensorischen Innervationsausfall bis zum Segment TH 11. Begleitet wurde das Krankheitsbild von vegetativen Symptomen wie Hypertension und Tachykardie . Zur Therapie wurde ein einmaliger Bolus von 40 mg Dexamethason i.v. verabreicht gefolgt von einer kontinuierlichen epiduralen Infusion von NaCl 0,9% 99 ml/h . Nach 6 h begannen sich die neurologischen Defizite langsam zurueckzubilden . Nach 12 h war der Patient symptomfrei . Komplikationen wie die geschilderte beruhen in aller Regel auf Irrtuemern , deren Auftreten zwar nicht unmoeglich , durch entsprechende Massnahmen jedoch unwahrscheinlicher gemacht werden kann . Zu solchen Massnahmen gehoert die farbliche Markierung von Leitungen , Filtern und Infusionsloesungen sowie die Verwendung von Spritzenpumpen mit einem groesseren Medikamentenreservoir , um die Haeufigkeit des Spritzenwechsels zu vermindern . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Bei einem 65jaehrigen Patienten wurden am ersten postoperativen Tag innerhalb von 3 h versehentlich 36 ml einer 7,45%-igen Kaliumchloridloesung in einen lumbalen Epiduralkatheter infundiert . Nach voruebergehenden Paraesthesien stellten sich als Folge der versehentlichen Infusion brennende Schmerzen in den Beinen ein , verbunden mit einem motorischen und sensorischen Innervationsausfall bis zum Segment TH 11. Begleitet wurde das Krankheitsbild von vegetativen Symptomen wie Hypertension und Tachykardie . Zur Therapie wurde ein einmaliger Bolus von 40 mg Dexamethason i.v. verabreicht gefolgt von einer kontinuierlichen epiduralen Infusion von NaCl 0,9% 99 ml/h . Nach 6 h begannen sich die neurologischen Defizite langsam zurueckzubilden . Nach 12 h war der Patient symptomfrei . Komplikationen wie die geschilderte beruhen in aller Regel auf Irrtuemern , deren Auftreten zwar nicht unmoeglich , durch entsprechende Massnahmen jedoch unwahrscheinlicher gemacht werden kann . Zu solchen Massnahmen gehoert die farbliche Markierung von Leitungen , Filtern und Infusionsloesungen sowie die Verwendung von Spritzenpumpen mit einem groesseren Medikamentenreservoir , um die Haeufigkeit des Spritzenwechsels zu vermindern .	[ "Bei", "einem", "65jaehrigen", "Patienten", "wurden", "am", "ersten", "postoperativen", "Tag", "innerhalb", "von", "3", "h", "versehentlich", "36", "ml", "einer", "7,45%-igen", "Kaliumchloridloesung", "in", "einen", "lumbalen", "Epiduralkatheter", "infundiert", ".", "Nach", "voruebergehenden", "Paraesthesien", "stellten", "sich", "als", "Folge", "der", "versehentlichen", "Infusion", "brennende", "Schmerzen", "in", "den", "Beinen", "ein", ",", "verbunden", "mit", "einem", "motorischen", "und", "sensorischen", "Innervationsausfall", "bis", "zum", "Segment", "TH", "11", ".", "Begleitet", "wurde", "das", "Krankheitsbild", "von", "vegetativen", "Symptomen", "wie", "Hypertension", "und", "Tachykardie", ".", "Zur", "Therapie", "wurde", "ein", "einmaliger", "Bolus", "von", "40", "mg", "Dexamethason", "i.v", ".", "verabreicht", "gefolgt", "von", "einer", "kontinuierlichen", "epiduralen", "Infusion", "von", "NaCl", "0,9", "%", "99", "ml", "/", "h", ".", "Nach", "6", "h", "begannen", "sich", "die", "neurologischen", "Defizite", "langsam", "zurueckzubilden", ".", "Nach", "12", "h", "war", "der", "Patient", "symptomfrei", ".", "Komplikationen", "wie", "die", "geschilderte", "beruhen", "in", "aller", "Regel", "auf", "Irrtuemern", ",", "deren", "Auftreten", "zwar", "nicht", "unmoeglich", ",", "durch", "entsprechende", "Massnahmen", "jedoch", "unwahrscheinlicher", "gemacht", "werden", "kann", ".", "Zu", "solchen", "Massnahmen", "gehoert", "die", "farbliche", "Markierung", "von", "Leitungen", ",", "Filtern", "und", "Infusionsloesungen", "sowie", "die", "Verwendung", "von", "Spritzenpumpen", "mit", "einem", "groesseren", "Medikamentenreservoir", ",", "um", "die", "Haeufigkeit", "des", "Spritzenwechsels", "zu", "vermindern", "." ]	[ "umlsterm" ]
Patienten is an umlsterm, Kaliumchloridloesung is an umlsterm, Paraesthesien is an umlsterm, Schmerzen is an umlsterm, Beinen is an umlsterm, Innervationsausfall is an umlsterm, Hypertension is an umlsterm, Tachykardie is an umlsterm, Therapie is an umlsterm, Dexamethason is an umlsterm, neurologischen Defizite is an umlsterm, Patient is an umlsterm, Komplikationen is an umlsterm, Leitungen is an umlsterm, Verwendung is an umlsterm, Spritzenpumpen is an umlsterm, Medikamentenreservoir is an umlsterm, Spritzenwechsels is an umlsterm	DerAnaesthesist.90480896.ger.abstr_task1	Sentence: Bei einem 65jaehrigen Patienten wurden am ersten postoperativen Tag innerhalb von 3 h versehentlich 36 ml einer 7,45%-igen Kaliumchloridloesung in einen lumbalen Epiduralkatheter infundiert . Nach voruebergehenden Paraesthesien stellten sich als Folge der versehentlichen Infusion brennende Schmerzen in den Beinen ein , verbunden mit einem motorischen und sensorischen Innervationsausfall bis zum Segment TH 11. Begleitet wurde das Krankheitsbild von vegetativen Symptomen wie Hypertension und Tachykardie . Zur Therapie wurde ein einmaliger Bolus von 40 mg Dexamethason i.v. verabreicht gefolgt von einer kontinuierlichen epiduralen Infusion von NaCl 0,9% 99 ml/h . Nach 6 h begannen sich die neurologischen Defizite langsam zurueckzubilden . Nach 12 h war der Patient symptomfrei . Komplikationen wie die geschilderte beruhen in aller Regel auf Irrtuemern , deren Auftreten zwar nicht unmoeglich , durch entsprechende Massnahmen jedoch unwahrscheinlicher gemacht werden kann . Zu solchen Massnahmen gehoert die farbliche Markierung von Leitungen , Filtern und Infusionsloesungen sowie die Verwendung von Spritzenpumpen mit einem groesseren Medikamentenreservoir , um die Haeufigkeit des Spritzenwechsels zu vermindern . Instructions: please typing these entity words according to sentence: Patienten, Kaliumchloridloesung, Paraesthesien, Schmerzen, Beinen, Innervationsausfall, Hypertension, Tachykardie, Therapie, Dexamethason, neurologischen Defizite, Patient, Komplikationen, Leitungen, Verwendung, Spritzenpumpen, Medikamentenreservoir, Spritzenwechsels Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Bei einem 65jaehrigen Patienten wurden am ersten postoperativen Tag innerhalb von 3 h versehentlich 36 ml einer 7,45%-igen Kaliumchloridloesung in einen lumbalen Epiduralkatheter infundiert . Nach voruebergehenden Paraesthesien stellten sich als Folge der versehentlichen Infusion brennende Schmerzen in den Beinen ein , verbunden mit einem motorischen und sensorischen Innervationsausfall bis zum Segment TH 11. Begleitet wurde das Krankheitsbild von vegetativen Symptomen wie Hypertension und Tachykardie . Zur Therapie wurde ein einmaliger Bolus von 40 mg Dexamethason i.v. verabreicht gefolgt von einer kontinuierlichen epiduralen Infusion von NaCl 0,9% 99 ml/h . Nach 6 h begannen sich die neurologischen Defizite langsam zurueckzubilden . Nach 12 h war der Patient symptomfrei . Komplikationen wie die geschilderte beruhen in aller Regel auf Irrtuemern , deren Auftreten zwar nicht unmoeglich , durch entsprechende Massnahmen jedoch unwahrscheinlicher gemacht werden kann . Zu solchen Massnahmen gehoert die farbliche Markierung von Leitungen , Filtern und Infusionsloesungen sowie die Verwendung von Spritzenpumpen mit einem groesseren Medikamentenreservoir , um die Haeufigkeit des Spritzenwechsels zu vermindern .	[ "Bei", "einem", "65jaehrigen", "Patienten", "wurden", "am", "ersten", "postoperativen", "Tag", "innerhalb", "von", "3", "h", "versehentlich", "36", "ml", "einer", "7,45%-igen", "Kaliumchloridloesung", "in", "einen", "lumbalen", "Epiduralkatheter", "infundiert", ".", "Nach", "voruebergehenden", "Paraesthesien", "stellten", "sich", "als", "Folge", "der", "versehentlichen", "Infusion", "brennende", "Schmerzen", "in", "den", "Beinen", "ein", ",", "verbunden", "mit", "einem", "motorischen", "und", "sensorischen", "Innervationsausfall", "bis", "zum", "Segment", "TH", "11", ".", "Begleitet", "wurde", "das", "Krankheitsbild", "von", "vegetativen", "Symptomen", "wie", "Hypertension", "und", "Tachykardie", ".", "Zur", "Therapie", "wurde", "ein", "einmaliger", "Bolus", "von", "40", "mg", "Dexamethason", "i.v", ".", "verabreicht", "gefolgt", "von", "einer", "kontinuierlichen", "epiduralen", "Infusion", "von", "NaCl", "0,9", "%", "99", "ml", "/", "h", ".", "Nach", "6", "h", "begannen", "sich", "die", "neurologischen", "Defizite", "langsam", "zurueckzubilden", ".", "Nach", "12", "h", "war", "der", "Patient", "symptomfrei", ".", "Komplikationen", "wie", "die", "geschilderte", "beruhen", "in", "aller", "Regel", "auf", "Irrtuemern", ",", "deren", "Auftreten", "zwar", "nicht", "unmoeglich", ",", "durch", "entsprechende", "Massnahmen", "jedoch", "unwahrscheinlicher", "gemacht", "werden", "kann", ".", "Zu", "solchen", "Massnahmen", "gehoert", "die", "farbliche", "Markierung", "von", "Leitungen", ",", "Filtern", "und", "Infusionsloesungen", "sowie", "die", "Verwendung", "von", "Spritzenpumpen", "mit", "einem", "groesseren", "Medikamentenreservoir", ",", "um", "die", "Haeufigkeit", "des", "Spritzenwechsels", "zu", "vermindern", "." ]	[ "umlsterm" ]
Patienten, Kaliumchloridloesung, Paraesthesien, Schmerzen, Beinen, Innervationsausfall, Hypertension, Tachykardie, Therapie, Dexamethason, neurologischen Defizite, Patient, Komplikationen, Leitungen, Verwendung, Spritzenpumpen, Medikamentenreservoir, Spritzenwechsels	DerAnaesthesist.90480896.ger.abstr_task2	Sentence: Bei einem 65jaehrigen Patienten wurden am ersten postoperativen Tag innerhalb von 3 h versehentlich 36 ml einer 7,45%-igen Kaliumchloridloesung in einen lumbalen Epiduralkatheter infundiert . Nach voruebergehenden Paraesthesien stellten sich als Folge der versehentlichen Infusion brennende Schmerzen in den Beinen ein , verbunden mit einem motorischen und sensorischen Innervationsausfall bis zum Segment TH 11. Begleitet wurde das Krankheitsbild von vegetativen Symptomen wie Hypertension und Tachykardie . Zur Therapie wurde ein einmaliger Bolus von 40 mg Dexamethason i.v. verabreicht gefolgt von einer kontinuierlichen epiduralen Infusion von NaCl 0,9% 99 ml/h . Nach 6 h begannen sich die neurologischen Defizite langsam zurueckzubilden . Nach 12 h war der Patient symptomfrei . Komplikationen wie die geschilderte beruhen in aller Regel auf Irrtuemern , deren Auftreten zwar nicht unmoeglich , durch entsprechende Massnahmen jedoch unwahrscheinlicher gemacht werden kann . Zu solchen Massnahmen gehoert die farbliche Markierung von Leitungen , Filtern und Infusionsloesungen sowie die Verwendung von Spritzenpumpen mit einem groesseren Medikamentenreservoir , um die Haeufigkeit des Spritzenwechsels zu vermindern . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Bei einem 65jaehrigen Patienten wurden am ersten postoperativen Tag innerhalb von 3 h versehentlich 36 ml einer 7,45%-igen Kaliumchloridloesung in einen lumbalen Epiduralkatheter infundiert . Nach voruebergehenden Paraesthesien stellten sich als Folge der versehentlichen Infusion brennende Schmerzen in den Beinen ein , verbunden mit einem motorischen und sensorischen Innervationsausfall bis zum Segment TH 11. Begleitet wurde das Krankheitsbild von vegetativen Symptomen wie Hypertension und Tachykardie . Zur Therapie wurde ein einmaliger Bolus von 40 mg Dexamethason i.v. verabreicht gefolgt von einer kontinuierlichen epiduralen Infusion von NaCl 0,9% 99 ml/h . Nach 6 h begannen sich die neurologischen Defizite langsam zurueckzubilden . Nach 12 h war der Patient symptomfrei . Komplikationen wie die geschilderte beruhen in aller Regel auf Irrtuemern , deren Auftreten zwar nicht unmoeglich , durch entsprechende Massnahmen jedoch unwahrscheinlicher gemacht werden kann . Zu solchen Massnahmen gehoert die farbliche Markierung von Leitungen , Filtern und Infusionsloesungen sowie die Verwendung von Spritzenpumpen mit einem groesseren Medikamentenreservoir , um die Haeufigkeit des Spritzenwechsels zu vermindern .	[ "Bei", "einem", "65jaehrigen", "Patienten", "wurden", "am", "ersten", "postoperativen", "Tag", "innerhalb", "von", "3", "h", "versehentlich", "36", "ml", "einer", "7,45%-igen", "Kaliumchloridloesung", "in", "einen", "lumbalen", "Epiduralkatheter", "infundiert", ".", "Nach", "voruebergehenden", "Paraesthesien", "stellten", "sich", "als", "Folge", "der", "versehentlichen", "Infusion", "brennende", "Schmerzen", "in", "den", "Beinen", "ein", ",", "verbunden", "mit", "einem", "motorischen", "und", "sensorischen", "Innervationsausfall", "bis", "zum", "Segment", "TH", "11", ".", "Begleitet", "wurde", "das", "Krankheitsbild", "von", "vegetativen", "Symptomen", "wie", "Hypertension", "und", "Tachykardie", ".", "Zur", "Therapie", "wurde", "ein", "einmaliger", "Bolus", "von", "40", "mg", "Dexamethason", "i.v", ".", "verabreicht", "gefolgt", "von", "einer", "kontinuierlichen", "epiduralen", "Infusion", "von", "NaCl", "0,9", "%", "99", "ml", "/", "h", ".", "Nach", "6", "h", "begannen", "sich", "die", "neurologischen", "Defizite", "langsam", "zurueckzubilden", ".", "Nach", "12", "h", "war", "der", "Patient", "symptomfrei", ".", "Komplikationen", "wie", "die", "geschilderte", "beruhen", "in", "aller", "Regel", "auf", "Irrtuemern", ",", "deren", "Auftreten", "zwar", "nicht", "unmoeglich", ",", "durch", "entsprechende", "Massnahmen", "jedoch", "unwahrscheinlicher", "gemacht", "werden", "kann", ".", "Zu", "solchen", "Massnahmen", "gehoert", "die", "farbliche", "Markierung", "von", "Leitungen", ",", "Filtern", "und", "Infusionsloesungen", "sowie", "die", "Verwendung", "von", "Spritzenpumpen", "mit", "einem", "groesseren", "Medikamentenreservoir", ",", "um", "die", "Haeufigkeit", "des", "Spritzenwechsels", "zu", "vermindern", "." ]	[ "umlsterm" ]
Abstract is an umlsterm, methylprednisolone is an umlsterm, neurologic deficits is an umlsterm, spinal cord injury is an umlsterm, National is an umlsterm, Spinal Cord Injury is an umlsterm, retrospective studies is an umlsterm, incidence is an umlsterm, complications is an umlsterm, intensive care is an umlsterm, hyperglycemia is an umlsterm, acidosis is an umlsterm, patients is an umlsterm, blunt injuries is an umlsterm, spinal cord injury is an umlsterm, adverse effects is an umlsterm, epinephrine is an umlsterm, methylprednisolone is an umlsterm, methylprednisolone is an umlsterm, patients is an umlsterm, catecholamine is an umlsterm	DerUnfallchirurg.01030495.eng.abstr_task0	Sentence: Abstract Large-dose methylprednisolone has been advocated to lessen neurologic deficits in spinal cord injury for nearly a decade despite confounding statistical results in the Second National Acute Spinal Cord Injury Study ( NASCIS-2). Recent retrospective studies found lack of significant functional improvement , increases in the incidence of infectious complications and an increase in ventilated and intensive care days in steroid-treated groups . We report on five cases with severe hyperglycemia and nonketotic metabolic acidosis in otherwise non-diabetic patients with multiple blunt injuries and an associated spinal cord injury . Those adverse effects were induced by epinephrine and aggravated by methylprednisolone . We conclude that high-dose methylprednisolone should be avoided in multiple injured or otherwise compromised patients potentially needing catecholamine support . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]	Abstract Large-dose methylprednisolone has been advocated to lessen neurologic deficits in spinal cord injury for nearly a decade despite confounding statistical results in the Second National Acute Spinal Cord Injury Study ( NASCIS-2). Recent retrospective studies found lack of significant functional improvement , increases in the incidence of infectious complications and an increase in ventilated and intensive care days in steroid-treated groups . We report on five cases with severe hyperglycemia and nonketotic metabolic acidosis in otherwise non-diabetic patients with multiple blunt injuries and an associated spinal cord injury . Those adverse effects were induced by epinephrine and aggravated by methylprednisolone . We conclude that high-dose methylprednisolone should be avoided in multiple injured or otherwise compromised patients potentially needing catecholamine support .	[ "Abstract", "Large", "-", "dose", "methylprednisolone", "has", "been", "advocated", "to", "lessen", "neurologic", "deficits", "in", "spinal", "cord", "injury", "for", "nearly", "a", "decade", "despite", "confounding", "statistical", "results", "in", "the", "Second", "National", "Acute", "Spinal", "Cord", "Injury", "Study", "(", "NASCIS-2", ")", ".", "Recent", "retrospective", "studies", "found", "lack", "of", "significant", "functional", "improvement", ",", "increases", "in", "the", "incidence", "of", "infectious", "complications", "and", "an", "increase", "in", "ventilated", "and", "intensive", "care", "days", "in", "steroid", "-", "treated", "groups", ".", "We", "report", "on", "five", "cases", "with", "severe", "hyperglycemia", "and", "nonketotic", "metabolic", "acidosis", "in", "otherwise", "non", "-", "diabetic", "patients", "with", "multiple", "blunt", "injuries", "and", "an", "associated", "spinal", "cord", "injury", ".", "Those", "adverse", "effects", "were", "induced", "by", "epinephrine", "and", "aggravated", "by", "methylprednisolone", ".", "We", "conclude", "that", "high", "-", "dose", "methylprednisolone", "should", "be", "avoided", "in", "multiple", "injured", "or", "otherwise", "compromised", "patients", "potentially", "needing", "catecholamine", "support", "." ]	[ "umlsterm" ]
Abstract is an umlsterm, methylprednisolone is an umlsterm, neurologic deficits is an umlsterm, spinal cord injury is an umlsterm, National is an umlsterm, Spinal Cord Injury is an umlsterm, retrospective studies is an umlsterm, incidence is an umlsterm, complications is an umlsterm, intensive care is an umlsterm, hyperglycemia is an umlsterm, acidosis is an umlsterm, patients is an umlsterm, blunt injuries is an umlsterm, spinal cord injury is an umlsterm, adverse effects is an umlsterm, epinephrine is an umlsterm, methylprednisolone is an umlsterm, methylprednisolone is an umlsterm, patients is an umlsterm, catecholamine is an umlsterm	DerUnfallchirurg.01030495.eng.abstr_task1	Sentence: Abstract Large-dose methylprednisolone has been advocated to lessen neurologic deficits in spinal cord injury for nearly a decade despite confounding statistical results in the Second National Acute Spinal Cord Injury Study ( NASCIS-2). Recent retrospective studies found lack of significant functional improvement , increases in the incidence of infectious complications and an increase in ventilated and intensive care days in steroid-treated groups . We report on five cases with severe hyperglycemia and nonketotic metabolic acidosis in otherwise non-diabetic patients with multiple blunt injuries and an associated spinal cord injury . Those adverse effects were induced by epinephrine and aggravated by methylprednisolone . We conclude that high-dose methylprednisolone should be avoided in multiple injured or otherwise compromised patients potentially needing catecholamine support . Instructions: please typing these entity words according to sentence: Abstract, methylprednisolone, neurologic deficits, spinal cord injury, National, Spinal Cord Injury, retrospective studies, incidence, complications, intensive care, hyperglycemia, acidosis, patients, blunt injuries, spinal cord injury, adverse effects, epinephrine, methylprednisolone, methylprednisolone, patients, catecholamine Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]	Abstract Large-dose methylprednisolone has been advocated to lessen neurologic deficits in spinal cord injury for nearly a decade despite confounding statistical results in the Second National Acute Spinal Cord Injury Study ( NASCIS-2). Recent retrospective studies found lack of significant functional improvement , increases in the incidence of infectious complications and an increase in ventilated and intensive care days in steroid-treated groups . We report on five cases with severe hyperglycemia and nonketotic metabolic acidosis in otherwise non-diabetic patients with multiple blunt injuries and an associated spinal cord injury . Those adverse effects were induced by epinephrine and aggravated by methylprednisolone . We conclude that high-dose methylprednisolone should be avoided in multiple injured or otherwise compromised patients potentially needing catecholamine support .	[ "Abstract", "Large", "-", "dose", "methylprednisolone", "has", "been", "advocated", "to", "lessen", "neurologic", "deficits", "in", "spinal", "cord", "injury", "for", "nearly", "a", "decade", "despite", "confounding", "statistical", "results", "in", "the", "Second", "National", "Acute", "Spinal", "Cord", "Injury", "Study", "(", "NASCIS-2", ")", ".", "Recent", "retrospective", "studies", "found", "lack", "of", "significant", "functional", "improvement", ",", "increases", "in", "the", "incidence", "of", "infectious", "complications", "and", "an", "increase", "in", "ventilated", "and", "intensive", "care", "days", "in", "steroid", "-", "treated", "groups", ".", "We", "report", "on", "five", "cases", "with", "severe", "hyperglycemia", "and", "nonketotic", "metabolic", "acidosis", "in", "otherwise", "non", "-", "diabetic", "patients", "with", "multiple", "blunt", "injuries", "and", "an", "associated", "spinal", "cord", "injury", ".", "Those", "adverse", "effects", "were", "induced", "by", "epinephrine", "and", "aggravated", "by", "methylprednisolone", ".", "We", "conclude", "that", "high", "-", "dose", "methylprednisolone", "should", "be", "avoided", "in", "multiple", "injured", "or", "otherwise", "compromised", "patients", "potentially", "needing", "catecholamine", "support", "." ]	[ "umlsterm" ]
Abstract, methylprednisolone, neurologic deficits, spinal cord injury, National, Spinal Cord Injury, retrospective studies, incidence, complications, intensive care, hyperglycemia, acidosis, patients, blunt injuries, spinal cord injury, adverse effects, epinephrine, methylprednisolone, methylprednisolone, patients, catecholamine	DerUnfallchirurg.01030495.eng.abstr_task2	Sentence: Abstract Large-dose methylprednisolone has been advocated to lessen neurologic deficits in spinal cord injury for nearly a decade despite confounding statistical results in the Second National Acute Spinal Cord Injury Study ( NASCIS-2). Recent retrospective studies found lack of significant functional improvement , increases in the incidence of infectious complications and an increase in ventilated and intensive care days in steroid-treated groups . We report on five cases with severe hyperglycemia and nonketotic metabolic acidosis in otherwise non-diabetic patients with multiple blunt injuries and an associated spinal cord injury . Those adverse effects were induced by epinephrine and aggravated by methylprednisolone . We conclude that high-dose methylprednisolone should be avoided in multiple injured or otherwise compromised patients potentially needing catecholamine support . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]	Abstract Large-dose methylprednisolone has been advocated to lessen neurologic deficits in spinal cord injury for nearly a decade despite confounding statistical results in the Second National Acute Spinal Cord Injury Study ( NASCIS-2). Recent retrospective studies found lack of significant functional improvement , increases in the incidence of infectious complications and an increase in ventilated and intensive care days in steroid-treated groups . We report on five cases with severe hyperglycemia and nonketotic metabolic acidosis in otherwise non-diabetic patients with multiple blunt injuries and an associated spinal cord injury . Those adverse effects were induced by epinephrine and aggravated by methylprednisolone . We conclude that high-dose methylprednisolone should be avoided in multiple injured or otherwise compromised patients potentially needing catecholamine support .	[ "Abstract", "Large", "-", "dose", "methylprednisolone", "has", "been", "advocated", "to", "lessen", "neurologic", "deficits", "in", "spinal", "cord", "injury", "for", "nearly", "a", "decade", "despite", "confounding", "statistical", "results", "in", "the", "Second", "National", "Acute", "Spinal", "Cord", "Injury", "Study", "(", "NASCIS-2", ")", ".", "Recent", "retrospective", "studies", "found", "lack", "of", "significant", "functional", "improvement", ",", "increases", "in", "the", "incidence", "of", "infectious", "complications", "and", "an", "increase", "in", "ventilated", "and", "intensive", "care", "days", "in", "steroid", "-", "treated", "groups", ".", "We", "report", "on", "five", "cases", "with", "severe", "hyperglycemia", "and", "nonketotic", "metabolic", "acidosis", "in", "otherwise", "non", "-", "diabetic", "patients", "with", "multiple", "blunt", "injuries", "and", "an", "associated", "spinal", "cord", "injury", ".", "Those", "adverse", "effects", "were", "induced", "by", "epinephrine", "and", "aggravated", "by", "methylprednisolone", ".", "We", "conclude", "that", "high", "-", "dose", "methylprednisolone", "should", "be", "avoided", "in", "multiple", "injured", "or", "otherwise", "compromised", "patients", "potentially", "needing", "catecholamine", "support", "." ]	[ "umlsterm" ]
male is an umlsterm, volunteers is an umlsterm, piroxicam is an umlsterm, period is an umlsterm	ZfuerRheumatologie.70560076.eng.abstr_task0	Sentence: The gastroduodenal tolerability of piroxicam--cyclodextrine was evaluated in a double-blind , parallel group study in 32 healthy male volunteers . The doses used were 20mg piroxicam--cyclodextrin vs 20mg piroxicam daily over a period of 14 days . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	The gastroduodenal tolerability of piroxicam--cyclodextrine was evaluated in a double-blind , parallel group study in 32 healthy male volunteers . The doses used were 20mg piroxicam--cyclodextrin vs 20mg piroxicam daily over a period of 14 days .	[ "The", "gastroduodenal", "tolerability", "of", "piroxicam", "--", "cyclodextrine", "was", "evaluated", "in", "a", "double", "-", "blind", ",", "parallel", "group", "study", "in", "32", "healthy", "male", "volunteers", ".", "The", "doses", "used", "were", "20", "mg", "piroxicam", "--", "cyclodextrin", "vs", "20", "mg", "piroxicam", "daily", "over", "a", "period", "of", "14", "days", "." ]	[ "umlsterm" ]
male is an umlsterm, volunteers is an umlsterm, piroxicam is an umlsterm, period is an umlsterm	ZfuerRheumatologie.70560076.eng.abstr_task1	Sentence: The gastroduodenal tolerability of piroxicam--cyclodextrine was evaluated in a double-blind , parallel group study in 32 healthy male volunteers . The doses used were 20mg piroxicam--cyclodextrin vs 20mg piroxicam daily over a period of 14 days . Instructions: please typing these entity words according to sentence: male, volunteers, piroxicam, period Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	The gastroduodenal tolerability of piroxicam--cyclodextrine was evaluated in a double-blind , parallel group study in 32 healthy male volunteers . The doses used were 20mg piroxicam--cyclodextrin vs 20mg piroxicam daily over a period of 14 days .	[ "The", "gastroduodenal", "tolerability", "of", "piroxicam", "--", "cyclodextrine", "was", "evaluated", "in", "a", "double", "-", "blind", ",", "parallel", "group", "study", "in", "32", "healthy", "male", "volunteers", ".", "The", "doses", "used", "were", "20", "mg", "piroxicam", "--", "cyclodextrin", "vs", "20", "mg", "piroxicam", "daily", "over", "a", "period", "of", "14", "days", "." ]	[ "umlsterm" ]

over 40 years is a Value, Medical examination is a Procedure, prior to participation in research is a Temporal, without is a Negation, history is a Observation, inner ear disease is a Condition

NCT02529475_inc_task1

Sentence: Major subjects of over 40 years (mean age of Meniere's disease 40 to 50 years) Informed consent signed Medical examination performed prior to participation in research Patients without history of inner ear disease Recipient of a French social security scheme Instructions: please typing these entity words according to sentence: over 40 years, Medical examination, prior to participation in research, without, history, inner ear disease Options: Temporal, Condition, Value, Observation, Procedure, Negation

[ "O", "O", "O", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Negation", "B-Observation", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Major subjects of over 40 years (mean age of Meniere's disease 40 to 50 years) Informed consent signed Medical examination performed prior to participation in research Patients without history of inner ear disease Recipient of a French social security scheme

[ "Major", "subjects", "of", "over", "40", "years", "(", "mean", "age", "of", "Meniere", "'s", "disease", "40", "to", "50", "years", ")", "\n", "Informed", "consent", "signed", "\n", "Medical", "examination", "performed", "prior", "to", "participation", "in", "research", "\n", "Patients", "without", "history", "of", "inner", "ear", "disease", "\n", "Recipient", "of", "a", "French", "social", "security", "scheme", "\n" ]

[ "Temporal", "Procedure", "Condition", "Value", "Observation", "Negation", "Person" ]

over 40 years, Medical examination, prior to participation in research, without, history, inner ear disease

NCT02529475_inc_task2

Sentence: Major subjects of over 40 years (mean age of Meniere's disease 40 to 50 years) Informed consent signed Medical examination performed prior to participation in research Patients without history of inner ear disease Recipient of a French social security scheme Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Negation", "B-Observation", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Major subjects of over 40 years (mean age of Meniere's disease 40 to 50 years) Informed consent signed Medical examination performed prior to participation in research Patients without history of inner ear disease Recipient of a French social security scheme

[ "Major", "subjects", "of", "over", "40", "years", "(", "mean", "age", "of", "Meniere", "'s", "disease", "40", "to", "50", "years", ")", "\n", "Informed", "consent", "signed", "\n", "Medical", "examination", "performed", "prior", "to", "participation", "in", "research", "\n", "Patients", "without", "history", "of", "inner", "ear", "disease", "\n", "Recipient", "of", "a", "French", "social", "security", "scheme", "\n" ]

[ "Temporal", "Procedure", "Condition", "Value", "Observation", "Negation", "Person" ]

Virtual reality intervention is a Intervention_Educational, older is a Participant_Age, women is a Participant_Sex, breast cancer is a Participant_Condition, virtual reality distraction intervention is a Intervention_Educational, symptom distress is a Outcome_Physical, 16 is a Participant_Sample-size, 50 and older is a Participant_Age, a head - mounted display ( Sony PC Glasstron PLM - S700 ) was used to display encompassing images and block competing stimuli during chemotherapy infusions . is a Intervention_Psychological, Symptom Distress Scale ( SDS ) is a Outcome_Physical, Revised Piper Fatigue Scale ( PFS ) , is a Outcome_Physical, State Anxiety Inventory ( SAI is a Outcome_Mental, VR distraction intervention during one chemotherapy treatment is a Intervention_Educational, no distraction intervention ( control condition ) is a Intervention_Control, decrease is a Outcome_Other, improved symptoms is a Outcome_Physical, cybersickness is a Outcome_Physical

13500_task0

Sentence: Virtual reality intervention for older women with breast cancer . This study examined the effects of a virtual reality distraction intervention on chemotherapy-related symptom distress levels in 16 women aged 50 and older . A cross-over design was used to answer the following research questions : ( 1 ) Is virtual reality an effective distraction intervention for reducing chemotherapy-related symptom distress levels in older women with breast cancer ? ( 2 ) Does virtual reality have a lasting effect ? Chemotherapy treatments are intensive and difficult to endure . One way to cope with chemotherapy-related symptom distress is through the use of distraction . For this study , a head-mounted display ( Sony PC Glasstron PLM - S700 ) was used to display encompassing images and block competing stimuli during chemotherapy infusions . The Symptom Distress Scale ( SDS ) , Revised Piper Fatigue Scale ( PFS ) , and the State Anxiety Inventory ( SAI ) were used to measure symptom distress . For two matched chemotherapy treatments , one pre-test and two post-test measures were employed . Participants were randomly assigned to receive the VR distraction intervention during one chemotherapy treatment and received no distraction intervention ( control condition ) during an alternate chemotherapy treatment . Analysis using paired t-tests demonstrated a significant decrease in the SAI ( p = 0.10 ) scores immediately following chemotherapy treatments when participants used VR . No significant changes were found in SDS or PFS values . There was a consistent trend toward improved symptoms on all measures 48 h following completion of chemotherapy . Evaluation of the intervention indicated that women thought the head mounted device was easy to use , they experienced no cybersickness , and 100 % would use VR again . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Psychological, Participant_Condition, Participant_Sex, Intervention_Control, Intervention_Educational, Outcome_Physical, Participant_Age, Participant_Sample-size, Outcome_Other, Outcome_Mental

[ "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Participant_Age", "B-Participant_Sex", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Virtual reality intervention for older women with breast cancer . This study examined the effects of a virtual reality distraction intervention on chemotherapy-related symptom distress levels in 16 women aged 50 and older . A cross-over design was used to answer the following research questions : ( 1 ) Is virtual reality an effective distraction intervention for reducing chemotherapy-related symptom distress levels in older women with breast cancer ? ( 2 ) Does virtual reality have a lasting effect ? Chemotherapy treatments are intensive and difficult to endure . One way to cope with chemotherapy-related symptom distress is through the use of distraction . For this study , a head-mounted display ( Sony PC Glasstron PLM - S700 ) was used to display encompassing images and block competing stimuli during chemotherapy infusions . The Symptom Distress Scale ( SDS ) , Revised Piper Fatigue Scale ( PFS ) , and the State Anxiety Inventory ( SAI ) were used to measure symptom distress . For two matched chemotherapy treatments , one pre-test and two post-test measures were employed . Participants were randomly assigned to receive the VR distraction intervention during one chemotherapy treatment and received no distraction intervention ( control condition ) during an alternate chemotherapy treatment . Analysis using paired t-tests demonstrated a significant decrease in the SAI ( p = 0.10 ) scores immediately following chemotherapy treatments when participants used VR . No significant changes were found in SDS or PFS values . There was a consistent trend toward improved symptoms on all measures 48 h following completion of chemotherapy . Evaluation of the intervention indicated that women thought the head mounted device was easy to use , they experienced no cybersickness , and 100 % would use VR again .

[ "Virtual", "reality", "intervention", "for", "older", "women", "with", "breast", "cancer", ".", "This", "study", "examined", "the", "effects", "of", "a", "virtual", "reality", "distraction", "intervention", "on", "chemotherapy", "-", "related", "symptom", "distress", "levels", "in", "16", "women", "aged", "50", "and", "older", ".", "A", "cross", "-", "over", "design", "was", "used", "to", "answer", "the", "following", "research", "questions", ":", "(", "1", ")", "Is", "virtual", "reality", "an", "effective", "distraction", "intervention", "for", "reducing", "chemotherapy", "-", "related", "symptom", "distress", "levels", "in", "older", "women", "with", "breast", "cancer", "?", "(", "2", ")", "Does", "virtual", "reality", "have", "a", "lasting", "effect", "?", "Chemotherapy", "treatments", "are", "intensive", "and", "difficult", "to", "endure", ".", "One", "way", "to", "cope", "with", "chemotherapy", "-", "related", "symptom", "distress", "is", "through", "the", "use", "of", "distraction", ".", "For", "this", "study", ",", "a", "head", "-", "mounted", "display", "(", "Sony", "PC", "Glasstron", "PLM", "-", "S700", ")", "was", "used", "to", "display", "encompassing", "images", "and", "block", "competing", "stimuli", "during", "chemotherapy", "infusions", ".", "The", "Symptom", "Distress", "Scale", "(", "SDS", ")", ",", "Revised", "Piper", "Fatigue", "Scale", "(", "PFS", ")", ",", "and", "the", "State", "Anxiety", "Inventory", "(", "SAI", ")", "were", "used", "to", "measure", "symptom", "distress", ".", "For", "two", "matched", "chemotherapy", "treatments", ",", "one", "pre", "-", "test", "and", "two", "post", "-", "test", "measures", "were", "employed", ".", "Participants", "were", "randomly", "assigned", "to", "receive", "the", "VR", "distraction", "intervention", "during", "one", "chemotherapy", "treatment", "and", "received", "no", "distraction", "intervention", "(", "control", "condition", ")", "during", "an", "alternate", "chemotherapy", "treatment", ".", "Analysis", "using", "paired", "t", "-", "tests", "demonstrated", "a", "significant", "decrease", "in", "the", "SAI", "(", "p", "=", "0.10", ")", "scores", "immediately", "following", "chemotherapy", "treatments", "when", "participants", "used", "VR", ".", "No", "significant", "changes", "were", "found", "in", "SDS", "or", "PFS", "values", ".", "There", "was", "a", "consistent", "trend", "toward", "improved", "symptoms", "on", "all", "measures", "48", "h", "following", "completion", "of", "chemotherapy", ".", "Evaluation", "of", "the", "intervention", "indicated", "that", "women", "thought", "the", "head", "mounted", "device", "was", "easy", "to", "use", ",", "they", "experienced", "no", "cybersickness", ",", "and", "100", "%", "would", "use", "VR", "again", "." ]

[ "Intervention_Psychological", "Intervention_Educational", "Intervention_Control", "Outcome_Physical", "Outcome_Mental", "Participant_Condition", "Participant_Age", "Outcome_Other", "Participant_Sex", "Participant_Sample-size" ]

Virtual reality intervention is a Intervention_Educational, older is a Participant_Age, women is a Participant_Sex, breast cancer is a Participant_Condition, virtual reality distraction intervention is a Intervention_Educational, symptom distress is a Outcome_Physical, 16 is a Participant_Sample-size, 50 and older is a Participant_Age, a head - mounted display ( Sony PC Glasstron PLM - S700 ) was used to display encompassing images and block competing stimuli during chemotherapy infusions . is a Intervention_Psychological, Symptom Distress Scale ( SDS ) is a Outcome_Physical, Revised Piper Fatigue Scale ( PFS ) , is a Outcome_Physical, State Anxiety Inventory ( SAI is a Outcome_Mental, VR distraction intervention during one chemotherapy treatment is a Intervention_Educational, no distraction intervention ( control condition ) is a Intervention_Control, decrease is a Outcome_Other, improved symptoms is a Outcome_Physical, cybersickness is a Outcome_Physical

13500_task1

Sentence: Virtual reality intervention for older women with breast cancer . This study examined the effects of a virtual reality distraction intervention on chemotherapy-related symptom distress levels in 16 women aged 50 and older . A cross-over design was used to answer the following research questions : ( 1 ) Is virtual reality an effective distraction intervention for reducing chemotherapy-related symptom distress levels in older women with breast cancer ? ( 2 ) Does virtual reality have a lasting effect ? Chemotherapy treatments are intensive and difficult to endure . One way to cope with chemotherapy-related symptom distress is through the use of distraction . For this study , a head-mounted display ( Sony PC Glasstron PLM - S700 ) was used to display encompassing images and block competing stimuli during chemotherapy infusions . The Symptom Distress Scale ( SDS ) , Revised Piper Fatigue Scale ( PFS ) , and the State Anxiety Inventory ( SAI ) were used to measure symptom distress . For two matched chemotherapy treatments , one pre-test and two post-test measures were employed . Participants were randomly assigned to receive the VR distraction intervention during one chemotherapy treatment and received no distraction intervention ( control condition ) during an alternate chemotherapy treatment . Analysis using paired t-tests demonstrated a significant decrease in the SAI ( p = 0.10 ) scores immediately following chemotherapy treatments when participants used VR . No significant changes were found in SDS or PFS values . There was a consistent trend toward improved symptoms on all measures 48 h following completion of chemotherapy . Evaluation of the intervention indicated that women thought the head mounted device was easy to use , they experienced no cybersickness , and 100 % would use VR again . Instructions: please typing these entity words according to sentence: Virtual reality intervention, older, women, breast cancer, virtual reality distraction intervention, symptom distress, 16, 50 and older, a head - mounted display ( Sony PC Glasstron PLM - S700 ) was used to display encompassing images and block competing stimuli during chemotherapy infusions ., Symptom Distress Scale ( SDS ), Revised Piper Fatigue Scale ( PFS ) ,, State Anxiety Inventory ( SAI, VR distraction intervention during one chemotherapy treatment, no distraction intervention ( control condition ), decrease, improved symptoms, cybersickness Options: Intervention_Psychological, Participant_Condition, Participant_Sex, Intervention_Control, Intervention_Educational, Outcome_Physical, Participant_Age, Participant_Sample-size, Outcome_Other, Outcome_Mental

[ "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Participant_Age", "B-Participant_Sex", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Virtual reality intervention for older women with breast cancer . This study examined the effects of a virtual reality distraction intervention on chemotherapy-related symptom distress levels in 16 women aged 50 and older . A cross-over design was used to answer the following research questions : ( 1 ) Is virtual reality an effective distraction intervention for reducing chemotherapy-related symptom distress levels in older women with breast cancer ? ( 2 ) Does virtual reality have a lasting effect ? Chemotherapy treatments are intensive and difficult to endure . One way to cope with chemotherapy-related symptom distress is through the use of distraction . For this study , a head-mounted display ( Sony PC Glasstron PLM - S700 ) was used to display encompassing images and block competing stimuli during chemotherapy infusions . The Symptom Distress Scale ( SDS ) , Revised Piper Fatigue Scale ( PFS ) , and the State Anxiety Inventory ( SAI ) were used to measure symptom distress . For two matched chemotherapy treatments , one pre-test and two post-test measures were employed . Participants were randomly assigned to receive the VR distraction intervention during one chemotherapy treatment and received no distraction intervention ( control condition ) during an alternate chemotherapy treatment . Analysis using paired t-tests demonstrated a significant decrease in the SAI ( p = 0.10 ) scores immediately following chemotherapy treatments when participants used VR . No significant changes were found in SDS or PFS values . There was a consistent trend toward improved symptoms on all measures 48 h following completion of chemotherapy . Evaluation of the intervention indicated that women thought the head mounted device was easy to use , they experienced no cybersickness , and 100 % would use VR again .

[ "Virtual", "reality", "intervention", "for", "older", "women", "with", "breast", "cancer", ".", "This", "study", "examined", "the", "effects", "of", "a", "virtual", "reality", "distraction", "intervention", "on", "chemotherapy", "-", "related", "symptom", "distress", "levels", "in", "16", "women", "aged", "50", "and", "older", ".", "A", "cross", "-", "over", "design", "was", "used", "to", "answer", "the", "following", "research", "questions", ":", "(", "1", ")", "Is", "virtual", "reality", "an", "effective", "distraction", "intervention", "for", "reducing", "chemotherapy", "-", "related", "symptom", "distress", "levels", "in", "older", "women", "with", "breast", "cancer", "?", "(", "2", ")", "Does", "virtual", "reality", "have", "a", "lasting", "effect", "?", "Chemotherapy", "treatments", "are", "intensive", "and", "difficult", "to", "endure", ".", "One", "way", "to", "cope", "with", "chemotherapy", "-", "related", "symptom", "distress", "is", "through", "the", "use", "of", "distraction", ".", "For", "this", "study", ",", "a", "head", "-", "mounted", "display", "(", "Sony", "PC", "Glasstron", "PLM", "-", "S700", ")", "was", "used", "to", "display", "encompassing", "images", "and", "block", "competing", "stimuli", "during", "chemotherapy", "infusions", ".", "The", "Symptom", "Distress", "Scale", "(", "SDS", ")", ",", "Revised", "Piper", "Fatigue", "Scale", "(", "PFS", ")", ",", "and", "the", "State", "Anxiety", "Inventory", "(", "SAI", ")", "were", "used", "to", "measure", "symptom", "distress", ".", "For", "two", "matched", "chemotherapy", "treatments", ",", "one", "pre", "-", "test", "and", "two", "post", "-", "test", "measures", "were", "employed", ".", "Participants", "were", "randomly", "assigned", "to", "receive", "the", "VR", "distraction", "intervention", "during", "one", "chemotherapy", "treatment", "and", "received", "no", "distraction", "intervention", "(", "control", "condition", ")", "during", "an", "alternate", "chemotherapy", "treatment", ".", "Analysis", "using", "paired", "t", "-", "tests", "demonstrated", "a", "significant", "decrease", "in", "the", "SAI", "(", "p", "=", "0.10", ")", "scores", "immediately", "following", "chemotherapy", "treatments", "when", "participants", "used", "VR", ".", "No", "significant", "changes", "were", "found", "in", "SDS", "or", "PFS", "values", ".", "There", "was", "a", "consistent", "trend", "toward", "improved", "symptoms", "on", "all", "measures", "48", "h", "following", "completion", "of", "chemotherapy", ".", "Evaluation", "of", "the", "intervention", "indicated", "that", "women", "thought", "the", "head", "mounted", "device", "was", "easy", "to", "use", ",", "they", "experienced", "no", "cybersickness", ",", "and", "100", "%", "would", "use", "VR", "again", "." ]

[ "Intervention_Psychological", "Intervention_Educational", "Intervention_Control", "Outcome_Physical", "Outcome_Mental", "Participant_Condition", "Participant_Age", "Outcome_Other", "Participant_Sex", "Participant_Sample-size" ]

Virtual reality intervention, older, women, breast cancer, virtual reality distraction intervention, symptom distress, 16, 50 and older, a head - mounted display ( Sony PC Glasstron PLM - S700 ) was used to display encompassing images and block competing stimuli during chemotherapy infusions ., Symptom Distress Scale ( SDS ), Revised Piper Fatigue Scale ( PFS ) ,, State Anxiety Inventory ( SAI, VR distraction intervention during one chemotherapy treatment, no distraction intervention ( control condition ), decrease, improved symptoms, cybersickness

13500_task2

Sentence: Virtual reality intervention for older women with breast cancer . This study examined the effects of a virtual reality distraction intervention on chemotherapy-related symptom distress levels in 16 women aged 50 and older . A cross-over design was used to answer the following research questions : ( 1 ) Is virtual reality an effective distraction intervention for reducing chemotherapy-related symptom distress levels in older women with breast cancer ? ( 2 ) Does virtual reality have a lasting effect ? Chemotherapy treatments are intensive and difficult to endure . One way to cope with chemotherapy-related symptom distress is through the use of distraction . For this study , a head-mounted display ( Sony PC Glasstron PLM - S700 ) was used to display encompassing images and block competing stimuli during chemotherapy infusions . The Symptom Distress Scale ( SDS ) , Revised Piper Fatigue Scale ( PFS ) , and the State Anxiety Inventory ( SAI ) were used to measure symptom distress . For two matched chemotherapy treatments , one pre-test and two post-test measures were employed . Participants were randomly assigned to receive the VR distraction intervention during one chemotherapy treatment and received no distraction intervention ( control condition ) during an alternate chemotherapy treatment . Analysis using paired t-tests demonstrated a significant decrease in the SAI ( p = 0.10 ) scores immediately following chemotherapy treatments when participants used VR . No significant changes were found in SDS or PFS values . There was a consistent trend toward improved symptoms on all measures 48 h following completion of chemotherapy . Evaluation of the intervention indicated that women thought the head mounted device was easy to use , they experienced no cybersickness , and 100 % would use VR again . Instructions: please extract entity words from the input sentence

[ "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Participant_Age", "B-Participant_Sex", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Virtual reality intervention for older women with breast cancer . This study examined the effects of a virtual reality distraction intervention on chemotherapy-related symptom distress levels in 16 women aged 50 and older . A cross-over design was used to answer the following research questions : ( 1 ) Is virtual reality an effective distraction intervention for reducing chemotherapy-related symptom distress levels in older women with breast cancer ? ( 2 ) Does virtual reality have a lasting effect ? Chemotherapy treatments are intensive and difficult to endure . One way to cope with chemotherapy-related symptom distress is through the use of distraction . For this study , a head-mounted display ( Sony PC Glasstron PLM - S700 ) was used to display encompassing images and block competing stimuli during chemotherapy infusions . The Symptom Distress Scale ( SDS ) , Revised Piper Fatigue Scale ( PFS ) , and the State Anxiety Inventory ( SAI ) were used to measure symptom distress . For two matched chemotherapy treatments , one pre-test and two post-test measures were employed . Participants were randomly assigned to receive the VR distraction intervention during one chemotherapy treatment and received no distraction intervention ( control condition ) during an alternate chemotherapy treatment . Analysis using paired t-tests demonstrated a significant decrease in the SAI ( p = 0.10 ) scores immediately following chemotherapy treatments when participants used VR . No significant changes were found in SDS or PFS values . There was a consistent trend toward improved symptoms on all measures 48 h following completion of chemotherapy . Evaluation of the intervention indicated that women thought the head mounted device was easy to use , they experienced no cybersickness , and 100 % would use VR again .

[ "Virtual", "reality", "intervention", "for", "older", "women", "with", "breast", "cancer", ".", "This", "study", "examined", "the", "effects", "of", "a", "virtual", "reality", "distraction", "intervention", "on", "chemotherapy", "-", "related", "symptom", "distress", "levels", "in", "16", "women", "aged", "50", "and", "older", ".", "A", "cross", "-", "over", "design", "was", "used", "to", "answer", "the", "following", "research", "questions", ":", "(", "1", ")", "Is", "virtual", "reality", "an", "effective", "distraction", "intervention", "for", "reducing", "chemotherapy", "-", "related", "symptom", "distress", "levels", "in", "older", "women", "with", "breast", "cancer", "?", "(", "2", ")", "Does", "virtual", "reality", "have", "a", "lasting", "effect", "?", "Chemotherapy", "treatments", "are", "intensive", "and", "difficult", "to", "endure", ".", "One", "way", "to", "cope", "with", "chemotherapy", "-", "related", "symptom", "distress", "is", "through", "the", "use", "of", "distraction", ".", "For", "this", "study", ",", "a", "head", "-", "mounted", "display", "(", "Sony", "PC", "Glasstron", "PLM", "-", "S700", ")", "was", "used", "to", "display", "encompassing", "images", "and", "block", "competing", "stimuli", "during", "chemotherapy", "infusions", ".", "The", "Symptom", "Distress", "Scale", "(", "SDS", ")", ",", "Revised", "Piper", "Fatigue", "Scale", "(", "PFS", ")", ",", "and", "the", "State", "Anxiety", "Inventory", "(", "SAI", ")", "were", "used", "to", "measure", "symptom", "distress", ".", "For", "two", "matched", "chemotherapy", "treatments", ",", "one", "pre", "-", "test", "and", "two", "post", "-", "test", "measures", "were", "employed", ".", "Participants", "were", "randomly", "assigned", "to", "receive", "the", "VR", "distraction", "intervention", "during", "one", "chemotherapy", "treatment", "and", "received", "no", "distraction", "intervention", "(", "control", "condition", ")", "during", "an", "alternate", "chemotherapy", "treatment", ".", "Analysis", "using", "paired", "t", "-", "tests", "demonstrated", "a", "significant", "decrease", "in", "the", "SAI", "(", "p", "=", "0.10", ")", "scores", "immediately", "following", "chemotherapy", "treatments", "when", "participants", "used", "VR", ".", "No", "significant", "changes", "were", "found", "in", "SDS", "or", "PFS", "values", ".", "There", "was", "a", "consistent", "trend", "toward", "improved", "symptoms", "on", "all", "measures", "48", "h", "following", "completion", "of", "chemotherapy", ".", "Evaluation", "of", "the", "intervention", "indicated", "that", "women", "thought", "the", "head", "mounted", "device", "was", "easy", "to", "use", ",", "they", "experienced", "no", "cybersickness", ",", "and", "100", "%", "would", "use", "VR", "again", "." ]

[ "Intervention_Psychological", "Intervention_Educational", "Intervention_Control", "Outcome_Physical", "Outcome_Mental", "Participant_Condition", "Participant_Age", "Outcome_Other", "Participant_Sex", "Participant_Sample-size" ]

Polydioxanone sternal sutures is a Intervention_Surgical, Sternal dehiscence is a Outcome_Physical, wound instability is a Outcome_Physical, complications is a Outcome_Adverse-effects, stainless steel is a Intervention_Surgical, efficacy is a Outcome_Other, polydioxanone ( PDS ) suture is a Intervention_Surgical, sternal closure is a Outcome_Physical, aseptic sternal complications is a Outcome_Adverse-effects, bone dehiscence is a Outcome_Physical, superficial wound instability is a Outcome_Physical, diabetes is a Outcome_Physical, osteoporosis is a Outcome_Physical

28527_task0

Sentence: Polydioxanone sternal sutures for prevention of sternal dehiscence . BACKGROUND Sternal dehiscence and wound instability are troublesome complications following median sternotomy . Classic sternal approximation with stainless steel wires may not be the ideal approach in patients predisposed to these complications . We tested the efficacy of polydioxanone ( PDS ) suture in sternal closure and in prevention of complications in comparison to steel wires in high-risk individuals . METHODS Three hundred sixty-six patients undergoing elective cardiac surgery with full median sternotomy and having body surface area ( BSA ) less than 1.5 m ( 2 ) were randomly assigned to receive PDS ( n = 181 ) or stainless steel ( SS , n = 185 ) sternal approximation . The study was focused on aseptic sternal complications , namely bone dehiscence and superficial wound instability . RESULTS Both bone dehiscence and superficial wound instability were less frequent in the PDS Group ( 4 and 3 cases in the SS Group , respectively , vs. no cases in the PDS Group ) . Cox proportional hazards regression model in the whole study population identified female sex , chronic renal insufficiency , diabetes , advanced age , lower sternal thickness , osteoporosis , corticosteroid therapy , and prolonged CPB or ventilation times as predisposing factors to any of the two studied sternal complications . DISCUSSION Data suggest that PDS suture can protect against development of aseptic sternal complications following median sternotomy in high-risk patients with little body mass . The adoption of PDS in other subsets of patients , i.e. , obese individuals , is to be questioned . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Outcome_Other, Outcome_Physical, Outcome_Adverse-effects, Intervention_Surgical

[ "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Polydioxanone sternal sutures for prevention of sternal dehiscence . BACKGROUND Sternal dehiscence and wound instability are troublesome complications following median sternotomy . Classic sternal approximation with stainless steel wires may not be the ideal approach in patients predisposed to these complications . We tested the efficacy of polydioxanone ( PDS ) suture in sternal closure and in prevention of complications in comparison to steel wires in high-risk individuals . METHODS Three hundred sixty-six patients undergoing elective cardiac surgery with full median sternotomy and having body surface area ( BSA ) less than 1.5 m ( 2 ) were randomly assigned to receive PDS ( n = 181 ) or stainless steel ( SS , n = 185 ) sternal approximation . The study was focused on aseptic sternal complications , namely bone dehiscence and superficial wound instability . RESULTS Both bone dehiscence and superficial wound instability were less frequent in the PDS Group ( 4 and 3 cases in the SS Group , respectively , vs. no cases in the PDS Group ) . Cox proportional hazards regression model in the whole study population identified female sex , chronic renal insufficiency , diabetes , advanced age , lower sternal thickness , osteoporosis , corticosteroid therapy , and prolonged CPB or ventilation times as predisposing factors to any of the two studied sternal complications . DISCUSSION Data suggest that PDS suture can protect against development of aseptic sternal complications following median sternotomy in high-risk patients with little body mass . The adoption of PDS in other subsets of patients , i.e. , obese individuals , is to be questioned .

[ "Polydioxanone", "sternal", "sutures", "for", "prevention", "of", "sternal", "dehiscence", ".", "BACKGROUND", "Sternal", "dehiscence", "and", "wound", "instability", "are", "troublesome", "complications", "following", "median", "sternotomy", ".", "Classic", "sternal", "approximation", "with", "stainless", "steel", "wires", "may", "not", "be", "the", "ideal", "approach", "in", "patients", "predisposed", "to", "these", "complications", ".", "We", "tested", "the", "efficacy", "of", "polydioxanone", "(", "PDS", ")", "suture", "in", "sternal", "closure", "and", "in", "prevention", "of", "complications", "in", "comparison", "to", "steel", "wires", "in", "high", "-", "risk", "individuals", ".", "METHODS", "Three", "hundred", "sixty", "-", "six", "patients", "undergoing", "elective", "cardiac", "surgery", "with", "full", "median", "sternotomy", "and", "having", "body", "surface", "area", "(", "BSA", ")", "less", "than", "1.5", "m", "(", "2", ")", "were", "randomly", "assigned", "to", "receive", "PDS", "(", "n", "=", "181", ")", "or", "stainless", "steel", "(", "SS", ",", "n", "=", "185", ")", "sternal", "approximation", ".", "The", "study", "was", "focused", "on", "aseptic", "sternal", "complications", ",", "namely", "bone", "dehiscence", "and", "superficial", "wound", "instability", ".", "RESULTS", "Both", "bone", "dehiscence", "and", "superficial", "wound", "instability", "were", "less", "frequent", "in", "the", "PDS", "Group", "(", "4", "and", "3", "cases", "in", "the", "SS", "Group", ",", "respectively", ",", "vs", ".", "no", "cases", "in", "the", "PDS", "Group", ")", ".", "Cox", "proportional", "hazards", "regression", "model", "in", "the", "whole", "study", "population", "identified", "female", "sex", ",", "chronic", "renal", "insufficiency", ",", "diabetes", ",", "advanced", "age", ",", "lower", "sternal", "thickness", ",", "osteoporosis", ",", "corticosteroid", "therapy", ",", "and", "prolonged", "CPB", "or", "ventilation", "times", "as", "predisposing", "factors", "to", "any", "of", "the", "two", "studied", "sternal", "complications", ".", "DISCUSSION", "Data", "suggest", "that", "PDS", "suture", "can", "protect", "against", "development", "of", "aseptic", "sternal", "complications", "following", "median", "sternotomy", "in", "high", "-", "risk", "patients", "with", "little", "body", "mass", ".", "The", "adoption", "of", "PDS", "in", "other", "subsets", "of", "patients", ",", "i.e", ".", ",", "obese", "individuals", ",", "is", "to", "be", "questioned", "." ]

[ "Intervention_Surgical", "Outcome_Physical", "Outcome_Adverse-effects", "Outcome_Other" ]

Polydioxanone sternal sutures is a Intervention_Surgical, Sternal dehiscence is a Outcome_Physical, wound instability is a Outcome_Physical, complications is a Outcome_Adverse-effects, stainless steel is a Intervention_Surgical, efficacy is a Outcome_Other, polydioxanone ( PDS ) suture is a Intervention_Surgical, sternal closure is a Outcome_Physical, aseptic sternal complications is a Outcome_Adverse-effects, bone dehiscence is a Outcome_Physical, superficial wound instability is a Outcome_Physical, diabetes is a Outcome_Physical, osteoporosis is a Outcome_Physical

28527_task1

Sentence: Polydioxanone sternal sutures for prevention of sternal dehiscence . BACKGROUND Sternal dehiscence and wound instability are troublesome complications following median sternotomy . Classic sternal approximation with stainless steel wires may not be the ideal approach in patients predisposed to these complications . We tested the efficacy of polydioxanone ( PDS ) suture in sternal closure and in prevention of complications in comparison to steel wires in high-risk individuals . METHODS Three hundred sixty-six patients undergoing elective cardiac surgery with full median sternotomy and having body surface area ( BSA ) less than 1.5 m ( 2 ) were randomly assigned to receive PDS ( n = 181 ) or stainless steel ( SS , n = 185 ) sternal approximation . The study was focused on aseptic sternal complications , namely bone dehiscence and superficial wound instability . RESULTS Both bone dehiscence and superficial wound instability were less frequent in the PDS Group ( 4 and 3 cases in the SS Group , respectively , vs. no cases in the PDS Group ) . Cox proportional hazards regression model in the whole study population identified female sex , chronic renal insufficiency , diabetes , advanced age , lower sternal thickness , osteoporosis , corticosteroid therapy , and prolonged CPB or ventilation times as predisposing factors to any of the two studied sternal complications . DISCUSSION Data suggest that PDS suture can protect against development of aseptic sternal complications following median sternotomy in high-risk patients with little body mass . The adoption of PDS in other subsets of patients , i.e. , obese individuals , is to be questioned . Instructions: please typing these entity words according to sentence: Polydioxanone sternal sutures, Sternal dehiscence, wound instability, complications, stainless steel, efficacy, polydioxanone ( PDS ) suture, sternal closure, aseptic sternal complications, bone dehiscence, superficial wound instability, diabetes, osteoporosis Options: Outcome_Other, Outcome_Physical, Outcome_Adverse-effects, Intervention_Surgical

[ "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Polydioxanone sternal sutures for prevention of sternal dehiscence . BACKGROUND Sternal dehiscence and wound instability are troublesome complications following median sternotomy . Classic sternal approximation with stainless steel wires may not be the ideal approach in patients predisposed to these complications . We tested the efficacy of polydioxanone ( PDS ) suture in sternal closure and in prevention of complications in comparison to steel wires in high-risk individuals . METHODS Three hundred sixty-six patients undergoing elective cardiac surgery with full median sternotomy and having body surface area ( BSA ) less than 1.5 m ( 2 ) were randomly assigned to receive PDS ( n = 181 ) or stainless steel ( SS , n = 185 ) sternal approximation . The study was focused on aseptic sternal complications , namely bone dehiscence and superficial wound instability . RESULTS Both bone dehiscence and superficial wound instability were less frequent in the PDS Group ( 4 and 3 cases in the SS Group , respectively , vs. no cases in the PDS Group ) . Cox proportional hazards regression model in the whole study population identified female sex , chronic renal insufficiency , diabetes , advanced age , lower sternal thickness , osteoporosis , corticosteroid therapy , and prolonged CPB or ventilation times as predisposing factors to any of the two studied sternal complications . DISCUSSION Data suggest that PDS suture can protect against development of aseptic sternal complications following median sternotomy in high-risk patients with little body mass . The adoption of PDS in other subsets of patients , i.e. , obese individuals , is to be questioned .

[ "Polydioxanone", "sternal", "sutures", "for", "prevention", "of", "sternal", "dehiscence", ".", "BACKGROUND", "Sternal", "dehiscence", "and", "wound", "instability", "are", "troublesome", "complications", "following", "median", "sternotomy", ".", "Classic", "sternal", "approximation", "with", "stainless", "steel", "wires", "may", "not", "be", "the", "ideal", "approach", "in", "patients", "predisposed", "to", "these", "complications", ".", "We", "tested", "the", "efficacy", "of", "polydioxanone", "(", "PDS", ")", "suture", "in", "sternal", "closure", "and", "in", "prevention", "of", "complications", "in", "comparison", "to", "steel", "wires", "in", "high", "-", "risk", "individuals", ".", "METHODS", "Three", "hundred", "sixty", "-", "six", "patients", "undergoing", "elective", "cardiac", "surgery", "with", "full", "median", "sternotomy", "and", "having", "body", "surface", "area", "(", "BSA", ")", "less", "than", "1.5", "m", "(", "2", ")", "were", "randomly", "assigned", "to", "receive", "PDS", "(", "n", "=", "181", ")", "or", "stainless", "steel", "(", "SS", ",", "n", "=", "185", ")", "sternal", "approximation", ".", "The", "study", "was", "focused", "on", "aseptic", "sternal", "complications", ",", "namely", "bone", "dehiscence", "and", "superficial", "wound", "instability", ".", "RESULTS", "Both", "bone", "dehiscence", "and", "superficial", "wound", "instability", "were", "less", "frequent", "in", "the", "PDS", "Group", "(", "4", "and", "3", "cases", "in", "the", "SS", "Group", ",", "respectively", ",", "vs", ".", "no", "cases", "in", "the", "PDS", "Group", ")", ".", "Cox", "proportional", "hazards", "regression", "model", "in", "the", "whole", "study", "population", "identified", "female", "sex", ",", "chronic", "renal", "insufficiency", ",", "diabetes", ",", "advanced", "age", ",", "lower", "sternal", "thickness", ",", "osteoporosis", ",", "corticosteroid", "therapy", ",", "and", "prolonged", "CPB", "or", "ventilation", "times", "as", "predisposing", "factors", "to", "any", "of", "the", "two", "studied", "sternal", "complications", ".", "DISCUSSION", "Data", "suggest", "that", "PDS", "suture", "can", "protect", "against", "development", "of", "aseptic", "sternal", "complications", "following", "median", "sternotomy", "in", "high", "-", "risk", "patients", "with", "little", "body", "mass", ".", "The", "adoption", "of", "PDS", "in", "other", "subsets", "of", "patients", ",", "i.e", ".", ",", "obese", "individuals", ",", "is", "to", "be", "questioned", "." ]

[ "Intervention_Surgical", "Outcome_Physical", "Outcome_Adverse-effects", "Outcome_Other" ]

Polydioxanone sternal sutures, Sternal dehiscence, wound instability, complications, stainless steel, efficacy, polydioxanone ( PDS ) suture, sternal closure, aseptic sternal complications, bone dehiscence, superficial wound instability, diabetes, osteoporosis

28527_task2

Sentence: Polydioxanone sternal sutures for prevention of sternal dehiscence . BACKGROUND Sternal dehiscence and wound instability are troublesome complications following median sternotomy . Classic sternal approximation with stainless steel wires may not be the ideal approach in patients predisposed to these complications . We tested the efficacy of polydioxanone ( PDS ) suture in sternal closure and in prevention of complications in comparison to steel wires in high-risk individuals . METHODS Three hundred sixty-six patients undergoing elective cardiac surgery with full median sternotomy and having body surface area ( BSA ) less than 1.5 m ( 2 ) were randomly assigned to receive PDS ( n = 181 ) or stainless steel ( SS , n = 185 ) sternal approximation . The study was focused on aseptic sternal complications , namely bone dehiscence and superficial wound instability . RESULTS Both bone dehiscence and superficial wound instability were less frequent in the PDS Group ( 4 and 3 cases in the SS Group , respectively , vs. no cases in the PDS Group ) . Cox proportional hazards regression model in the whole study population identified female sex , chronic renal insufficiency , diabetes , advanced age , lower sternal thickness , osteoporosis , corticosteroid therapy , and prolonged CPB or ventilation times as predisposing factors to any of the two studied sternal complications . DISCUSSION Data suggest that PDS suture can protect against development of aseptic sternal complications following median sternotomy in high-risk patients with little body mass . The adoption of PDS in other subsets of patients , i.e. , obese individuals , is to be questioned . Instructions: please extract entity words from the input sentence

[ "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Polydioxanone sternal sutures for prevention of sternal dehiscence . BACKGROUND Sternal dehiscence and wound instability are troublesome complications following median sternotomy . Classic sternal approximation with stainless steel wires may not be the ideal approach in patients predisposed to these complications . We tested the efficacy of polydioxanone ( PDS ) suture in sternal closure and in prevention of complications in comparison to steel wires in high-risk individuals . METHODS Three hundred sixty-six patients undergoing elective cardiac surgery with full median sternotomy and having body surface area ( BSA ) less than 1.5 m ( 2 ) were randomly assigned to receive PDS ( n = 181 ) or stainless steel ( SS , n = 185 ) sternal approximation . The study was focused on aseptic sternal complications , namely bone dehiscence and superficial wound instability . RESULTS Both bone dehiscence and superficial wound instability were less frequent in the PDS Group ( 4 and 3 cases in the SS Group , respectively , vs. no cases in the PDS Group ) . Cox proportional hazards regression model in the whole study population identified female sex , chronic renal insufficiency , diabetes , advanced age , lower sternal thickness , osteoporosis , corticosteroid therapy , and prolonged CPB or ventilation times as predisposing factors to any of the two studied sternal complications . DISCUSSION Data suggest that PDS suture can protect against development of aseptic sternal complications following median sternotomy in high-risk patients with little body mass . The adoption of PDS in other subsets of patients , i.e. , obese individuals , is to be questioned .

[ "Polydioxanone", "sternal", "sutures", "for", "prevention", "of", "sternal", "dehiscence", ".", "BACKGROUND", "Sternal", "dehiscence", "and", "wound", "instability", "are", "troublesome", "complications", "following", "median", "sternotomy", ".", "Classic", "sternal", "approximation", "with", "stainless", "steel", "wires", "may", "not", "be", "the", "ideal", "approach", "in", "patients", "predisposed", "to", "these", "complications", ".", "We", "tested", "the", "efficacy", "of", "polydioxanone", "(", "PDS", ")", "suture", "in", "sternal", "closure", "and", "in", "prevention", "of", "complications", "in", "comparison", "to", "steel", "wires", "in", "high", "-", "risk", "individuals", ".", "METHODS", "Three", "hundred", "sixty", "-", "six", "patients", "undergoing", "elective", "cardiac", "surgery", "with", "full", "median", "sternotomy", "and", "having", "body", "surface", "area", "(", "BSA", ")", "less", "than", "1.5", "m", "(", "2", ")", "were", "randomly", "assigned", "to", "receive", "PDS", "(", "n", "=", "181", ")", "or", "stainless", "steel", "(", "SS", ",", "n", "=", "185", ")", "sternal", "approximation", ".", "The", "study", "was", "focused", "on", "aseptic", "sternal", "complications", ",", "namely", "bone", "dehiscence", "and", "superficial", "wound", "instability", ".", "RESULTS", "Both", "bone", "dehiscence", "and", "superficial", "wound", "instability", "were", "less", "frequent", "in", "the", "PDS", "Group", "(", "4", "and", "3", "cases", "in", "the", "SS", "Group", ",", "respectively", ",", "vs", ".", "no", "cases", "in", "the", "PDS", "Group", ")", ".", "Cox", "proportional", "hazards", "regression", "model", "in", "the", "whole", "study", "population", "identified", "female", "sex", ",", "chronic", "renal", "insufficiency", ",", "diabetes", ",", "advanced", "age", ",", "lower", "sternal", "thickness", ",", "osteoporosis", ",", "corticosteroid", "therapy", ",", "and", "prolonged", "CPB", "or", "ventilation", "times", "as", "predisposing", "factors", "to", "any", "of", "the", "two", "studied", "sternal", "complications", ".", "DISCUSSION", "Data", "suggest", "that", "PDS", "suture", "can", "protect", "against", "development", "of", "aseptic", "sternal", "complications", "following", "median", "sternotomy", "in", "high", "-", "risk", "patients", "with", "little", "body", "mass", ".", "The", "adoption", "of", "PDS", "in", "other", "subsets", "of", "patients", ",", "i.e", ".", ",", "obese", "individuals", ",", "is", "to", "be", "questioned", "." ]

[ "Intervention_Surgical", "Outcome_Physical", "Outcome_Adverse-effects", "Outcome_Other" ]

use is an umlsterm, porcine is an umlsterm, skin is an umlsterm, human is an umlsterm, integument is an umlsterm, literature is an umlsterm, epidermis is an umlsterm, dermis is an umlsterm, human is an umlsterm, skin is an umlsterm, utilization is an umlsterm, porcine is an umlsterm, skin is an umlsterm, research is an umlsterm, use is an umlsterm, porcine is an umlsterm, skin is an umlsterm, research is an umlsterm, breeds is an umlsterm

DerHautarzt.60470178.eng.abstr_task0

Sentence: The use of porcine skin as a biomedical model for the human integument is discussed with reference to the literature . The epidermis and dermis can be used as a model as there are clear structural , functional and biochemical similarities with human skin layers . The actual utilization of porcine skin in dermatological research is reviewed . Practical difficulties are emphasized : in particular , the conditions required for use of porcine skin in experimental research , the most suitable breeds , and restrictions on biological interpretation of the results . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The use of porcine skin as a biomedical model for the human integument is discussed with reference to the literature . The epidermis and dermis can be used as a model as there are clear structural , functional and biochemical similarities with human skin layers . The actual utilization of porcine skin in dermatological research is reviewed . Practical difficulties are emphasized : in particular , the conditions required for use of porcine skin in experimental research , the most suitable breeds , and restrictions on biological interpretation of the results .

[ "The", "use", "of", "porcine", "skin", "as", "a", "biomedical", "model", "for", "the", "human", "integument", "is", "discussed", "with", "reference", "to", "the", "literature", ".", "The", "epidermis", "and", "dermis", "can", "be", "used", "as", "a", "model", "as", "there", "are", "clear", "structural", ",", "functional", "and", "biochemical", "similarities", "with", "human", "skin", "layers", ".", "The", "actual", "utilization", "of", "porcine", "skin", "in", "dermatological", "research", "is", "reviewed", ".", "Practical", "difficulties", "are", "emphasized", ":", "in", "particular", ",", "the", "conditions", "required", "for", "use", "of", "porcine", "skin", "in", "experimental", "research", ",", "the", "most", "suitable", "breeds", ",", "and", "restrictions", "on", "biological", "interpretation", "of", "the", "results", "." ]

[ "umlsterm" ]

use is an umlsterm, porcine is an umlsterm, skin is an umlsterm, human is an umlsterm, integument is an umlsterm, literature is an umlsterm, epidermis is an umlsterm, dermis is an umlsterm, human is an umlsterm, skin is an umlsterm, utilization is an umlsterm, porcine is an umlsterm, skin is an umlsterm, research is an umlsterm, use is an umlsterm, porcine is an umlsterm, skin is an umlsterm, research is an umlsterm, breeds is an umlsterm

DerHautarzt.60470178.eng.abstr_task1

Sentence: The use of porcine skin as a biomedical model for the human integument is discussed with reference to the literature . The epidermis and dermis can be used as a model as there are clear structural , functional and biochemical similarities with human skin layers . The actual utilization of porcine skin in dermatological research is reviewed . Practical difficulties are emphasized : in particular , the conditions required for use of porcine skin in experimental research , the most suitable breeds , and restrictions on biological interpretation of the results . Instructions: please typing these entity words according to sentence: use, porcine, skin, human, integument, literature, epidermis, dermis, human, skin, utilization, porcine, skin, research, use, porcine, skin, research, breeds Options: umlsterm

[ "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The use of porcine skin as a biomedical model for the human integument is discussed with reference to the literature . The epidermis and dermis can be used as a model as there are clear structural , functional and biochemical similarities with human skin layers . The actual utilization of porcine skin in dermatological research is reviewed . Practical difficulties are emphasized : in particular , the conditions required for use of porcine skin in experimental research , the most suitable breeds , and restrictions on biological interpretation of the results .

[ "The", "use", "of", "porcine", "skin", "as", "a", "biomedical", "model", "for", "the", "human", "integument", "is", "discussed", "with", "reference", "to", "the", "literature", ".", "The", "epidermis", "and", "dermis", "can", "be", "used", "as", "a", "model", "as", "there", "are", "clear", "structural", ",", "functional", "and", "biochemical", "similarities", "with", "human", "skin", "layers", ".", "The", "actual", "utilization", "of", "porcine", "skin", "in", "dermatological", "research", "is", "reviewed", ".", "Practical", "difficulties", "are", "emphasized", ":", "in", "particular", ",", "the", "conditions", "required", "for", "use", "of", "porcine", "skin", "in", "experimental", "research", ",", "the", "most", "suitable", "breeds", ",", "and", "restrictions", "on", "biological", "interpretation", "of", "the", "results", "." ]

[ "umlsterm" ]

use, porcine, skin, human, integument, literature, epidermis, dermis, human, skin, utilization, porcine, skin, research, use, porcine, skin, research, breeds

DerHautarzt.60470178.eng.abstr_task2

Sentence: The use of porcine skin as a biomedical model for the human integument is discussed with reference to the literature . The epidermis and dermis can be used as a model as there are clear structural , functional and biochemical similarities with human skin layers . The actual utilization of porcine skin in dermatological research is reviewed . Practical difficulties are emphasized : in particular , the conditions required for use of porcine skin in experimental research , the most suitable breeds , and restrictions on biological interpretation of the results . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The use of porcine skin as a biomedical model for the human integument is discussed with reference to the literature . The epidermis and dermis can be used as a model as there are clear structural , functional and biochemical similarities with human skin layers . The actual utilization of porcine skin in dermatological research is reviewed . Practical difficulties are emphasized : in particular , the conditions required for use of porcine skin in experimental research , the most suitable breeds , and restrictions on biological interpretation of the results .

[ "The", "use", "of", "porcine", "skin", "as", "a", "biomedical", "model", "for", "the", "human", "integument", "is", "discussed", "with", "reference", "to", "the", "literature", ".", "The", "epidermis", "and", "dermis", "can", "be", "used", "as", "a", "model", "as", "there", "are", "clear", "structural", ",", "functional", "and", "biochemical", "similarities", "with", "human", "skin", "layers", ".", "The", "actual", "utilization", "of", "porcine", "skin", "in", "dermatological", "research", "is", "reviewed", ".", "Practical", "difficulties", "are", "emphasized", ":", "in", "particular", ",", "the", "conditions", "required", "for", "use", "of", "porcine", "skin", "in", "experimental", "research", ",", "the", "most", "suitable", "breeds", ",", "and", "restrictions", "on", "biological", "interpretation", "of", "the", "results", "." ]

[ "umlsterm" ]

Stress incontinence is an umlsterm, form is an umlsterm, females is an umlsterm, method is an umlsterm, surgery is an umlsterm, bladder is an umlsterm, neck is an umlsterm, techniques is an umlsterm, bladder is an umlsterm, neck is an umlsterm, suspension is an umlsterm, women is an umlsterm, surgery is an umlsterm, postoperative is an umlsterm, patients is an umlsterm, surgical is an umlsterm, techniques is an umlsterm, patients is an umlsterm, patients is an umlsterm, patients is an umlsterm, technique is an umlsterm, obese is an umlsterm, patients is an umlsterm, regression is an umlsterm, time is an umlsterm, surgery is an umlsterm, method is an umlsterm, technique is an umlsterm, procedure is an umlsterm, method is an umlsterm, choice is an umlsterm, stress incontinence is an umlsterm

DerUrologeA.70360400.eng.abstr_task0

Sentence: Stress incontinence is the most frequent form of incontinence found in females . The usual method of surgery for this is to lift the bladder neck towards cranial and ventral . Two competitive techniques - bladder neck suspension in accordance with Stamey and colposuspension in accordance with Burch - were retrospectively investigated . A total of 95 women underwent surgery and it was possible to evaluate the postoperative course in 46 and 30 ( total 76 ) patients respectively . Initially , both surgical techniques demonstrated a very good success rate ( 91.3 % and 96.7 % resp. ) . However , the continence rate of the Stamey patients deteriorated after 6 weeks down to 78.3 % and after more than 2 years only 28.6 % of these patients were still completely continent ( mean follow-up 40.4 mths ) , whereas deterioration in the Burch patients was only 87 % ( mean follow-up 44.25 mths ) . The disappointing results with the Stamey technique did not correlate with the degree of initial continence . It was noted here that obese patients showed a greater tendency towards regression . The three cases of recurring incontinence after Burch colposuspension were already relapses at the time of surgery . With respect to long-term follow-up , our results with the Stamey method were distinctly poorer than with the Burch technique . Therefore , in our opinion , the Burch colposuspension procedure and fascioplasty should be the method of choice for the management of stress incontinence . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Stress incontinence is the most frequent form of incontinence found in females . The usual method of surgery for this is to lift the bladder neck towards cranial and ventral . Two competitive techniques - bladder neck suspension in accordance with Stamey and colposuspension in accordance with Burch - were retrospectively investigated . A total of 95 women underwent surgery and it was possible to evaluate the postoperative course in 46 and 30 ( total 76 ) patients respectively . Initially , both surgical techniques demonstrated a very good success rate ( 91.3 % and 96.7 % resp. ) . However , the continence rate of the Stamey patients deteriorated after 6 weeks down to 78.3 % and after more than 2 years only 28.6 % of these patients were still completely continent ( mean follow-up 40.4 mths ) , whereas deterioration in the Burch patients was only 87 % ( mean follow-up 44.25 mths ) . The disappointing results with the Stamey technique did not correlate with the degree of initial continence . It was noted here that obese patients showed a greater tendency towards regression . The three cases of recurring incontinence after Burch colposuspension were already relapses at the time of surgery . With respect to long-term follow-up , our results with the Stamey method were distinctly poorer than with the Burch technique . Therefore , in our opinion , the Burch colposuspension procedure and fascioplasty should be the method of choice for the management of stress incontinence .

[ "Stress", "incontinence", "is", "the", "most", "frequent", "form", "of", "incontinence", "found", "in", "females", ".", "The", "usual", "method", "of", "surgery", "for", "this", "is", "to", "lift", "the", "bladder", "neck", "towards", "cranial", "and", "ventral", ".", "Two", "competitive", "techniques", "-", "bladder", "neck", "suspension", "in", "accordance", "with", "Stamey", "and", "colposuspension", "in", "accordance", "with", "Burch", "-", "were", "retrospectively", "investigated", ".", "A", "total", "of", "95", "women", "underwent", "surgery", "and", "it", "was", "possible", "to", "evaluate", "the", "postoperative", "course", "in", "46", "and", "30", "(", "total", "76", ")", "patients", "respectively", ".", "Initially", ",", "both", "surgical", "techniques", "demonstrated", "a", "very", "good", "success", "rate", "(", "91.3", "%", "and", "96.7", "%", "resp", ".", ")", ".", "However", ",", "the", "continence", "rate", "of", "the", "Stamey", "patients", "deteriorated", "after", "6", "weeks", "down", "to", "78.3", "%", "and", "after", "more", "than", "2", "years", "only", "28.6", "%", "of", "these", "patients", "were", "still", "completely", "continent", "(", "mean", "follow", "-", "up", "40.4", "mths", ")", ",", "whereas", "deterioration", "in", "the", "Burch", "patients", "was", "only", "87", "%", "(", "mean", "follow", "-", "up", "44.25", "mths", ")", ".", "The", "disappointing", "results", "with", "the", "Stamey", "technique", "did", "not", "correlate", "with", "the", "degree", "of", "initial", "continence", ".", "It", "was", "noted", "here", "that", "obese", "patients", "showed", "a", "greater", "tendency", "towards", "regression", ".", "The", "three", "cases", "of", "recurring", "incontinence", "after", "Burch", "colposuspension", "were", "already", "relapses", "at", "the", "time", "of", "surgery", ".", "With", "respect", "to", "long", "-", "term", "follow", "-", "up", ",", "our", "results", "with", "the", "Stamey", "method", "were", "distinctly", "poorer", "than", "with", "the", "Burch", "technique", ".", "Therefore", ",", "in", "our", "opinion", ",", "the", "Burch", "colposuspension", "procedure", "and", "fascioplasty", "should", "be", "the", "method", "of", "choice", "for", "the", "management", "of", "stress", "incontinence", "." ]

[ "umlsterm" ]

Stress incontinence is an umlsterm, form is an umlsterm, females is an umlsterm, method is an umlsterm, surgery is an umlsterm, bladder is an umlsterm, neck is an umlsterm, techniques is an umlsterm, bladder is an umlsterm, neck is an umlsterm, suspension is an umlsterm, women is an umlsterm, surgery is an umlsterm, postoperative is an umlsterm, patients is an umlsterm, surgical is an umlsterm, techniques is an umlsterm, patients is an umlsterm, patients is an umlsterm, patients is an umlsterm, technique is an umlsterm, obese is an umlsterm, patients is an umlsterm, regression is an umlsterm, time is an umlsterm, surgery is an umlsterm, method is an umlsterm, technique is an umlsterm, procedure is an umlsterm, method is an umlsterm, choice is an umlsterm, stress incontinence is an umlsterm

DerUrologeA.70360400.eng.abstr_task1

Sentence: Stress incontinence is the most frequent form of incontinence found in females . The usual method of surgery for this is to lift the bladder neck towards cranial and ventral . Two competitive techniques - bladder neck suspension in accordance with Stamey and colposuspension in accordance with Burch - were retrospectively investigated . A total of 95 women underwent surgery and it was possible to evaluate the postoperative course in 46 and 30 ( total 76 ) patients respectively . Initially , both surgical techniques demonstrated a very good success rate ( 91.3 % and 96.7 % resp. ) . However , the continence rate of the Stamey patients deteriorated after 6 weeks down to 78.3 % and after more than 2 years only 28.6 % of these patients were still completely continent ( mean follow-up 40.4 mths ) , whereas deterioration in the Burch patients was only 87 % ( mean follow-up 44.25 mths ) . The disappointing results with the Stamey technique did not correlate with the degree of initial continence . It was noted here that obese patients showed a greater tendency towards regression . The three cases of recurring incontinence after Burch colposuspension were already relapses at the time of surgery . With respect to long-term follow-up , our results with the Stamey method were distinctly poorer than with the Burch technique . Therefore , in our opinion , the Burch colposuspension procedure and fascioplasty should be the method of choice for the management of stress incontinence . Instructions: please typing these entity words according to sentence: Stress incontinence, form, females, method, surgery, bladder, neck, techniques, bladder, neck, suspension, women, surgery, postoperative, patients, surgical, techniques, patients, patients, patients, technique, obese, patients, regression, time, surgery, method, technique, procedure, method, choice, stress incontinence Options: umlsterm

[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Stress incontinence is the most frequent form of incontinence found in females . The usual method of surgery for this is to lift the bladder neck towards cranial and ventral . Two competitive techniques - bladder neck suspension in accordance with Stamey and colposuspension in accordance with Burch - were retrospectively investigated . A total of 95 women underwent surgery and it was possible to evaluate the postoperative course in 46 and 30 ( total 76 ) patients respectively . Initially , both surgical techniques demonstrated a very good success rate ( 91.3 % and 96.7 % resp. ) . However , the continence rate of the Stamey patients deteriorated after 6 weeks down to 78.3 % and after more than 2 years only 28.6 % of these patients were still completely continent ( mean follow-up 40.4 mths ) , whereas deterioration in the Burch patients was only 87 % ( mean follow-up 44.25 mths ) . The disappointing results with the Stamey technique did not correlate with the degree of initial continence . It was noted here that obese patients showed a greater tendency towards regression . The three cases of recurring incontinence after Burch colposuspension were already relapses at the time of surgery . With respect to long-term follow-up , our results with the Stamey method were distinctly poorer than with the Burch technique . Therefore , in our opinion , the Burch colposuspension procedure and fascioplasty should be the method of choice for the management of stress incontinence .

[ "Stress", "incontinence", "is", "the", "most", "frequent", "form", "of", "incontinence", "found", "in", "females", ".", "The", "usual", "method", "of", "surgery", "for", "this", "is", "to", "lift", "the", "bladder", "neck", "towards", "cranial", "and", "ventral", ".", "Two", "competitive", "techniques", "-", "bladder", "neck", "suspension", "in", "accordance", "with", "Stamey", "and", "colposuspension", "in", "accordance", "with", "Burch", "-", "were", "retrospectively", "investigated", ".", "A", "total", "of", "95", "women", "underwent", "surgery", "and", "it", "was", "possible", "to", "evaluate", "the", "postoperative", "course", "in", "46", "and", "30", "(", "total", "76", ")", "patients", "respectively", ".", "Initially", ",", "both", "surgical", "techniques", "demonstrated", "a", "very", "good", "success", "rate", "(", "91.3", "%", "and", "96.7", "%", "resp", ".", ")", ".", "However", ",", "the", "continence", "rate", "of", "the", "Stamey", "patients", "deteriorated", "after", "6", "weeks", "down", "to", "78.3", "%", "and", "after", "more", "than", "2", "years", "only", "28.6", "%", "of", "these", "patients", "were", "still", "completely", "continent", "(", "mean", "follow", "-", "up", "40.4", "mths", ")", ",", "whereas", "deterioration", "in", "the", "Burch", "patients", "was", "only", "87", "%", "(", "mean", "follow", "-", "up", "44.25", "mths", ")", ".", "The", "disappointing", "results", "with", "the", "Stamey", "technique", "did", "not", "correlate", "with", "the", "degree", "of", "initial", "continence", ".", "It", "was", "noted", "here", "that", "obese", "patients", "showed", "a", "greater", "tendency", "towards", "regression", ".", "The", "three", "cases", "of", "recurring", "incontinence", "after", "Burch", "colposuspension", "were", "already", "relapses", "at", "the", "time", "of", "surgery", ".", "With", "respect", "to", "long", "-", "term", "follow", "-", "up", ",", "our", "results", "with", "the", "Stamey", "method", "were", "distinctly", "poorer", "than", "with", "the", "Burch", "technique", ".", "Therefore", ",", "in", "our", "opinion", ",", "the", "Burch", "colposuspension", "procedure", "and", "fascioplasty", "should", "be", "the", "method", "of", "choice", "for", "the", "management", "of", "stress", "incontinence", "." ]

[ "umlsterm" ]

Stress incontinence, form, females, method, surgery, bladder, neck, techniques, bladder, neck, suspension, women, surgery, postoperative, patients, surgical, techniques, patients, patients, patients, technique, obese, patients, regression, time, surgery, method, technique, procedure, method, choice, stress incontinence

DerUrologeA.70360400.eng.abstr_task2

Sentence: Stress incontinence is the most frequent form of incontinence found in females . The usual method of surgery for this is to lift the bladder neck towards cranial and ventral . Two competitive techniques - bladder neck suspension in accordance with Stamey and colposuspension in accordance with Burch - were retrospectively investigated . A total of 95 women underwent surgery and it was possible to evaluate the postoperative course in 46 and 30 ( total 76 ) patients respectively . Initially , both surgical techniques demonstrated a very good success rate ( 91.3 % and 96.7 % resp. ) . However , the continence rate of the Stamey patients deteriorated after 6 weeks down to 78.3 % and after more than 2 years only 28.6 % of these patients were still completely continent ( mean follow-up 40.4 mths ) , whereas deterioration in the Burch patients was only 87 % ( mean follow-up 44.25 mths ) . The disappointing results with the Stamey technique did not correlate with the degree of initial continence . It was noted here that obese patients showed a greater tendency towards regression . The three cases of recurring incontinence after Burch colposuspension were already relapses at the time of surgery . With respect to long-term follow-up , our results with the Stamey method were distinctly poorer than with the Burch technique . Therefore , in our opinion , the Burch colposuspension procedure and fascioplasty should be the method of choice for the management of stress incontinence . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Stress incontinence is the most frequent form of incontinence found in females . The usual method of surgery for this is to lift the bladder neck towards cranial and ventral . Two competitive techniques - bladder neck suspension in accordance with Stamey and colposuspension in accordance with Burch - were retrospectively investigated . A total of 95 women underwent surgery and it was possible to evaluate the postoperative course in 46 and 30 ( total 76 ) patients respectively . Initially , both surgical techniques demonstrated a very good success rate ( 91.3 % and 96.7 % resp. ) . However , the continence rate of the Stamey patients deteriorated after 6 weeks down to 78.3 % and after more than 2 years only 28.6 % of these patients were still completely continent ( mean follow-up 40.4 mths ) , whereas deterioration in the Burch patients was only 87 % ( mean follow-up 44.25 mths ) . The disappointing results with the Stamey technique did not correlate with the degree of initial continence . It was noted here that obese patients showed a greater tendency towards regression . The three cases of recurring incontinence after Burch colposuspension were already relapses at the time of surgery . With respect to long-term follow-up , our results with the Stamey method were distinctly poorer than with the Burch technique . Therefore , in our opinion , the Burch colposuspension procedure and fascioplasty should be the method of choice for the management of stress incontinence .

[ "Stress", "incontinence", "is", "the", "most", "frequent", "form", "of", "incontinence", "found", "in", "females", ".", "The", "usual", "method", "of", "surgery", "for", "this", "is", "to", "lift", "the", "bladder", "neck", "towards", "cranial", "and", "ventral", ".", "Two", "competitive", "techniques", "-", "bladder", "neck", "suspension", "in", "accordance", "with", "Stamey", "and", "colposuspension", "in", "accordance", "with", "Burch", "-", "were", "retrospectively", "investigated", ".", "A", "total", "of", "95", "women", "underwent", "surgery", "and", "it", "was", "possible", "to", "evaluate", "the", "postoperative", "course", "in", "46", "and", "30", "(", "total", "76", ")", "patients", "respectively", ".", "Initially", ",", "both", "surgical", "techniques", "demonstrated", "a", "very", "good", "success", "rate", "(", "91.3", "%", "and", "96.7", "%", "resp", ".", ")", ".", "However", ",", "the", "continence", "rate", "of", "the", "Stamey", "patients", "deteriorated", "after", "6", "weeks", "down", "to", "78.3", "%", "and", "after", "more", "than", "2", "years", "only", "28.6", "%", "of", "these", "patients", "were", "still", "completely", "continent", "(", "mean", "follow", "-", "up", "40.4", "mths", ")", ",", "whereas", "deterioration", "in", "the", "Burch", "patients", "was", "only", "87", "%", "(", "mean", "follow", "-", "up", "44.25", "mths", ")", ".", "The", "disappointing", "results", "with", "the", "Stamey", "technique", "did", "not", "correlate", "with", "the", "degree", "of", "initial", "continence", ".", "It", "was", "noted", "here", "that", "obese", "patients", "showed", "a", "greater", "tendency", "towards", "regression", ".", "The", "three", "cases", "of", "recurring", "incontinence", "after", "Burch", "colposuspension", "were", "already", "relapses", "at", "the", "time", "of", "surgery", ".", "With", "respect", "to", "long", "-", "term", "follow", "-", "up", ",", "our", "results", "with", "the", "Stamey", "method", "were", "distinctly", "poorer", "than", "with", "the", "Burch", "technique", ".", "Therefore", ",", "in", "our", "opinion", ",", "the", "Burch", "colposuspension", "procedure", "and", "fascioplasty", "should", "be", "the", "method", "of", "choice", "for", "the", "management", "of", "stress", "incontinence", "." ]

[ "umlsterm" ]

lenalidomide is a compound, beta - catenin is a protein

DS.d1259_task0

Sentence: We also found an inhibitory effect of lenalidomide on the associations between cadherin 5, beta-catenin and CD31, adherens junction proteins whose interaction is critical for endothelial cell cord formation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

We also found an inhibitory effect of lenalidomide on the associations between cadherin 5, beta-catenin and CD31, adherens junction proteins whose interaction is critical for endothelial cell cord formation.

[ "We", "also", "found", "an", "inhibitory", "effect", "of", "lenalidomide", "on", "the", "associations", "between", "cadherin", "5", ",", "beta", "-", "catenin", "and", "CD31", ",", "adherens", "junction", "proteins", "whose", "interaction", "is", "critical", "for", "endothelial", "cell", "cord", "formation", "." ]

[ "compound", "protein" ]

lenalidomide is a compound, beta - catenin is a protein

DS.d1259_task1

Sentence: We also found an inhibitory effect of lenalidomide on the associations between cadherin 5, beta-catenin and CD31, adherens junction proteins whose interaction is critical for endothelial cell cord formation. Instructions: please typing these entity words according to sentence: lenalidomide, beta - catenin Options: compound, protein

[ "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

We also found an inhibitory effect of lenalidomide on the associations between cadherin 5, beta-catenin and CD31, adherens junction proteins whose interaction is critical for endothelial cell cord formation.

[ "We", "also", "found", "an", "inhibitory", "effect", "of", "lenalidomide", "on", "the", "associations", "between", "cadherin", "5", ",", "beta", "-", "catenin", "and", "CD31", ",", "adherens", "junction", "proteins", "whose", "interaction", "is", "critical", "for", "endothelial", "cell", "cord", "formation", "." ]

[ "compound", "protein" ]

lenalidomide, beta - catenin

DS.d1259_task2

Sentence: We also found an inhibitory effect of lenalidomide on the associations between cadherin 5, beta-catenin and CD31, adherens junction proteins whose interaction is critical for endothelial cell cord formation. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

We also found an inhibitory effect of lenalidomide on the associations between cadherin 5, beta-catenin and CD31, adherens junction proteins whose interaction is critical for endothelial cell cord formation.

[ "We", "also", "found", "an", "inhibitory", "effect", "of", "lenalidomide", "on", "the", "associations", "between", "cadherin", "5", ",", "beta", "-", "catenin", "and", "CD31", ",", "adherens", "junction", "proteins", "whose", "interaction", "is", "critical", "for", "endothelial", "cell", "cord", "formation", "." ]

[ "compound", "protein" ]

PEG is a CHEMICAL, interferon - alpha2a is a GENE-Y, IFNAR2 is a GENE-Y, Type - I Interferons is a GENE-N, IFNAR1 is a GENE-Y, IFNAR2 is a GENE-Y, Human recombinant Interferon - alpha(2a ) is a GENE-Y, IFNalpha(2a ) is a GENE-Y, IFNalpha(2a ) is a GENE-Y, PEG is a CHEMICAL, IFNalpha(2a ) is a GENE-Y, IFNalpha(2a ) is a GENE-Y, lysine is a CHEMICAL, IFNalpha(2a ) is a GENE-Y, IFNAR2 is a GENE-Y, IFNalpha(2a ) is a GENE-Y, IFNalpha(2a ) is a GENE-Y, PEG is a CHEMICAL, IFNalpha(2a ) is a GENE-Y

22002_task0

Sentence: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Type-I Interferons exert antiviral and antiproliferative activities through the binding to a common cell surface receptor comprising two subunits, IFNAR1 and IFNAR2. Human recombinant Interferon-alpha(2a) (IFNalpha(2a)) is a potent drug (Roferon-A) used to treat various cancers and viral diseases including Hepatitis B/C infections. To significantly improve the pharmacological properties of the drug, a pegylated form of IFNalpha(2a) was developed (PEGASYS). This 40 kDa PEG-conjugated IFNalpha(2a) ((40)PEG-IFNalpha(2a)) is obtained by the covalent binding of one 40 kDa branched PEG-polymer to a lysine side-chain of IFNalpha(2a). Here, we report the detailed structural, kinetic, and thermodynamic analysis of the binding to the extracellular domain of the receptor IFNAR2 of (40)PEG-IFNalpha(2a) and its isolated positional isomers modified at K31, K134, K131, K121, K164, and K70, respectively, in comparison with unmodified IFNalpha(2a). Our binding studies, using the surface plasmon resonance technique, show that the pegylation does not abolish the binding to the receptor, but significantly reduces the affinity mainly due to a change of the association rate. The results are supported by modeling and simulation of the binding, using Self-Avoiding-Walk calculations for the polymer conformations. A correlation between the structural parameters and the kinetic and thermodynamic parameters of the binding of the positional isomers could be established. For the Isomer-K31 and -K164, the PEG-polymer attachment point is located in proximity to the binding interface, and the isomers display affinity in the range 150-520 nM in an enthalpy-driven binding process. In contrast for the Isomer-K134, -K131, -K121, and -K70, the PEG-polymer is attached remotely from the binding interface, and the isomers exhibit a higher affinity (32-76 nM) in an entropy-driven binding process. This study constitutes an essential collection of knowledge on which the interaction of (40)PEG-IFNalpha(2a) and its positional isomers with its cellular receptors can be better understood. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, GENE-Y, CHEMICAL

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Type-I Interferons exert antiviral and antiproliferative activities through the binding to a common cell surface receptor comprising two subunits, IFNAR1 and IFNAR2. Human recombinant Interferon-alpha(2a) (IFNalpha(2a)) is a potent drug (Roferon-A) used to treat various cancers and viral diseases including Hepatitis B/C infections. To significantly improve the pharmacological properties of the drug, a pegylated form of IFNalpha(2a) was developed (PEGASYS). This 40 kDa PEG-conjugated IFNalpha(2a) ((40)PEG-IFNalpha(2a)) is obtained by the covalent binding of one 40 kDa branched PEG-polymer to a lysine side-chain of IFNalpha(2a). Here, we report the detailed structural, kinetic, and thermodynamic analysis of the binding to the extracellular domain of the receptor IFNAR2 of (40)PEG-IFNalpha(2a) and its isolated positional isomers modified at K31, K134, K131, K121, K164, and K70, respectively, in comparison with unmodified IFNalpha(2a). Our binding studies, using the surface plasmon resonance technique, show that the pegylation does not abolish the binding to the receptor, but significantly reduces the affinity mainly due to a change of the association rate. The results are supported by modeling and simulation of the binding, using Self-Avoiding-Walk calculations for the polymer conformations. A correlation between the structural parameters and the kinetic and thermodynamic parameters of the binding of the positional isomers could be established. For the Isomer-K31 and -K164, the PEG-polymer attachment point is located in proximity to the binding interface, and the isomers display affinity in the range 150-520 nM in an enthalpy-driven binding process. In contrast for the Isomer-K134, -K131, -K121, and -K70, the PEG-polymer is attached remotely from the binding interface, and the isomers exhibit a higher affinity (32-76 nM) in an entropy-driven binding process. This study constitutes an essential collection of knowledge on which the interaction of (40)PEG-IFNalpha(2a) and its positional isomers with its cellular receptors can be better understood.

[ "Structural", ",", "kinetic", ",", "and", "thermodynamic", "analysis", "of", "the", "binding", "of", "the", "40", "kDa", "PEG", "-", "interferon", "-", "alpha2a", "and", "its", "individual", "positional", "isomers", "to", "the", "extracellular", "domain", "of", "the", "receptor", "IFNAR2", ".", "\n", "Type", "-", "I", "Interferons", "exert", "antiviral", "and", "antiproliferative", "activities", "through", "the", "binding", "to", "a", "common", "cell", "surface", "receptor", "comprising", "two", "subunits", ",", "IFNAR1", "and", "IFNAR2", ".", "Human", "recombinant", "Interferon", "-", "alpha(2a", ")", "(", "IFNalpha(2a", ")", ")", "is", "a", "potent", "drug", "(", "Roferon", "-", "A", ")", "used", "to", "treat", "various", "cancers", "and", "viral", "diseases", "including", "Hepatitis", "B", "/", "C", "infections", ".", "To", "significantly", "improve", "the", "pharmacological", "properties", "of", "the", "drug", ",", "a", "pegylated", "form", "of", "IFNalpha(2a", ")", "was", "developed", "(", "PEGASYS", ")", ".", "This", "40", "kDa", "PEG", "-", "conjugated", "IFNalpha(2a", ")", "(", "(", "40)PEG", "-", "IFNalpha(2a", ")", ")", "is", "obtained", "by", "the", "covalent", "binding", "of", "one", "40", "kDa", "branched", "PEG", "-", "polymer", "to", "a", "lysine", "side", "-", "chain", "of", "IFNalpha(2a", ")", ".", "Here", ",", "we", "report", "the", "detailed", "structural", ",", "kinetic", ",", "and", "thermodynamic", "analysis", "of", "the", "binding", "to", "the", "extracellular", "domain", "of", "the", "receptor", "IFNAR2", "of", "(", "40)PEG", "-", "IFNalpha(2a", ")", "and", "its", "isolated", "positional", "isomers", "modified", "at", "K31", ",", "K134", ",", "K131", ",", "K121", ",", "K164", ",", "and", "K70", ",", "respectively", ",", "in", "comparison", "with", "unmodified", "IFNalpha(2a", ")", ".", "Our", "binding", "studies", ",", "using", "the", "surface", "plasmon", "resonance", "technique", ",", "show", "that", "the", "pegylation", "does", "not", "abolish", "the", "binding", "to", "the", "receptor", ",", "but", "significantly", "reduces", "the", "affinity", "mainly", "due", "to", "a", "change", "of", "the", "association", "rate", ".", "The", "results", "are", "supported", "by", "modeling", "and", "simulation", "of", "the", "binding", ",", "using", "Self", "-", "Avoiding", "-", "Walk", "calculations", "for", "the", "polymer", "conformations", ".", "A", "correlation", "between", "the", "structural", "parameters", "and", "the", "kinetic", "and", "thermodynamic", "parameters", "of", "the", "binding", "of", "the", "positional", "isomers", "could", "be", "established", ".", "For", "the", "Isomer", "-", "K31", "and", "-K164", ",", "the", "PEG", "-", "polymer", "attachment", "point", "is", "located", "in", "proximity", "to", "the", "binding", "interface", ",", "and", "the", "isomers", "display", "affinity", "in", "the", "range", "150", "-", "520", "nM", "in", "an", "enthalpy", "-", "driven", "binding", "process", ".", "In", "contrast", "for", "the", "Isomer", "-", "K134", ",", "-K131", ",", "-K121", ",", "and", "-K70", ",", "the", "PEG", "-", "polymer", "is", "attached", "remotely", "from", "the", "binding", "interface", ",", "and", "the", "isomers", "exhibit", "a", "higher", "affinity", "(", "32", "-", "76", "nM", ")", "in", "an", "entropy", "-", "driven", "binding", "process", ".", "This", "study", "constitutes", "an", "essential", "collection", "of", "knowledge", "on", "which", "the", "interaction", "of", "(", "40)PEG", "-", "IFNalpha(2a", ")", "and", "its", "positional", "isomers", "with", "its", "cellular", "receptors", "can", "be", "better", "understood", "." ]

[ "GENE-Y", "GENE-N", "CHEMICAL" ]

PEG is a CHEMICAL, interferon - alpha2a is a GENE-Y, IFNAR2 is a GENE-Y, Type - I Interferons is a GENE-N, IFNAR1 is a GENE-Y, IFNAR2 is a GENE-Y, Human recombinant Interferon - alpha(2a ) is a GENE-Y, IFNalpha(2a ) is a GENE-Y, IFNalpha(2a ) is a GENE-Y, PEG is a CHEMICAL, IFNalpha(2a ) is a GENE-Y, IFNalpha(2a ) is a GENE-Y, lysine is a CHEMICAL, IFNalpha(2a ) is a GENE-Y, IFNAR2 is a GENE-Y, IFNalpha(2a ) is a GENE-Y, IFNalpha(2a ) is a GENE-Y, PEG is a CHEMICAL, IFNalpha(2a ) is a GENE-Y

22002_task1

Sentence: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Type-I Interferons exert antiviral and antiproliferative activities through the binding to a common cell surface receptor comprising two subunits, IFNAR1 and IFNAR2. Human recombinant Interferon-alpha(2a) (IFNalpha(2a)) is a potent drug (Roferon-A) used to treat various cancers and viral diseases including Hepatitis B/C infections. To significantly improve the pharmacological properties of the drug, a pegylated form of IFNalpha(2a) was developed (PEGASYS). This 40 kDa PEG-conjugated IFNalpha(2a) ((40)PEG-IFNalpha(2a)) is obtained by the covalent binding of one 40 kDa branched PEG-polymer to a lysine side-chain of IFNalpha(2a). Here, we report the detailed structural, kinetic, and thermodynamic analysis of the binding to the extracellular domain of the receptor IFNAR2 of (40)PEG-IFNalpha(2a) and its isolated positional isomers modified at K31, K134, K131, K121, K164, and K70, respectively, in comparison with unmodified IFNalpha(2a). Our binding studies, using the surface plasmon resonance technique, show that the pegylation does not abolish the binding to the receptor, but significantly reduces the affinity mainly due to a change of the association rate. The results are supported by modeling and simulation of the binding, using Self-Avoiding-Walk calculations for the polymer conformations. A correlation between the structural parameters and the kinetic and thermodynamic parameters of the binding of the positional isomers could be established. For the Isomer-K31 and -K164, the PEG-polymer attachment point is located in proximity to the binding interface, and the isomers display affinity in the range 150-520 nM in an enthalpy-driven binding process. In contrast for the Isomer-K134, -K131, -K121, and -K70, the PEG-polymer is attached remotely from the binding interface, and the isomers exhibit a higher affinity (32-76 nM) in an entropy-driven binding process. This study constitutes an essential collection of knowledge on which the interaction of (40)PEG-IFNalpha(2a) and its positional isomers with its cellular receptors can be better understood. Instructions: please typing these entity words according to sentence: PEG, interferon - alpha2a, IFNAR2, Type - I Interferons, IFNAR1, IFNAR2, Human recombinant Interferon - alpha(2a ), IFNalpha(2a ), IFNalpha(2a ), PEG, IFNalpha(2a ), IFNalpha(2a ), lysine, IFNalpha(2a ), IFNAR2, IFNalpha(2a ), IFNalpha(2a ), PEG, IFNalpha(2a ) Options: GENE-N, GENE-Y, CHEMICAL

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Type-I Interferons exert antiviral and antiproliferative activities through the binding to a common cell surface receptor comprising two subunits, IFNAR1 and IFNAR2. Human recombinant Interferon-alpha(2a) (IFNalpha(2a)) is a potent drug (Roferon-A) used to treat various cancers and viral diseases including Hepatitis B/C infections. To significantly improve the pharmacological properties of the drug, a pegylated form of IFNalpha(2a) was developed (PEGASYS). This 40 kDa PEG-conjugated IFNalpha(2a) ((40)PEG-IFNalpha(2a)) is obtained by the covalent binding of one 40 kDa branched PEG-polymer to a lysine side-chain of IFNalpha(2a). Here, we report the detailed structural, kinetic, and thermodynamic analysis of the binding to the extracellular domain of the receptor IFNAR2 of (40)PEG-IFNalpha(2a) and its isolated positional isomers modified at K31, K134, K131, K121, K164, and K70, respectively, in comparison with unmodified IFNalpha(2a). Our binding studies, using the surface plasmon resonance technique, show that the pegylation does not abolish the binding to the receptor, but significantly reduces the affinity mainly due to a change of the association rate. The results are supported by modeling and simulation of the binding, using Self-Avoiding-Walk calculations for the polymer conformations. A correlation between the structural parameters and the kinetic and thermodynamic parameters of the binding of the positional isomers could be established. For the Isomer-K31 and -K164, the PEG-polymer attachment point is located in proximity to the binding interface, and the isomers display affinity in the range 150-520 nM in an enthalpy-driven binding process. In contrast for the Isomer-K134, -K131, -K121, and -K70, the PEG-polymer is attached remotely from the binding interface, and the isomers exhibit a higher affinity (32-76 nM) in an entropy-driven binding process. This study constitutes an essential collection of knowledge on which the interaction of (40)PEG-IFNalpha(2a) and its positional isomers with its cellular receptors can be better understood.

[ "Structural", ",", "kinetic", ",", "and", "thermodynamic", "analysis", "of", "the", "binding", "of", "the", "40", "kDa", "PEG", "-", "interferon", "-", "alpha2a", "and", "its", "individual", "positional", "isomers", "to", "the", "extracellular", "domain", "of", "the", "receptor", "IFNAR2", ".", "\n", "Type", "-", "I", "Interferons", "exert", "antiviral", "and", "antiproliferative", "activities", "through", "the", "binding", "to", "a", "common", "cell", "surface", "receptor", "comprising", "two", "subunits", ",", "IFNAR1", "and", "IFNAR2", ".", "Human", "recombinant", "Interferon", "-", "alpha(2a", ")", "(", "IFNalpha(2a", ")", ")", "is", "a", "potent", "drug", "(", "Roferon", "-", "A", ")", "used", "to", "treat", "various", "cancers", "and", "viral", "diseases", "including", "Hepatitis", "B", "/", "C", "infections", ".", "To", "significantly", "improve", "the", "pharmacological", "properties", "of", "the", "drug", ",", "a", "pegylated", "form", "of", "IFNalpha(2a", ")", "was", "developed", "(", "PEGASYS", ")", ".", "This", "40", "kDa", "PEG", "-", "conjugated", "IFNalpha(2a", ")", "(", "(", "40)PEG", "-", "IFNalpha(2a", ")", ")", "is", "obtained", "by", "the", "covalent", "binding", "of", "one", "40", "kDa", "branched", "PEG", "-", "polymer", "to", "a", "lysine", "side", "-", "chain", "of", "IFNalpha(2a", ")", ".", "Here", ",", "we", "report", "the", "detailed", "structural", ",", "kinetic", ",", "and", "thermodynamic", "analysis", "of", "the", "binding", "to", "the", "extracellular", "domain", "of", "the", "receptor", "IFNAR2", "of", "(", "40)PEG", "-", "IFNalpha(2a", ")", "and", "its", "isolated", "positional", "isomers", "modified", "at", "K31", ",", "K134", ",", "K131", ",", "K121", ",", "K164", ",", "and", "K70", ",", "respectively", ",", "in", "comparison", "with", "unmodified", "IFNalpha(2a", ")", ".", "Our", "binding", "studies", ",", "using", "the", "surface", "plasmon", "resonance", "technique", ",", "show", "that", "the", "pegylation", "does", "not", "abolish", "the", "binding", "to", "the", "receptor", ",", "but", "significantly", "reduces", "the", "affinity", "mainly", "due", "to", "a", "change", "of", "the", "association", "rate", ".", "The", "results", "are", "supported", "by", "modeling", "and", "simulation", "of", "the", "binding", ",", "using", "Self", "-", "Avoiding", "-", "Walk", "calculations", "for", "the", "polymer", "conformations", ".", "A", "correlation", "between", "the", "structural", "parameters", "and", "the", "kinetic", "and", "thermodynamic", "parameters", "of", "the", "binding", "of", "the", "positional", "isomers", "could", "be", "established", ".", "For", "the", "Isomer", "-", "K31", "and", "-K164", ",", "the", "PEG", "-", "polymer", "attachment", "point", "is", "located", "in", "proximity", "to", "the", "binding", "interface", ",", "and", "the", "isomers", "display", "affinity", "in", "the", "range", "150", "-", "520", "nM", "in", "an", "enthalpy", "-", "driven", "binding", "process", ".", "In", "contrast", "for", "the", "Isomer", "-", "K134", ",", "-K131", ",", "-K121", ",", "and", "-K70", ",", "the", "PEG", "-", "polymer", "is", "attached", "remotely", "from", "the", "binding", "interface", ",", "and", "the", "isomers", "exhibit", "a", "higher", "affinity", "(", "32", "-", "76", "nM", ")", "in", "an", "entropy", "-", "driven", "binding", "process", ".", "This", "study", "constitutes", "an", "essential", "collection", "of", "knowledge", "on", "which", "the", "interaction", "of", "(", "40)PEG", "-", "IFNalpha(2a", ")", "and", "its", "positional", "isomers", "with", "its", "cellular", "receptors", "can", "be", "better", "understood", "." ]

[ "GENE-Y", "GENE-N", "CHEMICAL" ]

PEG, interferon - alpha2a, IFNAR2, Type - I Interferons, IFNAR1, IFNAR2, Human recombinant Interferon - alpha(2a ), IFNalpha(2a ), IFNalpha(2a ), PEG, IFNalpha(2a ), IFNalpha(2a ), lysine, IFNalpha(2a ), IFNAR2, IFNalpha(2a ), IFNalpha(2a ), PEG, IFNalpha(2a )

22002_task2

Sentence: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Type-I Interferons exert antiviral and antiproliferative activities through the binding to a common cell surface receptor comprising two subunits, IFNAR1 and IFNAR2. Human recombinant Interferon-alpha(2a) (IFNalpha(2a)) is a potent drug (Roferon-A) used to treat various cancers and viral diseases including Hepatitis B/C infections. To significantly improve the pharmacological properties of the drug, a pegylated form of IFNalpha(2a) was developed (PEGASYS). This 40 kDa PEG-conjugated IFNalpha(2a) ((40)PEG-IFNalpha(2a)) is obtained by the covalent binding of one 40 kDa branched PEG-polymer to a lysine side-chain of IFNalpha(2a). Here, we report the detailed structural, kinetic, and thermodynamic analysis of the binding to the extracellular domain of the receptor IFNAR2 of (40)PEG-IFNalpha(2a) and its isolated positional isomers modified at K31, K134, K131, K121, K164, and K70, respectively, in comparison with unmodified IFNalpha(2a). Our binding studies, using the surface plasmon resonance technique, show that the pegylation does not abolish the binding to the receptor, but significantly reduces the affinity mainly due to a change of the association rate. The results are supported by modeling and simulation of the binding, using Self-Avoiding-Walk calculations for the polymer conformations. A correlation between the structural parameters and the kinetic and thermodynamic parameters of the binding of the positional isomers could be established. For the Isomer-K31 and -K164, the PEG-polymer attachment point is located in proximity to the binding interface, and the isomers display affinity in the range 150-520 nM in an enthalpy-driven binding process. In contrast for the Isomer-K134, -K131, -K121, and -K70, the PEG-polymer is attached remotely from the binding interface, and the isomers exhibit a higher affinity (32-76 nM) in an entropy-driven binding process. This study constitutes an essential collection of knowledge on which the interaction of (40)PEG-IFNalpha(2a) and its positional isomers with its cellular receptors can be better understood. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Type-I Interferons exert antiviral and antiproliferative activities through the binding to a common cell surface receptor comprising two subunits, IFNAR1 and IFNAR2. Human recombinant Interferon-alpha(2a) (IFNalpha(2a)) is a potent drug (Roferon-A) used to treat various cancers and viral diseases including Hepatitis B/C infections. To significantly improve the pharmacological properties of the drug, a pegylated form of IFNalpha(2a) was developed (PEGASYS). This 40 kDa PEG-conjugated IFNalpha(2a) ((40)PEG-IFNalpha(2a)) is obtained by the covalent binding of one 40 kDa branched PEG-polymer to a lysine side-chain of IFNalpha(2a). Here, we report the detailed structural, kinetic, and thermodynamic analysis of the binding to the extracellular domain of the receptor IFNAR2 of (40)PEG-IFNalpha(2a) and its isolated positional isomers modified at K31, K134, K131, K121, K164, and K70, respectively, in comparison with unmodified IFNalpha(2a). Our binding studies, using the surface plasmon resonance technique, show that the pegylation does not abolish the binding to the receptor, but significantly reduces the affinity mainly due to a change of the association rate. The results are supported by modeling and simulation of the binding, using Self-Avoiding-Walk calculations for the polymer conformations. A correlation between the structural parameters and the kinetic and thermodynamic parameters of the binding of the positional isomers could be established. For the Isomer-K31 and -K164, the PEG-polymer attachment point is located in proximity to the binding interface, and the isomers display affinity in the range 150-520 nM in an enthalpy-driven binding process. In contrast for the Isomer-K134, -K131, -K121, and -K70, the PEG-polymer is attached remotely from the binding interface, and the isomers exhibit a higher affinity (32-76 nM) in an entropy-driven binding process. This study constitutes an essential collection of knowledge on which the interaction of (40)PEG-IFNalpha(2a) and its positional isomers with its cellular receptors can be better understood.

[ "Structural", ",", "kinetic", ",", "and", "thermodynamic", "analysis", "of", "the", "binding", "of", "the", "40", "kDa", "PEG", "-", "interferon", "-", "alpha2a", "and", "its", "individual", "positional", "isomers", "to", "the", "extracellular", "domain", "of", "the", "receptor", "IFNAR2", ".", "\n", "Type", "-", "I", "Interferons", "exert", "antiviral", "and", "antiproliferative", "activities", "through", "the", "binding", "to", "a", "common", "cell", "surface", "receptor", "comprising", "two", "subunits", ",", "IFNAR1", "and", "IFNAR2", ".", "Human", "recombinant", "Interferon", "-", "alpha(2a", ")", "(", "IFNalpha(2a", ")", ")", "is", "a", "potent", "drug", "(", "Roferon", "-", "A", ")", "used", "to", "treat", "various", "cancers", "and", "viral", "diseases", "including", "Hepatitis", "B", "/", "C", "infections", ".", "To", "significantly", "improve", "the", "pharmacological", "properties", "of", "the", "drug", ",", "a", "pegylated", "form", "of", "IFNalpha(2a", ")", "was", "developed", "(", "PEGASYS", ")", ".", "This", "40", "kDa", "PEG", "-", "conjugated", "IFNalpha(2a", ")", "(", "(", "40)PEG", "-", "IFNalpha(2a", ")", ")", "is", "obtained", "by", "the", "covalent", "binding", "of", "one", "40", "kDa", "branched", "PEG", "-", "polymer", "to", "a", "lysine", "side", "-", "chain", "of", "IFNalpha(2a", ")", ".", "Here", ",", "we", "report", "the", "detailed", "structural", ",", "kinetic", ",", "and", "thermodynamic", "analysis", "of", "the", "binding", "to", "the", "extracellular", "domain", "of", "the", "receptor", "IFNAR2", "of", "(", "40)PEG", "-", "IFNalpha(2a", ")", "and", "its", "isolated", "positional", "isomers", "modified", "at", "K31", ",", "K134", ",", "K131", ",", "K121", ",", "K164", ",", "and", "K70", ",", "respectively", ",", "in", "comparison", "with", "unmodified", "IFNalpha(2a", ")", ".", "Our", "binding", "studies", ",", "using", "the", "surface", "plasmon", "resonance", "technique", ",", "show", "that", "the", "pegylation", "does", "not", "abolish", "the", "binding", "to", "the", "receptor", ",", "but", "significantly", "reduces", "the", "affinity", "mainly", "due", "to", "a", "change", "of", "the", "association", "rate", ".", "The", "results", "are", "supported", "by", "modeling", "and", "simulation", "of", "the", "binding", ",", "using", "Self", "-", "Avoiding", "-", "Walk", "calculations", "for", "the", "polymer", "conformations", ".", "A", "correlation", "between", "the", "structural", "parameters", "and", "the", "kinetic", "and", "thermodynamic", "parameters", "of", "the", "binding", "of", "the", "positional", "isomers", "could", "be", "established", ".", "For", "the", "Isomer", "-", "K31", "and", "-K164", ",", "the", "PEG", "-", "polymer", "attachment", "point", "is", "located", "in", "proximity", "to", "the", "binding", "interface", ",", "and", "the", "isomers", "display", "affinity", "in", "the", "range", "150", "-", "520", "nM", "in", "an", "enthalpy", "-", "driven", "binding", "process", ".", "In", "contrast", "for", "the", "Isomer", "-", "K134", ",", "-K131", ",", "-K121", ",", "and", "-K70", ",", "the", "PEG", "-", "polymer", "is", "attached", "remotely", "from", "the", "binding", "interface", ",", "and", "the", "isomers", "exhibit", "a", "higher", "affinity", "(", "32", "-", "76", "nM", ")", "in", "an", "entropy", "-", "driven", "binding", "process", ".", "This", "study", "constitutes", "an", "essential", "collection", "of", "knowledge", "on", "which", "the", "interaction", "of", "(", "40)PEG", "-", "IFNalpha(2a", ")", "and", "its", "positional", "isomers", "with", "its", "cellular", "receptors", "can", "be", "better", "understood", "." ]

[ "GENE-Y", "GENE-N", "CHEMICAL" ]

peripheral nerves is a Habitat, peripheral nervous system is a Habitat, PNS is a Habitat, nerve is a Habitat, Schwann cells is a Habitat, glial cells of the PNS is a Habitat, Schwann cells is a Habitat, nerve injury is a Habitat, Schwann cell is a Habitat, nerve is a Habitat, human is a Habitat, Mycobacterium leprae is a Microorganism, Schwann cells of the adult PNS is a Habitat, M. leprae is a Microorganism, myelinated Schwann cells is a Habitat, injury is a Habitat, M. leprae is a Microorganism, myelin - free cells is a Habitat, M. leprae is a Microorganism, M. leprae is a Microorganism, cell is a Habitat, infected cells is a Habitat, adult Schwann cells is a Habitat, M. leprae is a Microorganism, PNS is a Habitat

27_task0

Sentence: Usage of signaling in neurodegeneration and regeneration of peripheral nerves by leprosy bacteria. Multiple signaling pathways play key regulatory roles during the development of peripheral nervous system (PNS) and also in neuroregeneration process following nerve degeneration. Schwann cells, the glial cells of the PNS, by interacting with neuronal (axonal) ligands, mainly neuregulins via receptor tyrosine kinase (RTK) complex, ErbB2/ErbB3, initiate intracellular signaling pathways to drive proliferation and differentiation of Schwann cells, both during development and the process of regeneration and re-myelination after nerve injury. One of the major signaling kinases, extracellular signal-regulated kinase-1/2 (ERK1/2), that is also a downstream signaling pathway of neuregulin-ErbB2/ErbB3 activation, has been identified as a key regulator of Schwann cell proliferation, differentiation, demyelination and nerve regeneration. Recent studies have provided evidence that the bacterium that causes human leprosy, Mycobacterium leprae that has a unique capacity to invade Schwann cells of the adult PNS, utilizes the neuregulin-ErbB2/ErbB3 associated signaling network to the bacterial advantage. M. leprae directly bind to ErbB2 on myelinated Schwann cells and activate the RTK by a novel route that bypasses the classical neuregulin/growth factor-induced ErbB2-ErbB3 heterodimerization, and subsequently induce downstream the canonical Erk1/2 signaling, leading to myelin breakdown and subsequent axonal damage. This initial injury provides a survival advantage for M. leprae as it induces de-differentiation and generates myelin-free cells, which are highly susceptible to M. leprae invasion and promote bacterial survival. Once invaded M. leprae activate Erk1/2 via a non-canonical pathway and subsequently increase the cell proliferation and maintain the infected cells in de-differentiated state, thereby preventing remyelination. Therefore, by subverting major RTKs and signaling pathways in adult Schwann cells M. leprae appear to propagate the bacterial niche and maintain survival within the PNS. These studies may also provide new insights into our understanding of signaling mechanisms involve in both neurodegeneration and neuroregeneration. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Habitat, Microorganism

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Usage of signaling in neurodegeneration and regeneration of peripheral nerves by leprosy bacteria. Multiple signaling pathways play key regulatory roles during the development of peripheral nervous system (PNS) and also in neuroregeneration process following nerve degeneration. Schwann cells, the glial cells of the PNS, by interacting with neuronal (axonal) ligands, mainly neuregulins via receptor tyrosine kinase (RTK) complex, ErbB2/ErbB3, initiate intracellular signaling pathways to drive proliferation and differentiation of Schwann cells, both during development and the process of regeneration and re-myelination after nerve injury. One of the major signaling kinases, extracellular signal-regulated kinase-1/2 (ERK1/2), that is also a downstream signaling pathway of neuregulin-ErbB2/ErbB3 activation, has been identified as a key regulator of Schwann cell proliferation, differentiation, demyelination and nerve regeneration. Recent studies have provided evidence that the bacterium that causes human leprosy, Mycobacterium leprae that has a unique capacity to invade Schwann cells of the adult PNS, utilizes the neuregulin-ErbB2/ErbB3 associated signaling network to the bacterial advantage. M. leprae directly bind to ErbB2 on myelinated Schwann cells and activate the RTK by a novel route that bypasses the classical neuregulin/growth factor-induced ErbB2-ErbB3 heterodimerization, and subsequently induce downstream the canonical Erk1/2 signaling, leading to myelin breakdown and subsequent axonal damage. This initial injury provides a survival advantage for M. leprae as it induces de-differentiation and generates myelin-free cells, which are highly susceptible to M. leprae invasion and promote bacterial survival. Once invaded M. leprae activate Erk1/2 via a non-canonical pathway and subsequently increase the cell proliferation and maintain the infected cells in de-differentiated state, thereby preventing remyelination. Therefore, by subverting major RTKs and signaling pathways in adult Schwann cells M. leprae appear to propagate the bacterial niche and maintain survival within the PNS. These studies may also provide new insights into our understanding of signaling mechanisms involve in both neurodegeneration and neuroregeneration.

[ "Usage", "of", "signaling", "in", "neurodegeneration", "and", "regeneration", "of", "peripheral", "nerves", "by", "leprosy", "bacteria", ".", "Multiple", "signaling", "pathways", "play", "key", "regulatory", "roles", "during", "the", "development", "of", "peripheral", "nervous", "system", "(", "PNS", ")", "and", "also", "in", "neuroregeneration", "process", "following", "nerve", "degeneration", ".", "Schwann", "cells", ",", "the", "glial", "cells", "of", "the", "PNS", ",", "by", "interacting", "with", "neuronal", "(", "axonal", ")", "ligands", ",", "mainly", "neuregulins", "via", "receptor", "tyrosine", "kinase", "(", "RTK", ")", "complex", ",", "ErbB2", "/", "ErbB3", ",", "initiate", "intracellular", "signaling", "pathways", "to", "drive", "proliferation", "and", "differentiation", "of", "Schwann", "cells", ",", "both", "during", "development", "and", "the", "process", "of", "regeneration", "and", "re", "-", "myelination", "after", "nerve", "injury", ".", "One", "of", "the", "major", "signaling", "kinases", ",", "extracellular", "signal", "-", "regulated", "kinase-1/2", "(", "ERK1/2", ")", ",", "that", "is", "also", "a", "downstream", "signaling", "pathway", "of", "neuregulin", "-", "ErbB2", "/", "ErbB3", "activation", ",", "has", "been", "identified", "as", "a", "key", "regulator", "of", "Schwann", "cell", "proliferation", ",", "differentiation", ",", "demyelination", "and", "nerve", "regeneration", ".", "Recent", "studies", "have", "provided", "evidence", "that", "the", "bacterium", "that", "causes", "human", "leprosy", ",", "Mycobacterium", "leprae", "that", "has", "a", "unique", "capacity", "to", "invade", "Schwann", "cells", "of", "the", "adult", "PNS", ",", "utilizes", "the", "neuregulin", "-", "ErbB2", "/", "ErbB3", "associated", "signaling", "network", "to", "the", "bacterial", "advantage", ".", "M.", "leprae", "directly", "bind", "to", "ErbB2", "on", "myelinated", "Schwann", "cells", "and", "activate", "the", "RTK", "by", "a", "novel", "route", "that", "bypasses", "the", "classical", "neuregulin", "/", "growth", "factor", "-", "induced", "ErbB2-ErbB3", "heterodimerization", ",", "and", "subsequently", "induce", "downstream", "the", "canonical", "Erk1/2", "signaling", ",", "leading", "to", "myelin", "breakdown", "and", "subsequent", "axonal", "damage", ".", "This", "initial", "injury", "provides", "a", "survival", "advantage", "for", "M.", "leprae", "as", "it", "induces", "de", "-", "differentiation", "and", "generates", "myelin", "-", "free", "cells", ",", "which", "are", "highly", "susceptible", "to", "M.", "leprae", "invasion", "and", "promote", "bacterial", "survival", ".", "Once", "invaded", "M.", "leprae", "activate", "Erk1/2", "via", "a", "non", "-", "canonical", "pathway", "and", "subsequently", "increase", "the", "cell", "proliferation", "and", "maintain", "the", "infected", "cells", "in", "de", "-", "differentiated", "state", ",", "thereby", "preventing", "remyelination", ".", "Therefore", ",", "by", "subverting", "major", "RTKs", "and", "signaling", "pathways", "in", "adult", "Schwann", "cells", "M.", "leprae", "appear", "to", "propagate", "the", "bacterial", "niche", "and", "maintain", "survival", "within", "the", "PNS", ".", "These", "studies", "may", "also", "provide", "new", "insights", "into", "our", "understanding", "of", "signaling", "mechanisms", "involve", "in", "both", "neurodegeneration", "and", "neuroregeneration", ".", " " ]

[ "Habitat", "Microorganism" ]

peripheral nerves is a Habitat, peripheral nervous system is a Habitat, PNS is a Habitat, nerve is a Habitat, Schwann cells is a Habitat, glial cells of the PNS is a Habitat, Schwann cells is a Habitat, nerve injury is a Habitat, Schwann cell is a Habitat, nerve is a Habitat, human is a Habitat, Mycobacterium leprae is a Microorganism, Schwann cells of the adult PNS is a Habitat, M. leprae is a Microorganism, myelinated Schwann cells is a Habitat, injury is a Habitat, M. leprae is a Microorganism, myelin - free cells is a Habitat, M. leprae is a Microorganism, M. leprae is a Microorganism, cell is a Habitat, infected cells is a Habitat, adult Schwann cells is a Habitat, M. leprae is a Microorganism, PNS is a Habitat

27_task1

Sentence: Usage of signaling in neurodegeneration and regeneration of peripheral nerves by leprosy bacteria. Multiple signaling pathways play key regulatory roles during the development of peripheral nervous system (PNS) and also in neuroregeneration process following nerve degeneration. Schwann cells, the glial cells of the PNS, by interacting with neuronal (axonal) ligands, mainly neuregulins via receptor tyrosine kinase (RTK) complex, ErbB2/ErbB3, initiate intracellular signaling pathways to drive proliferation and differentiation of Schwann cells, both during development and the process of regeneration and re-myelination after nerve injury. One of the major signaling kinases, extracellular signal-regulated kinase-1/2 (ERK1/2), that is also a downstream signaling pathway of neuregulin-ErbB2/ErbB3 activation, has been identified as a key regulator of Schwann cell proliferation, differentiation, demyelination and nerve regeneration. Recent studies have provided evidence that the bacterium that causes human leprosy, Mycobacterium leprae that has a unique capacity to invade Schwann cells of the adult PNS, utilizes the neuregulin-ErbB2/ErbB3 associated signaling network to the bacterial advantage. M. leprae directly bind to ErbB2 on myelinated Schwann cells and activate the RTK by a novel route that bypasses the classical neuregulin/growth factor-induced ErbB2-ErbB3 heterodimerization, and subsequently induce downstream the canonical Erk1/2 signaling, leading to myelin breakdown and subsequent axonal damage. This initial injury provides a survival advantage for M. leprae as it induces de-differentiation and generates myelin-free cells, which are highly susceptible to M. leprae invasion and promote bacterial survival. Once invaded M. leprae activate Erk1/2 via a non-canonical pathway and subsequently increase the cell proliferation and maintain the infected cells in de-differentiated state, thereby preventing remyelination. Therefore, by subverting major RTKs and signaling pathways in adult Schwann cells M. leprae appear to propagate the bacterial niche and maintain survival within the PNS. These studies may also provide new insights into our understanding of signaling mechanisms involve in both neurodegeneration and neuroregeneration. Instructions: please typing these entity words according to sentence: peripheral nerves, peripheral nervous system, PNS, nerve, Schwann cells, glial cells of the PNS, Schwann cells, nerve injury, Schwann cell, nerve, human, Mycobacterium leprae, Schwann cells of the adult PNS, M. leprae, myelinated Schwann cells, injury, M. leprae, myelin - free cells, M. leprae, M. leprae, cell, infected cells, adult Schwann cells, M. leprae, PNS Options: Habitat, Microorganism

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Usage of signaling in neurodegeneration and regeneration of peripheral nerves by leprosy bacteria. Multiple signaling pathways play key regulatory roles during the development of peripheral nervous system (PNS) and also in neuroregeneration process following nerve degeneration. Schwann cells, the glial cells of the PNS, by interacting with neuronal (axonal) ligands, mainly neuregulins via receptor tyrosine kinase (RTK) complex, ErbB2/ErbB3, initiate intracellular signaling pathways to drive proliferation and differentiation of Schwann cells, both during development and the process of regeneration and re-myelination after nerve injury. One of the major signaling kinases, extracellular signal-regulated kinase-1/2 (ERK1/2), that is also a downstream signaling pathway of neuregulin-ErbB2/ErbB3 activation, has been identified as a key regulator of Schwann cell proliferation, differentiation, demyelination and nerve regeneration. Recent studies have provided evidence that the bacterium that causes human leprosy, Mycobacterium leprae that has a unique capacity to invade Schwann cells of the adult PNS, utilizes the neuregulin-ErbB2/ErbB3 associated signaling network to the bacterial advantage. M. leprae directly bind to ErbB2 on myelinated Schwann cells and activate the RTK by a novel route that bypasses the classical neuregulin/growth factor-induced ErbB2-ErbB3 heterodimerization, and subsequently induce downstream the canonical Erk1/2 signaling, leading to myelin breakdown and subsequent axonal damage. This initial injury provides a survival advantage for M. leprae as it induces de-differentiation and generates myelin-free cells, which are highly susceptible to M. leprae invasion and promote bacterial survival. Once invaded M. leprae activate Erk1/2 via a non-canonical pathway and subsequently increase the cell proliferation and maintain the infected cells in de-differentiated state, thereby preventing remyelination. Therefore, by subverting major RTKs and signaling pathways in adult Schwann cells M. leprae appear to propagate the bacterial niche and maintain survival within the PNS. These studies may also provide new insights into our understanding of signaling mechanisms involve in both neurodegeneration and neuroregeneration.

[ "Usage", "of", "signaling", "in", "neurodegeneration", "and", "regeneration", "of", "peripheral", "nerves", "by", "leprosy", "bacteria", ".", "Multiple", "signaling", "pathways", "play", "key", "regulatory", "roles", "during", "the", "development", "of", "peripheral", "nervous", "system", "(", "PNS", ")", "and", "also", "in", "neuroregeneration", "process", "following", "nerve", "degeneration", ".", "Schwann", "cells", ",", "the", "glial", "cells", "of", "the", "PNS", ",", "by", "interacting", "with", "neuronal", "(", "axonal", ")", "ligands", ",", "mainly", "neuregulins", "via", "receptor", "tyrosine", "kinase", "(", "RTK", ")", "complex", ",", "ErbB2", "/", "ErbB3", ",", "initiate", "intracellular", "signaling", "pathways", "to", "drive", "proliferation", "and", "differentiation", "of", "Schwann", "cells", ",", "both", "during", "development", "and", "the", "process", "of", "regeneration", "and", "re", "-", "myelination", "after", "nerve", "injury", ".", "One", "of", "the", "major", "signaling", "kinases", ",", "extracellular", "signal", "-", "regulated", "kinase-1/2", "(", "ERK1/2", ")", ",", "that", "is", "also", "a", "downstream", "signaling", "pathway", "of", "neuregulin", "-", "ErbB2", "/", "ErbB3", "activation", ",", "has", "been", "identified", "as", "a", "key", "regulator", "of", "Schwann", "cell", "proliferation", ",", "differentiation", ",", "demyelination", "and", "nerve", "regeneration", ".", "Recent", "studies", "have", "provided", "evidence", "that", "the", "bacterium", "that", "causes", "human", "leprosy", ",", "Mycobacterium", "leprae", "that", "has", "a", "unique", "capacity", "to", "invade", "Schwann", "cells", "of", "the", "adult", "PNS", ",", "utilizes", "the", "neuregulin", "-", "ErbB2", "/", "ErbB3", "associated", "signaling", "network", "to", "the", "bacterial", "advantage", ".", "M.", "leprae", "directly", "bind", "to", "ErbB2", "on", "myelinated", "Schwann", "cells", "and", "activate", "the", "RTK", "by", "a", "novel", "route", "that", "bypasses", "the", "classical", "neuregulin", "/", "growth", "factor", "-", "induced", "ErbB2-ErbB3", "heterodimerization", ",", "and", "subsequently", "induce", "downstream", "the", "canonical", "Erk1/2", "signaling", ",", "leading", "to", "myelin", "breakdown", "and", "subsequent", "axonal", "damage", ".", "This", "initial", "injury", "provides", "a", "survival", "advantage", "for", "M.", "leprae", "as", "it", "induces", "de", "-", "differentiation", "and", "generates", "myelin", "-", "free", "cells", ",", "which", "are", "highly", "susceptible", "to", "M.", "leprae", "invasion", "and", "promote", "bacterial", "survival", ".", "Once", "invaded", "M.", "leprae", "activate", "Erk1/2", "via", "a", "non", "-", "canonical", "pathway", "and", "subsequently", "increase", "the", "cell", "proliferation", "and", "maintain", "the", "infected", "cells", "in", "de", "-", "differentiated", "state", ",", "thereby", "preventing", "remyelination", ".", "Therefore", ",", "by", "subverting", "major", "RTKs", "and", "signaling", "pathways", "in", "adult", "Schwann", "cells", "M.", "leprae", "appear", "to", "propagate", "the", "bacterial", "niche", "and", "maintain", "survival", "within", "the", "PNS", ".", "These", "studies", "may", "also", "provide", "new", "insights", "into", "our", "understanding", "of", "signaling", "mechanisms", "involve", "in", "both", "neurodegeneration", "and", "neuroregeneration", ".", " " ]

[ "Habitat", "Microorganism" ]

peripheral nerves, peripheral nervous system, PNS, nerve, Schwann cells, glial cells of the PNS, Schwann cells, nerve injury, Schwann cell, nerve, human, Mycobacterium leprae, Schwann cells of the adult PNS, M. leprae, myelinated Schwann cells, injury, M. leprae, myelin - free cells, M. leprae, M. leprae, cell, infected cells, adult Schwann cells, M. leprae, PNS

27_task2

Sentence: Usage of signaling in neurodegeneration and regeneration of peripheral nerves by leprosy bacteria. Multiple signaling pathways play key regulatory roles during the development of peripheral nervous system (PNS) and also in neuroregeneration process following nerve degeneration. Schwann cells, the glial cells of the PNS, by interacting with neuronal (axonal) ligands, mainly neuregulins via receptor tyrosine kinase (RTK) complex, ErbB2/ErbB3, initiate intracellular signaling pathways to drive proliferation and differentiation of Schwann cells, both during development and the process of regeneration and re-myelination after nerve injury. One of the major signaling kinases, extracellular signal-regulated kinase-1/2 (ERK1/2), that is also a downstream signaling pathway of neuregulin-ErbB2/ErbB3 activation, has been identified as a key regulator of Schwann cell proliferation, differentiation, demyelination and nerve regeneration. Recent studies have provided evidence that the bacterium that causes human leprosy, Mycobacterium leprae that has a unique capacity to invade Schwann cells of the adult PNS, utilizes the neuregulin-ErbB2/ErbB3 associated signaling network to the bacterial advantage. M. leprae directly bind to ErbB2 on myelinated Schwann cells and activate the RTK by a novel route that bypasses the classical neuregulin/growth factor-induced ErbB2-ErbB3 heterodimerization, and subsequently induce downstream the canonical Erk1/2 signaling, leading to myelin breakdown and subsequent axonal damage. This initial injury provides a survival advantage for M. leprae as it induces de-differentiation and generates myelin-free cells, which are highly susceptible to M. leprae invasion and promote bacterial survival. Once invaded M. leprae activate Erk1/2 via a non-canonical pathway and subsequently increase the cell proliferation and maintain the infected cells in de-differentiated state, thereby preventing remyelination. Therefore, by subverting major RTKs and signaling pathways in adult Schwann cells M. leprae appear to propagate the bacterial niche and maintain survival within the PNS. These studies may also provide new insights into our understanding of signaling mechanisms involve in both neurodegeneration and neuroregeneration. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Usage of signaling in neurodegeneration and regeneration of peripheral nerves by leprosy bacteria. Multiple signaling pathways play key regulatory roles during the development of peripheral nervous system (PNS) and also in neuroregeneration process following nerve degeneration. Schwann cells, the glial cells of the PNS, by interacting with neuronal (axonal) ligands, mainly neuregulins via receptor tyrosine kinase (RTK) complex, ErbB2/ErbB3, initiate intracellular signaling pathways to drive proliferation and differentiation of Schwann cells, both during development and the process of regeneration and re-myelination after nerve injury. One of the major signaling kinases, extracellular signal-regulated kinase-1/2 (ERK1/2), that is also a downstream signaling pathway of neuregulin-ErbB2/ErbB3 activation, has been identified as a key regulator of Schwann cell proliferation, differentiation, demyelination and nerve regeneration. Recent studies have provided evidence that the bacterium that causes human leprosy, Mycobacterium leprae that has a unique capacity to invade Schwann cells of the adult PNS, utilizes the neuregulin-ErbB2/ErbB3 associated signaling network to the bacterial advantage. M. leprae directly bind to ErbB2 on myelinated Schwann cells and activate the RTK by a novel route that bypasses the classical neuregulin/growth factor-induced ErbB2-ErbB3 heterodimerization, and subsequently induce downstream the canonical Erk1/2 signaling, leading to myelin breakdown and subsequent axonal damage. This initial injury provides a survival advantage for M. leprae as it induces de-differentiation and generates myelin-free cells, which are highly susceptible to M. leprae invasion and promote bacterial survival. Once invaded M. leprae activate Erk1/2 via a non-canonical pathway and subsequently increase the cell proliferation and maintain the infected cells in de-differentiated state, thereby preventing remyelination. Therefore, by subverting major RTKs and signaling pathways in adult Schwann cells M. leprae appear to propagate the bacterial niche and maintain survival within the PNS. These studies may also provide new insights into our understanding of signaling mechanisms involve in both neurodegeneration and neuroregeneration.

[ "Usage", "of", "signaling", "in", "neurodegeneration", "and", "regeneration", "of", "peripheral", "nerves", "by", "leprosy", "bacteria", ".", "Multiple", "signaling", "pathways", "play", "key", "regulatory", "roles", "during", "the", "development", "of", "peripheral", "nervous", "system", "(", "PNS", ")", "and", "also", "in", "neuroregeneration", "process", "following", "nerve", "degeneration", ".", "Schwann", "cells", ",", "the", "glial", "cells", "of", "the", "PNS", ",", "by", "interacting", "with", "neuronal", "(", "axonal", ")", "ligands", ",", "mainly", "neuregulins", "via", "receptor", "tyrosine", "kinase", "(", "RTK", ")", "complex", ",", "ErbB2", "/", "ErbB3", ",", "initiate", "intracellular", "signaling", "pathways", "to", "drive", "proliferation", "and", "differentiation", "of", "Schwann", "cells", ",", "both", "during", "development", "and", "the", "process", "of", "regeneration", "and", "re", "-", "myelination", "after", "nerve", "injury", ".", "One", "of", "the", "major", "signaling", "kinases", ",", "extracellular", "signal", "-", "regulated", "kinase-1/2", "(", "ERK1/2", ")", ",", "that", "is", "also", "a", "downstream", "signaling", "pathway", "of", "neuregulin", "-", "ErbB2", "/", "ErbB3", "activation", ",", "has", "been", "identified", "as", "a", "key", "regulator", "of", "Schwann", "cell", "proliferation", ",", "differentiation", ",", "demyelination", "and", "nerve", "regeneration", ".", "Recent", "studies", "have", "provided", "evidence", "that", "the", "bacterium", "that", "causes", "human", "leprosy", ",", "Mycobacterium", "leprae", "that", "has", "a", "unique", "capacity", "to", "invade", "Schwann", "cells", "of", "the", "adult", "PNS", ",", "utilizes", "the", "neuregulin", "-", "ErbB2", "/", "ErbB3", "associated", "signaling", "network", "to", "the", "bacterial", "advantage", ".", "M.", "leprae", "directly", "bind", "to", "ErbB2", "on", "myelinated", "Schwann", "cells", "and", "activate", "the", "RTK", "by", "a", "novel", "route", "that", "bypasses", "the", "classical", "neuregulin", "/", "growth", "factor", "-", "induced", "ErbB2-ErbB3", "heterodimerization", ",", "and", "subsequently", "induce", "downstream", "the", "canonical", "Erk1/2", "signaling", ",", "leading", "to", "myelin", "breakdown", "and", "subsequent", "axonal", "damage", ".", "This", "initial", "injury", "provides", "a", "survival", "advantage", "for", "M.", "leprae", "as", "it", "induces", "de", "-", "differentiation", "and", "generates", "myelin", "-", "free", "cells", ",", "which", "are", "highly", "susceptible", "to", "M.", "leprae", "invasion", "and", "promote", "bacterial", "survival", ".", "Once", "invaded", "M.", "leprae", "activate", "Erk1/2", "via", "a", "non", "-", "canonical", "pathway", "and", "subsequently", "increase", "the", "cell", "proliferation", "and", "maintain", "the", "infected", "cells", "in", "de", "-", "differentiated", "state", ",", "thereby", "preventing", "remyelination", ".", "Therefore", ",", "by", "subverting", "major", "RTKs", "and", "signaling", "pathways", "in", "adult", "Schwann", "cells", "M.", "leprae", "appear", "to", "propagate", "the", "bacterial", "niche", "and", "maintain", "survival", "within", "the", "PNS", ".", "These", "studies", "may", "also", "provide", "new", "insights", "into", "our", "understanding", "of", "signaling", "mechanisms", "involve", "in", "both", "neurodegeneration", "and", "neuroregeneration", ".", " " ]

[ "Habitat", "Microorganism" ]

IkappaBalpha is a Protein, IkappaBalpha is a Protein, IL-2 is a Protein, IFN - gamma is a Protein

231_task0

Sentence: Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells. Activation of the transcription factor nuclear factor-kappaB (NFkappaB) is impaired in T cells from patients with renal cell carcinomas (RCCs). In circulating T cells from a subset of patients with RCCs, the suppression of NFkappaB binding activity is downstream from the stimulus-induced degradation of the cytoplasmic factor IkappaBalpha. Tumor-derived soluble products from cultured RCC explants inhibit NFkappaB activity in T cells from healthy volunteers, despite a normal level of stimulus-induced IkappaBalpha degradation in these cells. The inhibitory agent has several features characteristic of a ganglioside, including sensitivity to neuraminidase but not protease treatment; hydrophobicity; and molecular weight less than 3 kDa. Indeed, we detected gangliosides in supernatants from RCC explants and not from adjacent normal kidney tissue. Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), suppressed NFkappaB binding activity in T cells and reduced expression of the cytokines IL-2 and IFN-gamma. Taken together, our findings suggest that tumor-derived gangliosides may blunt antitumor immune responses in patients with RCCs. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells. Activation of the transcription factor nuclear factor-kappaB (NFkappaB) is impaired in T cells from patients with renal cell carcinomas (RCCs). In circulating T cells from a subset of patients with RCCs, the suppression of NFkappaB binding activity is downstream from the stimulus-induced degradation of the cytoplasmic factor IkappaBalpha. Tumor-derived soluble products from cultured RCC explants inhibit NFkappaB activity in T cells from healthy volunteers, despite a normal level of stimulus-induced IkappaBalpha degradation in these cells. The inhibitory agent has several features characteristic of a ganglioside, including sensitivity to neuraminidase but not protease treatment; hydrophobicity; and molecular weight less than 3 kDa. Indeed, we detected gangliosides in supernatants from RCC explants and not from adjacent normal kidney tissue. Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), suppressed NFkappaB binding activity in T cells and reduced expression of the cytokines IL-2 and IFN-gamma. Taken together, our findings suggest that tumor-derived gangliosides may blunt antitumor immune responses in patients with RCCs.

[ "Renal", "cell", "carcinoma", "-", "derived", "gangliosides", "suppress", "nuclear", "factor", "-", "kappaB", "activation", "in", "T", "cells", ".", "\n", "Activation", "of", "the", "transcription", "factor", "nuclear", "factor", "-", "kappaB", "(", "NFkappaB", ")", "is", "impaired", "in", "T", "cells", "from", "patients", "with", "renal", "cell", "carcinomas", "(", "RCCs", ")", ".", "In", "circulating", "T", "cells", "from", "a", "subset", "of", "patients", "with", "RCCs", ",", "the", "suppression", "of", "NFkappaB", "binding", "activity", "is", "downstream", "from", "the", "stimulus", "-", "induced", "degradation", "of", "the", "cytoplasmic", "factor", "IkappaBalpha", ".", "Tumor", "-", "derived", "soluble", "products", "from", "cultured", "RCC", "explants", "inhibit", "NFkappaB", "activity", "in", "T", "cells", "from", "healthy", "volunteers", ",", "despite", "a", "normal", "level", "of", "stimulus", "-", "induced", "IkappaBalpha", "degradation", "in", "these", "cells", ".", "The", "inhibitory", "agent", "has", "several", "features", "characteristic", "of", "a", "ganglioside", ",", "including", "sensitivity", "to", "neuraminidase", "but", "not", "protease", "treatment", ";", "hydrophobicity", ";", "and", "molecular", "weight", "less", "than", "3", "kDa", ".", "Indeed", ",", "we", "detected", "gangliosides", "in", "supernatants", "from", "RCC", "explants", "and", "not", "from", "adjacent", "normal", "kidney", "tissue", ".", "Gangliosides", "prepared", "from", "RCC", "supernatants", ",", "as", "well", "as", "the", "purified", "bovine", "gangliosides", "G(m1", ")", "and", "G(d1a", ")", ",", "suppressed", "NFkappaB", "binding", "activity", "in", "T", "cells", "and", "reduced", "expression", "of", "the", "cytokines", "IL-2", "and", "IFN", "-", "gamma", ".", "Taken", "together", ",", "our", "findings", "suggest", "that", "tumor", "-", "derived", "gangliosides", "may", "blunt", "antitumor", "immune", "responses", "in", "patients", "with", "RCCs", "." ]

[ "Protein" ]

IkappaBalpha is a Protein, IkappaBalpha is a Protein, IL-2 is a Protein, IFN - gamma is a Protein

231_task1

Sentence: Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells. Activation of the transcription factor nuclear factor-kappaB (NFkappaB) is impaired in T cells from patients with renal cell carcinomas (RCCs). In circulating T cells from a subset of patients with RCCs, the suppression of NFkappaB binding activity is downstream from the stimulus-induced degradation of the cytoplasmic factor IkappaBalpha. Tumor-derived soluble products from cultured RCC explants inhibit NFkappaB activity in T cells from healthy volunteers, despite a normal level of stimulus-induced IkappaBalpha degradation in these cells. The inhibitory agent has several features characteristic of a ganglioside, including sensitivity to neuraminidase but not protease treatment; hydrophobicity; and molecular weight less than 3 kDa. Indeed, we detected gangliosides in supernatants from RCC explants and not from adjacent normal kidney tissue. Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), suppressed NFkappaB binding activity in T cells and reduced expression of the cytokines IL-2 and IFN-gamma. Taken together, our findings suggest that tumor-derived gangliosides may blunt antitumor immune responses in patients with RCCs. Instructions: please typing these entity words according to sentence: IkappaBalpha, IkappaBalpha, IL-2, IFN - gamma Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells. Activation of the transcription factor nuclear factor-kappaB (NFkappaB) is impaired in T cells from patients with renal cell carcinomas (RCCs). In circulating T cells from a subset of patients with RCCs, the suppression of NFkappaB binding activity is downstream from the stimulus-induced degradation of the cytoplasmic factor IkappaBalpha. Tumor-derived soluble products from cultured RCC explants inhibit NFkappaB activity in T cells from healthy volunteers, despite a normal level of stimulus-induced IkappaBalpha degradation in these cells. The inhibitory agent has several features characteristic of a ganglioside, including sensitivity to neuraminidase but not protease treatment; hydrophobicity; and molecular weight less than 3 kDa. Indeed, we detected gangliosides in supernatants from RCC explants and not from adjacent normal kidney tissue. Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), suppressed NFkappaB binding activity in T cells and reduced expression of the cytokines IL-2 and IFN-gamma. Taken together, our findings suggest that tumor-derived gangliosides may blunt antitumor immune responses in patients with RCCs.

[ "Renal", "cell", "carcinoma", "-", "derived", "gangliosides", "suppress", "nuclear", "factor", "-", "kappaB", "activation", "in", "T", "cells", ".", "\n", "Activation", "of", "the", "transcription", "factor", "nuclear", "factor", "-", "kappaB", "(", "NFkappaB", ")", "is", "impaired", "in", "T", "cells", "from", "patients", "with", "renal", "cell", "carcinomas", "(", "RCCs", ")", ".", "In", "circulating", "T", "cells", "from", "a", "subset", "of", "patients", "with", "RCCs", ",", "the", "suppression", "of", "NFkappaB", "binding", "activity", "is", "downstream", "from", "the", "stimulus", "-", "induced", "degradation", "of", "the", "cytoplasmic", "factor", "IkappaBalpha", ".", "Tumor", "-", "derived", "soluble", "products", "from", "cultured", "RCC", "explants", "inhibit", "NFkappaB", "activity", "in", "T", "cells", "from", "healthy", "volunteers", ",", "despite", "a", "normal", "level", "of", "stimulus", "-", "induced", "IkappaBalpha", "degradation", "in", "these", "cells", ".", "The", "inhibitory", "agent", "has", "several", "features", "characteristic", "of", "a", "ganglioside", ",", "including", "sensitivity", "to", "neuraminidase", "but", "not", "protease", "treatment", ";", "hydrophobicity", ";", "and", "molecular", "weight", "less", "than", "3", "kDa", ".", "Indeed", ",", "we", "detected", "gangliosides", "in", "supernatants", "from", "RCC", "explants", "and", "not", "from", "adjacent", "normal", "kidney", "tissue", ".", "Gangliosides", "prepared", "from", "RCC", "supernatants", ",", "as", "well", "as", "the", "purified", "bovine", "gangliosides", "G(m1", ")", "and", "G(d1a", ")", ",", "suppressed", "NFkappaB", "binding", "activity", "in", "T", "cells", "and", "reduced", "expression", "of", "the", "cytokines", "IL-2", "and", "IFN", "-", "gamma", ".", "Taken", "together", ",", "our", "findings", "suggest", "that", "tumor", "-", "derived", "gangliosides", "may", "blunt", "antitumor", "immune", "responses", "in", "patients", "with", "RCCs", "." ]

[ "Protein" ]

IkappaBalpha, IkappaBalpha, IL-2, IFN - gamma

231_task2

Sentence: Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells. Activation of the transcription factor nuclear factor-kappaB (NFkappaB) is impaired in T cells from patients with renal cell carcinomas (RCCs). In circulating T cells from a subset of patients with RCCs, the suppression of NFkappaB binding activity is downstream from the stimulus-induced degradation of the cytoplasmic factor IkappaBalpha. Tumor-derived soluble products from cultured RCC explants inhibit NFkappaB activity in T cells from healthy volunteers, despite a normal level of stimulus-induced IkappaBalpha degradation in these cells. The inhibitory agent has several features characteristic of a ganglioside, including sensitivity to neuraminidase but not protease treatment; hydrophobicity; and molecular weight less than 3 kDa. Indeed, we detected gangliosides in supernatants from RCC explants and not from adjacent normal kidney tissue. Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), suppressed NFkappaB binding activity in T cells and reduced expression of the cytokines IL-2 and IFN-gamma. Taken together, our findings suggest that tumor-derived gangliosides may blunt antitumor immune responses in patients with RCCs. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells. Activation of the transcription factor nuclear factor-kappaB (NFkappaB) is impaired in T cells from patients with renal cell carcinomas (RCCs). In circulating T cells from a subset of patients with RCCs, the suppression of NFkappaB binding activity is downstream from the stimulus-induced degradation of the cytoplasmic factor IkappaBalpha. Tumor-derived soluble products from cultured RCC explants inhibit NFkappaB activity in T cells from healthy volunteers, despite a normal level of stimulus-induced IkappaBalpha degradation in these cells. The inhibitory agent has several features characteristic of a ganglioside, including sensitivity to neuraminidase but not protease treatment; hydrophobicity; and molecular weight less than 3 kDa. Indeed, we detected gangliosides in supernatants from RCC explants and not from adjacent normal kidney tissue. Gangliosides prepared from RCC supernatants, as well as the purified bovine gangliosides G(m1) and G(d1a), suppressed NFkappaB binding activity in T cells and reduced expression of the cytokines IL-2 and IFN-gamma. Taken together, our findings suggest that tumor-derived gangliosides may blunt antitumor immune responses in patients with RCCs.

[ "Renal", "cell", "carcinoma", "-", "derived", "gangliosides", "suppress", "nuclear", "factor", "-", "kappaB", "activation", "in", "T", "cells", ".", "\n", "Activation", "of", "the", "transcription", "factor", "nuclear", "factor", "-", "kappaB", "(", "NFkappaB", ")", "is", "impaired", "in", "T", "cells", "from", "patients", "with", "renal", "cell", "carcinomas", "(", "RCCs", ")", ".", "In", "circulating", "T", "cells", "from", "a", "subset", "of", "patients", "with", "RCCs", ",", "the", "suppression", "of", "NFkappaB", "binding", "activity", "is", "downstream", "from", "the", "stimulus", "-", "induced", "degradation", "of", "the", "cytoplasmic", "factor", "IkappaBalpha", ".", "Tumor", "-", "derived", "soluble", "products", "from", "cultured", "RCC", "explants", "inhibit", "NFkappaB", "activity", "in", "T", "cells", "from", "healthy", "volunteers", ",", "despite", "a", "normal", "level", "of", "stimulus", "-", "induced", "IkappaBalpha", "degradation", "in", "these", "cells", ".", "The", "inhibitory", "agent", "has", "several", "features", "characteristic", "of", "a", "ganglioside", ",", "including", "sensitivity", "to", "neuraminidase", "but", "not", "protease", "treatment", ";", "hydrophobicity", ";", "and", "molecular", "weight", "less", "than", "3", "kDa", ".", "Indeed", ",", "we", "detected", "gangliosides", "in", "supernatants", "from", "RCC", "explants", "and", "not", "from", "adjacent", "normal", "kidney", "tissue", ".", "Gangliosides", "prepared", "from", "RCC", "supernatants", ",", "as", "well", "as", "the", "purified", "bovine", "gangliosides", "G(m1", ")", "and", "G(d1a", ")", ",", "suppressed", "NFkappaB", "binding", "activity", "in", "T", "cells", "and", "reduced", "expression", "of", "the", "cytokines", "IL-2", "and", "IFN", "-", "gamma", ".", "Taken", "together", ",", "our", "findings", "suggest", "that", "tumor", "-", "derived", "gangliosides", "may", "blunt", "antitumor", "immune", "responses", "in", "patients", "with", "RCCs", "." ]

[ "Protein" ]

Abstract is an umlsterm, transmissions is an umlsterm, hepatitis B is an umlsterm, hepatitis C is an umlsterm, HIV is an umlsterm, health care is an umlsterm, transmission is an umlsterm, patients is an umlsterm, patients is an umlsterm, HIV is an umlsterm, patients is an umlsterm, transmissions is an umlsterm, transmissions is an umlsterm, EEG is an umlsterm, transmissions is an umlsterm, infection control is an umlsterm, health care workers is an umlsterm, infection control is an umlsterm, measures is an umlsterm, risk is an umlsterm, transmission is an umlsterm, patients is an umlsterm, invasive procedures is an umlsterm, personnel is an umlsterm, disease is an umlsterm, devices is an umlsterm, risk of is an umlsterm, infection is an umlsterm, patients is an umlsterm, personnel is an umlsterm

DerChirurg.00710389.eng.abstr_task0

Sentence: Abstract . This report analyzes 46 cases of personnel-to-patient transmissions of hepatitis B ( HB ) , hepatitis C ( HC ) and HIV in health care settings . Similar circumstances were found for transmission of HB ( 40 cases , 404 infected patients ) , HC ( 4 cases , 224 infected patients ) and HIV ( 2 cases , 7 infected patients ) . Cases with the highest number of transmissions ( one anesthesiologist with 217 HC transmissions , and one EEG technologist with 75 HB transmissions ) were attributed to poor infection control practices . As long as infected health care workers ( HCW ) adhere to general infection control measures , a risk for transmission to patients exists only from infected surgeons who perform'xposure-prone invasive procedures ' . Whether changes in duties of infected HCW are necessary should be decided on an individual basis . Often , the infected personnel were assumed to have acquired the disease occupationally . Medical practices and devices bearing a risk of infection should constantly be reviewed with regard to risk for patients and personnel . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

Abstract . This report analyzes 46 cases of personnel-to-patient transmissions of hepatitis B ( HB ) , hepatitis C ( HC ) and HIV in health care settings . Similar circumstances were found for transmission of HB ( 40 cases , 404 infected patients ) , HC ( 4 cases , 224 infected patients ) and HIV ( 2 cases , 7 infected patients ) . Cases with the highest number of transmissions ( one anesthesiologist with 217 HC transmissions , and one EEG technologist with 75 HB transmissions ) were attributed to poor infection control practices . As long as infected health care workers ( HCW ) adhere to general infection control measures , a risk for transmission to patients exists only from infected surgeons who perform'xposure-prone invasive procedures ' . Whether changes in duties of infected HCW are necessary should be decided on an individual basis . Often , the infected personnel were assumed to have acquired the disease occupationally . Medical practices and devices bearing a risk of infection should constantly be reviewed with regard to risk for patients and personnel .

[ "Abstract", ".", "This", "report", "analyzes", "46", "cases", "of", "personnel", "-", "to", "-", "patient", "transmissions", "of", "hepatitis", "B", "(", "HB", ")", ",", "hepatitis", "C", "(", "HC", ")", "and", "HIV", "in", "health", "care", "settings", ".", "Similar", "circumstances", "were", "found", "for", "transmission", "of", "HB", "(", "40", "cases", ",", "404", "infected", "patients", ")", ",", "HC", "(", "4", "cases", ",", "224", "infected", "patients", ")", "and", "HIV", "(", "2", "cases", ",", "7", "infected", "patients", ")", ".", "Cases", "with", "the", "highest", "number", "of", "transmissions", "(", "one", "anesthesiologist", "with", "217", "HC", "transmissions", ",", "and", "one", "EEG", "technologist", "with", "75", "HB", "transmissions", ")", "were", "attributed", "to", "poor", "infection", "control", "practices", ".", "As", "long", "as", "infected", "health", "care", "workers", "(", "HCW", ")", "adhere", "to", "general", "infection", "control", "measures", ",", "a", "risk", "for", "transmission", "to", "patients", "exists", "only", "from", "infected", "surgeons", "who", "perform'xposure", "-", "prone", "invasive", "procedures", "'", ".", "Whether", "changes", "in", "duties", "of", "infected", "HCW", "are", "necessary", "should", "be", "decided", "on", "an", "individual", "basis", ".", "Often", ",", "the", "infected", "personnel", "were", "assumed", "to", "have", "acquired", "the", "disease", "occupationally", ".", "Medical", "practices", "and", "devices", "bearing", "a", "risk", "of", "infection", "should", "constantly", "be", "reviewed", "with", "regard", "to", "risk", "for", "patients", "and", "personnel", "." ]

[ "umlsterm" ]

Abstract is an umlsterm, transmissions is an umlsterm, hepatitis B is an umlsterm, hepatitis C is an umlsterm, HIV is an umlsterm, health care is an umlsterm, transmission is an umlsterm, patients is an umlsterm, patients is an umlsterm, HIV is an umlsterm, patients is an umlsterm, transmissions is an umlsterm, transmissions is an umlsterm, EEG is an umlsterm, transmissions is an umlsterm, infection control is an umlsterm, health care workers is an umlsterm, infection control is an umlsterm, measures is an umlsterm, risk is an umlsterm, transmission is an umlsterm, patients is an umlsterm, invasive procedures is an umlsterm, personnel is an umlsterm, disease is an umlsterm, devices is an umlsterm, risk of is an umlsterm, infection is an umlsterm, patients is an umlsterm, personnel is an umlsterm

DerChirurg.00710389.eng.abstr_task1

Sentence: Abstract . This report analyzes 46 cases of personnel-to-patient transmissions of hepatitis B ( HB ) , hepatitis C ( HC ) and HIV in health care settings . Similar circumstances were found for transmission of HB ( 40 cases , 404 infected patients ) , HC ( 4 cases , 224 infected patients ) and HIV ( 2 cases , 7 infected patients ) . Cases with the highest number of transmissions ( one anesthesiologist with 217 HC transmissions , and one EEG technologist with 75 HB transmissions ) were attributed to poor infection control practices . As long as infected health care workers ( HCW ) adhere to general infection control measures , a risk for transmission to patients exists only from infected surgeons who perform'xposure-prone invasive procedures ' . Whether changes in duties of infected HCW are necessary should be decided on an individual basis . Often , the infected personnel were assumed to have acquired the disease occupationally . Medical practices and devices bearing a risk of infection should constantly be reviewed with regard to risk for patients and personnel . Instructions: please typing these entity words according to sentence: Abstract, transmissions, hepatitis B, hepatitis C, HIV, health care, transmission, patients, patients, HIV, patients, transmissions, transmissions, EEG, transmissions, infection control, health care workers, infection control, measures, risk, transmission, patients, invasive procedures, personnel, disease, devices, risk of, infection, patients, personnel Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

Abstract . This report analyzes 46 cases of personnel-to-patient transmissions of hepatitis B ( HB ) , hepatitis C ( HC ) and HIV in health care settings . Similar circumstances were found for transmission of HB ( 40 cases , 404 infected patients ) , HC ( 4 cases , 224 infected patients ) and HIV ( 2 cases , 7 infected patients ) . Cases with the highest number of transmissions ( one anesthesiologist with 217 HC transmissions , and one EEG technologist with 75 HB transmissions ) were attributed to poor infection control practices . As long as infected health care workers ( HCW ) adhere to general infection control measures , a risk for transmission to patients exists only from infected surgeons who perform'xposure-prone invasive procedures ' . Whether changes in duties of infected HCW are necessary should be decided on an individual basis . Often , the infected personnel were assumed to have acquired the disease occupationally . Medical practices and devices bearing a risk of infection should constantly be reviewed with regard to risk for patients and personnel .

[ "Abstract", ".", "This", "report", "analyzes", "46", "cases", "of", "personnel", "-", "to", "-", "patient", "transmissions", "of", "hepatitis", "B", "(", "HB", ")", ",", "hepatitis", "C", "(", "HC", ")", "and", "HIV", "in", "health", "care", "settings", ".", "Similar", "circumstances", "were", "found", "for", "transmission", "of", "HB", "(", "40", "cases", ",", "404", "infected", "patients", ")", ",", "HC", "(", "4", "cases", ",", "224", "infected", "patients", ")", "and", "HIV", "(", "2", "cases", ",", "7", "infected", "patients", ")", ".", "Cases", "with", "the", "highest", "number", "of", "transmissions", "(", "one", "anesthesiologist", "with", "217", "HC", "transmissions", ",", "and", "one", "EEG", "technologist", "with", "75", "HB", "transmissions", ")", "were", "attributed", "to", "poor", "infection", "control", "practices", ".", "As", "long", "as", "infected", "health", "care", "workers", "(", "HCW", ")", "adhere", "to", "general", "infection", "control", "measures", ",", "a", "risk", "for", "transmission", "to", "patients", "exists", "only", "from", "infected", "surgeons", "who", "perform'xposure", "-", "prone", "invasive", "procedures", "'", ".", "Whether", "changes", "in", "duties", "of", "infected", "HCW", "are", "necessary", "should", "be", "decided", "on", "an", "individual", "basis", ".", "Often", ",", "the", "infected", "personnel", "were", "assumed", "to", "have", "acquired", "the", "disease", "occupationally", ".", "Medical", "practices", "and", "devices", "bearing", "a", "risk", "of", "infection", "should", "constantly", "be", "reviewed", "with", "regard", "to", "risk", "for", "patients", "and", "personnel", "." ]

[ "umlsterm" ]

Abstract, transmissions, hepatitis B, hepatitis C, HIV, health care, transmission, patients, patients, HIV, patients, transmissions, transmissions, EEG, transmissions, infection control, health care workers, infection control, measures, risk, transmission, patients, invasive procedures, personnel, disease, devices, risk of, infection, patients, personnel

DerChirurg.00710389.eng.abstr_task2

Sentence: Abstract . This report analyzes 46 cases of personnel-to-patient transmissions of hepatitis B ( HB ) , hepatitis C ( HC ) and HIV in health care settings . Similar circumstances were found for transmission of HB ( 40 cases , 404 infected patients ) , HC ( 4 cases , 224 infected patients ) and HIV ( 2 cases , 7 infected patients ) . Cases with the highest number of transmissions ( one anesthesiologist with 217 HC transmissions , and one EEG technologist with 75 HB transmissions ) were attributed to poor infection control practices . As long as infected health care workers ( HCW ) adhere to general infection control measures , a risk for transmission to patients exists only from infected surgeons who perform'xposure-prone invasive procedures ' . Whether changes in duties of infected HCW are necessary should be decided on an individual basis . Often , the infected personnel were assumed to have acquired the disease occupationally . Medical practices and devices bearing a risk of infection should constantly be reviewed with regard to risk for patients and personnel . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

Abstract . This report analyzes 46 cases of personnel-to-patient transmissions of hepatitis B ( HB ) , hepatitis C ( HC ) and HIV in health care settings . Similar circumstances were found for transmission of HB ( 40 cases , 404 infected patients ) , HC ( 4 cases , 224 infected patients ) and HIV ( 2 cases , 7 infected patients ) . Cases with the highest number of transmissions ( one anesthesiologist with 217 HC transmissions , and one EEG technologist with 75 HB transmissions ) were attributed to poor infection control practices . As long as infected health care workers ( HCW ) adhere to general infection control measures , a risk for transmission to patients exists only from infected surgeons who perform'xposure-prone invasive procedures ' . Whether changes in duties of infected HCW are necessary should be decided on an individual basis . Often , the infected personnel were assumed to have acquired the disease occupationally . Medical practices and devices bearing a risk of infection should constantly be reviewed with regard to risk for patients and personnel .

[ "Abstract", ".", "This", "report", "analyzes", "46", "cases", "of", "personnel", "-", "to", "-", "patient", "transmissions", "of", "hepatitis", "B", "(", "HB", ")", ",", "hepatitis", "C", "(", "HC", ")", "and", "HIV", "in", "health", "care", "settings", ".", "Similar", "circumstances", "were", "found", "for", "transmission", "of", "HB", "(", "40", "cases", ",", "404", "infected", "patients", ")", ",", "HC", "(", "4", "cases", ",", "224", "infected", "patients", ")", "and", "HIV", "(", "2", "cases", ",", "7", "infected", "patients", ")", ".", "Cases", "with", "the", "highest", "number", "of", "transmissions", "(", "one", "anesthesiologist", "with", "217", "HC", "transmissions", ",", "and", "one", "EEG", "technologist", "with", "75", "HB", "transmissions", ")", "were", "attributed", "to", "poor", "infection", "control", "practices", ".", "As", "long", "as", "infected", "health", "care", "workers", "(", "HCW", ")", "adhere", "to", "general", "infection", "control", "measures", ",", "a", "risk", "for", "transmission", "to", "patients", "exists", "only", "from", "infected", "surgeons", "who", "perform'xposure", "-", "prone", "invasive", "procedures", "'", ".", "Whether", "changes", "in", "duties", "of", "infected", "HCW", "are", "necessary", "should", "be", "decided", "on", "an", "individual", "basis", ".", "Often", ",", "the", "infected", "personnel", "were", "assumed", "to", "have", "acquired", "the", "disease", "occupationally", ".", "Medical", "practices", "and", "devices", "bearing", "a", "risk", "of", "infection", "should", "constantly", "be", "reviewed", "with", "regard", "to", "risk", "for", "patients", "and", "personnel", "." ]

[ "umlsterm" ]

Andreu is a NOMBRE_SUJETO_ASISTENCIA, Bernabe Loza is a NOMBRE_SUJETO_ASISTENCIA, 7845123 is a ID_SUJETO_ASISTENCIA, 23 56479608 12 is a ID_ASEGURAMIENTO, Girona is a TERRITORIO, 17006 is a TERRITORIO, 13/01/1978 is a FECHAS, España is a PAIS, 40 años is a EDAD_SUJETO_ASISTENCIA, 10/05/2018 is a FECHAS, 1330431 is a ID_CONTACTO_ASISTENCIAL, Paula Ortiz Ballujera is a NOMBRE_PERSONAL_SANITARIO, 17 17 85423 is a ID_TITULACION_PERSONAL_SANITARIO, varón is a SEXO_SUJETO_ASISTENCIA, 40 años is a EDAD_SUJETO_ASISTENCIA, Paula Ortiz Ballujera is a NOMBRE_PERSONAL_SANITARIO, Hospital Universitari de Girona Doctor Josep Trueta is a HOSPITAL, 17007 is a TERRITORIO, Girona is a TERRITORIO, España is a PAIS, ballujera@hotmail.com is a CORREO_ELECTRONICO

98_task0

Sentence: Nombre: Andreu. Apellidos: Bernabe Loza. NHC: 7845123. NASS: 23 56479608 12. Domicilio: Carrer de Joan Maragall, 26 2B. Localidad/ Provincia: Girona. CP: 17006. Datos asistenciales. Fecha de nacimiento: 13/01/1978. País: España. Edad: 40 años Sexo: H. Fecha de Ingreso: 10/05/2018 . Servicio: Medicina intensiva. Episodio: 1330431. Médico: Paula Ortiz Ballujera NºCol: 17 17 85423. Historia Actual: Se trata de un varón de 40 años que sufrió un accidente de coche. La TACHT al ingreso mostraba un seudoaneurisma de la aorta torácica a la salida de la arteria subclavia izquierda con un hematoma periaórtico extendido al mediastino posterior. El paciente ingresó en la UCI en respiración espontánea con tensión arterial sistólica (TAS) inferior a 120 mmHg. Se llevó a cabo un tratamiento conservador de las lesiones asociadas. A las 10 horas del ingreso en la UCI se le colocó una endoprótesis en la aorta torácica descendente por vía femoral izquierda, con oclusión parcial de la arteria subclavia izquierda. Fue dado de alta a planta a las 48 horas. Siguió controles con TACHT a los 7 días, al mes y a los 45 días. A los dos meses del accidente presentó una pericarditis aguda y ausencia de pulso radial izquierdo sin repercusión clínica. La TACHT mostraba una correcta localización de la endoprótesis. Remitido por: Dra. Paula Ortiz Ballujera. Servicio de Medicina Intensiva (UCI). Hospital Universitari de Girona Doctor Josep Trueta. Avda. de França, s/n. 17007 Girona. España. Correo electrónico: ballujera@hotmail.com Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, HOSPITAL, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_CONTACTO_ASISTENCIAL, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ID_CONTACTO_ASISTENCIAL", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "B-TERRITORIO", "O", "B-PAIS", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Nombre: Andreu. Apellidos: Bernabe Loza. NHC: 7845123. NASS: 23 56479608 12. Domicilio: Carrer de Joan Maragall, 26 2B. Localidad/ Provincia: Girona. CP: 17006. Datos asistenciales. Fecha de nacimiento: 13/01/1978. País: España. Edad: 40 años Sexo: H. Fecha de Ingreso: 10/05/2018 . Servicio: Medicina intensiva. Episodio: 1330431. Médico: Paula Ortiz Ballujera NºCol: 17 17 85423. Historia Actual: Se trata de un varón de 40 años que sufrió un accidente de coche. La TACHT al ingreso mostraba un seudoaneurisma de la aorta torácica a la salida de la arteria subclavia izquierda con un hematoma periaórtico extendido al mediastino posterior. El paciente ingresó en la UCI en respiración espontánea con tensión arterial sistólica (TAS) inferior a 120 mmHg. Se llevó a cabo un tratamiento conservador de las lesiones asociadas. A las 10 horas del ingreso en la UCI se le colocó una endoprótesis en la aorta torácica descendente por vía femoral izquierda, con oclusión parcial de la arteria subclavia izquierda. Fue dado de alta a planta a las 48 horas. Siguió controles con TACHT a los 7 días, al mes y a los 45 días. A los dos meses del accidente presentó una pericarditis aguda y ausencia de pulso radial izquierdo sin repercusión clínica. La TACHT mostraba una correcta localización de la endoprótesis. Remitido por: Dra. Paula Ortiz Ballujera. Servicio de Medicina Intensiva (UCI). Hospital Universitari de Girona Doctor Josep Trueta. Avda. de França, s/n. 17007 Girona. España. Correo electrónico: ballujera@hotmail.com

[ "Nombre", ":", " ", "Andreu", ".", "\n", "Apellidos", ":", "Bernabe", "Loza", ".", "\n", "NHC", ":", "7845123", ".", "\n", "NASS", ":", "23", "56479608", "12", ".", "\n", "Domicilio", ":", "Carrer", "de", "Joan", "Maragall", ",", "26", "2B.", "\n", "Localidad/", "Provincia", ":", "Girona", ".", "\n", "CP", ":", "17006", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "13/01/1978", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "40", "años", " ", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "10/05/2018", ".", "\n", "Servicio", ":", "Medicina", "intensiva", ".", "\n", "Episodio", ":", "1330431", ".", "\n", "Médico", ":", "Paula", "Ortiz", "Ballujera", "NºCol", ":", "17", "17", "85423", ".", "\n", "Historia", "Actual", ":", "Se", "trata", "de", "un", "varón", "de", "40", "años", "que", "sufrió", "un", "accidente", "de", "coche", ".", "La", "TACHT", "al", "ingreso", "mostraba", "un", "seudoaneurisma", "de", "la", "aorta", "torácica", "a", "la", "salida", "de", "la", "arteria", "subclavia", "izquierda", "con", "un", "hematoma", "periaórtico", "extendido", "al", "mediastino", "posterior", ".", "El", "paciente", "ingresó", "en", "la", "UCI", "en", "respiración", "espontánea", "con", "tensión", "arterial", "sistólica", "(", "TAS", ")", "inferior", "a", "120", "mmHg", ".", "Se", "llevó", "a", "cabo", "un", "tratamiento", "conservador", "de", "las", "lesiones", "asociadas", ".", "\n", "A", "las", "10", "horas", "del", "ingreso", "en", "la", "UCI", "se", "le", "colocó", "una", "endoprótesis", "en", "la", "aorta", "torácica", "descendente", "por", "vía", "femoral", "izquierda", ",", "con", "oclusión", "parcial", "de", "la", "arteria", "subclavia", "izquierda", ".", "Fue", "dado", "de", "alta", "a", "planta", "a", "las", "48", "horas", ".", "Siguió", "controles", "con", "TACHT", "a", "los", "7", "días", ",", "al", "mes", "y", "a", "los", "45", "días", ".", "\n", "A", "los", "dos", "meses", "del", "accidente", "presentó", "una", "pericarditis", "aguda", "y", "ausencia", "de", "pulso", "radial", "izquierdo", "sin", "repercusión", "clínica", ".", "La", "TACHT", "mostraba", "una", "correcta", "localización", "de", "la", "endoprótesis", ".", "\n", "Remitido", "por", ":", "Dra", ".", "Paula", "Ortiz", "Ballujera", ".", "Servicio", "de", "Medicina", "Intensiva", "(", "UCI", ")", ".", "Hospital", "Universitari", "de", "Girona", "Doctor", "Josep", "Trueta", ".", "Avda", ".", "de", "França", ",", "s", "/", "n.", "17007", "Girona", ".", "España", ".", "Correo", "electrónico", ":", "ballujera@hotmail.com", "\n" ]

[ "HOSPITAL", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_CONTACTO_ASISTENCIAL", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]

Andreu is a NOMBRE_SUJETO_ASISTENCIA, Bernabe Loza is a NOMBRE_SUJETO_ASISTENCIA, 7845123 is a ID_SUJETO_ASISTENCIA, 23 56479608 12 is a ID_ASEGURAMIENTO, Girona is a TERRITORIO, 17006 is a TERRITORIO, 13/01/1978 is a FECHAS, España is a PAIS, 40 años is a EDAD_SUJETO_ASISTENCIA, 10/05/2018 is a FECHAS, 1330431 is a ID_CONTACTO_ASISTENCIAL, Paula Ortiz Ballujera is a NOMBRE_PERSONAL_SANITARIO, 17 17 85423 is a ID_TITULACION_PERSONAL_SANITARIO, varón is a SEXO_SUJETO_ASISTENCIA, 40 años is a EDAD_SUJETO_ASISTENCIA, Paula Ortiz Ballujera is a NOMBRE_PERSONAL_SANITARIO, Hospital Universitari de Girona Doctor Josep Trueta is a HOSPITAL, 17007 is a TERRITORIO, Girona is a TERRITORIO, España is a PAIS, ballujera@hotmail.com is a CORREO_ELECTRONICO

98_task1

Sentence: Nombre: Andreu. Apellidos: Bernabe Loza. NHC: 7845123. NASS: 23 56479608 12. Domicilio: Carrer de Joan Maragall, 26 2B. Localidad/ Provincia: Girona. CP: 17006. Datos asistenciales. Fecha de nacimiento: 13/01/1978. País: España. Edad: 40 años Sexo: H. Fecha de Ingreso: 10/05/2018 . Servicio: Medicina intensiva. Episodio: 1330431. Médico: Paula Ortiz Ballujera NºCol: 17 17 85423. Historia Actual: Se trata de un varón de 40 años que sufrió un accidente de coche. La TACHT al ingreso mostraba un seudoaneurisma de la aorta torácica a la salida de la arteria subclavia izquierda con un hematoma periaórtico extendido al mediastino posterior. El paciente ingresó en la UCI en respiración espontánea con tensión arterial sistólica (TAS) inferior a 120 mmHg. Se llevó a cabo un tratamiento conservador de las lesiones asociadas. A las 10 horas del ingreso en la UCI se le colocó una endoprótesis en la aorta torácica descendente por vía femoral izquierda, con oclusión parcial de la arteria subclavia izquierda. Fue dado de alta a planta a las 48 horas. Siguió controles con TACHT a los 7 días, al mes y a los 45 días. A los dos meses del accidente presentó una pericarditis aguda y ausencia de pulso radial izquierdo sin repercusión clínica. La TACHT mostraba una correcta localización de la endoprótesis. Remitido por: Dra. Paula Ortiz Ballujera. Servicio de Medicina Intensiva (UCI). Hospital Universitari de Girona Doctor Josep Trueta. Avda. de França, s/n. 17007 Girona. España. Correo electrónico: ballujera@hotmail.com Instructions: please typing these entity words according to sentence: Andreu, Bernabe Loza, 7845123, 23 56479608 12, Girona, 17006, 13/01/1978, España, 40 años, 10/05/2018, 1330431, Paula Ortiz Ballujera, 17 17 85423, varón, 40 años, Paula Ortiz Ballujera, Hospital Universitari de Girona Doctor Josep Trueta, 17007, Girona, España, ballujera@hotmail.com Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, HOSPITAL, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_CONTACTO_ASISTENCIAL, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ID_CONTACTO_ASISTENCIAL", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "B-TERRITORIO", "O", "B-PAIS", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Nombre: Andreu. Apellidos: Bernabe Loza. NHC: 7845123. NASS: 23 56479608 12. Domicilio: Carrer de Joan Maragall, 26 2B. Localidad/ Provincia: Girona. CP: 17006. Datos asistenciales. Fecha de nacimiento: 13/01/1978. País: España. Edad: 40 años Sexo: H. Fecha de Ingreso: 10/05/2018 . Servicio: Medicina intensiva. Episodio: 1330431. Médico: Paula Ortiz Ballujera NºCol: 17 17 85423. Historia Actual: Se trata de un varón de 40 años que sufrió un accidente de coche. La TACHT al ingreso mostraba un seudoaneurisma de la aorta torácica a la salida de la arteria subclavia izquierda con un hematoma periaórtico extendido al mediastino posterior. El paciente ingresó en la UCI en respiración espontánea con tensión arterial sistólica (TAS) inferior a 120 mmHg. Se llevó a cabo un tratamiento conservador de las lesiones asociadas. A las 10 horas del ingreso en la UCI se le colocó una endoprótesis en la aorta torácica descendente por vía femoral izquierda, con oclusión parcial de la arteria subclavia izquierda. Fue dado de alta a planta a las 48 horas. Siguió controles con TACHT a los 7 días, al mes y a los 45 días. A los dos meses del accidente presentó una pericarditis aguda y ausencia de pulso radial izquierdo sin repercusión clínica. La TACHT mostraba una correcta localización de la endoprótesis. Remitido por: Dra. Paula Ortiz Ballujera. Servicio de Medicina Intensiva (UCI). Hospital Universitari de Girona Doctor Josep Trueta. Avda. de França, s/n. 17007 Girona. España. Correo electrónico: ballujera@hotmail.com

[ "Nombre", ":", " ", "Andreu", ".", "\n", "Apellidos", ":", "Bernabe", "Loza", ".", "\n", "NHC", ":", "7845123", ".", "\n", "NASS", ":", "23", "56479608", "12", ".", "\n", "Domicilio", ":", "Carrer", "de", "Joan", "Maragall", ",", "26", "2B.", "\n", "Localidad/", "Provincia", ":", "Girona", ".", "\n", "CP", ":", "17006", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "13/01/1978", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "40", "años", " ", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "10/05/2018", ".", "\n", "Servicio", ":", "Medicina", "intensiva", ".", "\n", "Episodio", ":", "1330431", ".", "\n", "Médico", ":", "Paula", "Ortiz", "Ballujera", "NºCol", ":", "17", "17", "85423", ".", "\n", "Historia", "Actual", ":", "Se", "trata", "de", "un", "varón", "de", "40", "años", "que", "sufrió", "un", "accidente", "de", "coche", ".", "La", "TACHT", "al", "ingreso", "mostraba", "un", "seudoaneurisma", "de", "la", "aorta", "torácica", "a", "la", "salida", "de", "la", "arteria", "subclavia", "izquierda", "con", "un", "hematoma", "periaórtico", "extendido", "al", "mediastino", "posterior", ".", "El", "paciente", "ingresó", "en", "la", "UCI", "en", "respiración", "espontánea", "con", "tensión", "arterial", "sistólica", "(", "TAS", ")", "inferior", "a", "120", "mmHg", ".", "Se", "llevó", "a", "cabo", "un", "tratamiento", "conservador", "de", "las", "lesiones", "asociadas", ".", "\n", "A", "las", "10", "horas", "del", "ingreso", "en", "la", "UCI", "se", "le", "colocó", "una", "endoprótesis", "en", "la", "aorta", "torácica", "descendente", "por", "vía", "femoral", "izquierda", ",", "con", "oclusión", "parcial", "de", "la", "arteria", "subclavia", "izquierda", ".", "Fue", "dado", "de", "alta", "a", "planta", "a", "las", "48", "horas", ".", "Siguió", "controles", "con", "TACHT", "a", "los", "7", "días", ",", "al", "mes", "y", "a", "los", "45", "días", ".", "\n", "A", "los", "dos", "meses", "del", "accidente", "presentó", "una", "pericarditis", "aguda", "y", "ausencia", "de", "pulso", "radial", "izquierdo", "sin", "repercusión", "clínica", ".", "La", "TACHT", "mostraba", "una", "correcta", "localización", "de", "la", "endoprótesis", ".", "\n", "Remitido", "por", ":", "Dra", ".", "Paula", "Ortiz", "Ballujera", ".", "Servicio", "de", "Medicina", "Intensiva", "(", "UCI", ")", ".", "Hospital", "Universitari", "de", "Girona", "Doctor", "Josep", "Trueta", ".", "Avda", ".", "de", "França", ",", "s", "/", "n.", "17007", "Girona", ".", "España", ".", "Correo", "electrónico", ":", "ballujera@hotmail.com", "\n" ]

[ "HOSPITAL", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_CONTACTO_ASISTENCIAL", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]

Andreu, Bernabe Loza, 7845123, 23 56479608 12, Girona, 17006, 13/01/1978, España, 40 años, 10/05/2018, 1330431, Paula Ortiz Ballujera, 17 17 85423, varón, 40 años, Paula Ortiz Ballujera, Hospital Universitari de Girona Doctor Josep Trueta, 17007, Girona, España, ballujera@hotmail.com

98_task2

Sentence: Nombre: Andreu. Apellidos: Bernabe Loza. NHC: 7845123. NASS: 23 56479608 12. Domicilio: Carrer de Joan Maragall, 26 2B. Localidad/ Provincia: Girona. CP: 17006. Datos asistenciales. Fecha de nacimiento: 13/01/1978. País: España. Edad: 40 años Sexo: H. Fecha de Ingreso: 10/05/2018 . Servicio: Medicina intensiva. Episodio: 1330431. Médico: Paula Ortiz Ballujera NºCol: 17 17 85423. Historia Actual: Se trata de un varón de 40 años que sufrió un accidente de coche. La TACHT al ingreso mostraba un seudoaneurisma de la aorta torácica a la salida de la arteria subclavia izquierda con un hematoma periaórtico extendido al mediastino posterior. El paciente ingresó en la UCI en respiración espontánea con tensión arterial sistólica (TAS) inferior a 120 mmHg. Se llevó a cabo un tratamiento conservador de las lesiones asociadas. A las 10 horas del ingreso en la UCI se le colocó una endoprótesis en la aorta torácica descendente por vía femoral izquierda, con oclusión parcial de la arteria subclavia izquierda. Fue dado de alta a planta a las 48 horas. Siguió controles con TACHT a los 7 días, al mes y a los 45 días. A los dos meses del accidente presentó una pericarditis aguda y ausencia de pulso radial izquierdo sin repercusión clínica. La TACHT mostraba una correcta localización de la endoprótesis. Remitido por: Dra. Paula Ortiz Ballujera. Servicio de Medicina Intensiva (UCI). Hospital Universitari de Girona Doctor Josep Trueta. Avda. de França, s/n. 17007 Girona. España. Correo electrónico: ballujera@hotmail.com Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ID_CONTACTO_ASISTENCIAL", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "B-TERRITORIO", "O", "B-PAIS", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Nombre: Andreu. Apellidos: Bernabe Loza. NHC: 7845123. NASS: 23 56479608 12. Domicilio: Carrer de Joan Maragall, 26 2B. Localidad/ Provincia: Girona. CP: 17006. Datos asistenciales. Fecha de nacimiento: 13/01/1978. País: España. Edad: 40 años Sexo: H. Fecha de Ingreso: 10/05/2018 . Servicio: Medicina intensiva. Episodio: 1330431. Médico: Paula Ortiz Ballujera NºCol: 17 17 85423. Historia Actual: Se trata de un varón de 40 años que sufrió un accidente de coche. La TACHT al ingreso mostraba un seudoaneurisma de la aorta torácica a la salida de la arteria subclavia izquierda con un hematoma periaórtico extendido al mediastino posterior. El paciente ingresó en la UCI en respiración espontánea con tensión arterial sistólica (TAS) inferior a 120 mmHg. Se llevó a cabo un tratamiento conservador de las lesiones asociadas. A las 10 horas del ingreso en la UCI se le colocó una endoprótesis en la aorta torácica descendente por vía femoral izquierda, con oclusión parcial de la arteria subclavia izquierda. Fue dado de alta a planta a las 48 horas. Siguió controles con TACHT a los 7 días, al mes y a los 45 días. A los dos meses del accidente presentó una pericarditis aguda y ausencia de pulso radial izquierdo sin repercusión clínica. La TACHT mostraba una correcta localización de la endoprótesis. Remitido por: Dra. Paula Ortiz Ballujera. Servicio de Medicina Intensiva (UCI). Hospital Universitari de Girona Doctor Josep Trueta. Avda. de França, s/n. 17007 Girona. España. Correo electrónico: ballujera@hotmail.com

[ "Nombre", ":", " ", "Andreu", ".", "\n", "Apellidos", ":", "Bernabe", "Loza", ".", "\n", "NHC", ":", "7845123", ".", "\n", "NASS", ":", "23", "56479608", "12", ".", "\n", "Domicilio", ":", "Carrer", "de", "Joan", "Maragall", ",", "26", "2B.", "\n", "Localidad/", "Provincia", ":", "Girona", ".", "\n", "CP", ":", "17006", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "13/01/1978", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "40", "años", " ", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "10/05/2018", ".", "\n", "Servicio", ":", "Medicina", "intensiva", ".", "\n", "Episodio", ":", "1330431", ".", "\n", "Médico", ":", "Paula", "Ortiz", "Ballujera", "NºCol", ":", "17", "17", "85423", ".", "\n", "Historia", "Actual", ":", "Se", "trata", "de", "un", "varón", "de", "40", "años", "que", "sufrió", "un", "accidente", "de", "coche", ".", "La", "TACHT", "al", "ingreso", "mostraba", "un", "seudoaneurisma", "de", "la", "aorta", "torácica", "a", "la", "salida", "de", "la", "arteria", "subclavia", "izquierda", "con", "un", "hematoma", "periaórtico", "extendido", "al", "mediastino", "posterior", ".", "El", "paciente", "ingresó", "en", "la", "UCI", "en", "respiración", "espontánea", "con", "tensión", "arterial", "sistólica", "(", "TAS", ")", "inferior", "a", "120", "mmHg", ".", "Se", "llevó", "a", "cabo", "un", "tratamiento", "conservador", "de", "las", "lesiones", "asociadas", ".", "\n", "A", "las", "10", "horas", "del", "ingreso", "en", "la", "UCI", "se", "le", "colocó", "una", "endoprótesis", "en", "la", "aorta", "torácica", "descendente", "por", "vía", "femoral", "izquierda", ",", "con", "oclusión", "parcial", "de", "la", "arteria", "subclavia", "izquierda", ".", "Fue", "dado", "de", "alta", "a", "planta", "a", "las", "48", "horas", ".", "Siguió", "controles", "con", "TACHT", "a", "los", "7", "días", ",", "al", "mes", "y", "a", "los", "45", "días", ".", "\n", "A", "los", "dos", "meses", "del", "accidente", "presentó", "una", "pericarditis", "aguda", "y", "ausencia", "de", "pulso", "radial", "izquierdo", "sin", "repercusión", "clínica", ".", "La", "TACHT", "mostraba", "una", "correcta", "localización", "de", "la", "endoprótesis", ".", "\n", "Remitido", "por", ":", "Dra", ".", "Paula", "Ortiz", "Ballujera", ".", "Servicio", "de", "Medicina", "Intensiva", "(", "UCI", ")", ".", "Hospital", "Universitari", "de", "Girona", "Doctor", "Josep", "Trueta", ".", "Avda", ".", "de", "França", ",", "s", "/", "n.", "17007", "Girona", ".", "España", ".", "Correo", "electrónico", ":", "ballujera@hotmail.com", "\n" ]

[ "HOSPITAL", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "EDAD_SUJETO_ASISTENCIA", "ID_CONTACTO_ASISTENCIAL", "ID_SUJETO_ASISTENCIA", "PAIS", "TERRITORIO", "SEXO_SUJETO_ASISTENCIA" ]

pimecrolimus is a Intervention_Pharmacological, cetuximab - associated acnelike eruption is a Participant_Condition, cetuximab - related facial rash . is a Participant_Condition, 24 is a Participant_Sample-size, metastatic colorectal cancer with cetuximab facial rash is a Participant_Condition, lesion counts is a Outcome_Physical, rash severity is a Outcome_Physical, Pimecrolimus is a Intervention_Pharmacological

41389_task0

Sentence: A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption . BACKGROUND Clinical trials addressing the acneiform rash associated with epidermal growth factor receptor inhibitors are lacking . OBJECTIVE We evaluated the ability of topical pimecrolimus to reduce the severity of cetuximab-related facial rash . METHODS In all , 24 patients with metastatic colorectal cancer with cetuximab facial rash received twice daily pimecrolimus application for 5 weeks to half of the face . At baseline , week 2 , and week 5 , a dermatologist performed facial lesion counts , patients reported perceived severity of rash-related symptoms , and standardized facial photographs were obtained for blinded evaluation of global rash severity . RESULTS Treatment sides had greater decrease in lesion counts than observation sides of face at weeks 2 ( P < .001 ) and 5 ( P = .02 ) . However , there were no significant differences in patients ' assessment of symptoms and in review of facial photographs for rash severity between treatment and observation sides . LIMITATIONS This study was not placebo controlled . CONCLUSIONS Pimecrolimus application did not translate into clinically meaningful benefit for patients with cetuximab-related facial rash . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Physical, Participant_Condition, Participant_Sample-size

[ "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption . BACKGROUND Clinical trials addressing the acneiform rash associated with epidermal growth factor receptor inhibitors are lacking . OBJECTIVE We evaluated the ability of topical pimecrolimus to reduce the severity of cetuximab-related facial rash . METHODS In all , 24 patients with metastatic colorectal cancer with cetuximab facial rash received twice daily pimecrolimus application for 5 weeks to half of the face . At baseline , week 2 , and week 5 , a dermatologist performed facial lesion counts , patients reported perceived severity of rash-related symptoms , and standardized facial photographs were obtained for blinded evaluation of global rash severity . RESULTS Treatment sides had greater decrease in lesion counts than observation sides of face at weeks 2 ( P < .001 ) and 5 ( P = .02 ) . However , there were no significant differences in patients ' assessment of symptoms and in review of facial photographs for rash severity between treatment and observation sides . LIMITATIONS This study was not placebo controlled . CONCLUSIONS Pimecrolimus application did not translate into clinically meaningful benefit for patients with cetuximab-related facial rash .

[ "A", "prospective", "randomized", "trial", "of", "topical", "pimecrolimus", "for", "cetuximab", "-", "associated", "acnelike", "eruption", ".", "BACKGROUND", "Clinical", "trials", "addressing", "the", "acneiform", "rash", "associated", "with", "epidermal", "growth", "factor", "receptor", "inhibitors", "are", "lacking", ".", "OBJECTIVE", "We", "evaluated", "the", "ability", "of", "topical", "pimecrolimus", "to", "reduce", "the", "severity", "of", "cetuximab", "-", "related", "facial", "rash", ".", "METHODS", "In", "all", ",", "24", "patients", "with", "metastatic", "colorectal", "cancer", "with", "cetuximab", "facial", "rash", "received", "twice", "daily", "pimecrolimus", "application", "for", "5", "weeks", "to", "half", "of", "the", "face", ".", "At", "baseline", ",", "week", "2", ",", "and", "week", "5", ",", "a", "dermatologist", "performed", "facial", "lesion", "counts", ",", "patients", "reported", "perceived", "severity", "of", "rash", "-", "related", "symptoms", ",", "and", "standardized", "facial", "photographs", "were", "obtained", "for", "blinded", "evaluation", "of", "global", "rash", "severity", ".", "RESULTS", "Treatment", "sides", "had", "greater", "decrease", "in", "lesion", "counts", "than", "observation", "sides", "of", "face", "at", "weeks", "2", "(", "P", "<", ".001", ")", "and", "5", "(", "P", "=", ".02", ")", ".", "However", ",", "there", "were", "no", "significant", "differences", "in", "patients", "'", "assessment", "of", "symptoms", "and", "in", "review", "of", "facial", "photographs", "for", "rash", "severity", "between", "treatment", "and", "observation", "sides", ".", "LIMITATIONS", "This", "study", "was", "not", "placebo", "controlled", ".", "CONCLUSIONS", "Pimecrolimus", "application", "did", "not", "translate", "into", "clinically", "meaningful", "benefit", "for", "patients", "with", "cetuximab", "-", "related", "facial", "rash", "." ]

[ "Participant_Condition", "Outcome_Physical", "Intervention_Pharmacological", "Participant_Sample-size" ]

pimecrolimus is a Intervention_Pharmacological, cetuximab - associated acnelike eruption is a Participant_Condition, cetuximab - related facial rash . is a Participant_Condition, 24 is a Participant_Sample-size, metastatic colorectal cancer with cetuximab facial rash is a Participant_Condition, lesion counts is a Outcome_Physical, rash severity is a Outcome_Physical, Pimecrolimus is a Intervention_Pharmacological

41389_task1

Sentence: A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption . BACKGROUND Clinical trials addressing the acneiform rash associated with epidermal growth factor receptor inhibitors are lacking . OBJECTIVE We evaluated the ability of topical pimecrolimus to reduce the severity of cetuximab-related facial rash . METHODS In all , 24 patients with metastatic colorectal cancer with cetuximab facial rash received twice daily pimecrolimus application for 5 weeks to half of the face . At baseline , week 2 , and week 5 , a dermatologist performed facial lesion counts , patients reported perceived severity of rash-related symptoms , and standardized facial photographs were obtained for blinded evaluation of global rash severity . RESULTS Treatment sides had greater decrease in lesion counts than observation sides of face at weeks 2 ( P < .001 ) and 5 ( P = .02 ) . However , there were no significant differences in patients ' assessment of symptoms and in review of facial photographs for rash severity between treatment and observation sides . LIMITATIONS This study was not placebo controlled . CONCLUSIONS Pimecrolimus application did not translate into clinically meaningful benefit for patients with cetuximab-related facial rash . Instructions: please typing these entity words according to sentence: pimecrolimus, cetuximab - associated acnelike eruption, cetuximab - related facial rash ., 24, metastatic colorectal cancer with cetuximab facial rash, lesion counts, rash severity, Pimecrolimus Options: Intervention_Pharmacological, Outcome_Physical, Participant_Condition, Participant_Sample-size

[ "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption . BACKGROUND Clinical trials addressing the acneiform rash associated with epidermal growth factor receptor inhibitors are lacking . OBJECTIVE We evaluated the ability of topical pimecrolimus to reduce the severity of cetuximab-related facial rash . METHODS In all , 24 patients with metastatic colorectal cancer with cetuximab facial rash received twice daily pimecrolimus application for 5 weeks to half of the face . At baseline , week 2 , and week 5 , a dermatologist performed facial lesion counts , patients reported perceived severity of rash-related symptoms , and standardized facial photographs were obtained for blinded evaluation of global rash severity . RESULTS Treatment sides had greater decrease in lesion counts than observation sides of face at weeks 2 ( P < .001 ) and 5 ( P = .02 ) . However , there were no significant differences in patients ' assessment of symptoms and in review of facial photographs for rash severity between treatment and observation sides . LIMITATIONS This study was not placebo controlled . CONCLUSIONS Pimecrolimus application did not translate into clinically meaningful benefit for patients with cetuximab-related facial rash .

[ "A", "prospective", "randomized", "trial", "of", "topical", "pimecrolimus", "for", "cetuximab", "-", "associated", "acnelike", "eruption", ".", "BACKGROUND", "Clinical", "trials", "addressing", "the", "acneiform", "rash", "associated", "with", "epidermal", "growth", "factor", "receptor", "inhibitors", "are", "lacking", ".", "OBJECTIVE", "We", "evaluated", "the", "ability", "of", "topical", "pimecrolimus", "to", "reduce", "the", "severity", "of", "cetuximab", "-", "related", "facial", "rash", ".", "METHODS", "In", "all", ",", "24", "patients", "with", "metastatic", "colorectal", "cancer", "with", "cetuximab", "facial", "rash", "received", "twice", "daily", "pimecrolimus", "application", "for", "5", "weeks", "to", "half", "of", "the", "face", ".", "At", "baseline", ",", "week", "2", ",", "and", "week", "5", ",", "a", "dermatologist", "performed", "facial", "lesion", "counts", ",", "patients", "reported", "perceived", "severity", "of", "rash", "-", "related", "symptoms", ",", "and", "standardized", "facial", "photographs", "were", "obtained", "for", "blinded", "evaluation", "of", "global", "rash", "severity", ".", "RESULTS", "Treatment", "sides", "had", "greater", "decrease", "in", "lesion", "counts", "than", "observation", "sides", "of", "face", "at", "weeks", "2", "(", "P", "<", ".001", ")", "and", "5", "(", "P", "=", ".02", ")", ".", "However", ",", "there", "were", "no", "significant", "differences", "in", "patients", "'", "assessment", "of", "symptoms", "and", "in", "review", "of", "facial", "photographs", "for", "rash", "severity", "between", "treatment", "and", "observation", "sides", ".", "LIMITATIONS", "This", "study", "was", "not", "placebo", "controlled", ".", "CONCLUSIONS", "Pimecrolimus", "application", "did", "not", "translate", "into", "clinically", "meaningful", "benefit", "for", "patients", "with", "cetuximab", "-", "related", "facial", "rash", "." ]

[ "Participant_Condition", "Outcome_Physical", "Intervention_Pharmacological", "Participant_Sample-size" ]

pimecrolimus, cetuximab - associated acnelike eruption, cetuximab - related facial rash ., 24, metastatic colorectal cancer with cetuximab facial rash, lesion counts, rash severity, Pimecrolimus

41389_task2

Sentence: A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption . BACKGROUND Clinical trials addressing the acneiform rash associated with epidermal growth factor receptor inhibitors are lacking . OBJECTIVE We evaluated the ability of topical pimecrolimus to reduce the severity of cetuximab-related facial rash . METHODS In all , 24 patients with metastatic colorectal cancer with cetuximab facial rash received twice daily pimecrolimus application for 5 weeks to half of the face . At baseline , week 2 , and week 5 , a dermatologist performed facial lesion counts , patients reported perceived severity of rash-related symptoms , and standardized facial photographs were obtained for blinded evaluation of global rash severity . RESULTS Treatment sides had greater decrease in lesion counts than observation sides of face at weeks 2 ( P < .001 ) and 5 ( P = .02 ) . However , there were no significant differences in patients ' assessment of symptoms and in review of facial photographs for rash severity between treatment and observation sides . LIMITATIONS This study was not placebo controlled . CONCLUSIONS Pimecrolimus application did not translate into clinically meaningful benefit for patients with cetuximab-related facial rash . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption . BACKGROUND Clinical trials addressing the acneiform rash associated with epidermal growth factor receptor inhibitors are lacking . OBJECTIVE We evaluated the ability of topical pimecrolimus to reduce the severity of cetuximab-related facial rash . METHODS In all , 24 patients with metastatic colorectal cancer with cetuximab facial rash received twice daily pimecrolimus application for 5 weeks to half of the face . At baseline , week 2 , and week 5 , a dermatologist performed facial lesion counts , patients reported perceived severity of rash-related symptoms , and standardized facial photographs were obtained for blinded evaluation of global rash severity . RESULTS Treatment sides had greater decrease in lesion counts than observation sides of face at weeks 2 ( P < .001 ) and 5 ( P = .02 ) . However , there were no significant differences in patients ' assessment of symptoms and in review of facial photographs for rash severity between treatment and observation sides . LIMITATIONS This study was not placebo controlled . CONCLUSIONS Pimecrolimus application did not translate into clinically meaningful benefit for patients with cetuximab-related facial rash .

[ "A", "prospective", "randomized", "trial", "of", "topical", "pimecrolimus", "for", "cetuximab", "-", "associated", "acnelike", "eruption", ".", "BACKGROUND", "Clinical", "trials", "addressing", "the", "acneiform", "rash", "associated", "with", "epidermal", "growth", "factor", "receptor", "inhibitors", "are", "lacking", ".", "OBJECTIVE", "We", "evaluated", "the", "ability", "of", "topical", "pimecrolimus", "to", "reduce", "the", "severity", "of", "cetuximab", "-", "related", "facial", "rash", ".", "METHODS", "In", "all", ",", "24", "patients", "with", "metastatic", "colorectal", "cancer", "with", "cetuximab", "facial", "rash", "received", "twice", "daily", "pimecrolimus", "application", "for", "5", "weeks", "to", "half", "of", "the", "face", ".", "At", "baseline", ",", "week", "2", ",", "and", "week", "5", ",", "a", "dermatologist", "performed", "facial", "lesion", "counts", ",", "patients", "reported", "perceived", "severity", "of", "rash", "-", "related", "symptoms", ",", "and", "standardized", "facial", "photographs", "were", "obtained", "for", "blinded", "evaluation", "of", "global", "rash", "severity", ".", "RESULTS", "Treatment", "sides", "had", "greater", "decrease", "in", "lesion", "counts", "than", "observation", "sides", "of", "face", "at", "weeks", "2", "(", "P", "<", ".001", ")", "and", "5", "(", "P", "=", ".02", ")", ".", "However", ",", "there", "were", "no", "significant", "differences", "in", "patients", "'", "assessment", "of", "symptoms", "and", "in", "review", "of", "facial", "photographs", "for", "rash", "severity", "between", "treatment", "and", "observation", "sides", ".", "LIMITATIONS", "This", "study", "was", "not", "placebo", "controlled", ".", "CONCLUSIONS", "Pimecrolimus", "application", "did", "not", "translate", "into", "clinically", "meaningful", "benefit", "for", "patients", "with", "cetuximab", "-", "related", "facial", "rash", "." ]

[ "Participant_Condition", "Outcome_Physical", "Intervention_Pharmacological", "Participant_Sample-size" ]

systemischen Sklerodermie is an umlsterm, Rolle is an umlsterm, Zellen is an umlsterm, Plazenta is an umlsterm, Schwangerschaft is an umlsterm, Ueberleben is an umlsterm, weiblichen is an umlsterm, T - Zellen is an umlsterm, Zellen is an umlsterm, Hautgewebe is an umlsterm, Y - Chromosomen - spezifischen is an umlsterm, Patienten is an umlsterm

DerHautarzt.00510059.ger.abstr_task0

Sentence: Ein persistierender zellulaerer Mikrochimerismus koennte in der Pathogenese der systemischen Sklerodermie ( SSc ) eine Rolle spielen . Der Mikrochimerismus entsteht durch den Transport fetaler Zellen durch die Plazenta waehrend der Schwangerschaft in die maternale Zirkulation und deren Ueberleben aufgrund einer weitgehenden HLA-Klasse-II-Kompatibilitaet . Bei weiblichen SSc-Patienten wurde die Anwesenheit von fetalen CD3-positiven T-Zellen in der maternalen Zirkulation und von fetalen Zellen im befallenen Hautgewebe in Form von Y-Chromosomen-spezifischen DNA-Sequenzen nachgewiesen . Der persistierende Mikrochimerismus koennte bei bestimmten Patienten ueber eine fetoantimaternale Graft-versus-Host-aehnliche Reaktion eine SSc ausloesen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Ein persistierender zellulaerer Mikrochimerismus koennte in der Pathogenese der systemischen Sklerodermie ( SSc ) eine Rolle spielen . Der Mikrochimerismus entsteht durch den Transport fetaler Zellen durch die Plazenta waehrend der Schwangerschaft in die maternale Zirkulation und deren Ueberleben aufgrund einer weitgehenden HLA-Klasse-II-Kompatibilitaet . Bei weiblichen SSc-Patienten wurde die Anwesenheit von fetalen CD3-positiven T-Zellen in der maternalen Zirkulation und von fetalen Zellen im befallenen Hautgewebe in Form von Y-Chromosomen-spezifischen DNA-Sequenzen nachgewiesen . Der persistierende Mikrochimerismus koennte bei bestimmten Patienten ueber eine fetoantimaternale Graft-versus-Host-aehnliche Reaktion eine SSc ausloesen .

[ "Ein", "persistierender", "zellulaerer", "Mikrochimerismus", "koennte", "in", "der", "Pathogenese", "der", "systemischen", "Sklerodermie", "(", "SSc", ")", "eine", "Rolle", "spielen", ".", "Der", "Mikrochimerismus", "entsteht", "durch", "den", "Transport", "fetaler", "Zellen", "durch", "die", "Plazenta", "waehrend", "der", "Schwangerschaft", "in", "die", "maternale", "Zirkulation", "und", "deren", "Ueberleben", "aufgrund", "einer", "weitgehenden", "HLA", "-", "Klasse", "-", "II", "-", "Kompatibilitaet", ".", "Bei", "weiblichen", "SSc", "-", "Patienten", "wurde", "die", "Anwesenheit", "von", "fetalen", "CD3-positiven", "T", "-", "Zellen", "in", "der", "maternalen", "Zirkulation", "und", "von", "fetalen", "Zellen", "im", "befallenen", "Hautgewebe", "in", "Form", "von", "Y", "-", "Chromosomen", "-", "spezifischen", "DNA", "-", "Sequenzen", "nachgewiesen", ".", "Der", "persistierende", "Mikrochimerismus", "koennte", "bei", "bestimmten", "Patienten", "ueber", "eine", "fetoantimaternale", "Graft", "-", "versus", "-", "Host", "-", "aehnliche", "Reaktion", "eine", "SSc", "ausloesen", "." ]

[ "umlsterm" ]

systemischen Sklerodermie is an umlsterm, Rolle is an umlsterm, Zellen is an umlsterm, Plazenta is an umlsterm, Schwangerschaft is an umlsterm, Ueberleben is an umlsterm, weiblichen is an umlsterm, T - Zellen is an umlsterm, Zellen is an umlsterm, Hautgewebe is an umlsterm, Y - Chromosomen - spezifischen is an umlsterm, Patienten is an umlsterm

DerHautarzt.00510059.ger.abstr_task1

Sentence: Ein persistierender zellulaerer Mikrochimerismus koennte in der Pathogenese der systemischen Sklerodermie ( SSc ) eine Rolle spielen . Der Mikrochimerismus entsteht durch den Transport fetaler Zellen durch die Plazenta waehrend der Schwangerschaft in die maternale Zirkulation und deren Ueberleben aufgrund einer weitgehenden HLA-Klasse-II-Kompatibilitaet . Bei weiblichen SSc-Patienten wurde die Anwesenheit von fetalen CD3-positiven T-Zellen in der maternalen Zirkulation und von fetalen Zellen im befallenen Hautgewebe in Form von Y-Chromosomen-spezifischen DNA-Sequenzen nachgewiesen . Der persistierende Mikrochimerismus koennte bei bestimmten Patienten ueber eine fetoantimaternale Graft-versus-Host-aehnliche Reaktion eine SSc ausloesen . Instructions: please typing these entity words according to sentence: systemischen Sklerodermie, Rolle, Zellen, Plazenta, Schwangerschaft, Ueberleben, weiblichen, T - Zellen, Zellen, Hautgewebe, Y - Chromosomen - spezifischen, Patienten Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Ein persistierender zellulaerer Mikrochimerismus koennte in der Pathogenese der systemischen Sklerodermie ( SSc ) eine Rolle spielen . Der Mikrochimerismus entsteht durch den Transport fetaler Zellen durch die Plazenta waehrend der Schwangerschaft in die maternale Zirkulation und deren Ueberleben aufgrund einer weitgehenden HLA-Klasse-II-Kompatibilitaet . Bei weiblichen SSc-Patienten wurde die Anwesenheit von fetalen CD3-positiven T-Zellen in der maternalen Zirkulation und von fetalen Zellen im befallenen Hautgewebe in Form von Y-Chromosomen-spezifischen DNA-Sequenzen nachgewiesen . Der persistierende Mikrochimerismus koennte bei bestimmten Patienten ueber eine fetoantimaternale Graft-versus-Host-aehnliche Reaktion eine SSc ausloesen .

[ "Ein", "persistierender", "zellulaerer", "Mikrochimerismus", "koennte", "in", "der", "Pathogenese", "der", "systemischen", "Sklerodermie", "(", "SSc", ")", "eine", "Rolle", "spielen", ".", "Der", "Mikrochimerismus", "entsteht", "durch", "den", "Transport", "fetaler", "Zellen", "durch", "die", "Plazenta", "waehrend", "der", "Schwangerschaft", "in", "die", "maternale", "Zirkulation", "und", "deren", "Ueberleben", "aufgrund", "einer", "weitgehenden", "HLA", "-", "Klasse", "-", "II", "-", "Kompatibilitaet", ".", "Bei", "weiblichen", "SSc", "-", "Patienten", "wurde", "die", "Anwesenheit", "von", "fetalen", "CD3-positiven", "T", "-", "Zellen", "in", "der", "maternalen", "Zirkulation", "und", "von", "fetalen", "Zellen", "im", "befallenen", "Hautgewebe", "in", "Form", "von", "Y", "-", "Chromosomen", "-", "spezifischen", "DNA", "-", "Sequenzen", "nachgewiesen", ".", "Der", "persistierende", "Mikrochimerismus", "koennte", "bei", "bestimmten", "Patienten", "ueber", "eine", "fetoantimaternale", "Graft", "-", "versus", "-", "Host", "-", "aehnliche", "Reaktion", "eine", "SSc", "ausloesen", "." ]

[ "umlsterm" ]

systemischen Sklerodermie, Rolle, Zellen, Plazenta, Schwangerschaft, Ueberleben, weiblichen, T - Zellen, Zellen, Hautgewebe, Y - Chromosomen - spezifischen, Patienten

DerHautarzt.00510059.ger.abstr_task2

Sentence: Ein persistierender zellulaerer Mikrochimerismus koennte in der Pathogenese der systemischen Sklerodermie ( SSc ) eine Rolle spielen . Der Mikrochimerismus entsteht durch den Transport fetaler Zellen durch die Plazenta waehrend der Schwangerschaft in die maternale Zirkulation und deren Ueberleben aufgrund einer weitgehenden HLA-Klasse-II-Kompatibilitaet . Bei weiblichen SSc-Patienten wurde die Anwesenheit von fetalen CD3-positiven T-Zellen in der maternalen Zirkulation und von fetalen Zellen im befallenen Hautgewebe in Form von Y-Chromosomen-spezifischen DNA-Sequenzen nachgewiesen . Der persistierende Mikrochimerismus koennte bei bestimmten Patienten ueber eine fetoantimaternale Graft-versus-Host-aehnliche Reaktion eine SSc ausloesen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Ein persistierender zellulaerer Mikrochimerismus koennte in der Pathogenese der systemischen Sklerodermie ( SSc ) eine Rolle spielen . Der Mikrochimerismus entsteht durch den Transport fetaler Zellen durch die Plazenta waehrend der Schwangerschaft in die maternale Zirkulation und deren Ueberleben aufgrund einer weitgehenden HLA-Klasse-II-Kompatibilitaet . Bei weiblichen SSc-Patienten wurde die Anwesenheit von fetalen CD3-positiven T-Zellen in der maternalen Zirkulation und von fetalen Zellen im befallenen Hautgewebe in Form von Y-Chromosomen-spezifischen DNA-Sequenzen nachgewiesen . Der persistierende Mikrochimerismus koennte bei bestimmten Patienten ueber eine fetoantimaternale Graft-versus-Host-aehnliche Reaktion eine SSc ausloesen .

[ "Ein", "persistierender", "zellulaerer", "Mikrochimerismus", "koennte", "in", "der", "Pathogenese", "der", "systemischen", "Sklerodermie", "(", "SSc", ")", "eine", "Rolle", "spielen", ".", "Der", "Mikrochimerismus", "entsteht", "durch", "den", "Transport", "fetaler", "Zellen", "durch", "die", "Plazenta", "waehrend", "der", "Schwangerschaft", "in", "die", "maternale", "Zirkulation", "und", "deren", "Ueberleben", "aufgrund", "einer", "weitgehenden", "HLA", "-", "Klasse", "-", "II", "-", "Kompatibilitaet", ".", "Bei", "weiblichen", "SSc", "-", "Patienten", "wurde", "die", "Anwesenheit", "von", "fetalen", "CD3-positiven", "T", "-", "Zellen", "in", "der", "maternalen", "Zirkulation", "und", "von", "fetalen", "Zellen", "im", "befallenen", "Hautgewebe", "in", "Form", "von", "Y", "-", "Chromosomen", "-", "spezifischen", "DNA", "-", "Sequenzen", "nachgewiesen", ".", "Der", "persistierende", "Mikrochimerismus", "koennte", "bei", "bestimmten", "Patienten", "ueber", "eine", "fetoantimaternale", "Graft", "-", "versus", "-", "Host", "-", "aehnliche", "Reaktion", "eine", "SSc", "ausloesen", "." ]

[ "umlsterm" ]

transforming growth factor ( TGF)-beta1 is a Protein

10064064_task0

Sentence: AML and Ets proteins regulate the I alpha1 germ-line promoter. The immunoglobulin heavy chain (IgH) class switch recombination of B lymphocytes preferentially targets unrearranged IgH genes that have already been rendered transcriptionally active. Transcription of the germ-line IgH genes is controlled by intervening (I) regions upstream of their switch regions. The I alpha1 promoter activates transcription of the human germ-line C alpha1 gene for IgA1 and mediates the transforming growth factor (TGF)-beta1 responsiveness of this locus. Here we show that the I alpha1 promoter contains several binding sites for the AML/PEBP2/CBF family of transcription factors and that AML and Ets proteins are major regulators of the basal and TGF-beta-inducible promoter activity. Our data constitute a starting point for studies to elucidate the molecular mechanism by which TGF-beta regulates IgA production. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

AML and Ets proteins regulate the I alpha1 germ-line promoter. The immunoglobulin heavy chain (IgH) class switch recombination of B lymphocytes preferentially targets unrearranged IgH genes that have already been rendered transcriptionally active. Transcription of the germ-line IgH genes is controlled by intervening (I) regions upstream of their switch regions. The I alpha1 promoter activates transcription of the human germ-line C alpha1 gene for IgA1 and mediates the transforming growth factor (TGF)-beta1 responsiveness of this locus. Here we show that the I alpha1 promoter contains several binding sites for the AML/PEBP2/CBF family of transcription factors and that AML and Ets proteins are major regulators of the basal and TGF-beta-inducible promoter activity. Our data constitute a starting point for studies to elucidate the molecular mechanism by which TGF-beta regulates IgA production.

[ "AML", "and", "Ets", "proteins", "regulate", "the", "I", "alpha1", "germ", "-", "line", "promoter", ".", "\n", "The", "immunoglobulin", "heavy", "chain", "(", "IgH", ")", "class", "switch", "recombination", "of", "B", "lymphocytes", "preferentially", "targets", "unrearranged", "IgH", "genes", "that", "have", "already", "been", "rendered", "transcriptionally", "active", ".", "Transcription", "of", "the", "germ", "-", "line", "IgH", "genes", "is", "controlled", "by", "intervening", "(", "I", ")", "regions", "upstream", "of", "their", "switch", "regions", ".", "The", "I", "alpha1", "promoter", "activates", "transcription", "of", "the", "human", "germ", "-", "line", "C", "alpha1", "gene", "for", "IgA1", "and", "mediates", "the", "transforming", "growth", "factor", "(", "TGF)-beta1", "responsiveness", "of", "this", "locus", ".", "Here", "we", "show", "that", "the", "I", "alpha1", "promoter", "contains", "several", "binding", "sites", "for", "the", "AML", "/", "PEBP2", "/", "CBF", "family", "of", "transcription", "factors", "and", "that", "AML", "and", "Ets", "proteins", "are", "major", "regulators", "of", "the", "basal", "and", "TGF", "-", "beta", "-", "inducible", "promoter", "activity", ".", "Our", "data", "constitute", "a", "starting", "point", "for", "studies", "to", "elucidate", "the", "molecular", "mechanism", "by", "which", "TGF", "-", "beta", "regulates", "IgA", "production", "." ]

[ "Protein" ]

transforming growth factor ( TGF)-beta1 is a Protein

10064064_task1

Sentence: AML and Ets proteins regulate the I alpha1 germ-line promoter. The immunoglobulin heavy chain (IgH) class switch recombination of B lymphocytes preferentially targets unrearranged IgH genes that have already been rendered transcriptionally active. Transcription of the germ-line IgH genes is controlled by intervening (I) regions upstream of their switch regions. The I alpha1 promoter activates transcription of the human germ-line C alpha1 gene for IgA1 and mediates the transforming growth factor (TGF)-beta1 responsiveness of this locus. Here we show that the I alpha1 promoter contains several binding sites for the AML/PEBP2/CBF family of transcription factors and that AML and Ets proteins are major regulators of the basal and TGF-beta-inducible promoter activity. Our data constitute a starting point for studies to elucidate the molecular mechanism by which TGF-beta regulates IgA production. Instructions: please typing these entity words according to sentence: transforming growth factor ( TGF)-beta1 Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

AML and Ets proteins regulate the I alpha1 germ-line promoter. The immunoglobulin heavy chain (IgH) class switch recombination of B lymphocytes preferentially targets unrearranged IgH genes that have already been rendered transcriptionally active. Transcription of the germ-line IgH genes is controlled by intervening (I) regions upstream of their switch regions. The I alpha1 promoter activates transcription of the human germ-line C alpha1 gene for IgA1 and mediates the transforming growth factor (TGF)-beta1 responsiveness of this locus. Here we show that the I alpha1 promoter contains several binding sites for the AML/PEBP2/CBF family of transcription factors and that AML and Ets proteins are major regulators of the basal and TGF-beta-inducible promoter activity. Our data constitute a starting point for studies to elucidate the molecular mechanism by which TGF-beta regulates IgA production.

[ "AML", "and", "Ets", "proteins", "regulate", "the", "I", "alpha1", "germ", "-", "line", "promoter", ".", "\n", "The", "immunoglobulin", "heavy", "chain", "(", "IgH", ")", "class", "switch", "recombination", "of", "B", "lymphocytes", "preferentially", "targets", "unrearranged", "IgH", "genes", "that", "have", "already", "been", "rendered", "transcriptionally", "active", ".", "Transcription", "of", "the", "germ", "-", "line", "IgH", "genes", "is", "controlled", "by", "intervening", "(", "I", ")", "regions", "upstream", "of", "their", "switch", "regions", ".", "The", "I", "alpha1", "promoter", "activates", "transcription", "of", "the", "human", "germ", "-", "line", "C", "alpha1", "gene", "for", "IgA1", "and", "mediates", "the", "transforming", "growth", "factor", "(", "TGF)-beta1", "responsiveness", "of", "this", "locus", ".", "Here", "we", "show", "that", "the", "I", "alpha1", "promoter", "contains", "several", "binding", "sites", "for", "the", "AML", "/", "PEBP2", "/", "CBF", "family", "of", "transcription", "factors", "and", "that", "AML", "and", "Ets", "proteins", "are", "major", "regulators", "of", "the", "basal", "and", "TGF", "-", "beta", "-", "inducible", "promoter", "activity", ".", "Our", "data", "constitute", "a", "starting", "point", "for", "studies", "to", "elucidate", "the", "molecular", "mechanism", "by", "which", "TGF", "-", "beta", "regulates", "IgA", "production", "." ]

[ "Protein" ]

transforming growth factor ( TGF)-beta1

10064064_task2

Sentence: AML and Ets proteins regulate the I alpha1 germ-line promoter. The immunoglobulin heavy chain (IgH) class switch recombination of B lymphocytes preferentially targets unrearranged IgH genes that have already been rendered transcriptionally active. Transcription of the germ-line IgH genes is controlled by intervening (I) regions upstream of their switch regions. The I alpha1 promoter activates transcription of the human germ-line C alpha1 gene for IgA1 and mediates the transforming growth factor (TGF)-beta1 responsiveness of this locus. Here we show that the I alpha1 promoter contains several binding sites for the AML/PEBP2/CBF family of transcription factors and that AML and Ets proteins are major regulators of the basal and TGF-beta-inducible promoter activity. Our data constitute a starting point for studies to elucidate the molecular mechanism by which TGF-beta regulates IgA production. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

AML and Ets proteins regulate the I alpha1 germ-line promoter. The immunoglobulin heavy chain (IgH) class switch recombination of B lymphocytes preferentially targets unrearranged IgH genes that have already been rendered transcriptionally active. Transcription of the germ-line IgH genes is controlled by intervening (I) regions upstream of their switch regions. The I alpha1 promoter activates transcription of the human germ-line C alpha1 gene for IgA1 and mediates the transforming growth factor (TGF)-beta1 responsiveness of this locus. Here we show that the I alpha1 promoter contains several binding sites for the AML/PEBP2/CBF family of transcription factors and that AML and Ets proteins are major regulators of the basal and TGF-beta-inducible promoter activity. Our data constitute a starting point for studies to elucidate the molecular mechanism by which TGF-beta regulates IgA production.

[ "AML", "and", "Ets", "proteins", "regulate", "the", "I", "alpha1", "germ", "-", "line", "promoter", ".", "\n", "The", "immunoglobulin", "heavy", "chain", "(", "IgH", ")", "class", "switch", "recombination", "of", "B", "lymphocytes", "preferentially", "targets", "unrearranged", "IgH", "genes", "that", "have", "already", "been", "rendered", "transcriptionally", "active", ".", "Transcription", "of", "the", "germ", "-", "line", "IgH", "genes", "is", "controlled", "by", "intervening", "(", "I", ")", "regions", "upstream", "of", "their", "switch", "regions", ".", "The", "I", "alpha1", "promoter", "activates", "transcription", "of", "the", "human", "germ", "-", "line", "C", "alpha1", "gene", "for", "IgA1", "and", "mediates", "the", "transforming", "growth", "factor", "(", "TGF)-beta1", "responsiveness", "of", "this", "locus", ".", "Here", "we", "show", "that", "the", "I", "alpha1", "promoter", "contains", "several", "binding", "sites", "for", "the", "AML", "/", "PEBP2", "/", "CBF", "family", "of", "transcription", "factors", "and", "that", "AML", "and", "Ets", "proteins", "are", "major", "regulators", "of", "the", "basal", "and", "TGF", "-", "beta", "-", "inducible", "promoter", "activity", ".", "Our", "data", "constitute", "a", "starting", "point", "for", "studies", "to", "elucidate", "the", "molecular", "mechanism", "by", "which", "TGF", "-", "beta", "regulates", "IgA", "production", "." ]

[ "Protein" ]

device is an umlsterm, electrode is an umlsterm, blood is an umlsterm, oxygen is an umlsterm, CO2 is an umlsterm, temperature is an umlsterm, Paratrend is an umlsterm, Wycombe is an umlsterm, probe is an umlsterm, blood gas is an umlsterm, fiberoptic is an umlsterm, measurement is an umlsterm, haemoglobin is an umlsterm

DerAnaesthesist.70460329.eng.abstr_task0

Sentence: Introduction : Recently , a compact multisensor device 0.5 mm in diameter has become available with a miniaturised Clark electrode for measuring blood oxygen tension and two optical fibres for measuring CO2 tension , pH , and temperature ( Paratrend 7 , Biomedical Sensors , High Wycombe , UK ) . We used this new probe for continuous blood gas monitoring in the jugular bulb as an alternative to the commonly used fiberoptic spectrophotometric oximetric measurement of haemoglobin saturation . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]

Introduction : Recently , a compact multisensor device 0.5 mm in diameter has become available with a miniaturised Clark electrode for measuring blood oxygen tension and two optical fibres for measuring CO2 tension , pH , and temperature ( Paratrend 7 , Biomedical Sensors , High Wycombe , UK ) . We used this new probe for continuous blood gas monitoring in the jugular bulb as an alternative to the commonly used fiberoptic spectrophotometric oximetric measurement of haemoglobin saturation .

[ "Introduction", ":", "Recently", ",", "a", "compact", "multisensor", "device", "0.5", "mm", "in", "diameter", "has", "become", "available", "with", "a", "miniaturised", "Clark", "electrode", "for", "measuring", "blood", "oxygen", "tension", "and", "two", "optical", "fibres", "for", "measuring", "CO2", "tension", ",", "pH", ",", "and", "temperature", "(", "Paratrend", "7", ",", "Biomedical", "Sensors", ",", "High", "Wycombe", ",", "UK", ")", ".", "We", "used", "this", "new", "probe", "for", "continuous", "blood", "gas", "monitoring", "in", "the", "jugular", "bulb", "as", "an", "alternative", "to", "the", "commonly", "used", "fiberoptic", "spectrophotometric", "oximetric", "measurement", "of", "haemoglobin", "saturation", "." ]

[ "umlsterm" ]

device is an umlsterm, electrode is an umlsterm, blood is an umlsterm, oxygen is an umlsterm, CO2 is an umlsterm, temperature is an umlsterm, Paratrend is an umlsterm, Wycombe is an umlsterm, probe is an umlsterm, blood gas is an umlsterm, fiberoptic is an umlsterm, measurement is an umlsterm, haemoglobin is an umlsterm

DerAnaesthesist.70460329.eng.abstr_task1

Sentence: Introduction : Recently , a compact multisensor device 0.5 mm in diameter has become available with a miniaturised Clark electrode for measuring blood oxygen tension and two optical fibres for measuring CO2 tension , pH , and temperature ( Paratrend 7 , Biomedical Sensors , High Wycombe , UK ) . We used this new probe for continuous blood gas monitoring in the jugular bulb as an alternative to the commonly used fiberoptic spectrophotometric oximetric measurement of haemoglobin saturation . Instructions: please typing these entity words according to sentence: device, electrode, blood, oxygen, CO2, temperature, Paratrend, Wycombe, probe, blood gas, fiberoptic, measurement, haemoglobin Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]

Introduction : Recently , a compact multisensor device 0.5 mm in diameter has become available with a miniaturised Clark electrode for measuring blood oxygen tension and two optical fibres for measuring CO2 tension , pH , and temperature ( Paratrend 7 , Biomedical Sensors , High Wycombe , UK ) . We used this new probe for continuous blood gas monitoring in the jugular bulb as an alternative to the commonly used fiberoptic spectrophotometric oximetric measurement of haemoglobin saturation .

[ "Introduction", ":", "Recently", ",", "a", "compact", "multisensor", "device", "0.5", "mm", "in", "diameter", "has", "become", "available", "with", "a", "miniaturised", "Clark", "electrode", "for", "measuring", "blood", "oxygen", "tension", "and", "two", "optical", "fibres", "for", "measuring", "CO2", "tension", ",", "pH", ",", "and", "temperature", "(", "Paratrend", "7", ",", "Biomedical", "Sensors", ",", "High", "Wycombe", ",", "UK", ")", ".", "We", "used", "this", "new", "probe", "for", "continuous", "blood", "gas", "monitoring", "in", "the", "jugular", "bulb", "as", "an", "alternative", "to", "the", "commonly", "used", "fiberoptic", "spectrophotometric", "oximetric", "measurement", "of", "haemoglobin", "saturation", "." ]

[ "umlsterm" ]

device, electrode, blood, oxygen, CO2, temperature, Paratrend, Wycombe, probe, blood gas, fiberoptic, measurement, haemoglobin

DerAnaesthesist.70460329.eng.abstr_task2

Sentence: Introduction : Recently , a compact multisensor device 0.5 mm in diameter has become available with a miniaturised Clark electrode for measuring blood oxygen tension and two optical fibres for measuring CO2 tension , pH , and temperature ( Paratrend 7 , Biomedical Sensors , High Wycombe , UK ) . We used this new probe for continuous blood gas monitoring in the jugular bulb as an alternative to the commonly used fiberoptic spectrophotometric oximetric measurement of haemoglobin saturation . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]

Introduction : Recently , a compact multisensor device 0.5 mm in diameter has become available with a miniaturised Clark electrode for measuring blood oxygen tension and two optical fibres for measuring CO2 tension , pH , and temperature ( Paratrend 7 , Biomedical Sensors , High Wycombe , UK ) . We used this new probe for continuous blood gas monitoring in the jugular bulb as an alternative to the commonly used fiberoptic spectrophotometric oximetric measurement of haemoglobin saturation .

[ "Introduction", ":", "Recently", ",", "a", "compact", "multisensor", "device", "0.5", "mm", "in", "diameter", "has", "become", "available", "with", "a", "miniaturised", "Clark", "electrode", "for", "measuring", "blood", "oxygen", "tension", "and", "two", "optical", "fibres", "for", "measuring", "CO2", "tension", ",", "pH", ",", "and", "temperature", "(", "Paratrend", "7", ",", "Biomedical", "Sensors", ",", "High", "Wycombe", ",", "UK", ")", ".", "We", "used", "this", "new", "probe", "for", "continuous", "blood", "gas", "monitoring", "in", "the", "jugular", "bulb", "as", "an", "alternative", "to", "the", "commonly", "used", "fiberoptic", "spectrophotometric", "oximetric", "measurement", "of", "haemoglobin", "saturation", "." ]

[ "umlsterm" ]

therapy is an umlsterm, squamous cell carcinomas is an umlsterm, surgery is an umlsterm, radiotherapy is an umlsterm, chemotherapy is an umlsterm, therapeutic is an umlsterm, treatment failures is an umlsterm, mutations is an umlsterm, tumor is an umlsterm, gene is an umlsterm, therapeutic is an umlsterm, gene is an umlsterm, today 's is an umlsterm, therapy is an umlsterm, patients is an umlsterm, squamous cell carcinomas is an umlsterm, oral cavity is an umlsterm, biopsy is an umlsterm, patients is an umlsterm, biopsy is an umlsterm, analysis is an umlsterm, radiation is an umlsterm, treatment is an umlsterm, patients is an umlsterm, patients is an umlsterm, tumors is an umlsterm, tumors is an umlsterm, residual tumors is an umlsterm, radiation is an umlsterm, treatment is an umlsterm, p53 protein is an umlsterm, immunohistochemistry is an umlsterm, tumors is an umlsterm, radiation therapy is an umlsterm, tissue is an umlsterm, origin is an umlsterm, tumor is an umlsterm

MundKieferGesichtschirurgie.80020011.eng.abstr_task0

Sentence: Multimodal therapy of oral squamous cell carcinomas today is based on surgery , radiotherapy and chemotherapy . Despite the combination of all three therapeutic options , there is still a large number of treatment failures and therefore major questions remain . Recent investigations suggest that mutations of the p53 tumor supressor gene may account for some of the therapeutic failures . Inactivation of the gene may be an important determinant of the efficiacy of today's multimodal therapy protocols . In 90 patients with squamous cell carcinomas of the oral cavity biopsy specimens were taken before and after preoperative radiochemotherapy . From all patients , biopsy and resection material was available for immunohistochemical analysis of p53. After radiation treatment , 51 patients ( 57% ) showed a complete response ; 39 patients ( 43% ) only showed a partial response or did not respond at all . Among the responders , 82% of the pretherapeutic tumors were p53 positive , whereas among the nonresponders only 56% of the pretherapeutic tumors were p53 positive . The majority of the residual tumors were also p53 negative according to immunohistology after radiation treatment . In our study , detection of p53 protein by immunohistochemistry seemed to be connected with a more radiosensitive reaction of the tumors . Nevertheless , successful strategies for radiation therapy may need to take into account the tissue of origin and the status of p53 in the tumor . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Multimodal therapy of oral squamous cell carcinomas today is based on surgery , radiotherapy and chemotherapy . Despite the combination of all three therapeutic options , there is still a large number of treatment failures and therefore major questions remain . Recent investigations suggest that mutations of the p53 tumor supressor gene may account for some of the therapeutic failures . Inactivation of the gene may be an important determinant of the efficiacy of today's multimodal therapy protocols . In 90 patients with squamous cell carcinomas of the oral cavity biopsy specimens were taken before and after preoperative radiochemotherapy . From all patients , biopsy and resection material was available for immunohistochemical analysis of p53. After radiation treatment , 51 patients ( 57% ) showed a complete response ; 39 patients ( 43% ) only showed a partial response or did not respond at all . Among the responders , 82% of the pretherapeutic tumors were p53 positive , whereas among the nonresponders only 56% of the pretherapeutic tumors were p53 positive . The majority of the residual tumors were also p53 negative according to immunohistology after radiation treatment . In our study , detection of p53 protein by immunohistochemistry seemed to be connected with a more radiosensitive reaction of the tumors . Nevertheless , successful strategies for radiation therapy may need to take into account the tissue of origin and the status of p53 in the tumor .

[ "Multimodal", "therapy", "of", "oral", "squamous", "cell", "carcinomas", "today", "is", "based", "on", "surgery", ",", "radiotherapy", "and", "chemotherapy", ".", "Despite", "the", "combination", "of", "all", "three", "therapeutic", "options", ",", "there", "is", "still", "a", "large", "number", "of", "treatment", "failures", "and", "therefore", "major", "questions", "remain", ".", "Recent", "investigations", "suggest", "that", "mutations", "of", "the", "p53", "tumor", "supressor", "gene", "may", "account", "for", "some", "of", "the", "therapeutic", "failures", ".", "Inactivation", "of", "the", "gene", "may", "be", "an", "important", "determinant", "of", "the", "efficiacy", "of", "today", "'s", "multimodal", "therapy", "protocols", ".", "In", "90", "patients", "with", "squamous", "cell", "carcinomas", "of", "the", "oral", "cavity", "biopsy", "specimens", "were", "taken", "before", "and", "after", "preoperative", "radiochemotherapy", ".", "From", "all", "patients", ",", "biopsy", "and", "resection", "material", "was", "available", "for", "immunohistochemical", "analysis", "of", "p53", ".", "After", "radiation", "treatment", ",", "51", "patients", "(", "57", "%", ")", "showed", "a", "complete", "response", ";", "39", "patients", "(", "43", "%", ")", "only", "showed", "a", "partial", "response", "or", "did", "not", "respond", "at", "all", ".", "Among", "the", "responders", ",", "82", "%", "of", "the", "pretherapeutic", "tumors", "were", "p53", "positive", ",", "whereas", "among", "the", "nonresponders", "only", "56", "%", "of", "the", "pretherapeutic", "tumors", "were", "p53", "positive", ".", "The", "majority", "of", "the", "residual", "tumors", "were", "also", "p53", "negative", "according", "to", "immunohistology", "after", "radiation", "treatment", ".", "In", "our", "study", ",", "detection", "of", "p53", "protein", "by", "immunohistochemistry", "seemed", "to", "be", "connected", "with", "a", "more", "radiosensitive", "reaction", "of", "the", "tumors", ".", "Nevertheless", ",", "successful", "strategies", "for", "radiation", "therapy", "may", "need", "to", "take", "into", "account", "the", "tissue", "of", "origin", "and", "the", "status", "of", "p53", "in", "the", "tumor", "." ]

[ "umlsterm" ]

therapy is an umlsterm, squamous cell carcinomas is an umlsterm, surgery is an umlsterm, radiotherapy is an umlsterm, chemotherapy is an umlsterm, therapeutic is an umlsterm, treatment failures is an umlsterm, mutations is an umlsterm, tumor is an umlsterm, gene is an umlsterm, therapeutic is an umlsterm, gene is an umlsterm, today 's is an umlsterm, therapy is an umlsterm, patients is an umlsterm, squamous cell carcinomas is an umlsterm, oral cavity is an umlsterm, biopsy is an umlsterm, patients is an umlsterm, biopsy is an umlsterm, analysis is an umlsterm, radiation is an umlsterm, treatment is an umlsterm, patients is an umlsterm, patients is an umlsterm, tumors is an umlsterm, tumors is an umlsterm, residual tumors is an umlsterm, radiation is an umlsterm, treatment is an umlsterm, p53 protein is an umlsterm, immunohistochemistry is an umlsterm, tumors is an umlsterm, radiation therapy is an umlsterm, tissue is an umlsterm, origin is an umlsterm, tumor is an umlsterm

MundKieferGesichtschirurgie.80020011.eng.abstr_task1

Sentence: Multimodal therapy of oral squamous cell carcinomas today is based on surgery , radiotherapy and chemotherapy . Despite the combination of all three therapeutic options , there is still a large number of treatment failures and therefore major questions remain . Recent investigations suggest that mutations of the p53 tumor supressor gene may account for some of the therapeutic failures . Inactivation of the gene may be an important determinant of the efficiacy of today's multimodal therapy protocols . In 90 patients with squamous cell carcinomas of the oral cavity biopsy specimens were taken before and after preoperative radiochemotherapy . From all patients , biopsy and resection material was available for immunohistochemical analysis of p53. After radiation treatment , 51 patients ( 57% ) showed a complete response ; 39 patients ( 43% ) only showed a partial response or did not respond at all . Among the responders , 82% of the pretherapeutic tumors were p53 positive , whereas among the nonresponders only 56% of the pretherapeutic tumors were p53 positive . The majority of the residual tumors were also p53 negative according to immunohistology after radiation treatment . In our study , detection of p53 protein by immunohistochemistry seemed to be connected with a more radiosensitive reaction of the tumors . Nevertheless , successful strategies for radiation therapy may need to take into account the tissue of origin and the status of p53 in the tumor . Instructions: please typing these entity words according to sentence: therapy, squamous cell carcinomas, surgery, radiotherapy, chemotherapy, therapeutic, treatment failures, mutations, tumor, gene, therapeutic, gene, today 's, therapy, patients, squamous cell carcinomas, oral cavity, biopsy, patients, biopsy, analysis, radiation, treatment, patients, patients, tumors, tumors, residual tumors, radiation, treatment, p53 protein, immunohistochemistry, tumors, radiation therapy, tissue, origin, tumor Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Multimodal therapy of oral squamous cell carcinomas today is based on surgery , radiotherapy and chemotherapy . Despite the combination of all three therapeutic options , there is still a large number of treatment failures and therefore major questions remain . Recent investigations suggest that mutations of the p53 tumor supressor gene may account for some of the therapeutic failures . Inactivation of the gene may be an important determinant of the efficiacy of today's multimodal therapy protocols . In 90 patients with squamous cell carcinomas of the oral cavity biopsy specimens were taken before and after preoperative radiochemotherapy . From all patients , biopsy and resection material was available for immunohistochemical analysis of p53. After radiation treatment , 51 patients ( 57% ) showed a complete response ; 39 patients ( 43% ) only showed a partial response or did not respond at all . Among the responders , 82% of the pretherapeutic tumors were p53 positive , whereas among the nonresponders only 56% of the pretherapeutic tumors were p53 positive . The majority of the residual tumors were also p53 negative according to immunohistology after radiation treatment . In our study , detection of p53 protein by immunohistochemistry seemed to be connected with a more radiosensitive reaction of the tumors . Nevertheless , successful strategies for radiation therapy may need to take into account the tissue of origin and the status of p53 in the tumor .

[ "Multimodal", "therapy", "of", "oral", "squamous", "cell", "carcinomas", "today", "is", "based", "on", "surgery", ",", "radiotherapy", "and", "chemotherapy", ".", "Despite", "the", "combination", "of", "all", "three", "therapeutic", "options", ",", "there", "is", "still", "a", "large", "number", "of", "treatment", "failures", "and", "therefore", "major", "questions", "remain", ".", "Recent", "investigations", "suggest", "that", "mutations", "of", "the", "p53", "tumor", "supressor", "gene", "may", "account", "for", "some", "of", "the", "therapeutic", "failures", ".", "Inactivation", "of", "the", "gene", "may", "be", "an", "important", "determinant", "of", "the", "efficiacy", "of", "today", "'s", "multimodal", "therapy", "protocols", ".", "In", "90", "patients", "with", "squamous", "cell", "carcinomas", "of", "the", "oral", "cavity", "biopsy", "specimens", "were", "taken", "before", "and", "after", "preoperative", "radiochemotherapy", ".", "From", "all", "patients", ",", "biopsy", "and", "resection", "material", "was", "available", "for", "immunohistochemical", "analysis", "of", "p53", ".", "After", "radiation", "treatment", ",", "51", "patients", "(", "57", "%", ")", "showed", "a", "complete", "response", ";", "39", "patients", "(", "43", "%", ")", "only", "showed", "a", "partial", "response", "or", "did", "not", "respond", "at", "all", ".", "Among", "the", "responders", ",", "82", "%", "of", "the", "pretherapeutic", "tumors", "were", "p53", "positive", ",", "whereas", "among", "the", "nonresponders", "only", "56", "%", "of", "the", "pretherapeutic", "tumors", "were", "p53", "positive", ".", "The", "majority", "of", "the", "residual", "tumors", "were", "also", "p53", "negative", "according", "to", "immunohistology", "after", "radiation", "treatment", ".", "In", "our", "study", ",", "detection", "of", "p53", "protein", "by", "immunohistochemistry", "seemed", "to", "be", "connected", "with", "a", "more", "radiosensitive", "reaction", "of", "the", "tumors", ".", "Nevertheless", ",", "successful", "strategies", "for", "radiation", "therapy", "may", "need", "to", "take", "into", "account", "the", "tissue", "of", "origin", "and", "the", "status", "of", "p53", "in", "the", "tumor", "." ]

[ "umlsterm" ]

therapy, squamous cell carcinomas, surgery, radiotherapy, chemotherapy, therapeutic, treatment failures, mutations, tumor, gene, therapeutic, gene, today 's, therapy, patients, squamous cell carcinomas, oral cavity, biopsy, patients, biopsy, analysis, radiation, treatment, patients, patients, tumors, tumors, residual tumors, radiation, treatment, p53 protein, immunohistochemistry, tumors, radiation therapy, tissue, origin, tumor

MundKieferGesichtschirurgie.80020011.eng.abstr_task2

Sentence: Multimodal therapy of oral squamous cell carcinomas today is based on surgery , radiotherapy and chemotherapy . Despite the combination of all three therapeutic options , there is still a large number of treatment failures and therefore major questions remain . Recent investigations suggest that mutations of the p53 tumor supressor gene may account for some of the therapeutic failures . Inactivation of the gene may be an important determinant of the efficiacy of today's multimodal therapy protocols . In 90 patients with squamous cell carcinomas of the oral cavity biopsy specimens were taken before and after preoperative radiochemotherapy . From all patients , biopsy and resection material was available for immunohistochemical analysis of p53. After radiation treatment , 51 patients ( 57% ) showed a complete response ; 39 patients ( 43% ) only showed a partial response or did not respond at all . Among the responders , 82% of the pretherapeutic tumors were p53 positive , whereas among the nonresponders only 56% of the pretherapeutic tumors were p53 positive . The majority of the residual tumors were also p53 negative according to immunohistology after radiation treatment . In our study , detection of p53 protein by immunohistochemistry seemed to be connected with a more radiosensitive reaction of the tumors . Nevertheless , successful strategies for radiation therapy may need to take into account the tissue of origin and the status of p53 in the tumor . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Multimodal therapy of oral squamous cell carcinomas today is based on surgery , radiotherapy and chemotherapy . Despite the combination of all three therapeutic options , there is still a large number of treatment failures and therefore major questions remain . Recent investigations suggest that mutations of the p53 tumor supressor gene may account for some of the therapeutic failures . Inactivation of the gene may be an important determinant of the efficiacy of today's multimodal therapy protocols . In 90 patients with squamous cell carcinomas of the oral cavity biopsy specimens were taken before and after preoperative radiochemotherapy . From all patients , biopsy and resection material was available for immunohistochemical analysis of p53. After radiation treatment , 51 patients ( 57% ) showed a complete response ; 39 patients ( 43% ) only showed a partial response or did not respond at all . Among the responders , 82% of the pretherapeutic tumors were p53 positive , whereas among the nonresponders only 56% of the pretherapeutic tumors were p53 positive . The majority of the residual tumors were also p53 negative according to immunohistology after radiation treatment . In our study , detection of p53 protein by immunohistochemistry seemed to be connected with a more radiosensitive reaction of the tumors . Nevertheless , successful strategies for radiation therapy may need to take into account the tissue of origin and the status of p53 in the tumor .

[ "Multimodal", "therapy", "of", "oral", "squamous", "cell", "carcinomas", "today", "is", "based", "on", "surgery", ",", "radiotherapy", "and", "chemotherapy", ".", "Despite", "the", "combination", "of", "all", "three", "therapeutic", "options", ",", "there", "is", "still", "a", "large", "number", "of", "treatment", "failures", "and", "therefore", "major", "questions", "remain", ".", "Recent", "investigations", "suggest", "that", "mutations", "of", "the", "p53", "tumor", "supressor", "gene", "may", "account", "for", "some", "of", "the", "therapeutic", "failures", ".", "Inactivation", "of", "the", "gene", "may", "be", "an", "important", "determinant", "of", "the", "efficiacy", "of", "today", "'s", "multimodal", "therapy", "protocols", ".", "In", "90", "patients", "with", "squamous", "cell", "carcinomas", "of", "the", "oral", "cavity", "biopsy", "specimens", "were", "taken", "before", "and", "after", "preoperative", "radiochemotherapy", ".", "From", "all", "patients", ",", "biopsy", "and", "resection", "material", "was", "available", "for", "immunohistochemical", "analysis", "of", "p53", ".", "After", "radiation", "treatment", ",", "51", "patients", "(", "57", "%", ")", "showed", "a", "complete", "response", ";", "39", "patients", "(", "43", "%", ")", "only", "showed", "a", "partial", "response", "or", "did", "not", "respond", "at", "all", ".", "Among", "the", "responders", ",", "82", "%", "of", "the", "pretherapeutic", "tumors", "were", "p53", "positive", ",", "whereas", "among", "the", "nonresponders", "only", "56", "%", "of", "the", "pretherapeutic", "tumors", "were", "p53", "positive", ".", "The", "majority", "of", "the", "residual", "tumors", "were", "also", "p53", "negative", "according", "to", "immunohistology", "after", "radiation", "treatment", ".", "In", "our", "study", ",", "detection", "of", "p53", "protein", "by", "immunohistochemistry", "seemed", "to", "be", "connected", "with", "a", "more", "radiosensitive", "reaction", "of", "the", "tumors", ".", "Nevertheless", ",", "successful", "strategies", "for", "radiation", "therapy", "may", "need", "to", "take", "into", "account", "the", "tissue", "of", "origin", "and", "the", "status", "of", "p53", "in", "the", "tumor", "." ]

[ "umlsterm" ]

use is an umlsterm, grafts is an umlsterm, treatment is an umlsterm, urethral strictures is an umlsterm, patients is an umlsterm, urologic surgery is an umlsterm, urethral strictures is an umlsterm, patients is an umlsterm, donor is an umlsterm, sutures is an umlsterm, patients is an umlsterm, Lyodura is an umlsterm, patients is an umlsterm, wound is an umlsterm, patients is an umlsterm, Donor is an umlsterm, pain is an umlsterm, patients is an umlsterm, visual analogue scale is an umlsterm, postoperative is an umlsterm, patients is an umlsterm, pain is an umlsterm, rigidity is an umlsterm, patients is an umlsterm, regeneration is an umlsterm, donor is an umlsterm, mucosa is an umlsterm, period is an umlsterm, scar is an umlsterm, complication is an umlsterm, mouth is an umlsterm, stenosis is an umlsterm, parotid duct is an umlsterm, hypesthesia is an umlsterm

MundKieferGesichtschirurgie.90030034.eng.abstr_task0

Sentence: The use of free buccal mucosal grafts in the treatment of urethral strictures has become very popular . In 1996 and 1997 we harvested free buccal mucosal grafts up to 7 cm long and 4 cm wide from 12 patients who underwent urologic surgery for urethral strictures . In 2 patients the donor site was closed primarily by sutures . Four patients received Lyodura and another 4 patients received Syspurderm as temporary wound coverage . In 2 patients Ethisorp patches were used . Donor site pain was judged by the patients on a visual analogue scale during the first postoperative week . The 2 patients who received the Ethisorp patches complained of more intense pain , probably caused by the rigidity of the material . In all patients regeneration of the donor site mucosa was good . During the follow-up period of 4-18 months scar formation at the lower vestibulum was noticed as the only complication . Permanent limitation of mouth opening , stenosis of the parotid duct or hypesthesia did not occur . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]

The use of free buccal mucosal grafts in the treatment of urethral strictures has become very popular . In 1996 and 1997 we harvested free buccal mucosal grafts up to 7 cm long and 4 cm wide from 12 patients who underwent urologic surgery for urethral strictures . In 2 patients the donor site was closed primarily by sutures . Four patients received Lyodura and another 4 patients received Syspurderm as temporary wound coverage . In 2 patients Ethisorp patches were used . Donor site pain was judged by the patients on a visual analogue scale during the first postoperative week . The 2 patients who received the Ethisorp patches complained of more intense pain , probably caused by the rigidity of the material . In all patients regeneration of the donor site mucosa was good . During the follow-up period of 4-18 months scar formation at the lower vestibulum was noticed as the only complication . Permanent limitation of mouth opening , stenosis of the parotid duct or hypesthesia did not occur .

[ "The", "use", "of", "free", "buccal", "mucosal", "grafts", "in", "the", "treatment", "of", "urethral", "strictures", "has", "become", "very", "popular", ".", "In", "1996", "and", "1997", "we", "harvested", "free", "buccal", "mucosal", "grafts", "up", "to", "7", "cm", "long", "and", "4", "cm", "wide", "from", "12", "patients", "who", "underwent", "urologic", "surgery", "for", "urethral", "strictures", ".", "In", "2", "patients", "the", "donor", "site", "was", "closed", "primarily", "by", "sutures", ".", "Four", "patients", "received", "Lyodura", "and", "another", "4", "patients", "received", "Syspurderm", "as", "temporary", "wound", "coverage", ".", "In", "2", "patients", "Ethisorp", "patches", "were", "used", ".", "Donor", "site", "pain", "was", "judged", "by", "the", "patients", "on", "a", "visual", "analogue", "scale", "during", "the", "first", "postoperative", "week", ".", "The", "2", "patients", "who", "received", "the", "Ethisorp", "patches", "complained", "of", "more", "intense", "pain", ",", "probably", "caused", "by", "the", "rigidity", "of", "the", "material", ".", "In", "all", "patients", "regeneration", "of", "the", "donor", "site", "mucosa", "was", "good", ".", "During", "the", "follow", "-", "up", "period", "of", "4", "-", "18", "months", "scar", "formation", "at", "the", "lower", "vestibulum", "was", "noticed", "as", "the", "only", "complication", ".", "Permanent", "limitation", "of", "mouth", "opening", ",", "stenosis", "of", "the", "parotid", "duct", "or", "hypesthesia", "did", "not", "occur", "." ]

[ "umlsterm" ]

use is an umlsterm, grafts is an umlsterm, treatment is an umlsterm, urethral strictures is an umlsterm, patients is an umlsterm, urologic surgery is an umlsterm, urethral strictures is an umlsterm, patients is an umlsterm, donor is an umlsterm, sutures is an umlsterm, patients is an umlsterm, Lyodura is an umlsterm, patients is an umlsterm, wound is an umlsterm, patients is an umlsterm, Donor is an umlsterm, pain is an umlsterm, patients is an umlsterm, visual analogue scale is an umlsterm, postoperative is an umlsterm, patients is an umlsterm, pain is an umlsterm, rigidity is an umlsterm, patients is an umlsterm, regeneration is an umlsterm, donor is an umlsterm, mucosa is an umlsterm, period is an umlsterm, scar is an umlsterm, complication is an umlsterm, mouth is an umlsterm, stenosis is an umlsterm, parotid duct is an umlsterm, hypesthesia is an umlsterm

MundKieferGesichtschirurgie.90030034.eng.abstr_task1

Sentence: The use of free buccal mucosal grafts in the treatment of urethral strictures has become very popular . In 1996 and 1997 we harvested free buccal mucosal grafts up to 7 cm long and 4 cm wide from 12 patients who underwent urologic surgery for urethral strictures . In 2 patients the donor site was closed primarily by sutures . Four patients received Lyodura and another 4 patients received Syspurderm as temporary wound coverage . In 2 patients Ethisorp patches were used . Donor site pain was judged by the patients on a visual analogue scale during the first postoperative week . The 2 patients who received the Ethisorp patches complained of more intense pain , probably caused by the rigidity of the material . In all patients regeneration of the donor site mucosa was good . During the follow-up period of 4-18 months scar formation at the lower vestibulum was noticed as the only complication . Permanent limitation of mouth opening , stenosis of the parotid duct or hypesthesia did not occur . Instructions: please typing these entity words according to sentence: use, grafts, treatment, urethral strictures, patients, urologic surgery, urethral strictures, patients, donor, sutures, patients, Lyodura, patients, wound, patients, Donor, pain, patients, visual analogue scale, postoperative, patients, pain, rigidity, patients, regeneration, donor, mucosa, period, scar, complication, mouth, stenosis, parotid duct, hypesthesia Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]

The use of free buccal mucosal grafts in the treatment of urethral strictures has become very popular . In 1996 and 1997 we harvested free buccal mucosal grafts up to 7 cm long and 4 cm wide from 12 patients who underwent urologic surgery for urethral strictures . In 2 patients the donor site was closed primarily by sutures . Four patients received Lyodura and another 4 patients received Syspurderm as temporary wound coverage . In 2 patients Ethisorp patches were used . Donor site pain was judged by the patients on a visual analogue scale during the first postoperative week . The 2 patients who received the Ethisorp patches complained of more intense pain , probably caused by the rigidity of the material . In all patients regeneration of the donor site mucosa was good . During the follow-up period of 4-18 months scar formation at the lower vestibulum was noticed as the only complication . Permanent limitation of mouth opening , stenosis of the parotid duct or hypesthesia did not occur .

[ "The", "use", "of", "free", "buccal", "mucosal", "grafts", "in", "the", "treatment", "of", "urethral", "strictures", "has", "become", "very", "popular", ".", "In", "1996", "and", "1997", "we", "harvested", "free", "buccal", "mucosal", "grafts", "up", "to", "7", "cm", "long", "and", "4", "cm", "wide", "from", "12", "patients", "who", "underwent", "urologic", "surgery", "for", "urethral", "strictures", ".", "In", "2", "patients", "the", "donor", "site", "was", "closed", "primarily", "by", "sutures", ".", "Four", "patients", "received", "Lyodura", "and", "another", "4", "patients", "received", "Syspurderm", "as", "temporary", "wound", "coverage", ".", "In", "2", "patients", "Ethisorp", "patches", "were", "used", ".", "Donor", "site", "pain", "was", "judged", "by", "the", "patients", "on", "a", "visual", "analogue", "scale", "during", "the", "first", "postoperative", "week", ".", "The", "2", "patients", "who", "received", "the", "Ethisorp", "patches", "complained", "of", "more", "intense", "pain", ",", "probably", "caused", "by", "the", "rigidity", "of", "the", "material", ".", "In", "all", "patients", "regeneration", "of", "the", "donor", "site", "mucosa", "was", "good", ".", "During", "the", "follow", "-", "up", "period", "of", "4", "-", "18", "months", "scar", "formation", "at", "the", "lower", "vestibulum", "was", "noticed", "as", "the", "only", "complication", ".", "Permanent", "limitation", "of", "mouth", "opening", ",", "stenosis", "of", "the", "parotid", "duct", "or", "hypesthesia", "did", "not", "occur", "." ]

[ "umlsterm" ]

use, grafts, treatment, urethral strictures, patients, urologic surgery, urethral strictures, patients, donor, sutures, patients, Lyodura, patients, wound, patients, Donor, pain, patients, visual analogue scale, postoperative, patients, pain, rigidity, patients, regeneration, donor, mucosa, period, scar, complication, mouth, stenosis, parotid duct, hypesthesia

MundKieferGesichtschirurgie.90030034.eng.abstr_task2

Sentence: The use of free buccal mucosal grafts in the treatment of urethral strictures has become very popular . In 1996 and 1997 we harvested free buccal mucosal grafts up to 7 cm long and 4 cm wide from 12 patients who underwent urologic surgery for urethral strictures . In 2 patients the donor site was closed primarily by sutures . Four patients received Lyodura and another 4 patients received Syspurderm as temporary wound coverage . In 2 patients Ethisorp patches were used . Donor site pain was judged by the patients on a visual analogue scale during the first postoperative week . The 2 patients who received the Ethisorp patches complained of more intense pain , probably caused by the rigidity of the material . In all patients regeneration of the donor site mucosa was good . During the follow-up period of 4-18 months scar formation at the lower vestibulum was noticed as the only complication . Permanent limitation of mouth opening , stenosis of the parotid duct or hypesthesia did not occur . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]

The use of free buccal mucosal grafts in the treatment of urethral strictures has become very popular . In 1996 and 1997 we harvested free buccal mucosal grafts up to 7 cm long and 4 cm wide from 12 patients who underwent urologic surgery for urethral strictures . In 2 patients the donor site was closed primarily by sutures . Four patients received Lyodura and another 4 patients received Syspurderm as temporary wound coverage . In 2 patients Ethisorp patches were used . Donor site pain was judged by the patients on a visual analogue scale during the first postoperative week . The 2 patients who received the Ethisorp patches complained of more intense pain , probably caused by the rigidity of the material . In all patients regeneration of the donor site mucosa was good . During the follow-up period of 4-18 months scar formation at the lower vestibulum was noticed as the only complication . Permanent limitation of mouth opening , stenosis of the parotid duct or hypesthesia did not occur .

[ "The", "use", "of", "free", "buccal", "mucosal", "grafts", "in", "the", "treatment", "of", "urethral", "strictures", "has", "become", "very", "popular", ".", "In", "1996", "and", "1997", "we", "harvested", "free", "buccal", "mucosal", "grafts", "up", "to", "7", "cm", "long", "and", "4", "cm", "wide", "from", "12", "patients", "who", "underwent", "urologic", "surgery", "for", "urethral", "strictures", ".", "In", "2", "patients", "the", "donor", "site", "was", "closed", "primarily", "by", "sutures", ".", "Four", "patients", "received", "Lyodura", "and", "another", "4", "patients", "received", "Syspurderm", "as", "temporary", "wound", "coverage", ".", "In", "2", "patients", "Ethisorp", "patches", "were", "used", ".", "Donor", "site", "pain", "was", "judged", "by", "the", "patients", "on", "a", "visual", "analogue", "scale", "during", "the", "first", "postoperative", "week", ".", "The", "2", "patients", "who", "received", "the", "Ethisorp", "patches", "complained", "of", "more", "intense", "pain", ",", "probably", "caused", "by", "the", "rigidity", "of", "the", "material", ".", "In", "all", "patients", "regeneration", "of", "the", "donor", "site", "mucosa", "was", "good", ".", "During", "the", "follow", "-", "up", "period", "of", "4", "-", "18", "months", "scar", "formation", "at", "the", "lower", "vestibulum", "was", "noticed", "as", "the", "only", "complication", ".", "Permanent", "limitation", "of", "mouth", "opening", ",", "stenosis", "of", "the", "parotid", "duct", "or", "hypesthesia", "did", "not", "occur", "." ]

[ "umlsterm" ]

pyruvate kinase erythroid - specific promoter is a Entity, L is a Protein, R - PK is a Protein, L - PK is a Protein, promoters is a Entity, cis- is a Entity, trans - acting elements is a Entity, L is a Protein, promoter is a Entity, R - PK is a Protein, cap site is a Entity, reporter gene is a Entity, minimal promoter is a Entity, DNA binding sites is a Entity, GATA-1 is a Protein, GATA binding site is a Entity, AGATAA is a Entity, TFIID binding site is a Entity, TFIID is a Entity, GATA binding site is a Entity, TFIID binding site is a Entity, binding sites is a Entity, R - PK is a Protein, minimal promoter is a Entity, elements is a Entity, hGATA-1 is a Protein, R - PK is a Protein, promoter is a Entity

29_task0

Sentence: Transcriptional regulation of the pyruvate kinase erythroid-specific promoter. Mammal pyruvate kinases are encoded by two genes. The L gene produces the erythroid (R-PK) or the hepatic (L-PK) isozymes by the alternative use of two promoters. We report the characterization of the cis- and trans-acting elements involved in the tissue-specific activity of the L gene erythroid promoter. A R-PK DNA fragment extending from -870 to +54 relative to the cap site confers erythroid specificity to a reporter gene. Within this region, we define a minimal promoter (-62 to +54) that displays erythroid-specific activity and contains two DNA binding sites. One, located at -50, binds members of the CCACC/Sp1 family and the other, located at -20, binds the erythroid factor GATA-1. Although the -20 GATA binding site (AGATAA) is also a potential TFIID binding site, it does not bind TFIID. Furthermore, the substitution of this GATA binding site by a canonical TFIID binding site suppresses the promoter activity. Mutations and deletions of both sites indicate that only the association of CCACC/Sp1 and GATA binding sites can drive efficient and tissue-specific expression of this R-PK minimal promoter. Finally, by co-transfection experiments, we study the elements involved in the hGATA-1 transactivation of the R-PK promoter in HeLa cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O" ]

Transcriptional regulation of the pyruvate kinase erythroid-specific promoter. Mammal pyruvate kinases are encoded by two genes. The L gene produces the erythroid (R-PK) or the hepatic (L-PK) isozymes by the alternative use of two promoters. We report the characterization of the cis- and trans-acting elements involved in the tissue-specific activity of the L gene erythroid promoter. A R-PK DNA fragment extending from -870 to +54 relative to the cap site confers erythroid specificity to a reporter gene. Within this region, we define a minimal promoter (-62 to +54) that displays erythroid-specific activity and contains two DNA binding sites. One, located at -50, binds members of the CCACC/Sp1 family and the other, located at -20, binds the erythroid factor GATA-1. Although the -20 GATA binding site (AGATAA) is also a potential TFIID binding site, it does not bind TFIID. Furthermore, the substitution of this GATA binding site by a canonical TFIID binding site suppresses the promoter activity. Mutations and deletions of both sites indicate that only the association of CCACC/Sp1 and GATA binding sites can drive efficient and tissue-specific expression of this R-PK minimal promoter. Finally, by co-transfection experiments, we study the elements involved in the hGATA-1 transactivation of the R-PK promoter in HeLa cells.

[ "Transcriptional", "regulation", "of", "the", "pyruvate", "kinase", "erythroid", "-", "specific", "promoter", ".", "\n", "Mammal", "pyruvate", "kinases", "are", "encoded", "by", "two", "genes", ".", "The", "L", "gene", "produces", "the", "erythroid", "(", "R", "-", "PK", ")", "or", "the", "hepatic", "(", "L", "-", "PK", ")", "isozymes", "by", "the", "alternative", "use", "of", "two", "promoters", ".", "We", "report", "the", "characterization", "of", "the", "cis-", "and", "trans", "-", "acting", "elements", "involved", "in", "the", "tissue", "-", "specific", "activity", "of", "the", "L", "gene", "erythroid", "promoter", ".", "A", "R", "-", "PK", "DNA", "fragment", "extending", "from", "-870", "to", "+54", "relative", "to", "the", "cap", "site", "confers", "erythroid", "specificity", "to", "a", "reporter", "gene", ".", "Within", "this", "region", ",", "we", "define", "a", "minimal", "promoter", "(", "-62", "to", "+54", ")", "that", "displays", "erythroid", "-", "specific", "activity", "and", "contains", "two", "DNA", "binding", "sites", ".", "One", ",", "located", "at", "-50", ",", "binds", "members", "of", "the", "CCACC", "/", "Sp1", "family", "and", "the", "other", ",", "located", "at", "-20", ",", "binds", "the", "erythroid", "factor", "GATA-1", ".", "Although", "the", "-20", "GATA", "binding", "site", "(", "AGATAA", ")", "is", "also", "a", "potential", "TFIID", "binding", "site", ",", "it", "does", "not", "bind", "TFIID", ".", "Furthermore", ",", "the", "substitution", "of", "this", "GATA", "binding", "site", "by", "a", "canonical", "TFIID", "binding", "site", "suppresses", "the", "promoter", "activity", ".", "Mutations", "and", "deletions", "of", "both", "sites", "indicate", "that", "only", "the", "association", "of", "CCACC", "/", "Sp1", "and", "GATA", "binding", "sites", "can", "drive", "efficient", "and", "tissue", "-", "specific", "expression", "of", "this", "R", "-", "PK", "minimal", "promoter", ".", "Finally", ",", "by", "co", "-", "transfection", "experiments", ",", "we", "study", "the", "elements", "involved", "in", "the", "hGATA-1", "transactivation", "of", "the", "R", "-", "PK", "promoter", "in", "HeLa", "cells", ".", "\n" ]

[ "Entity", "Protein" ]

pyruvate kinase erythroid - specific promoter is a Entity, L is a Protein, R - PK is a Protein, L - PK is a Protein, promoters is a Entity, cis- is a Entity, trans - acting elements is a Entity, L is a Protein, promoter is a Entity, R - PK is a Protein, cap site is a Entity, reporter gene is a Entity, minimal promoter is a Entity, DNA binding sites is a Entity, GATA-1 is a Protein, GATA binding site is a Entity, AGATAA is a Entity, TFIID binding site is a Entity, TFIID is a Entity, GATA binding site is a Entity, TFIID binding site is a Entity, binding sites is a Entity, R - PK is a Protein, minimal promoter is a Entity, elements is a Entity, hGATA-1 is a Protein, R - PK is a Protein, promoter is a Entity

29_task1

Sentence: Transcriptional regulation of the pyruvate kinase erythroid-specific promoter. Mammal pyruvate kinases are encoded by two genes. The L gene produces the erythroid (R-PK) or the hepatic (L-PK) isozymes by the alternative use of two promoters. We report the characterization of the cis- and trans-acting elements involved in the tissue-specific activity of the L gene erythroid promoter. A R-PK DNA fragment extending from -870 to +54 relative to the cap site confers erythroid specificity to a reporter gene. Within this region, we define a minimal promoter (-62 to +54) that displays erythroid-specific activity and contains two DNA binding sites. One, located at -50, binds members of the CCACC/Sp1 family and the other, located at -20, binds the erythroid factor GATA-1. Although the -20 GATA binding site (AGATAA) is also a potential TFIID binding site, it does not bind TFIID. Furthermore, the substitution of this GATA binding site by a canonical TFIID binding site suppresses the promoter activity. Mutations and deletions of both sites indicate that only the association of CCACC/Sp1 and GATA binding sites can drive efficient and tissue-specific expression of this R-PK minimal promoter. Finally, by co-transfection experiments, we study the elements involved in the hGATA-1 transactivation of the R-PK promoter in HeLa cells. Instructions: please typing these entity words according to sentence: pyruvate kinase erythroid - specific promoter, L, R - PK, L - PK, promoters, cis-, trans - acting elements, L, promoter, R - PK, cap site, reporter gene, minimal promoter, DNA binding sites, GATA-1, GATA binding site, AGATAA, TFIID binding site, TFIID, GATA binding site, TFIID binding site, binding sites, R - PK, minimal promoter, elements, hGATA-1, R - PK, promoter Options: Entity, Protein

[ "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O" ]

Transcriptional regulation of the pyruvate kinase erythroid-specific promoter. Mammal pyruvate kinases are encoded by two genes. The L gene produces the erythroid (R-PK) or the hepatic (L-PK) isozymes by the alternative use of two promoters. We report the characterization of the cis- and trans-acting elements involved in the tissue-specific activity of the L gene erythroid promoter. A R-PK DNA fragment extending from -870 to +54 relative to the cap site confers erythroid specificity to a reporter gene. Within this region, we define a minimal promoter (-62 to +54) that displays erythroid-specific activity and contains two DNA binding sites. One, located at -50, binds members of the CCACC/Sp1 family and the other, located at -20, binds the erythroid factor GATA-1. Although the -20 GATA binding site (AGATAA) is also a potential TFIID binding site, it does not bind TFIID. Furthermore, the substitution of this GATA binding site by a canonical TFIID binding site suppresses the promoter activity. Mutations and deletions of both sites indicate that only the association of CCACC/Sp1 and GATA binding sites can drive efficient and tissue-specific expression of this R-PK minimal promoter. Finally, by co-transfection experiments, we study the elements involved in the hGATA-1 transactivation of the R-PK promoter in HeLa cells.

[ "Transcriptional", "regulation", "of", "the", "pyruvate", "kinase", "erythroid", "-", "specific", "promoter", ".", "\n", "Mammal", "pyruvate", "kinases", "are", "encoded", "by", "two", "genes", ".", "The", "L", "gene", "produces", "the", "erythroid", "(", "R", "-", "PK", ")", "or", "the", "hepatic", "(", "L", "-", "PK", ")", "isozymes", "by", "the", "alternative", "use", "of", "two", "promoters", ".", "We", "report", "the", "characterization", "of", "the", "cis-", "and", "trans", "-", "acting", "elements", "involved", "in", "the", "tissue", "-", "specific", "activity", "of", "the", "L", "gene", "erythroid", "promoter", ".", "A", "R", "-", "PK", "DNA", "fragment", "extending", "from", "-870", "to", "+54", "relative", "to", "the", "cap", "site", "confers", "erythroid", "specificity", "to", "a", "reporter", "gene", ".", "Within", "this", "region", ",", "we", "define", "a", "minimal", "promoter", "(", "-62", "to", "+54", ")", "that", "displays", "erythroid", "-", "specific", "activity", "and", "contains", "two", "DNA", "binding", "sites", ".", "One", ",", "located", "at", "-50", ",", "binds", "members", "of", "the", "CCACC", "/", "Sp1", "family", "and", "the", "other", ",", "located", "at", "-20", ",", "binds", "the", "erythroid", "factor", "GATA-1", ".", "Although", "the", "-20", "GATA", "binding", "site", "(", "AGATAA", ")", "is", "also", "a", "potential", "TFIID", "binding", "site", ",", "it", "does", "not", "bind", "TFIID", ".", "Furthermore", ",", "the", "substitution", "of", "this", "GATA", "binding", "site", "by", "a", "canonical", "TFIID", "binding", "site", "suppresses", "the", "promoter", "activity", ".", "Mutations", "and", "deletions", "of", "both", "sites", "indicate", "that", "only", "the", "association", "of", "CCACC", "/", "Sp1", "and", "GATA", "binding", "sites", "can", "drive", "efficient", "and", "tissue", "-", "specific", "expression", "of", "this", "R", "-", "PK", "minimal", "promoter", ".", "Finally", ",", "by", "co", "-", "transfection", "experiments", ",", "we", "study", "the", "elements", "involved", "in", "the", "hGATA-1", "transactivation", "of", "the", "R", "-", "PK", "promoter", "in", "HeLa", "cells", ".", "\n" ]

[ "Entity", "Protein" ]

pyruvate kinase erythroid - specific promoter, L, R - PK, L - PK, promoters, cis-, trans - acting elements, L, promoter, R - PK, cap site, reporter gene, minimal promoter, DNA binding sites, GATA-1, GATA binding site, AGATAA, TFIID binding site, TFIID, GATA binding site, TFIID binding site, binding sites, R - PK, minimal promoter, elements, hGATA-1, R - PK, promoter

29_task2

Sentence: Transcriptional regulation of the pyruvate kinase erythroid-specific promoter. Mammal pyruvate kinases are encoded by two genes. The L gene produces the erythroid (R-PK) or the hepatic (L-PK) isozymes by the alternative use of two promoters. We report the characterization of the cis- and trans-acting elements involved in the tissue-specific activity of the L gene erythroid promoter. A R-PK DNA fragment extending from -870 to +54 relative to the cap site confers erythroid specificity to a reporter gene. Within this region, we define a minimal promoter (-62 to +54) that displays erythroid-specific activity and contains two DNA binding sites. One, located at -50, binds members of the CCACC/Sp1 family and the other, located at -20, binds the erythroid factor GATA-1. Although the -20 GATA binding site (AGATAA) is also a potential TFIID binding site, it does not bind TFIID. Furthermore, the substitution of this GATA binding site by a canonical TFIID binding site suppresses the promoter activity. Mutations and deletions of both sites indicate that only the association of CCACC/Sp1 and GATA binding sites can drive efficient and tissue-specific expression of this R-PK minimal promoter. Finally, by co-transfection experiments, we study the elements involved in the hGATA-1 transactivation of the R-PK promoter in HeLa cells. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O" ]

Transcriptional regulation of the pyruvate kinase erythroid-specific promoter. Mammal pyruvate kinases are encoded by two genes. The L gene produces the erythroid (R-PK) or the hepatic (L-PK) isozymes by the alternative use of two promoters. We report the characterization of the cis- and trans-acting elements involved in the tissue-specific activity of the L gene erythroid promoter. A R-PK DNA fragment extending from -870 to +54 relative to the cap site confers erythroid specificity to a reporter gene. Within this region, we define a minimal promoter (-62 to +54) that displays erythroid-specific activity and contains two DNA binding sites. One, located at -50, binds members of the CCACC/Sp1 family and the other, located at -20, binds the erythroid factor GATA-1. Although the -20 GATA binding site (AGATAA) is also a potential TFIID binding site, it does not bind TFIID. Furthermore, the substitution of this GATA binding site by a canonical TFIID binding site suppresses the promoter activity. Mutations and deletions of both sites indicate that only the association of CCACC/Sp1 and GATA binding sites can drive efficient and tissue-specific expression of this R-PK minimal promoter. Finally, by co-transfection experiments, we study the elements involved in the hGATA-1 transactivation of the R-PK promoter in HeLa cells.

[ "Transcriptional", "regulation", "of", "the", "pyruvate", "kinase", "erythroid", "-", "specific", "promoter", ".", "\n", "Mammal", "pyruvate", "kinases", "are", "encoded", "by", "two", "genes", ".", "The", "L", "gene", "produces", "the", "erythroid", "(", "R", "-", "PK", ")", "or", "the", "hepatic", "(", "L", "-", "PK", ")", "isozymes", "by", "the", "alternative", "use", "of", "two", "promoters", ".", "We", "report", "the", "characterization", "of", "the", "cis-", "and", "trans", "-", "acting", "elements", "involved", "in", "the", "tissue", "-", "specific", "activity", "of", "the", "L", "gene", "erythroid", "promoter", ".", "A", "R", "-", "PK", "DNA", "fragment", "extending", "from", "-870", "to", "+54", "relative", "to", "the", "cap", "site", "confers", "erythroid", "specificity", "to", "a", "reporter", "gene", ".", "Within", "this", "region", ",", "we", "define", "a", "minimal", "promoter", "(", "-62", "to", "+54", ")", "that", "displays", "erythroid", "-", "specific", "activity", "and", "contains", "two", "DNA", "binding", "sites", ".", "One", ",", "located", "at", "-50", ",", "binds", "members", "of", "the", "CCACC", "/", "Sp1", "family", "and", "the", "other", ",", "located", "at", "-20", ",", "binds", "the", "erythroid", "factor", "GATA-1", ".", "Although", "the", "-20", "GATA", "binding", "site", "(", "AGATAA", ")", "is", "also", "a", "potential", "TFIID", "binding", "site", ",", "it", "does", "not", "bind", "TFIID", ".", "Furthermore", ",", "the", "substitution", "of", "this", "GATA", "binding", "site", "by", "a", "canonical", "TFIID", "binding", "site", "suppresses", "the", "promoter", "activity", ".", "Mutations", "and", "deletions", "of", "both", "sites", "indicate", "that", "only", "the", "association", "of", "CCACC", "/", "Sp1", "and", "GATA", "binding", "sites", "can", "drive", "efficient", "and", "tissue", "-", "specific", "expression", "of", "this", "R", "-", "PK", "minimal", "promoter", ".", "Finally", ",", "by", "co", "-", "transfection", "experiments", ",", "we", "study", "the", "elements", "involved", "in", "the", "hGATA-1", "transactivation", "of", "the", "R", "-", "PK", "promoter", "in", "HeLa", "cells", ".", "\n" ]

[ "Entity", "Protein" ]

adjuvant interferon effectiveness is a Outcome_Other, kidney carcinoma with high risk of relapse " ] is a Participant_Condition

49596_task0

Sentence: [ Presentation of a randomized multicenter study protocol . " Evaluation of adjuvant interferon effectiveness after radical nephrectomy in kidney carcinoma with high risk of relapse " ] . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Outcome_Other, Participant_Condition

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O" ]

[ Presentation of a randomized multicenter study protocol . " Evaluation of adjuvant interferon effectiveness after radical nephrectomy in kidney carcinoma with high risk of relapse " ] .

[ "[", "Presentation", "of", "a", "randomized", "multicenter", "study", "protocol", ".", "\"", "Evaluation", "of", "adjuvant", "interferon", "effectiveness", "after", "radical", "nephrectomy", "in", "kidney", "carcinoma", "with", "high", "risk", "of", "relapse", "\"", "]", "." ]

[ "Participant_Condition", "Outcome_Other", "Intervention_Pharmacological" ]

adjuvant interferon effectiveness is a Outcome_Other, kidney carcinoma with high risk of relapse " ] is a Participant_Condition

49596_task1

Sentence: [ Presentation of a randomized multicenter study protocol . " Evaluation of adjuvant interferon effectiveness after radical nephrectomy in kidney carcinoma with high risk of relapse " ] . Instructions: please typing these entity words according to sentence: adjuvant interferon effectiveness, kidney carcinoma with high risk of relapse " ] Options: Outcome_Other, Participant_Condition

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O" ]

[ Presentation of a randomized multicenter study protocol . " Evaluation of adjuvant interferon effectiveness after radical nephrectomy in kidney carcinoma with high risk of relapse " ] .

[ "[", "Presentation", "of", "a", "randomized", "multicenter", "study", "protocol", ".", "\"", "Evaluation", "of", "adjuvant", "interferon", "effectiveness", "after", "radical", "nephrectomy", "in", "kidney", "carcinoma", "with", "high", "risk", "of", "relapse", "\"", "]", "." ]

[ "Participant_Condition", "Outcome_Other", "Intervention_Pharmacological" ]

adjuvant interferon effectiveness, kidney carcinoma with high risk of relapse " ]

49596_task2

Sentence: [ Presentation of a randomized multicenter study protocol . " Evaluation of adjuvant interferon effectiveness after radical nephrectomy in kidney carcinoma with high risk of relapse " ] . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O" ]

[ Presentation of a randomized multicenter study protocol . " Evaluation of adjuvant interferon effectiveness after radical nephrectomy in kidney carcinoma with high risk of relapse " ] .

[ "[", "Presentation", "of", "a", "randomized", "multicenter", "study", "protocol", ".", "\"", "Evaluation", "of", "adjuvant", "interferon", "effectiveness", "after", "radical", "nephrectomy", "in", "kidney", "carcinoma", "with", "high", "risk", "of", "relapse", "\"", "]", "." ]

[ "Participant_Condition", "Outcome_Other", "Intervention_Pharmacological" ]

Arbeit is an umlsterm, Analyse is an umlsterm, Knochenbildung is an umlsterm, Periostlappen is an umlsterm, Ratte is an umlsterm, Periostlappen is an umlsterm, Periostseite is an umlsterm, Periostlappen is an umlsterm, Oberschenkelmuskulatur is an umlsterm, Tiere is an umlsterm, Tiere is an umlsterm, Periostlappens is an umlsterm, Knochenbildung is an umlsterm, Knochenbildung is an umlsterm, Knochen is an umlsterm, radiologisch is an umlsterm, radiologische is an umlsterm, Knochenformation is an umlsterm, Ratten is an umlsterm, Periostlappen is an umlsterm, Knochenbildung is an umlsterm, Periostlappen is an umlsterm, Periostlappen is an umlsterm, Knochenbildung is an umlsterm, Periost is an umlsterm, Knochenbildung is an umlsterm, Knochendefekte is an umlsterm, Periostlappens is an umlsterm, Knochensegment is an umlsterm, Periostlappen is an umlsterm

MundKieferGesichtschirurgie.0004s454.ger.abstr_task0

Sentence: Ziel dieser Arbeit war die Analyse von orthotoper und heterotoper Knochenbildung mit Hilfe einer strukturellen Polylaktatmatrix ( OPLA/HY ) , dem osteoinduktiven rh-BMP-2 und einem vaskularisierten Periostlappen . An der Ratte wurde ein an den saphenischen Gefaessen gestielter Periostlappen von der medialen Tibiaoberflaeche praepariert , mit der Periostseite als Innenauskleidung zu einer Kammer geformt und in die Leiste transportiert . In diese Kammer wurde die OPLA/HY-Matrix mit und ohne BMP eingepackt bzw. dieser vaskularisierte Periostlappen " leer " durch die Oberschenkelmuskulatur nach dorsal zu einem Femurdefekt transferiert und um die OPLA/HY-Matrix mit und ohne BMP gewickelt . Die Tiere wurden in 10 Gruppen ( 82 Tiere ) unterteilt . Der Effekt des vaskularisierten Periostlappens mit oder ohne OPLA/HY-Matrix und mit oder ohne rh-BMP-2 wurde in der Leiste ( heterotope Knochenbildung ) anhand von 6 Gruppen und im Femurdefekt ( orthotope Knochenbildung ) anhand von 4 Gruppen untersucht . Die Praesenz und Dichte von neuem Knochen in der Leiste und im Femurdefekt wurden radiologisch und histologisch nach 4 und 8 Wochen evaluiert . Eine radiologische und histologische Knochenformation in der Leiste ( heterotop ) konnte nur bei Ratten mit vaskularisiertem Periostlappen , OPLA/HY-Matrix und rh-BMP-2 demonstriert werden , waehrend bei den Femurdefekten auch eine zunehmende Knochenbildung ( orthotop ) mit der OPLA/HY-Matrix und rh-BMP-2 mit und ohne Periostlappen feststellbar war . Der Periostlappen bewirkte jedoch eine staerkere Knochenbildung am Rand mit definierter Begrenzung des Defekts . 4 Faktoren - autonome Vaskularitaet , Osteoprogenitorzellen enthaltendes Periost , eine strukturelle Matrix und BMP - sind fuer eine optimale Knochenbildung sowohl heterotop in der Leiste als auch orthotop im Femurdefekt notwendig . Aufgrund dieser Ergebnisse koennten potenziell in Zukunft Knochendefekte oder Pseudarthrosen mit Hilfe eines vaskularisierten Periostlappens , einer Matrix und BMP erfolgreich rekonstruiert werden . Alternativ koennte ein vaskularisiertes Knochensegment fern von einem Defekt in einem vaskularisierten Periostlappen praefabriziert und sekundaer mikrochirurgisch in den Defekt transferiert werden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Ziel dieser Arbeit war die Analyse von orthotoper und heterotoper Knochenbildung mit Hilfe einer strukturellen Polylaktatmatrix ( OPLA/HY ) , dem osteoinduktiven rh-BMP-2 und einem vaskularisierten Periostlappen . An der Ratte wurde ein an den saphenischen Gefaessen gestielter Periostlappen von der medialen Tibiaoberflaeche praepariert , mit der Periostseite als Innenauskleidung zu einer Kammer geformt und in die Leiste transportiert . In diese Kammer wurde die OPLA/HY-Matrix mit und ohne BMP eingepackt bzw. dieser vaskularisierte Periostlappen " leer " durch die Oberschenkelmuskulatur nach dorsal zu einem Femurdefekt transferiert und um die OPLA/HY-Matrix mit und ohne BMP gewickelt . Die Tiere wurden in 10 Gruppen ( 82 Tiere ) unterteilt . Der Effekt des vaskularisierten Periostlappens mit oder ohne OPLA/HY-Matrix und mit oder ohne rh-BMP-2 wurde in der Leiste ( heterotope Knochenbildung ) anhand von 6 Gruppen und im Femurdefekt ( orthotope Knochenbildung ) anhand von 4 Gruppen untersucht . Die Praesenz und Dichte von neuem Knochen in der Leiste und im Femurdefekt wurden radiologisch und histologisch nach 4 und 8 Wochen evaluiert . Eine radiologische und histologische Knochenformation in der Leiste ( heterotop ) konnte nur bei Ratten mit vaskularisiertem Periostlappen , OPLA/HY-Matrix und rh-BMP-2 demonstriert werden , waehrend bei den Femurdefekten auch eine zunehmende Knochenbildung ( orthotop ) mit der OPLA/HY-Matrix und rh-BMP-2 mit und ohne Periostlappen feststellbar war . Der Periostlappen bewirkte jedoch eine staerkere Knochenbildung am Rand mit definierter Begrenzung des Defekts . 4 Faktoren - autonome Vaskularitaet , Osteoprogenitorzellen enthaltendes Periost , eine strukturelle Matrix und BMP - sind fuer eine optimale Knochenbildung sowohl heterotop in der Leiste als auch orthotop im Femurdefekt notwendig . Aufgrund dieser Ergebnisse koennten potenziell in Zukunft Knochendefekte oder Pseudarthrosen mit Hilfe eines vaskularisierten Periostlappens , einer Matrix und BMP erfolgreich rekonstruiert werden . Alternativ koennte ein vaskularisiertes Knochensegment fern von einem Defekt in einem vaskularisierten Periostlappen praefabriziert und sekundaer mikrochirurgisch in den Defekt transferiert werden .

[ "Ziel", "dieser", "Arbeit", "war", "die", "Analyse", "von", "orthotoper", "und", "heterotoper", "Knochenbildung", "mit", "Hilfe", "einer", "strukturellen", "Polylaktatmatrix", "(", "OPLA", "/", "HY", ")", ",", "dem", "osteoinduktiven", "rh", "-", "BMP-2", "und", "einem", "vaskularisierten", "Periostlappen", ".", "An", "der", "Ratte", "wurde", "ein", "an", "den", "saphenischen", "Gefaessen", "gestielter", "Periostlappen", "von", "der", "medialen", "Tibiaoberflaeche", "praepariert", ",", "mit", "der", "Periostseite", "als", "Innenauskleidung", "zu", "einer", "Kammer", "geformt", "und", "in", "die", "Leiste", "transportiert", ".", "In", "diese", "Kammer", "wurde", "die", "OPLA", "/", "HY", "-", "Matrix", "mit", "und", "ohne", "BMP", "eingepackt", "bzw", ".", "dieser", "vaskularisierte", "Periostlappen", "\"", "leer", "\"", "durch", "die", "Oberschenkelmuskulatur", "nach", "dorsal", "zu", "einem", "Femurdefekt", "transferiert", "und", "um", "die", "OPLA", "/", "HY", "-", "Matrix", "mit", "und", "ohne", "BMP", "gewickelt", ".", "Die", "Tiere", "wurden", "in", "10", "Gruppen", "(", "82", "Tiere", ")", "unterteilt", ".", "Der", "Effekt", "des", "vaskularisierten", "Periostlappens", "mit", "oder", "ohne", "OPLA", "/", "HY", "-", "Matrix", "und", "mit", "oder", "ohne", "rh", "-", "BMP-2", "wurde", "in", "der", "Leiste", "(", "heterotope", "Knochenbildung", ")", "anhand", "von", "6", "Gruppen", "und", "im", "Femurdefekt", "(", "orthotope", "Knochenbildung", ")", "anhand", "von", "4", "Gruppen", "untersucht", ".", "Die", "Praesenz", "und", "Dichte", "von", "neuem", "Knochen", "in", "der", "Leiste", "und", "im", "Femurdefekt", "wurden", "radiologisch", "und", "histologisch", "nach", "4", "und", "8", "Wochen", "evaluiert", ".", "Eine", "radiologische", "und", "histologische", "Knochenformation", "in", "der", "Leiste", "(", "heterotop", ")", "konnte", "nur", "bei", "Ratten", "mit", "vaskularisiertem", "Periostlappen", ",", "OPLA", "/", "HY", "-", "Matrix", "und", "rh", "-", "BMP-2", "demonstriert", "werden", ",", "waehrend", "bei", "den", "Femurdefekten", "auch", "eine", "zunehmende", "Knochenbildung", "(", "orthotop", ")", "mit", "der", "OPLA", "/", "HY", "-", "Matrix", "und", "rh", "-", "BMP-2", "mit", "und", "ohne", "Periostlappen", "feststellbar", "war", ".", "Der", "Periostlappen", "bewirkte", "jedoch", "eine", "staerkere", "Knochenbildung", "am", "Rand", "mit", "definierter", "Begrenzung", "des", "Defekts", ".", "4", "Faktoren", "-", "autonome", "Vaskularitaet", ",", "Osteoprogenitorzellen", "enthaltendes", "Periost", ",", "eine", "strukturelle", "Matrix", "und", "BMP", "-", "sind", "fuer", "eine", "optimale", "Knochenbildung", "sowohl", "heterotop", "in", "der", "Leiste", "als", "auch", "orthotop", "im", "Femurdefekt", "notwendig", ".", "Aufgrund", "dieser", "Ergebnisse", "koennten", "potenziell", "in", "Zukunft", "Knochendefekte", "oder", "Pseudarthrosen", "mit", "Hilfe", "eines", "vaskularisierten", "Periostlappens", ",", "einer", "Matrix", "und", "BMP", "erfolgreich", "rekonstruiert", "werden", ".", "Alternativ", "koennte", "ein", "vaskularisiertes", "Knochensegment", "fern", "von", "einem", "Defekt", "in", "einem", "vaskularisierten", "Periostlappen", "praefabriziert", "und", "sekundaer", "mikrochirurgisch", "in", "den", "Defekt", "transferiert", "werden", "." ]

[ "umlsterm" ]

Arbeit is an umlsterm, Analyse is an umlsterm, Knochenbildung is an umlsterm, Periostlappen is an umlsterm, Ratte is an umlsterm, Periostlappen is an umlsterm, Periostseite is an umlsterm, Periostlappen is an umlsterm, Oberschenkelmuskulatur is an umlsterm, Tiere is an umlsterm, Tiere is an umlsterm, Periostlappens is an umlsterm, Knochenbildung is an umlsterm, Knochenbildung is an umlsterm, Knochen is an umlsterm, radiologisch is an umlsterm, radiologische is an umlsterm, Knochenformation is an umlsterm, Ratten is an umlsterm, Periostlappen is an umlsterm, Knochenbildung is an umlsterm, Periostlappen is an umlsterm, Periostlappen is an umlsterm, Knochenbildung is an umlsterm, Periost is an umlsterm, Knochenbildung is an umlsterm, Knochendefekte is an umlsterm, Periostlappens is an umlsterm, Knochensegment is an umlsterm, Periostlappen is an umlsterm

MundKieferGesichtschirurgie.0004s454.ger.abstr_task1

Sentence: Ziel dieser Arbeit war die Analyse von orthotoper und heterotoper Knochenbildung mit Hilfe einer strukturellen Polylaktatmatrix ( OPLA/HY ) , dem osteoinduktiven rh-BMP-2 und einem vaskularisierten Periostlappen . An der Ratte wurde ein an den saphenischen Gefaessen gestielter Periostlappen von der medialen Tibiaoberflaeche praepariert , mit der Periostseite als Innenauskleidung zu einer Kammer geformt und in die Leiste transportiert . In diese Kammer wurde die OPLA/HY-Matrix mit und ohne BMP eingepackt bzw. dieser vaskularisierte Periostlappen " leer " durch die Oberschenkelmuskulatur nach dorsal zu einem Femurdefekt transferiert und um die OPLA/HY-Matrix mit und ohne BMP gewickelt . Die Tiere wurden in 10 Gruppen ( 82 Tiere ) unterteilt . Der Effekt des vaskularisierten Periostlappens mit oder ohne OPLA/HY-Matrix und mit oder ohne rh-BMP-2 wurde in der Leiste ( heterotope Knochenbildung ) anhand von 6 Gruppen und im Femurdefekt ( orthotope Knochenbildung ) anhand von 4 Gruppen untersucht . Die Praesenz und Dichte von neuem Knochen in der Leiste und im Femurdefekt wurden radiologisch und histologisch nach 4 und 8 Wochen evaluiert . Eine radiologische und histologische Knochenformation in der Leiste ( heterotop ) konnte nur bei Ratten mit vaskularisiertem Periostlappen , OPLA/HY-Matrix und rh-BMP-2 demonstriert werden , waehrend bei den Femurdefekten auch eine zunehmende Knochenbildung ( orthotop ) mit der OPLA/HY-Matrix und rh-BMP-2 mit und ohne Periostlappen feststellbar war . Der Periostlappen bewirkte jedoch eine staerkere Knochenbildung am Rand mit definierter Begrenzung des Defekts . 4 Faktoren - autonome Vaskularitaet , Osteoprogenitorzellen enthaltendes Periost , eine strukturelle Matrix und BMP - sind fuer eine optimale Knochenbildung sowohl heterotop in der Leiste als auch orthotop im Femurdefekt notwendig . Aufgrund dieser Ergebnisse koennten potenziell in Zukunft Knochendefekte oder Pseudarthrosen mit Hilfe eines vaskularisierten Periostlappens , einer Matrix und BMP erfolgreich rekonstruiert werden . Alternativ koennte ein vaskularisiertes Knochensegment fern von einem Defekt in einem vaskularisierten Periostlappen praefabriziert und sekundaer mikrochirurgisch in den Defekt transferiert werden . Instructions: please typing these entity words according to sentence: Arbeit, Analyse, Knochenbildung, Periostlappen, Ratte, Periostlappen, Periostseite, Periostlappen, Oberschenkelmuskulatur, Tiere, Tiere, Periostlappens, Knochenbildung, Knochenbildung, Knochen, radiologisch, radiologische, Knochenformation, Ratten, Periostlappen, Knochenbildung, Periostlappen, Periostlappen, Knochenbildung, Periost, Knochenbildung, Knochendefekte, Periostlappens, Knochensegment, Periostlappen Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Ziel dieser Arbeit war die Analyse von orthotoper und heterotoper Knochenbildung mit Hilfe einer strukturellen Polylaktatmatrix ( OPLA/HY ) , dem osteoinduktiven rh-BMP-2 und einem vaskularisierten Periostlappen . An der Ratte wurde ein an den saphenischen Gefaessen gestielter Periostlappen von der medialen Tibiaoberflaeche praepariert , mit der Periostseite als Innenauskleidung zu einer Kammer geformt und in die Leiste transportiert . In diese Kammer wurde die OPLA/HY-Matrix mit und ohne BMP eingepackt bzw. dieser vaskularisierte Periostlappen " leer " durch die Oberschenkelmuskulatur nach dorsal zu einem Femurdefekt transferiert und um die OPLA/HY-Matrix mit und ohne BMP gewickelt . Die Tiere wurden in 10 Gruppen ( 82 Tiere ) unterteilt . Der Effekt des vaskularisierten Periostlappens mit oder ohne OPLA/HY-Matrix und mit oder ohne rh-BMP-2 wurde in der Leiste ( heterotope Knochenbildung ) anhand von 6 Gruppen und im Femurdefekt ( orthotope Knochenbildung ) anhand von 4 Gruppen untersucht . Die Praesenz und Dichte von neuem Knochen in der Leiste und im Femurdefekt wurden radiologisch und histologisch nach 4 und 8 Wochen evaluiert . Eine radiologische und histologische Knochenformation in der Leiste ( heterotop ) konnte nur bei Ratten mit vaskularisiertem Periostlappen , OPLA/HY-Matrix und rh-BMP-2 demonstriert werden , waehrend bei den Femurdefekten auch eine zunehmende Knochenbildung ( orthotop ) mit der OPLA/HY-Matrix und rh-BMP-2 mit und ohne Periostlappen feststellbar war . Der Periostlappen bewirkte jedoch eine staerkere Knochenbildung am Rand mit definierter Begrenzung des Defekts . 4 Faktoren - autonome Vaskularitaet , Osteoprogenitorzellen enthaltendes Periost , eine strukturelle Matrix und BMP - sind fuer eine optimale Knochenbildung sowohl heterotop in der Leiste als auch orthotop im Femurdefekt notwendig . Aufgrund dieser Ergebnisse koennten potenziell in Zukunft Knochendefekte oder Pseudarthrosen mit Hilfe eines vaskularisierten Periostlappens , einer Matrix und BMP erfolgreich rekonstruiert werden . Alternativ koennte ein vaskularisiertes Knochensegment fern von einem Defekt in einem vaskularisierten Periostlappen praefabriziert und sekundaer mikrochirurgisch in den Defekt transferiert werden .

[ "Ziel", "dieser", "Arbeit", "war", "die", "Analyse", "von", "orthotoper", "und", "heterotoper", "Knochenbildung", "mit", "Hilfe", "einer", "strukturellen", "Polylaktatmatrix", "(", "OPLA", "/", "HY", ")", ",", "dem", "osteoinduktiven", "rh", "-", "BMP-2", "und", "einem", "vaskularisierten", "Periostlappen", ".", "An", "der", "Ratte", "wurde", "ein", "an", "den", "saphenischen", "Gefaessen", "gestielter", "Periostlappen", "von", "der", "medialen", "Tibiaoberflaeche", "praepariert", ",", "mit", "der", "Periostseite", "als", "Innenauskleidung", "zu", "einer", "Kammer", "geformt", "und", "in", "die", "Leiste", "transportiert", ".", "In", "diese", "Kammer", "wurde", "die", "OPLA", "/", "HY", "-", "Matrix", "mit", "und", "ohne", "BMP", "eingepackt", "bzw", ".", "dieser", "vaskularisierte", "Periostlappen", "\"", "leer", "\"", "durch", "die", "Oberschenkelmuskulatur", "nach", "dorsal", "zu", "einem", "Femurdefekt", "transferiert", "und", "um", "die", "OPLA", "/", "HY", "-", "Matrix", "mit", "und", "ohne", "BMP", "gewickelt", ".", "Die", "Tiere", "wurden", "in", "10", "Gruppen", "(", "82", "Tiere", ")", "unterteilt", ".", "Der", "Effekt", "des", "vaskularisierten", "Periostlappens", "mit", "oder", "ohne", "OPLA", "/", "HY", "-", "Matrix", "und", "mit", "oder", "ohne", "rh", "-", "BMP-2", "wurde", "in", "der", "Leiste", "(", "heterotope", "Knochenbildung", ")", "anhand", "von", "6", "Gruppen", "und", "im", "Femurdefekt", "(", "orthotope", "Knochenbildung", ")", "anhand", "von", "4", "Gruppen", "untersucht", ".", "Die", "Praesenz", "und", "Dichte", "von", "neuem", "Knochen", "in", "der", "Leiste", "und", "im", "Femurdefekt", "wurden", "radiologisch", "und", "histologisch", "nach", "4", "und", "8", "Wochen", "evaluiert", ".", "Eine", "radiologische", "und", "histologische", "Knochenformation", "in", "der", "Leiste", "(", "heterotop", ")", "konnte", "nur", "bei", "Ratten", "mit", "vaskularisiertem", "Periostlappen", ",", "OPLA", "/", "HY", "-", "Matrix", "und", "rh", "-", "BMP-2", "demonstriert", "werden", ",", "waehrend", "bei", "den", "Femurdefekten", "auch", "eine", "zunehmende", "Knochenbildung", "(", "orthotop", ")", "mit", "der", "OPLA", "/", "HY", "-", "Matrix", "und", "rh", "-", "BMP-2", "mit", "und", "ohne", "Periostlappen", "feststellbar", "war", ".", "Der", "Periostlappen", "bewirkte", "jedoch", "eine", "staerkere", "Knochenbildung", "am", "Rand", "mit", "definierter", "Begrenzung", "des", "Defekts", ".", "4", "Faktoren", "-", "autonome", "Vaskularitaet", ",", "Osteoprogenitorzellen", "enthaltendes", "Periost", ",", "eine", "strukturelle", "Matrix", "und", "BMP", "-", "sind", "fuer", "eine", "optimale", "Knochenbildung", "sowohl", "heterotop", "in", "der", "Leiste", "als", "auch", "orthotop", "im", "Femurdefekt", "notwendig", ".", "Aufgrund", "dieser", "Ergebnisse", "koennten", "potenziell", "in", "Zukunft", "Knochendefekte", "oder", "Pseudarthrosen", "mit", "Hilfe", "eines", "vaskularisierten", "Periostlappens", ",", "einer", "Matrix", "und", "BMP", "erfolgreich", "rekonstruiert", "werden", ".", "Alternativ", "koennte", "ein", "vaskularisiertes", "Knochensegment", "fern", "von", "einem", "Defekt", "in", "einem", "vaskularisierten", "Periostlappen", "praefabriziert", "und", "sekundaer", "mikrochirurgisch", "in", "den", "Defekt", "transferiert", "werden", "." ]

[ "umlsterm" ]

Arbeit, Analyse, Knochenbildung, Periostlappen, Ratte, Periostlappen, Periostseite, Periostlappen, Oberschenkelmuskulatur, Tiere, Tiere, Periostlappens, Knochenbildung, Knochenbildung, Knochen, radiologisch, radiologische, Knochenformation, Ratten, Periostlappen, Knochenbildung, Periostlappen, Periostlappen, Knochenbildung, Periost, Knochenbildung, Knochendefekte, Periostlappens, Knochensegment, Periostlappen

MundKieferGesichtschirurgie.0004s454.ger.abstr_task2

Sentence: Ziel dieser Arbeit war die Analyse von orthotoper und heterotoper Knochenbildung mit Hilfe einer strukturellen Polylaktatmatrix ( OPLA/HY ) , dem osteoinduktiven rh-BMP-2 und einem vaskularisierten Periostlappen . An der Ratte wurde ein an den saphenischen Gefaessen gestielter Periostlappen von der medialen Tibiaoberflaeche praepariert , mit der Periostseite als Innenauskleidung zu einer Kammer geformt und in die Leiste transportiert . In diese Kammer wurde die OPLA/HY-Matrix mit und ohne BMP eingepackt bzw. dieser vaskularisierte Periostlappen " leer " durch die Oberschenkelmuskulatur nach dorsal zu einem Femurdefekt transferiert und um die OPLA/HY-Matrix mit und ohne BMP gewickelt . Die Tiere wurden in 10 Gruppen ( 82 Tiere ) unterteilt . Der Effekt des vaskularisierten Periostlappens mit oder ohne OPLA/HY-Matrix und mit oder ohne rh-BMP-2 wurde in der Leiste ( heterotope Knochenbildung ) anhand von 6 Gruppen und im Femurdefekt ( orthotope Knochenbildung ) anhand von 4 Gruppen untersucht . Die Praesenz und Dichte von neuem Knochen in der Leiste und im Femurdefekt wurden radiologisch und histologisch nach 4 und 8 Wochen evaluiert . Eine radiologische und histologische Knochenformation in der Leiste ( heterotop ) konnte nur bei Ratten mit vaskularisiertem Periostlappen , OPLA/HY-Matrix und rh-BMP-2 demonstriert werden , waehrend bei den Femurdefekten auch eine zunehmende Knochenbildung ( orthotop ) mit der OPLA/HY-Matrix und rh-BMP-2 mit und ohne Periostlappen feststellbar war . Der Periostlappen bewirkte jedoch eine staerkere Knochenbildung am Rand mit definierter Begrenzung des Defekts . 4 Faktoren - autonome Vaskularitaet , Osteoprogenitorzellen enthaltendes Periost , eine strukturelle Matrix und BMP - sind fuer eine optimale Knochenbildung sowohl heterotop in der Leiste als auch orthotop im Femurdefekt notwendig . Aufgrund dieser Ergebnisse koennten potenziell in Zukunft Knochendefekte oder Pseudarthrosen mit Hilfe eines vaskularisierten Periostlappens , einer Matrix und BMP erfolgreich rekonstruiert werden . Alternativ koennte ein vaskularisiertes Knochensegment fern von einem Defekt in einem vaskularisierten Periostlappen praefabriziert und sekundaer mikrochirurgisch in den Defekt transferiert werden . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Ziel dieser Arbeit war die Analyse von orthotoper und heterotoper Knochenbildung mit Hilfe einer strukturellen Polylaktatmatrix ( OPLA/HY ) , dem osteoinduktiven rh-BMP-2 und einem vaskularisierten Periostlappen . An der Ratte wurde ein an den saphenischen Gefaessen gestielter Periostlappen von der medialen Tibiaoberflaeche praepariert , mit der Periostseite als Innenauskleidung zu einer Kammer geformt und in die Leiste transportiert . In diese Kammer wurde die OPLA/HY-Matrix mit und ohne BMP eingepackt bzw. dieser vaskularisierte Periostlappen " leer " durch die Oberschenkelmuskulatur nach dorsal zu einem Femurdefekt transferiert und um die OPLA/HY-Matrix mit und ohne BMP gewickelt . Die Tiere wurden in 10 Gruppen ( 82 Tiere ) unterteilt . Der Effekt des vaskularisierten Periostlappens mit oder ohne OPLA/HY-Matrix und mit oder ohne rh-BMP-2 wurde in der Leiste ( heterotope Knochenbildung ) anhand von 6 Gruppen und im Femurdefekt ( orthotope Knochenbildung ) anhand von 4 Gruppen untersucht . Die Praesenz und Dichte von neuem Knochen in der Leiste und im Femurdefekt wurden radiologisch und histologisch nach 4 und 8 Wochen evaluiert . Eine radiologische und histologische Knochenformation in der Leiste ( heterotop ) konnte nur bei Ratten mit vaskularisiertem Periostlappen , OPLA/HY-Matrix und rh-BMP-2 demonstriert werden , waehrend bei den Femurdefekten auch eine zunehmende Knochenbildung ( orthotop ) mit der OPLA/HY-Matrix und rh-BMP-2 mit und ohne Periostlappen feststellbar war . Der Periostlappen bewirkte jedoch eine staerkere Knochenbildung am Rand mit definierter Begrenzung des Defekts . 4 Faktoren - autonome Vaskularitaet , Osteoprogenitorzellen enthaltendes Periost , eine strukturelle Matrix und BMP - sind fuer eine optimale Knochenbildung sowohl heterotop in der Leiste als auch orthotop im Femurdefekt notwendig . Aufgrund dieser Ergebnisse koennten potenziell in Zukunft Knochendefekte oder Pseudarthrosen mit Hilfe eines vaskularisierten Periostlappens , einer Matrix und BMP erfolgreich rekonstruiert werden . Alternativ koennte ein vaskularisiertes Knochensegment fern von einem Defekt in einem vaskularisierten Periostlappen praefabriziert und sekundaer mikrochirurgisch in den Defekt transferiert werden .

[ "Ziel", "dieser", "Arbeit", "war", "die", "Analyse", "von", "orthotoper", "und", "heterotoper", "Knochenbildung", "mit", "Hilfe", "einer", "strukturellen", "Polylaktatmatrix", "(", "OPLA", "/", "HY", ")", ",", "dem", "osteoinduktiven", "rh", "-", "BMP-2", "und", "einem", "vaskularisierten", "Periostlappen", ".", "An", "der", "Ratte", "wurde", "ein", "an", "den", "saphenischen", "Gefaessen", "gestielter", "Periostlappen", "von", "der", "medialen", "Tibiaoberflaeche", "praepariert", ",", "mit", "der", "Periostseite", "als", "Innenauskleidung", "zu", "einer", "Kammer", "geformt", "und", "in", "die", "Leiste", "transportiert", ".", "In", "diese", "Kammer", "wurde", "die", "OPLA", "/", "HY", "-", "Matrix", "mit", "und", "ohne", "BMP", "eingepackt", "bzw", ".", "dieser", "vaskularisierte", "Periostlappen", "\"", "leer", "\"", "durch", "die", "Oberschenkelmuskulatur", "nach", "dorsal", "zu", "einem", "Femurdefekt", "transferiert", "und", "um", "die", "OPLA", "/", "HY", "-", "Matrix", "mit", "und", "ohne", "BMP", "gewickelt", ".", "Die", "Tiere", "wurden", "in", "10", "Gruppen", "(", "82", "Tiere", ")", "unterteilt", ".", "Der", "Effekt", "des", "vaskularisierten", "Periostlappens", "mit", "oder", "ohne", "OPLA", "/", "HY", "-", "Matrix", "und", "mit", "oder", "ohne", "rh", "-", "BMP-2", "wurde", "in", "der", "Leiste", "(", "heterotope", "Knochenbildung", ")", "anhand", "von", "6", "Gruppen", "und", "im", "Femurdefekt", "(", "orthotope", "Knochenbildung", ")", "anhand", "von", "4", "Gruppen", "untersucht", ".", "Die", "Praesenz", "und", "Dichte", "von", "neuem", "Knochen", "in", "der", "Leiste", "und", "im", "Femurdefekt", "wurden", "radiologisch", "und", "histologisch", "nach", "4", "und", "8", "Wochen", "evaluiert", ".", "Eine", "radiologische", "und", "histologische", "Knochenformation", "in", "der", "Leiste", "(", "heterotop", ")", "konnte", "nur", "bei", "Ratten", "mit", "vaskularisiertem", "Periostlappen", ",", "OPLA", "/", "HY", "-", "Matrix", "und", "rh", "-", "BMP-2", "demonstriert", "werden", ",", "waehrend", "bei", "den", "Femurdefekten", "auch", "eine", "zunehmende", "Knochenbildung", "(", "orthotop", ")", "mit", "der", "OPLA", "/", "HY", "-", "Matrix", "und", "rh", "-", "BMP-2", "mit", "und", "ohne", "Periostlappen", "feststellbar", "war", ".", "Der", "Periostlappen", "bewirkte", "jedoch", "eine", "staerkere", "Knochenbildung", "am", "Rand", "mit", "definierter", "Begrenzung", "des", "Defekts", ".", "4", "Faktoren", "-", "autonome", "Vaskularitaet", ",", "Osteoprogenitorzellen", "enthaltendes", "Periost", ",", "eine", "strukturelle", "Matrix", "und", "BMP", "-", "sind", "fuer", "eine", "optimale", "Knochenbildung", "sowohl", "heterotop", "in", "der", "Leiste", "als", "auch", "orthotop", "im", "Femurdefekt", "notwendig", ".", "Aufgrund", "dieser", "Ergebnisse", "koennten", "potenziell", "in", "Zukunft", "Knochendefekte", "oder", "Pseudarthrosen", "mit", "Hilfe", "eines", "vaskularisierten", "Periostlappens", ",", "einer", "Matrix", "und", "BMP", "erfolgreich", "rekonstruiert", "werden", ".", "Alternativ", "koennte", "ein", "vaskularisiertes", "Knochensegment", "fern", "von", "einem", "Defekt", "in", "einem", "vaskularisierten", "Periostlappen", "praefabriziert", "und", "sekundaer", "mikrochirurgisch", "in", "den", "Defekt", "transferiert", "werden", "." ]

[ "umlsterm" ]

Kniegelenkverletzungen is an umlsterm, Arthroskopie is an umlsterm, Kniegelenk is an umlsterm, Diagnose is an umlsterm, Arthroskopie is an umlsterm, Kniegelenkuntersuchung is an umlsterm, Verletzungen is an umlsterm, Wachstumsalter is an umlsterm, Arthroskopie is an umlsterm, Diagnostik is an umlsterm, Kindern is an umlsterm, Wachstumsfugen is an umlsterm, Kinder is an umlsterm, Krankengut is an umlsterm, Patientenguts is an umlsterm, Befunderhebung is an umlsterm, Arthroskopie is an umlsterm, Diagnose is an umlsterm, Verletzungen is an umlsterm, Arthroskopie is an umlsterm, Kreuzbandrupturen is an umlsterm, Seitenbandverletzungen is an umlsterm, Patellaluxationen is an umlsterm, Arthroskopie is an umlsterm, Haemarthros is an umlsterm, Verletzung is an umlsterm, Techniken is an umlsterm, Arthroskopie is an umlsterm, wachsenden is an umlsterm, Kniegelenk is an umlsterm, Arthroskopie is an umlsterm, Kniegelenkverletzungen is an umlsterm

Arthroskopie.80110011.ger.abstr_task0

Sentence: Von frischen Kniegelenkverletzungen des Erwachsenen ist bekannt , dass bei der klinischen Erstuntersuchung haeufig nicht alle Befunde erfasst werden . Erst durch die Arthroskopie wird der Nachweis zusaetzlicher uebersehener Befunde , gefuehrt . Auch fuer das verletzte kindliche Kniegelenk ist die geringe Treffsicherheit der klinischen Diagnose bekannt . Trotzdem wurde der Einsatz der Arthroskopie zunaechst nur zoegernd akzeptiert . Dabei wurde schon in den 80er Jahren von verschiedenen Autoren auf die Problematik der klinischen Kniegelenkuntersuchung bei akuten Verletzungen im Wachstumsalter sowie auf die Bedeutung der Arthroskopie zur Optimierung der Diagnostik hingewiesen . An 2 verschiedenen Gruppen von Kindern und Jugendlichen mit noch offenen bzw. noch nicht geschlossenen Wachstumsfugen der Jahre von 1985-1988 und 1987-1996 wurde eine vergleichende Untersuchung durchgefuehrt . Es handelte sich dabei um Kinder und Jugendliche aus dem klinikeigenen Krankengut im Alter zwischen 6 und 15 Jahren . Anhand dieses Patientenguts wurde die Diskrepanz zwischen dem klinischen Erstbefund und der Befunderhebung durch Arthroskopie aufgezeigt . Die Differenz zwischen dem klinischen Erstbefund und der arthroskopisch erhobenen Diagnose lag in der ersten Gruppe bei ca. 45% und in der 2. , spaeter untersuchten Gruppe bei ca. 36% . Sowohl isolierte als auch kombinierte Verletzungen waren erst durch die Arthroskopie erfasst worden . Im Vordergrund standen dabei ligamentaere vordere Kreuzbandrupturen , mediale Seitenbandverletzungen und Meniskuslaesionen . Patellaluxationen mit Retinaculumrupturen sowie mit osteochondralen Fragmenten , die der klinischen Erstuntersuchung entgangen waren , wurden ebenfalls in beiden Gruppen erst durch die Arthroskopie nachgewiesen . Der Haemarthros erwies sich als wichtigster Hinweis auf den Schweregrad der Verletzung . Trotz der neuen , bildgebenden Techniken , wie dem MRI , kommt dem Einsatz der Arthroskopie auch am wachsenden Kniegelenk aufgrund der gleichzeitigen diagnostischen und therapeutischen Moeglichkeiten eine besondere Bedeutung zu . Diese zunehmend etablierte Feststellung soll der Anlass dafuer sein , die Arthroskopie generell in das Management akuter Kniegelenkverletzungen im Wachtumsalter einzubeziehen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Von frischen Kniegelenkverletzungen des Erwachsenen ist bekannt , dass bei der klinischen Erstuntersuchung haeufig nicht alle Befunde erfasst werden . Erst durch die Arthroskopie wird der Nachweis zusaetzlicher uebersehener Befunde , gefuehrt . Auch fuer das verletzte kindliche Kniegelenk ist die geringe Treffsicherheit der klinischen Diagnose bekannt . Trotzdem wurde der Einsatz der Arthroskopie zunaechst nur zoegernd akzeptiert . Dabei wurde schon in den 80er Jahren von verschiedenen Autoren auf die Problematik der klinischen Kniegelenkuntersuchung bei akuten Verletzungen im Wachstumsalter sowie auf die Bedeutung der Arthroskopie zur Optimierung der Diagnostik hingewiesen . An 2 verschiedenen Gruppen von Kindern und Jugendlichen mit noch offenen bzw. noch nicht geschlossenen Wachstumsfugen der Jahre von 1985-1988 und 1987-1996 wurde eine vergleichende Untersuchung durchgefuehrt . Es handelte sich dabei um Kinder und Jugendliche aus dem klinikeigenen Krankengut im Alter zwischen 6 und 15 Jahren . Anhand dieses Patientenguts wurde die Diskrepanz zwischen dem klinischen Erstbefund und der Befunderhebung durch Arthroskopie aufgezeigt . Die Differenz zwischen dem klinischen Erstbefund und der arthroskopisch erhobenen Diagnose lag in der ersten Gruppe bei ca. 45% und in der 2. , spaeter untersuchten Gruppe bei ca. 36% . Sowohl isolierte als auch kombinierte Verletzungen waren erst durch die Arthroskopie erfasst worden . Im Vordergrund standen dabei ligamentaere vordere Kreuzbandrupturen , mediale Seitenbandverletzungen und Meniskuslaesionen . Patellaluxationen mit Retinaculumrupturen sowie mit osteochondralen Fragmenten , die der klinischen Erstuntersuchung entgangen waren , wurden ebenfalls in beiden Gruppen erst durch die Arthroskopie nachgewiesen . Der Haemarthros erwies sich als wichtigster Hinweis auf den Schweregrad der Verletzung . Trotz der neuen , bildgebenden Techniken , wie dem MRI , kommt dem Einsatz der Arthroskopie auch am wachsenden Kniegelenk aufgrund der gleichzeitigen diagnostischen und therapeutischen Moeglichkeiten eine besondere Bedeutung zu . Diese zunehmend etablierte Feststellung soll der Anlass dafuer sein , die Arthroskopie generell in das Management akuter Kniegelenkverletzungen im Wachtumsalter einzubeziehen .

[ "Von", "frischen", "Kniegelenkverletzungen", "des", "Erwachsenen", "ist", "bekannt", ",", "dass", "bei", "der", "klinischen", "Erstuntersuchung", "haeufig", "nicht", "alle", "Befunde", "erfasst", "werden", ".", "Erst", "durch", "die", "Arthroskopie", "wird", "der", "Nachweis", "zusaetzlicher", "uebersehener", "Befunde", ",", "gefuehrt", ".", "Auch", "fuer", "das", "verletzte", "kindliche", "Kniegelenk", "ist", "die", "geringe", "Treffsicherheit", "der", "klinischen", "Diagnose", "bekannt", ".", "Trotzdem", "wurde", "der", "Einsatz", "der", "Arthroskopie", "zunaechst", "nur", "zoegernd", "akzeptiert", ".", "Dabei", "wurde", "schon", "in", "den", "80er", "Jahren", "von", "verschiedenen", "Autoren", "auf", "die", "Problematik", "der", "klinischen", "Kniegelenkuntersuchung", "bei", "akuten", "Verletzungen", "im", "Wachstumsalter", "sowie", "auf", "die", "Bedeutung", "der", "Arthroskopie", "zur", "Optimierung", "der", "Diagnostik", "hingewiesen", ".", "An", "2", "verschiedenen", "Gruppen", "von", "Kindern", "und", "Jugendlichen", "mit", "noch", "offenen", "bzw", ".", "noch", "nicht", "geschlossenen", "Wachstumsfugen", "der", "Jahre", "von", "1985", "-", "1988", "und", "1987", "-", "1996", "wurde", "eine", "vergleichende", "Untersuchung", "durchgefuehrt", ".", "Es", "handelte", "sich", "dabei", "um", "Kinder", "und", "Jugendliche", "aus", "dem", "klinikeigenen", "Krankengut", "im", "Alter", "zwischen", "6", "und", "15", "Jahren", ".", "Anhand", "dieses", "Patientenguts", "wurde", "die", "Diskrepanz", "zwischen", "dem", "klinischen", "Erstbefund", "und", "der", "Befunderhebung", "durch", "Arthroskopie", "aufgezeigt", ".", "Die", "Differenz", "zwischen", "dem", "klinischen", "Erstbefund", "und", "der", "arthroskopisch", "erhobenen", "Diagnose", "lag", "in", "der", "ersten", "Gruppe", "bei", "ca", ".", "45", "%", "und", "in", "der", "2", ".", ",", "spaeter", "untersuchten", "Gruppe", "bei", "ca", ".", "36", "%", ".", "Sowohl", "isolierte", "als", "auch", "kombinierte", "Verletzungen", "waren", "erst", "durch", "die", "Arthroskopie", "erfasst", "worden", ".", "Im", "Vordergrund", "standen", "dabei", "ligamentaere", "vordere", "Kreuzbandrupturen", ",", "mediale", "Seitenbandverletzungen", "und", "Meniskuslaesionen", ".", "Patellaluxationen", "mit", "Retinaculumrupturen", "sowie", "mit", "osteochondralen", "Fragmenten", ",", "die", "der", "klinischen", "Erstuntersuchung", "entgangen", "waren", ",", "wurden", "ebenfalls", "in", "beiden", "Gruppen", "erst", "durch", "die", "Arthroskopie", "nachgewiesen", ".", "Der", "Haemarthros", "erwies", "sich", "als", "wichtigster", "Hinweis", "auf", "den", "Schweregrad", "der", "Verletzung", ".", "Trotz", "der", "neuen", ",", "bildgebenden", "Techniken", ",", "wie", "dem", "MRI", ",", "kommt", "dem", "Einsatz", "der", "Arthroskopie", "auch", "am", "wachsenden", "Kniegelenk", "aufgrund", "der", "gleichzeitigen", "diagnostischen", "und", "therapeutischen", "Moeglichkeiten", "eine", "besondere", "Bedeutung", "zu", ".", "Diese", "zunehmend", "etablierte", "Feststellung", "soll", "der", "Anlass", "dafuer", "sein", ",", "die", "Arthroskopie", "generell", "in", "das", "Management", "akuter", "Kniegelenkverletzungen", "im", "Wachtumsalter", "einzubeziehen", "." ]

[ "umlsterm" ]

Kniegelenkverletzungen is an umlsterm, Arthroskopie is an umlsterm, Kniegelenk is an umlsterm, Diagnose is an umlsterm, Arthroskopie is an umlsterm, Kniegelenkuntersuchung is an umlsterm, Verletzungen is an umlsterm, Wachstumsalter is an umlsterm, Arthroskopie is an umlsterm, Diagnostik is an umlsterm, Kindern is an umlsterm, Wachstumsfugen is an umlsterm, Kinder is an umlsterm, Krankengut is an umlsterm, Patientenguts is an umlsterm, Befunderhebung is an umlsterm, Arthroskopie is an umlsterm, Diagnose is an umlsterm, Verletzungen is an umlsterm, Arthroskopie is an umlsterm, Kreuzbandrupturen is an umlsterm, Seitenbandverletzungen is an umlsterm, Patellaluxationen is an umlsterm, Arthroskopie is an umlsterm, Haemarthros is an umlsterm, Verletzung is an umlsterm, Techniken is an umlsterm, Arthroskopie is an umlsterm, wachsenden is an umlsterm, Kniegelenk is an umlsterm, Arthroskopie is an umlsterm, Kniegelenkverletzungen is an umlsterm

Arthroskopie.80110011.ger.abstr_task1

Sentence: Von frischen Kniegelenkverletzungen des Erwachsenen ist bekannt , dass bei der klinischen Erstuntersuchung haeufig nicht alle Befunde erfasst werden . Erst durch die Arthroskopie wird der Nachweis zusaetzlicher uebersehener Befunde , gefuehrt . Auch fuer das verletzte kindliche Kniegelenk ist die geringe Treffsicherheit der klinischen Diagnose bekannt . Trotzdem wurde der Einsatz der Arthroskopie zunaechst nur zoegernd akzeptiert . Dabei wurde schon in den 80er Jahren von verschiedenen Autoren auf die Problematik der klinischen Kniegelenkuntersuchung bei akuten Verletzungen im Wachstumsalter sowie auf die Bedeutung der Arthroskopie zur Optimierung der Diagnostik hingewiesen . An 2 verschiedenen Gruppen von Kindern und Jugendlichen mit noch offenen bzw. noch nicht geschlossenen Wachstumsfugen der Jahre von 1985-1988 und 1987-1996 wurde eine vergleichende Untersuchung durchgefuehrt . Es handelte sich dabei um Kinder und Jugendliche aus dem klinikeigenen Krankengut im Alter zwischen 6 und 15 Jahren . Anhand dieses Patientenguts wurde die Diskrepanz zwischen dem klinischen Erstbefund und der Befunderhebung durch Arthroskopie aufgezeigt . Die Differenz zwischen dem klinischen Erstbefund und der arthroskopisch erhobenen Diagnose lag in der ersten Gruppe bei ca. 45% und in der 2. , spaeter untersuchten Gruppe bei ca. 36% . Sowohl isolierte als auch kombinierte Verletzungen waren erst durch die Arthroskopie erfasst worden . Im Vordergrund standen dabei ligamentaere vordere Kreuzbandrupturen , mediale Seitenbandverletzungen und Meniskuslaesionen . Patellaluxationen mit Retinaculumrupturen sowie mit osteochondralen Fragmenten , die der klinischen Erstuntersuchung entgangen waren , wurden ebenfalls in beiden Gruppen erst durch die Arthroskopie nachgewiesen . Der Haemarthros erwies sich als wichtigster Hinweis auf den Schweregrad der Verletzung . Trotz der neuen , bildgebenden Techniken , wie dem MRI , kommt dem Einsatz der Arthroskopie auch am wachsenden Kniegelenk aufgrund der gleichzeitigen diagnostischen und therapeutischen Moeglichkeiten eine besondere Bedeutung zu . Diese zunehmend etablierte Feststellung soll der Anlass dafuer sein , die Arthroskopie generell in das Management akuter Kniegelenkverletzungen im Wachtumsalter einzubeziehen . Instructions: please typing these entity words according to sentence: Kniegelenkverletzungen, Arthroskopie, Kniegelenk, Diagnose, Arthroskopie, Kniegelenkuntersuchung, Verletzungen, Wachstumsalter, Arthroskopie, Diagnostik, Kindern, Wachstumsfugen, Kinder, Krankengut, Patientenguts, Befunderhebung, Arthroskopie, Diagnose, Verletzungen, Arthroskopie, Kreuzbandrupturen, Seitenbandverletzungen, Patellaluxationen, Arthroskopie, Haemarthros, Verletzung, Techniken, Arthroskopie, wachsenden, Kniegelenk, Arthroskopie, Kniegelenkverletzungen Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Von frischen Kniegelenkverletzungen des Erwachsenen ist bekannt , dass bei der klinischen Erstuntersuchung haeufig nicht alle Befunde erfasst werden . Erst durch die Arthroskopie wird der Nachweis zusaetzlicher uebersehener Befunde , gefuehrt . Auch fuer das verletzte kindliche Kniegelenk ist die geringe Treffsicherheit der klinischen Diagnose bekannt . Trotzdem wurde der Einsatz der Arthroskopie zunaechst nur zoegernd akzeptiert . Dabei wurde schon in den 80er Jahren von verschiedenen Autoren auf die Problematik der klinischen Kniegelenkuntersuchung bei akuten Verletzungen im Wachstumsalter sowie auf die Bedeutung der Arthroskopie zur Optimierung der Diagnostik hingewiesen . An 2 verschiedenen Gruppen von Kindern und Jugendlichen mit noch offenen bzw. noch nicht geschlossenen Wachstumsfugen der Jahre von 1985-1988 und 1987-1996 wurde eine vergleichende Untersuchung durchgefuehrt . Es handelte sich dabei um Kinder und Jugendliche aus dem klinikeigenen Krankengut im Alter zwischen 6 und 15 Jahren . Anhand dieses Patientenguts wurde die Diskrepanz zwischen dem klinischen Erstbefund und der Befunderhebung durch Arthroskopie aufgezeigt . Die Differenz zwischen dem klinischen Erstbefund und der arthroskopisch erhobenen Diagnose lag in der ersten Gruppe bei ca. 45% und in der 2. , spaeter untersuchten Gruppe bei ca. 36% . Sowohl isolierte als auch kombinierte Verletzungen waren erst durch die Arthroskopie erfasst worden . Im Vordergrund standen dabei ligamentaere vordere Kreuzbandrupturen , mediale Seitenbandverletzungen und Meniskuslaesionen . Patellaluxationen mit Retinaculumrupturen sowie mit osteochondralen Fragmenten , die der klinischen Erstuntersuchung entgangen waren , wurden ebenfalls in beiden Gruppen erst durch die Arthroskopie nachgewiesen . Der Haemarthros erwies sich als wichtigster Hinweis auf den Schweregrad der Verletzung . Trotz der neuen , bildgebenden Techniken , wie dem MRI , kommt dem Einsatz der Arthroskopie auch am wachsenden Kniegelenk aufgrund der gleichzeitigen diagnostischen und therapeutischen Moeglichkeiten eine besondere Bedeutung zu . Diese zunehmend etablierte Feststellung soll der Anlass dafuer sein , die Arthroskopie generell in das Management akuter Kniegelenkverletzungen im Wachtumsalter einzubeziehen .

[ "Von", "frischen", "Kniegelenkverletzungen", "des", "Erwachsenen", "ist", "bekannt", ",", "dass", "bei", "der", "klinischen", "Erstuntersuchung", "haeufig", "nicht", "alle", "Befunde", "erfasst", "werden", ".", "Erst", "durch", "die", "Arthroskopie", "wird", "der", "Nachweis", "zusaetzlicher", "uebersehener", "Befunde", ",", "gefuehrt", ".", "Auch", "fuer", "das", "verletzte", "kindliche", "Kniegelenk", "ist", "die", "geringe", "Treffsicherheit", "der", "klinischen", "Diagnose", "bekannt", ".", "Trotzdem", "wurde", "der", "Einsatz", "der", "Arthroskopie", "zunaechst", "nur", "zoegernd", "akzeptiert", ".", "Dabei", "wurde", "schon", "in", "den", "80er", "Jahren", "von", "verschiedenen", "Autoren", "auf", "die", "Problematik", "der", "klinischen", "Kniegelenkuntersuchung", "bei", "akuten", "Verletzungen", "im", "Wachstumsalter", "sowie", "auf", "die", "Bedeutung", "der", "Arthroskopie", "zur", "Optimierung", "der", "Diagnostik", "hingewiesen", ".", "An", "2", "verschiedenen", "Gruppen", "von", "Kindern", "und", "Jugendlichen", "mit", "noch", "offenen", "bzw", ".", "noch", "nicht", "geschlossenen", "Wachstumsfugen", "der", "Jahre", "von", "1985", "-", "1988", "und", "1987", "-", "1996", "wurde", "eine", "vergleichende", "Untersuchung", "durchgefuehrt", ".", "Es", "handelte", "sich", "dabei", "um", "Kinder", "und", "Jugendliche", "aus", "dem", "klinikeigenen", "Krankengut", "im", "Alter", "zwischen", "6", "und", "15", "Jahren", ".", "Anhand", "dieses", "Patientenguts", "wurde", "die", "Diskrepanz", "zwischen", "dem", "klinischen", "Erstbefund", "und", "der", "Befunderhebung", "durch", "Arthroskopie", "aufgezeigt", ".", "Die", "Differenz", "zwischen", "dem", "klinischen", "Erstbefund", "und", "der", "arthroskopisch", "erhobenen", "Diagnose", "lag", "in", "der", "ersten", "Gruppe", "bei", "ca", ".", "45", "%", "und", "in", "der", "2", ".", ",", "spaeter", "untersuchten", "Gruppe", "bei", "ca", ".", "36", "%", ".", "Sowohl", "isolierte", "als", "auch", "kombinierte", "Verletzungen", "waren", "erst", "durch", "die", "Arthroskopie", "erfasst", "worden", ".", "Im", "Vordergrund", "standen", "dabei", "ligamentaere", "vordere", "Kreuzbandrupturen", ",", "mediale", "Seitenbandverletzungen", "und", "Meniskuslaesionen", ".", "Patellaluxationen", "mit", "Retinaculumrupturen", "sowie", "mit", "osteochondralen", "Fragmenten", ",", "die", "der", "klinischen", "Erstuntersuchung", "entgangen", "waren", ",", "wurden", "ebenfalls", "in", "beiden", "Gruppen", "erst", "durch", "die", "Arthroskopie", "nachgewiesen", ".", "Der", "Haemarthros", "erwies", "sich", "als", "wichtigster", "Hinweis", "auf", "den", "Schweregrad", "der", "Verletzung", ".", "Trotz", "der", "neuen", ",", "bildgebenden", "Techniken", ",", "wie", "dem", "MRI", ",", "kommt", "dem", "Einsatz", "der", "Arthroskopie", "auch", "am", "wachsenden", "Kniegelenk", "aufgrund", "der", "gleichzeitigen", "diagnostischen", "und", "therapeutischen", "Moeglichkeiten", "eine", "besondere", "Bedeutung", "zu", ".", "Diese", "zunehmend", "etablierte", "Feststellung", "soll", "der", "Anlass", "dafuer", "sein", ",", "die", "Arthroskopie", "generell", "in", "das", "Management", "akuter", "Kniegelenkverletzungen", "im", "Wachtumsalter", "einzubeziehen", "." ]

[ "umlsterm" ]

Kniegelenkverletzungen, Arthroskopie, Kniegelenk, Diagnose, Arthroskopie, Kniegelenkuntersuchung, Verletzungen, Wachstumsalter, Arthroskopie, Diagnostik, Kindern, Wachstumsfugen, Kinder, Krankengut, Patientenguts, Befunderhebung, Arthroskopie, Diagnose, Verletzungen, Arthroskopie, Kreuzbandrupturen, Seitenbandverletzungen, Patellaluxationen, Arthroskopie, Haemarthros, Verletzung, Techniken, Arthroskopie, wachsenden, Kniegelenk, Arthroskopie, Kniegelenkverletzungen

Arthroskopie.80110011.ger.abstr_task2

Sentence: Von frischen Kniegelenkverletzungen des Erwachsenen ist bekannt , dass bei der klinischen Erstuntersuchung haeufig nicht alle Befunde erfasst werden . Erst durch die Arthroskopie wird der Nachweis zusaetzlicher uebersehener Befunde , gefuehrt . Auch fuer das verletzte kindliche Kniegelenk ist die geringe Treffsicherheit der klinischen Diagnose bekannt . Trotzdem wurde der Einsatz der Arthroskopie zunaechst nur zoegernd akzeptiert . Dabei wurde schon in den 80er Jahren von verschiedenen Autoren auf die Problematik der klinischen Kniegelenkuntersuchung bei akuten Verletzungen im Wachstumsalter sowie auf die Bedeutung der Arthroskopie zur Optimierung der Diagnostik hingewiesen . An 2 verschiedenen Gruppen von Kindern und Jugendlichen mit noch offenen bzw. noch nicht geschlossenen Wachstumsfugen der Jahre von 1985-1988 und 1987-1996 wurde eine vergleichende Untersuchung durchgefuehrt . Es handelte sich dabei um Kinder und Jugendliche aus dem klinikeigenen Krankengut im Alter zwischen 6 und 15 Jahren . Anhand dieses Patientenguts wurde die Diskrepanz zwischen dem klinischen Erstbefund und der Befunderhebung durch Arthroskopie aufgezeigt . Die Differenz zwischen dem klinischen Erstbefund und der arthroskopisch erhobenen Diagnose lag in der ersten Gruppe bei ca. 45% und in der 2. , spaeter untersuchten Gruppe bei ca. 36% . Sowohl isolierte als auch kombinierte Verletzungen waren erst durch die Arthroskopie erfasst worden . Im Vordergrund standen dabei ligamentaere vordere Kreuzbandrupturen , mediale Seitenbandverletzungen und Meniskuslaesionen . Patellaluxationen mit Retinaculumrupturen sowie mit osteochondralen Fragmenten , die der klinischen Erstuntersuchung entgangen waren , wurden ebenfalls in beiden Gruppen erst durch die Arthroskopie nachgewiesen . Der Haemarthros erwies sich als wichtigster Hinweis auf den Schweregrad der Verletzung . Trotz der neuen , bildgebenden Techniken , wie dem MRI , kommt dem Einsatz der Arthroskopie auch am wachsenden Kniegelenk aufgrund der gleichzeitigen diagnostischen und therapeutischen Moeglichkeiten eine besondere Bedeutung zu . Diese zunehmend etablierte Feststellung soll der Anlass dafuer sein , die Arthroskopie generell in das Management akuter Kniegelenkverletzungen im Wachtumsalter einzubeziehen . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Von frischen Kniegelenkverletzungen des Erwachsenen ist bekannt , dass bei der klinischen Erstuntersuchung haeufig nicht alle Befunde erfasst werden . Erst durch die Arthroskopie wird der Nachweis zusaetzlicher uebersehener Befunde , gefuehrt . Auch fuer das verletzte kindliche Kniegelenk ist die geringe Treffsicherheit der klinischen Diagnose bekannt . Trotzdem wurde der Einsatz der Arthroskopie zunaechst nur zoegernd akzeptiert . Dabei wurde schon in den 80er Jahren von verschiedenen Autoren auf die Problematik der klinischen Kniegelenkuntersuchung bei akuten Verletzungen im Wachstumsalter sowie auf die Bedeutung der Arthroskopie zur Optimierung der Diagnostik hingewiesen . An 2 verschiedenen Gruppen von Kindern und Jugendlichen mit noch offenen bzw. noch nicht geschlossenen Wachstumsfugen der Jahre von 1985-1988 und 1987-1996 wurde eine vergleichende Untersuchung durchgefuehrt . Es handelte sich dabei um Kinder und Jugendliche aus dem klinikeigenen Krankengut im Alter zwischen 6 und 15 Jahren . Anhand dieses Patientenguts wurde die Diskrepanz zwischen dem klinischen Erstbefund und der Befunderhebung durch Arthroskopie aufgezeigt . Die Differenz zwischen dem klinischen Erstbefund und der arthroskopisch erhobenen Diagnose lag in der ersten Gruppe bei ca. 45% und in der 2. , spaeter untersuchten Gruppe bei ca. 36% . Sowohl isolierte als auch kombinierte Verletzungen waren erst durch die Arthroskopie erfasst worden . Im Vordergrund standen dabei ligamentaere vordere Kreuzbandrupturen , mediale Seitenbandverletzungen und Meniskuslaesionen . Patellaluxationen mit Retinaculumrupturen sowie mit osteochondralen Fragmenten , die der klinischen Erstuntersuchung entgangen waren , wurden ebenfalls in beiden Gruppen erst durch die Arthroskopie nachgewiesen . Der Haemarthros erwies sich als wichtigster Hinweis auf den Schweregrad der Verletzung . Trotz der neuen , bildgebenden Techniken , wie dem MRI , kommt dem Einsatz der Arthroskopie auch am wachsenden Kniegelenk aufgrund der gleichzeitigen diagnostischen und therapeutischen Moeglichkeiten eine besondere Bedeutung zu . Diese zunehmend etablierte Feststellung soll der Anlass dafuer sein , die Arthroskopie generell in das Management akuter Kniegelenkverletzungen im Wachtumsalter einzubeziehen .

[ "Von", "frischen", "Kniegelenkverletzungen", "des", "Erwachsenen", "ist", "bekannt", ",", "dass", "bei", "der", "klinischen", "Erstuntersuchung", "haeufig", "nicht", "alle", "Befunde", "erfasst", "werden", ".", "Erst", "durch", "die", "Arthroskopie", "wird", "der", "Nachweis", "zusaetzlicher", "uebersehener", "Befunde", ",", "gefuehrt", ".", "Auch", "fuer", "das", "verletzte", "kindliche", "Kniegelenk", "ist", "die", "geringe", "Treffsicherheit", "der", "klinischen", "Diagnose", "bekannt", ".", "Trotzdem", "wurde", "der", "Einsatz", "der", "Arthroskopie", "zunaechst", "nur", "zoegernd", "akzeptiert", ".", "Dabei", "wurde", "schon", "in", "den", "80er", "Jahren", "von", "verschiedenen", "Autoren", "auf", "die", "Problematik", "der", "klinischen", "Kniegelenkuntersuchung", "bei", "akuten", "Verletzungen", "im", "Wachstumsalter", "sowie", "auf", "die", "Bedeutung", "der", "Arthroskopie", "zur", "Optimierung", "der", "Diagnostik", "hingewiesen", ".", "An", "2", "verschiedenen", "Gruppen", "von", "Kindern", "und", "Jugendlichen", "mit", "noch", "offenen", "bzw", ".", "noch", "nicht", "geschlossenen", "Wachstumsfugen", "der", "Jahre", "von", "1985", "-", "1988", "und", "1987", "-", "1996", "wurde", "eine", "vergleichende", "Untersuchung", "durchgefuehrt", ".", "Es", "handelte", "sich", "dabei", "um", "Kinder", "und", "Jugendliche", "aus", "dem", "klinikeigenen", "Krankengut", "im", "Alter", "zwischen", "6", "und", "15", "Jahren", ".", "Anhand", "dieses", "Patientenguts", "wurde", "die", "Diskrepanz", "zwischen", "dem", "klinischen", "Erstbefund", "und", "der", "Befunderhebung", "durch", "Arthroskopie", "aufgezeigt", ".", "Die", "Differenz", "zwischen", "dem", "klinischen", "Erstbefund", "und", "der", "arthroskopisch", "erhobenen", "Diagnose", "lag", "in", "der", "ersten", "Gruppe", "bei", "ca", ".", "45", "%", "und", "in", "der", "2", ".", ",", "spaeter", "untersuchten", "Gruppe", "bei", "ca", ".", "36", "%", ".", "Sowohl", "isolierte", "als", "auch", "kombinierte", "Verletzungen", "waren", "erst", "durch", "die", "Arthroskopie", "erfasst", "worden", ".", "Im", "Vordergrund", "standen", "dabei", "ligamentaere", "vordere", "Kreuzbandrupturen", ",", "mediale", "Seitenbandverletzungen", "und", "Meniskuslaesionen", ".", "Patellaluxationen", "mit", "Retinaculumrupturen", "sowie", "mit", "osteochondralen", "Fragmenten", ",", "die", "der", "klinischen", "Erstuntersuchung", "entgangen", "waren", ",", "wurden", "ebenfalls", "in", "beiden", "Gruppen", "erst", "durch", "die", "Arthroskopie", "nachgewiesen", ".", "Der", "Haemarthros", "erwies", "sich", "als", "wichtigster", "Hinweis", "auf", "den", "Schweregrad", "der", "Verletzung", ".", "Trotz", "der", "neuen", ",", "bildgebenden", "Techniken", ",", "wie", "dem", "MRI", ",", "kommt", "dem", "Einsatz", "der", "Arthroskopie", "auch", "am", "wachsenden", "Kniegelenk", "aufgrund", "der", "gleichzeitigen", "diagnostischen", "und", "therapeutischen", "Moeglichkeiten", "eine", "besondere", "Bedeutung", "zu", ".", "Diese", "zunehmend", "etablierte", "Feststellung", "soll", "der", "Anlass", "dafuer", "sein", ",", "die", "Arthroskopie", "generell", "in", "das", "Management", "akuter", "Kniegelenkverletzungen", "im", "Wachtumsalter", "einzubeziehen", "." ]

[ "umlsterm" ]

Heimdiagnostik is an umlsterm, schlafbezogener is an umlsterm, Atmungsstoerungen is an umlsterm, Zeit is an umlsterm, Geraete is an umlsterm, Geraet is an umlsterm, Geraets is an umlsterm, Arzt is an umlsterm, Patient is an umlsterm, Belastbarkeit is an umlsterm, Geraets is an umlsterm, Software is an umlsterm, Handauswertung is an umlsterm, Patienten is an umlsterm, Geschlechts is an umlsterm, obstruktiven Schlafapnoe is an umlsterm, Patienten is an umlsterm, Aerzten is an umlsterm, Patienten is an umlsterm, selbst is an umlsterm, Patienten is an umlsterm, Handauswertung is an umlsterm, Geraets is an umlsterm, Patienten is an umlsterm, Handauswertung is an umlsterm, Geraet is an umlsterm, Patienten is an umlsterm, selbst is an umlsterm, Polysomnographie is an umlsterm

HNO.90470249.ger.abstr_task0

Sentence: In der ambulanten Heimdiagnostik schlafbezogener Atmungsstoerungen kommen seit einiger Zeit 7kanalige Geraete zum Einsatz . Ein solches Geraet ist das POLY-MESAM ( Fa. MAP ) . Der vorliegende 1. Teil der Studie hat die Handhabung des Geraets fuer Arzt und Patient , die technische Belastbarkeit des Geraets und die Zuverlaessigkeit der automatischen Auswertung durch die zugehoerige Software vs. Handauswertung prospektiv untersucht . 104 Patienten beiderlei Geschlechts und mit unterschiedlichem Schweregrad einer obstruktiven Schlafapnoe wurden untersucht . Die ersten 51 Patienten wurden am Abend in der Klinik von 2 Aerzten an das POLY-MESAM-Geraet angeschlossen und ueber seine Funktionen unterrichtet . Die 2. Serie von 53 Patienten bekam am Nachmittag lediglich eine Einweisung in das POLY-MESAM-Geraet und hat den Anschluss zu Hause selbst vollzogen . Das Befinden der Patienten wurde mittels einer visuellen Analogskala festgehalten . Die automatische Auswertung wurde mit einer Handauswertung verglichen . Die Studie hat insgesamt knapp 6% unbrauchbare Ergebnisse erbracht . Die Akzeptanz des Geraets durch die Patienten ist mit bis zu 94,3% ausgesprochen hoch . Bezueglich des Apnoe-Hypopnoe-Indexes ( AHI ) ist die Korrelation zwischen automatischer ( AHI=11,1) und Handauswertung ( AHI=11,3) sehr gut . Das Geraet laesst sich aufgrund seiner soliden Bauart und Bedienungsfreundlichkeit sehr gut als ambulante Screeningmethode fuer obstruktive Schlafatmungsstoerungen durch den Patienten selbst einsetzen . Validierungsuntersuchungen mittels simultaner Polysomnographie sind Gegenstand des 2. Teils der Studie . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In der ambulanten Heimdiagnostik schlafbezogener Atmungsstoerungen kommen seit einiger Zeit 7kanalige Geraete zum Einsatz . Ein solches Geraet ist das POLY-MESAM ( Fa. MAP ) . Der vorliegende 1. Teil der Studie hat die Handhabung des Geraets fuer Arzt und Patient , die technische Belastbarkeit des Geraets und die Zuverlaessigkeit der automatischen Auswertung durch die zugehoerige Software vs. Handauswertung prospektiv untersucht . 104 Patienten beiderlei Geschlechts und mit unterschiedlichem Schweregrad einer obstruktiven Schlafapnoe wurden untersucht . Die ersten 51 Patienten wurden am Abend in der Klinik von 2 Aerzten an das POLY-MESAM-Geraet angeschlossen und ueber seine Funktionen unterrichtet . Die 2. Serie von 53 Patienten bekam am Nachmittag lediglich eine Einweisung in das POLY-MESAM-Geraet und hat den Anschluss zu Hause selbst vollzogen . Das Befinden der Patienten wurde mittels einer visuellen Analogskala festgehalten . Die automatische Auswertung wurde mit einer Handauswertung verglichen . Die Studie hat insgesamt knapp 6% unbrauchbare Ergebnisse erbracht . Die Akzeptanz des Geraets durch die Patienten ist mit bis zu 94,3% ausgesprochen hoch . Bezueglich des Apnoe-Hypopnoe-Indexes ( AHI ) ist die Korrelation zwischen automatischer ( AHI=11,1) und Handauswertung ( AHI=11,3) sehr gut . Das Geraet laesst sich aufgrund seiner soliden Bauart und Bedienungsfreundlichkeit sehr gut als ambulante Screeningmethode fuer obstruktive Schlafatmungsstoerungen durch den Patienten selbst einsetzen . Validierungsuntersuchungen mittels simultaner Polysomnographie sind Gegenstand des 2. Teils der Studie .

[ "In", "der", "ambulanten", "Heimdiagnostik", "schlafbezogener", "Atmungsstoerungen", "kommen", "seit", "einiger", "Zeit", "7kanalige", "Geraete", "zum", "Einsatz", ".", "Ein", "solches", "Geraet", "ist", "das", "POLY", "-", "MESAM", "(", "Fa", ".", "MAP", ")", ".", "Der", "vorliegende", "1", ".", "Teil", "der", "Studie", "hat", "die", "Handhabung", "des", "Geraets", "fuer", "Arzt", "und", "Patient", ",", "die", "technische", "Belastbarkeit", "des", "Geraets", "und", "die", "Zuverlaessigkeit", "der", "automatischen", "Auswertung", "durch", "die", "zugehoerige", "Software", "vs", ".", "Handauswertung", "prospektiv", "untersucht", ".", "104", "Patienten", "beiderlei", "Geschlechts", "und", "mit", "unterschiedlichem", "Schweregrad", "einer", "obstruktiven", "Schlafapnoe", "wurden", "untersucht", ".", "Die", "ersten", "51", "Patienten", "wurden", "am", "Abend", "in", "der", "Klinik", "von", "2", "Aerzten", "an", "das", "POLY", "-", "MESAM", "-", "Geraet", "angeschlossen", "und", "ueber", "seine", "Funktionen", "unterrichtet", ".", "Die", "2", ".", "Serie", "von", "53", "Patienten", "bekam", "am", "Nachmittag", "lediglich", "eine", "Einweisung", "in", "das", "POLY", "-", "MESAM", "-", "Geraet", "und", "hat", "den", "Anschluss", "zu", "Hause", "selbst", "vollzogen", ".", "Das", "Befinden", "der", "Patienten", "wurde", "mittels", "einer", "visuellen", "Analogskala", "festgehalten", ".", "Die", "automatische", "Auswertung", "wurde", "mit", "einer", "Handauswertung", "verglichen", ".", "Die", "Studie", "hat", "insgesamt", "knapp", "6", "%", "unbrauchbare", "Ergebnisse", "erbracht", ".", "Die", "Akzeptanz", "des", "Geraets", "durch", "die", "Patienten", "ist", "mit", "bis", "zu", "94,3", "%", "ausgesprochen", "hoch", ".", "Bezueglich", "des", "Apnoe", "-", "Hypopnoe", "-", "Indexes", "(", "AHI", ")", "ist", "die", "Korrelation", "zwischen", "automatischer", "(", "AHI=11,1", ")", "und", "Handauswertung", "(", "AHI=11,3", ")", "sehr", "gut", ".", "Das", "Geraet", "laesst", "sich", "aufgrund", "seiner", "soliden", "Bauart", "und", "Bedienungsfreundlichkeit", "sehr", "gut", "als", "ambulante", "Screeningmethode", "fuer", "obstruktive", "Schlafatmungsstoerungen", "durch", "den", "Patienten", "selbst", "einsetzen", ".", "Validierungsuntersuchungen", "mittels", "simultaner", "Polysomnographie", "sind", "Gegenstand", "des", "2", ".", "Teils", "der", "Studie", "." ]

[ "umlsterm" ]

Heimdiagnostik is an umlsterm, schlafbezogener is an umlsterm, Atmungsstoerungen is an umlsterm, Zeit is an umlsterm, Geraete is an umlsterm, Geraet is an umlsterm, Geraets is an umlsterm, Arzt is an umlsterm, Patient is an umlsterm, Belastbarkeit is an umlsterm, Geraets is an umlsterm, Software is an umlsterm, Handauswertung is an umlsterm, Patienten is an umlsterm, Geschlechts is an umlsterm, obstruktiven Schlafapnoe is an umlsterm, Patienten is an umlsterm, Aerzten is an umlsterm, Patienten is an umlsterm, selbst is an umlsterm, Patienten is an umlsterm, Handauswertung is an umlsterm, Geraets is an umlsterm, Patienten is an umlsterm, Handauswertung is an umlsterm, Geraet is an umlsterm, Patienten is an umlsterm, selbst is an umlsterm, Polysomnographie is an umlsterm

HNO.90470249.ger.abstr_task1

Sentence: In der ambulanten Heimdiagnostik schlafbezogener Atmungsstoerungen kommen seit einiger Zeit 7kanalige Geraete zum Einsatz . Ein solches Geraet ist das POLY-MESAM ( Fa. MAP ) . Der vorliegende 1. Teil der Studie hat die Handhabung des Geraets fuer Arzt und Patient , die technische Belastbarkeit des Geraets und die Zuverlaessigkeit der automatischen Auswertung durch die zugehoerige Software vs. Handauswertung prospektiv untersucht . 104 Patienten beiderlei Geschlechts und mit unterschiedlichem Schweregrad einer obstruktiven Schlafapnoe wurden untersucht . Die ersten 51 Patienten wurden am Abend in der Klinik von 2 Aerzten an das POLY-MESAM-Geraet angeschlossen und ueber seine Funktionen unterrichtet . Die 2. Serie von 53 Patienten bekam am Nachmittag lediglich eine Einweisung in das POLY-MESAM-Geraet und hat den Anschluss zu Hause selbst vollzogen . Das Befinden der Patienten wurde mittels einer visuellen Analogskala festgehalten . Die automatische Auswertung wurde mit einer Handauswertung verglichen . Die Studie hat insgesamt knapp 6% unbrauchbare Ergebnisse erbracht . Die Akzeptanz des Geraets durch die Patienten ist mit bis zu 94,3% ausgesprochen hoch . Bezueglich des Apnoe-Hypopnoe-Indexes ( AHI ) ist die Korrelation zwischen automatischer ( AHI=11,1) und Handauswertung ( AHI=11,3) sehr gut . Das Geraet laesst sich aufgrund seiner soliden Bauart und Bedienungsfreundlichkeit sehr gut als ambulante Screeningmethode fuer obstruktive Schlafatmungsstoerungen durch den Patienten selbst einsetzen . Validierungsuntersuchungen mittels simultaner Polysomnographie sind Gegenstand des 2. Teils der Studie . Instructions: please typing these entity words according to sentence: Heimdiagnostik, schlafbezogener, Atmungsstoerungen, Zeit, Geraete, Geraet, Geraets, Arzt, Patient, Belastbarkeit, Geraets, Software, Handauswertung, Patienten, Geschlechts, obstruktiven Schlafapnoe, Patienten, Aerzten, Patienten, selbst, Patienten, Handauswertung, Geraets, Patienten, Handauswertung, Geraet, Patienten, selbst, Polysomnographie Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In der ambulanten Heimdiagnostik schlafbezogener Atmungsstoerungen kommen seit einiger Zeit 7kanalige Geraete zum Einsatz . Ein solches Geraet ist das POLY-MESAM ( Fa. MAP ) . Der vorliegende 1. Teil der Studie hat die Handhabung des Geraets fuer Arzt und Patient , die technische Belastbarkeit des Geraets und die Zuverlaessigkeit der automatischen Auswertung durch die zugehoerige Software vs. Handauswertung prospektiv untersucht . 104 Patienten beiderlei Geschlechts und mit unterschiedlichem Schweregrad einer obstruktiven Schlafapnoe wurden untersucht . Die ersten 51 Patienten wurden am Abend in der Klinik von 2 Aerzten an das POLY-MESAM-Geraet angeschlossen und ueber seine Funktionen unterrichtet . Die 2. Serie von 53 Patienten bekam am Nachmittag lediglich eine Einweisung in das POLY-MESAM-Geraet und hat den Anschluss zu Hause selbst vollzogen . Das Befinden der Patienten wurde mittels einer visuellen Analogskala festgehalten . Die automatische Auswertung wurde mit einer Handauswertung verglichen . Die Studie hat insgesamt knapp 6% unbrauchbare Ergebnisse erbracht . Die Akzeptanz des Geraets durch die Patienten ist mit bis zu 94,3% ausgesprochen hoch . Bezueglich des Apnoe-Hypopnoe-Indexes ( AHI ) ist die Korrelation zwischen automatischer ( AHI=11,1) und Handauswertung ( AHI=11,3) sehr gut . Das Geraet laesst sich aufgrund seiner soliden Bauart und Bedienungsfreundlichkeit sehr gut als ambulante Screeningmethode fuer obstruktive Schlafatmungsstoerungen durch den Patienten selbst einsetzen . Validierungsuntersuchungen mittels simultaner Polysomnographie sind Gegenstand des 2. Teils der Studie .

[ "In", "der", "ambulanten", "Heimdiagnostik", "schlafbezogener", "Atmungsstoerungen", "kommen", "seit", "einiger", "Zeit", "7kanalige", "Geraete", "zum", "Einsatz", ".", "Ein", "solches", "Geraet", "ist", "das", "POLY", "-", "MESAM", "(", "Fa", ".", "MAP", ")", ".", "Der", "vorliegende", "1", ".", "Teil", "der", "Studie", "hat", "die", "Handhabung", "des", "Geraets", "fuer", "Arzt", "und", "Patient", ",", "die", "technische", "Belastbarkeit", "des", "Geraets", "und", "die", "Zuverlaessigkeit", "der", "automatischen", "Auswertung", "durch", "die", "zugehoerige", "Software", "vs", ".", "Handauswertung", "prospektiv", "untersucht", ".", "104", "Patienten", "beiderlei", "Geschlechts", "und", "mit", "unterschiedlichem", "Schweregrad", "einer", "obstruktiven", "Schlafapnoe", "wurden", "untersucht", ".", "Die", "ersten", "51", "Patienten", "wurden", "am", "Abend", "in", "der", "Klinik", "von", "2", "Aerzten", "an", "das", "POLY", "-", "MESAM", "-", "Geraet", "angeschlossen", "und", "ueber", "seine", "Funktionen", "unterrichtet", ".", "Die", "2", ".", "Serie", "von", "53", "Patienten", "bekam", "am", "Nachmittag", "lediglich", "eine", "Einweisung", "in", "das", "POLY", "-", "MESAM", "-", "Geraet", "und", "hat", "den", "Anschluss", "zu", "Hause", "selbst", "vollzogen", ".", "Das", "Befinden", "der", "Patienten", "wurde", "mittels", "einer", "visuellen", "Analogskala", "festgehalten", ".", "Die", "automatische", "Auswertung", "wurde", "mit", "einer", "Handauswertung", "verglichen", ".", "Die", "Studie", "hat", "insgesamt", "knapp", "6", "%", "unbrauchbare", "Ergebnisse", "erbracht", ".", "Die", "Akzeptanz", "des", "Geraets", "durch", "die", "Patienten", "ist", "mit", "bis", "zu", "94,3", "%", "ausgesprochen", "hoch", ".", "Bezueglich", "des", "Apnoe", "-", "Hypopnoe", "-", "Indexes", "(", "AHI", ")", "ist", "die", "Korrelation", "zwischen", "automatischer", "(", "AHI=11,1", ")", "und", "Handauswertung", "(", "AHI=11,3", ")", "sehr", "gut", ".", "Das", "Geraet", "laesst", "sich", "aufgrund", "seiner", "soliden", "Bauart", "und", "Bedienungsfreundlichkeit", "sehr", "gut", "als", "ambulante", "Screeningmethode", "fuer", "obstruktive", "Schlafatmungsstoerungen", "durch", "den", "Patienten", "selbst", "einsetzen", ".", "Validierungsuntersuchungen", "mittels", "simultaner", "Polysomnographie", "sind", "Gegenstand", "des", "2", ".", "Teils", "der", "Studie", "." ]

[ "umlsterm" ]

Heimdiagnostik, schlafbezogener, Atmungsstoerungen, Zeit, Geraete, Geraet, Geraets, Arzt, Patient, Belastbarkeit, Geraets, Software, Handauswertung, Patienten, Geschlechts, obstruktiven Schlafapnoe, Patienten, Aerzten, Patienten, selbst, Patienten, Handauswertung, Geraets, Patienten, Handauswertung, Geraet, Patienten, selbst, Polysomnographie

HNO.90470249.ger.abstr_task2

Sentence: In der ambulanten Heimdiagnostik schlafbezogener Atmungsstoerungen kommen seit einiger Zeit 7kanalige Geraete zum Einsatz . Ein solches Geraet ist das POLY-MESAM ( Fa. MAP ) . Der vorliegende 1. Teil der Studie hat die Handhabung des Geraets fuer Arzt und Patient , die technische Belastbarkeit des Geraets und die Zuverlaessigkeit der automatischen Auswertung durch die zugehoerige Software vs. Handauswertung prospektiv untersucht . 104 Patienten beiderlei Geschlechts und mit unterschiedlichem Schweregrad einer obstruktiven Schlafapnoe wurden untersucht . Die ersten 51 Patienten wurden am Abend in der Klinik von 2 Aerzten an das POLY-MESAM-Geraet angeschlossen und ueber seine Funktionen unterrichtet . Die 2. Serie von 53 Patienten bekam am Nachmittag lediglich eine Einweisung in das POLY-MESAM-Geraet und hat den Anschluss zu Hause selbst vollzogen . Das Befinden der Patienten wurde mittels einer visuellen Analogskala festgehalten . Die automatische Auswertung wurde mit einer Handauswertung verglichen . Die Studie hat insgesamt knapp 6% unbrauchbare Ergebnisse erbracht . Die Akzeptanz des Geraets durch die Patienten ist mit bis zu 94,3% ausgesprochen hoch . Bezueglich des Apnoe-Hypopnoe-Indexes ( AHI ) ist die Korrelation zwischen automatischer ( AHI=11,1) und Handauswertung ( AHI=11,3) sehr gut . Das Geraet laesst sich aufgrund seiner soliden Bauart und Bedienungsfreundlichkeit sehr gut als ambulante Screeningmethode fuer obstruktive Schlafatmungsstoerungen durch den Patienten selbst einsetzen . Validierungsuntersuchungen mittels simultaner Polysomnographie sind Gegenstand des 2. Teils der Studie . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In der ambulanten Heimdiagnostik schlafbezogener Atmungsstoerungen kommen seit einiger Zeit 7kanalige Geraete zum Einsatz . Ein solches Geraet ist das POLY-MESAM ( Fa. MAP ) . Der vorliegende 1. Teil der Studie hat die Handhabung des Geraets fuer Arzt und Patient , die technische Belastbarkeit des Geraets und die Zuverlaessigkeit der automatischen Auswertung durch die zugehoerige Software vs. Handauswertung prospektiv untersucht . 104 Patienten beiderlei Geschlechts und mit unterschiedlichem Schweregrad einer obstruktiven Schlafapnoe wurden untersucht . Die ersten 51 Patienten wurden am Abend in der Klinik von 2 Aerzten an das POLY-MESAM-Geraet angeschlossen und ueber seine Funktionen unterrichtet . Die 2. Serie von 53 Patienten bekam am Nachmittag lediglich eine Einweisung in das POLY-MESAM-Geraet und hat den Anschluss zu Hause selbst vollzogen . Das Befinden der Patienten wurde mittels einer visuellen Analogskala festgehalten . Die automatische Auswertung wurde mit einer Handauswertung verglichen . Die Studie hat insgesamt knapp 6% unbrauchbare Ergebnisse erbracht . Die Akzeptanz des Geraets durch die Patienten ist mit bis zu 94,3% ausgesprochen hoch . Bezueglich des Apnoe-Hypopnoe-Indexes ( AHI ) ist die Korrelation zwischen automatischer ( AHI=11,1) und Handauswertung ( AHI=11,3) sehr gut . Das Geraet laesst sich aufgrund seiner soliden Bauart und Bedienungsfreundlichkeit sehr gut als ambulante Screeningmethode fuer obstruktive Schlafatmungsstoerungen durch den Patienten selbst einsetzen . Validierungsuntersuchungen mittels simultaner Polysomnographie sind Gegenstand des 2. Teils der Studie .

[ "In", "der", "ambulanten", "Heimdiagnostik", "schlafbezogener", "Atmungsstoerungen", "kommen", "seit", "einiger", "Zeit", "7kanalige", "Geraete", "zum", "Einsatz", ".", "Ein", "solches", "Geraet", "ist", "das", "POLY", "-", "MESAM", "(", "Fa", ".", "MAP", ")", ".", "Der", "vorliegende", "1", ".", "Teil", "der", "Studie", "hat", "die", "Handhabung", "des", "Geraets", "fuer", "Arzt", "und", "Patient", ",", "die", "technische", "Belastbarkeit", "des", "Geraets", "und", "die", "Zuverlaessigkeit", "der", "automatischen", "Auswertung", "durch", "die", "zugehoerige", "Software", "vs", ".", "Handauswertung", "prospektiv", "untersucht", ".", "104", "Patienten", "beiderlei", "Geschlechts", "und", "mit", "unterschiedlichem", "Schweregrad", "einer", "obstruktiven", "Schlafapnoe", "wurden", "untersucht", ".", "Die", "ersten", "51", "Patienten", "wurden", "am", "Abend", "in", "der", "Klinik", "von", "2", "Aerzten", "an", "das", "POLY", "-", "MESAM", "-", "Geraet", "angeschlossen", "und", "ueber", "seine", "Funktionen", "unterrichtet", ".", "Die", "2", ".", "Serie", "von", "53", "Patienten", "bekam", "am", "Nachmittag", "lediglich", "eine", "Einweisung", "in", "das", "POLY", "-", "MESAM", "-", "Geraet", "und", "hat", "den", "Anschluss", "zu", "Hause", "selbst", "vollzogen", ".", "Das", "Befinden", "der", "Patienten", "wurde", "mittels", "einer", "visuellen", "Analogskala", "festgehalten", ".", "Die", "automatische", "Auswertung", "wurde", "mit", "einer", "Handauswertung", "verglichen", ".", "Die", "Studie", "hat", "insgesamt", "knapp", "6", "%", "unbrauchbare", "Ergebnisse", "erbracht", ".", "Die", "Akzeptanz", "des", "Geraets", "durch", "die", "Patienten", "ist", "mit", "bis", "zu", "94,3", "%", "ausgesprochen", "hoch", ".", "Bezueglich", "des", "Apnoe", "-", "Hypopnoe", "-", "Indexes", "(", "AHI", ")", "ist", "die", "Korrelation", "zwischen", "automatischer", "(", "AHI=11,1", ")", "und", "Handauswertung", "(", "AHI=11,3", ")", "sehr", "gut", ".", "Das", "Geraet", "laesst", "sich", "aufgrund", "seiner", "soliden", "Bauart", "und", "Bedienungsfreundlichkeit", "sehr", "gut", "als", "ambulante", "Screeningmethode", "fuer", "obstruktive", "Schlafatmungsstoerungen", "durch", "den", "Patienten", "selbst", "einsetzen", ".", "Validierungsuntersuchungen", "mittels", "simultaner", "Polysomnographie", "sind", "Gegenstand", "des", "2", ".", "Teils", "der", "Studie", "." ]

[ "umlsterm" ]

Antonio is a NOMBRE_SUJETO_ASISTENCIA, Pagudo Henao is a NOMBRE_SUJETO_ASISTENCIA, 987345 is a ID_SUJETO_ASISTENCIA, Cundinamarca , Cra . 15a # 26 is a CALLE, Bogotá is a TERRITORIO, 15/06/1979 is a FECHAS, Colombia is a PAIS, 38 años is a EDAD_SUJETO_ASISTENCIA, 03/05/2018 is a FECHAS, Ricardo Galán Suárez is a NOMBRE_PERSONAL_SANITARIO, Varón is a SEXO_SUJETO_ASISTENCIA, 38 años is a EDAD_SUJETO_ASISTENCIA, fuerza policial is a PROFESION, Ricardo Galán Suárez is a NOMBRE_PERSONAL_SANITARIO, Hospital Militar Çentral is a HOSPITAL, Carrera 3 # 49 - 00 is a CALLE, Bogotá D.C. is a TERRITORIO, Colombia is a PAIS, ricgalan@gmail.com is a CORREO_ELECTRONICO

258_task0

Sentence: Nombre: Antonio. Apellidos: Pagudo Henao. NHC: 987345. Domicilio: Cundinamarca, Cra. 15a #26. Localidad/ Provincia: Bogotá. Datos asistenciales. Fecha de nacimiento: 15/06/1979. País: Colombia. Edad: 38 años Sexo: H. Fecha de Ingreso: 03/05/2018. Médico:Ricardo Galán Suárez . Historia del paciente: Varón de 38 años que trabaja como miembro de la fuerza policial y que sufre un accidente de tránsito en calidad de motociclista con traumatismo contundente en mano izquierda en hiperextensión. Inicialmente es visto por el Servicio de Urgencias donde le toman radiografía de la mano sin encontrar fracturas, por lo que es tratado con vendaje, analgesia y reposo. Dos meses después el paciente consulta en otra institución médica por dolor persistente y limitación funcional; se le toman nuevas radiografías en las que se observa fractura de polo distal del escafoides, y se le practica tratamiento ortopédico cerrado con férula durante 4 semanas tras las que se le indica rehabilitación con terapia física que siguió durante 6 meses. Tratamiento realizado en otra institución médica. Un año después regresa a la consulta médica nuevamente por persistencia de dolor y limitación funcional, por lo que es remitido a nuestro Servicio de Cirugía de Mano, donde solicitamos tomografía axial computarizada (TAC) y resonancia nuclear magnética (RNM) con contraste de la mano y muñeca izquierdas, encontrando necrosis del polo distal del escafoides. Con este diagnóstico, decidimos realizar tratamiento quirúrgico mediante artrodesis escafo-trapecio-trapezoide con placa. Remitido por: Dr. Ricardo Galán Suárez. Servicio de Cirugía Plástica Hospital Militar Çentral Carrera 3 # 49-00 Bogotá D.C. Colombia Correo electrónico: ricgalan@gmail.com. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, PROFESION, FECHAS, HOSPITAL, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "B-PROFESION", "I-PROFESION", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "I-TERRITORIO", "B-PAIS", "O", "O", "O", "B-CORREO_ELECTRONICO", "O", "O" ]

Nombre: Antonio. Apellidos: Pagudo Henao. NHC: 987345. Domicilio: Cundinamarca, Cra. 15a #26. Localidad/ Provincia: Bogotá. Datos asistenciales. Fecha de nacimiento: 15/06/1979. País: Colombia. Edad: 38 años Sexo: H. Fecha de Ingreso: 03/05/2018. Médico:Ricardo Galán Suárez . Historia del paciente: Varón de 38 años que trabaja como miembro de la fuerza policial y que sufre un accidente de tránsito en calidad de motociclista con traumatismo contundente en mano izquierda en hiperextensión. Inicialmente es visto por el Servicio de Urgencias donde le toman radiografía de la mano sin encontrar fracturas, por lo que es tratado con vendaje, analgesia y reposo. Dos meses después el paciente consulta en otra institución médica por dolor persistente y limitación funcional; se le toman nuevas radiografías en las que se observa fractura de polo distal del escafoides, y se le practica tratamiento ortopédico cerrado con férula durante 4 semanas tras las que se le indica rehabilitación con terapia física que siguió durante 6 meses. Tratamiento realizado en otra institución médica. Un año después regresa a la consulta médica nuevamente por persistencia de dolor y limitación funcional, por lo que es remitido a nuestro Servicio de Cirugía de Mano, donde solicitamos tomografía axial computarizada (TAC) y resonancia nuclear magnética (RNM) con contraste de la mano y muñeca izquierdas, encontrando necrosis del polo distal del escafoides. Con este diagnóstico, decidimos realizar tratamiento quirúrgico mediante artrodesis escafo-trapecio-trapezoide con placa. Remitido por: Dr. Ricardo Galán Suárez. Servicio de Cirugía Plástica Hospital Militar Çentral Carrera 3 # 49-00 Bogotá D.C. Colombia Correo electrónico: ricgalan@gmail.com.

[ "Nombre", ":", " ", "Antonio", ".", "\n", "Apellidos", ":", "Pagudo", "Henao", ".", "\n", "NHC", ":", "987345", ".", "\n", "Domicilio", ":", "Cundinamarca", ",", "Cra", ".", "15a", "#", "26", ".", "\n", "Localidad/", "Provincia", ":", "Bogotá", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "15/06/1979", ".", "\n", "País", ":", "Colombia", ".", "\n", "Edad", ":", "38", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "03/05/2018", ".", "\n", "Médico", ":", "Ricardo", "Galán", "Suárez", ".", "\n", "Historia", "del", "paciente", ":", "Varón", "de", "38", "años", "que", "trabaja", "como", "miembro", "de", "la", "fuerza", "policial", "y", "que", "sufre", "un", "accidente", "de", "tránsito", "en", "calidad", "de", "motociclista", "con", "traumatismo", "contundente", "en", "mano", "izquierda", "en", "hiperextensión", ".", "Inicialmente", "es", "visto", "por", "el", "Servicio", "de", "Urgencias", "donde", "le", "toman", "radiografía", "de", "la", "mano", "sin", "encontrar", "fracturas", ",", "por", "lo", "que", "es", "tratado", "con", "vendaje", ",", "analgesia", "y", "reposo", ".", "\n", "Dos", "meses", "después", "el", "paciente", "consulta", "en", "otra", "institución", "médica", "por", "dolor", "persistente", "y", "limitación", "funcional", ";", "se", "le", "toman", "nuevas", "radiografías", "en", "las", "que", "se", "observa", "fractura", "de", "polo", "distal", "del", "escafoides", ",", "y", "se", "le", "practica", "tratamiento", "ortopédico", "cerrado", "con", "férula", "durante", "4", "semanas", "tras", "las", "que", "se", "le", "indica", "rehabilitación", "con", "terapia", "física", "que", "siguió", "durante", "6", "meses", ".", "Tratamiento", "realizado", "en", "otra", "institución", "médica", ".", "\n", "Un", "año", "después", "regresa", "a", "la", "consulta", "médica", "nuevamente", "por", "persistencia", "de", "dolor", "y", "limitación", "funcional", ",", "por", "lo", "que", "es", "remitido", "a", "nuestro", "Servicio", "de", "Cirugía", "de", "Mano", ",", "donde", "solicitamos", "tomografía", "axial", "computarizada", "(", "TAC", ")", "y", "resonancia", "nuclear", "magnética", "(", "RNM", ")", "con", "contraste", "de", "la", "mano", "y", "muñeca", "izquierdas", ",", "encontrando", "necrosis", "del", "polo", "distal", "del", "escafoides", ".", "Con", "este", "diagnóstico", ",", "decidimos", "realizar", "tratamiento", "quirúrgico", "mediante", "artrodesis", "escafo", "-", "trapecio", "-", "trapezoide", "con", "placa", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Ricardo", "Galán", "Suárez", ".", "Servicio", "de", "Cirugía", "Plástica", "Hospital", "Militar", "Çentral", "Carrera", "3", "#", "49", "-", "00", "Bogotá", "D.C.", "Colombia", "Correo", "electrónico", ":", "ricgalan@gmail.com", ".", "\n" ]

[ "CALLE", "HOSPITAL", "NOMBRE_PERSONAL_SANITARIO", "CORREO_ELECTRONICO", "PROFESION", "NOMBRE_SUJETO_ASISTENCIA", "TERRITORIO", "FECHAS", "PAIS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "SEXO_SUJETO_ASISTENCIA" ]

Antonio is a NOMBRE_SUJETO_ASISTENCIA, Pagudo Henao is a NOMBRE_SUJETO_ASISTENCIA, 987345 is a ID_SUJETO_ASISTENCIA, Cundinamarca , Cra . 15a # 26 is a CALLE, Bogotá is a TERRITORIO, 15/06/1979 is a FECHAS, Colombia is a PAIS, 38 años is a EDAD_SUJETO_ASISTENCIA, 03/05/2018 is a FECHAS, Ricardo Galán Suárez is a NOMBRE_PERSONAL_SANITARIO, Varón is a SEXO_SUJETO_ASISTENCIA, 38 años is a EDAD_SUJETO_ASISTENCIA, fuerza policial is a PROFESION, Ricardo Galán Suárez is a NOMBRE_PERSONAL_SANITARIO, Hospital Militar Çentral is a HOSPITAL, Carrera 3 # 49 - 00 is a CALLE, Bogotá D.C. is a TERRITORIO, Colombia is a PAIS, ricgalan@gmail.com is a CORREO_ELECTRONICO

258_task1

Sentence: Nombre: Antonio. Apellidos: Pagudo Henao. NHC: 987345. Domicilio: Cundinamarca, Cra. 15a #26. Localidad/ Provincia: Bogotá. Datos asistenciales. Fecha de nacimiento: 15/06/1979. País: Colombia. Edad: 38 años Sexo: H. Fecha de Ingreso: 03/05/2018. Médico:Ricardo Galán Suárez . Historia del paciente: Varón de 38 años que trabaja como miembro de la fuerza policial y que sufre un accidente de tránsito en calidad de motociclista con traumatismo contundente en mano izquierda en hiperextensión. Inicialmente es visto por el Servicio de Urgencias donde le toman radiografía de la mano sin encontrar fracturas, por lo que es tratado con vendaje, analgesia y reposo. Dos meses después el paciente consulta en otra institución médica por dolor persistente y limitación funcional; se le toman nuevas radiografías en las que se observa fractura de polo distal del escafoides, y se le practica tratamiento ortopédico cerrado con férula durante 4 semanas tras las que se le indica rehabilitación con terapia física que siguió durante 6 meses. Tratamiento realizado en otra institución médica. Un año después regresa a la consulta médica nuevamente por persistencia de dolor y limitación funcional, por lo que es remitido a nuestro Servicio de Cirugía de Mano, donde solicitamos tomografía axial computarizada (TAC) y resonancia nuclear magnética (RNM) con contraste de la mano y muñeca izquierdas, encontrando necrosis del polo distal del escafoides. Con este diagnóstico, decidimos realizar tratamiento quirúrgico mediante artrodesis escafo-trapecio-trapezoide con placa. Remitido por: Dr. Ricardo Galán Suárez. Servicio de Cirugía Plástica Hospital Militar Çentral Carrera 3 # 49-00 Bogotá D.C. Colombia Correo electrónico: ricgalan@gmail.com. Instructions: please typing these entity words according to sentence: Antonio, Pagudo Henao, 987345, Cundinamarca , Cra . 15a # 26, Bogotá, 15/06/1979, Colombia, 38 años, 03/05/2018, Ricardo Galán Suárez, Varón, 38 años, fuerza policial, Ricardo Galán Suárez, Hospital Militar Çentral, Carrera 3 # 49 - 00, Bogotá D.C., Colombia, ricgalan@gmail.com Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, PROFESION, FECHAS, HOSPITAL, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "B-PROFESION", "I-PROFESION", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "I-TERRITORIO", "B-PAIS", "O", "O", "O", "B-CORREO_ELECTRONICO", "O", "O" ]

Nombre: Antonio. Apellidos: Pagudo Henao. NHC: 987345. Domicilio: Cundinamarca, Cra. 15a #26. Localidad/ Provincia: Bogotá. Datos asistenciales. Fecha de nacimiento: 15/06/1979. País: Colombia. Edad: 38 años Sexo: H. Fecha de Ingreso: 03/05/2018. Médico:Ricardo Galán Suárez . Historia del paciente: Varón de 38 años que trabaja como miembro de la fuerza policial y que sufre un accidente de tránsito en calidad de motociclista con traumatismo contundente en mano izquierda en hiperextensión. Inicialmente es visto por el Servicio de Urgencias donde le toman radiografía de la mano sin encontrar fracturas, por lo que es tratado con vendaje, analgesia y reposo. Dos meses después el paciente consulta en otra institución médica por dolor persistente y limitación funcional; se le toman nuevas radiografías en las que se observa fractura de polo distal del escafoides, y se le practica tratamiento ortopédico cerrado con férula durante 4 semanas tras las que se le indica rehabilitación con terapia física que siguió durante 6 meses. Tratamiento realizado en otra institución médica. Un año después regresa a la consulta médica nuevamente por persistencia de dolor y limitación funcional, por lo que es remitido a nuestro Servicio de Cirugía de Mano, donde solicitamos tomografía axial computarizada (TAC) y resonancia nuclear magnética (RNM) con contraste de la mano y muñeca izquierdas, encontrando necrosis del polo distal del escafoides. Con este diagnóstico, decidimos realizar tratamiento quirúrgico mediante artrodesis escafo-trapecio-trapezoide con placa. Remitido por: Dr. Ricardo Galán Suárez. Servicio de Cirugía Plástica Hospital Militar Çentral Carrera 3 # 49-00 Bogotá D.C. Colombia Correo electrónico: ricgalan@gmail.com.

[ "Nombre", ":", " ", "Antonio", ".", "\n", "Apellidos", ":", "Pagudo", "Henao", ".", "\n", "NHC", ":", "987345", ".", "\n", "Domicilio", ":", "Cundinamarca", ",", "Cra", ".", "15a", "#", "26", ".", "\n", "Localidad/", "Provincia", ":", "Bogotá", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "15/06/1979", ".", "\n", "País", ":", "Colombia", ".", "\n", "Edad", ":", "38", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "03/05/2018", ".", "\n", "Médico", ":", "Ricardo", "Galán", "Suárez", ".", "\n", "Historia", "del", "paciente", ":", "Varón", "de", "38", "años", "que", "trabaja", "como", "miembro", "de", "la", "fuerza", "policial", "y", "que", "sufre", "un", "accidente", "de", "tránsito", "en", "calidad", "de", "motociclista", "con", "traumatismo", "contundente", "en", "mano", "izquierda", "en", "hiperextensión", ".", "Inicialmente", "es", "visto", "por", "el", "Servicio", "de", "Urgencias", "donde", "le", "toman", "radiografía", "de", "la", "mano", "sin", "encontrar", "fracturas", ",", "por", "lo", "que", "es", "tratado", "con", "vendaje", ",", "analgesia", "y", "reposo", ".", "\n", "Dos", "meses", "después", "el", "paciente", "consulta", "en", "otra", "institución", "médica", "por", "dolor", "persistente", "y", "limitación", "funcional", ";", "se", "le", "toman", "nuevas", "radiografías", "en", "las", "que", "se", "observa", "fractura", "de", "polo", "distal", "del", "escafoides", ",", "y", "se", "le", "practica", "tratamiento", "ortopédico", "cerrado", "con", "férula", "durante", "4", "semanas", "tras", "las", "que", "se", "le", "indica", "rehabilitación", "con", "terapia", "física", "que", "siguió", "durante", "6", "meses", ".", "Tratamiento", "realizado", "en", "otra", "institución", "médica", ".", "\n", "Un", "año", "después", "regresa", "a", "la", "consulta", "médica", "nuevamente", "por", "persistencia", "de", "dolor", "y", "limitación", "funcional", ",", "por", "lo", "que", "es", "remitido", "a", "nuestro", "Servicio", "de", "Cirugía", "de", "Mano", ",", "donde", "solicitamos", "tomografía", "axial", "computarizada", "(", "TAC", ")", "y", "resonancia", "nuclear", "magnética", "(", "RNM", ")", "con", "contraste", "de", "la", "mano", "y", "muñeca", "izquierdas", ",", "encontrando", "necrosis", "del", "polo", "distal", "del", "escafoides", ".", "Con", "este", "diagnóstico", ",", "decidimos", "realizar", "tratamiento", "quirúrgico", "mediante", "artrodesis", "escafo", "-", "trapecio", "-", "trapezoide", "con", "placa", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Ricardo", "Galán", "Suárez", ".", "Servicio", "de", "Cirugía", "Plástica", "Hospital", "Militar", "Çentral", "Carrera", "3", "#", "49", "-", "00", "Bogotá", "D.C.", "Colombia", "Correo", "electrónico", ":", "ricgalan@gmail.com", ".", "\n" ]

[ "CALLE", "HOSPITAL", "NOMBRE_PERSONAL_SANITARIO", "CORREO_ELECTRONICO", "PROFESION", "NOMBRE_SUJETO_ASISTENCIA", "TERRITORIO", "FECHAS", "PAIS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "SEXO_SUJETO_ASISTENCIA" ]

Antonio, Pagudo Henao, 987345, Cundinamarca , Cra . 15a # 26, Bogotá, 15/06/1979, Colombia, 38 años, 03/05/2018, Ricardo Galán Suárez, Varón, 38 años, fuerza policial, Ricardo Galán Suárez, Hospital Militar Çentral, Carrera 3 # 49 - 00, Bogotá D.C., Colombia, ricgalan@gmail.com

258_task2

Sentence: Nombre: Antonio. Apellidos: Pagudo Henao. NHC: 987345. Domicilio: Cundinamarca, Cra. 15a #26. Localidad/ Provincia: Bogotá. Datos asistenciales. Fecha de nacimiento: 15/06/1979. País: Colombia. Edad: 38 años Sexo: H. Fecha de Ingreso: 03/05/2018. Médico:Ricardo Galán Suárez . Historia del paciente: Varón de 38 años que trabaja como miembro de la fuerza policial y que sufre un accidente de tránsito en calidad de motociclista con traumatismo contundente en mano izquierda en hiperextensión. Inicialmente es visto por el Servicio de Urgencias donde le toman radiografía de la mano sin encontrar fracturas, por lo que es tratado con vendaje, analgesia y reposo. Dos meses después el paciente consulta en otra institución médica por dolor persistente y limitación funcional; se le toman nuevas radiografías en las que se observa fractura de polo distal del escafoides, y se le practica tratamiento ortopédico cerrado con férula durante 4 semanas tras las que se le indica rehabilitación con terapia física que siguió durante 6 meses. Tratamiento realizado en otra institución médica. Un año después regresa a la consulta médica nuevamente por persistencia de dolor y limitación funcional, por lo que es remitido a nuestro Servicio de Cirugía de Mano, donde solicitamos tomografía axial computarizada (TAC) y resonancia nuclear magnética (RNM) con contraste de la mano y muñeca izquierdas, encontrando necrosis del polo distal del escafoides. Con este diagnóstico, decidimos realizar tratamiento quirúrgico mediante artrodesis escafo-trapecio-trapezoide con placa. Remitido por: Dr. Ricardo Galán Suárez. Servicio de Cirugía Plástica Hospital Militar Çentral Carrera 3 # 49-00 Bogotá D.C. Colombia Correo electrónico: ricgalan@gmail.com. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "B-PROFESION", "I-PROFESION", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "I-TERRITORIO", "B-PAIS", "O", "O", "O", "B-CORREO_ELECTRONICO", "O", "O" ]

Nombre: Antonio. Apellidos: Pagudo Henao. NHC: 987345. Domicilio: Cundinamarca, Cra. 15a #26. Localidad/ Provincia: Bogotá. Datos asistenciales. Fecha de nacimiento: 15/06/1979. País: Colombia. Edad: 38 años Sexo: H. Fecha de Ingreso: 03/05/2018. Médico:Ricardo Galán Suárez . Historia del paciente: Varón de 38 años que trabaja como miembro de la fuerza policial y que sufre un accidente de tránsito en calidad de motociclista con traumatismo contundente en mano izquierda en hiperextensión. Inicialmente es visto por el Servicio de Urgencias donde le toman radiografía de la mano sin encontrar fracturas, por lo que es tratado con vendaje, analgesia y reposo. Dos meses después el paciente consulta en otra institución médica por dolor persistente y limitación funcional; se le toman nuevas radiografías en las que se observa fractura de polo distal del escafoides, y se le practica tratamiento ortopédico cerrado con férula durante 4 semanas tras las que se le indica rehabilitación con terapia física que siguió durante 6 meses. Tratamiento realizado en otra institución médica. Un año después regresa a la consulta médica nuevamente por persistencia de dolor y limitación funcional, por lo que es remitido a nuestro Servicio de Cirugía de Mano, donde solicitamos tomografía axial computarizada (TAC) y resonancia nuclear magnética (RNM) con contraste de la mano y muñeca izquierdas, encontrando necrosis del polo distal del escafoides. Con este diagnóstico, decidimos realizar tratamiento quirúrgico mediante artrodesis escafo-trapecio-trapezoide con placa. Remitido por: Dr. Ricardo Galán Suárez. Servicio de Cirugía Plástica Hospital Militar Çentral Carrera 3 # 49-00 Bogotá D.C. Colombia Correo electrónico: ricgalan@gmail.com.

[ "Nombre", ":", " ", "Antonio", ".", "\n", "Apellidos", ":", "Pagudo", "Henao", ".", "\n", "NHC", ":", "987345", ".", "\n", "Domicilio", ":", "Cundinamarca", ",", "Cra", ".", "15a", "#", "26", ".", "\n", "Localidad/", "Provincia", ":", "Bogotá", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "15/06/1979", ".", "\n", "País", ":", "Colombia", ".", "\n", "Edad", ":", "38", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "03/05/2018", ".", "\n", "Médico", ":", "Ricardo", "Galán", "Suárez", ".", "\n", "Historia", "del", "paciente", ":", "Varón", "de", "38", "años", "que", "trabaja", "como", "miembro", "de", "la", "fuerza", "policial", "y", "que", "sufre", "un", "accidente", "de", "tránsito", "en", "calidad", "de", "motociclista", "con", "traumatismo", "contundente", "en", "mano", "izquierda", "en", "hiperextensión", ".", "Inicialmente", "es", "visto", "por", "el", "Servicio", "de", "Urgencias", "donde", "le", "toman", "radiografía", "de", "la", "mano", "sin", "encontrar", "fracturas", ",", "por", "lo", "que", "es", "tratado", "con", "vendaje", ",", "analgesia", "y", "reposo", ".", "\n", "Dos", "meses", "después", "el", "paciente", "consulta", "en", "otra", "institución", "médica", "por", "dolor", "persistente", "y", "limitación", "funcional", ";", "se", "le", "toman", "nuevas", "radiografías", "en", "las", "que", "se", "observa", "fractura", "de", "polo", "distal", "del", "escafoides", ",", "y", "se", "le", "practica", "tratamiento", "ortopédico", "cerrado", "con", "férula", "durante", "4", "semanas", "tras", "las", "que", "se", "le", "indica", "rehabilitación", "con", "terapia", "física", "que", "siguió", "durante", "6", "meses", ".", "Tratamiento", "realizado", "en", "otra", "institución", "médica", ".", "\n", "Un", "año", "después", "regresa", "a", "la", "consulta", "médica", "nuevamente", "por", "persistencia", "de", "dolor", "y", "limitación", "funcional", ",", "por", "lo", "que", "es", "remitido", "a", "nuestro", "Servicio", "de", "Cirugía", "de", "Mano", ",", "donde", "solicitamos", "tomografía", "axial", "computarizada", "(", "TAC", ")", "y", "resonancia", "nuclear", "magnética", "(", "RNM", ")", "con", "contraste", "de", "la", "mano", "y", "muñeca", "izquierdas", ",", "encontrando", "necrosis", "del", "polo", "distal", "del", "escafoides", ".", "Con", "este", "diagnóstico", ",", "decidimos", "realizar", "tratamiento", "quirúrgico", "mediante", "artrodesis", "escafo", "-", "trapecio", "-", "trapezoide", "con", "placa", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Ricardo", "Galán", "Suárez", ".", "Servicio", "de", "Cirugía", "Plástica", "Hospital", "Militar", "Çentral", "Carrera", "3", "#", "49", "-", "00", "Bogotá", "D.C.", "Colombia", "Correo", "electrónico", ":", "ricgalan@gmail.com", ".", "\n" ]

[ "CALLE", "HOSPITAL", "NOMBRE_PERSONAL_SANITARIO", "CORREO_ELECTRONICO", "PROFESION", "NOMBRE_SUJETO_ASISTENCIA", "TERRITORIO", "FECHAS", "PAIS", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "SEXO_SUJETO_ASISTENCIA" ]

Effects is a Outcome_Other, telmisartan is a Intervention_Pharmacological, enalapril is a Intervention_Pharmacological, mild to moderate chronic kidney disease is a Participant_Condition, chronic kidney disease ( CKD ) . is a Participant_Condition, urinary liver - type fatty acid - binding protein ( L - FABP ) is a Outcome_Physical, endothelin ( ET ) -1 levels is a Outcome_Physical, mild CKD is a Participant_Condition, Thirty CKD patients is a Participant_Condition, mild to moderate renal insufficiency is a Participant_Condition, 20 men and 10 women is a Participant_Sex, 37 years ; estimated glomerular filtration rate ( eGFR ) > 60 mL min ( -1 ) and blood pressure > 130/85 mmHg ) were included in the study . is a Participant_Age, telmisartan at 80 mg day ( -1 ) is a Intervention_Pharmacological, enalapril at 10 mg day ( -1 ) is a Intervention_Pharmacological, serum creatinine , eGFR is a Outcome_Physical, urinary protein is a Outcome_Physical, ET-1 is a Outcome_Physical, blood pressure reduction rate is a Outcome_Physical, Urinary protein is a Outcome_Physical, ET-1 levels is a Outcome_Physical, reduction rates is a Outcome_Physical, urinary markers is a Outcome_Physical

46354_task0

Sentence: Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease . BACKGROUND Blocking the renin-angiotensin system ( RAS ) with angiotensin receptor blockers or angiotensin-converting enzyme inhibitors protects against renal injury in patients with chronic kidney disease ( CKD ) . The aim of this study was to compare the chronic effects of telmisartan and enalapril on proteinuria , urinary liver-type fatty acid-binding protein ( L-FABP ) and endothelin ( ET ) -1 levels in patients with mild CKD . MATERIALS AND METHODS Thirty CKD patients with mild to moderate renal insufficiency ( 20 men and 10 women ; mean age , 37 years ; estimated glomerular filtration rate ( eGFR ) > 60 mL min ( -1 ) and blood pressure > 130/85 mmHg ) were included in the study . Patients were randomly assigned to receive telmisartan at 80 mg day ( -1 ) ( n = 15 ) or enalapril at 10 mg day ( -1 ) ( n = 15 ) . We measured blood pressure , serum creatinine , eGFR , urinary protein , L-FABP and ET-1 before the start of treatment and 6 and 12 months after the start of treatment . RESULTS The blood pressure reduction rate was similar between the two groups . Urinary protein , L-FABP and ET-1 levels were significantly reduced in both groups 6 and 12 months ( P < 0.001 ) after treatment , but the reduction rates were more pronounced in patients receiving telmisartan than in those receiving enalapril ( P < 0.001 ) . Estimated glomerular filtration rate was increased similarly in both groups at 12 months . CONCLUSIONS The study results suggest that telmisartan results in a greater reduction of urinary markers than does enalapril and that this effect occurs by a mechanism independent of blood pressure reduction . It would be needed to investigate whether the differences may be distinct or not the same when other dosages are used . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Sex, Participant_Condition, Outcome_Physical, Participant_Age, Outcome_Other

[ "B-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Sex", "I-Participant_Sex", "I-Participant_Sex", "I-Participant_Sex", "I-Participant_Sex", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease . BACKGROUND Blocking the renin-angiotensin system ( RAS ) with angiotensin receptor blockers or angiotensin-converting enzyme inhibitors protects against renal injury in patients with chronic kidney disease ( CKD ) . The aim of this study was to compare the chronic effects of telmisartan and enalapril on proteinuria , urinary liver-type fatty acid-binding protein ( L-FABP ) and endothelin ( ET ) -1 levels in patients with mild CKD . MATERIALS AND METHODS Thirty CKD patients with mild to moderate renal insufficiency ( 20 men and 10 women ; mean age , 37 years ; estimated glomerular filtration rate ( eGFR ) > 60 mL min ( -1 ) and blood pressure > 130/85 mmHg ) were included in the study . Patients were randomly assigned to receive telmisartan at 80 mg day ( -1 ) ( n = 15 ) or enalapril at 10 mg day ( -1 ) ( n = 15 ) . We measured blood pressure , serum creatinine , eGFR , urinary protein , L-FABP and ET-1 before the start of treatment and 6 and 12 months after the start of treatment . RESULTS The blood pressure reduction rate was similar between the two groups . Urinary protein , L-FABP and ET-1 levels were significantly reduced in both groups 6 and 12 months ( P < 0.001 ) after treatment , but the reduction rates were more pronounced in patients receiving telmisartan than in those receiving enalapril ( P < 0.001 ) . Estimated glomerular filtration rate was increased similarly in both groups at 12 months . CONCLUSIONS The study results suggest that telmisartan results in a greater reduction of urinary markers than does enalapril and that this effect occurs by a mechanism independent of blood pressure reduction . It would be needed to investigate whether the differences may be distinct or not the same when other dosages are used .

[ "Effects", "of", "telmisartan", "and", "enalapril", "on", "renoprotection", "in", "patients", "with", "mild", "to", "moderate", "chronic", "kidney", "disease", ".", "BACKGROUND", "Blocking", "the", "renin", "-", "angiotensin", "system", "(", "RAS", ")", "with", "angiotensin", "receptor", "blockers", "or", "angiotensin", "-", "converting", "enzyme", "inhibitors", "protects", "against", "renal", "injury", "in", "patients", "with", "chronic", "kidney", "disease", "(", "CKD", ")", ".", "The", "aim", "of", "this", "study", "was", "to", "compare", "the", "chronic", "effects", "of", "telmisartan", "and", "enalapril", "on", "proteinuria", ",", "urinary", "liver", "-", "type", "fatty", "acid", "-", "binding", "protein", "(", "L", "-", "FABP", ")", "and", "endothelin", "(", "ET", ")", "-1", "levels", "in", "patients", "with", "mild", "CKD", ".", "MATERIALS", "AND", "METHODS", "Thirty", "CKD", "patients", "with", "mild", "to", "moderate", "renal", "insufficiency", "(", "20", "men", "and", "10", "women", ";", "mean", "age", ",", "37", "years", ";", "estimated", "glomerular", "filtration", "rate", "(", "eGFR", ")", ">", "60", "mL", "min", "(", "-1", ")", "and", "blood", "pressure", ">", "130/85", "mmHg", ")", "were", "included", "in", "the", "study", ".", "Patients", "were", "randomly", "assigned", "to", "receive", "telmisartan", "at", "80", "mg", "day", "(", "-1", ")", "(", "n", "=", "15", ")", "or", "enalapril", "at", "10", "mg", "day", "(", "-1", ")", "(", "n", "=", "15", ")", ".", "We", "measured", "blood", "pressure", ",", "serum", "creatinine", ",", "eGFR", ",", "urinary", "protein", ",", "L", "-", "FABP", "and", "ET-1", "before", "the", "start", "of", "treatment", "and", "6", "and", "12", "months", "after", "the", "start", "of", "treatment", ".", "RESULTS", "The", "blood", "pressure", "reduction", "rate", "was", "similar", "between", "the", "two", "groups", ".", "Urinary", "protein", ",", "L", "-", "FABP", "and", "ET-1", "levels", "were", "significantly", "reduced", "in", "both", "groups", "6", "and", "12", "months", "(", "P", "<", "0.001", ")", "after", "treatment", ",", "but", "the", "reduction", "rates", "were", "more", "pronounced", "in", "patients", "receiving", "telmisartan", "than", "in", "those", "receiving", "enalapril", "(", "P", "<", "0.001", ")", ".", "Estimated", "glomerular", "filtration", "rate", "was", "increased", "similarly", "in", "both", "groups", "at", "12", "months", ".", "CONCLUSIONS", "The", "study", "results", "suggest", "that", "telmisartan", "results", "in", "a", "greater", "reduction", "of", "urinary", "markers", "than", "does", "enalapril", "and", "that", "this", "effect", "occurs", "by", "a", "mechanism", "independent", "of", "blood", "pressure", "reduction", ".", "It", "would", "be", "needed", "to", "investigate", "whether", "the", "differences", "may", "be", "distinct", "or", "not", "the", "same", "when", "other", "dosages", "are", "used", "." ]

[ "Participant_Age", "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Participant_Sex", "Outcome_Other" ]

Effects is a Outcome_Other, telmisartan is a Intervention_Pharmacological, enalapril is a Intervention_Pharmacological, mild to moderate chronic kidney disease is a Participant_Condition, chronic kidney disease ( CKD ) . is a Participant_Condition, urinary liver - type fatty acid - binding protein ( L - FABP ) is a Outcome_Physical, endothelin ( ET ) -1 levels is a Outcome_Physical, mild CKD is a Participant_Condition, Thirty CKD patients is a Participant_Condition, mild to moderate renal insufficiency is a Participant_Condition, 20 men and 10 women is a Participant_Sex, 37 years ; estimated glomerular filtration rate ( eGFR ) > 60 mL min ( -1 ) and blood pressure > 130/85 mmHg ) were included in the study . is a Participant_Age, telmisartan at 80 mg day ( -1 ) is a Intervention_Pharmacological, enalapril at 10 mg day ( -1 ) is a Intervention_Pharmacological, serum creatinine , eGFR is a Outcome_Physical, urinary protein is a Outcome_Physical, ET-1 is a Outcome_Physical, blood pressure reduction rate is a Outcome_Physical, Urinary protein is a Outcome_Physical, ET-1 levels is a Outcome_Physical, reduction rates is a Outcome_Physical, urinary markers is a Outcome_Physical

46354_task1

Sentence: Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease . BACKGROUND Blocking the renin-angiotensin system ( RAS ) with angiotensin receptor blockers or angiotensin-converting enzyme inhibitors protects against renal injury in patients with chronic kidney disease ( CKD ) . The aim of this study was to compare the chronic effects of telmisartan and enalapril on proteinuria , urinary liver-type fatty acid-binding protein ( L-FABP ) and endothelin ( ET ) -1 levels in patients with mild CKD . MATERIALS AND METHODS Thirty CKD patients with mild to moderate renal insufficiency ( 20 men and 10 women ; mean age , 37 years ; estimated glomerular filtration rate ( eGFR ) > 60 mL min ( -1 ) and blood pressure > 130/85 mmHg ) were included in the study . Patients were randomly assigned to receive telmisartan at 80 mg day ( -1 ) ( n = 15 ) or enalapril at 10 mg day ( -1 ) ( n = 15 ) . We measured blood pressure , serum creatinine , eGFR , urinary protein , L-FABP and ET-1 before the start of treatment and 6 and 12 months after the start of treatment . RESULTS The blood pressure reduction rate was similar between the two groups . Urinary protein , L-FABP and ET-1 levels were significantly reduced in both groups 6 and 12 months ( P < 0.001 ) after treatment , but the reduction rates were more pronounced in patients receiving telmisartan than in those receiving enalapril ( P < 0.001 ) . Estimated glomerular filtration rate was increased similarly in both groups at 12 months . CONCLUSIONS The study results suggest that telmisartan results in a greater reduction of urinary markers than does enalapril and that this effect occurs by a mechanism independent of blood pressure reduction . It would be needed to investigate whether the differences may be distinct or not the same when other dosages are used . Instructions: please typing these entity words according to sentence: Effects, telmisartan, enalapril, mild to moderate chronic kidney disease, chronic kidney disease ( CKD ) ., urinary liver - type fatty acid - binding protein ( L - FABP ), endothelin ( ET ) -1 levels, mild CKD, Thirty CKD patients, mild to moderate renal insufficiency, 20 men and 10 women, 37 years ; estimated glomerular filtration rate ( eGFR ) > 60 mL min ( -1 ) and blood pressure > 130/85 mmHg ) were included in the study ., telmisartan at 80 mg day ( -1 ), enalapril at 10 mg day ( -1 ), serum creatinine , eGFR, urinary protein, ET-1, blood pressure reduction rate, Urinary protein, ET-1 levels, reduction rates, urinary markers Options: Intervention_Pharmacological, Participant_Sex, Participant_Condition, Outcome_Physical, Participant_Age, Outcome_Other

[ "B-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Sex", "I-Participant_Sex", "I-Participant_Sex", "I-Participant_Sex", "I-Participant_Sex", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease . BACKGROUND Blocking the renin-angiotensin system ( RAS ) with angiotensin receptor blockers or angiotensin-converting enzyme inhibitors protects against renal injury in patients with chronic kidney disease ( CKD ) . The aim of this study was to compare the chronic effects of telmisartan and enalapril on proteinuria , urinary liver-type fatty acid-binding protein ( L-FABP ) and endothelin ( ET ) -1 levels in patients with mild CKD . MATERIALS AND METHODS Thirty CKD patients with mild to moderate renal insufficiency ( 20 men and 10 women ; mean age , 37 years ; estimated glomerular filtration rate ( eGFR ) > 60 mL min ( -1 ) and blood pressure > 130/85 mmHg ) were included in the study . Patients were randomly assigned to receive telmisartan at 80 mg day ( -1 ) ( n = 15 ) or enalapril at 10 mg day ( -1 ) ( n = 15 ) . We measured blood pressure , serum creatinine , eGFR , urinary protein , L-FABP and ET-1 before the start of treatment and 6 and 12 months after the start of treatment . RESULTS The blood pressure reduction rate was similar between the two groups . Urinary protein , L-FABP and ET-1 levels were significantly reduced in both groups 6 and 12 months ( P < 0.001 ) after treatment , but the reduction rates were more pronounced in patients receiving telmisartan than in those receiving enalapril ( P < 0.001 ) . Estimated glomerular filtration rate was increased similarly in both groups at 12 months . CONCLUSIONS The study results suggest that telmisartan results in a greater reduction of urinary markers than does enalapril and that this effect occurs by a mechanism independent of blood pressure reduction . It would be needed to investigate whether the differences may be distinct or not the same when other dosages are used .

[ "Effects", "of", "telmisartan", "and", "enalapril", "on", "renoprotection", "in", "patients", "with", "mild", "to", "moderate", "chronic", "kidney", "disease", ".", "BACKGROUND", "Blocking", "the", "renin", "-", "angiotensin", "system", "(", "RAS", ")", "with", "angiotensin", "receptor", "blockers", "or", "angiotensin", "-", "converting", "enzyme", "inhibitors", "protects", "against", "renal", "injury", "in", "patients", "with", "chronic", "kidney", "disease", "(", "CKD", ")", ".", "The", "aim", "of", "this", "study", "was", "to", "compare", "the", "chronic", "effects", "of", "telmisartan", "and", "enalapril", "on", "proteinuria", ",", "urinary", "liver", "-", "type", "fatty", "acid", "-", "binding", "protein", "(", "L", "-", "FABP", ")", "and", "endothelin", "(", "ET", ")", "-1", "levels", "in", "patients", "with", "mild", "CKD", ".", "MATERIALS", "AND", "METHODS", "Thirty", "CKD", "patients", "with", "mild", "to", "moderate", "renal", "insufficiency", "(", "20", "men", "and", "10", "women", ";", "mean", "age", ",", "37", "years", ";", "estimated", "glomerular", "filtration", "rate", "(", "eGFR", ")", ">", "60", "mL", "min", "(", "-1", ")", "and", "blood", "pressure", ">", "130/85", "mmHg", ")", "were", "included", "in", "the", "study", ".", "Patients", "were", "randomly", "assigned", "to", "receive", "telmisartan", "at", "80", "mg", "day", "(", "-1", ")", "(", "n", "=", "15", ")", "or", "enalapril", "at", "10", "mg", "day", "(", "-1", ")", "(", "n", "=", "15", ")", ".", "We", "measured", "blood", "pressure", ",", "serum", "creatinine", ",", "eGFR", ",", "urinary", "protein", ",", "L", "-", "FABP", "and", "ET-1", "before", "the", "start", "of", "treatment", "and", "6", "and", "12", "months", "after", "the", "start", "of", "treatment", ".", "RESULTS", "The", "blood", "pressure", "reduction", "rate", "was", "similar", "between", "the", "two", "groups", ".", "Urinary", "protein", ",", "L", "-", "FABP", "and", "ET-1", "levels", "were", "significantly", "reduced", "in", "both", "groups", "6", "and", "12", "months", "(", "P", "<", "0.001", ")", "after", "treatment", ",", "but", "the", "reduction", "rates", "were", "more", "pronounced", "in", "patients", "receiving", "telmisartan", "than", "in", "those", "receiving", "enalapril", "(", "P", "<", "0.001", ")", ".", "Estimated", "glomerular", "filtration", "rate", "was", "increased", "similarly", "in", "both", "groups", "at", "12", "months", ".", "CONCLUSIONS", "The", "study", "results", "suggest", "that", "telmisartan", "results", "in", "a", "greater", "reduction", "of", "urinary", "markers", "than", "does", "enalapril", "and", "that", "this", "effect", "occurs", "by", "a", "mechanism", "independent", "of", "blood", "pressure", "reduction", ".", "It", "would", "be", "needed", "to", "investigate", "whether", "the", "differences", "may", "be", "distinct", "or", "not", "the", "same", "when", "other", "dosages", "are", "used", "." ]

[ "Participant_Age", "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Participant_Sex", "Outcome_Other" ]

Effects, telmisartan, enalapril, mild to moderate chronic kidney disease, chronic kidney disease ( CKD ) ., urinary liver - type fatty acid - binding protein ( L - FABP ), endothelin ( ET ) -1 levels, mild CKD, Thirty CKD patients, mild to moderate renal insufficiency, 20 men and 10 women, 37 years ; estimated glomerular filtration rate ( eGFR ) > 60 mL min ( -1 ) and blood pressure > 130/85 mmHg ) were included in the study ., telmisartan at 80 mg day ( -1 ), enalapril at 10 mg day ( -1 ), serum creatinine , eGFR, urinary protein, ET-1, blood pressure reduction rate, Urinary protein, ET-1 levels, reduction rates, urinary markers

46354_task2

Sentence: Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease . BACKGROUND Blocking the renin-angiotensin system ( RAS ) with angiotensin receptor blockers or angiotensin-converting enzyme inhibitors protects against renal injury in patients with chronic kidney disease ( CKD ) . The aim of this study was to compare the chronic effects of telmisartan and enalapril on proteinuria , urinary liver-type fatty acid-binding protein ( L-FABP ) and endothelin ( ET ) -1 levels in patients with mild CKD . MATERIALS AND METHODS Thirty CKD patients with mild to moderate renal insufficiency ( 20 men and 10 women ; mean age , 37 years ; estimated glomerular filtration rate ( eGFR ) > 60 mL min ( -1 ) and blood pressure > 130/85 mmHg ) were included in the study . Patients were randomly assigned to receive telmisartan at 80 mg day ( -1 ) ( n = 15 ) or enalapril at 10 mg day ( -1 ) ( n = 15 ) . We measured blood pressure , serum creatinine , eGFR , urinary protein , L-FABP and ET-1 before the start of treatment and 6 and 12 months after the start of treatment . RESULTS The blood pressure reduction rate was similar between the two groups . Urinary protein , L-FABP and ET-1 levels were significantly reduced in both groups 6 and 12 months ( P < 0.001 ) after treatment , but the reduction rates were more pronounced in patients receiving telmisartan than in those receiving enalapril ( P < 0.001 ) . Estimated glomerular filtration rate was increased similarly in both groups at 12 months . CONCLUSIONS The study results suggest that telmisartan results in a greater reduction of urinary markers than does enalapril and that this effect occurs by a mechanism independent of blood pressure reduction . It would be needed to investigate whether the differences may be distinct or not the same when other dosages are used . Instructions: please extract entity words from the input sentence

[ "B-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Sex", "I-Participant_Sex", "I-Participant_Sex", "I-Participant_Sex", "I-Participant_Sex", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease . BACKGROUND Blocking the renin-angiotensin system ( RAS ) with angiotensin receptor blockers or angiotensin-converting enzyme inhibitors protects against renal injury in patients with chronic kidney disease ( CKD ) . The aim of this study was to compare the chronic effects of telmisartan and enalapril on proteinuria , urinary liver-type fatty acid-binding protein ( L-FABP ) and endothelin ( ET ) -1 levels in patients with mild CKD . MATERIALS AND METHODS Thirty CKD patients with mild to moderate renal insufficiency ( 20 men and 10 women ; mean age , 37 years ; estimated glomerular filtration rate ( eGFR ) > 60 mL min ( -1 ) and blood pressure > 130/85 mmHg ) were included in the study . Patients were randomly assigned to receive telmisartan at 80 mg day ( -1 ) ( n = 15 ) or enalapril at 10 mg day ( -1 ) ( n = 15 ) . We measured blood pressure , serum creatinine , eGFR , urinary protein , L-FABP and ET-1 before the start of treatment and 6 and 12 months after the start of treatment . RESULTS The blood pressure reduction rate was similar between the two groups . Urinary protein , L-FABP and ET-1 levels were significantly reduced in both groups 6 and 12 months ( P < 0.001 ) after treatment , but the reduction rates were more pronounced in patients receiving telmisartan than in those receiving enalapril ( P < 0.001 ) . Estimated glomerular filtration rate was increased similarly in both groups at 12 months . CONCLUSIONS The study results suggest that telmisartan results in a greater reduction of urinary markers than does enalapril and that this effect occurs by a mechanism independent of blood pressure reduction . It would be needed to investigate whether the differences may be distinct or not the same when other dosages are used .

[ "Effects", "of", "telmisartan", "and", "enalapril", "on", "renoprotection", "in", "patients", "with", "mild", "to", "moderate", "chronic", "kidney", "disease", ".", "BACKGROUND", "Blocking", "the", "renin", "-", "angiotensin", "system", "(", "RAS", ")", "with", "angiotensin", "receptor", "blockers", "or", "angiotensin", "-", "converting", "enzyme", "inhibitors", "protects", "against", "renal", "injury", "in", "patients", "with", "chronic", "kidney", "disease", "(", "CKD", ")", ".", "The", "aim", "of", "this", "study", "was", "to", "compare", "the", "chronic", "effects", "of", "telmisartan", "and", "enalapril", "on", "proteinuria", ",", "urinary", "liver", "-", "type", "fatty", "acid", "-", "binding", "protein", "(", "L", "-", "FABP", ")", "and", "endothelin", "(", "ET", ")", "-1", "levels", "in", "patients", "with", "mild", "CKD", ".", "MATERIALS", "AND", "METHODS", "Thirty", "CKD", "patients", "with", "mild", "to", "moderate", "renal", "insufficiency", "(", "20", "men", "and", "10", "women", ";", "mean", "age", ",", "37", "years", ";", "estimated", "glomerular", "filtration", "rate", "(", "eGFR", ")", ">", "60", "mL", "min", "(", "-1", ")", "and", "blood", "pressure", ">", "130/85", "mmHg", ")", "were", "included", "in", "the", "study", ".", "Patients", "were", "randomly", "assigned", "to", "receive", "telmisartan", "at", "80", "mg", "day", "(", "-1", ")", "(", "n", "=", "15", ")", "or", "enalapril", "at", "10", "mg", "day", "(", "-1", ")", "(", "n", "=", "15", ")", ".", "We", "measured", "blood", "pressure", ",", "serum", "creatinine", ",", "eGFR", ",", "urinary", "protein", ",", "L", "-", "FABP", "and", "ET-1", "before", "the", "start", "of", "treatment", "and", "6", "and", "12", "months", "after", "the", "start", "of", "treatment", ".", "RESULTS", "The", "blood", "pressure", "reduction", "rate", "was", "similar", "between", "the", "two", "groups", ".", "Urinary", "protein", ",", "L", "-", "FABP", "and", "ET-1", "levels", "were", "significantly", "reduced", "in", "both", "groups", "6", "and", "12", "months", "(", "P", "<", "0.001", ")", "after", "treatment", ",", "but", "the", "reduction", "rates", "were", "more", "pronounced", "in", "patients", "receiving", "telmisartan", "than", "in", "those", "receiving", "enalapril", "(", "P", "<", "0.001", ")", ".", "Estimated", "glomerular", "filtration", "rate", "was", "increased", "similarly", "in", "both", "groups", "at", "12", "months", ".", "CONCLUSIONS", "The", "study", "results", "suggest", "that", "telmisartan", "results", "in", "a", "greater", "reduction", "of", "urinary", "markers", "than", "does", "enalapril", "and", "that", "this", "effect", "occurs", "by", "a", "mechanism", "independent", "of", "blood", "pressure", "reduction", ".", "It", "would", "be", "needed", "to", "investigate", "whether", "the", "differences", "may", "be", "distinct", "or", "not", "the", "same", "when", "other", "dosages", "are", "used", "." ]

[ "Participant_Age", "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Participant_Sex", "Outcome_Other" ]

Behandlung is an umlsterm, Histologie is an umlsterm, Rumpfhautbasalioms is an umlsterm, Tumor is an umlsterm, photodynamischen Therapie is an umlsterm, Gewebe is an umlsterm, Licht is an umlsterm, Tumors is an umlsterm, Diagnostik is an umlsterm, Therapieformen is an umlsterm, Tumor is an umlsterm, Effizienz is an umlsterm, gezieltem is an umlsterm

DerHautarzt.60470438.ger.abstr_task0

Sentence: Es wird die Behandlung eines grossflaechigen Basalioms ( ca. 10x6 cm ) an der rechten Mamma einer 48jaehrigen Patientin dargestellt . Aufgrund der Histologie eines oberflaechlichen Rumpfhautbasalioms entschlossen wir uns , den Tumor mit der photodynamischen Therapie ( PDT ) zu behandeln . Hierzu wurden -Aminolaevulinsaeure ( -ALA , 20% ) topisch aufgetragen und das Gewebe mit rotem Licht ( 570-750 nm ; 180 J/cm2) bestrahlt . Die PDT wurde zweimal wiederholt . Hierdurch konnte klinisch eine nahezu vollstaendige Remission des Tumors erzielt werden . In der photodynamischen Diagnostik ( PDD ) zeigten sich aber noch deutlich einige persistierende , z.T. die Mamille infiltrierende Basaliominseln . Diese wurden durch Exzision entfernt und anschliessend wurde der Defekt mittels einer Mamillenplastik verschlossen . Durch die Kombination der beiden Therapieformen konnte der grossflaechige Tumor mit einem ausgezeichneten kosmetischen Ergebnis behandelt werden . Die Falldarstellung soll zum einen die Grenzen der topischen PDT , zum anderen die Effizienz der PDD bei gezieltem Einsatz darstellen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Es wird die Behandlung eines grossflaechigen Basalioms ( ca. 10x6 cm ) an der rechten Mamma einer 48jaehrigen Patientin dargestellt . Aufgrund der Histologie eines oberflaechlichen Rumpfhautbasalioms entschlossen wir uns , den Tumor mit der photodynamischen Therapie ( PDT ) zu behandeln . Hierzu wurden -Aminolaevulinsaeure ( -ALA , 20% ) topisch aufgetragen und das Gewebe mit rotem Licht ( 570-750 nm ; 180 J/cm2) bestrahlt . Die PDT wurde zweimal wiederholt . Hierdurch konnte klinisch eine nahezu vollstaendige Remission des Tumors erzielt werden . In der photodynamischen Diagnostik ( PDD ) zeigten sich aber noch deutlich einige persistierende , z.T. die Mamille infiltrierende Basaliominseln . Diese wurden durch Exzision entfernt und anschliessend wurde der Defekt mittels einer Mamillenplastik verschlossen . Durch die Kombination der beiden Therapieformen konnte der grossflaechige Tumor mit einem ausgezeichneten kosmetischen Ergebnis behandelt werden . Die Falldarstellung soll zum einen die Grenzen der topischen PDT , zum anderen die Effizienz der PDD bei gezieltem Einsatz darstellen .

[ "Es", "wird", "die", "Behandlung", "eines", "grossflaechigen", "Basalioms", "(", "ca", ".", "10x6", "cm", ")", "an", "der", "rechten", "Mamma", "einer", "48jaehrigen", "Patientin", "dargestellt", ".", "Aufgrund", "der", "Histologie", "eines", "oberflaechlichen", "Rumpfhautbasalioms", "entschlossen", "wir", "uns", ",", "den", "Tumor", "mit", "der", "photodynamischen", "Therapie", "(", "PDT", ")", "zu", "behandeln", ".", "Hierzu", "wurden", "-Aminolaevulinsaeure", "(", "-ALA", ",", "20", "%", ")", "topisch", "aufgetragen", "und", "das", "Gewebe", "mit", "rotem", "Licht", "(", "570", "-", "750", "nm", ";", "180", "J", "/", "cm2", ")", "bestrahlt", ".", "Die", "PDT", "wurde", "zweimal", "wiederholt", ".", "Hierdurch", "konnte", "klinisch", "eine", "nahezu", "vollstaendige", "Remission", "des", "Tumors", "erzielt", "werden", ".", "In", "der", "photodynamischen", "Diagnostik", "(", "PDD", ")", "zeigten", "sich", "aber", "noch", "deutlich", "einige", "persistierende", ",", "z.", "T.", "die", "Mamille", "infiltrierende", "Basaliominseln", ".", "Diese", "wurden", "durch", "Exzision", "entfernt", "und", "anschliessend", "wurde", "der", "Defekt", "mittels", "einer", "Mamillenplastik", "verschlossen", ".", "Durch", "die", "Kombination", "der", "beiden", "Therapieformen", "konnte", "der", "grossflaechige", "Tumor", "mit", "einem", "ausgezeichneten", "kosmetischen", "Ergebnis", "behandelt", "werden", ".", "Die", "Falldarstellung", "soll", "zum", "einen", "die", "Grenzen", "der", "topischen", "PDT", ",", "zum", "anderen", "die", "Effizienz", "der", "PDD", "bei", "gezieltem", "Einsatz", "darstellen", "." ]

[ "umlsterm" ]

Behandlung is an umlsterm, Histologie is an umlsterm, Rumpfhautbasalioms is an umlsterm, Tumor is an umlsterm, photodynamischen Therapie is an umlsterm, Gewebe is an umlsterm, Licht is an umlsterm, Tumors is an umlsterm, Diagnostik is an umlsterm, Therapieformen is an umlsterm, Tumor is an umlsterm, Effizienz is an umlsterm, gezieltem is an umlsterm

DerHautarzt.60470438.ger.abstr_task1

Sentence: Es wird die Behandlung eines grossflaechigen Basalioms ( ca. 10x6 cm ) an der rechten Mamma einer 48jaehrigen Patientin dargestellt . Aufgrund der Histologie eines oberflaechlichen Rumpfhautbasalioms entschlossen wir uns , den Tumor mit der photodynamischen Therapie ( PDT ) zu behandeln . Hierzu wurden -Aminolaevulinsaeure ( -ALA , 20% ) topisch aufgetragen und das Gewebe mit rotem Licht ( 570-750 nm ; 180 J/cm2) bestrahlt . Die PDT wurde zweimal wiederholt . Hierdurch konnte klinisch eine nahezu vollstaendige Remission des Tumors erzielt werden . In der photodynamischen Diagnostik ( PDD ) zeigten sich aber noch deutlich einige persistierende , z.T. die Mamille infiltrierende Basaliominseln . Diese wurden durch Exzision entfernt und anschliessend wurde der Defekt mittels einer Mamillenplastik verschlossen . Durch die Kombination der beiden Therapieformen konnte der grossflaechige Tumor mit einem ausgezeichneten kosmetischen Ergebnis behandelt werden . Die Falldarstellung soll zum einen die Grenzen der topischen PDT , zum anderen die Effizienz der PDD bei gezieltem Einsatz darstellen . Instructions: please typing these entity words according to sentence: Behandlung, Histologie, Rumpfhautbasalioms, Tumor, photodynamischen Therapie, Gewebe, Licht, Tumors, Diagnostik, Therapieformen, Tumor, Effizienz, gezieltem Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Es wird die Behandlung eines grossflaechigen Basalioms ( ca. 10x6 cm ) an der rechten Mamma einer 48jaehrigen Patientin dargestellt . Aufgrund der Histologie eines oberflaechlichen Rumpfhautbasalioms entschlossen wir uns , den Tumor mit der photodynamischen Therapie ( PDT ) zu behandeln . Hierzu wurden -Aminolaevulinsaeure ( -ALA , 20% ) topisch aufgetragen und das Gewebe mit rotem Licht ( 570-750 nm ; 180 J/cm2) bestrahlt . Die PDT wurde zweimal wiederholt . Hierdurch konnte klinisch eine nahezu vollstaendige Remission des Tumors erzielt werden . In der photodynamischen Diagnostik ( PDD ) zeigten sich aber noch deutlich einige persistierende , z.T. die Mamille infiltrierende Basaliominseln . Diese wurden durch Exzision entfernt und anschliessend wurde der Defekt mittels einer Mamillenplastik verschlossen . Durch die Kombination der beiden Therapieformen konnte der grossflaechige Tumor mit einem ausgezeichneten kosmetischen Ergebnis behandelt werden . Die Falldarstellung soll zum einen die Grenzen der topischen PDT , zum anderen die Effizienz der PDD bei gezieltem Einsatz darstellen .

[ "Es", "wird", "die", "Behandlung", "eines", "grossflaechigen", "Basalioms", "(", "ca", ".", "10x6", "cm", ")", "an", "der", "rechten", "Mamma", "einer", "48jaehrigen", "Patientin", "dargestellt", ".", "Aufgrund", "der", "Histologie", "eines", "oberflaechlichen", "Rumpfhautbasalioms", "entschlossen", "wir", "uns", ",", "den", "Tumor", "mit", "der", "photodynamischen", "Therapie", "(", "PDT", ")", "zu", "behandeln", ".", "Hierzu", "wurden", "-Aminolaevulinsaeure", "(", "-ALA", ",", "20", "%", ")", "topisch", "aufgetragen", "und", "das", "Gewebe", "mit", "rotem", "Licht", "(", "570", "-", "750", "nm", ";", "180", "J", "/", "cm2", ")", "bestrahlt", ".", "Die", "PDT", "wurde", "zweimal", "wiederholt", ".", "Hierdurch", "konnte", "klinisch", "eine", "nahezu", "vollstaendige", "Remission", "des", "Tumors", "erzielt", "werden", ".", "In", "der", "photodynamischen", "Diagnostik", "(", "PDD", ")", "zeigten", "sich", "aber", "noch", "deutlich", "einige", "persistierende", ",", "z.", "T.", "die", "Mamille", "infiltrierende", "Basaliominseln", ".", "Diese", "wurden", "durch", "Exzision", "entfernt", "und", "anschliessend", "wurde", "der", "Defekt", "mittels", "einer", "Mamillenplastik", "verschlossen", ".", "Durch", "die", "Kombination", "der", "beiden", "Therapieformen", "konnte", "der", "grossflaechige", "Tumor", "mit", "einem", "ausgezeichneten", "kosmetischen", "Ergebnis", "behandelt", "werden", ".", "Die", "Falldarstellung", "soll", "zum", "einen", "die", "Grenzen", "der", "topischen", "PDT", ",", "zum", "anderen", "die", "Effizienz", "der", "PDD", "bei", "gezieltem", "Einsatz", "darstellen", "." ]

[ "umlsterm" ]

Behandlung, Histologie, Rumpfhautbasalioms, Tumor, photodynamischen Therapie, Gewebe, Licht, Tumors, Diagnostik, Therapieformen, Tumor, Effizienz, gezieltem

DerHautarzt.60470438.ger.abstr_task2

Sentence: Es wird die Behandlung eines grossflaechigen Basalioms ( ca. 10x6 cm ) an der rechten Mamma einer 48jaehrigen Patientin dargestellt . Aufgrund der Histologie eines oberflaechlichen Rumpfhautbasalioms entschlossen wir uns , den Tumor mit der photodynamischen Therapie ( PDT ) zu behandeln . Hierzu wurden -Aminolaevulinsaeure ( -ALA , 20% ) topisch aufgetragen und das Gewebe mit rotem Licht ( 570-750 nm ; 180 J/cm2) bestrahlt . Die PDT wurde zweimal wiederholt . Hierdurch konnte klinisch eine nahezu vollstaendige Remission des Tumors erzielt werden . In der photodynamischen Diagnostik ( PDD ) zeigten sich aber noch deutlich einige persistierende , z.T. die Mamille infiltrierende Basaliominseln . Diese wurden durch Exzision entfernt und anschliessend wurde der Defekt mittels einer Mamillenplastik verschlossen . Durch die Kombination der beiden Therapieformen konnte der grossflaechige Tumor mit einem ausgezeichneten kosmetischen Ergebnis behandelt werden . Die Falldarstellung soll zum einen die Grenzen der topischen PDT , zum anderen die Effizienz der PDD bei gezieltem Einsatz darstellen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Es wird die Behandlung eines grossflaechigen Basalioms ( ca. 10x6 cm ) an der rechten Mamma einer 48jaehrigen Patientin dargestellt . Aufgrund der Histologie eines oberflaechlichen Rumpfhautbasalioms entschlossen wir uns , den Tumor mit der photodynamischen Therapie ( PDT ) zu behandeln . Hierzu wurden -Aminolaevulinsaeure ( -ALA , 20% ) topisch aufgetragen und das Gewebe mit rotem Licht ( 570-750 nm ; 180 J/cm2) bestrahlt . Die PDT wurde zweimal wiederholt . Hierdurch konnte klinisch eine nahezu vollstaendige Remission des Tumors erzielt werden . In der photodynamischen Diagnostik ( PDD ) zeigten sich aber noch deutlich einige persistierende , z.T. die Mamille infiltrierende Basaliominseln . Diese wurden durch Exzision entfernt und anschliessend wurde der Defekt mittels einer Mamillenplastik verschlossen . Durch die Kombination der beiden Therapieformen konnte der grossflaechige Tumor mit einem ausgezeichneten kosmetischen Ergebnis behandelt werden . Die Falldarstellung soll zum einen die Grenzen der topischen PDT , zum anderen die Effizienz der PDD bei gezieltem Einsatz darstellen .

[ "Es", "wird", "die", "Behandlung", "eines", "grossflaechigen", "Basalioms", "(", "ca", ".", "10x6", "cm", ")", "an", "der", "rechten", "Mamma", "einer", "48jaehrigen", "Patientin", "dargestellt", ".", "Aufgrund", "der", "Histologie", "eines", "oberflaechlichen", "Rumpfhautbasalioms", "entschlossen", "wir", "uns", ",", "den", "Tumor", "mit", "der", "photodynamischen", "Therapie", "(", "PDT", ")", "zu", "behandeln", ".", "Hierzu", "wurden", "-Aminolaevulinsaeure", "(", "-ALA", ",", "20", "%", ")", "topisch", "aufgetragen", "und", "das", "Gewebe", "mit", "rotem", "Licht", "(", "570", "-", "750", "nm", ";", "180", "J", "/", "cm2", ")", "bestrahlt", ".", "Die", "PDT", "wurde", "zweimal", "wiederholt", ".", "Hierdurch", "konnte", "klinisch", "eine", "nahezu", "vollstaendige", "Remission", "des", "Tumors", "erzielt", "werden", ".", "In", "der", "photodynamischen", "Diagnostik", "(", "PDD", ")", "zeigten", "sich", "aber", "noch", "deutlich", "einige", "persistierende", ",", "z.", "T.", "die", "Mamille", "infiltrierende", "Basaliominseln", ".", "Diese", "wurden", "durch", "Exzision", "entfernt", "und", "anschliessend", "wurde", "der", "Defekt", "mittels", "einer", "Mamillenplastik", "verschlossen", ".", "Durch", "die", "Kombination", "der", "beiden", "Therapieformen", "konnte", "der", "grossflaechige", "Tumor", "mit", "einem", "ausgezeichneten", "kosmetischen", "Ergebnis", "behandelt", "werden", ".", "Die", "Falldarstellung", "soll", "zum", "einen", "die", "Grenzen", "der", "topischen", "PDT", ",", "zum", "anderen", "die", "Effizienz", "der", "PDD", "bei", "gezieltem", "Einsatz", "darstellen", "." ]

[ "umlsterm" ]

Sp1 is a protein

1.0alpha7.train.354_task0

Sentence: The results of this study suggest that the third positive response element at bp 125 also binds Sp1. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O" ]

The results of this study suggest that the third positive response element at bp 125 also binds Sp1.

[ "The", "results", "of", "this", "study", "suggest", "that", "the", "third", "positive", "response", "element", "at", " ", "bp", " ", "125", "also", "binds", " ", "Sp1", "." ]

[ "protein" ]

Sp1 is a protein

1.0alpha7.train.354_task1

Sentence: The results of this study suggest that the third positive response element at bp 125 also binds Sp1. Instructions: please typing these entity words according to sentence: Sp1 Options: protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O" ]

The results of this study suggest that the third positive response element at bp 125 also binds Sp1.

[ "The", "results", "of", "this", "study", "suggest", "that", "the", "third", "positive", "response", "element", "at", " ", "bp", " ", "125", "also", "binds", " ", "Sp1", "." ]

[ "protein" ]

Sp1

1.0alpha7.train.354_task2

Sentence: The results of this study suggest that the third positive response element at bp 125 also binds Sp1. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O" ]

The results of this study suggest that the third positive response element at bp 125 also binds Sp1.

[ "The", "results", "of", "this", "study", "suggest", "that", "the", "third", "positive", "response", "element", "at", " ", "bp", " ", "125", "also", "binds", " ", "Sp1", "." ]

[ "protein" ]

Sentinel lymph node detection is a Outcome_Physical, adjuvant therapy is a Intervention_Pharmacological, sensibility in detect positive nodes is a Outcome_Physical, stage and prognosis is a Outcome_Physical, utilizing either patent blue alone , or in association with radiotracer based on technetium 99 m colloid solution in a randomized fashion is a Intervention_Physical, mean number of sentinel nodes per patient is a Outcome_Other, transoperative lympho - scintigraphy is a Outcome_Physical, extra sentinel nodes is a Outcome_Physical, association of hematoxylin and eosin and immunohistochemical examination is a Outcome_Physical, feasible is a Outcome_Other, simple is a Outcome_Other, produce upstage is a Outcome_Other, Blue staining and radio guided techniques is a Intervention_Physical, safe is a Outcome_Other, accuracy is a Outcome_Other, lymph drainage is a Outcome_Physical, Upstaging rate is a Outcome_Other, chemotherapy is a Intervention_Pharmacological

29074_task0

Sentence: [ Sentinel lymph node detection in colorectal cancer : importance , techniques and results ] . BACKGROUND AND AIM Considering that lymph node status is a key factor in colorectal cancer staging , and the main determinant for adjuvant therapy of colorectal cancer being this therapy , responsible for a significant increase in colorectal cancer patients survival , the staging methods should be the most accurate possible in order to offer this individuals the opportunity to be adequate treated in order to achieve the best survival possible . Sentinel lymph node study is progressively being popularized as a method that increases sensibility in detect positive nodes to reveal a more accurate stage and prognosis in colorectal cancer patients . PATIENTS AND METHODS Thirty one colorectal cancer patients were prospectively studied and sentinel lymph node was identified in 100 % of the cases utilizing either patent blue alone , or in association with radiotracer based on technetium 99m colloid solution in a randomized fashion . RESULTS The mean number of sentinel nodes per patient was 1.96 ranging from 1 to 3 nodes . With the addition of transoperative lympho-scintigraphy five extra sentinel nodes , not identified by the blue dye alone , were identified and considered for histopathology study . In four cases ( 12.9 % ) the sentinel lymph node was the only site of metastasis , all of them being detected by association of hematoxylin and eosin and immunohistochemical examination . CONCLUSION Sentinel lymph node detection and analysis is feasible , technique is relatively simple and is able to produce upstage in colorectal cancer . Blue staining and radio guided techniques are both safe and their superposition has shown good results in terms of increase accuracy in our experience . There was no aberrant lymph drainage that would alter resection margins in patients studied . Upstaging rate , identifying potential candidates for adjuvant therapy was 12.9 % ( 4/31 ) . To this individuals chemotherapy could be a chance to increase their global survival . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Outcome_Other, Intervention_Pharmacological, Outcome_Physical

[ "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

[ Sentinel lymph node detection in colorectal cancer : importance , techniques and results ] . BACKGROUND AND AIM Considering that lymph node status is a key factor in colorectal cancer staging , and the main determinant for adjuvant therapy of colorectal cancer being this therapy , responsible for a significant increase in colorectal cancer patients survival , the staging methods should be the most accurate possible in order to offer this individuals the opportunity to be adequate treated in order to achieve the best survival possible . Sentinel lymph node study is progressively being popularized as a method that increases sensibility in detect positive nodes to reveal a more accurate stage and prognosis in colorectal cancer patients . PATIENTS AND METHODS Thirty one colorectal cancer patients were prospectively studied and sentinel lymph node was identified in 100 % of the cases utilizing either patent blue alone , or in association with radiotracer based on technetium 99m colloid solution in a randomized fashion . RESULTS The mean number of sentinel nodes per patient was 1.96 ranging from 1 to 3 nodes . With the addition of transoperative lympho-scintigraphy five extra sentinel nodes , not identified by the blue dye alone , were identified and considered for histopathology study . In four cases ( 12.9 % ) the sentinel lymph node was the only site of metastasis , all of them being detected by association of hematoxylin and eosin and immunohistochemical examination . CONCLUSION Sentinel lymph node detection and analysis is feasible , technique is relatively simple and is able to produce upstage in colorectal cancer . Blue staining and radio guided techniques are both safe and their superposition has shown good results in terms of increase accuracy in our experience . There was no aberrant lymph drainage that would alter resection margins in patients studied . Upstaging rate , identifying potential candidates for adjuvant therapy was 12.9 % ( 4/31 ) . To this individuals chemotherapy could be a chance to increase their global survival .

[ "[", "Sentinel", "lymph", "node", "detection", "in", "colorectal", "cancer", ":", "importance", ",", "techniques", "and", "results", "]", ".", "BACKGROUND", "AND", "AIM", "Considering", "that", "lymph", "node", "status", "is", "a", "key", "factor", "in", "colorectal", "cancer", "staging", ",", "and", "the", "main", "determinant", "for", "adjuvant", "therapy", "of", "colorectal", "cancer", "being", "this", "therapy", ",", "responsible", "for", "a", "significant", "increase", "in", "colorectal", "cancer", "patients", "survival", ",", "the", "staging", "methods", "should", "be", "the", "most", "accurate", "possible", "in", "order", "to", "offer", "this", "individuals", "the", "opportunity", "to", "be", "adequate", "treated", "in", "order", "to", "achieve", "the", "best", "survival", "possible", ".", "Sentinel", "lymph", "node", "study", "is", "progressively", "being", "popularized", "as", "a", "method", "that", "increases", "sensibility", "in", "detect", "positive", "nodes", "to", "reveal", "a", "more", "accurate", "stage", "and", "prognosis", "in", "colorectal", "cancer", "patients", ".", "PATIENTS", "AND", "METHODS", "Thirty", "one", "colorectal", "cancer", "patients", "were", "prospectively", "studied", "and", "sentinel", "lymph", "node", "was", "identified", "in", "100", "%", "of", "the", "cases", "utilizing", "either", "patent", "blue", "alone", ",", "or", "in", "association", "with", "radiotracer", "based", "on", "technetium", "99", "m", "colloid", "solution", "in", "a", "randomized", "fashion", ".", "RESULTS", "The", "mean", "number", "of", "sentinel", "nodes", "per", "patient", "was", "1.96", "ranging", "from", "1", "to", "3", "nodes", ".", "With", "the", "addition", "of", "transoperative", "lympho", "-", "scintigraphy", "five", "extra", "sentinel", "nodes", ",", "not", "identified", "by", "the", "blue", "dye", "alone", ",", "were", "identified", "and", "considered", "for", "histopathology", "study", ".", "In", "four", "cases", "(", "12.9", "%", ")", "the", "sentinel", "lymph", "node", "was", "the", "only", "site", "of", "metastasis", ",", "all", "of", "them", "being", "detected", "by", "association", "of", "hematoxylin", "and", "eosin", "and", "immunohistochemical", "examination", ".", "CONCLUSION", "Sentinel", "lymph", "node", "detection", "and", "analysis", "is", "feasible", ",", "technique", "is", "relatively", "simple", "and", "is", "able", "to", "produce", "upstage", "in", "colorectal", "cancer", ".", "Blue", "staining", "and", "radio", "guided", "techniques", "are", "both", "safe", "and", "their", "superposition", "has", "shown", "good", "results", "in", "terms", "of", "increase", "accuracy", "in", "our", "experience", ".", "There", "was", "no", "aberrant", "lymph", "drainage", "that", "would", "alter", "resection", "margins", "in", "patients", "studied", ".", "Upstaging", "rate", ",", "identifying", "potential", "candidates", "for", "adjuvant", "therapy", "was", "12.9", "%", "(", "4/31", ")", ".", "To", "this", "individuals", "chemotherapy", "could", "be", "a", "chance", "to", "increase", "their", "global", "survival", "." ]

[ "Intervention_Physical", "Outcome_Physical", "Outcome_Other", "Intervention_Pharmacological" ]

Sentinel lymph node detection is a Outcome_Physical, adjuvant therapy is a Intervention_Pharmacological, sensibility in detect positive nodes is a Outcome_Physical, stage and prognosis is a Outcome_Physical, utilizing either patent blue alone , or in association with radiotracer based on technetium 99 m colloid solution in a randomized fashion is a Intervention_Physical, mean number of sentinel nodes per patient is a Outcome_Other, transoperative lympho - scintigraphy is a Outcome_Physical, extra sentinel nodes is a Outcome_Physical, association of hematoxylin and eosin and immunohistochemical examination is a Outcome_Physical, feasible is a Outcome_Other, simple is a Outcome_Other, produce upstage is a Outcome_Other, Blue staining and radio guided techniques is a Intervention_Physical, safe is a Outcome_Other, accuracy is a Outcome_Other, lymph drainage is a Outcome_Physical, Upstaging rate is a Outcome_Other, chemotherapy is a Intervention_Pharmacological

29074_task1

Sentence: [ Sentinel lymph node detection in colorectal cancer : importance , techniques and results ] . BACKGROUND AND AIM Considering that lymph node status is a key factor in colorectal cancer staging , and the main determinant for adjuvant therapy of colorectal cancer being this therapy , responsible for a significant increase in colorectal cancer patients survival , the staging methods should be the most accurate possible in order to offer this individuals the opportunity to be adequate treated in order to achieve the best survival possible . Sentinel lymph node study is progressively being popularized as a method that increases sensibility in detect positive nodes to reveal a more accurate stage and prognosis in colorectal cancer patients . PATIENTS AND METHODS Thirty one colorectal cancer patients were prospectively studied and sentinel lymph node was identified in 100 % of the cases utilizing either patent blue alone , or in association with radiotracer based on technetium 99m colloid solution in a randomized fashion . RESULTS The mean number of sentinel nodes per patient was 1.96 ranging from 1 to 3 nodes . With the addition of transoperative lympho-scintigraphy five extra sentinel nodes , not identified by the blue dye alone , were identified and considered for histopathology study . In four cases ( 12.9 % ) the sentinel lymph node was the only site of metastasis , all of them being detected by association of hematoxylin and eosin and immunohistochemical examination . CONCLUSION Sentinel lymph node detection and analysis is feasible , technique is relatively simple and is able to produce upstage in colorectal cancer . Blue staining and radio guided techniques are both safe and their superposition has shown good results in terms of increase accuracy in our experience . There was no aberrant lymph drainage that would alter resection margins in patients studied . Upstaging rate , identifying potential candidates for adjuvant therapy was 12.9 % ( 4/31 ) . To this individuals chemotherapy could be a chance to increase their global survival . Instructions: please typing these entity words according to sentence: Sentinel lymph node detection, adjuvant therapy, sensibility in detect positive nodes, stage and prognosis, utilizing either patent blue alone , or in association with radiotracer based on technetium 99 m colloid solution in a randomized fashion, mean number of sentinel nodes per patient, transoperative lympho - scintigraphy, extra sentinel nodes, association of hematoxylin and eosin and immunohistochemical examination, feasible, simple, produce upstage, Blue staining and radio guided techniques, safe, accuracy, lymph drainage, Upstaging rate, chemotherapy Options: Intervention_Physical, Outcome_Other, Intervention_Pharmacological, Outcome_Physical

[ "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

[ Sentinel lymph node detection in colorectal cancer : importance , techniques and results ] . BACKGROUND AND AIM Considering that lymph node status is a key factor in colorectal cancer staging , and the main determinant for adjuvant therapy of colorectal cancer being this therapy , responsible for a significant increase in colorectal cancer patients survival , the staging methods should be the most accurate possible in order to offer this individuals the opportunity to be adequate treated in order to achieve the best survival possible . Sentinel lymph node study is progressively being popularized as a method that increases sensibility in detect positive nodes to reveal a more accurate stage and prognosis in colorectal cancer patients . PATIENTS AND METHODS Thirty one colorectal cancer patients were prospectively studied and sentinel lymph node was identified in 100 % of the cases utilizing either patent blue alone , or in association with radiotracer based on technetium 99m colloid solution in a randomized fashion . RESULTS The mean number of sentinel nodes per patient was 1.96 ranging from 1 to 3 nodes . With the addition of transoperative lympho-scintigraphy five extra sentinel nodes , not identified by the blue dye alone , were identified and considered for histopathology study . In four cases ( 12.9 % ) the sentinel lymph node was the only site of metastasis , all of them being detected by association of hematoxylin and eosin and immunohistochemical examination . CONCLUSION Sentinel lymph node detection and analysis is feasible , technique is relatively simple and is able to produce upstage in colorectal cancer . Blue staining and radio guided techniques are both safe and their superposition has shown good results in terms of increase accuracy in our experience . There was no aberrant lymph drainage that would alter resection margins in patients studied . Upstaging rate , identifying potential candidates for adjuvant therapy was 12.9 % ( 4/31 ) . To this individuals chemotherapy could be a chance to increase their global survival .

[ "[", "Sentinel", "lymph", "node", "detection", "in", "colorectal", "cancer", ":", "importance", ",", "techniques", "and", "results", "]", ".", "BACKGROUND", "AND", "AIM", "Considering", "that", "lymph", "node", "status", "is", "a", "key", "factor", "in", "colorectal", "cancer", "staging", ",", "and", "the", "main", "determinant", "for", "adjuvant", "therapy", "of", "colorectal", "cancer", "being", "this", "therapy", ",", "responsible", "for", "a", "significant", "increase", "in", "colorectal", "cancer", "patients", "survival", ",", "the", "staging", "methods", "should", "be", "the", "most", "accurate", "possible", "in", "order", "to", "offer", "this", "individuals", "the", "opportunity", "to", "be", "adequate", "treated", "in", "order", "to", "achieve", "the", "best", "survival", "possible", ".", "Sentinel", "lymph", "node", "study", "is", "progressively", "being", "popularized", "as", "a", "method", "that", "increases", "sensibility", "in", "detect", "positive", "nodes", "to", "reveal", "a", "more", "accurate", "stage", "and", "prognosis", "in", "colorectal", "cancer", "patients", ".", "PATIENTS", "AND", "METHODS", "Thirty", "one", "colorectal", "cancer", "patients", "were", "prospectively", "studied", "and", "sentinel", "lymph", "node", "was", "identified", "in", "100", "%", "of", "the", "cases", "utilizing", "either", "patent", "blue", "alone", ",", "or", "in", "association", "with", "radiotracer", "based", "on", "technetium", "99", "m", "colloid", "solution", "in", "a", "randomized", "fashion", ".", "RESULTS", "The", "mean", "number", "of", "sentinel", "nodes", "per", "patient", "was", "1.96", "ranging", "from", "1", "to", "3", "nodes", ".", "With", "the", "addition", "of", "transoperative", "lympho", "-", "scintigraphy", "five", "extra", "sentinel", "nodes", ",", "not", "identified", "by", "the", "blue", "dye", "alone", ",", "were", "identified", "and", "considered", "for", "histopathology", "study", ".", "In", "four", "cases", "(", "12.9", "%", ")", "the", "sentinel", "lymph", "node", "was", "the", "only", "site", "of", "metastasis", ",", "all", "of", "them", "being", "detected", "by", "association", "of", "hematoxylin", "and", "eosin", "and", "immunohistochemical", "examination", ".", "CONCLUSION", "Sentinel", "lymph", "node", "detection", "and", "analysis", "is", "feasible", ",", "technique", "is", "relatively", "simple", "and", "is", "able", "to", "produce", "upstage", "in", "colorectal", "cancer", ".", "Blue", "staining", "and", "radio", "guided", "techniques", "are", "both", "safe", "and", "their", "superposition", "has", "shown", "good", "results", "in", "terms", "of", "increase", "accuracy", "in", "our", "experience", ".", "There", "was", "no", "aberrant", "lymph", "drainage", "that", "would", "alter", "resection", "margins", "in", "patients", "studied", ".", "Upstaging", "rate", ",", "identifying", "potential", "candidates", "for", "adjuvant", "therapy", "was", "12.9", "%", "(", "4/31", ")", ".", "To", "this", "individuals", "chemotherapy", "could", "be", "a", "chance", "to", "increase", "their", "global", "survival", "." ]

[ "Intervention_Physical", "Outcome_Physical", "Outcome_Other", "Intervention_Pharmacological" ]

Sentinel lymph node detection, adjuvant therapy, sensibility in detect positive nodes, stage and prognosis, utilizing either patent blue alone , or in association with radiotracer based on technetium 99 m colloid solution in a randomized fashion, mean number of sentinel nodes per patient, transoperative lympho - scintigraphy, extra sentinel nodes, association of hematoxylin and eosin and immunohistochemical examination, feasible, simple, produce upstage, Blue staining and radio guided techniques, safe, accuracy, lymph drainage, Upstaging rate, chemotherapy

29074_task2

Sentence: [ Sentinel lymph node detection in colorectal cancer : importance , techniques and results ] . BACKGROUND AND AIM Considering that lymph node status is a key factor in colorectal cancer staging , and the main determinant for adjuvant therapy of colorectal cancer being this therapy , responsible for a significant increase in colorectal cancer patients survival , the staging methods should be the most accurate possible in order to offer this individuals the opportunity to be adequate treated in order to achieve the best survival possible . Sentinel lymph node study is progressively being popularized as a method that increases sensibility in detect positive nodes to reveal a more accurate stage and prognosis in colorectal cancer patients . PATIENTS AND METHODS Thirty one colorectal cancer patients were prospectively studied and sentinel lymph node was identified in 100 % of the cases utilizing either patent blue alone , or in association with radiotracer based on technetium 99m colloid solution in a randomized fashion . RESULTS The mean number of sentinel nodes per patient was 1.96 ranging from 1 to 3 nodes . With the addition of transoperative lympho-scintigraphy five extra sentinel nodes , not identified by the blue dye alone , were identified and considered for histopathology study . In four cases ( 12.9 % ) the sentinel lymph node was the only site of metastasis , all of them being detected by association of hematoxylin and eosin and immunohistochemical examination . CONCLUSION Sentinel lymph node detection and analysis is feasible , technique is relatively simple and is able to produce upstage in colorectal cancer . Blue staining and radio guided techniques are both safe and their superposition has shown good results in terms of increase accuracy in our experience . There was no aberrant lymph drainage that would alter resection margins in patients studied . Upstaging rate , identifying potential candidates for adjuvant therapy was 12.9 % ( 4/31 ) . To this individuals chemotherapy could be a chance to increase their global survival . Instructions: please extract entity words from the input sentence

[ "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

[ Sentinel lymph node detection in colorectal cancer : importance , techniques and results ] . BACKGROUND AND AIM Considering that lymph node status is a key factor in colorectal cancer staging , and the main determinant for adjuvant therapy of colorectal cancer being this therapy , responsible for a significant increase in colorectal cancer patients survival , the staging methods should be the most accurate possible in order to offer this individuals the opportunity to be adequate treated in order to achieve the best survival possible . Sentinel lymph node study is progressively being popularized as a method that increases sensibility in detect positive nodes to reveal a more accurate stage and prognosis in colorectal cancer patients . PATIENTS AND METHODS Thirty one colorectal cancer patients were prospectively studied and sentinel lymph node was identified in 100 % of the cases utilizing either patent blue alone , or in association with radiotracer based on technetium 99m colloid solution in a randomized fashion . RESULTS The mean number of sentinel nodes per patient was 1.96 ranging from 1 to 3 nodes . With the addition of transoperative lympho-scintigraphy five extra sentinel nodes , not identified by the blue dye alone , were identified and considered for histopathology study . In four cases ( 12.9 % ) the sentinel lymph node was the only site of metastasis , all of them being detected by association of hematoxylin and eosin and immunohistochemical examination . CONCLUSION Sentinel lymph node detection and analysis is feasible , technique is relatively simple and is able to produce upstage in colorectal cancer . Blue staining and radio guided techniques are both safe and their superposition has shown good results in terms of increase accuracy in our experience . There was no aberrant lymph drainage that would alter resection margins in patients studied . Upstaging rate , identifying potential candidates for adjuvant therapy was 12.9 % ( 4/31 ) . To this individuals chemotherapy could be a chance to increase their global survival .

[ "[", "Sentinel", "lymph", "node", "detection", "in", "colorectal", "cancer", ":", "importance", ",", "techniques", "and", "results", "]", ".", "BACKGROUND", "AND", "AIM", "Considering", "that", "lymph", "node", "status", "is", "a", "key", "factor", "in", "colorectal", "cancer", "staging", ",", "and", "the", "main", "determinant", "for", "adjuvant", "therapy", "of", "colorectal", "cancer", "being", "this", "therapy", ",", "responsible", "for", "a", "significant", "increase", "in", "colorectal", "cancer", "patients", "survival", ",", "the", "staging", "methods", "should", "be", "the", "most", "accurate", "possible", "in", "order", "to", "offer", "this", "individuals", "the", "opportunity", "to", "be", "adequate", "treated", "in", "order", "to", "achieve", "the", "best", "survival", "possible", ".", "Sentinel", "lymph", "node", "study", "is", "progressively", "being", "popularized", "as", "a", "method", "that", "increases", "sensibility", "in", "detect", "positive", "nodes", "to", "reveal", "a", "more", "accurate", "stage", "and", "prognosis", "in", "colorectal", "cancer", "patients", ".", "PATIENTS", "AND", "METHODS", "Thirty", "one", "colorectal", "cancer", "patients", "were", "prospectively", "studied", "and", "sentinel", "lymph", "node", "was", "identified", "in", "100", "%", "of", "the", "cases", "utilizing", "either", "patent", "blue", "alone", ",", "or", "in", "association", "with", "radiotracer", "based", "on", "technetium", "99", "m", "colloid", "solution", "in", "a", "randomized", "fashion", ".", "RESULTS", "The", "mean", "number", "of", "sentinel", "nodes", "per", "patient", "was", "1.96", "ranging", "from", "1", "to", "3", "nodes", ".", "With", "the", "addition", "of", "transoperative", "lympho", "-", "scintigraphy", "five", "extra", "sentinel", "nodes", ",", "not", "identified", "by", "the", "blue", "dye", "alone", ",", "were", "identified", "and", "considered", "for", "histopathology", "study", ".", "In", "four", "cases", "(", "12.9", "%", ")", "the", "sentinel", "lymph", "node", "was", "the", "only", "site", "of", "metastasis", ",", "all", "of", "them", "being", "detected", "by", "association", "of", "hematoxylin", "and", "eosin", "and", "immunohistochemical", "examination", ".", "CONCLUSION", "Sentinel", "lymph", "node", "detection", "and", "analysis", "is", "feasible", ",", "technique", "is", "relatively", "simple", "and", "is", "able", "to", "produce", "upstage", "in", "colorectal", "cancer", ".", "Blue", "staining", "and", "radio", "guided", "techniques", "are", "both", "safe", "and", "their", "superposition", "has", "shown", "good", "results", "in", "terms", "of", "increase", "accuracy", "in", "our", "experience", ".", "There", "was", "no", "aberrant", "lymph", "drainage", "that", "would", "alter", "resection", "margins", "in", "patients", "studied", ".", "Upstaging", "rate", ",", "identifying", "potential", "candidates", "for", "adjuvant", "therapy", "was", "12.9", "%", "(", "4/31", ")", ".", "To", "this", "individuals", "chemotherapy", "could", "be", "a", "chance", "to", "increase", "their", "global", "survival", "." ]

[ "Intervention_Physical", "Outcome_Physical", "Outcome_Other", "Intervention_Pharmacological" ]

ATP is a CHEMICAL, GLUT4 is a GENE-Y, Glucose is a CHEMICAL, PI3Kγ is a GENE-Y, Akt is a GENE-N, AS160 is a GENE-Y

23274898_task0

Sentence: Electrical Stimuli Release ATP to Increase GLUT4 Translocation and Glucose Uptake via PI3Kγ-Akt-AS160 in Skeletal Muscle Cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, GENE-Y, CHEMICAL

[ "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "B-GENE-N", "O", "B-GENE-Y", "O", "O", "O", "O", "O" ]

Electrical Stimuli Release ATP to Increase GLUT4 Translocation and Glucose Uptake via PI3Kγ-Akt-AS160 in Skeletal Muscle Cells.

[ "Electrical", "Stimuli", "Release", "ATP", "to", "Increase", "GLUT4", "Translocation", "and", "Glucose", "Uptake", "via", "PI3Kγ", "-", "Akt", "-", "AS160", "in", "Skeletal", "Muscle", "Cells", "." ]

[ "GENE-Y", "GENE-N", "CHEMICAL" ]

ATP is a CHEMICAL, GLUT4 is a GENE-Y, Glucose is a CHEMICAL, PI3Kγ is a GENE-Y, Akt is a GENE-N, AS160 is a GENE-Y

23274898_task1

Sentence: Electrical Stimuli Release ATP to Increase GLUT4 Translocation and Glucose Uptake via PI3Kγ-Akt-AS160 in Skeletal Muscle Cells. Instructions: please typing these entity words according to sentence: ATP, GLUT4, Glucose, PI3Kγ, Akt, AS160 Options: GENE-N, GENE-Y, CHEMICAL

[ "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "B-GENE-N", "O", "B-GENE-Y", "O", "O", "O", "O", "O" ]

Electrical Stimuli Release ATP to Increase GLUT4 Translocation and Glucose Uptake via PI3Kγ-Akt-AS160 in Skeletal Muscle Cells.

[ "Electrical", "Stimuli", "Release", "ATP", "to", "Increase", "GLUT4", "Translocation", "and", "Glucose", "Uptake", "via", "PI3Kγ", "-", "Akt", "-", "AS160", "in", "Skeletal", "Muscle", "Cells", "." ]

[ "GENE-Y", "GENE-N", "CHEMICAL" ]

ATP, GLUT4, Glucose, PI3Kγ, Akt, AS160

23274898_task2

Sentence: Electrical Stimuli Release ATP to Increase GLUT4 Translocation and Glucose Uptake via PI3Kγ-Akt-AS160 in Skeletal Muscle Cells. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "B-GENE-N", "O", "B-GENE-Y", "O", "O", "O", "O", "O" ]

Electrical Stimuli Release ATP to Increase GLUT4 Translocation and Glucose Uptake via PI3Kγ-Akt-AS160 in Skeletal Muscle Cells.

[ "Electrical", "Stimuli", "Release", "ATP", "to", "Increase", "GLUT4", "Translocation", "and", "Glucose", "Uptake", "via", "PI3Kγ", "-", "Akt", "-", "AS160", "in", "Skeletal", "Muscle", "Cells", "." ]

[ "GENE-Y", "GENE-N", "CHEMICAL" ]

Risperidone is a Intervention_Pharmacological, children is a Participant_Age, autism is a Participant_Condition, placebo - controlled is a Intervention_Control, . is a Outcome_Physical, risperidone is a Intervention_Pharmacological, hyperactivity is a Outcome_Mental, 40 is a Participant_Sample-size, ages ranged from 2 to 9 years is a Participant_Age, total is a Outcome_Physical, Childhood Autism Rating Scale is a Outcome_Mental, Childhood Autism Rating Scale score is a Outcome_Mental, Children ' s Global Assessment Scale score is a Outcome_Mental, social responsiveness is a Outcome_Mental, nonverbal communication is a Outcome_Mental, symptoms of is a Outcome_Physical, aggression is a Outcome_Mental, appetite is a Outcome_Physical, weight gain is a Outcome_Physical, mild sedation is a Outcome_Physical, transient dyskinesias is a Outcome_Physical, global functioning is a Outcome_Mental, reducing is a Outcome_Physical

27871_task0

Sentence: Risperidone in children with autism : randomized , placebo-controlled , double-blind study . Some open-label studies suggest that risperidone can be useful in the treatment of certain target symptoms in children with autism . We aimed to study whether the use of risperidone in comparison with placebo improved functioning in children with autism with regard to behavior ( aggressiveness , hyperactivity , irritability ) , social and emotional responsiveness , and communication skills . We conducted a randomized , double-blind , placebo-controlled trial with 40 consecutive children with autism , whose ages ranged from 2 to 9 years , who were receiving either risperidone or placebo given orally at a dose of 1 mg/day for 6 months . Autism symptoms were monitored periodically . The outcome variables were total scores on the Childhood Autism Rating Scale ( CARS ) and the Children 's Global Assessment Scale ( CGAS ) after 6 months . Of the 40 children enrolled , 39 completed the trial over a period of 18 months ; 19 received risperidone , and 20 received placebo . In the risperidone group , 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children 's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children 's Global Assessment Scale score in the placebo group ( P < .001 and P = .035 , respectively ) . Risperidone also improved social responsiveness and nonverbal communication and reduced the symptoms of hyperactivity and aggression . Risperidone was associated with increased appetite and a mild weight gain , mild sedation in 20 % , and transient dyskinesias in three children . Risperidone improved global functioning and social responsiveness while reducing hyperactivity and aggression in children with autism and was well tolerated . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Participant_Age, Participant_Sample-size, Outcome_Mental

[ "B-Intervention_Pharmacological", "O", "B-Participant_Age", "O", "B-Participant_Condition", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Risperidone in children with autism : randomized , placebo-controlled , double-blind study . Some open-label studies suggest that risperidone can be useful in the treatment of certain target symptoms in children with autism . We aimed to study whether the use of risperidone in comparison with placebo improved functioning in children with autism with regard to behavior ( aggressiveness , hyperactivity , irritability ) , social and emotional responsiveness , and communication skills . We conducted a randomized , double-blind , placebo-controlled trial with 40 consecutive children with autism , whose ages ranged from 2 to 9 years , who were receiving either risperidone or placebo given orally at a dose of 1 mg/day for 6 months . Autism symptoms were monitored periodically . The outcome variables were total scores on the Childhood Autism Rating Scale ( CARS ) and the Children 's Global Assessment Scale ( CGAS ) after 6 months . Of the 40 children enrolled , 39 completed the trial over a period of 18 months ; 19 received risperidone , and 20 received placebo . In the risperidone group , 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children 's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children 's Global Assessment Scale score in the placebo group ( P < .001 and P = .035 , respectively ) . Risperidone also improved social responsiveness and nonverbal communication and reduced the symptoms of hyperactivity and aggression . Risperidone was associated with increased appetite and a mild weight gain , mild sedation in 20 % , and transient dyskinesias in three children . Risperidone improved global functioning and social responsiveness while reducing hyperactivity and aggression in children with autism and was well tolerated .

[ "Risperidone", "in", "children", "with", "autism", ":", "randomized", ",", "placebo", "-", "controlled", ",", "double", "-", "blind", "study", ".", "Some", "open", "-", "label", "studies", "suggest", "that", "risperidone", "can", "be", "useful", "in", "the", "treatment", "of", "certain", "target", "symptoms", "in", "children", "with", "autism", ".", "We", "aimed", "to", "study", "whether", "the", "use", "of", "risperidone", "in", "comparison", "with", "placebo", "improved", "functioning", "in", "children", "with", "autism", "with", "regard", "to", "behavior", "(", "aggressiveness", ",", "hyperactivity", ",", "irritability", ")", ",", "social", "and", "emotional", "responsiveness", ",", "and", "communication", "skills", ".", "We", "conducted", "a", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", "trial", "with", "40", "consecutive", "children", "with", "autism", ",", "whose", "ages", "ranged", "from", "2", "to", "9", "years", ",", "who", "were", "receiving", "either", "risperidone", "or", "placebo", "given", "orally", "at", "a", "dose", "of", "1", "mg", "/", "day", "for", "6", "months", ".", "Autism", "symptoms", "were", "monitored", "periodically", ".", "The", "outcome", "variables", "were", "total", "scores", "on", "the", "Childhood", "Autism", "Rating", "Scale", "(", "CARS", ")", "and", "the", "Children", "'", "s", "Global", "Assessment", "Scale", "(", "CGAS", ")", "after", "6", "months", ".", "Of", "the", "40", "children", "enrolled", ",", "39", "completed", "the", "trial", "over", "a", "period", "of", "18", "months", ";", "19", "received", "risperidone", ",", "and", "20", "received", "placebo", ".", "In", "the", "risperidone", "group", ",", "12", "of", "19", "children", "showed", "improvement", "in", "the", "total", "Childhood", "Autism", "Rating", "Scale", "score", "and", "17", "of", "19", "children", "in", "the", "Children", "'", "s", "Global", "Assessment", "Scale", "score", "compared", "with", "0", "of", "20", "children", "for", "the", "Childhood", "Autism", "Rating", "Scale", "score", "and", "2", "of", "20", "children", "for", "the", "Children", "'", "s", "Global", "Assessment", "Scale", "score", "in", "the", "placebo", "group", "(", "P", "<", ".001", "and", "P", "=", ".035", ",", "respectively", ")", ".", "Risperidone", "also", "improved", "social", "responsiveness", "and", "nonverbal", "communication", "and", "reduced", "the", "symptoms", "of", "hyperactivity", "and", "aggression", ".", "Risperidone", "was", "associated", "with", "increased", "appetite", "and", "a", "mild", "weight", "gain", ",", "mild", "sedation", "in", "20", "%", ",", "and", "transient", "dyskinesias", "in", "three", "children", ".", "Risperidone", "improved", "global", "functioning", "and", "social", "responsiveness", "while", "reducing", "hyperactivity", "and", "aggression", "in", "children", "with", "autism", "and", "was", "well", "tolerated", "." ]

[ "Outcome_Mental", "Participant_Age", "Outcome_Physical", "Intervention_Control", "Intervention_Pharmacological", "Participant_Condition", "Outcome_Other", "Participant_Sample-size" ]

Risperidone is a Intervention_Pharmacological, children is a Participant_Age, autism is a Participant_Condition, placebo - controlled is a Intervention_Control, . is a Outcome_Physical, risperidone is a Intervention_Pharmacological, hyperactivity is a Outcome_Mental, 40 is a Participant_Sample-size, ages ranged from 2 to 9 years is a Participant_Age, total is a Outcome_Physical, Childhood Autism Rating Scale is a Outcome_Mental, Childhood Autism Rating Scale score is a Outcome_Mental, Children ' s Global Assessment Scale score is a Outcome_Mental, social responsiveness is a Outcome_Mental, nonverbal communication is a Outcome_Mental, symptoms of is a Outcome_Physical, aggression is a Outcome_Mental, appetite is a Outcome_Physical, weight gain is a Outcome_Physical, mild sedation is a Outcome_Physical, transient dyskinesias is a Outcome_Physical, global functioning is a Outcome_Mental, reducing is a Outcome_Physical

27871_task1

Sentence: Risperidone in children with autism : randomized , placebo-controlled , double-blind study . Some open-label studies suggest that risperidone can be useful in the treatment of certain target symptoms in children with autism . We aimed to study whether the use of risperidone in comparison with placebo improved functioning in children with autism with regard to behavior ( aggressiveness , hyperactivity , irritability ) , social and emotional responsiveness , and communication skills . We conducted a randomized , double-blind , placebo-controlled trial with 40 consecutive children with autism , whose ages ranged from 2 to 9 years , who were receiving either risperidone or placebo given orally at a dose of 1 mg/day for 6 months . Autism symptoms were monitored periodically . The outcome variables were total scores on the Childhood Autism Rating Scale ( CARS ) and the Children 's Global Assessment Scale ( CGAS ) after 6 months . Of the 40 children enrolled , 39 completed the trial over a period of 18 months ; 19 received risperidone , and 20 received placebo . In the risperidone group , 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children 's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children 's Global Assessment Scale score in the placebo group ( P < .001 and P = .035 , respectively ) . Risperidone also improved social responsiveness and nonverbal communication and reduced the symptoms of hyperactivity and aggression . Risperidone was associated with increased appetite and a mild weight gain , mild sedation in 20 % , and transient dyskinesias in three children . Risperidone improved global functioning and social responsiveness while reducing hyperactivity and aggression in children with autism and was well tolerated . Instructions: please typing these entity words according to sentence: Risperidone, children, autism, placebo - controlled, ., risperidone, hyperactivity, 40, ages ranged from 2 to 9 years, total, Childhood Autism Rating Scale, Childhood Autism Rating Scale score, Children ' s Global Assessment Scale score, social responsiveness, nonverbal communication, symptoms of, aggression, appetite, weight gain, mild sedation, transient dyskinesias, global functioning, reducing Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Participant_Age, Participant_Sample-size, Outcome_Mental

[ "B-Intervention_Pharmacological", "O", "B-Participant_Age", "O", "B-Participant_Condition", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Risperidone in children with autism : randomized , placebo-controlled , double-blind study . Some open-label studies suggest that risperidone can be useful in the treatment of certain target symptoms in children with autism . We aimed to study whether the use of risperidone in comparison with placebo improved functioning in children with autism with regard to behavior ( aggressiveness , hyperactivity , irritability ) , social and emotional responsiveness , and communication skills . We conducted a randomized , double-blind , placebo-controlled trial with 40 consecutive children with autism , whose ages ranged from 2 to 9 years , who were receiving either risperidone or placebo given orally at a dose of 1 mg/day for 6 months . Autism symptoms were monitored periodically . The outcome variables were total scores on the Childhood Autism Rating Scale ( CARS ) and the Children 's Global Assessment Scale ( CGAS ) after 6 months . Of the 40 children enrolled , 39 completed the trial over a period of 18 months ; 19 received risperidone , and 20 received placebo . In the risperidone group , 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children 's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children 's Global Assessment Scale score in the placebo group ( P < .001 and P = .035 , respectively ) . Risperidone also improved social responsiveness and nonverbal communication and reduced the symptoms of hyperactivity and aggression . Risperidone was associated with increased appetite and a mild weight gain , mild sedation in 20 % , and transient dyskinesias in three children . Risperidone improved global functioning and social responsiveness while reducing hyperactivity and aggression in children with autism and was well tolerated .

[ "Risperidone", "in", "children", "with", "autism", ":", "randomized", ",", "placebo", "-", "controlled", ",", "double", "-", "blind", "study", ".", "Some", "open", "-", "label", "studies", "suggest", "that", "risperidone", "can", "be", "useful", "in", "the", "treatment", "of", "certain", "target", "symptoms", "in", "children", "with", "autism", ".", "We", "aimed", "to", "study", "whether", "the", "use", "of", "risperidone", "in", "comparison", "with", "placebo", "improved", "functioning", "in", "children", "with", "autism", "with", "regard", "to", "behavior", "(", "aggressiveness", ",", "hyperactivity", ",", "irritability", ")", ",", "social", "and", "emotional", "responsiveness", ",", "and", "communication", "skills", ".", "We", "conducted", "a", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", "trial", "with", "40", "consecutive", "children", "with", "autism", ",", "whose", "ages", "ranged", "from", "2", "to", "9", "years", ",", "who", "were", "receiving", "either", "risperidone", "or", "placebo", "given", "orally", "at", "a", "dose", "of", "1", "mg", "/", "day", "for", "6", "months", ".", "Autism", "symptoms", "were", "monitored", "periodically", ".", "The", "outcome", "variables", "were", "total", "scores", "on", "the", "Childhood", "Autism", "Rating", "Scale", "(", "CARS", ")", "and", "the", "Children", "'", "s", "Global", "Assessment", "Scale", "(", "CGAS", ")", "after", "6", "months", ".", "Of", "the", "40", "children", "enrolled", ",", "39", "completed", "the", "trial", "over", "a", "period", "of", "18", "months", ";", "19", "received", "risperidone", ",", "and", "20", "received", "placebo", ".", "In", "the", "risperidone", "group", ",", "12", "of", "19", "children", "showed", "improvement", "in", "the", "total", "Childhood", "Autism", "Rating", "Scale", "score", "and", "17", "of", "19", "children", "in", "the", "Children", "'", "s", "Global", "Assessment", "Scale", "score", "compared", "with", "0", "of", "20", "children", "for", "the", "Childhood", "Autism", "Rating", "Scale", "score", "and", "2", "of", "20", "children", "for", "the", "Children", "'", "s", "Global", "Assessment", "Scale", "score", "in", "the", "placebo", "group", "(", "P", "<", ".001", "and", "P", "=", ".035", ",", "respectively", ")", ".", "Risperidone", "also", "improved", "social", "responsiveness", "and", "nonverbal", "communication", "and", "reduced", "the", "symptoms", "of", "hyperactivity", "and", "aggression", ".", "Risperidone", "was", "associated", "with", "increased", "appetite", "and", "a", "mild", "weight", "gain", ",", "mild", "sedation", "in", "20", "%", ",", "and", "transient", "dyskinesias", "in", "three", "children", ".", "Risperidone", "improved", "global", "functioning", "and", "social", "responsiveness", "while", "reducing", "hyperactivity", "and", "aggression", "in", "children", "with", "autism", "and", "was", "well", "tolerated", "." ]

[ "Outcome_Mental", "Participant_Age", "Outcome_Physical", "Intervention_Control", "Intervention_Pharmacological", "Participant_Condition", "Outcome_Other", "Participant_Sample-size" ]

Risperidone, children, autism, placebo - controlled, ., risperidone, hyperactivity, 40, ages ranged from 2 to 9 years, total, Childhood Autism Rating Scale, Childhood Autism Rating Scale score, Children ' s Global Assessment Scale score, social responsiveness, nonverbal communication, symptoms of, aggression, appetite, weight gain, mild sedation, transient dyskinesias, global functioning, reducing

27871_task2

Sentence: Risperidone in children with autism : randomized , placebo-controlled , double-blind study . Some open-label studies suggest that risperidone can be useful in the treatment of certain target symptoms in children with autism . We aimed to study whether the use of risperidone in comparison with placebo improved functioning in children with autism with regard to behavior ( aggressiveness , hyperactivity , irritability ) , social and emotional responsiveness , and communication skills . We conducted a randomized , double-blind , placebo-controlled trial with 40 consecutive children with autism , whose ages ranged from 2 to 9 years , who were receiving either risperidone or placebo given orally at a dose of 1 mg/day for 6 months . Autism symptoms were monitored periodically . The outcome variables were total scores on the Childhood Autism Rating Scale ( CARS ) and the Children 's Global Assessment Scale ( CGAS ) after 6 months . Of the 40 children enrolled , 39 completed the trial over a period of 18 months ; 19 received risperidone , and 20 received placebo . In the risperidone group , 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children 's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children 's Global Assessment Scale score in the placebo group ( P < .001 and P = .035 , respectively ) . Risperidone also improved social responsiveness and nonverbal communication and reduced the symptoms of hyperactivity and aggression . Risperidone was associated with increased appetite and a mild weight gain , mild sedation in 20 % , and transient dyskinesias in three children . Risperidone improved global functioning and social responsiveness while reducing hyperactivity and aggression in children with autism and was well tolerated . Instructions: please extract entity words from the input sentence

[ "B-Intervention_Pharmacological", "O", "B-Participant_Age", "O", "B-Participant_Condition", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Risperidone in children with autism : randomized , placebo-controlled , double-blind study . Some open-label studies suggest that risperidone can be useful in the treatment of certain target symptoms in children with autism . We aimed to study whether the use of risperidone in comparison with placebo improved functioning in children with autism with regard to behavior ( aggressiveness , hyperactivity , irritability ) , social and emotional responsiveness , and communication skills . We conducted a randomized , double-blind , placebo-controlled trial with 40 consecutive children with autism , whose ages ranged from 2 to 9 years , who were receiving either risperidone or placebo given orally at a dose of 1 mg/day for 6 months . Autism symptoms were monitored periodically . The outcome variables were total scores on the Childhood Autism Rating Scale ( CARS ) and the Children 's Global Assessment Scale ( CGAS ) after 6 months . Of the 40 children enrolled , 39 completed the trial over a period of 18 months ; 19 received risperidone , and 20 received placebo . In the risperidone group , 12 of 19 children showed improvement in the total Childhood Autism Rating Scale score and 17 of 19 children in the Children 's Global Assessment Scale score compared with 0 of 20 children for the Childhood Autism Rating Scale score and 2 of 20 children for the Children 's Global Assessment Scale score in the placebo group ( P < .001 and P = .035 , respectively ) . Risperidone also improved social responsiveness and nonverbal communication and reduced the symptoms of hyperactivity and aggression . Risperidone was associated with increased appetite and a mild weight gain , mild sedation in 20 % , and transient dyskinesias in three children . Risperidone improved global functioning and social responsiveness while reducing hyperactivity and aggression in children with autism and was well tolerated .

[ "Risperidone", "in", "children", "with", "autism", ":", "randomized", ",", "placebo", "-", "controlled", ",", "double", "-", "blind", "study", ".", "Some", "open", "-", "label", "studies", "suggest", "that", "risperidone", "can", "be", "useful", "in", "the", "treatment", "of", "certain", "target", "symptoms", "in", "children", "with", "autism", ".", "We", "aimed", "to", "study", "whether", "the", "use", "of", "risperidone", "in", "comparison", "with", "placebo", "improved", "functioning", "in", "children", "with", "autism", "with", "regard", "to", "behavior", "(", "aggressiveness", ",", "hyperactivity", ",", "irritability", ")", ",", "social", "and", "emotional", "responsiveness", ",", "and", "communication", "skills", ".", "We", "conducted", "a", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", "trial", "with", "40", "consecutive", "children", "with", "autism", ",", "whose", "ages", "ranged", "from", "2", "to", "9", "years", ",", "who", "were", "receiving", "either", "risperidone", "or", "placebo", "given", "orally", "at", "a", "dose", "of", "1", "mg", "/", "day", "for", "6", "months", ".", "Autism", "symptoms", "were", "monitored", "periodically", ".", "The", "outcome", "variables", "were", "total", "scores", "on", "the", "Childhood", "Autism", "Rating", "Scale", "(", "CARS", ")", "and", "the", "Children", "'", "s", "Global", "Assessment", "Scale", "(", "CGAS", ")", "after", "6", "months", ".", "Of", "the", "40", "children", "enrolled", ",", "39", "completed", "the", "trial", "over", "a", "period", "of", "18", "months", ";", "19", "received", "risperidone", ",", "and", "20", "received", "placebo", ".", "In", "the", "risperidone", "group", ",", "12", "of", "19", "children", "showed", "improvement", "in", "the", "total", "Childhood", "Autism", "Rating", "Scale", "score", "and", "17", "of", "19", "children", "in", "the", "Children", "'", "s", "Global", "Assessment", "Scale", "score", "compared", "with", "0", "of", "20", "children", "for", "the", "Childhood", "Autism", "Rating", "Scale", "score", "and", "2", "of", "20", "children", "for", "the", "Children", "'", "s", "Global", "Assessment", "Scale", "score", "in", "the", "placebo", "group", "(", "P", "<", ".001", "and", "P", "=", ".035", ",", "respectively", ")", ".", "Risperidone", "also", "improved", "social", "responsiveness", "and", "nonverbal", "communication", "and", "reduced", "the", "symptoms", "of", "hyperactivity", "and", "aggression", ".", "Risperidone", "was", "associated", "with", "increased", "appetite", "and", "a", "mild", "weight", "gain", ",", "mild", "sedation", "in", "20", "%", ",", "and", "transient", "dyskinesias", "in", "three", "children", ".", "Risperidone", "improved", "global", "functioning", "and", "social", "responsiveness", "while", "reducing", "hyperactivity", "and", "aggression", "in", "children", "with", "autism", "and", "was", "well", "tolerated", "." ]

[ "Outcome_Mental", "Participant_Age", "Outcome_Physical", "Intervention_Control", "Intervention_Pharmacological", "Participant_Condition", "Outcome_Other", "Participant_Sample-size" ]

proteasomal is a Cellular_component, mitochondrial is a Cellular_component, mitochondrial is a Cellular_component, mitochondria is a Cellular_component, mitochondria is a Cellular_component, mitochondrial membrane is a Cellular_component, mitochondrial is a Cellular_component, cell is a Cell, proteasomal is a Cellular_component, mitochondrial is a Cellular_component, mitochondrial is a Cellular_component, cellular is a Cell, mitochondria is a Cellular_component, mitochondrial is a Cellular_component, mitochondrial is a Cellular_component, mitochondrial is a Cellular_component

PMC-3124045-caption-01_task0

Sentence: Parkin regulates the proteasomal degradation of PARIS and PGC-1alpha-dependent mitochondrial biogenesis. (A) Normal physiological conditions that maintain mitochondrial homeostasis: PINK1 recruits parkin to the mitochondria, where these two proteins interact to eliminate abnormal mitochondria through mitophagy. Alterations in mitochondrial membrane potential (DeltaPsim; a key indicator of mitochondrial physiology and cell viability) initiate the PINK1-parkin cascade of events that lead to mitophagy. Furthermore, parkin ubiquitylates and thereby promotes proteasomal degradation of PARIS. Because PARIS represses the expression of PGC-1alpha, degradation of PARIS by parkin allows PGC-1alpha-dependent gene expression and enables mitochondrial biogenesis. Parkin seems to be an integral regulator of mitochondrial homeostasis, controlling both degradation and biogenesis. (B) Loss of parkin function as a result of familial mutations (in the case of AR-PD) or aging, environmental or cellular stress (in the case of sporadic PD) leads to the accumulation of abnormal mitochondria, owing to faulty mitophagy. In addition, PARIS accumulates and represses PGC-1alpha, preventing mitochondrial biogenesis. Loss of parkin function does not tip the balance between mitochondrial biogenesis and degradation to either side, but leads to a general breakdown of mitochondrial homeostasis that can ultimately lead to PD. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Cellular_component, Cell

[ "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Parkin regulates the proteasomal degradation of PARIS and PGC-1alpha-dependent mitochondrial biogenesis. (A) Normal physiological conditions that maintain mitochondrial homeostasis: PINK1 recruits parkin to the mitochondria, where these two proteins interact to eliminate abnormal mitochondria through mitophagy. Alterations in mitochondrial membrane potential (DeltaPsim; a key indicator of mitochondrial physiology and cell viability) initiate the PINK1-parkin cascade of events that lead to mitophagy. Furthermore, parkin ubiquitylates and thereby promotes proteasomal degradation of PARIS. Because PARIS represses the expression of PGC-1alpha, degradation of PARIS by parkin allows PGC-1alpha-dependent gene expression and enables mitochondrial biogenesis. Parkin seems to be an integral regulator of mitochondrial homeostasis, controlling both degradation and biogenesis. (B) Loss of parkin function as a result of familial mutations (in the case of AR-PD) or aging, environmental or cellular stress (in the case of sporadic PD) leads to the accumulation of abnormal mitochondria, owing to faulty mitophagy. In addition, PARIS accumulates and represses PGC-1alpha, preventing mitochondrial biogenesis. Loss of parkin function does not tip the balance between mitochondrial biogenesis and degradation to either side, but leads to a general breakdown of mitochondrial homeostasis that can ultimately lead to PD.

[ "Parkin", "regulates", "the", "proteasomal", "degradation", "of", "PARIS", "and", "PGC-1alpha", "-", "dependent", "mitochondrial", "biogenesis", ".", "(", "A", ")", "Normal", "physiological", "conditions", "that", "maintain", "mitochondrial", "homeostasis", ":", "PINK1", "recruits", "parkin", "to", "the", "mitochondria", ",", "where", "these", "two", "proteins", "interact", "to", "eliminate", "abnormal", "mitochondria", "through", "mitophagy", ".", "Alterations", "in", "mitochondrial", "membrane", "potential", "(", "DeltaPsim", ";", "a", "key", "indicator", "of", "mitochondrial", "physiology", "and", "cell", "viability", ")", "initiate", "the", "PINK1-parkin", "cascade", "of", "events", "that", "lead", "to", "mitophagy", ".", "Furthermore", ",", "parkin", "ubiquitylates", "and", "thereby", "promotes", "proteasomal", "degradation", "of", "PARIS", ".", "Because", "PARIS", "represses", "the", "expression", "of", "PGC-1alpha", ",", "degradation", "of", "PARIS", "by", "parkin", "allows", "PGC-1alpha", "-", "dependent", "gene", "expression", "and", "enables", "mitochondrial", "biogenesis", ".", "Parkin", "seems", "to", "be", "an", "integral", "regulator", "of", "mitochondrial", "homeostasis", ",", "controlling", "both", "degradation", "and", "biogenesis", ".", "(", "B", ")", "Loss", "of", "parkin", "function", "as", "a", "result", "of", "familial", "mutations", "(", "in", "the", "case", "of", "AR", "-", "PD", ")", "or", "aging", ",", "environmental", "or", "cellular", "stress", "(", "in", "the", "case", "of", "sporadic", "PD", ")", "leads", "to", "the", "accumulation", "of", "abnormal", "mitochondria", ",", "owing", "to", "faulty", "mitophagy", ".", "In", "addition", ",", "PARIS", "accumulates", "and", "represses", "PGC-1alpha", ",", "preventing", "mitochondrial", "biogenesis", ".", "Loss", "of", "parkin", "function", "does", "not", "tip", "the", "balance", "between", "mitochondrial", "biogenesis", "and", "degradation", "to", "either", "side", ",", "but", "leads", "to", "a", "general", "breakdown", "of", "mitochondrial", "homeostasis", "that", "can", "ultimately", "lead", "to", "PD", ".", "\n" ]

[ "Cellular_component", "Cell" ]

proteasomal is a Cellular_component, mitochondrial is a Cellular_component, mitochondrial is a Cellular_component, mitochondria is a Cellular_component, mitochondria is a Cellular_component, mitochondrial membrane is a Cellular_component, mitochondrial is a Cellular_component, cell is a Cell, proteasomal is a Cellular_component, mitochondrial is a Cellular_component, mitochondrial is a Cellular_component, cellular is a Cell, mitochondria is a Cellular_component, mitochondrial is a Cellular_component, mitochondrial is a Cellular_component, mitochondrial is a Cellular_component

PMC-3124045-caption-01_task1

Sentence: Parkin regulates the proteasomal degradation of PARIS and PGC-1alpha-dependent mitochondrial biogenesis. (A) Normal physiological conditions that maintain mitochondrial homeostasis: PINK1 recruits parkin to the mitochondria, where these two proteins interact to eliminate abnormal mitochondria through mitophagy. Alterations in mitochondrial membrane potential (DeltaPsim; a key indicator of mitochondrial physiology and cell viability) initiate the PINK1-parkin cascade of events that lead to mitophagy. Furthermore, parkin ubiquitylates and thereby promotes proteasomal degradation of PARIS. Because PARIS represses the expression of PGC-1alpha, degradation of PARIS by parkin allows PGC-1alpha-dependent gene expression and enables mitochondrial biogenesis. Parkin seems to be an integral regulator of mitochondrial homeostasis, controlling both degradation and biogenesis. (B) Loss of parkin function as a result of familial mutations (in the case of AR-PD) or aging, environmental or cellular stress (in the case of sporadic PD) leads to the accumulation of abnormal mitochondria, owing to faulty mitophagy. In addition, PARIS accumulates and represses PGC-1alpha, preventing mitochondrial biogenesis. Loss of parkin function does not tip the balance between mitochondrial biogenesis and degradation to either side, but leads to a general breakdown of mitochondrial homeostasis that can ultimately lead to PD. Instructions: please typing these entity words according to sentence: proteasomal, mitochondrial, mitochondrial, mitochondria, mitochondria, mitochondrial membrane, mitochondrial, cell, proteasomal, mitochondrial, mitochondrial, cellular, mitochondria, mitochondrial, mitochondrial, mitochondrial Options: Cellular_component, Cell

[ "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Parkin regulates the proteasomal degradation of PARIS and PGC-1alpha-dependent mitochondrial biogenesis. (A) Normal physiological conditions that maintain mitochondrial homeostasis: PINK1 recruits parkin to the mitochondria, where these two proteins interact to eliminate abnormal mitochondria through mitophagy. Alterations in mitochondrial membrane potential (DeltaPsim; a key indicator of mitochondrial physiology and cell viability) initiate the PINK1-parkin cascade of events that lead to mitophagy. Furthermore, parkin ubiquitylates and thereby promotes proteasomal degradation of PARIS. Because PARIS represses the expression of PGC-1alpha, degradation of PARIS by parkin allows PGC-1alpha-dependent gene expression and enables mitochondrial biogenesis. Parkin seems to be an integral regulator of mitochondrial homeostasis, controlling both degradation and biogenesis. (B) Loss of parkin function as a result of familial mutations (in the case of AR-PD) or aging, environmental or cellular stress (in the case of sporadic PD) leads to the accumulation of abnormal mitochondria, owing to faulty mitophagy. In addition, PARIS accumulates and represses PGC-1alpha, preventing mitochondrial biogenesis. Loss of parkin function does not tip the balance between mitochondrial biogenesis and degradation to either side, but leads to a general breakdown of mitochondrial homeostasis that can ultimately lead to PD.

[ "Parkin", "regulates", "the", "proteasomal", "degradation", "of", "PARIS", "and", "PGC-1alpha", "-", "dependent", "mitochondrial", "biogenesis", ".", "(", "A", ")", "Normal", "physiological", "conditions", "that", "maintain", "mitochondrial", "homeostasis", ":", "PINK1", "recruits", "parkin", "to", "the", "mitochondria", ",", "where", "these", "two", "proteins", "interact", "to", "eliminate", "abnormal", "mitochondria", "through", "mitophagy", ".", "Alterations", "in", "mitochondrial", "membrane", "potential", "(", "DeltaPsim", ";", "a", "key", "indicator", "of", "mitochondrial", "physiology", "and", "cell", "viability", ")", "initiate", "the", "PINK1-parkin", "cascade", "of", "events", "that", "lead", "to", "mitophagy", ".", "Furthermore", ",", "parkin", "ubiquitylates", "and", "thereby", "promotes", "proteasomal", "degradation", "of", "PARIS", ".", "Because", "PARIS", "represses", "the", "expression", "of", "PGC-1alpha", ",", "degradation", "of", "PARIS", "by", "parkin", "allows", "PGC-1alpha", "-", "dependent", "gene", "expression", "and", "enables", "mitochondrial", "biogenesis", ".", "Parkin", "seems", "to", "be", "an", "integral", "regulator", "of", "mitochondrial", "homeostasis", ",", "controlling", "both", "degradation", "and", "biogenesis", ".", "(", "B", ")", "Loss", "of", "parkin", "function", "as", "a", "result", "of", "familial", "mutations", "(", "in", "the", "case", "of", "AR", "-", "PD", ")", "or", "aging", ",", "environmental", "or", "cellular", "stress", "(", "in", "the", "case", "of", "sporadic", "PD", ")", "leads", "to", "the", "accumulation", "of", "abnormal", "mitochondria", ",", "owing", "to", "faulty", "mitophagy", ".", "In", "addition", ",", "PARIS", "accumulates", "and", "represses", "PGC-1alpha", ",", "preventing", "mitochondrial", "biogenesis", ".", "Loss", "of", "parkin", "function", "does", "not", "tip", "the", "balance", "between", "mitochondrial", "biogenesis", "and", "degradation", "to", "either", "side", ",", "but", "leads", "to", "a", "general", "breakdown", "of", "mitochondrial", "homeostasis", "that", "can", "ultimately", "lead", "to", "PD", ".", "\n" ]

[ "Cellular_component", "Cell" ]

proteasomal, mitochondrial, mitochondrial, mitochondria, mitochondria, mitochondrial membrane, mitochondrial, cell, proteasomal, mitochondrial, mitochondrial, cellular, mitochondria, mitochondrial, mitochondrial, mitochondrial

PMC-3124045-caption-01_task2

Sentence: Parkin regulates the proteasomal degradation of PARIS and PGC-1alpha-dependent mitochondrial biogenesis. (A) Normal physiological conditions that maintain mitochondrial homeostasis: PINK1 recruits parkin to the mitochondria, where these two proteins interact to eliminate abnormal mitochondria through mitophagy. Alterations in mitochondrial membrane potential (DeltaPsim; a key indicator of mitochondrial physiology and cell viability) initiate the PINK1-parkin cascade of events that lead to mitophagy. Furthermore, parkin ubiquitylates and thereby promotes proteasomal degradation of PARIS. Because PARIS represses the expression of PGC-1alpha, degradation of PARIS by parkin allows PGC-1alpha-dependent gene expression and enables mitochondrial biogenesis. Parkin seems to be an integral regulator of mitochondrial homeostasis, controlling both degradation and biogenesis. (B) Loss of parkin function as a result of familial mutations (in the case of AR-PD) or aging, environmental or cellular stress (in the case of sporadic PD) leads to the accumulation of abnormal mitochondria, owing to faulty mitophagy. In addition, PARIS accumulates and represses PGC-1alpha, preventing mitochondrial biogenesis. Loss of parkin function does not tip the balance between mitochondrial biogenesis and degradation to either side, but leads to a general breakdown of mitochondrial homeostasis that can ultimately lead to PD. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Parkin regulates the proteasomal degradation of PARIS and PGC-1alpha-dependent mitochondrial biogenesis. (A) Normal physiological conditions that maintain mitochondrial homeostasis: PINK1 recruits parkin to the mitochondria, where these two proteins interact to eliminate abnormal mitochondria through mitophagy. Alterations in mitochondrial membrane potential (DeltaPsim; a key indicator of mitochondrial physiology and cell viability) initiate the PINK1-parkin cascade of events that lead to mitophagy. Furthermore, parkin ubiquitylates and thereby promotes proteasomal degradation of PARIS. Because PARIS represses the expression of PGC-1alpha, degradation of PARIS by parkin allows PGC-1alpha-dependent gene expression and enables mitochondrial biogenesis. Parkin seems to be an integral regulator of mitochondrial homeostasis, controlling both degradation and biogenesis. (B) Loss of parkin function as a result of familial mutations (in the case of AR-PD) or aging, environmental or cellular stress (in the case of sporadic PD) leads to the accumulation of abnormal mitochondria, owing to faulty mitophagy. In addition, PARIS accumulates and represses PGC-1alpha, preventing mitochondrial biogenesis. Loss of parkin function does not tip the balance between mitochondrial biogenesis and degradation to either side, but leads to a general breakdown of mitochondrial homeostasis that can ultimately lead to PD.

[ "Parkin", "regulates", "the", "proteasomal", "degradation", "of", "PARIS", "and", "PGC-1alpha", "-", "dependent", "mitochondrial", "biogenesis", ".", "(", "A", ")", "Normal", "physiological", "conditions", "that", "maintain", "mitochondrial", "homeostasis", ":", "PINK1", "recruits", "parkin", "to", "the", "mitochondria", ",", "where", "these", "two", "proteins", "interact", "to", "eliminate", "abnormal", "mitochondria", "through", "mitophagy", ".", "Alterations", "in", "mitochondrial", "membrane", "potential", "(", "DeltaPsim", ";", "a", "key", "indicator", "of", "mitochondrial", "physiology", "and", "cell", "viability", ")", "initiate", "the", "PINK1-parkin", "cascade", "of", "events", "that", "lead", "to", "mitophagy", ".", "Furthermore", ",", "parkin", "ubiquitylates", "and", "thereby", "promotes", "proteasomal", "degradation", "of", "PARIS", ".", "Because", "PARIS", "represses", "the", "expression", "of", "PGC-1alpha", ",", "degradation", "of", "PARIS", "by", "parkin", "allows", "PGC-1alpha", "-", "dependent", "gene", "expression", "and", "enables", "mitochondrial", "biogenesis", ".", "Parkin", "seems", "to", "be", "an", "integral", "regulator", "of", "mitochondrial", "homeostasis", ",", "controlling", "both", "degradation", "and", "biogenesis", ".", "(", "B", ")", "Loss", "of", "parkin", "function", "as", "a", "result", "of", "familial", "mutations", "(", "in", "the", "case", "of", "AR", "-", "PD", ")", "or", "aging", ",", "environmental", "or", "cellular", "stress", "(", "in", "the", "case", "of", "sporadic", "PD", ")", "leads", "to", "the", "accumulation", "of", "abnormal", "mitochondria", ",", "owing", "to", "faulty", "mitophagy", ".", "In", "addition", ",", "PARIS", "accumulates", "and", "represses", "PGC-1alpha", ",", "preventing", "mitochondrial", "biogenesis", ".", "Loss", "of", "parkin", "function", "does", "not", "tip", "the", "balance", "between", "mitochondrial", "biogenesis", "and", "degradation", "to", "either", "side", ",", "but", "leads", "to", "a", "general", "breakdown", "of", "mitochondrial", "homeostasis", "that", "can", "ultimately", "lead", "to", "PD", ".", "\n" ]

[ "Cellular_component", "Cell" ]

Gelenkblockierung is an umlsterm, Behandlung is an umlsterm, Patienten is an umlsterm, Kopfgelenke is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Gelenkspiels is an umlsterm, Gelenk is an umlsterm, selbst is an umlsterm

ManuelleMedizin.70350056.ger.abstr_task0

Sentence: Seit langem wird immer wieder nach einem Substrat der Gelenkblockierung gesucht . Es sind diesbezueglich verschiedene Theorien entwickelt worden , von denen aber keine allein saemtliche klinische Erscheinungen der Blockierungen oder der deblockierenden Behandlung erklaeren kann . Es wurden 50 Patienten mit Blockierungen der HWS von den Kopfgelenke bis zum zervikothorakalen Uebergang und 8 Patienten mit Iliosakralgelenkblockierungen in Narkose untersucht . Bei 8 Patienten waren unter Muskelrelaxierung die HWS - Blockierungen nicht mehr nachweisbar . Nach Narkoseausleitung waren sie bei 6 dieser Patienten wieder vorhanden . Die ISG - Blockierungen zeigten keinen veraenderten Befund bei Untersuchung in Narkose . Es konnte damit gezeigt werden , dass es mehrere Mechanismen fuer die Blockierung geben muss . Bei den in Narkose nicht nachzuweisenden und hinterher wieder aufgetretenen Blockierungen ist eine muskulaere Aethiogenese anzunehmen . In der Mehrzahl der Faelle ist allerdings die Stoerung des Gelenkspiels im Gelenk selbst zu suchen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O" ]

Seit langem wird immer wieder nach einem Substrat der Gelenkblockierung gesucht . Es sind diesbezueglich verschiedene Theorien entwickelt worden , von denen aber keine allein saemtliche klinische Erscheinungen der Blockierungen oder der deblockierenden Behandlung erklaeren kann . Es wurden 50 Patienten mit Blockierungen der HWS von den Kopfgelenke bis zum zervikothorakalen Uebergang und 8 Patienten mit Iliosakralgelenkblockierungen in Narkose untersucht . Bei 8 Patienten waren unter Muskelrelaxierung die HWS - Blockierungen nicht mehr nachweisbar . Nach Narkoseausleitung waren sie bei 6 dieser Patienten wieder vorhanden . Die ISG - Blockierungen zeigten keinen veraenderten Befund bei Untersuchung in Narkose . Es konnte damit gezeigt werden , dass es mehrere Mechanismen fuer die Blockierung geben muss . Bei den in Narkose nicht nachzuweisenden und hinterher wieder aufgetretenen Blockierungen ist eine muskulaere Aethiogenese anzunehmen . In der Mehrzahl der Faelle ist allerdings die Stoerung des Gelenkspiels im Gelenk selbst zu suchen .

[ "Seit", "langem", "wird", "immer", "wieder", "nach", "einem", "Substrat", "der", "Gelenkblockierung", "gesucht", ".", "Es", "sind", "diesbezueglich", "verschiedene", "Theorien", "entwickelt", "worden", ",", "von", "denen", "aber", "keine", "allein", "saemtliche", "klinische", "Erscheinungen", "der", "Blockierungen", "oder", "der", "deblockierenden", "Behandlung", "erklaeren", "kann", ".", "Es", "wurden", "50", "Patienten", "mit", "Blockierungen", "der", "HWS", "von", "den", "Kopfgelenke", "bis", "zum", "zervikothorakalen", "Uebergang", "und", "8", "Patienten", "mit", "Iliosakralgelenkblockierungen", "in", "Narkose", "untersucht", ".", "Bei", "8", "Patienten", "waren", "unter", "Muskelrelaxierung", "die", "HWS", "-", "Blockierungen", "nicht", "mehr", "nachweisbar", ".", "Nach", "Narkoseausleitung", "waren", "sie", "bei", "6", "dieser", "Patienten", "wieder", "vorhanden", ".", "Die", "ISG", "-", "Blockierungen", "zeigten", "keinen", "veraenderten", "Befund", "bei", "Untersuchung", "in", "Narkose", ".", "Es", "konnte", "damit", "gezeigt", "werden", ",", "dass", "es", "mehrere", "Mechanismen", "fuer", "die", "Blockierung", "geben", "muss", ".", "Bei", "den", "in", "Narkose", "nicht", "nachzuweisenden", "und", "hinterher", "wieder", "aufgetretenen", "Blockierungen", "ist", "eine", "muskulaere", "Aethiogenese", "anzunehmen", ".", "In", "der", "Mehrzahl", "der", "Faelle", "ist", "allerdings", "die", "Stoerung", "des", "Gelenkspiels", "im", "Gelenk", "selbst", "zu", "suchen", "." ]

[ "umlsterm" ]

Gelenkblockierung is an umlsterm, Behandlung is an umlsterm, Patienten is an umlsterm, Kopfgelenke is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Gelenkspiels is an umlsterm, Gelenk is an umlsterm, selbst is an umlsterm

ManuelleMedizin.70350056.ger.abstr_task1

Sentence: Seit langem wird immer wieder nach einem Substrat der Gelenkblockierung gesucht . Es sind diesbezueglich verschiedene Theorien entwickelt worden , von denen aber keine allein saemtliche klinische Erscheinungen der Blockierungen oder der deblockierenden Behandlung erklaeren kann . Es wurden 50 Patienten mit Blockierungen der HWS von den Kopfgelenke bis zum zervikothorakalen Uebergang und 8 Patienten mit Iliosakralgelenkblockierungen in Narkose untersucht . Bei 8 Patienten waren unter Muskelrelaxierung die HWS - Blockierungen nicht mehr nachweisbar . Nach Narkoseausleitung waren sie bei 6 dieser Patienten wieder vorhanden . Die ISG - Blockierungen zeigten keinen veraenderten Befund bei Untersuchung in Narkose . Es konnte damit gezeigt werden , dass es mehrere Mechanismen fuer die Blockierung geben muss . Bei den in Narkose nicht nachzuweisenden und hinterher wieder aufgetretenen Blockierungen ist eine muskulaere Aethiogenese anzunehmen . In der Mehrzahl der Faelle ist allerdings die Stoerung des Gelenkspiels im Gelenk selbst zu suchen . Instructions: please typing these entity words according to sentence: Gelenkblockierung, Behandlung, Patienten, Kopfgelenke, Patienten, Patienten, Patienten, Gelenkspiels, Gelenk, selbst Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O" ]

Seit langem wird immer wieder nach einem Substrat der Gelenkblockierung gesucht . Es sind diesbezueglich verschiedene Theorien entwickelt worden , von denen aber keine allein saemtliche klinische Erscheinungen der Blockierungen oder der deblockierenden Behandlung erklaeren kann . Es wurden 50 Patienten mit Blockierungen der HWS von den Kopfgelenke bis zum zervikothorakalen Uebergang und 8 Patienten mit Iliosakralgelenkblockierungen in Narkose untersucht . Bei 8 Patienten waren unter Muskelrelaxierung die HWS - Blockierungen nicht mehr nachweisbar . Nach Narkoseausleitung waren sie bei 6 dieser Patienten wieder vorhanden . Die ISG - Blockierungen zeigten keinen veraenderten Befund bei Untersuchung in Narkose . Es konnte damit gezeigt werden , dass es mehrere Mechanismen fuer die Blockierung geben muss . Bei den in Narkose nicht nachzuweisenden und hinterher wieder aufgetretenen Blockierungen ist eine muskulaere Aethiogenese anzunehmen . In der Mehrzahl der Faelle ist allerdings die Stoerung des Gelenkspiels im Gelenk selbst zu suchen .

[ "Seit", "langem", "wird", "immer", "wieder", "nach", "einem", "Substrat", "der", "Gelenkblockierung", "gesucht", ".", "Es", "sind", "diesbezueglich", "verschiedene", "Theorien", "entwickelt", "worden", ",", "von", "denen", "aber", "keine", "allein", "saemtliche", "klinische", "Erscheinungen", "der", "Blockierungen", "oder", "der", "deblockierenden", "Behandlung", "erklaeren", "kann", ".", "Es", "wurden", "50", "Patienten", "mit", "Blockierungen", "der", "HWS", "von", "den", "Kopfgelenke", "bis", "zum", "zervikothorakalen", "Uebergang", "und", "8", "Patienten", "mit", "Iliosakralgelenkblockierungen", "in", "Narkose", "untersucht", ".", "Bei", "8", "Patienten", "waren", "unter", "Muskelrelaxierung", "die", "HWS", "-", "Blockierungen", "nicht", "mehr", "nachweisbar", ".", "Nach", "Narkoseausleitung", "waren", "sie", "bei", "6", "dieser", "Patienten", "wieder", "vorhanden", ".", "Die", "ISG", "-", "Blockierungen", "zeigten", "keinen", "veraenderten", "Befund", "bei", "Untersuchung", "in", "Narkose", ".", "Es", "konnte", "damit", "gezeigt", "werden", ",", "dass", "es", "mehrere", "Mechanismen", "fuer", "die", "Blockierung", "geben", "muss", ".", "Bei", "den", "in", "Narkose", "nicht", "nachzuweisenden", "und", "hinterher", "wieder", "aufgetretenen", "Blockierungen", "ist", "eine", "muskulaere", "Aethiogenese", "anzunehmen", ".", "In", "der", "Mehrzahl", "der", "Faelle", "ist", "allerdings", "die", "Stoerung", "des", "Gelenkspiels", "im", "Gelenk", "selbst", "zu", "suchen", "." ]

[ "umlsterm" ]

Gelenkblockierung, Behandlung, Patienten, Kopfgelenke, Patienten, Patienten, Patienten, Gelenkspiels, Gelenk, selbst

ManuelleMedizin.70350056.ger.abstr_task2

Sentence: Seit langem wird immer wieder nach einem Substrat der Gelenkblockierung gesucht . Es sind diesbezueglich verschiedene Theorien entwickelt worden , von denen aber keine allein saemtliche klinische Erscheinungen der Blockierungen oder der deblockierenden Behandlung erklaeren kann . Es wurden 50 Patienten mit Blockierungen der HWS von den Kopfgelenke bis zum zervikothorakalen Uebergang und 8 Patienten mit Iliosakralgelenkblockierungen in Narkose untersucht . Bei 8 Patienten waren unter Muskelrelaxierung die HWS - Blockierungen nicht mehr nachweisbar . Nach Narkoseausleitung waren sie bei 6 dieser Patienten wieder vorhanden . Die ISG - Blockierungen zeigten keinen veraenderten Befund bei Untersuchung in Narkose . Es konnte damit gezeigt werden , dass es mehrere Mechanismen fuer die Blockierung geben muss . Bei den in Narkose nicht nachzuweisenden und hinterher wieder aufgetretenen Blockierungen ist eine muskulaere Aethiogenese anzunehmen . In der Mehrzahl der Faelle ist allerdings die Stoerung des Gelenkspiels im Gelenk selbst zu suchen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O" ]

Seit langem wird immer wieder nach einem Substrat der Gelenkblockierung gesucht . Es sind diesbezueglich verschiedene Theorien entwickelt worden , von denen aber keine allein saemtliche klinische Erscheinungen der Blockierungen oder der deblockierenden Behandlung erklaeren kann . Es wurden 50 Patienten mit Blockierungen der HWS von den Kopfgelenke bis zum zervikothorakalen Uebergang und 8 Patienten mit Iliosakralgelenkblockierungen in Narkose untersucht . Bei 8 Patienten waren unter Muskelrelaxierung die HWS - Blockierungen nicht mehr nachweisbar . Nach Narkoseausleitung waren sie bei 6 dieser Patienten wieder vorhanden . Die ISG - Blockierungen zeigten keinen veraenderten Befund bei Untersuchung in Narkose . Es konnte damit gezeigt werden , dass es mehrere Mechanismen fuer die Blockierung geben muss . Bei den in Narkose nicht nachzuweisenden und hinterher wieder aufgetretenen Blockierungen ist eine muskulaere Aethiogenese anzunehmen . In der Mehrzahl der Faelle ist allerdings die Stoerung des Gelenkspiels im Gelenk selbst zu suchen .

[ "Seit", "langem", "wird", "immer", "wieder", "nach", "einem", "Substrat", "der", "Gelenkblockierung", "gesucht", ".", "Es", "sind", "diesbezueglich", "verschiedene", "Theorien", "entwickelt", "worden", ",", "von", "denen", "aber", "keine", "allein", "saemtliche", "klinische", "Erscheinungen", "der", "Blockierungen", "oder", "der", "deblockierenden", "Behandlung", "erklaeren", "kann", ".", "Es", "wurden", "50", "Patienten", "mit", "Blockierungen", "der", "HWS", "von", "den", "Kopfgelenke", "bis", "zum", "zervikothorakalen", "Uebergang", "und", "8", "Patienten", "mit", "Iliosakralgelenkblockierungen", "in", "Narkose", "untersucht", ".", "Bei", "8", "Patienten", "waren", "unter", "Muskelrelaxierung", "die", "HWS", "-", "Blockierungen", "nicht", "mehr", "nachweisbar", ".", "Nach", "Narkoseausleitung", "waren", "sie", "bei", "6", "dieser", "Patienten", "wieder", "vorhanden", ".", "Die", "ISG", "-", "Blockierungen", "zeigten", "keinen", "veraenderten", "Befund", "bei", "Untersuchung", "in", "Narkose", ".", "Es", "konnte", "damit", "gezeigt", "werden", ",", "dass", "es", "mehrere", "Mechanismen", "fuer", "die", "Blockierung", "geben", "muss", ".", "Bei", "den", "in", "Narkose", "nicht", "nachzuweisenden", "und", "hinterher", "wieder", "aufgetretenen", "Blockierungen", "ist", "eine", "muskulaere", "Aethiogenese", "anzunehmen", ".", "In", "der", "Mehrzahl", "der", "Faelle", "ist", "allerdings", "die", "Stoerung", "des", "Gelenkspiels", "im", "Gelenk", "selbst", "zu", "suchen", "." ]

[ "umlsterm" ]

Patienten is an umlsterm, Kaliumchloridloesung is an umlsterm, Paraesthesien is an umlsterm, Schmerzen is an umlsterm, Beinen is an umlsterm, Innervationsausfall is an umlsterm, Hypertension is an umlsterm, Tachykardie is an umlsterm, Therapie is an umlsterm, Dexamethason is an umlsterm, neurologischen Defizite is an umlsterm, Patient is an umlsterm, Komplikationen is an umlsterm, Leitungen is an umlsterm, Verwendung is an umlsterm, Spritzenpumpen is an umlsterm, Medikamentenreservoir is an umlsterm, Spritzenwechsels is an umlsterm

DerAnaesthesist.90480896.ger.abstr_task0

Sentence: Bei einem 65jaehrigen Patienten wurden am ersten postoperativen Tag innerhalb von 3 h versehentlich 36 ml einer 7,45%-igen Kaliumchloridloesung in einen lumbalen Epiduralkatheter infundiert . Nach voruebergehenden Paraesthesien stellten sich als Folge der versehentlichen Infusion brennende Schmerzen in den Beinen ein , verbunden mit einem motorischen und sensorischen Innervationsausfall bis zum Segment TH 11. Begleitet wurde das Krankheitsbild von vegetativen Symptomen wie Hypertension und Tachykardie . Zur Therapie wurde ein einmaliger Bolus von 40 mg Dexamethason i.v. verabreicht gefolgt von einer kontinuierlichen epiduralen Infusion von NaCl 0,9% 99 ml/h . Nach 6 h begannen sich die neurologischen Defizite langsam zurueckzubilden . Nach 12 h war der Patient symptomfrei . Komplikationen wie die geschilderte beruhen in aller Regel auf Irrtuemern , deren Auftreten zwar nicht unmoeglich , durch entsprechende Massnahmen jedoch unwahrscheinlicher gemacht werden kann . Zu solchen Massnahmen gehoert die farbliche Markierung von Leitungen , Filtern und Infusionsloesungen sowie die Verwendung von Spritzenpumpen mit einem groesseren Medikamentenreservoir , um die Haeufigkeit des Spritzenwechsels zu vermindern . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Bei einem 65jaehrigen Patienten wurden am ersten postoperativen Tag innerhalb von 3 h versehentlich 36 ml einer 7,45%-igen Kaliumchloridloesung in einen lumbalen Epiduralkatheter infundiert . Nach voruebergehenden Paraesthesien stellten sich als Folge der versehentlichen Infusion brennende Schmerzen in den Beinen ein , verbunden mit einem motorischen und sensorischen Innervationsausfall bis zum Segment TH 11. Begleitet wurde das Krankheitsbild von vegetativen Symptomen wie Hypertension und Tachykardie . Zur Therapie wurde ein einmaliger Bolus von 40 mg Dexamethason i.v. verabreicht gefolgt von einer kontinuierlichen epiduralen Infusion von NaCl 0,9% 99 ml/h . Nach 6 h begannen sich die neurologischen Defizite langsam zurueckzubilden . Nach 12 h war der Patient symptomfrei . Komplikationen wie die geschilderte beruhen in aller Regel auf Irrtuemern , deren Auftreten zwar nicht unmoeglich , durch entsprechende Massnahmen jedoch unwahrscheinlicher gemacht werden kann . Zu solchen Massnahmen gehoert die farbliche Markierung von Leitungen , Filtern und Infusionsloesungen sowie die Verwendung von Spritzenpumpen mit einem groesseren Medikamentenreservoir , um die Haeufigkeit des Spritzenwechsels zu vermindern .

[ "Bei", "einem", "65jaehrigen", "Patienten", "wurden", "am", "ersten", "postoperativen", "Tag", "innerhalb", "von", "3", "h", "versehentlich", "36", "ml", "einer", "7,45%-igen", "Kaliumchloridloesung", "in", "einen", "lumbalen", "Epiduralkatheter", "infundiert", ".", "Nach", "voruebergehenden", "Paraesthesien", "stellten", "sich", "als", "Folge", "der", "versehentlichen", "Infusion", "brennende", "Schmerzen", "in", "den", "Beinen", "ein", ",", "verbunden", "mit", "einem", "motorischen", "und", "sensorischen", "Innervationsausfall", "bis", "zum", "Segment", "TH", "11", ".", "Begleitet", "wurde", "das", "Krankheitsbild", "von", "vegetativen", "Symptomen", "wie", "Hypertension", "und", "Tachykardie", ".", "Zur", "Therapie", "wurde", "ein", "einmaliger", "Bolus", "von", "40", "mg", "Dexamethason", "i.v", ".", "verabreicht", "gefolgt", "von", "einer", "kontinuierlichen", "epiduralen", "Infusion", "von", "NaCl", "0,9", "%", "99", "ml", "/", "h", ".", "Nach", "6", "h", "begannen", "sich", "die", "neurologischen", "Defizite", "langsam", "zurueckzubilden", ".", "Nach", "12", "h", "war", "der", "Patient", "symptomfrei", ".", "Komplikationen", "wie", "die", "geschilderte", "beruhen", "in", "aller", "Regel", "auf", "Irrtuemern", ",", "deren", "Auftreten", "zwar", "nicht", "unmoeglich", ",", "durch", "entsprechende", "Massnahmen", "jedoch", "unwahrscheinlicher", "gemacht", "werden", "kann", ".", "Zu", "solchen", "Massnahmen", "gehoert", "die", "farbliche", "Markierung", "von", "Leitungen", ",", "Filtern", "und", "Infusionsloesungen", "sowie", "die", "Verwendung", "von", "Spritzenpumpen", "mit", "einem", "groesseren", "Medikamentenreservoir", ",", "um", "die", "Haeufigkeit", "des", "Spritzenwechsels", "zu", "vermindern", "." ]

[ "umlsterm" ]

Patienten is an umlsterm, Kaliumchloridloesung is an umlsterm, Paraesthesien is an umlsterm, Schmerzen is an umlsterm, Beinen is an umlsterm, Innervationsausfall is an umlsterm, Hypertension is an umlsterm, Tachykardie is an umlsterm, Therapie is an umlsterm, Dexamethason is an umlsterm, neurologischen Defizite is an umlsterm, Patient is an umlsterm, Komplikationen is an umlsterm, Leitungen is an umlsterm, Verwendung is an umlsterm, Spritzenpumpen is an umlsterm, Medikamentenreservoir is an umlsterm, Spritzenwechsels is an umlsterm

DerAnaesthesist.90480896.ger.abstr_task1

Sentence: Bei einem 65jaehrigen Patienten wurden am ersten postoperativen Tag innerhalb von 3 h versehentlich 36 ml einer 7,45%-igen Kaliumchloridloesung in einen lumbalen Epiduralkatheter infundiert . Nach voruebergehenden Paraesthesien stellten sich als Folge der versehentlichen Infusion brennende Schmerzen in den Beinen ein , verbunden mit einem motorischen und sensorischen Innervationsausfall bis zum Segment TH 11. Begleitet wurde das Krankheitsbild von vegetativen Symptomen wie Hypertension und Tachykardie . Zur Therapie wurde ein einmaliger Bolus von 40 mg Dexamethason i.v. verabreicht gefolgt von einer kontinuierlichen epiduralen Infusion von NaCl 0,9% 99 ml/h . Nach 6 h begannen sich die neurologischen Defizite langsam zurueckzubilden . Nach 12 h war der Patient symptomfrei . Komplikationen wie die geschilderte beruhen in aller Regel auf Irrtuemern , deren Auftreten zwar nicht unmoeglich , durch entsprechende Massnahmen jedoch unwahrscheinlicher gemacht werden kann . Zu solchen Massnahmen gehoert die farbliche Markierung von Leitungen , Filtern und Infusionsloesungen sowie die Verwendung von Spritzenpumpen mit einem groesseren Medikamentenreservoir , um die Haeufigkeit des Spritzenwechsels zu vermindern . Instructions: please typing these entity words according to sentence: Patienten, Kaliumchloridloesung, Paraesthesien, Schmerzen, Beinen, Innervationsausfall, Hypertension, Tachykardie, Therapie, Dexamethason, neurologischen Defizite, Patient, Komplikationen, Leitungen, Verwendung, Spritzenpumpen, Medikamentenreservoir, Spritzenwechsels Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Bei einem 65jaehrigen Patienten wurden am ersten postoperativen Tag innerhalb von 3 h versehentlich 36 ml einer 7,45%-igen Kaliumchloridloesung in einen lumbalen Epiduralkatheter infundiert . Nach voruebergehenden Paraesthesien stellten sich als Folge der versehentlichen Infusion brennende Schmerzen in den Beinen ein , verbunden mit einem motorischen und sensorischen Innervationsausfall bis zum Segment TH 11. Begleitet wurde das Krankheitsbild von vegetativen Symptomen wie Hypertension und Tachykardie . Zur Therapie wurde ein einmaliger Bolus von 40 mg Dexamethason i.v. verabreicht gefolgt von einer kontinuierlichen epiduralen Infusion von NaCl 0,9% 99 ml/h . Nach 6 h begannen sich die neurologischen Defizite langsam zurueckzubilden . Nach 12 h war der Patient symptomfrei . Komplikationen wie die geschilderte beruhen in aller Regel auf Irrtuemern , deren Auftreten zwar nicht unmoeglich , durch entsprechende Massnahmen jedoch unwahrscheinlicher gemacht werden kann . Zu solchen Massnahmen gehoert die farbliche Markierung von Leitungen , Filtern und Infusionsloesungen sowie die Verwendung von Spritzenpumpen mit einem groesseren Medikamentenreservoir , um die Haeufigkeit des Spritzenwechsels zu vermindern .

[ "Bei", "einem", "65jaehrigen", "Patienten", "wurden", "am", "ersten", "postoperativen", "Tag", "innerhalb", "von", "3", "h", "versehentlich", "36", "ml", "einer", "7,45%-igen", "Kaliumchloridloesung", "in", "einen", "lumbalen", "Epiduralkatheter", "infundiert", ".", "Nach", "voruebergehenden", "Paraesthesien", "stellten", "sich", "als", "Folge", "der", "versehentlichen", "Infusion", "brennende", "Schmerzen", "in", "den", "Beinen", "ein", ",", "verbunden", "mit", "einem", "motorischen", "und", "sensorischen", "Innervationsausfall", "bis", "zum", "Segment", "TH", "11", ".", "Begleitet", "wurde", "das", "Krankheitsbild", "von", "vegetativen", "Symptomen", "wie", "Hypertension", "und", "Tachykardie", ".", "Zur", "Therapie", "wurde", "ein", "einmaliger", "Bolus", "von", "40", "mg", "Dexamethason", "i.v", ".", "verabreicht", "gefolgt", "von", "einer", "kontinuierlichen", "epiduralen", "Infusion", "von", "NaCl", "0,9", "%", "99", "ml", "/", "h", ".", "Nach", "6", "h", "begannen", "sich", "die", "neurologischen", "Defizite", "langsam", "zurueckzubilden", ".", "Nach", "12", "h", "war", "der", "Patient", "symptomfrei", ".", "Komplikationen", "wie", "die", "geschilderte", "beruhen", "in", "aller", "Regel", "auf", "Irrtuemern", ",", "deren", "Auftreten", "zwar", "nicht", "unmoeglich", ",", "durch", "entsprechende", "Massnahmen", "jedoch", "unwahrscheinlicher", "gemacht", "werden", "kann", ".", "Zu", "solchen", "Massnahmen", "gehoert", "die", "farbliche", "Markierung", "von", "Leitungen", ",", "Filtern", "und", "Infusionsloesungen", "sowie", "die", "Verwendung", "von", "Spritzenpumpen", "mit", "einem", "groesseren", "Medikamentenreservoir", ",", "um", "die", "Haeufigkeit", "des", "Spritzenwechsels", "zu", "vermindern", "." ]

[ "umlsterm" ]

Patienten, Kaliumchloridloesung, Paraesthesien, Schmerzen, Beinen, Innervationsausfall, Hypertension, Tachykardie, Therapie, Dexamethason, neurologischen Defizite, Patient, Komplikationen, Leitungen, Verwendung, Spritzenpumpen, Medikamentenreservoir, Spritzenwechsels

DerAnaesthesist.90480896.ger.abstr_task2

Sentence: Bei einem 65jaehrigen Patienten wurden am ersten postoperativen Tag innerhalb von 3 h versehentlich 36 ml einer 7,45%-igen Kaliumchloridloesung in einen lumbalen Epiduralkatheter infundiert . Nach voruebergehenden Paraesthesien stellten sich als Folge der versehentlichen Infusion brennende Schmerzen in den Beinen ein , verbunden mit einem motorischen und sensorischen Innervationsausfall bis zum Segment TH 11. Begleitet wurde das Krankheitsbild von vegetativen Symptomen wie Hypertension und Tachykardie . Zur Therapie wurde ein einmaliger Bolus von 40 mg Dexamethason i.v. verabreicht gefolgt von einer kontinuierlichen epiduralen Infusion von NaCl 0,9% 99 ml/h . Nach 6 h begannen sich die neurologischen Defizite langsam zurueckzubilden . Nach 12 h war der Patient symptomfrei . Komplikationen wie die geschilderte beruhen in aller Regel auf Irrtuemern , deren Auftreten zwar nicht unmoeglich , durch entsprechende Massnahmen jedoch unwahrscheinlicher gemacht werden kann . Zu solchen Massnahmen gehoert die farbliche Markierung von Leitungen , Filtern und Infusionsloesungen sowie die Verwendung von Spritzenpumpen mit einem groesseren Medikamentenreservoir , um die Haeufigkeit des Spritzenwechsels zu vermindern . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Bei einem 65jaehrigen Patienten wurden am ersten postoperativen Tag innerhalb von 3 h versehentlich 36 ml einer 7,45%-igen Kaliumchloridloesung in einen lumbalen Epiduralkatheter infundiert . Nach voruebergehenden Paraesthesien stellten sich als Folge der versehentlichen Infusion brennende Schmerzen in den Beinen ein , verbunden mit einem motorischen und sensorischen Innervationsausfall bis zum Segment TH 11. Begleitet wurde das Krankheitsbild von vegetativen Symptomen wie Hypertension und Tachykardie . Zur Therapie wurde ein einmaliger Bolus von 40 mg Dexamethason i.v. verabreicht gefolgt von einer kontinuierlichen epiduralen Infusion von NaCl 0,9% 99 ml/h . Nach 6 h begannen sich die neurologischen Defizite langsam zurueckzubilden . Nach 12 h war der Patient symptomfrei . Komplikationen wie die geschilderte beruhen in aller Regel auf Irrtuemern , deren Auftreten zwar nicht unmoeglich , durch entsprechende Massnahmen jedoch unwahrscheinlicher gemacht werden kann . Zu solchen Massnahmen gehoert die farbliche Markierung von Leitungen , Filtern und Infusionsloesungen sowie die Verwendung von Spritzenpumpen mit einem groesseren Medikamentenreservoir , um die Haeufigkeit des Spritzenwechsels zu vermindern .

[ "Bei", "einem", "65jaehrigen", "Patienten", "wurden", "am", "ersten", "postoperativen", "Tag", "innerhalb", "von", "3", "h", "versehentlich", "36", "ml", "einer", "7,45%-igen", "Kaliumchloridloesung", "in", "einen", "lumbalen", "Epiduralkatheter", "infundiert", ".", "Nach", "voruebergehenden", "Paraesthesien", "stellten", "sich", "als", "Folge", "der", "versehentlichen", "Infusion", "brennende", "Schmerzen", "in", "den", "Beinen", "ein", ",", "verbunden", "mit", "einem", "motorischen", "und", "sensorischen", "Innervationsausfall", "bis", "zum", "Segment", "TH", "11", ".", "Begleitet", "wurde", "das", "Krankheitsbild", "von", "vegetativen", "Symptomen", "wie", "Hypertension", "und", "Tachykardie", ".", "Zur", "Therapie", "wurde", "ein", "einmaliger", "Bolus", "von", "40", "mg", "Dexamethason", "i.v", ".", "verabreicht", "gefolgt", "von", "einer", "kontinuierlichen", "epiduralen", "Infusion", "von", "NaCl", "0,9", "%", "99", "ml", "/", "h", ".", "Nach", "6", "h", "begannen", "sich", "die", "neurologischen", "Defizite", "langsam", "zurueckzubilden", ".", "Nach", "12", "h", "war", "der", "Patient", "symptomfrei", ".", "Komplikationen", "wie", "die", "geschilderte", "beruhen", "in", "aller", "Regel", "auf", "Irrtuemern", ",", "deren", "Auftreten", "zwar", "nicht", "unmoeglich", ",", "durch", "entsprechende", "Massnahmen", "jedoch", "unwahrscheinlicher", "gemacht", "werden", "kann", ".", "Zu", "solchen", "Massnahmen", "gehoert", "die", "farbliche", "Markierung", "von", "Leitungen", ",", "Filtern", "und", "Infusionsloesungen", "sowie", "die", "Verwendung", "von", "Spritzenpumpen", "mit", "einem", "groesseren", "Medikamentenreservoir", ",", "um", "die", "Haeufigkeit", "des", "Spritzenwechsels", "zu", "vermindern", "." ]

[ "umlsterm" ]

Abstract is an umlsterm, methylprednisolone is an umlsterm, neurologic deficits is an umlsterm, spinal cord injury is an umlsterm, National is an umlsterm, Spinal Cord Injury is an umlsterm, retrospective studies is an umlsterm, incidence is an umlsterm, complications is an umlsterm, intensive care is an umlsterm, hyperglycemia is an umlsterm, acidosis is an umlsterm, patients is an umlsterm, blunt injuries is an umlsterm, spinal cord injury is an umlsterm, adverse effects is an umlsterm, epinephrine is an umlsterm, methylprednisolone is an umlsterm, methylprednisolone is an umlsterm, patients is an umlsterm, catecholamine is an umlsterm

DerUnfallchirurg.01030495.eng.abstr_task0

Sentence: Abstract Large-dose methylprednisolone has been advocated to lessen neurologic deficits in spinal cord injury for nearly a decade despite confounding statistical results in the Second National Acute Spinal Cord Injury Study ( NASCIS-2). Recent retrospective studies found lack of significant functional improvement , increases in the incidence of infectious complications and an increase in ventilated and intensive care days in steroid-treated groups . We report on five cases with severe hyperglycemia and nonketotic metabolic acidosis in otherwise non-diabetic patients with multiple blunt injuries and an associated spinal cord injury . Those adverse effects were induced by epinephrine and aggravated by methylprednisolone . We conclude that high-dose methylprednisolone should be avoided in multiple injured or otherwise compromised patients potentially needing catecholamine support . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]

Abstract Large-dose methylprednisolone has been advocated to lessen neurologic deficits in spinal cord injury for nearly a decade despite confounding statistical results in the Second National Acute Spinal Cord Injury Study ( NASCIS-2). Recent retrospective studies found lack of significant functional improvement , increases in the incidence of infectious complications and an increase in ventilated and intensive care days in steroid-treated groups . We report on five cases with severe hyperglycemia and nonketotic metabolic acidosis in otherwise non-diabetic patients with multiple blunt injuries and an associated spinal cord injury . Those adverse effects were induced by epinephrine and aggravated by methylprednisolone . We conclude that high-dose methylprednisolone should be avoided in multiple injured or otherwise compromised patients potentially needing catecholamine support .

[ "Abstract", "Large", "-", "dose", "methylprednisolone", "has", "been", "advocated", "to", "lessen", "neurologic", "deficits", "in", "spinal", "cord", "injury", "for", "nearly", "a", "decade", "despite", "confounding", "statistical", "results", "in", "the", "Second", "National", "Acute", "Spinal", "Cord", "Injury", "Study", "(", "NASCIS-2", ")", ".", "Recent", "retrospective", "studies", "found", "lack", "of", "significant", "functional", "improvement", ",", "increases", "in", "the", "incidence", "of", "infectious", "complications", "and", "an", "increase", "in", "ventilated", "and", "intensive", "care", "days", "in", "steroid", "-", "treated", "groups", ".", "We", "report", "on", "five", "cases", "with", "severe", "hyperglycemia", "and", "nonketotic", "metabolic", "acidosis", "in", "otherwise", "non", "-", "diabetic", "patients", "with", "multiple", "blunt", "injuries", "and", "an", "associated", "spinal", "cord", "injury", ".", "Those", "adverse", "effects", "were", "induced", "by", "epinephrine", "and", "aggravated", "by", "methylprednisolone", ".", "We", "conclude", "that", "high", "-", "dose", "methylprednisolone", "should", "be", "avoided", "in", "multiple", "injured", "or", "otherwise", "compromised", "patients", "potentially", "needing", "catecholamine", "support", "." ]

[ "umlsterm" ]

Abstract is an umlsterm, methylprednisolone is an umlsterm, neurologic deficits is an umlsterm, spinal cord injury is an umlsterm, National is an umlsterm, Spinal Cord Injury is an umlsterm, retrospective studies is an umlsterm, incidence is an umlsterm, complications is an umlsterm, intensive care is an umlsterm, hyperglycemia is an umlsterm, acidosis is an umlsterm, patients is an umlsterm, blunt injuries is an umlsterm, spinal cord injury is an umlsterm, adverse effects is an umlsterm, epinephrine is an umlsterm, methylprednisolone is an umlsterm, methylprednisolone is an umlsterm, patients is an umlsterm, catecholamine is an umlsterm

DerUnfallchirurg.01030495.eng.abstr_task1

Sentence: Abstract Large-dose methylprednisolone has been advocated to lessen neurologic deficits in spinal cord injury for nearly a decade despite confounding statistical results in the Second National Acute Spinal Cord Injury Study ( NASCIS-2). Recent retrospective studies found lack of significant functional improvement , increases in the incidence of infectious complications and an increase in ventilated and intensive care days in steroid-treated groups . We report on five cases with severe hyperglycemia and nonketotic metabolic acidosis in otherwise non-diabetic patients with multiple blunt injuries and an associated spinal cord injury . Those adverse effects were induced by epinephrine and aggravated by methylprednisolone . We conclude that high-dose methylprednisolone should be avoided in multiple injured or otherwise compromised patients potentially needing catecholamine support . Instructions: please typing these entity words according to sentence: Abstract, methylprednisolone, neurologic deficits, spinal cord injury, National, Spinal Cord Injury, retrospective studies, incidence, complications, intensive care, hyperglycemia, acidosis, patients, blunt injuries, spinal cord injury, adverse effects, epinephrine, methylprednisolone, methylprednisolone, patients, catecholamine Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]

Abstract Large-dose methylprednisolone has been advocated to lessen neurologic deficits in spinal cord injury for nearly a decade despite confounding statistical results in the Second National Acute Spinal Cord Injury Study ( NASCIS-2). Recent retrospective studies found lack of significant functional improvement , increases in the incidence of infectious complications and an increase in ventilated and intensive care days in steroid-treated groups . We report on five cases with severe hyperglycemia and nonketotic metabolic acidosis in otherwise non-diabetic patients with multiple blunt injuries and an associated spinal cord injury . Those adverse effects were induced by epinephrine and aggravated by methylprednisolone . We conclude that high-dose methylprednisolone should be avoided in multiple injured or otherwise compromised patients potentially needing catecholamine support .

[ "Abstract", "Large", "-", "dose", "methylprednisolone", "has", "been", "advocated", "to", "lessen", "neurologic", "deficits", "in", "spinal", "cord", "injury", "for", "nearly", "a", "decade", "despite", "confounding", "statistical", "results", "in", "the", "Second", "National", "Acute", "Spinal", "Cord", "Injury", "Study", "(", "NASCIS-2", ")", ".", "Recent", "retrospective", "studies", "found", "lack", "of", "significant", "functional", "improvement", ",", "increases", "in", "the", "incidence", "of", "infectious", "complications", "and", "an", "increase", "in", "ventilated", "and", "intensive", "care", "days", "in", "steroid", "-", "treated", "groups", ".", "We", "report", "on", "five", "cases", "with", "severe", "hyperglycemia", "and", "nonketotic", "metabolic", "acidosis", "in", "otherwise", "non", "-", "diabetic", "patients", "with", "multiple", "blunt", "injuries", "and", "an", "associated", "spinal", "cord", "injury", ".", "Those", "adverse", "effects", "were", "induced", "by", "epinephrine", "and", "aggravated", "by", "methylprednisolone", ".", "We", "conclude", "that", "high", "-", "dose", "methylprednisolone", "should", "be", "avoided", "in", "multiple", "injured", "or", "otherwise", "compromised", "patients", "potentially", "needing", "catecholamine", "support", "." ]

[ "umlsterm" ]

Abstract, methylprednisolone, neurologic deficits, spinal cord injury, National, Spinal Cord Injury, retrospective studies, incidence, complications, intensive care, hyperglycemia, acidosis, patients, blunt injuries, spinal cord injury, adverse effects, epinephrine, methylprednisolone, methylprednisolone, patients, catecholamine

DerUnfallchirurg.01030495.eng.abstr_task2

Sentence: Abstract Large-dose methylprednisolone has been advocated to lessen neurologic deficits in spinal cord injury for nearly a decade despite confounding statistical results in the Second National Acute Spinal Cord Injury Study ( NASCIS-2). Recent retrospective studies found lack of significant functional improvement , increases in the incidence of infectious complications and an increase in ventilated and intensive care days in steroid-treated groups . We report on five cases with severe hyperglycemia and nonketotic metabolic acidosis in otherwise non-diabetic patients with multiple blunt injuries and an associated spinal cord injury . Those adverse effects were induced by epinephrine and aggravated by methylprednisolone . We conclude that high-dose methylprednisolone should be avoided in multiple injured or otherwise compromised patients potentially needing catecholamine support . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]

Abstract Large-dose methylprednisolone has been advocated to lessen neurologic deficits in spinal cord injury for nearly a decade despite confounding statistical results in the Second National Acute Spinal Cord Injury Study ( NASCIS-2). Recent retrospective studies found lack of significant functional improvement , increases in the incidence of infectious complications and an increase in ventilated and intensive care days in steroid-treated groups . We report on five cases with severe hyperglycemia and nonketotic metabolic acidosis in otherwise non-diabetic patients with multiple blunt injuries and an associated spinal cord injury . Those adverse effects were induced by epinephrine and aggravated by methylprednisolone . We conclude that high-dose methylprednisolone should be avoided in multiple injured or otherwise compromised patients potentially needing catecholamine support .

[ "Abstract", "Large", "-", "dose", "methylprednisolone", "has", "been", "advocated", "to", "lessen", "neurologic", "deficits", "in", "spinal", "cord", "injury", "for", "nearly", "a", "decade", "despite", "confounding", "statistical", "results", "in", "the", "Second", "National", "Acute", "Spinal", "Cord", "Injury", "Study", "(", "NASCIS-2", ")", ".", "Recent", "retrospective", "studies", "found", "lack", "of", "significant", "functional", "improvement", ",", "increases", "in", "the", "incidence", "of", "infectious", "complications", "and", "an", "increase", "in", "ventilated", "and", "intensive", "care", "days", "in", "steroid", "-", "treated", "groups", ".", "We", "report", "on", "five", "cases", "with", "severe", "hyperglycemia", "and", "nonketotic", "metabolic", "acidosis", "in", "otherwise", "non", "-", "diabetic", "patients", "with", "multiple", "blunt", "injuries", "and", "an", "associated", "spinal", "cord", "injury", ".", "Those", "adverse", "effects", "were", "induced", "by", "epinephrine", "and", "aggravated", "by", "methylprednisolone", ".", "We", "conclude", "that", "high", "-", "dose", "methylprednisolone", "should", "be", "avoided", "in", "multiple", "injured", "or", "otherwise", "compromised", "patients", "potentially", "needing", "catecholamine", "support", "." ]

[ "umlsterm" ]

male is an umlsterm, volunteers is an umlsterm, piroxicam is an umlsterm, period is an umlsterm

ZfuerRheumatologie.70560076.eng.abstr_task0

Sentence: The gastroduodenal tolerability of piroxicam--cyclodextrine was evaluated in a double-blind , parallel group study in 32 healthy male volunteers . The doses used were 20mg piroxicam--cyclodextrin vs 20mg piroxicam daily over a period of 14 days . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

The gastroduodenal tolerability of piroxicam--cyclodextrine was evaluated in a double-blind , parallel group study in 32 healthy male volunteers . The doses used were 20mg piroxicam--cyclodextrin vs 20mg piroxicam daily over a period of 14 days .

[ "The", "gastroduodenal", "tolerability", "of", "piroxicam", "--", "cyclodextrine", "was", "evaluated", "in", "a", "double", "-", "blind", ",", "parallel", "group", "study", "in", "32", "healthy", "male", "volunteers", ".", "The", "doses", "used", "were", "20", "mg", "piroxicam", "--", "cyclodextrin", "vs", "20", "mg", "piroxicam", "daily", "over", "a", "period", "of", "14", "days", "." ]

[ "umlsterm" ]

male is an umlsterm, volunteers is an umlsterm, piroxicam is an umlsterm, period is an umlsterm

ZfuerRheumatologie.70560076.eng.abstr_task1

Sentence: The gastroduodenal tolerability of piroxicam--cyclodextrine was evaluated in a double-blind , parallel group study in 32 healthy male volunteers . The doses used were 20mg piroxicam--cyclodextrin vs 20mg piroxicam daily over a period of 14 days . Instructions: please typing these entity words according to sentence: male, volunteers, piroxicam, period Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

The gastroduodenal tolerability of piroxicam--cyclodextrine was evaluated in a double-blind , parallel group study in 32 healthy male volunteers . The doses used were 20mg piroxicam--cyclodextrin vs 20mg piroxicam daily over a period of 14 days .

[ "The", "gastroduodenal", "tolerability", "of", "piroxicam", "--", "cyclodextrine", "was", "evaluated", "in", "a", "double", "-", "blind", ",", "parallel", "group", "study", "in", "32", "healthy", "male", "volunteers", ".", "The", "doses", "used", "were", "20", "mg", "piroxicam", "--", "cyclodextrin", "vs", "20", "mg", "piroxicam", "daily", "over", "a", "period", "of", "14", "days", "." ]

[ "umlsterm" ]